<SEC-DOCUMENT>0000950170-25-107618.txt : 20250813
<SEC-HEADER>0000950170-25-107618.hdr.sgml : 20250813
<ACCEPTANCE-DATETIME>20250813070332
ACCESSION NUMBER:		0000950170-25-107618
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250813
DATE AS OF CHANGE:		20250813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		251208953

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>spry-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-12T20:18:01.2232+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:spry="http://ars-pharma.com/20250630" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ad4d9779-575d-4186-8b1b-fc1541c2406f" name="ecd:TrdArrDuration" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" format="ixt-sec:durday">225</ix:nonNumeric><ix:nonNumeric id="F_3dd4a219-c3f1-45c4-a510-ce89c31b117c" name="ecd:TrdArrDuration" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" format="ixt-sec:durday">723</ix:nonNumeric><ix:nonNumeric id="F_f950c7d7-a7c7-4646-8766-6c37be33debe" name="ecd:TrdArrDuration" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" format="ixt-sec:durday">723</ix:nonNumeric><ix:nonNumeric id="F_1d23aaee-7552-4452-9655-3f8609a8fe5d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01">Q2</ix:nonNumeric><ix:nonNumeric id="F_3d174add-7623-4ae8-9797-d84da1eb32db" name="ecd:TrdArrDuration" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" format="ixt-sec:durday">723</ix:nonNumeric><ix:nonNumeric id="F_d8473ea2-8b5c-4cce-9351-7c2f730e1c07" name="ecd:TrdArrDuration" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" format="ixt-sec:durday">723</ix:nonNumeric><ix:nonNumeric id="F_e324cbe0-4ca3-4579-93c8-f86f08039a95" name="dei:AmendmentFlag" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01">false</ix:nonNumeric><ix:nonNumeric id="F_8c4dbcf9-929d-4c9e-87d4-8a5fbf679880" name="dei:EntityCentralIndexKey" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01">0001671858</ix:nonNumeric><ix:nonNumeric id="F_ebefd36b-fe27-48f4-bfba-f1b716fcaabf" name="dei:CurrentFiscalYearEndDate" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01">--12-31</ix:nonNumeric><ix:nonNumeric id="F_8dc82fb0-1b46-4787-a221-9fc255c4e9d0" name="ecd:TrdArrDuration" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" format="ixt-sec:durday">366</ix:nonNumeric><ix:nonFraction id="F_55f58a5e-df5f-428b-a6a9-abe7b92f60d3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1ceb97c8-7d6c-486d-a483-90c72cdf6027" name="us-gaap:CommitmentsAndContingencies" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a0276b15-2565-43a7-b2cc-bff166e8c881" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" unitRef="U_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonFraction id="F_626c3f50-1884-4203-bf7b-50eea6c01f4f" name="us-gaap:NumberOfOperatingSegments" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_84bd9e86-c4c0-4576-8d3c-cc8e99b6414a" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="spry-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="C_807c7cfb-8b89-40e4-984b-323428f58c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_828dc3d1-fee8-4736-9111-5a0102de64e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8337c8b0-3081-4566-b477-4a0f04a2f5aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83b0f481-c291-42bf-a1fd-628b8759542f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83d2f352-620d-436d-9ef5-e92a513b8f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_869de754-f3e6-4177-9331-4ed5d47c7e01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86b564d1-cec7-431b-b172-b26077a97bfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87fd2cd8-129a-414e-99c1-03cc3ad545e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8855f418-1ce9-40e1-ba74-585019621581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88a3e244-24a0-4aeb-bc44-0d55744142b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a13184c-6bcb-4906-a160-a36e0d4656ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8af74f27-94e0-4415-9f6e-42b1b5332edb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b011e99-1250-4ca4-a497-f2a90edcba13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b918b45-e66c-471b-9415-84b94cdb93dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bf5456c-aadb-4e60-b041-d6db39979b70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c487881-ba76-4097-b6c8-427e2b451999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c610e5a-69e3-4dbb-91d0-cbfccda23506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">spry:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dd7ea83-dd18-4eb9-9282-167ae56ead5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e9dbd5e-9d63-4ed5-9644-7a43dd445156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f694959-366e-4e19-a611-37c4b53e615c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90480581-aab4-4026-b4e1-0aeaa37e50ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91159948-e700-40b8-abf5-96f418841f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91a268b1-3615-40a5-ae0c-938276bfc07f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureAwardsOrOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91a3dda9-27ba-40ae-acc1-7312fbbb4c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9409939c-9f3f-4a0a-9fa8-269dcaf95cb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_952043ab-5fba-4c7d-bfff-86d859fc075f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsGrantedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_955465f7-5718-4609-97eb-6c7ac882fbc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95e31fb6-2b47-410f-b070-55db285d63d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95f04ac1-14ef-4698-b351-83ecaff48cdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98d3f585-f5dc-49db-8505-5f7d6f4a006b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98f4fdcb-e4e1-4865-9ef5-c4363da98d19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9926d4b4-fa02-421b-8525-65d964045c82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99e7eb22-c9bf-4bcf-8348-7f1f227a5e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99ec2511-459f-4c45-8f1e-cd91504cd76d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a4b43ec-ca53-4df2-bd72-e2b244eaca24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:CommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ab27dfe-3c05-41c3-886f-a2b0e4136b85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c214f10-a914-4d27-a1b0-da1ea243e703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c7e6e23-0000-4ddc-a5c9-a2b708744fd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:ROWLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fd25023-3042-461b-9a6d-57b976f28f60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2016And2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a16758cc-95a6-438f-b28f-9eb55360c257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a17bc1f5-5be5-45a5-b3d5-0e7a29e42cf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1b6d996-a8c0-4025-9859-7563f538ccfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a207a717-bac8-486f-8afe-c9df9c813261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3dc6a53-1c90-4d3f-b90b-fea8237b5cd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:OrbiMedAdvisorsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a417b738-34c6-435f-98b6-b7335b68b8a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-23</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a650b87a-1c00-4b79-a58c-69715046ebb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a668bc1e-23db-4ea8-85ec-8d8056d6f34d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7e67462-553c-488d-9b14-c09155e03b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9963800-3add-4281-aca5-d9f4f016ca70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9a7be28-24b1-4e30-816e-ff9e76477575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:LauraShawverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac30d314-86f3-4148-b29a-7d12452b392a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad92b4a7-9dd4-43d7-8f4e-0ecdae3b7b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae56245d-14e4-4425-a73a-af69dd8543a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af065405-07da-4d8f-9aad-88eb0dcc47a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af689524-2c04-42d2-a16f-31b2d40284b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b04c992f-7141-450b-a7c4-9f61a9eb497b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b05d88b5-cf1f-422b-b672-31550bb59ffd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0d7c1bf-c559-41f1-bb73-15d4ca13613b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1018c50-39c0-4a1e-a69c-876377e82ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2af9dda-1f32-4532-acbd-bda315dd18f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2e00eb5-14d4-4be6-9263-605eaadf4494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3290235-3d4c-4e7f-9944-799740aa251b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4c93365-0858-428d-a34d-b5add11a9639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5cccac4-7ff4-4dd5-9952-e4d8fb70e5e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b67f6b97-19bd-4541-ba67-b60ffde15be3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfRecordatiLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6c4e388-e63f-477d-add2-c9ae15d79bd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b79419a0-d171-46d7-996c-18c142afc6c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8271b46-8d08-46dd-ad0b-ac8a80d68454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b92085ed-7b67-4267-a76c-73095df42f5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b963ff18-7450-4060-ad3c-efc70564a546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9e6449d-ad47-43a6-9843-3ac845071d45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba7df335-5578-421e-8c2a-d36e33edcb60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:OrbiMedAdvisorsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb2d95de-4594-438d-9c55-a3a55b7278da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbfe4e30-cf8e-45b4-9694-9eb0e8f2297b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd86d1ef-eeff-4adf-8a19-f69f6a8e45f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdb38646-dad4-46e9-bb80-804ebaf2c503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:RestrictedStockUnitsGrantedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bea2c90b-ecb9-4b59-93cf-dda1fa71fada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_beeef49f-dee6-4fb9-a634-f1430f58cd42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf13c693-c4c5-4d64-bff3-5e485417c1b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf31afc7-406c-4630-becf-7735028ce61b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf5281ce-db7a-495f-ab02-93574c48462a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfd38f7d-69e0-47b4-8cde-fe7dddca6c40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bff2f443-6b3b-461a-ba19-428c01a04487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c12a3d9a-b30c-47d9-bb6d-6f0ae9453472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureAwardsOrOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2299308-80d9-4f3e-8124-02a70b3c491a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c263fc35-be1c-4365-9aa0-2c5ad53934fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c28eee89-e582-4ada-b83c-1d83ed541c9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2c7df1f-3bbc-45b1-969f-8aabc9c9acc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c38ed128-079d-4241-b04b-554e67e4475f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c59d3a87-64b2-48e5-b806-8ca9b8489a28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c703154e-f609-4897-84a5-dd320a085d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c77c3709-162d-4edf-953a-4ab1c1e3faef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7d4f909-e24a-452d-82cf-9bb2659ab99f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7e544c9-751c-4210-b224-6b0035e4618e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8ac2384-1b58-47dc-915d-83a7ba54ecc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca70d85e-c0cc-4722-8d9c-3028532be956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc8627a9-0c70-4d03-b571-48b53e518a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccda22c2-6677-4cce-ab78-990354649056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">spry:EuropeanMedicinesAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccfcc4d8-af04-4d3d-b28f-3c979e5d0771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ceb11ad1-2588-4e17-af28-fe15173ba3d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfed3148-1f6d-4764-881f-dc1ce6517210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d04fa5cc-8928-4685-ad0a-fe068b728fac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d088454f-4075-431f-b4bb-11f7b482ba95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0bb372c-0ecd-453e-b973-012e84044734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d10f176e-9429-4ccb-a20f-413c86b3a44b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d188a46c-d138-46be-af79-eb7c3b01af79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:CapitalizedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1c3a878-557f-48fb-9597-d12ba95d1e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:OmpiSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d905b4b3-9373-4262-8390-864c35ac6e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9365522-fb46-46b1-bc6e-284e0bac324d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d93ac729-d7c9-434a-8a9b-7e60266ca1ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dad879fd-9fd0-4630-936d-24ba4a2d140a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:TitleAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db43d886-40d2-497e-a347-d9adf0486580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbca97a3-dc8a-458f-86e0-c938df8b9878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">spry:HeadquartersAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcc2baa6-8c87-4f57-a3dc-79e85b7ce8e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcce5799-5869-4e9b-9399-9d7c6125048f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcdc4492-adbe-44e9-8b69-d68a7d4bae66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd3a8cfa-4023-4a91-9e13-79918b2abe74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dda44404-ce43-4ae0-930d-c039cfc589f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddc169de-f0a1-4298-8916-2c62ad23e107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddff9d59-8efa-4f5b-b496-c704a0bada3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de447bf5-c664-451c-be04-6c477bce8fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df005c86-508d-44b0-ae4f-f72b61e895e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df32a54d-3ac5-44ae-877c-73959c6f6097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4a29c9-2002-49c3-bbf7-c84fa9b0edbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0a90922-dcd0-49c2-a9be-fb3989e9dc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0fe3c7b-f600-4c9b-b811-bf543aef3ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e127c89b-57cc-45dd-88e0-5952c92514a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EuropeanEconomicAreaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e154ceb7-5441-4be7-956a-04c0dc49d336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1d0ae97-b485-4671-bf99-135c430e8fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3d262bc-6795-406d-8d91-24b3907b6289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6beb23c-440b-4e94-b575-d556e723f9a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8814f36-7086-44f4-9a53-259022c64732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eae13608-8a7d-49cd-b8b1-4837d9244b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaee139f-06ad-4880-b611-5bd0dea21a98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:LauraShawverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efde3903-153e-4b55-ad5d-f7a9987f9a59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f02958dd-2171-4f6b-bf03-9a0ffab81bfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f04745e7-fc61-4f44-a90e-0375301533ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0d8db66-c63b-4744-af9a-66b508f6e408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c8cad0-d5f3-4e51-9804-2b151cd3b1f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1fd271e-7bfe-45dd-855c-01e649527ae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3358bc3-9806-4dc0-ae94-6af64c1d3c84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f340b5d5-a46d-487a-bb76-a006e0f3faee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:TitleAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f342e672-771e-4d11-b09d-5aa31a2a64f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4436849-9fcc-4497-a985-5fa9db7ac33e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5b73dfd-e33e-4e24-ab07-812aebbe06f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f685dc68-99f3-45c7-888f-f64255a00ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f686fc0b-340d-4ecf-a20d-89f3341462b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9587472-b812-4c26-9f12-b181d477afd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9b7e8e0-49aa-425f-b6ac-7a1e94633629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faf7e39c-0f29-434d-b6fb-e1d303cebf23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RenaissanceLakewoodLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb686167-75bd-4d07-b3af-efcd511a43d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd906f79-8562-4a95-bd43-4d251d2344c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb3d59c-08cc-44f9-9f9d-a605f5002728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_004bb578-b8b4-4b1e-b080-94149f0f6733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_021eefc7-cfee-4d52-8b2d-03167d9c4f45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0290e712-16a0-4589-8318-f1315dc7c60a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:CommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-24</xbrli:startDate><xbrli:endDate>2025-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">spry:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05f55f90-a226-4553-acf7-98941d6f746b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_060127b3-af69-4d7f-a100-67b6e7eb8bca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_064e952a-b57a-45b7-b072-cc0c1681aeea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_072805c1-e17f-45e5-a672-6a75206ddbb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_081fe4fa-2c69-4289-b02a-3b63500a1252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0833639e-5a42-456b-b01e-000950904f01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09f9802b-bfdd-4db9-acd2-6c382a188d1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aeae9af-4a88-43bd-a834-adb7075f5c02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bd8344d-6c3d-4f4c-9193-8180e76f5899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d03ed93-9080-4cf9-9b33-e460f48b48e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d090888-c874-48f6-b153-a3c2f3e3fe8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2016And2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e0c015a-4832-4ce2-aa6e-7f1681a3ba80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f4f1f4e-cff5-4294-8295-0850b8d49cb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fc3a621-041e-400f-9a4b-601457b85fd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10d6fbd1-42f4-43a6-a7b7-6fc8c0df13bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1168bae1-a4d7-42ba-a4a1-1aaae5e9cecd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12bac910-38cc-4107-8957-20fd4415cbd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13db5f9c-2f06-4b3c-be00-958784249b0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_147fd450-9410-4b8e-a22c-51b186dd1d12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_150214a2-c270-468d-9a06-7728c1a7db0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16dc4749-c6ec-4139-b8ad-4dcea1d2fb78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18b0f553-9076-4f15-9748-2023f42761a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18b0fdd1-a485-4c6b-9072-308bd98cfbbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1becd9ce-e5df-4cc7-96cc-1fff890d77d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:KathleenScottMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c56c487-e024-4724-81ae-947caaa88834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d2c0919-4138-4410-8ede-0f80ab424b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d5db0ae-f190-4d5e-9227-dbb3463af2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1db62f10-470a-43d8-99c5-9ef506d240f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef13204-b17d-483a-99d0-289ce05e08db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f628d09-1530-45b7-881c-0af4b02a1014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ffef034-5c87-41ce-88e2-2b53d4ffa344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20001566-4a25-416a-94b7-ca46e23b8755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2196e376-19a2-4b1d-bec7-939794646f60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21fe8e44-bec9-4153-ad91-5b5867687e88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2241ca04-d0e3-4458-81a0-72b7a112643d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EquitySalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">spry:EquityOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_238c6043-2b99-4906-9c2c-f32a420101fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24048e4a-2861-4e82-9a25-7bcab8c32310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_247f0be8-9254-4ed7-af0a-c83a543c7393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2534ad0d-4f31-47a1-99a9-04102ea40a7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2798c3f2-23d6-4afc-8238-e8955f00db8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2799d300-1237-43a9-b5b0-5d5699ea13d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_286db13c-dcd3-4bda-8947-71e23b80ce46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_295e6502-8b12-4686-a1ab-212436254537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_298d2778-7e68-42a6-ac6a-7d397a9e29f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">spry:NewDrugApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a05683e-e9ad-48bf-82d5-1bac47afff01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c9e3e1d-19ca-41b7-84e3-5196425f10d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e38c3cc-e6d7-4425-85b9-bc2d6e8c7279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:AggregateSaleOfRecordatiLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e65281f-ba53-4d3f-a689-1260aaaf239d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31e9248e-ea58-43c7-baab-8f7cb2a5c62d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3384a69b-8620-4b79-a234-cd7344debc19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3571bb42-9451-44e2-9e1c-0598970a2964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35887e57-d648-48c5-aa33-441fa8e48cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:KathleenScottMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_374c6b30-c221-46de-a6b2-30e2bb48619d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_375c7fdb-6931-4298-a1cb-0a3d7c761910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38363ca6-7cce-4222-abc8-30485789e9f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38aa7ddf-8d81-40f0-b406-1b66b957af89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38ebd40d-47cc-434d-adce-a43b467c8b30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a9f4cd4-fb54-4828-96ba-ce70b60363d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b5b2d22-53f7-4c9d-8b99-321480d17789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b7fe764-d042-4e16-bcf8-711a85614de6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b8087a0-6412-4ff5-90a6-c0f272af562e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c5642d7-6f8a-4a44-acf5-5d6d63e1e69e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c6b92a6-dd38-411f-8214-dba5099c8f52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:RestrictedStockUnitsGrantedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cf5d1b5-d177-4592-87ff-f0e88882461a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e249227-20e2-4988-9bf2-7e870713555f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EuropeanEconomicAreaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f30c2eb-5568-4234-8acd-723e1a049bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f547b95-0c7d-4909-a139-bea14be39173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4029b4bb-de28-4de7-8408-45df90688cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41ef6930-d9f2-4459-a547-37d492c3f1c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43967981-d479-4db2-8fce-ee96cfa44034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_450d35f9-0df1-4549-a5f8-a9c9ea015932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45813144-0748-490f-bd01-ce77ea3bf89b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_460d3d8c-ddbf-4c5d-a288-dca013f2b32b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_470f916f-7869-4e25-8dd3-760ff2bc2856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47e7fcde-f00c-42a6-a53e-32799f721460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_486e30e1-067a-4d74-b32c-7b5cd57c48a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4883e707-b9b1-4461-b2de-ffc404f7e7bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_490ab03b-38cf-4134-9ab1-2f6b7f250c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49c47b49-d4ac-4136-84a2-4bc4a2103d17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d5e4244-5624-4eb9-83c5-28bcd9c0f0f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d7fc657-c0ab-4f3d-9b5c-9106d31bfc5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fc5fa74-f0e8-45a7-8703-dc0cc39277c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fc6cb5f-4180-41ac-b434-d6945583ee10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50bfc96e-86b2-4bfa-93e5-4dd89fe4840d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51ba7095-5039-485e-900a-2f239350359c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51f70a11-69b0-4dbd-9cc6-efbfee56c21f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53ececee-4b8b-4df1-8752-18134066f9be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_551d5f3f-f834-4e2e-af4a-07c630cc9151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_563a8ff6-fcbe-42af-ac8a-285febbe3949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-09</xbrli:startDate><xbrli:endDate>2024-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58518720-4bc3-47a8-a449-980f97f2e742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59f4bf3a-7f8e-4ad6-a506-194c1950572a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a15e9e6-1bc3-4167-8e8e-c79dcf3954c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a8cb702-3dbe-4910-ae11-39b78feaa28c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c380126-d22f-440a-80fa-e358a5a088b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c7ce1c8-b99f-46f8-92aa-5a9614bb368d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d036733-4b5d-4177-a142-b4f41043ac6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d09679a-e12c-4e0f-932f-d6350e656399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d3ab776-018e-4dde-8537-5db78360a3b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ed4cad0-90aa-4443-919a-3ab354fd0721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:CapitalizedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">spry:FairValueInputsLevel1AndLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65ed12ba-e864-459f-ae4c-a7e1d4cf3b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-30</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6770ee9a-57e6-4eef-bbaf-3da967bec8b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_681b9e90-c822-4025-8193-e866cdf0d681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b05c4b6-d7fb-473f-ab92-1227f461cbd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c6d2854-3599-431a-a593-98e4379c15e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ccd2d37-27d6-4e02-9364-bcfbddaf6936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ec3f271-be32-423b-9498-2f0527f50596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6edac6ab-835a-4f3c-a70b-1468370bc85c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f03d69b-1284-4bc4-8234-9a7df3551bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f2fdca3-8c4d-435f-b8c0-6a77fe46d870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EquitySalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">spry:EquityOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_704928fd-7ecc-4aeb-aad1-e86385ad44c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_707e3c08-3d58-422c-9b32-bda32bcab502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_707ffda4-d1e9-4317-b368-b5b461d89663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70a2fe72-2e5d-43a9-845b-e6ad6d4e993a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71398ff7-c6c1-4c72-ad74-10d8e3e3bf31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72c960a2-6882-42be-9586-209e84ad98f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72dc1e89-7658-40c1-8ca3-952db65ab782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_758bf922-ece9-4a0b-b463-8ee0919f4a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_758fe697-6dbc-4923-9ddf-258ba4a7c8ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75927173-b0be-40a6-8cb0-9cafd6cc1be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76f794c5-9e6a-42a7-b227-1abf0ce9a252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7763ab6b-709b-4a5c-8ecc-4d9c9531a9e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77cdd9e5-e0da-4ed0-91c5-452beda8f96e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:ROWLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_783dccc0-475e-4692-b8a3-08a49e9999dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">spry:FairValueInputsLevel1AndLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b9bded7-8bb0-4033-b376-cee3038595c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d4c367f-9884-46d1-8862-8e2ef2c52541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d548bc4-9a01-48d0-9705-9105c2226181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsGrantedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dfae0a7-c976-445c-9186-28e526f9917d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:OmpiSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e3f31da-ca14-42b4-8b0b-1e8aeb740579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ec42259-6316-479d-8953-352d08d61678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7efb2cf9-3f33-4407-a356-10f47479dfdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f5fc329-380e-42ec-8c1f-ae79663067f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>spry:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Doctor"><xbrli:measure>spry:Doctor</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:3in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3d1a69c-3526-47f0-8446-eecbcc1ae152" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:3in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0378e3ae-bf42-4733-82db-009973ae9d8e" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d0fbaf-2805-48e6-a8e8-646d446d4f8f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6340f8a6-abd4-4d6a-875c-3957669c7cbd" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a202602-6a2a-4337-9d46-578d1e6e7c00" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79416c9e-7d5b-4ea9-8dd2-e59aaab23009" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39756</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:3in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e10d1d8f-50fa-4225-a266-d696e53686c7" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:3in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"/>
      <td style="width:50%;box-sizing:content-box;"/>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d14d7c17-130b-4c3d-af0e-d28ce32399c2" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_35ed6db7-5205-4e12-8c11-e14559df1e5b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-1489190</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
     </tr>
     <tr style="height:4.3pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_428af333-e844-4a33-a3dc-5b94de48209b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11682 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_b5c8bb64-ee03-49d9-9fdc-a9a867ad5702" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cbc300d6-debf-4ede-839a-e4f82beb720d" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_7b2b0dc1-f35d-478f-a0e2-6254df6c65ba" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c4218a8b-4cf1-40b7-a78c-c4fff3b8e997" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b870d62-529e-47ca-957d-a6905526b040" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bd31892-0d09-40ec-9702-7d39149ce488" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">771-9307</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:3in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;box-sizing:content-box;"/>
      <td style="width:33.333%;box-sizing:content-box;"/>
      <td style="width:33.333%;box-sizing:content-box;"/>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_00784e88-198d-4b07-93d1-a2befff57750" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, par value $0.0001 per share</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_76891632-8f31-4673-949b-aa4f1f71f466" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SPRY</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_772d4642-8376-4818-a22a-a42fd1c83a1c" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6789284-9ea4-4eb4-9a17-441218e2b7cf" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a7a5f18-8a67-4579-a4cb-3cfe9e25585f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:21.277%;box-sizing:content-box;"/>
      <td style="width:51.672%;box-sizing:content-box;"/>
      <td style="width:24.012%;box-sizing:content-box;"/>
      <td style="width:3.04%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c7d796bb-0ced-4b3e-885d-a92dee2df45b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_250edfec-ecc9-4dc0-85a3-a0e0c2b1563a" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6bf1412b-3e26-4bfd-8a07-da2a1d251981" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3590ffc-ba24-4052-ae85-1dcab1a32062" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  &#9744;    No  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48a5969c-49a1-4573-9e11-e0e95705ece3" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ugust 11, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_280097ee-3d9b-4ba8-9411-d6b17efff9c9" contextRef="C_45813144-0748-490f-bd01-ce77ea3bf89b" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,826,337</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of registrant&#8217;s common stock, $0.0001 par value per share, outstanding.</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:10%;box-sizing:content-box;"/>
      <td style="width:80%;box-sizing:content-box;"/>
      <td style="width:10%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#parti_item1_fs"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#fs_bs"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#fs_is"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#fs_sse"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#fs_socf"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#fs_notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#parti_item2_mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#parti_item3_marketrisk"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#parti_item4_controls"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partii_item1_legal"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partii_item1a_riskfactors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partii_item2_equitysales"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partii_item5_other"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partii_item6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future economic conditions or performance, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net product revenues and net product sales;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research and development plans, including planned clinical trials, for our current or future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected timing for reporting data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) review of our post-approval variation for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 mg;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to submit regulatory filings for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in additional geographies in collaboration with our partners and the timing thereof;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected timing for regulatory review decisions for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commercial potential of and commercialization strategy for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the markets (including annual sales opportunities) for our current and future product candidates, as well as for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for its currently approved indications in the United States and the European Union (&#8220;EU&#8221;), the projected growth thereof, and our, and our collaboration and marketing partners&#8217;, ability to capture and grow those markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected competitive position;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our potential to become the standard in treatment and transform the treatment of allergic reactions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attaining and maintaining favorable coverage;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected intellectual property protection for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legislative and regulatory developments in the United States and foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates regarding anticipated operating losses, capital requirements and needs for additional funds;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any future product candidate; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements of belief and any statement of assumptions underlying any of the foregoing.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the context otherwise indicates, references in this Quarterly Report to the terms &#8220;ARS&#8221;, &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; refer to ARS Pharmaceuticals, Inc. and its consolidated subsidiaries, and references to our &#8220;common stock&#8221; refers to our voting common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a trademark of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, our trademarks and trade names referred to in this Quarterly Report appear without the </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor, to our trademark and trade names. The use or display of other companies&#8217; trade names or trademarks do not suggest or imply a relationship or affiliation with, or endorsement or sponsorship of us by, any other companies.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the material risks associated with our business include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the successful commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the United States and in the EU for its currently approved indications in those jurisdictions. To the extent </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is not commercially successful, our business, financial condition and results of operations would be materially adversely affected, and the price of our common stock would likely decline.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates may fail to achieve the degree of market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or profits.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to achieve and maintain adequate levels of third-party payor coverage and reimbursement for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on reasonable pricing terms, its commercial success may be severely hindered.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitive products may reduce or eliminate the commercial opportunity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current and future intranasal epinephrine technology product candidates. If our competitors develop technologies or product candidates more rapidly than us, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop our current or future intranasal epinephrine technology product candidates, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional indications, or experience significant delays in doing so, the commercial potential of our current or future intranasal epinephrine technology product candidates or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will be more limited.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the U.S. Food and Drug Administration (&#8220;FDA&#8221;) does not conclude that our current or future intranasal epinephrine technology product candidates, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional indications, satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates or additional indications under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates or additional indications will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us or any of our current and future licensing and collaboration partners could divert our resources and attention, cause us to incur substantial liabilities and limit commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our information technology systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely completely on third parties to manufacture and warehouse both our domestic and international supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on international third-party licensees and assignees for the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates outside the United States. If these third parties are not successful in their development and commercialization efforts or if these third parties fail to meet their contractual, regulatory or other obligations, our business and results of operations could be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our timing of sales and results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development activities or commercialization efforts.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends on our ability to obtain and maintain sufficient intellectual property protection for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our current and future intranasal epinephrine technology product candidates and other proprietary technologies.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="parti_financialinfo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I &#8211; FINANCIAL INFORMATION</span></p><p style="margin-left:0.75pt;text-indent:-48.95pt;padding-left:48.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="parti_item1_fs"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fs_bs"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except par value and share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc6e2b4-e80b-4f1f-b5b1-0836d0f0c40d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,540</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3b2cf0-b8a8-4ca0-aaa9-73da35e81a4f" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,817</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_438b2d94-d948-469b-9c48-06475cd0aa6d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,590</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b58d3eb-cae7-47ff-acf9-242057bb805d" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,205</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d0ec9f4-fa86-465f-9185-0a74b90f7e94" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,126</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d580372-0043-417f-a2ca-e58a8a94299c" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,175</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_286fc6de-7f7b-4cc9-a0c4-c1ba525c3d45" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:InventoryCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,738</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ccf3749-5133-47f8-8bdf-a3f0096d68c3" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:InventoryCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,212</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62b28f30-b1f8-4bd0-9351-11c101d2c35d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,442</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc76e95-b1bc-4665-924b-74c9f671d212" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,886</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_025c9ad3-8223-41c5-ad94-85601f16cf1f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,436</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_495c1d83-4710-4db2-8d47-dc2841846ee8" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334,295</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term inventories</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b199f355-2288-443d-ab3c-65444889c847" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,374</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20211350-d9b3-4248-ae70-a950180ce33c" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,307</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f27c8ccd-1daf-4da8-9105-cec35607fcf9" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,564</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_567231c0-106c-47bc-8bb1-cbc9c1803206" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9350ca24-ef37-408d-85a1-f75da56c3af5" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,075</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9256fa-2f89-4c16-84cb-d77e13897692" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,029</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f90e2594-b8e3-4ef7-8025-cf47705d2d7f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,972</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156a1ebf-1ee1-4da9-ab66-7e7c4cfe66ad" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,371</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb7416cc-33b3-4304-be7c-266e9b69f65c" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,051</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61b1480b-e4ec-461d-b090-17fb6e458e18" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,114</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c039731c-ed5f-4fbc-b2c0-b9ec54a2f179" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,472</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4a0131e-c9ad-4638-b422-8aca6356ee51" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,153</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities (including related party amounts of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23a9616b-e112-4e5f-836a-3b19bacb955e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,091</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e34408f-a795-4a12-93db-773279330c2d" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">656</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c010c547-75c7-485e-9067-963cc10dd083" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,264</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a98c28-c6a2-4475-84f4-33e762961b75" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,841</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liability, current</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96bf2f6-a8a7-4237-ab9e-a4311b552631" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">746</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8802588-ef47-4af3-bd8d-4b5c63dfa65d" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">557</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability, current</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fe93b52-5837-42ea-83ea-38cc639a9e88" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_557ea347-97c3-44e2-ba6d-ee40ecfef75a" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c408262c-7491-497f-9adf-3bab18f3abd8" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,599</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff429793-1d34-4964-af21-a6bf98200048" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,440</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing liability</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f8fd067-a92f-4fd1-afd6-1e9e10c8f209" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:FinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,959</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68d5592f-7250-43b4-a33b-d610e793527a" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:FinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,383</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liability, net of current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e64c7779-0a2e-456d-a0a4-81cd1f56dbd5" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a2bb907-e8d2-4cc5-a647-7198d4847900" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f759ee-4679-4a24-b236-926c6f9a4b9e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,072</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d05c9550-f8c1-41f2-9002-e40f4cb6db5f" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ccfa7a2-af0e-4a07-9f8d-3d10b9c83b74" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,418</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45ca28bd-be4a-4084-b197-0a6839fe23bc" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fc66b76-fea1-404f-a884-d2cdb653389b" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,151</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2e23254-4ab6-408f-8bfd-2c4d4c26a56e" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,355</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_55f58a5e-df5f-428b-a6a9-abe7b92f60d3;"><span style="-sec-ix-hidden:F_1ceb97c8-7d6c-486d-a483-90c72cdf6027;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 9)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_708ba146-4db8-480f-a47e-32024a252e3a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_76d353b0-fc97-455e-b8cd-c9b7a7289dcd" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d674b6fb-d151-4557-a3ec-3b3428b844b2" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_65e83f6c-d15d-456a-a61a-90b50b5fb418" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b51edb2-98f9-4b7d-993a-f8083d8960a0" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a2b5298e-0335-4605-9668-521a26f4b91a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_38126b5f-e352-4feb-a24d-3b5e519da551" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ffe9aa1c-d50b-4f23-90e5-e0b93cf0857a" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at June 30, 2025 and December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_626b22e2-3a88-47ba-944b-b05020a658db" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e796df2-77cd-499a-8999-881fbf610f6f" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90e14721-8d31-4971-803f-cd0a68add7fa" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d86b1b8f-da89-4abd-873f-7f28a658dfb3" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25685330-a5f8-4349-8939-c098dc7bbc0a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5d9f953f-1a57-410e-b691-572e79364840" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b33a0ac2-8007-4ed9-8d6e-6cb6194bd26e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1572344f-41a8-43ee-b532-b5f74839e99a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,697,658</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81032eb2-a2ef-46bd-adc6-b21b7ab7f365" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ef3c5c53-7f0c-4e34-85b6-26f1178c52f4" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">97,954,172</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e58e74-aa74-48c1-b146-51fd67fac905" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d57f2ac-650c-452e-b0ed-0baf5136fe84" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ee4257-648f-4149-a6eb-6b6df2cdccec" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,485</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b84b5fb3-ca9f-4757-a059-37a5a589a919" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,873</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive (loss) gain, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b607d579-8fed-475c-984f-3661008d3b9b" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3f0b36-4b89-4480-a783-3514a11178a5" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c868f22-a520-4b2f-afa9-8fb68e96617d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">202,128</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c5336a8-a179-42a2-8adc-ed2d8585c48e" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123,305</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce9c3ef6-c011-47bd-aa96-dd1ec038e9bc" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,321</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99a34ae8-62c0-4000-934d-1fedd9e10384" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,798</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d169661-1a86-4590-87be-4b3df2ec2e99" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,472</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11b200bf-b732-40fa-ad9d-b9e8ec7e125c" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,153</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fs_is"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:46.4%;box-sizing:content-box;"/>
      <td style="width:1.12%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.280000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.12%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.280000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.12%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.280000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.12%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.280000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91460fa9-6712-4a67-9826-6e753f3e6edc" contextRef="C_783dccc0-475e-4692-b8a3-08a49e9999dd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,800</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ae07ec-7e5f-4c23-85a9-dffd8275fcef" contextRef="C_828dc3d1-fee8-4736-9111-5a0102de64e0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_075a45b0-2b54-43ef-80ed-1dd88ae1cb6e" contextRef="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,563</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65d351a9-6c8a-4c27-80c5-f16270d207fe" contextRef="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5de03b1-b859-45c8-a028-944b9ffb27a2" contextRef="C_21fe8e44-bec9-4153-ad91-5b5867687e88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,594</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db086b31-1c22-4205-a571-472bfe3c4903" contextRef="C_4fc6cb5f-4180-41ac-b434-d6945583ee10" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9c00d7-bcf6-47ba-a309-9615eb39e6f0" contextRef="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,804</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf2c02b1-f84f-4ca8-8b50-b64d7344cd03" contextRef="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ebdd02f-4639-4e76-bd8b-0ba808cb80f8" contextRef="C_8855f418-1ce9-40e1-ba74-585019621581" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e17296d-ce50-44a2-98b6-075a37625f07" contextRef="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f730172-730f-4afc-a96d-0e29f601adac" contextRef="C_83b0f481-c291-42bf-a1fd-628b8759542f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ddb225-ee0d-4db6-9c5e-70ce3f908afe" contextRef="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d5ca5ec-bf8a-40f9-8225-22746c8f758c" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,717</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_181eb934-f6aa-4fdc-b682-8b444b1b37f2" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16d37dae-66e3-4cf3-a1a4-67063f7877b2" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,690</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e54caa9-6750-4e9f-b258-7bc243e58b14" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold (including related party amounts of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14ac524f-d257-4ead-b6ea-d5069d0b0c7d" contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">866</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5855747d-f025-42e3-91f7-09ecd12fecb8" contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d301a45f-814d-4346-9f62-294bae2714ac" contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,354</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8fec7db-afff-414c-97e0-04801363e2a0" contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4edadcab-b4f6-4398-b277-f79402a3ae6b" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="spry:CostOfGoodsSoldOperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,984</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39c6df06-fcee-4709-b4ab-465004c05041" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="spry:CostOfGoodsSoldOperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6de63a6-e407-4662-8769-91776be6f9ee" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:CostOfGoodsSoldOperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,078</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_932b9afa-a2c9-453a-9401-6f4864788552" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="spry:CostOfGoodsSoldOperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development (including related party amounts of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c48420-9d55-4cce-8b7e-c50424f5fa07" contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">582</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_610e9fbe-9f6b-486d-93a6-af00b88de340" contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b5cca3-2317-42cc-b963-58ab37d7fd2d" contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,245</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa014c4d-ac37-4cd4-98d1-36fc579eda8b" contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,245</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d230eb62-af6a-4b77-aded-343507386cee" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c700361-cbde-4fc6-9f72-5b8e82e885aa" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,896</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcfab2e1-7844-4f5f-a36d-b9981a55a2be" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,987</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05cd1eff-f8b5-478e-ad45-880ee348a43d" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,130</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative (including related party amounts of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07d8e294-4d6f-4066-ba99-6a6f778f3921" contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9b5224-2ff3-442b-b85e-d0244249cd62" contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6113fb4-cd0b-4ca8-ad63-e8317b4e7abf" contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ce73430-484b-40b7-911e-f453137ba640" contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc62dbb-2519-4648-9b29-4b272b3f5c7a" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,312</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1b056ba-a623-4a3f-b797-c595da255562" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,944</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0dbbc07-46d5-48c4-8dbf-a2a7fb1ee3f7" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,416</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c416001-a4c7-42ab-838e-b91ba6759e5d" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,902</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98dd517e-3ad7-4e0a-9fe6-b5687ecd28b2" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36ddd976-d4bf-46ea-a50e-a5ba6a0a031a" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,840</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deb3b4c2-54ef-4a01-aa7c-9e9473e5d810" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,481</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd2131f-a741-493a-b7f6-4c0bdc86bd24" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,032</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56168117-f847-4c47-93da-e32efd713a1d" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47,614</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ebaf6f7-32f3-4c74-bfe9-457327df03ef" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,340</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41c5bb16-e9d6-44d8-afe6-2f9e9939a76e" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,791</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8344235-ce38-4e81-b7ee-4f8359c6d1e4" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,532</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea80c87c-d258-474f-acd8-03482f858af8" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e56d9603-396a-4d76-b112-2981a0ee1082" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,824</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14542fe9-1a72-409a-964e-25500d870e08" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,968</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e223c9-02cd-4d38-a90e-b12ddc4db5c8" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,724</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e60c861-7c9c-4f01-90f9-83b81c10a57d" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,883</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_facf1c16-5e0d-4f92-9f1d-ce369e42324d" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,516</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3ce8e9d-39e5-4aa5-afa0-7f0e45fad6be" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,823</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ef94d14-6be9-4e73-8f88-8ff6ea29d19a" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,808</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b73ecd-09c1-4fcd-aef7-252d18281b72" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6bdc8f8-226a-413a-9aa8-1695cc8a1697" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a382285a-f646-4307-9dc1-821c9b133372" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">266</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c14505d-2621-4a59-b895-5034f428357b" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfd0d1e5-4574-40c1-b0bb-7162da42ba37" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,001</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82f92cfd-2bef-4498-b64f-98ae260eb469" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,537</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc5976e-ca0f-4685-9a07-6d43b8a82d66" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">79,089</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4483cf1b-5ffb-46a5-98b6-f3c09229aa96" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,002</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fb532db-0a36-436a-91ac-c7a4079408d0" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_80987f4b-2c1f-4e62-9c15-ac27a0fdcc1a" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.46</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21b7db48-8484-496f-bf49-16e39917f133" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fb225c9e-1279-426d-8a65-0eed7f95e048" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.13</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf95aa3-9ca0-4e14-8073-cdeeb626da74" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4fad5f8d-3f95-4c06-a20c-3022634e894b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.80</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ea323f7-88c3-496f-830d-83b271f3e612" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ad9abca3-91a2-4d3e-8838-7d8c700c3dd0" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a09d95d1-ffd9-49b2-8e98-b83dbf6197ee" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3d17650d-10fd-47e4-a0f3-eb1dd61e3bb0" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,361,771</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c43be36-2a08-49a7-b931-2158764ac752" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3831fd35-0cfc-4840-8c69-63da320f6b33" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">96,827,687</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59c2f059-b42f-4b00-b18a-adba39f86fbb" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fa59b2af-72b3-4d8f-b452-6363a51f6dd3" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,212,035</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cdceb14-c371-4963-b6fc-ccd8215076c0" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7e5c6b0a-2b25-47d7-9d61-12fdb0956b28" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">96,656,690</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fs_sse"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:39.86%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.42%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.960000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in Capital</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss), Net</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556e6449-1a85-4a83-82f8-56863e04ff85" contextRef="C_3f547b95-0c7d-4909-a139-bea14be39173" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">97,954,172</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0448d27d-86c0-4298-9b04-651d0f6b6825" contextRef="C_3f547b95-0c7d-4909-a139-bea14be39173" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac99ebe6-235d-467e-9c4f-430d2d25136c" contextRef="C_f685dc68-99f3-45c7-888f-f64255a00ab0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,873</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274434f9-aa33-495d-9109-5ff141897c3d" contextRef="C_5a15e9e6-1bc3-4167-8e8e-c79dcf3954c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc3f7181-d019-4bd5-92b0-a1fe2b541cc1" contextRef="C_c38ed128-079d-4241-b04b-554e67e4475f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123,305</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_493ef0f0-3000-4436-8fd0-4467a78e4b09" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,798</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options and release of restricted stock units</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcf34cf7-de05-4d1d-9fc0-9e8f66c0478b" contextRef="C_a1b6d996-a8c0-4025-9859-7563f538ccfb" name="spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">175,632</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b73562-a16c-498b-ac22-bc2468c0c17c" contextRef="C_1c56c487-e024-4724-81ae-947caaa88834" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">725</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae746763-0918-4681-ba9a-2ea967753ddc" contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">725</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f8d1bff-6b78-4963-9314-62b55611ab2d" contextRef="C_1c56c487-e024-4724-81ae-947caaa88834" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,539</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10ded9c2-64a6-40e6-b9fa-1a28a7bb273b" contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,539</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2570a442-7e75-4cb9-ace4-621e50e2c24b" contextRef="C_d04fa5cc-8928-4685-ad0a-fe068b728fac" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75516c4c-6146-4535-b06e-138315c3d65a" contextRef="C_cc8627a9-0c70-4d03-b571-48b53e518a3e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,940</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006bdf4c-1a36-4146-bbd0-93caf71f16a1" contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,088</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b86abe5b-00af-47f9-87fa-5f711dbdd55c" contextRef="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,129,804</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5aa59d8-d47d-4ba4-b764-21ce0464b671" contextRef="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b56b860-8908-4acb-a7ed-65db9c7b1806" contextRef="C_0fc3a621-041e-400f-9a4b-601457b85fd3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386,137</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b20b52f1-4d1f-4542-aad3-b5cb69d8b1ae" contextRef="C_b9e6449d-ad47-43a6-9843-3ac845071d45" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700490fa-096f-419a-9f88-c1a04f3ec230" contextRef="C_71398ff7-c6c1-4c72-ad74-10d8e3e3bf31" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">157,245</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b25a917-ed17-4535-be41-3f5acca2bf78" contextRef="C_4fc5fa74-f0e8-45a7-8703-dc0cc39277c4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228,974</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options and issuance of common stock under the employee stock purchase plan</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63ab889f-8bba-4f14-a749-3c19322907d2" contextRef="C_6c6d2854-3599-431a-a593-98e4379c15e6" name="spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">567,854</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3713e92-6a3c-4056-ad31-22cd349d62fe" contextRef="C_bf5281ce-db7a-495f-ab02-93574c48462a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,697</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b45c7aa-88e0-4f3e-befa-05fcd235db72" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,697</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9c25701-f5a9-4774-ab92-802a8936625f" contextRef="C_bf5281ce-db7a-495f-ab02-93574c48462a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,651</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908c601f-c499-40a9-9a80-e7620bc1fcfa" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,651</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd87c66-3c95-42f9-97a7-aa5a5261e46b" contextRef="C_6b05c4b6-d7fb-473f-ab92-1227f461cbd1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9312463e-38db-4f5c-ac48-2fab9670a0a8" contextRef="C_72c960a2-6882-42be-9586-209e84ad98f1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,883</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50ee9da-5b60-40e9-8637-99c169b9fe64" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,001</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d12d911a-4be4-43eb-8419-0f5a9e537fae" contextRef="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,697,658</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9c5cfc9-7ef7-4482-abf6-2c26239a8d41" contextRef="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edd5dc1d-0207-4b52-b859-86a3c4269fa1" contextRef="C_9926d4b4-fa02-421b-8525-65d964045c82" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,485</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d26a2a0-a875-4e99-a26b-545595da1eba" contextRef="C_df4a29c9-2002-49c3-bbf7-c84fa9b0edbb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fd93687-c627-46a8-875c-0972bbfb30d8" contextRef="C_ca70d85e-c0cc-4722-8d9c-3028532be956" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">202,128</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0638ce1f-ac37-4452-a724-d895d49bc715" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,321</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:39.86%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.42%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.9399999999999995%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.960000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in Capital</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss), Net</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9718a38a-389b-4d7b-9773-a367a4897175" contextRef="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,414,963</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ded89d74-89db-48ce-89e7-f76e21e36f89" contextRef="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80387429-a18c-4a13-8904-f06530a0fafe" contextRef="C_7d4c367f-9884-46d1-8862-8e2ef2c52541" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,004</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69057f78-454c-4783-9cc9-c2127aaba2c5" contextRef="C_e8814f36-7086-44f4-9a53-259022c64732" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e040b05a-8c0e-45cc-91f9-8699ac61e483" contextRef="C_b1018c50-39c0-4a1e-a69c-876377e82ea5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,303</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43866600-4223-4731-91a8-79fe3ed078fc" contextRef="C_3571bb42-9451-44e2-9e1c-0598970a2964" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,760</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options and release of restricted stock units</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_766fb98b-8738-4db9-80ab-57d7e621d857" contextRef="C_374c6b30-c221-46de-a6b2-30e2bb48619d" name="spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">159,086</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a307e75-c311-4506-8584-21793b629e02" contextRef="C_060127b3-af69-4d7f-a100-67b6e7eb8bca" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4950d941-e1b7-4a06-9665-154a5a183cf9" contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e99f2f-fb0b-40e0-81fd-d8c6a3008ba3" contextRef="C_060127b3-af69-4d7f-a100-67b6e7eb8bca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,315</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_625f6c0b-ad07-41fd-af23-901b8bb0a723" contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,315</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211e897e-350d-4e97-bf55-44f04605f3c0" contextRef="C_c263fc35-be1c-4365-9aa0-2c5ad53934fd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">173</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02a799e0-8748-422a-846a-4e861d20c45b" contextRef="C_f3358bc3-9806-4dc0-ae94-6af64c1d3c84" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,292</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25d66cde-fdf3-4963-9748-5314dc0f1596" contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,465</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbbccb0d-1add-44cd-8f89-964a40acd972" contextRef="C_5c380126-d22f-440a-80fa-e358a5a088b2" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,574,049</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d8182a4-e318-4680-93cf-dec46ee74ae0" contextRef="C_5c380126-d22f-440a-80fa-e358a5a088b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac467b50-b2ac-4d5a-a682-33fd6ded2ee2" contextRef="C_bd86d1ef-eeff-4adf-8a19-f69f6a8e45f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,577</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2498e404-e8a2-4748-93b1-854765625dd7" contextRef="C_dcdc4492-adbe-44e9-8b69-d68a7d4bae66" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8849c4be-3de0-4b0f-a281-4822b1a4a3ba" contextRef="C_cfed3148-1f6d-4764-881f-dc1ce6517210" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,595</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5ea83f7-b53e-4839-972f-628de5c7aafd" contextRef="C_490ab03b-38cf-4134-9ab1-2f6b7f250c1e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,868</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e95efca-de09-477d-b350-815e37c54a1e" contextRef="C_51ba7095-5039-485e-900a-2f239350359c" name="spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">365,748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1bb7d68-483b-48f6-b558-99eb6abdaa99" contextRef="C_efde3903-153e-4b55-ad5d-f7a9987f9a59" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">545</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb4e13db-0f6c-4495-8bd2-a37cea57b1d4" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">545</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a222ae2-d660-4614-b1b8-44a26289af63" contextRef="C_efde3903-153e-4b55-ad5d-f7a9987f9a59" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35f21e8d-cafe-4fb7-8e71-54dde6d292ae" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b09703dd-9b70-47c6-9e98-f88ef4f79906" contextRef="C_09f9802b-bfdd-4db9-acd2-6c382a188d1e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a72e06c5-af0a-4c5b-877e-15e27d990e49" contextRef="C_707ffda4-d1e9-4317-b368-b5b461d89663" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,516</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac608a8d-d98f-4d8d-b842-dc1b5c64a329" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,537</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9f1cf0a-9b99-487d-901d-a47a379c9bc3" contextRef="C_b963ff18-7450-4060-ad3c-efc70564a546" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,939,797</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ef7c79e-e837-4336-bb4b-3da6b7e18618" contextRef="C_b963ff18-7450-4060-ad3c-efc70564a546" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30ccf8f2-69a7-4acf-95b4-19ec8beca29c" contextRef="C_9409939c-9f3f-4a0a-9fa8-269dcaf95cb6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369,487</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68475ac-6c0b-4475-a7fc-e7b86c58ea87" contextRef="C_43967981-d479-4db2-8fce-ee96cfa44034" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1819fc5-dcbf-4f60-bcfa-c2456e6664b9" contextRef="C_704928fd-7ecc-4aeb-aad1-e86385ad44c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">154,111</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7641e822-b380-4b02-94f5-705a5b0d12d6" contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,241</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:11in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fs_socf"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:69.434%;box-sizing:content-box;"/>
      <td style="width:1.5%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11.782%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.5%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11.782%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d34aadf-7848-4635-8817-e7ac41a3b94d" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,823</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74dfca08-945d-4199-aff2-b76e371d3cea" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,808</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f635ad57-30d6-41c5-bff7-539f71f4cfc9" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,669</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1faf0b2a-e512-4bde-a0f9-0fca19a28b86" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,680</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_076270de-3fae-4e0c-81f1-4831f1a6480b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">559</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4641e531-d8d8-418e-8d9a-de0201804593" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion on investments, net of amortization</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8696176-021e-4103-8483-2cfda1e60950" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,428</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c84947-3dd0-46c6-b665-6739ab1f87a2" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,884</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for inventory reserve</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b020fb8d-6190-4bf7-93aa-30b3cd17fc8d" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,160</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9990977c-3e67-446c-bed5-c3412d8a4ed3" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0f28214-0165-4c10-994f-abf98df382e7" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,375</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7feaa0c7-79ef-4a8e-822d-b591dd4fa70e" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_175ae11c-8b44-417a-b5f5-9242af9c60e1" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,232</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02ed5771-7dba-4721-8379-9625a9d60077" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_523b78f6-92d4-44aa-98ee-b6bb9708e635" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">697</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d653d4-61eb-4177-9543-fcdbc68bf566" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,564</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donation of equipment</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c340a2-acd6-4e16-a868-5db0b0c16bc8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:IncreaseDecreaseInDonationOfEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a67833d1-0a52-4656-b63e-92e5cd407570" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="spry:IncreaseDecreaseInDonationOfEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97039375-082f-411d-a2e2-215df0d5aa81" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,981</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d88cc909-317c-4a0d-aaf0-f284887bffbd" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,410</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset and lease liability, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63976016-538c-441b-98f8-dfe9a24facb0" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:OperatingRightOfUseAssetsAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55cbfa7-9e90-4ff1-ac5e-ffec72297263" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="spry:OperatingRightOfUseAssetsAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liability</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35bc1872-4054-4695-a5ec-c5a9e6c56880" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce6b1378-b1cb-4727-b340-6dfc4021d978" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents used in operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0bf602c-bbbb-4cec-a93a-df9f9d42ab98" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,334</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4237fca8-24a8-47bc-9325-01d6d65d0324" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,989</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of short-term investments, available-for-sale</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8036098-7023-45c4-89be-96d98d01b566" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,723</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_570e8b52-2e2e-468a-ac41-68b1e6127b62" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,038</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of short-term investments, available-for-sale</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79aebf01-8005-4419-bb7b-474bccb9f6e7" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af91feab-2e16-465e-a577-8dddb4e37c19" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,000</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f77dee2-bf60-4ddc-93c3-502a3bdaa5af" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6264e468-e0cb-4c98-8b90-a347adbca1b2" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents provided by (used in) investing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2596cf38-155f-411c-aabc-814da9d17662" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,635</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ad15f8-ef79-42b1-8995-2a9efd292683" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,159</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2264a341-96d7-4c29-b915-960e9ac70b94" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d0b54ef-8bdf-44ef-8f69-358c524a098f" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">803</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents provided by financing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55bab86f-f574-486c-814a-d4add87db736" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_404f6e12-4447-4df9-8700-5fbe3c578e2e" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">803</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78cc131a-519f-4b20-9e5a-ba95ef17a8f8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9fbf403-cdbb-4326-ae8e-e18b6524f713" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,345</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294fe00e-67bd-4fd1-b0e4-6bdb121d233e" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,817</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4592d43b-1e87-424b-9a87-1476cb922b2d" contextRef="C_3571bb42-9451-44e2-9e1c-0598970a2964" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,971</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f66cd343-471f-4207-81bf-e6f7010701cc" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,540</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5202cab0-285a-4531-a7bd-97dbadb571e0" contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,626</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets included in accounts payable and accrued liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_177aaeaa-659b-40e6-81a9-6643d7a7c688" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab55ba1a-b947-4c6b-b4c4-b806d37c3154" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing liability included in accounts receivable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e1ef613-9edc-403c-93bb-0ea4d2d5c4bb" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:FinancingLiabilityIncludedInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,576</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5820ff2-fce0-4971-a869-3f2ab0949806" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="spry:FinancingLiabilityIncludedInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset obtained in exchange for operating lease obligations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abc7c796-7497-41d3-81fb-922fa2a48a39" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_459172eb-3208-471b-94d4-768a82476d7d" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fs_notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fceb9b3-ae1e-4b53-a74e-b34893b1fc79" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc. (&#8220;ARS&#8221;, &#8220;ARS Pharma&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the commercialization and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (currently identified in the EU by the trade name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the first and only FDA and European Commission-approved needle-free epinephrine product, and the first new delivery method for epinephrine in more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9a0adf6-8acc-4814-b73e-ad0134674320" contextRef="C_b8271b46-8d08-46dd-ad0b-ac8a80d68454" name="spry:PeriodForFirstNewDeliveryMethodOfEpinephrine" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incorporated in Delaware in January 2016 and is located in San Diego, California. The Company has a wholly owned subsidiary, ARS Pharmaceuticals Operations, Inc., incorporated in Delaware in August 2015, through which it conducts substantially all its operations. ARS Pharmaceuticals Operations, Inc. has a wholly owned subsidiary in Ireland, ARS Pharmaceuticals IRL, Limited, to facilitate the filing of regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in European countries.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses in most years since its inception and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d28211-fc8c-4051-9f01-1aff22acb697" contextRef="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">202.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. The Company had cash, cash equivalents, and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8134b28-ea24-4797-a2a9-7d350bcc0366" contextRef="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">240.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and has not generated positive cash flows from operations in most years. To date, the Company has funded its operations primarily with proceeds from the merger with Silverback in November 2022 (the &#8220;Merger&#8221;), private placement of convertible preferred stock, issuance of common stock, licensing, supply and distribution agreements, bank debt, and net product sales. The Company&#8217;s currently available cash, cash equivalents, and short-term investments as of June 30, 2025 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date these financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From August 5, 2015 (inception) through June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has devoted substantially all of its efforts to developing intellectual property, conducting product development and clinical trials, organizing and staffing the Company, business planning, raising capital, building infrastructure, pre-commercial and commercial activities, and providing general and administrative support for these operations. The Company has a limited operating history, and the sales and income potential of the Company&#8217;s business and market are unproven. Management expects operating expenses to increase for the foreseeable future, and there can be no assurance that the Company will achieve profitability in the future, or if achieved, that it will be sustained on a continuing basis.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9e006611-d697-4014-b43c-33020c34d997" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_ssap"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div><ix:nonNumeric id="F_9a78dd46-7507-4e36-b9fe-8aabe141d463" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_9a78dd46-7507-4e36-b9fe-8aabe141d463_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s financial statements are presented on a condensed consolidated basis, which include the accounts of ARS Pharmaceuticals, Inc., ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#8217;s functional and reporting currency is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income in the condensed consolidated statements of operations and comprehensive loss. All adjustments considered necessary for a fair presentation have been included.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_1" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9a78dd46-7507-4e36-b9fe-8aabe141d463_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, the condensed consolidated statements of stockholders&#8217; equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, are unaudited. The balance sheet as of December 31, 2024 was derived from the audited financial statements as of and for the year ended December 31, 2024. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of June 30, 2025, the condensed consolidated results of its operations for the three and six months ended June 30, 2025 and 2024, and its cash flows for the six months ended June 30, 2025 and 2024. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2025 and 2024 are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other period.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e501b86a-2ca9-42f9-947b-100b193722eb" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed consolidated financial statements are revenue recognized under collaboration agreements, accruals for variable components of product revenue, accruals for research and development expenses, and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e3af28f-e6b4-42f1-94c2-f2b16f353cc2" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash readily available in checking, money market mutual funds, and short-term investments with remaining maturities when purchased of 90 days or less. The Company considers all highly liquid investments with remaining maturities when purchased of 90 days or less to be cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1439fab-9e00-4ffb-b644-85b5aff75837" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable and Allowance for Credit Losses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable includes trade accounts receivable from product sales to customers, partner receivables for reimbursable research and development costs, royalties, license fees, and milestone payments under the Company&#8217;s collaboration agreements, and partner receivables for supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the Company&#8217;s supply agreements. Trade accounts receivable are recorded at wholesale acquisition cost (&#8220;WAC&#8221;), less purchase price discounts, prompt pay discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company&#8217;s estimate of losses over the life of the receivables. The Company determines the allowance for credit losses for accounts receivable based on each customer&#8217;s or partner&#8217;s accounts receivable balance and age, their financial condition, and the general economic environment. The Company must also use professional judgment for its allowance for credit losses on trade accounts receivable as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was commercially launched in September 2024 and historical data is limited. The Company is currently operating under the Title Agreement (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with its Title Agent (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the Title Agent retains all credit and collection risk on product sales to the Company&#8217;s wholesale distributors and pharmacy customers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f567c8df-c275-4a77-8236-94c15b0eeb5a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_823e69f4-3caa-4a5c-ae18-07ec9730d30c" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was deemed necessary at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 or December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_2" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_452d9c37-0e06-4814-b217-6b2bf7f61534" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests excess cash in investment grade fixed income securities. These investments are included in short-term investments on the condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss) gain, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Realized gains and losses on the sale of securities are recognized in net loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0652903-2825-47e0-bc2a-cd84935368cd" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and short-term investments are carried at fair value. The carrying amounts of all accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, and contract liability are considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ed77a5a-3e7c-4191-9124-edcbe339e81a" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its financial instruments portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also subject to credit risk related to its accounts receivable from product sales and revenue under collaboration and supply agreements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is distributed primarily through wholesale distributors and pharmacies. These entities are not obligated to purchase any set number of units and they distribute </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on demand as orders are received. The Company enters into collaboration and supply agreements with pharmaceutical companies under which the Company is entitled to receive payments for royalties, license fees, milestone achievements, reimbursable costs for research and development services, and supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company extends credit to its customers and partners in the normal course of business after evaluating their overall financial condition. As stated above, the Company is currently operating under the Title Agreement with its Title Agent and the Title Agent retains all credit and collection risk on sales to the Company&#8217;s wholesale distributors and pharmacy customers. The Company&#8217;s Title Agent accounts for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5c35c4b-d3fd-4e2b-a05d-53b4f0b06997" contextRef="C_f340b5d5-a46d-487a-bb76-a006e0f3faee" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c382b4-c0aa-4e8d-a932-448369a18cbe" contextRef="C_dad879fd-9fd0-4630-936d-24ba4a2d140a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s accounts receivable balance as of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. One additional customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee85f94f-dd19-477b-9796-b3dca9523d93" contextRef="C_76f794c5-9e6a-42a7-b227-1abf0ce9a252" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of accounts receivable as of June 30, 2025. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, four and six customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e99ea4ea-a1aa-43ea-924c-d158ee83663c" contextRef="C_8dd7ea83-dd18-4eb9-9282-167ae56ead5d" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fd14c282-239e-4e08-b3b9-b4d0a5dd222b" contextRef="C_f9b7e8e0-49aa-425f-b6ac-7a1e94633629" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5b0cad06-450b-4880-b8c0-77d475efdebf" contextRef="C_ae56245d-14e4-4425-a73a-af69dd8543a2" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_32f5d02c-4c72-4d0d-bc03-7aca3c05f393" contextRef="C_2534ad0d-4f31-47a1-99a9-04102ea40a7b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">82</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e976b586-a9fa-449b-b4c6-504d06819ca4" contextRef="C_5d3ab776-018e-4dde-8537-5db78360a3b6" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9422260f-2739-4058-b1d5-54d3660626e1" contextRef="C_b5cccac4-7ff4-4dd5-9952-e4d8fb70e5e9" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6eb62f63-3188-4403-ab84-84f5d9525e76" contextRef="C_c7e544c9-751c-4210-b224-6b0035e4618e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_38534594-8003-4475-a0e2-ead34bfd6a28" contextRef="C_c59d3a87-64b2-48e5-b806-8ca9b8489a28" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c8c81a47-5e5a-41c1-9f99-4714884a5c66" contextRef="C_e6beb23c-440b-4e94-b575-d556e723f9a2" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_33844e9f-19b8-4b7c-9f4d-2468cbb93d7d" contextRef="C_147fd450-9410-4b8e-a22c-51b186dd1d12" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">96</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, with each individual customer ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b80eac6-37d6-485e-a16b-67ba3c430b7c" contextRef="C_a16758cc-95a6-438f-b28f-9eb55360c257" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b87aa97-1146-43f9-bf48-e62035d34d6b" contextRef="C_91a3dda9-27ba-40ae-acc1-7312fbbb4c65" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fb7e07f4-6cfb-405f-a216-0778e4f846e8" contextRef="C_ac30d314-86f3-4148-b29a-7d12452b392a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6aa679e8-18cc-40de-961d-a401b8c24eaa" contextRef="C_49c47b49-d4ac-4136-84a2-4bc4a2103d17" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90725aa6-3d6f-443b-a11c-b32e68f1eac2" contextRef="C_486e30e1-067a-4d74-b32c-7b5cd57c48a6" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b11e49bb-12e7-4ec6-9ed4-40012ff2dd16" contextRef="C_12bac910-38cc-4107-8957-20fd4415cbd0" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7520f997-b34b-4e16-9ff5-38ed8d41cdd5" contextRef="C_d0bb372c-0ecd-453e-b973-012e84044734" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b832164f-00af-44f5-adb3-8ed6615a442a" contextRef="C_eae13608-8a7d-49cd-b8b1-4837d9244b48" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5fe81c-b295-4fcf-a089-852c579d759c" contextRef="C_3c5642d7-6f8a-4a44-acf5-5d6d63e1e69e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_20a5671d-b2da-410d-baff-ed988cec0122" contextRef="C_8bf5456c-aadb-4e60-b041-d6db39979b70" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0e77d18a-963b-4dd5-8c79-c499ae347925" contextRef="C_470f916f-7869-4e25-8dd3-760ff2bc2856" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_24387df7-bc57-4174-8496-9cf491a93f18" contextRef="C_47e7fcde-f00c-42a6-a53e-32799f721460" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e0ad0975-2cb5-43b0-9212-581e92b8bfaf" contextRef="C_2196e376-19a2-4b1d-bec7-939794646f60" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_35f12412-a27e-475e-80ea-fecbade9323e" contextRef="C_3384a69b-8620-4b79-a234-cd7344debc19" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e38c1e-bfb9-4905-889e-4947a75a85e8" contextRef="C_8e9dbd5e-9d63-4ed5-9644-7a43dd445156" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b48092df-045a-4ec1-9fab-c6250457e971" contextRef="C_5d09679a-e12c-4e0f-932f-d6350e656399" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a4cafdec-6a9a-414e-9ae2-2bd2d6b32e43" contextRef="C_bbfe4e30-cf8e-45b4-9694-9eb0e8f2297b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca924d42-96a3-4491-bacd-e3d7a89b90f5" contextRef="C_72dc1e89-7658-40c1-8ca3-952db65ab782" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_59ab10ef-06a9-4319-a7fa-bb6b8b589d1c" contextRef="C_758bf922-ece9-4a0b-b463-8ee0919f4a31" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8ca7a594-1415-40b1-8821-5b8cf5df6bdb" contextRef="C_b05d88b5-cf1f-422b-b672-31550bb59ffd" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, respectively. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025, one customer accounted for all revenue under collaboration agreements and supply agreements. For the three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, one customer accounted for all revenue under collaboration agreements, and there was no product sales or revenue under supply agreements. Historically, the Company has not experienced any credit losses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7d3f55d-c0fa-4205-8764-124ee40259e8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process, and include labor and overhead. Inventories are stated at the lower of cost or net realizable value, and are determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered. Such impairment charges, if any, are recorded in cost of goods sold on the condensed consolidated statements of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes inventory costs after regulatory approval, when future commercialization is considered probable, and a future economic benefit is expected to be realized. Prior to regulatory approval, the Company records inventory costs as research and development expenses. As such, when regulatory approval is received, this may result in zero-cost inventory which does not have a carrying value. This inventory is available to the Company to utilize for commercial operations as well as ongoing research and development activities.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_3" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59b28ef8-97e1-405b-8bd0-0a92a99bf764" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally five years. Repair and maintenance costs are charged to expense as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09882667-e449-4288-b042-a668f25a48d6" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate, including its eventual residual value. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. The Company has not recognized any impairment losses from inception through June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d6b957-7c56-421f-b382-3f9577dc7a9e" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the initial classification and measurement of its right-of-use (&#8220;ROU&#8221;) asset and lease liabilities at the lease commencement date and thereafter, if modified. The Company recognizes a ROU asset for its operating leases with lease terms greater than 12 months. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The lease liability is calculated by using the present value of all lease payments, with the present value determined by using the incremental borrowing rate for operating leases determined by using the incremental borrowing rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment as well as a review of peer companies. Variable charges for common area maintenance and other variable costs are recognized as expense as incurred. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c1c88e7-0328-47d1-bb47-4648892fd168" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true" continuedAt="F_7c1c88e7-0328-47d1-bb47-4648892fd168_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_7c1c88e7-0328-47d1-bb47-4648892fd168_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e17711ab-6368-4772-94b0-80e0c7b58342" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues consist of product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and revenue derived from its collaboration, out-licensing, and supply agreements. See </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on product revenue, and </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on revenue from collaboration agreements, out-licensing agreements, and supply agreements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). The provisions of ASC 606 require the following steps to determine revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, determines whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_4" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b604bd9-a1a6-472e-8555-12c2bfa57c9e" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true" continuedAt="F_2b604bd9-a1a6-472e-8555-12c2bfa57c9e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2b604bd9-a1a6-472e-8555-12c2bfa57c9e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold primarily consists of direct and indirect costs related to the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, supply agreement fees, and royalties on product sales. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, costs incurred for the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initially reflects a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d441152c-c69f-4da7-ab32-8cb5bbc46588" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, external research and development costs incurred under agreements with contract research organizations, investigative sites and consultants to conduct clinical studies, costs related to compliance with regulatory requirements, costs related to manufacturing the Company&#8217;s product candidates (including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prior to FDA approval in August 2024) for clinical trials, and other allocated expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for research and development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company uses judgments and estimates to determine the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee60ff92-d0d4-4394-8cef-c6b4cd2f2267" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true" continuedAt="F_ee60ff92-d0d4-4394-8cef-c6b4cd2f2267_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Costs</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ee60ff92-d0d4-4394-8cef-c6b4cd2f2267_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative costs are expensed in the period incurred. Selling, general and administrative costs primarily consist of marketing-related expenses, salaries and related expenses for personnel, including meals and travel-related expenses incurred by the sales team, stock-based compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax, and other consulting services, and insurance costs.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e195c082-bc0a-4b9a-9863-9296a6864c13" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for producing advertising are expensed when incurred. Costs for communicating advertising, such as search engine marketing, banner advertisements, social media advertisements, and print advertisements, are recorded as prepaid expenses and then expensed when the advertisement occurs. For the three and six months ended June 30, 2025, advertising costs were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f15ebee-ca47-4ff4-93e2-289a6828401e" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e369646e-7c3f-4128-9050-159fa617ac17" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863fb5da-eb22-4c6c-a29f-38e4609a2f86" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:AdvertisingExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_224cc319-0255-46a0-8640-88744bc67ae1" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:AdvertisingExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advertising costs were incurred for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f0075e1-3c02-4291-a813-409c7c2d1781" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:PatentsCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8b56833-4be6-4c87-8981-33a7e6744102" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:LicenseFeesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Fees</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred to acquire technology licenses and milestone payments made on existing agreements are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_5" continuedAt="F_9e006611-d697-4014-b43c-33020c34d997_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d649d82a-6800-4a96-8a32-60aebe1bee72" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes expense for awards subject to performance-based milestones over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and recognizes forfeitures as they occur. In the event that stock-based awards are granted in contemplation of or shortly before a planned release of material non-public information, and such information is expected to result in a material increase in the share price of the Company&#8217;s common stock, the Company may consider whether an adjustment to the observable market price is required when estimating the grant date fair value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df3ae300-b895-4605-af26-aef4745b00dd" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss typically consists of the change in unrealized gains and losses on available-for-sale securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6c96b38-17f5-4fed-8b62-9fbba01a0416" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_e6c96b38-17f5-4fed-8b62-9fbba01a0416_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e6c96b38-17f5-4fed-8b62-9fbba01a0416_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95201d32-412d-4b6a-9783-a47ec5d6d1e8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_eaf4cf64-7856-4047-a356-c7e4bd0a28fe" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, stock options, warrants, and unvested restricted stock units, are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3abcc79d-34e7-475a-a88d-509609608955" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_3abcc79d-34e7-475a-a88d-509609608955_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:66.967%;box-sizing:content-box;"/>
            <td style="width:1.16%;box-sizing:content-box;"/>
            <td style="width:1%;box-sizing:content-box;"/>
            <td style="width:13.357%;box-sizing:content-box;"/>
            <td style="width:1%;box-sizing:content-box;"/>
            <td style="width:1.16%;box-sizing:content-box;"/>
            <td style="width:1%;box-sizing:content-box;"/>
            <td style="width:13.357%;box-sizing:content-box;"/>
            <td style="width:1%;box-sizing:content-box;"/>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of June 30,</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2894a0d8-585a-411d-bb19-eecd01169766" contextRef="C_c7d4f909-e24a-452d-82cf-9bb2659ab99f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,456</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_128c84d2-f8bd-4787-abd7-79f1c6c8f9ee" contextRef="C_9ab27dfe-3c05-41c3-886f-a2b0e4136b85" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,456</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f61962f1-8ddc-45ef-ae8b-f663bd16d9cd" contextRef="C_3b8087a0-6412-4ff5-90a6-c0f272af562e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,271,990</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_924e92e9-ddb4-4e66-be4f-0011d35ab288" contextRef="C_f686fc0b-340d-4ecf-a20d-89f3341462b6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,436,432</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f54edde6-3983-43fc-9009-090fe130a214" contextRef="C_dcce5799-5869-4e9b-9399-9d7c6125048f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,382</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90f78ff5-e4f2-4cbb-bbf0-880d2b8ff74b" contextRef="C_af689524-2c04-42d2-a16f-31b2d40284b6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_870302c2-624d-42de-8e50-5e3b75538372" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,318,828</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccb39a9b-e046-486d-bbff-bb40a96b4917" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,484,651</ix:nonFraction></span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
          </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_3abcc79d-34e7-475a-a88d-509609608955_1"></ix:continuation></div><div><ix:nonNumeric id="F_96a39e89-33e3-46b9-a7c4-cf3cfa4a9d60" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_96a39e89-33e3-46b9-a7c4-cf3cfa4a9d60_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280)&#8211;Improvements to Reportable Segment Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-07&#8221;), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 was effective for the Company on January 1, 2024 for annual periods and on January 1, 2025 for interim periods. The adoption of ASU 2023-07 resulted in enhanced disclosures as included in </span><a href="#fn_segments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 15 &#8211; Segment Information</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and did not impact the Company&#8217;s condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8212; Not Yet Adopted</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards, other than those noted below, and any issued but not yet effective standards will not have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_9e006611-d697-4014-b43c-33020c34d997_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_96a39e89-33e3-46b9-a7c4-cf3cfa4a9d60_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Income Taxes (Topic 740)&#8211;Improvements to Income Tax Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-09&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The amendments in this update are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company does not expect to early adopt the new standard. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2023-09 on the financial statements and related disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2024-03&#8221;). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the income statement within continuing operations of public business entities. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact of adoption of this ASU on the Company&#8217;s disclosures is currently being evaluated.</span></p></ix:continuation></div></ix:continuation></div><div><ix:nonNumeric id="F_d79c6628-446f-4476-9d2a-534cd9f8a47f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_d79c6628-446f-4476-9d2a-534cd9f8a47f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_revenue"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Revenue</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues consist primarily of product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue derived from its collaboration and out-licensing agreements, and revenue from its supply agreements. See </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for further discussion related to revenue from collaboration, out-licensing, and supply agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was approved by the FDA in August 2024, and the Company began generating product revenue from sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024. The Company uses a third-party logistics provider (&#8220;3PL Agent&#8221;) to fulfill orders of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Company&#8217;s customers. The 3PL Agent provides services to the Company that include warehousing, distribution, order and accounts receivable management, and data management.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a title model agreement (&#8220;Title Agreement&#8221;) with an affiliate of the 3PL Agent (the &#8220;Title Agent&#8221;) so that the Title Agent may purchase and take title to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and then sell it to the Company&#8217;s wholesale distributors and pharmacy customers that have contracted to make a purchase. Under the Title Agreement, the economic substance of the transaction is such that the Company does not recognize revenue until </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is sold and title has transferred from the Title Agent to a wholesale distributor or pharmacy.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into sales agreements with pharmacies that are not subject to the Title Agreement. Under these agreements, the pharmacy holds </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under consignment. Under the consignment model, the Company recognizes revenue when </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is sold to a patient, at which point title transfers from the Company directly to the patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product revenue is recorded with each sale at the transaction price, net of reserves for variable components, including but not limited to distribution service fees, prompt pay discounts, product returns, chargebacks, rebates, and co-payment assistance, which are collectively referred to as &#8220;Gross-to-Net Adjustments.&#8221; Estimates for Gross-to-Net Adjustments are reassessed each reporting period, and adjustments are recorded on a cumulative catch-up basis, which would affect product revenue and net loss in the period of adjustment. Trade accounts receivable due to the Company from contracts with its customers are stated in the condensed consolidated balance sheet, net of various allowances as described in the Accounts Receivable and Allowance for Credit Losses policy in </span><a href="#fn_ssap"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components. Variable consideration is included in the transaction price only to the extent it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d79c6628-446f-4476-9d2a-534cd9f8a47f_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain Gross-to-Net Adjustments. The specific considerations that the Company uses in estimating the amounts related to Gross-to-Net Adjustments are as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distribution Service Fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchased amount. These fees are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial Pharmacy Discounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides discounts to its pharmacy customers. These discounts are a contractually fixed percentage of WAC and are a direct reduction from the WAC price they are charged. They are calculated at the time of sale based on the purchased amount. These discounts are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prompt Pay Discounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company incentivizes on time invoice payments through prompt pay discounts. Prompt pay discounts are typically taken by customers, so an estimate of the discount is recorded at the time of sale based on the purchased amount. Prompt pay discount estimates are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chargebacks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain government entities and covered entities (e.g. Veterans Administration, 340B covered entities) can purchase the product at a price discounted below WAC. The difference between the government or covered entity purchase price and WAC will be charged back to the Company. The Company estimates the amount of chargebacks based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rebates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides commercial rebates to pharmacy benefit managers and managed care organizations and is subject to mandatory discount obligations under the Medicare, Medicaid, and Tricare programs. The rebate amounts for these programs are determined by contractual arrangements or statutory requirements. Rebates are owed after the product has been dispensed to a patient and the Company has been invoiced. The Company estimates the amount in rebates based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-payment Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company offers co-payment assistance programs to commercially insured patients whose insurance requires a co-payment to be made when filling their prescription. The Company estimates the amount of co-payment assistance based on the expected volume and the average buy down rate associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment programs estimates are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Returns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Customers have the right to return damaged product, product that is within six months or less of the labeled expiration date, or product that is past the expiration date by no more than twelve months. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was commercially launched in September 2024 and due to the lack of historical sales and returns data, the Company used professional judgment and industry data to estimate returns. As time passes and historical data becomes available, the Company will use historical sales and returns data to estimate future product returns. A r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserve for potential product returns is recorded as other current liabilities on the condensed consolidated balance sheets.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_398b6d63-a0a0-4cb8-8b17-0dc7e870d985" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:InventoryDisclosureTextBlock" escape="true" continuedAt="F_398b6d63-a0a0-4cb8-8b17-0dc7e870d985_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_inventories"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Inventories</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company began to capitalize the inventory costs associated with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon FDA approval in August 2024 when future commercialization was considered probable, and it was determined that the inventory had a probable future economic benefit. These inventory costs consist primarily of purchased materials, third-party manufacturing costs, and packaging and serialization services. Noncurrent inventory consists of inventory anticipated to remain on hand for more than one year from the balance sheet date.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_398b6d63-a0a0-4cb8-8b17-0dc7e870d985_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d53e583-7627-46aa-a5f5-96351ca43a0b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:ScheduleOfInventoryTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized inventories consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cafea093-0519-425b-9019-a68165266383" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,784</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d494cf-f9ba-443a-a8db-a450bbbf6b0a" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,674</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in process</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2675c25a-cbed-4803-944c-5471cf29965e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75be4421-5058-41e6-88f1-5396e4233541" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_929de8bb-614c-4b85-b6fa-d2262a40514e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,488</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_249446dc-3176-4da6-8c2a-ac23af8f1aa7" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,826</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory reserve</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f01d3d-e59c-4a78-9f24-6d3b9200019d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,160</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe227823-e49b-49df-a048-78d992b069b7" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a1dbdc-f1c0-4db6-b1e9-b3749bad81be" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,112</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc7f21a-7689-4bba-9afe-f3412807db53" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,519</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reported as:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6945d913-e88c-4ebe-bd15-71dfd5c4578c" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:InventoryCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,738</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae006e8-3e47-4070-aedb-535e623a7791" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:InventoryCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,212</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72e90930-5d2c-41e7-94a7-56d6ddd6da31" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,374</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efdc31a8-1bfe-4645-b9e5-9aaea345e614" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,307</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd0ff421-3761-4fcc-b23f-74c9d622171c" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,112</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e1a2699-a516-45f7-b052-b955c442ed0d" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,519</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to FDA approval in August 2024, costs incurred for the manufacturing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which upon approval resulted in zero-cost inventory. The Company held </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8672090e-d255-47a3-bbcc-2eb84c44a014" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:ZeroCostInventory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc2d7f9-d7dc-406a-98d4-791d9de200ec" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:ZeroCostInventory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in zero-cost inventory as of June 30, 2025 and December 31, 2024, respe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ctively, none of which was determined to be obsolete as of each period end. The Company expects to fully utilize its zero-cost inventory in future periods.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_21e90473-c6a5-449a-8507-65b82686ea77" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true" continuedAt="F_21e90473-c6a5-449a-8507-65b82686ea77_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_fv_measurements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Fair Value Measurements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11%;box-sizing:content-box;"/>
        <td style="width:3%;box-sizing:content-box;"/>
        <td style="width:86%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unobservable inputs in which little or </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82b75faf-b012-4e1e-b79f-1054885018e1" contextRef="C_dda44404-ce43-4ae0-930d-c039cfc589f0" name="spry:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></p></td>
       </tr>
      </table><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_629ad40a-f151-4d3f-952d-90ddcf636408" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table identifies the Company&#8217;s assets that were measured at fair value on a recurring basis (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.42%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:8.42%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.08%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.960000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.08%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.960000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.08%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.960000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.08%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.960000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efbb2db1-5626-4366-b737-a17c31a48c4b" contextRef="C_de447bf5-c664-451c-be04-6c477bce8fb5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,248</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51cb474e-de7a-48cd-9497-8424e469df2a" contextRef="C_af065405-07da-4d8f-9aad-88eb0dcc47a7" name="spry:CashAndCashEquivalentsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b72f57e-a026-4dd6-903c-2ff444178e2d" contextRef="C_8f694959-366e-4e19-a611-37c4b53e615c" name="spry:CashAndCashEquivalentsGrossUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4861a3fd-b89c-42fd-9206-06fb93f5d666" contextRef="C_de447bf5-c664-451c-be04-6c477bce8fb5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,248</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7e51df-ec2b-488f-96e8-9413b5f50d94" contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bcaa1b4-1ecb-4ce4-898f-aad04a2607b2" contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2" name="spry:CashAndCashEquivalentsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd17bfcc-af7b-458d-bd12-684a1a623e6f" contextRef="C_16dc4749-c6ec-4139-b8ad-4dcea1d2fb78" name="spry:CashAndCashEquivalentsGrossUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2299c92a-7a5b-44eb-b9ad-3b481cab69d7" contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca23a617-c5bc-4cc3-84c5-ebd677d75c63" contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,636</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb78e716-6ce4-4f39-9260-294108d4419b" contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa856c9d-b3de-475c-ac20-3923df3bb0a5" contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6777c266-5223-4b64-add4-13cc3ab8fc49" contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,590</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_622dea28-b039-460b-ad8e-0c828fb21cc2" contextRef="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77" name="spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,884</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d80d4f-53f5-41e1-bf58-642dd5172ce3" contextRef="C_41ef6930-d9f2-4459-a547-37d492c3f1c2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ad6a021-99a3-4207-a51c-0cd05882743f" contextRef="C_41ef6930-d9f2-4459-a547-37d492c3f1c2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bd4a23-702e-4418-a168-4d0c0183d71f" contextRef="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77" name="spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,838</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea3b7ede-8098-47b4-a930-97cc373e8d31" contextRef="C_91159948-e700-40b8-abf5-96f418841f9a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,506</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e5b7c6f-85ec-4707-8e96-6c9f757f2162" contextRef="C_fb686167-75bd-4d07-b3af-efcd511a43d8" name="spry:CashAndCashEquivalentsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6ca374f-dfc6-494f-94f1-4c254cd22f2b" contextRef="C_5a8cb702-3dbe-4910-ae11-39b78feaa28c" name="spry:CashAndCashEquivalentsGrossUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa1deca9-3b74-424d-bdbc-4901598ec6d0" contextRef="C_91159948-e700-40b8-abf5-96f418841f9a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,506</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2746e649-6006-4982-a09d-6bf34833b274" contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,382</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_684e2ee2-46cc-4221-a3a0-9927dda5d874" contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef" name="spry:CashAndCashEquivalentsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9d084b0-8f68-44ac-b497-ee7d1b643753" contextRef="C_90480581-aab4-4026-b4e1-0aeaa37e50ff" name="spry:CashAndCashEquivalentsGrossUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_251ce7ac-2594-45ff-98e7-4e47127fc2e5" contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,387</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cffe487-919d-4a44-82cd-1ffcea6e4337" contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,990</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10744d6-a060-49b3-8c79-e509030df903" contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0af805da-8cc3-4777-b35d-415fcc6a339a" contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b53eee-2f10-4a57-bd1a-2193ad8b0340" contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,205</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5c47043-e8fd-4d93-8347-e39026497d58" contextRef="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5" name="spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,878</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aae00729-7105-4361-973a-56ad3586de0b" contextRef="C_83d2f352-620d-436d-9ef5-e92a513b8f77" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99bec9e2-3b71-457f-be00-b8a3f6cebc13" contextRef="C_83d2f352-620d-436d-9ef5-e92a513b8f77" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab8f4508-01a3-48ab-8dbf-3f39774dde49" contextRef="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5" name="spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,098</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57cdecce-22eb-4b56-88c3-4fcbea6bace9" contextRef="C_072805c1-e17f-45e5-a672-6a75206ddbb8" name="spry:Fairvalueliabilitieslevel2Tolevel1Transfersamount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods present</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed. During the three and six months ended June 30, 2025, the Company purchased </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_423adf0c-912a-4c0a-a829-844176d7c064" contextRef="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0e872d0-6812-40cc-b589-9ace7cde2b28" contextRef="C_1d2c0919-4138-4410-8ede-0f80ab424b2f" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">65.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in short-term investments and there were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce2102cb-9c6b-41dc-bdff-dbc9bd41bbcb" contextRef="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9323b7ca-c516-4157-bb30-37d1572f4eb5" contextRef="C_1d2c0919-4138-4410-8ede-0f80ab424b2f" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in maturities of short-term investments. During the three and six months ended June 30, 2024, the Company purchased </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61158e58-be1f-40d6-8b51-043a650a6b0e" contextRef="C_d9365522-fb46-46b1-bc6e-284e0bac324d" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">87.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4af39e70-ee4b-41f6-82a6-5b5c4ee69173" contextRef="C_95e31fb6-2b47-410f-b070-55db285d63d5" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">151.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in short-term investments and there were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c1a7329-9e9c-4dff-848f-6631546a4105" contextRef="C_d9365522-fb46-46b1-bc6e-284e0bac324d" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21df220c-d618-4eed-a99b-375f90e1cf5a" contextRef="C_95e31fb6-2b47-410f-b070-55db285d63d5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in maturities of short-term investments.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_21e90473-c6a5-449a-8507-65b82686ea77_1" continuedAt="F_21e90473-c6a5-449a-8507-65b82686ea77_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is less than one year from the respective balance sheet date. The Company's money market mutual fund holdings are highly liquid and invest primarily in cash and U.S. Treasury securities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c94f94a-48f1-469d-a239-fb1ed7120278" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce745dbd-9bd2-48df-8e2a-2d7a7b47444d" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net unrealized loss on available-for-sale securities for the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0276b15-2565-43a7-b2cc-bff166e8c881;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immaterial</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e36138ed-8651-419e-9ea7-1dafaf7c978a" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unrealized loss on available-for-sale securities for the three and six months ended June 30, 2024, respectively. Management determined that the gross unrealized losses on the Company&#8217;s available-for-sale securities as of June 30, 2025 were primarily attributable to current economic and market conditions and not credit risk. As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b880d8f4-1326-4eed-a073-7a477886b9d1" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9bf4f453-410c-403a-a617-8b702c9321da" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was recorded. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell any investments prior to recovery of its amortized cost basis, which is expected to be at maturity.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest on the Company's available-for-sale securities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69127b1b-5bf4-4f76-8058-bd3b208c1c62" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and is included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheet.</span></p></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_21e90473-c6a5-449a-8507-65b82686ea77_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35ded23c-7ee7-4fff-99cc-86eb74489f96" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2aa87d44-0f73-4e84-8bb2-abb5d7f107ba" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any liabilities that were measured at fair value on a recurring basis.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_df2e3118-6ac9-471d-b239-2d860db91273" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_bs_details"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Details</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c57609eb-867c-4b3d-a9d3-18e819207f25" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid marketing</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58a3eb52-68ce-4aaa-bfdc-6aa3be1df187" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:PrepaidMarketingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,447</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c98f860b-5814-4e17-bbaa-878ffed05487" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:PrepaidMarketingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,169</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0efad83-c4be-442e-b4f2-4a045831e8f7" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,012</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3da57052-6b35-447d-a31b-19f44a2b07cb" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,261</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d1a3d85-59fa-479b-a29d-ea50f91ae115" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6270ccd-3e2f-485c-964b-cac90ae0b354" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">987</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d1e4225-b206-4aca-bbce-e509d50b3007" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,027</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc89d0b2-e902-4f84-b5cd-8627eb538634" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fa51434-b382-4ff8-b62a-5e6c16a31802" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,442</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b844b4-85c1-474f-8b9a-4823706f4da1" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,886</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_803a1fe9-6215-4347-8b15-cd70728b5ec0" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid supply agreement fee</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95001ded-cfed-4c7a-9c67-b14d4be07480" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:PrepaidSupplyAgreementFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,863</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a99d4c-58e0-496d-a1b0-3f73db730cd7" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:PrepaidSupplyAgreementFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized software implementation costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a7ba691-f63e-4f2e-abb5-5c0b8345fa42" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CapitalizedComputerSoftwareNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91e0f54d-b4a8-4f1d-a029-58abd685df33" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CapitalizedComputerSoftwareNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5098b0bb-e24c-4089-8fe6-3a139fc1ca94" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,051</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1045cc5-01c4-4fb5-8f21-51d1fdc7476d" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,114</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8abd34a2-d5b1-434e-89f8-a13c57dbd4aa" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_8abd34a2-d5b1-434e-89f8-a13c57dbd4aa_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efbf22d4-7fa0-4e8f-bead-e769a73303ee" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,559</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd1c0aa-7990-41c0-89bc-610c0e99c837" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,870</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d0f4b03-d0c9-4724-8357-60eba64002ee" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:AccruedGrossToNetAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,341</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7d04b41-cb85-4347-b4e7-7bb5df98ec87" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:AccruedGrossToNetAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,179</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued marketing related expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76966d8e-bbb7-4021-a19b-ef197b634a94" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccruedMarketingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d55e50c5-854f-4cbb-beff-36965a519547" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccruedMarketingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,855</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_035de0ca-d4f6-4f7f-9423-3b7269579fab" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,306</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_196bc8b6-c848-4077-8996-c35cbafcd529" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,293</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued inventory</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50818bf9-4a82-46d0-beaf-a79e59f081e9" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:AccruedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3f6205a-7770-4951-8dac-f440c171be99" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:AccruedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,255</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ea0b222-76c6-4fc9-baa7-eb0ca146071b" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5418ddd6-e220-4b85-9a26-07c294c44f94" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,389</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccaebbcb-e337-487e-acf3-f4e747ade2f5" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,264</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc510ef-9494-469e-8d7c-e5c770b04911" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,841</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_8abd34a2-d5b1-434e-89f8-a13c57dbd4aa_1"></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_799c8266-91e8-4c67-a406-ae3e8481c934" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="F_799c8266-91e8-4c67-a406-ae3e8481c934_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_intangibleassetsnet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Intangible assets, net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_inlicense_supply"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10 &#8211; In-Licensing and Supply</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Aegis Agreement the Company capitalized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_017081a2-7cc4-49f6-b66e-219e503019c7" contextRef="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment in August 2024 and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41081089-bb88-4049-8e43-2c5c9dc6f7ef" contextRef="C_1168bae1-a4d7-42ba-a4a1-1aaae5e9cecd" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment in September 2024. Capitalized milestone payments are amortized on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c94add7f-169f-4e06-b5c6-59138d773618" contextRef="C_5ed4cad0-90aa-4443-919a-3ab354fd0721" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Recordati Termination Agreement the Company capitalized the achievement of a &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a532ffa1-27aa-461d-b64b-2a3c40282af4" contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b" name="spry:CapitalizedMilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82c8b203-0f58-43e7-8c9d-337016682d2a" contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) milestone in June 2025. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized milestone payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are amortized on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5d418f2-2c0a-4e1c-9614-0d7b29afc39e" contextRef="C_d188a46c-d138-46be-af79-eb7c3b01af79" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in June 2025.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_799c8266-91e8-4c67-a406-ae3e8481c934_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_041c5527-7e2c-4e81-ad3d-8b53b0e4db31" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net, all of which are finite-lived, consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized milestone payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccb06058-7e27-4766-a2cf-d47ed90ee87d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,360</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_633708e8-cd7b-4134-b260-d831788c6f4e" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9579b8eb-015d-461b-a820-31238815321d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e1f115-323b-4850-a82f-ad731c42ef0a" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47faf510-fb4c-4cfa-8b1a-58d4f4fd018d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,972</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77507b9d-c5c4-4ee9-a4b5-73aaa1ac9d08" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,371</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortization expense for the three and six months ended June 30, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d08b821-2dd4-4339-a317-dd8e8f2587c4" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66567eb8-6d0d-4514-9ffe-27a161e05447" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90f52db1-14e0-4831-b791-702ac1d3381a" contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> int</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">angible assets were held as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8600a2e0-5520-416f-8fb0-d13bb91d5e28" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42546271-6dd5-47b8-a8c1-04bf4baf830b" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amortization expense recognized for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4c4b00d-8878-43e6-b4e2-7e6036fd795b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true" continuedAt="F_e4c4b00d-8878-43e6-b4e2-7e6036fd795b_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, estimated future amortization expense for capitalized intangible assets for the next five years is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"/>
          <td style="width:1.94%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:15.823%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81af259a-0da0-4ff5-aa55-b3fd27917854" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54531f6-8db3-4f8f-b15f-5b251965d880" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368a15fb-3f31-4943-b896-026b89d741b4" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe7d450-2532-4ee4-8b89-a794bca10589" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc70c231-a234-4881-bebd-611c4fe05acc" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bab8b53-dd80-4951-a0e0-c1d1ae914349" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,544</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_e4c4b00d-8878-43e6-b4e2-7e6036fd795b_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a2123611-81bf-4d0f-89af-227f2a6c8102" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_collab_outlicense"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Collaboration, Out-Licensing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Related Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into collaboration and licensing agreements, including supply and distribution, to license certain rights to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; clinical, regulatory, and/or commercial milestone payments; payment for clinical and commercial supply; and royalties or a transfer price on the net sales of licensed products.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, revenue is recognized from non-refundable, upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If the license is subject to repurchase by the Company, at its option, control of the license is not considered transferred to the customer, and in such case, the Company would account for the proceeds allocated to such license as either a financing obligation or a lease in accordance with ASC 606. Future amounts received related to the license which is subject to the Company&#8217;s repurchase, such as royalties or milestone payments, would be accounted for as additional financing proceeds and would increase the financing obligation on the Company&#8217;s condensed consolidated balance sheet. The Company would record such financing obligation as revenue when the right to repurchase has lapsed or was exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If the license is not a distinct performance obligation, the Company evaluates the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the inception of each arrangement that includes clinical, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within the Company&#8217;s control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized when the underlying performance obligation has been met.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_1" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction Price Allocation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of each arrangement, the Company identifies its distinct performance obligations and allocates the transaction price to the performance obligations based upon their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. The best evidence of standalone selling price is an observable price of a good or service when sold separately by an entity in similar circumstances to similar customers. Since the Company typically does not have such evidence, the Company estimates standalone selling price so that the amount that is allocated to each performance obligation equals the amount that the Company expects to receive for transferring the promised goods or services. The methods that the Company uses to make such estimates include (1) the adjusted market assessment approach, under which the Company forecasts product sales in the appropriate market, considers probability of commercialization success, and estimates discount rates; and (2) the expected cost of satisfying the performance obligations inclusive of a reasonable margin, also known as the expected cost plus margin approach.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For arrangements that contain research and development commitments, any arrangement consideration allocated to the research and development work is recognized as the underlying services are performed over the research and development term, if the criteria for over time recognition are met. If the over time recognition criteria are not met, research and development performance obligations are recognized at a point in time, when the research and development work is completed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical and Commercial Supply</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered customer options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. Revenue from product sales to the Company&#8217;s collaboration partners is recognized at the point in time that the collaboration partner obtains control, which is typically based upon the terms of delivery of the product.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty/Transfer Price Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For arrangements that include sales-based royalties or transfer price, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alfresa Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, the Company signed a Letter of Intent (&#8220;LOI&#8221;) with Alfresa Pharma Corporation (&#8220;Alfresa&#8221;) for the right to negotiate a definitive agreement for the exclusive license and sublicensable right to develop, register, import, manufacture and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan in exchange for an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9498d6ad-8860-44a5-b9f1-dd599faa7596" contextRef="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In April 2020, the Company entered into a Collaboration and License Agreement for the rights pursuant to the LOI. Under the agreement, the Company delivered a license to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">technology, completed a required clinical study, and remains obligated to use commercially reasonable efforts to develop and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Japan. The parties agreed to share the cost of any additional clinical studies required for approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan. Alfresa is solely responsible for regulatory and commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use in Japan. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in Japan; or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0df202cf-4eb0-44e7-ac33-7306c81eaeee" contextRef="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2" name="spry:LicenseAgreementExpirationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d422a3-06cc-489c-a7b0-8486086687da" contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received under the LOI, the Company was initially eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f8eae68-72ba-4612-b47b-7b036cbd6162" contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c" name="spry:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain clinical and regulatory milestones. Further, the Company is eligible to receive a negotiable transfer price expected to be in the low double-digit percentage on net sales subject to the regulatory approval to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified the following performance obligations: the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and research and development services, both of which have been completed. The Company determined the initial transaction price to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_690feb1d-66d6-48c5-907a-1d40fa337522" contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c" name="spry:InitialTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which includes a clinical milestone as it was deemed not probable of significant reversal at the inception of the agreement. Due to the uncertainty in the achievement of the regulatory and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_2" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_223aa4ef-9866-4477-9bb6-7319013964c5" contextRef="C_2798c3f2-23d6-4afc-8238-e8955f00db8e" name="spry:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon the completion of a clinical milestone in Japan. In November 2024, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbfe16cb-e273-491f-946b-5a361d5f66e0" contextRef="C_247f0be8-9254-4ed7-af0a-c83a543c7393" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon the completion of a regulatory milestone in Japan. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b402d2-f716-4a6a-bbae-10928355d475" contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba" name="spry:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments that the Company was eligible to earn, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef56bbb-31c2-4122-a60a-24bf08b9a1b6" contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba" name="spry:MilestonePaymentsEarned" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has been earned and a final $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f3328b4-96f2-4394-b4f6-9cddea32c13a" contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba" name="spry:RemainingRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million regulatory milestone remains. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69e36887-916e-4409-9dc0-83b250f8b81d" contextRef="C_6edac6ab-835a-4f3c-a70b-1468370bc85c" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_87cf47e8-aca7-449c-88d5-846f96c0802e" contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d2d8ae3c-a6c6-4aa5-bad0-27c076d5610c" contextRef="C_b3290235-3d4c-4e7f-9944-799740aa251b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_930e79e2-a01d-45c6-8f45-70a0a9dc67d7" contextRef="C_bea2c90b-ecb9-4b59-93cf-dda1fa71fada" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue related to the Alfresa Agreement. As of both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80a0bd7c-d311-4816-abc5-f91a3149bff1" contextRef="C_bf13c693-c4c5-4d64-bff3-5e485417c1b2" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9dcb2b04-9c8e-491b-8a7c-2d3a79f6eda9" contextRef="C_1db62f10-470a-43d8-99c5-9ef506d240f9" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contract liability recorded for the final regulatory milestone.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recordati Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2020, the Company entered into a License and Supply Agreement (the &#8220;Recordati Agreement&#8221;) with Recordati Ireland, Ltd. (&#8220;Recordati&#8221;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Europe and certain European Free Trade Association, Russia/the Commonwealth of Independent States, Middle East and African countries (the &#8220;Recordati Territory&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the terms of the Recordati Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91d09ba8-065e-4868-bb21-e3bdc7e17f82" contextRef="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and a regulatory milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ae3f43-4c5f-4770-99bb-fe37fdac1d78" contextRef="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified the following performance obligations: the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Recordati Territory and the research and development services. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8f62e8e-99ef-4cdc-a876-187618d3df01" contextRef="C_38aa7ddf-8d81-40f0-b406-1b66b957af89" name="spry:InitialTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, at inception of the contract, the variable consideration associated with future milestone payments was fully constrained and excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation. In November 2020, the Company earned a regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a0b602b-f66b-49d4-93e1-3e5968672f33" contextRef="C_0aeae9af-4a88-43bd-a834-adb7075f5c02" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 22, 2023, the Company and Recordati entered into a termination agreement (the &#8220;Recordati Termination Agreement&#8221;), pursuant to which, among other things, the Company and Recordati agreed to terminate the Recordati Agreement. Pursuant to the Recordati Termination Agreement, the Company reacquired all of the Recordati Rights, paid Recordati a one-time upfront payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78e907d0-9353-4e0f-a728-1f93414ae646" contextRef="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d" name="spry:UpfrontPayment" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0f2f67d-ee9a-4695-a205-a64fdc8538de" contextRef="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars), and has agreed to pay additional payments upon achievement of certain milestones including: (i) an EMA regulatory milestone payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b3d4445-c526-4a38-80a7-6a77b6702e77" contextRef="C_ccda22c2-6677-4cce-ab78-990354649056" name="spry:MilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (ii) a milestone payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f000907f-cf69-4d7a-8414-ff9f6141b316" contextRef="C_b67f6b97-19bd-4541-ba67-b60ffde15be3" name="spry:MilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory, and (iii) royalty payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54f2f1ea-99ae-44f1-b2ca-d463d1bd7955" contextRef="C_2e38c3cc-e6d7-4425-85b9-bc2d6e8c7279" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate from sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory (collectively, the &#8220;Recordati Rights&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the Recordati Rights at the time of entering into the Recordati Termination Agreement had no alternative future use and therefore recorded the &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f38cc3b8-bf3d-44d6-853a-2d0caf091643" contextRef="C_0833639e-5a42-456b-b01e-000950904f01" name="spry:UpfrontPayment" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment to Recordati as an in-process research and development (&#8220;IPR&amp;D&#8221;) expense presented within research and development expense. The Recordati Termination Agreement ended the Company&#8217;s performance obligations pursuant to the Recordati Agreement and consequently the existing contract liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63c6465f-435c-4528-ab74-c3942536d712" contextRef="C_feb3d59c-08cc-44f9-9f9d-a605f5002728" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million previously received from Recordati was recorded against IPR&amp;D expense presented within research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. Accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3befb8f-4a6d-4845-bdab-4dbf505a9d58" contextRef="C_a417b738-34c6-435f-98b6-b7335b68b8a7" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue has been recognized subsequent to the Recordati Termination Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the EMA regulatory milestone was met and a &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c906248e-230a-45a0-bb6b-cef2d1e626ab" contextRef="C_8b918b45-e66c-471b-9415-84b94cdb93dc" name="spry:MilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddcb7fa9-f32e-4e33-b156-7674be5feb39" contextRef="C_8b918b45-e66c-471b-9415-84b94cdb93dc" name="spry:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) expense was recorded in research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company paid the EMA regulatory milestone to Recordati in July 2024. In June 2025, the first commercial sale milestone was met for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory. As a result, the Company capitalized the &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62954855-1d52-4113-bcf9-0c90421362f9" contextRef="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2" name="spry:AggregateMilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e705a902-2c59-48e2-aa4f-7031630ea2a4" contextRef="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2" name="spry:AggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory to intangible assets in the accompanying condensed consolidated balance sheets. The Company paid the first commercial sale milestone to Recordati in July 2025. The intangible assets will be amortized through the cost of goods sold in the accompanying condensed consolidated statements of operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive loss on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f849b96-09c7-4ad1-85eb-1192ce28a841" contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_851e8267-ee33-4c36-b0dc-dc13264a696c" contextRef="C_375c7fdb-6931-4298-a1cb-0a3d7c761910" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3311e9eb-369e-403d-a8ed-d8d533a1f5d7" contextRef="C_70a2fe72-2e5d-43a9-845b-e6ad6d4e993a" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty expense from the sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Recordati Territory as cost of goods sold in the accompanying consolidated statements of operations and comprehensive loss.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_3" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_4"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatrix Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, the Company entered into a Collaboration and Distribution Agreement with Pediatrix Therapeutics, Inc. (&#8220;Pediatrix&#8221;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the People&#8217;s Republic of China, Taiwan, Macau, and Hong Kong (the &#8220;Pediatrix Territory&#8221;). Under the agreement, Pediatrix is responsible, at its sole cost and expense, for all ongoing development work that is necessary for or otherwise supports regulatory approval in the Pediatrix Territory, including all clinical trials, and activities related to post-approval commitments and commercialization tests. In addition, Pediatrix is responsible for commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use. The Company is responsible for the manufacturing of product for clinical studies as well as commercial supply, all at a negotiated transfer price. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in the Pediatrix Territory, (ii) the expiration of all regulatory exclusivities that cover </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Pediatrix Territory, or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bffd98d9-6476-4ff8-85b9-ee05630d090f" contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2" name="spry:LicenseAgreementExpirationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Pediatrix Territory.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4afd9259-6e1f-4165-8059-432dd1275155" contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In addition, the Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e30b8752-8733-4c8a-b4a7-79a6f2467c7f" contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2" name="spry:RegulatoryAndCommercialSalesMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">84.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain regulatory and commercial sales milestones. The next eligible milestone is a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7767ed02-bfc4-4e99-8c3c-63d0c601a978" contextRef="C_f0d8db66-c63b-4744-af9a-66b508f6e408" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million regulatory milestone. Subject to regulatory approval, the Company will earn tiered royalties in the low double-digits on annual net sales in the region and will receive a per unit supply price for the sale of commercial supply to Pediatrix.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified performance obligations related to the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Pediatrix Territory and manufacturing of product for clinical studies and commercial supply. The Company concluded that the license was distinct from potential supply obligation. The supply provisions are effectively options granted to Pediatrix to purchase future goods and did not contain a material right. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7132d68a-87dc-4c87-b34d-0c398752ae21" contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2" name="spry:InitialTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. The Company recognized revenue of the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_740f1cf2-0618-4d88-98d9-957a304295b0" contextRef="C_3f30c2eb-5568-4234-8acd-723e1a049bc1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Seqirus Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a License and Distribution Agreement (the &#8220;Seqirus Agreement&#8221;) with Seqirus Pty, Ltd. (&#8220;Seqirus&#8221;) for the exclusive license to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Australia and New Zealand (the &#8220;Seqirus Territory&#8221;). Under the Seqirus Agreement, the Company is responsible for the transfer of know-how, which includes regulatory materials, regulatory data, and commercialization data, and also for the manufacturing of product for commercial supply which is available to Seqirus at a negotiated price. Seqirus is solely responsible for all regulatory and commercialization activities in the Seqirus Territory. Either party may terminate the Seqirus Agreement for certain breaches. Unless terminated earlier by either or both parties, the initial term of the Seqirus Agreement is 15 years from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Seqirus Territory. The Seqirus Agreement will automatically renew for two-year periods unless either party gives a notice to terminate at least 12 months prior to the end of the initial or any renewal term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Seqirus Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e95e614-7eb8-4c96-a296-d0e10ada179a" contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in May 2024. In addition, the Company was eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf22e430-9e74-463d-8a67-19b6321990c6" contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b" name="spry:RegulatoryAndCommercialSalesMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain event milestones. Subject to regulatory approval in Australia and New Zealand, the Company will also receive a per unit supply price for the sale of commercial supply to Seqirus.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified one performance obligation which is the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how. The Company determined that the option to purchase the commercial supply does not represent a material right. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c72c090-3a0a-4939-8a07-f78a64b6e301" contextRef="C_f4436849-9fcc-4497-a985-5fa9db7ac33e" name="spry:InitialTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the regulatory milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The variable consideration will be reassessed at each reporting period. In May 2024, the Company delivered the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how and recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1622b577-fcb7-495f-8c83-db32b21e387b" contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue. In August 2024, the first milestone event was met and the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31475a81-f243-4ecf-859d-35ff8e6ccddc" contextRef="C_75927173-b0be-40a6-8cb0-9cafd6cc1be4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_4" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_5"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Collaboration Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company entered into a Collaboration, License and Distribution Agreement (the &#8220;ALK Collaboration Agreement&#8221;) with ALK-Abell&#243; A/S (&#8220;ALK&#8221;). Pursuant to the ALK Collaboration Agreement, the Company granted to ALK a worldwide (other than the United States, Japan, mainland China, Hong Kong, Taiwan, Macau, Australia and New Zealand) (&#8220;ALK Territory&#8221;), exclusive license under certain of the Company&#8217;s patents and know-how to develop, manufacture and commercialize products containing epinephrine administered intranasally, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the trade name for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the European Union) (epinephrine nasal spray) (&#8220;Products&#8221;), for all human uses, including the immediate or emergency treatment of allergic reactions (including Type I) and anaphylaxis and urticaria, and other future indications as agreed by the parties. If the Company develops any new intranasally administered product that contains epinephrine and files a new drug application in the United States for such product (&#8220;New Product&#8221;), upon ALK&#8217;s request such New Product will be included as a Product under the ALK Collaboration Agreement, subject to ALK bearing the costs of development of such New Product for its licensed territory.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, the Company is obligated to transfer to ALK the existing marketing authorizations for the Products in the ALK Territory. The Company is also required to conduct certain development and regulatory activities for Products in support of obtaining further regulatory approval of Products in the ALK Territory and will transfer such regulatory approvals to ALK. ALK is obligated to use commercially reasonable efforts to obtain and maintain regulatory approval for Products through the European Commission and within specified countries within the ALK Territory. Following such approval for a Product in each indication within specified countries within the ALK Territory, ALK is obligated to use commercially reasonable efforts to commercialize such Product in such indication in such countries and to achieve first commercial sale of a Product in certain countries in accordance with a timeline specified in the ALK Collaboration Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, ALK made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fec10b6-50b2-41b0-8c4f-9fd442093755" contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">145.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment to the Company in November 2024, and the Company earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d0b5ba-fd3c-4395-8950-b2fe0e2ce2e7" contextRef="C_004bb578-b8b4-4b1e-b080-94149f0f6733" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the ALK Territory in June 2025. The Company is eligible to receive additional outstanding regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c924423e-09ae-43ab-b321-5624a182456b" contextRef="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and sales-based milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_521ca523-b3a1-4849-8b67-a32bf84ff334" contextRef="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f" name="spry:SalesBasedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, provided that $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8b30e5-3c19-4e58-9d26-122700a1ee08" contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef" name="spry:ContingentSalesBasedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such sales-based milestones are contingent upon the Company obtaining regulatory approval for the Product in Canada by a specified time. The Company is entitled to receive tiered royalty payments on net sales in the mid- to high-teens, subject to certain standard reductions and offsets. Royalties will be payable, on a Product-by-Product and country-by-country basis, until the latest of the expiration of the licensed patents covering such Product in such country, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aba2311-6f77-42e6-baf9-8707ee6014b7" contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef" name="spry:LicenseAgreementExpirationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the first commercial sale of such Product in such country, or expiration of regulatory exclusivity for such Product in such country.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract will expire upon the expiration of the last-to-expire royalty term for all Products in the ALK Territory, unless terminated earlier. Either the Company or ALK may terminate the ALK Collaboration Agreement in the case of the other party&#8217;s insolvency or in the event of an uncured material breach of the other party, except that the Company may not terminate the ALK Collaboration Agreement for ALK&#8217;s material breach of its commercial diligence obligations. ALK may terminate the ALK Collaboration Agreement for convenience upon 12 months&#8217; prior written notice or for a safety or regulatory concern. The Company may terminate the ALK Collaboration Agreement in the event ALK makes certain challenges to certain of the Company&#8217;s patents. Prior to a change of control and outside of a set period of time after which the Company commences change of control negotiations, the Company may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area (&#8220;EEA&#8221;) upon prior written notice to ALK and payment of a termination fee that is the higher of an agreed mid-nine digit amount and the fair market value of the Products business in the EEA at the time of such termination (the &#8220;Repurchase Option&#8221;). The Company may also terminate the ALK Collaboration Agreement if ALK commercializes a non-injectable epinephrine product or manufactures such a product in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ALK Collaboration Agreement, the Company and ALK also entered into a commercial supply agreement (the &#8220;ALK Supply Agreement&#8221;) in November 2024, under which the Company will supply ALK&#8217;s requirements (and ALK will purchase from the Company its requirements) of Products for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f9c0aa9-9d89-4047-9514-94d6d2b63c22" contextRef="C_563a8ff6-fcbe-42af-ac8a-285febbe3949" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a specified supply price, after which ALK may elect to transition to itself or its contract manufacturer the manufacture and supply of Products. The contract term for the ALK Supply Agreement is coterminous with the ALK Collaboration Agreement. Either the Company or ALK may terminate the ALK Supply Agreement in the event of an uncured material breach of the other party.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_5" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_6"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Assessment</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the ALK Collaboration Agreement and the ALK Supply Agreement qualify as a contract with a customer under ASC 606 as one combined arrangement. The Company identified the following performance obligations: (i) exclusive commercialization license in the European Economic Area (the &#8220;EEA License&#8221;); (ii) exclusive commercialization license in the rest of the ALK Territory (the &#8220;ROW License&#8221;) and; (iii) five separate development and regulatory services performance obligations. The Company also evaluated the (i) promise to add a New Product and new indications to the ALK Collaboration Agreement, and (ii) the promises under the ALK Supply Agreement, and concluded that these promises did not meet the definition of a performance obligation nor did these promises convey a material right to ALK.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c043903-f31c-4139-9e05-31d04cade507" contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">145.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is the estimated transaction price at contract inception. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outstanding regulatory milestone payments (totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_872e2872-747f-4ad7-b001-db589de88155" contextRef="C_38363ca6-7cce-4222-abc8-30485789e9f7" name="spry:RegulatoryMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) were fully constrained at contract inception and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a result of the uncertainty of whether any of the milestones will be achieved. In making the assessment of the constraint utilizing the most likely amount method, the Company considered the stage of development, and the risks associated with the remaining development required to achieve the milestones, as well as whether the achievement of the milestone is outside the control of the Company or ALK. The Company determined that the commercial milestone ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ca5eab9-48d5-4f17-8432-1918566d45ef" contextRef="C_38363ca6-7cce-4222-abc8-30485789e9f7" name="spry:CommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and the sales-based milestones and royalties will be recognized on the later of when the related sales occur or when control of the associated license has been transferred, as the Company determined that such sales-based consideration relates predominantly to the licenses granted to ALK. The Company reevaluates the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and will include regulatory milestones in the transaction price if it is probable that a significant revenue reversal will not occur in future periods.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At contract inception, the Company determined the estimated standalone selling prices for each performance obligation in order to allocate the transaction price among the performance obligations. The standalone selling price for the licenses was estimated using the adjusted market assessment approach. Under this method, the Company forecasted future cash flows expected in the ALK Territory, the probability of commercialization success, and a market discount rate. To estimate the standalone selling prices of the development and regulatory services, the Company forecasted its expected costs of satisfying each performance obligation inclusive of an appropriate margin for that service.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the total transaction price to each performance obligation on a relative standalone selling price basis and determined whether revenue should be recognized at a point in time or over time. The Company allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32486b5c-31a1-4bae-ae7d-c408f8ebf421" contextRef="C_3e249227-20e2-4988-9bf2-7e870713555f" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the EEA License performance obligation; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c200a0d7-d5cf-4d3a-81cc-25f9da091302" contextRef="C_9c7e6e23-0000-4ddc-a5c9-a2b708744fd4" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">73.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the ROW License performance obligation; and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94ca9f3a-ccd2-417b-8723-3ce4bec4a9bb" contextRef="C_9c214f10-a914-4d27-a1b0-da1ea243e703" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the development and regulatory services performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue should be recognized when, or as, an entity satisfies a performance obligation by transferring a promised good or service to a customer, i.e., when the customer obtains control of the good or service. The licenses granted to ALK are being accounted for as distinct performance obligations. The licenses relate to functional intellectual property for which revenue is recognized at a point in time. In the case of the EEA License, the Company evaluated the impact of the Company&#8217;s Repurchase Option, and determined that, as a result of the Company&#8217;s ability to repurchase the license, control of the EEA License has not been transferred to ALK under ASC 606. The Company determined that the transaction price allocated to the EEA License should be accounted for as a financing liability, due to the repurchase price being greater than the original selling price of this performance obligation. Control of the EEA License will not be considered transferred to ALK until such time that the Repurchase Option lapses, which under the terms of the ALK Collaboration Agreement, will occur upon the expiration of the contract, or exercise by the Company of the Repurchase Option. In November 2024, the Company recognized the transaction price allocated to the EEA License of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ecc0b65-871d-44df-b43d-4b6f7769af6b" contextRef="C_e127c89b-57cc-45dd-88e0-5952c92514a1" name="spry:FinancingLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a financing liability.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of the ROW License, the point in time for recognition of revenue was shortly after the inception of the contract because the customer obtained control of the license and was able to use and benefit from its right to use the intellectual property at that po</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">int. In November 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb6f861b-36b4-4752-b1d0-e6ad646f66b6" contextRef="C_77cdd9e5-e0da-4ed0-91c5-452beda8f96e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">73.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue for the transaction price allocated to the ROW License.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_6" continuedAt="F_a2123611-81bf-4d0f-89af-227f2a6c8102_7"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and regulatory services performance obligations under the ALK Collaboration Agreement each represent a separate performance obligation. The development and regulatory services, which are transferred to the customer over time, were provided to ALK from inception of the agreement and are expected to continue through 2028. Revenue related to the development and regulatory services performance obligations was initially recorded as contract liability and is being recognized as services are performed based on the costs incurred through the end of each reporting period, as a percentage of the estimated total costs to be incurred for these performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In November 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_153f108a-9c9d-4328-a261-97b7f6994524" contextRef="C_b0d7c1bf-c559-41f1-bb73-15d4ca13613b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the development and regulatory services performance obligations. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51502627-81fb-430c-8ec8-0f2475357c2b" contextRef="C_8af74f27-94e0-4415-9f6e-42b1b5332edb" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3db24d7-1ae4-47a4-8bda-026dede3e4a3" contextRef="C_d10f176e-9429-4ccb-a20f-413c86b3a44b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the development and regulatory services performance obligations, respectively, which is recorded as revenue under collaboration agreements in the accompanying condensed consolidated statement of operations and comprehensive loss. As of June 30, 2025, the accompanying consolidated balance sheet includes a contract liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ded735a-ffc9-4ecf-85ac-c1e286111ce3" contextRef="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million classified as current and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e408e9c7-9d35-4e23-949a-8f2ad4b1f778" contextRef="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million classified as noncurrent associated with these performance obligations and based on the expected period of performance for the development and regulatory services.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, ALK completed the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the ALK Territory, and the Company began generating revenue from product sales to ALK, earned royalties from the use of the EEA License, and also earned the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba8d23d8-50fb-4823-b984-03c80d12aef6" contextRef="C_e3d262bc-6795-406d-8d91-24b3907b6289" name="spry:CommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commercial milestone. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62d4e84b-70ae-4274-9241-2a867c4d5974" contextRef="C_e3d262bc-6795-406d-8d91-24b3907b6289" name="spry:CommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commercial milestone, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c71250-2fd0-47de-bc02-cdcd7f65b9ee" contextRef="C_0290e712-16a0-4589-8318-f1315dc7c60a" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9e7a3bab-e5eb-40ad-81bf-1bed62233efe" contextRef="C_9a4b43ec-ca53-4df2-bd72-e2b244eaca24" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized as revenue under collaboration agreements for the three and six months ended June 30, 2025 in the accompanying condensed consolidated statement of operations and comprehensive loss. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_451464a4-da9c-46c3-9f5b-39d8fbae368a" contextRef="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0" name="spry:IncreaseToTheFinancingLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the EEA license and recognized as an increase to the financing liability, along with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f07823c0-b513-410b-ba7d-cfbc16fc9937" contextRef="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0" name="spry:RoyaltyIncomeNotRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to royalties earned in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had accounts receivable and contract liability balances of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b77abf5-9550-4da1-b674-f41ca0fe910b" contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f236f0af-fd29-4948-81b6-ed2105d6a2e1" contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associated with the ALK Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Contract Liability</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f129467-b39c-4e78-8824-9134d808db7f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the contract liability from the ALK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"/>
          <td style="width:1.58%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.68%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_587cdb62-5f9e-41d8-b8e2-c47624a75336" contextRef="C_0bd8344d-6c3d-4f4c-9193-8180e76f5899" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,089</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized under the ALK Collaboration Agreement</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b7c46c2-3ddc-4abd-9232-02cd66b08111" contextRef="C_551d5f3f-f834-4e2e-af4a-07c630cc9151" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09492cc3-ec82-4048-90a0-926257d2f5f0" contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,849</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Financing Liability</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the financing liability from the ALK Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"/>
          <td style="width:1.58%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.68%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b3c214c-affe-473b-8efb-775cb75222ff" contextRef="C_7e3f31da-ca14-42b4-8b0b-1e8aeb740579" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,383</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial milestone allocated to the EEA License</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19754c0e-cd98-4440-9cae-5685040ae4d4" contextRef="C_d1c3a878-557f-48fb-9597-d12ba95d1e11" name="spry:IncreaseToTheFinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,435</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales-based royalties earned in the EEA</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c28ee824-0caa-4181-8ca1-c8f8d8a7e77b" contextRef="C_d1c3a878-557f-48fb-9597-d12ba95d1e11" name="spry:RoyaltyIncomeAllocatedToTheEEALicense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e129e0a7-f7a3-4df0-a8f2-be8e3e491be8" contextRef="C_c703154e-f609-4897-84a5-dd320a085d31" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,959</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Co-Promotion Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, the Company and ALK-Abell&#243;, Inc. (&#8220;ALK U.S.&#8221;, an affiliate of ALK) entered into a co-promotion agreement (the &#8220;ALK Co-Promotion Agreement&#8221;) to co-promote </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca92c3e1-361d-4445-815c-2261df757889" contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4" name="spry:NumberOfPediatricians" unitRef="U_Doctor" decimals="0" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specified pediatricians and other prescribers in the U.S. Accordingly, the Company granted ALK U.S. a non-exclusive, royalty-free license to use the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to the terms of the ALK Co-Promotion Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Co-Promotion Agreement, ALK U.S. was obligated to start its promotion activities in May 2025 and meet specified ramp-up milestones and minimum detail requirements, using sales representatives that meet specific qualifications. In addition, during the term of the ALK Co-Promotion Agreement and for 180 days thereafter, ALK U.S. will not market, sell or manufacture any injection product containing epinephrine in the U.S.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is the principal of all sales transactions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. and, subject to the terms of the ALK Co-Promotion Agreement, continues to have sole responsibility for all U.S. commercialization activities, including marketing, medical affairs, market access, production, distribution, pharmacovigilance, quality and safety.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a2123611-81bf-4d0f-89af-227f2a6c8102_7"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay ALK U.S. a base fee to compensate ALK U.S. for its promotion activities.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_989d352b-ca76-4b57-9e4d-aec8ad12de14" contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4" name="us-gaap:CollaborativeArrangementRightsAndObligations"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Payments to ALK U.S. for the services performed during the first year of the arrangement will be deferred and paid in the second year of the arrangement. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from the Company starting in the second year of the arrangement equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c1fa8a7-8a12-485c-9140-35032cf4a8b5" contextRef="C_064e952a-b57a-45b7-b072-cc0c1681aeea" name="spry:PerformanceBasedBonusPaymentsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19b9b6f5-8a56-4297-be41-fba18d28901b" contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4" name="spry:ThresholdPercentageOfValueChangeInEquitySecurities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% market share threshold during years three and four of the arrangement.</span></ix:nonNumeric></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ALK Co-Promotion Agreement expires on the fourth anniversary of the commencement of promotion activities thereunder. Either party may terminate the ALK Co-Promotion Agreement in the event of an uncured material breach of the other party or for either party&#8217;s change of control. The Company may terminate the ALK Co-Promotion Agreement in the case of ALK U.S.&#8217;s insolvency, if ALK U.S. fails to meet specified ramp-up timelines, or if ALK U.S. markets, sells or commercializes any non-injection product containing epinephrine in the U.S. After the first six months, the Company may terminate the ALK Co-Promotion Agreement if minimum detail requirements are not met for a consecutive three-month period. After the first year, the Company may terminate the ALK Co-Promotion agreement for any reason or no reason for a fee (as described below). After the first year, ALK U.S. may terminate the ALK Co-Promotion Agreement for any reason or no reason, and the Company may terminate the agreement in the event ALK U.S. restructures its sales force.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the ALK Co-Promotion Agreement by the Company for convenience, so long as ALK U.S. has met specified performance thresholds during the term, the Company is obligated to pay ALK U.S. a specified mid-to-low double-digit percentage of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified mid-quartile market share threshold that increases over time up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a1ef7e8-0c26-4c6a-a555-23a18f75693f" contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4" name="spry:ThresholdPercentageOfValueChangeInEquitySecurities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for a specified period after termination, which period decreases in duration the later that the termination occurs. Upon termination of the ALK Co-Promotion Agreement by the Company in connection with a change of control of the Company, the Company is obligated to pay ALK U.S. a one-time mid-seven digit to low eight-digit termination fee in an amount that increases the later that the termination occurs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated the terms of the ALK Co-Promotion Agreement and determined that it is a vendor arrangement with ALK U.S. During the three and six months ended June 30, 2025, the Company has recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05ae8e2d-32df-4b1b-a74b-273adf0d5091" contextRef="C_3cf5d1b5-d177-4592-87ff-f0e88882461a" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_edd1dca6-a364-4e25-9714-c9c7b3db8f1f" contextRef="C_0f4f1f4e-cff5-4294-8295-0850b8d49cb5" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9869b299-8890-4658-b664-5eafed3a1488" contextRef="C_ccfcc4d8-af04-4d3d-b28f-3c979e5d0771" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in ALK-related selling, general, and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss, and the corresponding liability was recorded in other accrued liabilities in the accompanying condensed consolidated balance sheet as of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_commitmentscontingencies"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30c25de7-59dd-4755-a53d-eebf628aa5a2" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04227f3e-33ce-48d5-b512-1e0da0f97d6b" contextRef="C_8c610e5a-69e3-4dbb-91d0-cbfccda23506" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> noncancelable office space lease for its current headquarters location in San Diego, California. Under the terms of the agreement, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8586e76c-fc2e-4bf4-8526-a7a4fa2675e4" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is no option to extend the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company is subject to additional charges for common area maintenance and other costs.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Monthly rental payments due under the lease commenced on December 6, 2021 and escalate through the lease term. The Company prepaid the first month&#8217;s rent upon execution of the lease, and the lease agreement provided full rent abatement for the second and third months of the rental term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there was not an implicit rate within the lease, the discount rate was determined by using a set of peer companies incremental borrowing rates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_eda2d732-2fe1-420d-9870-fbe8aef5ac14" contextRef="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7" name="us-gaap:LesseeOperatingLeaseDescription" continuedAt="F_eda2d732-2fe1-420d-9870-fbe8aef5ac14_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the Company entered into a lease amendment to its headquarters location lease (the &#8220;Headquarters Amendment&#8221;), pursuant to which the Company will relocate to a new office space located in the same building. In May 2025, the Company took possession of the new office space upon substantial completion of the landlord&#8217;s work. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term of the new office space is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21edd13f-7922-40c8-bf22-3992601da88f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. Monthly lease payments increased when the Company took possession of the new office space and will escalate through the lease term, resulting in an annualized payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978a43a6-f1ad-45c0-a613-5143fb1083b7" contextRef="C_707e3c08-3d58-422c-9b32-bda32bcab502" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company remains subject to additional charges for common area maintenance and other costs. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d8ca5cd-7eea-4175-8728-faa9de5e18ce" contextRef="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has one option to extend the lease for an additional term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09da0a7a-9a68-4711-aeee-0d0181992013" contextRef="C_a17bc1f5-5be5-45a5-b3d5-0e7a29e42cf9" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the monthly payment amounts would be determined by the landlord at the then-prevailing rate.</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_eda2d732-2fe1-420d-9870-fbe8aef5ac14_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon entering into the Headquarters Amendment, the Company remeasured the right-of-use asset and lease liability pertaining to its current headquarters, and as a result recorded an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2616c7a3-6fd0-4e63-9204-0a16a571c596" contextRef="C_dbca97a3-dc8a-458f-86e0-c938df8b9878" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to both its right-of-use asset and lease liability on its condensed consolidated balance sheet. Upon possession of the new office space, the Company recognized a right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ebfc77-727d-4452-8e52-5aa0eb03239c" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on its condensed consolidated balance sheet. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there was not an implicit rate within the lease amendment, a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_442dadf2-7215-483a-97a9-5e755b2d3a3f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% was determined using a set of peer companies&#8217; incremental borrowing rates.</span></p></ix:continuation></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0_1" continuedAt="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0_2"><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d4a2b5c-871a-4ab1-bcfc-954cff1b53bd" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes supplemental lease information (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.1%;box-sizing:content-box;"/>
          <td style="width:1.24%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.344000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.24%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.344000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.24%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.9030000000000005%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.24%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.344000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_573c2aa6-13f0-4f1a-8939-c73d9f07b67b" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67fc17b5-e5e9-4378-89f0-c1f4092224ce" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_829ba460-d5bf-4cf4-9300-fef0db3c7aef" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54605b14-acdd-4bd8-9641-0b8c0f16fc52" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0d05305-8e7d-470d-a4bb-743ae10b17e5" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0c8d14-e581-4bb1-b83c-822199e170a4" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b850523a-0395-4611-ab17-98ad57e08f1f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b20bfc-cca8-49a8-b884-3480c865d6ae" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">______________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs in each of the three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were immaterial.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a5248bd-e58a-42b9-a1ef-3a26c594c354" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, future minimum non-cancelable operating lease payments are as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"/>
          <td style="width:1.94%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:15.823%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_115553f5-9cc5-4c8f-8f41-71e71f52e5e6" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a07e55-b6d7-4da8-8112-550e20fae76c" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0932ad01-ce0d-40ba-a3fc-cf809915dd3a" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff5afacd-28f0-479f-aae5-3aaef1d59809" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52951485-ffcf-4b65-8f96-6e2034297262" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,864</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b07a369c-8f33-4bf5-af77-6765712e03f7" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b1ad6c-dc26-475c-a558-35aa4c299fda" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,661</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less lease liability, current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14589b1d-196d-43d0-a067-065fdfc2a31e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01267790-0086-49e4-8e30-7f34a2e39918" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,072</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 24, 2023, Aera A/S, an IP consultancy firm in Denmark representing an unidentified opponent, filed a notice of opposition with the European Patent Office (the &#8220;EPO&#8221;) in respect of EP 3678649 (the &#8220;EP &#8216;649 Patent&#8221;), which is a patent directed to a nasal spray formulation of epinephrine, and uses thereof. The Company filed a response to the notice of opposition on December 15, 2023. The EPO scheduled oral proceedings on October 7, 2025, and the Company will continue to vigorously defend the EP &#8216;649 Patent. The results of any notice of opposition are inherently unpredictable and uncertain and could result in the EPO finding the patent to be invalid or unenforceable.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 25, 2025, Aptargroup, Inc. and Aptar France SAS (collectively, &#8220;Aptar&#8221;) filed a suit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. in the United States District Court for the Southern District of New York. Aptar alleges the Company violated the Defend Trade Secrets Act (18 USC &#167; 1836), misappropriated trade secrets under New York state law, and committed various breaches of contract. The complaint was served to the Company, and the Company filed a motion to dismiss on June 12, 2025. Aptar subsequently filed opposition to the motion to dismiss on July 28, 2025. The Company intends to vigorously defend itself in this matter.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of the outcome, involvement in legal proceedings may have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. The Company cannot predict the outcome of these suits, and failure by the Company to obtain favorable resolutions could have a material adverse effect on its business, results of operations, and financial condition. The Company&#8217;s chances of success on the merits of these suits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of June 30, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as described above, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or other body pending or, to the knowledge of the Company&#8217;s executive officers, threatened against or affecting the Company, the Company&#8217;s common stock, any of its subsidiaries or its subsidiaries&#8217; officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unconditional Purchase Obligations and Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unconditional purchase obligations and commitments are defined as agreements to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, the Company enters into arrangements with suppliers, manufacturers, and various other companies that supply goods or services. These arrangements can include unconditional purchase obligations and commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to the supply of raw materials is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4c5ea98-9800-40ac-b4d5-9bee7a532d04" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">57.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payment obligations by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42be5ae7-f24d-4a59-b857-4153a5254ac2" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f93810f6-9daf-46b4-b832-64ed529a5602" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15b90e97-8ca2-4e84-ba10-517922a1c77d" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2028 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba034426-d802-4d84-9645-98511de93c66" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63ef0387-f91e-490b-9afc-9951163179d0" contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487" name="spry:UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year thereafter through 2035. During the three and six months ended June 30, 2025, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1203bc50-dadd-43fa-91bf-e6376e6b1370" contextRef="C_88a3e244-24a0-4aeb-bc44-0d55744142b3" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c007bd8-8667-482f-9624-72d02a7b3b39" contextRef="C_87fd2cd8-129a-414e-99c1-03cc3ad545e7" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under these agreements, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c429187-531f-4a1a-aff6-a01475b981f5" contextRef="C_4d7fc657-c0ab-4f3d-9b5c-9106d31bfc5a" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7e7c3cd9-2133-479c-9b92-49179a9e2de9" contextRef="C_dd3a8cfa-4023-4a91-9e13-79918b2abe74" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under these agreements during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of commitments related to the ALK Co-Promotion Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e98e4f3-47f0-4a2a-962e-99b418daa2d7" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025. Payment obligations by year are as follows: 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_794bfe7f-0e3f-4c1a-a606-9d37a338ea9d" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f8abfe0-7658-48dd-a824-484e33bfd6eb" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitmentDueInSecondYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e8aa86-9280-48f2-9600-7c177178779b" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitmentDueInThirdYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c24846b-141f-4b76-ad7b-23bab67e090c" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitmentDueInFourthYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2029</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bca16c4-15be-4fa7-b7db-7b988be45369" contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097" name="us-gaap:OtherCommitmentDueInFifthYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e065a27-a71a-409a-b0d1-05524a2ad4f8" contextRef="C_f342e672-771e-4d11-b09d-5aa31a2a64f1" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_97413cda-41d0-4885-afd4-5e60aaa229f6" contextRef="C_7b9bded7-8bb0-4033-b376-cee3038595c4" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8414434e-5b12-4808-8ebd-f9af719bde8c" contextRef="C_2799d300-1237-43a9-b5b0-5d5699ea13d6" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d6d5c34f-dc53-454a-8734-de7b43fb3b64" contextRef="C_98f4fdcb-e4e1-4865-9ef5-c4363da98d19" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made under this agreement during the three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of commitments related to a corporate sponsorship agreement with Food Allergy Research and Education, Inc. is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c54689a2-5038-4590-9226-3d737a182b8f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payments by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05eb94de-de24-42d3-827e-1e695131daa4" contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be13f876-539f-4675-86a3-b5c524183265" contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310" name="us-gaap:OtherCommitmentDueInSecondYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_545cb3b1-7057-4b9f-b3dc-d45f9a7b7bd4" contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310" name="us-gaap:OtherCommitmentDueInThirdYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). During the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e37d979-7590-4f70-89e8-61ca9e28da1b" contextRef="C_7f5fc329-380e-42ec-8c1f-ae79663067f3" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d384c0-5307-4ef9-b84c-dc37916cf0a2" contextRef="C_c2299308-80d9-4f3e-8124-02a70b3c491a" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under this agreement, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98eebff6-bd49-471c-9c52-61887bdb0f52" contextRef="C_10d6fbd1-42f4-43a6-a7b7-6fc8c0df13bb" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c810e3df-68f6-420e-8b66-abffe6ef9bc4" contextRef="C_a9963800-3add-4281-aca5-d9f4f016ca70" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under this agreement during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to hosted software license subscription fees is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8644b45a-b3ff-4aa6-a816-a19152020336" contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payments by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c553ee-6951-45aa-8522-e253c8ba3a52" contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7994de6-86da-43da-aaf1-eaaabd37d308" contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ec5f2fc-68ed-4c8f-a0a1-4eaf987174a8" contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). During the three and six months ended June 30, 2025, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1104608-51d9-405b-a315-fb75d4f6025b" contextRef="C_c2c7df1f-3bbc-45b1-969f-8aabc9c9acc2" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a087a57f-e96f-4838-80df-bf7961af6523" contextRef="C_ceb11ad1-2588-4e17-af28-fe15173ba3d7" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under this agreement, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a26fdd-7a5a-4436-8676-c4b50e170dba" contextRef="C_bfd38f7d-69e0-47b4-8cde-fe7dddca6c40" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cfcd9388-7e4f-4d15-a88e-c52cd5db0459" contextRef="C_1d5db0ae-f190-4d5e-9227-dbb3463af2c0" name="spry:UnrecordedUnconditionalPurchaseObligationsPaid" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under this agreement during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts above do not represent the entire anticipated spend in the future but represent only those items for which the Company is contractually obligated. For this reason, these amounts do not provide an indication of the Company&#8217;s expected future cash outflows related to purchases and commitments.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:InLicensingandsupplyTextblock" escape="true" continuedAt="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_inlicense_supply"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. In-Licensing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Aegis</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2018, the Company entered into a License Agreement (the &#8220;Aegis Agreement&#8221;) with Aegis Therapeutics, LLC (&#8220;Aegis&#8221;), a wholly owned subsidiary of Neurelis, Inc. Under the Aegis Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable, rights to certain proprietary Aegis technology, patent rights and know-how to develop and commercialize epinephrine products. The Company utilizes this technology in its sole commercial product, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As consideration for the license, the Company paid an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6edf3f49-2022-49dc-97fa-630522240e53" contextRef="C_c8ac2384-1b58-47dc-915d-83a7ba54ecc7" name="spry:UpfrontLicenseFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which was recorded in research and development expenses in the condensed consolidated statement of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aded3d4a-6c34-4181-9892-1271c617938a" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of certain regulatory and commercial milestones. Regulatory milestone payments under the Aegis Agreement are recorded upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, regulatory milestone payments were recorded as research and development expenses in the condensed consolidated statement of operations. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7785afc9-7ee7-411d-9265-064761a7b15b" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:RegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Aegis upon the achievement of a regulatory milestone during 2019, and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dfcb68a-1080-4026-87e2-152ce92bffb1" contextRef="C_d93ac729-d7c9-434a-8a9b-7e60266ca1ba" name="spry:RegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Aegis upon the FDA&#8217;s acceptance of the Company&#8217;s new drug application submission for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which occurred in the third quarter of 2022. Since the approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory milestone payments have been capitalized as intangible assets in the accompanying condensed consolidated balance sheets. Amortization expense has been recorded to cost of goods sold, in the accompanying condensed consolidated statements of operations and comprehensive loss, on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_831b2cae-30fc-4d1d-8bda-47e178608b7e" contextRef="C_0e0c015a-4832-4ce2-aa6e-7f1681a3ba80" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In August 2024, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c59ff8f2-5308-4c8d-a39d-22eb95edf5b2" contextRef="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was met for achieving FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96ff58b8-6cd0-4fd8-a214-2cb0606df432" contextRef="C_e0a90922-dcd0-49c2-a9be-fb3989e9dc06" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was met for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a result, the Company capitalized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c221013-f6c0-4ec1-8cc8-b56fec1511f3" contextRef="C_b4c93365-0858-428d-a34d-b5add11a9639" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as intangible assets in the accompanying condensed consolidated balance sheets in the third quarter of 2024. The Company paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99e7e65d-f63b-4966-94ab-ab08caec73dc" contextRef="C_298d2778-7e68-42a6-ac6a-7d397a9e29f5" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone for achieving FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024 and paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad4b56a9-15fe-45fe-b6d9-14c824a52156" contextRef="C_beeef49f-dee6-4fb9-a634-f1430f58cd42" name="spry:CapitalizedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in October 2024. The next milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da439673-46cc-4d27-85a2-623472373555" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:MilestonePaymentDueOnAchievementOfAnnualSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is due upon the achievement of certain annual net product sales.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also pays royalties based on a mid-single-digit percentage of net product sales on its or its sublicensees&#8217; net sales of the Licensed Products (as defined in the Aegis Agreement) on a product-by-product basis. Royalties are recorded to cost of goods sold in the period the related product revenue is recognized.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, OrbiMed Advisors LLC (&#8220;OrbiMed&#8221;) entered into an agreement with Aegis, to purchase the rights, royalty interests, and related sales milestone payments on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will make all future payments under the Aegis Agreement to OrbiMed. As described in </span><a href="#fn_relatedparties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14 &#8211; Related Party Transactions</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a member of the Company&#8217;s Board of Directors is a General Partner at OrbiMed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe_1" continuedAt="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is responsible for reimbursing Aegis for patent costs incurred in connection with prosecuting and maintaining patent rights that are specific to epinephrine or epinephrine </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54f6651-0780-414b-9502-3aa7ee8c46e3" contextRef="C_2a05683e-e9ad-48bf-82d5-1bac47afff01" name="spry:LegalPatentFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_76957d54-f231-4ed5-b093-cc6f88e88e74" contextRef="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6" name="spry:LegalPatentFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_08a9f815-6b60-4df5-95a0-c4b67356e5e6" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:LegalPatentFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_217b13c0-97fa-4705-ba8c-6dca98307fce" contextRef="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017" name="spry:LegalPatentFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expenses were recognized in connection with legal patent fees for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8952ce7-a310-4432-9f10-9ea9c13f5539" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:NoticePeriodDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Aegis Agreement with 30 days writt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">en notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.</span></ix:nonNumeric></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the Aegis Agreement, the Company also entered into a supply agreement (the &#8220;Aegis Supply Agreement&#8221;) with Aegis that allows the Company to purchase materials for preclinical, development and commercial use at predetermined prices. The Company may elect to have Aegis supply minimum quantities but there are no minimum or maximum purchase obligations under the Aegis Supply Agreement unless this election is made. The parties may terminate the Aegis Supply Agreement at any time by mutual agreement. In addition, the parties may terminate the Aegis Supply Agreement in the event of certain breaches of the Aegis Supply Agreement or upon the earlier of the expiration or termination of the Aegis Agreement or June 2028. The Aegis Supply Agreement term may be extended by mutual written agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Aegis Supply Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd846bc2-85de-45e3-8ac0-c75c80b3e734" contextRef="C_2a05683e-e9ad-48bf-82d5-1bac47afff01" name="spry:SupplyAgreementExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7401ec6f-6322-4da0-abc7-062da80fdaab" contextRef="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6" name="spry:SupplyAgreementExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0429bba1-99de-4f43-bfac-3bd6a4ab39bb" contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b" name="spry:SupplyAgreementExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e2558d86-dde6-4325-9057-67b2cc33fbcb" contextRef="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017" name="spry:SupplyAgreementExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made to Aegis in each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreement with Renaissance</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2020, the Company entered into a manufacturing agreement with Renaissance Lakewood, LLC (&#8220;Renaissance&#8221;), which was subsequently amended in July 2023, September 2024, and July 2025 (the &#8220;Renaissance Agreement&#8221;). Pursuant to the Renaissance Agreement, Renaissance agreed to manufacture for, and provide to the Company, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nasal unit dose sprays (&#8220;Renaissance Products&#8221;). The Company is obligated to provide Renaissance with certain supplies to manufacture the Renaissance Products and to purchase from Renaissance a mid-double-digit percentage of the Company&#8217;s annual aggregate Renaissance Product requirements in the EU, and a high double-digit percentage of the Company&#8217;s annual aggregate Renaissance Product requirements in the U.S. The Renaissance Agreement contains conventional commercial pharmaceutical manufacturing provisions including certain minimum purchase amounts to be determined in the future based on forecast needs and minimum batch size projections. The Company may also request Renaissance to perform certain services related to the Renaissance Product, for which the Company will pay reasonable compensation to Renaissance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the amendment in September 2024, the amended initial term of the Renaissance Agreement commenced on September 17, 2024, and will terminate (a) for Renaissance Product designated for commercial sale in the U.S., on December 31 immediately following the fifth anniversary of the initial U.S. launch date (&#8220;U.S. Initial Term&#8221;), and (b) for Renaissance Product designated for commercial sale in the EU, on December 31 immediately following the fifth anniversary of the initial EU launch date (&#8220;EU Initial Term&#8221;), in each case unless earlier terminated by one of the parties. The U.S. Initial Term and EU Initial Term automatically renew for successive two-year terms (&#8220;Renewal Term&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b49ba2ee-c94d-455a-a1a2-2ac9ebed6aeb" contextRef="C_faf7e39c-0f29-434d-b6fb-e1d303cebf23" name="us-gaap:ContractTerminationClaimsDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Supply Agreement with Ompi</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company entered into a supply agreement (the &#8220;Ompi Supply Agreement&#8221;) with Nuova Ompi S.r.l. (&#8220;Ompi&#8221;), pursuant to which Ompi has agreed to supply glass microvials to support the Company&#8217;s manufacture and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Ompi Supply Agreement, the Company has committed to purchase, and Ompi has committed to supply, specified annual minimum quantities of glass microvials, which may be increased with prior notice by the Company or through the rolling forecast process, subject to a specified annual cap. Ompi is obligated to establish the relevant manufacturing force, assets and capabilities needed to comply with its supply obligations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, as partial consideration for the supply arrangement, the Company made an upfront payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1de15d30-f6f9-480f-94ea-1cfc9622a762" contextRef="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991" name="spry:UpfrontPayment" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d20b3490-d19f-469a-8176-7479a1d5ecac" contextRef="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991" name="spry:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) to Ompi. The supply price for the glass microvials is specified in the Ompi Supply Agreement, subject to an annual adjustment that is capped at a specified percentage except in the case of material and extraordinary increase in Ompi&#8217;s cost of manufacturing the glass microvials.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ompi Supply Agreement will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87acdcba-f595-4a9a-8abd-2edb48a8ee37" contextRef="C_7dfae0a7-c976-445c-9186-28e526f9917d" name="spry:SupplyAgreementExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and may be terminated (i) upon the parties&#8217; mutual written consent, (ii) by the Company for any reasonable business reasons (in which case the termination will become effective at the end of the following calendar year), or (iii) by the non-breaching party if the other party is in material breach of the Ompi Supply Agreement and fails to cure such breach within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_482a296b-ae25-497d-abc5-f8298073c5a5" contextRef="C_7dfae0a7-c976-445c-9186-28e526f9917d" name="spry:AgreementTerminationDueToMaterialBreach" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after receipt of notice thereof from the non-breaching party.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e77a85a8-8fcb-4b9c-a7a9-98208d8c48c6" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized Shares</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce13f3ac-8001-40f5-a502-ece21c33698d" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f684d17c-7278-48cf-8237-dd2cccd0676c" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bb61955-e2eb-4256-b947-18de1d868539" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_345903e8-b6c8-40b5-bc8c-664e8aba9a1f" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_976d4521-fd28-49af-8293-a363b3f1207b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.56%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.88%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:11.56%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f1df26b-5f3e-4745-a991-31293eaf7493" contextRef="C_952043ab-5fba-4c7d-bfff-86d859fc075f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,271,990</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe569e2d-1cc8-41c1-8031-75716592a7c6" contextRef="C_7d548bc4-9a01-48d0-9705-9105c2226181" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,161,180</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_216f5a82-951e-4d57-bc8a-f77fadbfe330" contextRef="C_3c6b92a6-dd38-411f-8214-dba5099c8f52" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,382</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9df5731b-ff9a-4b1f-9cc4-7865576f4695" contextRef="C_bdb38646-dad4-46e9-bb80-804ebaf2c503" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future awards or option grants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50611d8e-7fcf-47a1-8612-c9b13336ff78" contextRef="C_c12a3d9a-b30c-47d9-bb6d-6f0ae9453472" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,062,484</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77855711-4d05-4406-b06d-d1c605e69f08" contextRef="C_91a268b1-3615-40a5-ae0c-938276bfc07f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,905,773</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future employee stock purchase plan issuances</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_738491d3-ba6c-4c94-86e5-17f1cce8a140" contextRef="C_df005c86-508d-44b0-ae4f-f72b61e895e8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,811,182</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9684cd83-bbe3-4499-be46-7906cc64f998" contextRef="C_4d5e4244-5624-4eb9-83c5-28bcd9c0f0f1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,223,100</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb4b293d-3c95-4ebb-b919-ac88699d80df" contextRef="C_ad92b4a7-9dd4-43d7-8f4e-0ecdae3b7b74" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">45,456</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b251656b-3b59-4744-a892-7bf0a0d92190" contextRef="C_3a9f4cd4-fb54-4828-96ba-ce70b60363d6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">45,456</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3ec372f-503d-4ff2-b321-b0fc69f17b82" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,192,494</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e519692-a8a8-41d9-b816-de4263ae81cd" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,338,272</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Offerings</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the Company filed an automatic shelf registration statement on Form S-3ASR with the Securities and Exchange Commission which became effective upon filing (the &#8220;Shelf Registration Statement&#8221;). The Shelf Registration Statement allows the Company, from time to time, to offer and sell any combination of shares of the Company&#8217;s common stock and preferred stock, various series of debt securities, and/or warrants to purchase any of such securities, either individually or in combination with other securities, in one or more offerings. The Company simultaneously entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales agreement (the &#8220;Equity</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Agreement&#8221;) wit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">h Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) to allow the Company to offer, sell and issue shares of the Company&#8217;s common stock from time to time through Cantor acting as sales agent and up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c026c1-839a-4ef5-b39b-4232fb2a83cd" contextRef="C_6f2fdca3-8c4d-435f-b8c0-6a77fe46d870" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_855a93ec-e60d-4819-a71b-dcad86057b31" contextRef="C_2241ca04-d0e3-4458-81a0-72b7a112643d" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities have been sold pursuant to the Shelf Registration Statement or Equity Sales Agreement.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_c4204177-b4e2-49ae-945b-7c7efca0ab19" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_sbc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16495948-839f-46d2-b66d-7fa61f842761" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adcb83f2-e1e2-4c62-81c5-8a54b29f8e7f" contextRef="C_59f4bf3a-7f8e-4ad6-a506-194c1950572a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7ae8d92-49fe-4abe-988c-6e8f3a3e904b" contextRef="C_31e9248e-ea58-43c7-baab-8f7cb2a5c62d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_236db389-4dba-427b-8a21-a97d38d4c313" contextRef="C_150214a2-c270-468d-9a06-7728c1a7db0d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25215e1e-6707-4370-912a-1a6d5df5535d" contextRef="C_b92085ed-7b67-4267-a76c-73095df42f5b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_708e384a-3367-44e7-921c-1aed963af213" contextRef="C_05f55f90-a226-4553-acf7-98941d6f746b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,707</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea8e3c66-0a11-4909-8606-43cac381afa5" contextRef="C_b04c992f-7141-450b-a7c4-9f61a9eb497b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,452</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf39a3f6-2a3d-4f1b-8764-f182e06b7072" contextRef="C_ddc169de-f0a1-4298-8916-2c62ad23e107" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,342</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b85095a2-7d60-4fe9-8450-3a45bbe84303" contextRef="C_6f03d69b-1284-4bc4-8234-9a7df3551bf6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,856</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75619626-30d3-47c2-9ee0-d51a7e3a24e8" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,371</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0a7a6e9-22e9-484e-8b13-a2b44002fe02" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e86ddd3-ea6e-47cc-9c40-12896f55928f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,669</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4783232-9501-4246-b495-3df7525dbed5" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,680</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three and six months ended June 30, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_6fe07844-3b64-4ecb-a095-d31264bd87af" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6283136f-edf0-4b21-9472-3f9b46cd0a15" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on of stock compensation expense was capitalized into inventory, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c25b28-5f51-4d23-895c-0c5b48218258" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9ca0ff0d-bf8e-4842-9c42-6f24d261efb7" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense was capitalized into inventory during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the total unrecognized stock-based compensation expense related to outstanding employee options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce26cab0-ef12-4dae-b77c-6cdb91a70eec" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b09c37bf-d560-45bd-a349-9f99e01b9d5c" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbfeeb73-93d7-40b1-bd5b-a643b28921f0" contextRef="C_021eefc7-cfee-4d52-8b2d-03167d9c4f45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,382</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b461ce6-f7dd-4368-8dba-f73d1ffe1e9d" contextRef="C_081fe4fa-2c69-4289-b02a-3b63500a1252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted stock units outstanding, respectively.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_1" continuedAt="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f6aea47-b498-42ff-b95b-15b81a3fe2a7" contextRef="C_65ed12ba-e864-459f-ae4c-a7e1d4cf3b23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverba</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ck&#8217;s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db2dfb74-02e4-42b7-a991-a1aa6125ff38" contextRef="C_8c487881-ba76-4097-b6c8-427e2b451999" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,918</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db1ddc84-8cc0-4bd8-b93e-aeff6ca47dd5" contextRef="C_8337c8b0-3081-4566-b477-4a0f04a2f5aa" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,679</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></ix:nonNumeric></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_19f40a36-f8b2-4942-90f1-4acccd52e4b1" contextRef="C_0d090888-c874-48f6-b153-a3c2f3e3fe8a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,737,116</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were authorized under the 2016 and 2020 Equity Incentive Plans, of which </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_13f38460-33e9-4ad1-9a8d-a09e84489536" contextRef="C_9fd25023-3042-461b-9a6d-57b976f28f60" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,765,139</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99d6f5d5-a0a1-423b-b31d-e4b87ea017bf" contextRef="C_9fd25023-3042-461b-9a6d-57b976f28f60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,033,358</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were outstanding. As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e1672a2-b858-4ed3-9b01-167b607d09b6" contextRef="C_7ec42259-6316-479d-8953-352d08d61678" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,634,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were authorized under the 2018 Equity Incentive Plan, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01732960-7574-4458-b6d9-04997ac326fe" contextRef="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">297,345</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fcb7fe8-716a-48cd-8bf2-ef51f400e798" contextRef="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,240,014</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were outstanding. The Company does not intend to grant future stock options or other equity awards under the 2016 or 2018 Equity Incentive Plans.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the Company&#8217;s equity incentive plans expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c26e16c-77d1-4bf9-8603-54949aa517a2" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of grant and generally vest over a four-year period, with vesting either occurring at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e905fe69-c3a0-41ef-a0a3-80d67c3b6d6b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% at the end of the first year and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to the Company&#8217;s non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ab653d3-86c5-4d6d-a553-9c186aacb11a" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 is as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.11%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.662%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:8.942%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.662%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.182%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subject to</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Life (Years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d7a00e2-1741-466f-bb34-89f66d988ce7" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,161,180</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e55efcdd-545c-450e-91e0-a7996c683caf" contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.63</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10644691-54ea-4654-b3d9-f38bfbc2f9c8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,158,150</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_341d4803-6597-4e62-8b5e-29feb1f9c4af" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.54</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0825b49-dc9e-4313-ad50-ec95523b3c62" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">630,187</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fc93b38-28b0-42c1-a9f5-2028d07e6f34" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.07</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85f6c4a3-aa13-4251-94ba-ffe7ac37d626" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">417,153</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fbd9d3c-6096-41f2-8f3e-c45599ccc044" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.23</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d37625cd-9a61-45aa-aa7b-76876618ae92" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,271,990</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2aa0678-67b9-4b88-8aa2-f9f665c3d709" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.51</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d5341043-c0b4-4330-bb8b-be49d4da0617" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f42548e-20de-483b-b37f-2a0b45a48efe" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,541</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c863744d-ecc7-4ae9-b29c-2b5f88a4784e" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,540,712</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7bf0d38-962e-42c8-b76a-c847b56e14fe" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.72</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f408892f-c581-4315-af02-e9b4c5045563" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5dda70c-b835-44b4-8d81-ffd584d44569" contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,815</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercisable shares subject to options outstanding at June 30, 2025 in the table above include vested and early exercisable awards. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock for all options that were in-the-money at June 30, 2025. The aggregate intrinsic value of options exercised during the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64feec86-edff-427e-ab41-a67868f63e00" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d629feb4-ba6c-4200-946e-dd16a1705e84" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of option grants for the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_643a242a-c65b-4511-bb61-a4fe25d74692" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2ae5e9a-ccb6-418a-8065-808a72249966" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The total fair value of shares vested during the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49e97d89-03c8-402b-bbda-3b91b62707c0" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9781d35-d6c5-402c-ab7b-84131e203401" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f070790-3737-4614-8d40-ce912517731b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted was estimated using a Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the following weighted-average assumptions:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.343%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.343%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fdb99798-fee1-4d27-becc-24f247a5ba0f" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c92eee71-6e06-4543-b845-906531f1de42" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8abb5c-dc11-42f1-93b6-ee5309a4f3f3" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">86.7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b62c7884-d79e-4297-9072-356ee8564738" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">94.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44982bdb-1f28-4d95-8f8d-f6d008127dad" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ada4fed-40eb-4e94-ab96-1d6ce3bd0110" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a47bf71e-2973-480b-bfe8-00a76264b243" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd763901-abd4-466e-83a9-ab962b27d822" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of stock options was determined using the Black-Scholes assumptions below. Each of these inputs is subjective and generally requires significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The fair market value of the Company&#8217;s common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_2" continuedAt="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the Company&#8217;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free Interest Rate. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></p></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c4204177-b4e2-49ae-945b-7c7efca0ab19_3"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend Yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71c6dae0-2a7e-48b9-8457-08bd5a3976dc" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_ebp"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Employee Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company adopted a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#8217;s U.S. employees. The plan allows eligible employees to defer, at the employee&#8217;s discretion, pretax compensation up to the Internal Revenue Service (the &#8220;IRS&#8221;) annual limits. The Company matches up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_487e4808-d8cb-499a-871a-c2480b6a7386" contextRef="C_1ef13204-b17d-483a-99d0-289ce05e08db" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s pay that they contribute to the plan, subject to IRS limitations. Expenses associated with the Company&#8217;s matching contribution totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e031ab-ad8d-4c82-be2c-ae3e617e344b" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:DefinedContributionPlanAdministrativeExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebb02820-077a-4a45-9d66-adef8dbe606d" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:DefinedContributionPlanAdministrativeExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2025, respectively. Expenses associated with the Company&#8217;s matching contribution totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0af3b6be-935a-42d3-8303-4255717f6c00" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:DefinedContributionPlanAdministrativeExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c21873-538c-452f-bdc8-cfc929f907c7" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:DefinedContributionPlanAdministrativeExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2d5cecf-c4dc-44d8-b77b-46904410f5fd" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_relatedparties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Related-Party Transactions</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2015, the Company entered into a consulting agreement, superseded in July 2022, for regulatory and development services with Pacific-Link Regulatory Consulting, Inc., an entity owned by the President/Chief Executive Officer/director and his spouse, the Chief Medical Officer of the Company. The Company incurred consulting expenses related to this agreement totaling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a9a620b-cad2-4ee4-9469-673fb9cefab9" contextRef="C_f1c8cad0-d5f3-4e51-9804-2b151cd3b1f2" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5832a40f-b3a8-4ccd-8e46-c1979ef61d78" contextRef="C_286db13c-dcd3-4bda-8947-71e23b80ce46" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2025, respectively, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13fc4b5d-3ebb-4736-97c9-b376493b69c0" contextRef="C_d088454f-4075-431f-b4bb-11f7b482ba95" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a18db0f-4bb9-45f5-b342-8158e44f3369" contextRef="C_ddff9d59-8efa-4f5b-b496-c704a0bada3e" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2024, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company entered into a consulting agreement with Marlinspike Group, LLC (&#8220;Marlinspike Group&#8221;) to provide management, business consulting services and business development support. The managing member of Marlinspike Group is the Chair of the Board of Directors of the Company and one of its stockholders. The Company incurred expenses related to this agreement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_346343d7-a501-44e1-a5bc-ab6e9fc2be19" contextRef="C_2c9e3e1d-19ca-41b7-84e3-5196425f10d7" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a9f1d7ed-53aa-4f8c-8846-280312913bb1" contextRef="C_db43d886-40d2-497e-a347-d9adf0486580" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d820ca1f-853a-408c-8cd3-8672cea31103" contextRef="C_1ffef034-5c87-41ce-88e2-2b53d4ffa344" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f694f81d-8de7-44d8-b481-144c0fd7c89e" contextRef="C_758fe697-6dbc-4923-9ddf-258ba4a7c8ea" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2021, the Company entered into a consulting agreement, as amended in April 2022, with a member of the Board of Directors of the Company for general advice and assistance with the development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any future product candidates. As compensation for the consulting services the Company granted the member of the Board of Directors </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d435f204-f9c1-49c7-bc9c-34d29f7c50ff" contextRef="C_50bfc96e-86b2-4bfa-93e5-4dd89fe4840d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">590,950</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options that vest over a four-ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ar period. The Company incurred less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39fe83fe-adb0-49ae-90f8-46cfe7b540de" contextRef="C_4883e707-b9b1-4461-b2de-ffc404f7e7bd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_13b9d2e6-dafd-4316-afe6-0a2d0691d0ea" contextRef="C_2e65281f-ba53-4d3f-a689-1260aaaf239d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d650a30b-6751-4af1-9182-f0ade5cc6098" contextRef="C_b2af9dda-1f32-4532-acbd-bda315dd18f0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_81162a53-d20f-431c-8b9d-e1ce92def27b" contextRef="C_5d036733-4b5d-4177-a142-b4f41043ac6a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in stock-based compensation expense related to this agreement in each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_inlicense_supply"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10 &#8211; In-Licensing and Supply</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company is required to make milestone payments to Aegis upon achievement of certain regulatory and commercial milestones, and royalty payments to Aegis based on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2024, OrbiMed entered into an agreement with Aegis to purchase the rights, royalty interests, and related sales milestone payments on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A member of the Company&#8217;s Board of Directors is a General Partner at OrbiMed. The Company incurred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a79e279-1fba-45c0-932d-86b7840d5d11" contextRef="C_ba7df335-5578-421e-8c2a-d36e33edcb60" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea785081-d9c2-4bd9-aa52-74715c45553f" contextRef="C_a3dc6a53-1c90-4d3f-b90b-fea8237b5cd5" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty expense payable to OrbiMed during the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_14970636-4061-4c31-9288-f4b79dac5128" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_14970636-4061-4c31-9288-f4b79dac5128_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fn_segments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reports segment information using the management approach and views its operations and manages its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_626c3f50-1884-4203-bf7b-50eea6c01f4f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_909281c7-ede0-4bba-b36a-471c7ddb5563" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;), who is the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_84bd9e86-c4c0-4576-8d3c-cc8e99b6414a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, allocates resources and evaluates the performance of the operating segment based on historical and projected product sales, segment operating expenses, and condensed consolidated net loss, as reflected in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accompanying condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated statements of operations and comprehensive loss, which is the segment measure of loss.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_14970636-4061-4c31-9288-f4b79dac5128_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The segment reports that are provided to the CODM are tracked against the Company&#8217;s internally budgeted expenses. The segment operating expense categories consist primarily of the Company&#8217;s functional departments: Clinical, Development, Medical Affairs, Sales and Marketing, and General and Administrative. The CODM does not review assets when evaluating the operating segment&#8217;s performance; therefore, this information is not presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0014c33-75d5-4b1b-8417-36bbcea6dfc8" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_e0014c33-75d5-4b1b-8417-36bbcea6dfc8_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment reporting for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e183f9f8-4cf9-45bf-b1b7-be8bff3f98f9" contextRef="C_783dccc0-475e-4692-b8a3-08a49e9999dd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,800</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e166274-2a49-495c-8bc5-052e999de2a5" contextRef="C_828dc3d1-fee8-4736-9111-5a0102de64e0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94f9190-6f88-4d53-9acb-149b2afcf6b0" contextRef="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,563</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_696fdf12-7e71-4560-8ae6-6e7d56c78811" contextRef="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce21211-7c59-4dbb-9aa1-4e5ee054fa61" contextRef="C_21fe8e44-bec9-4153-ad91-5b5867687e88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,594</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d51b5c6-b483-491a-b0e6-beedb06f5188" contextRef="C_4fc6cb5f-4180-41ac-b434-d6945583ee10" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf22dfa-f11c-4542-915e-eb1e89ae873b" contextRef="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,804</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b8d9579-3980-4857-a5b8-bd939cfca472" contextRef="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5411d89-235e-4dcf-ab6c-f3eea401a1ef" contextRef="C_8855f418-1ce9-40e1-ba74-585019621581" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7adb092a-c6c3-4a5e-90ba-04c032ceddd7" contextRef="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db5deb2-d8a9-43f4-ac67-ca50e1b32e6c" contextRef="C_83b0f481-c291-42bf-a1fd-628b8759542f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e27f1ca6-9c9e-471c-b747-526c64af946c" contextRef="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11d8ba90-a450-4057-bedd-99391fad1738" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,717</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c318ac1d-cfbd-44e4-b6cc-4157ad17ff47" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6524c2ab-f461-448e-9fd8-8265179dc50e" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,690</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d8add8f-1c4e-4953-a606-57bf56feefa9" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment operating expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b1b8fd-3d79-45bd-b7ae-1d8e1b535d8f" contextRef="C_bb2d95de-4594-438d-9c55-a3a55b7278da" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,984</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_204095b2-9150-406e-89f5-35ba339eed98" contextRef="C_95f04ac1-14ef-4698-b351-83ecaff48cdb" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9cb926f-1131-4c03-b67c-5cb09d51c324" contextRef="C_86b564d1-cec7-431b-b172-b26077a97bfe" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,078</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7df24e8-d5aa-479f-8d8d-55dfde2faae8" contextRef="C_f9587472-b812-4c26-9f12-b181d477afd4" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e00e262-faca-4f0a-bf72-8000d655302f" contextRef="C_4029b4bb-de28-4de7-8408-45df90688cf8" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,250</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d903610f-6bfe-4a1f-9fbb-c743408cd6ef" contextRef="C_6ccd2d37-27d6-4e02-9364-bcfbddaf6936" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,226</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11847366-3b53-4464-8e20-e739d1f4784a" contextRef="C_e154ceb7-5441-4be7-956a-04c0dc49d336" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,454</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d7475aa-7b35-49db-9ff5-1b22d53562b3" contextRef="C_681b9e90-c822-4025-8193-e866cdf0d681" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,042</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd7c537-d4ab-4c38-ac6e-15295426e7f3" contextRef="C_fd906f79-8562-4a95-bd43-4d251d2344c8" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,151</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc496ca4-efbc-4e6a-b38a-6e102f21ec0d" contextRef="C_a668bc1e-23db-4ea8-85ec-8d8056d6f34d" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,591</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_889b85dc-249b-4afb-97e1-8754e33f5992" contextRef="C_99e7eb22-c9bf-4bcf-8348-7f1f227a5e4c" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,252</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbf26e1e-ffc1-4623-b8ad-442703c08d2d" contextRef="C_f1fd271e-7bfe-45dd-855c-01e649527ae5" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,099</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medical affairs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bca549a-d054-469f-873e-e7999698fce7" contextRef="C_3b7fe764-d042-4e16-bcf8-711a85614de6" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d061cdd-73ea-476a-af10-9cbf77dbbacf" contextRef="C_6770ee9a-57e6-4eef-bbaf-3da967bec8b1" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbf89ae6-346f-4a2f-8dea-040cd896d135" contextRef="C_7efb2cf9-3f33-4407-a356-10f47479dfdb" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c220a0e6-7515-4848-be62-fee8827f3074" contextRef="C_18b0fdd1-a485-4c6b-9072-308bd98cfbbe" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5acf1f-ed38-46de-b4ff-2ba50c03e4cf" contextRef="C_51f70a11-69b0-4dbd-9cc6-efbfee56c21f" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,925</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc036b93-ce08-4181-93a9-5906eb7516a5" contextRef="C_b79419a0-d171-46d7-996c-18c142afc6c1" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,694</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d3f8ad6-2328-45a3-9848-3558f99383ac" contextRef="C_53ececee-4b8b-4df1-8752-18134066f9be" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,682</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86e43333-3378-45a7-af13-1d66312f8fc2" contextRef="C_7763ab6b-709b-4a5c-8ecc-4d9c9531a9e9" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,145</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_213777b4-4c1e-4ca0-bb2a-8fca5239344c" contextRef="C_5c7ce1c8-b99f-46f8-92aa-5a9614bb368d" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,118</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89f98c42-f1bf-4205-9687-2a3d66266b53" contextRef="C_38ebd40d-47cc-434d-adce-a43b467c8b30" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,505</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f37908b-fdc1-44c3-96f5-f3bc4e82e7aa" contextRef="C_0d03ed93-9080-4cf9-9b33-e460f48b48e1" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,837</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db8acede-c8f5-41ad-8f72-dd72b44d7e1c" contextRef="C_f5b73dfd-e33e-4e24-ab07-812aebbe06f1" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,195</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77004250-c7db-4e90-9ea5-bd740ad8e83a" contextRef="C_8a13184c-6bcb-4906-a160-a36e0d4656ae" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,371</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d3ecbd1-3618-405d-ad90-cc3a5a629364" contextRef="C_1f628d09-1530-45b7-881c-0af4b02a1014" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c58b982-3968-4bbb-bc01-5f6433ef8b1d" contextRef="C_295e6502-8b12-4686-a1ab-212436254537" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,669</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5a15d02-4546-40ca-adbf-8a71920be95d" contextRef="C_dcc2baa6-8c87-4f57-a3dc-79e85b7ce8e5" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,680</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d530643-fb81-489b-8ace-a607680de573" contextRef="C_955465f7-5718-4609-97eb-6c7ac882fbc5" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ac2eb8e-3ae5-47ff-91e0-6553d18e70ce" contextRef="C_f02958dd-2171-4f6b-bf03-9a0ffab81bfe" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_783ae627-7304-49ec-b2e0-2a28e81639cd" contextRef="C_e0fe3c7b-f600-4c9b-b811-bf543aef3ed8" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57094773-6143-40f6-9604-0f18f00464f2" contextRef="C_450d35f9-0df1-4549-a5f8-a9c9ea015932" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total segment operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320b958e-f0dc-40ee-acf5-1e5a31ecea24" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,331</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8df8a0e2-a13e-451c-abc3-9c1efdaeb83d" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,840</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b6e4bf-8b01-420b-9f6c-86dd841214ed" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,481</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a536844-0ba5-46a2-824b-2d01f995032c" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="spry:SegmentOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,032</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f257f533-f6f9-4607-9f3a-4d29ace2a04e" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47,614</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34705c22-253d-4134-9fad-769a16b3e7c2" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,340</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9e5ad84-6228-4b7c-95bb-ce8737fd465b" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,791</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b71846b-8684-4f9f-9b66-9a439c180ae3" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,532</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44ff2847-df83-47ee-b184-c6f597afd840" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,731</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef58853-f835-4883-9bf8-7cb93c94a72f" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,824</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34a9d4af-397c-4930-9ba5-9228b0b1e908" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,968</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a83ec7a5-ea03-4157-b27c-955320eac071" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,724</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86108058-b6bd-4125-98c8-e7dd6908876f" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,883</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad30f7af-74d5-4d19-bf07-0c7f675c42e6" contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,516</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540f1b64-bf99-4627-ad2f-36b68ea4d621" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,823</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_678e1b06-75f6-428e-a481-8970b867ea82" contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,808</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_e0014c33-75d5-4b1b-8417-36bbcea6dfc8_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c84b6f20-e06b-4885-901f-0165de3de986" contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.  The Company is currently evaluating the provisions of the new law and the potential effects on its financial position, results of operations, and cash flows. As of the date of these financial statements, the Company has not completed its assessment, and therefore no adjustments have been made.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="parti_item2_mda"><span id="parti_item1_mda"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis together with our unaudited condensed consolidated financial statements and related notes thereto included in &#8220;Item 1. Financial Statements (Unaudited)&#8221; of this Quarterly Report on Form 10-Q and the audited financial statements and related notes thereto as of and for the year ended December 31, 2024 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March 20, 2025. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see the section above entitled &#8220;Forward Looking Statements.&#8221; As a result of many factors, including those factors set forth in the under the caption &#8220;Item 1A. Risk Factors&#8221; of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Risk Factors&#8221; section of this Quarterly Report to gain an understanding of the various factors that could cause actual results to differ materially from our forward-looking statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biopharmaceutical company focused on the commercialization and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(currently identified in the European Union (&#8220;EU&#8221;) by the tradename </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is the first and only U.S. Food and Drug Administration (&#8220;FDA&#8221;) and European Commission-approved needle-free epinephrine product, and the first new delivery method for epinephrine in more than 35 years. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions (including repeat dosing and allergen challenge). We believe the market opportunity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States alone is significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the current list price for a two-pack of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our target total gross-to-net yield, the estimated 6.5 million patients currently prescribed an epinephrine autoinjector in the United States represents an initial addressable market opportunity of approximately $3 billion in annual net sales, while the remaining 13.5 million diagnosed patients that have not been prescribed an epinephrine product represent an additional addressable market opportunity of approximately $7 billion in annual net sales.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s &#8220;no needle, no injection&#8221; approach addresses a significant unmet need in the use of epinephrine, which, except for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is currently approved only in injectable formulations for the emergency treatment of Type I allergic reactions. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, approximately 20 million people have been diagnosed and experienced severe Type I allergic reactions that may lead to anaphylaxis, and approximately 6.5 million were prescribed an epinephrine autoinjector. However (in 2023, for example), only 3.2 million filled their active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector with them due to the many drawbacks of these devices.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These drawbacks include the use of needles, which can result in patient and caregiver injury as well as hesitation and delays in administration due principally to apprehension and pain of needles, allowing the allergic reaction to progress in severity leading to symptoms that seriously impact patient quality of life, to potential need for emergency services and/or hospitalizations, and to life-threatening symptoms or events. In particular, intra-muscular injections are subject to dosing errors and risk of accidental blood vessel injections, which can cause a significant spike in the intravascular delivery of epinephrine potentially leading to serious cardiovascular complications or events. In aggregate, we estimate that up to 90% of patients prescribed an epinephrine device are not achieving an optimal treatment outcome today.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We believe </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates&#8217; design, particularly the compact size and &#8220;no needle, no injection&#8221; delivery, eliminates needle-related apprehension and pain, improves portability and ease of use, is highly reliable, and will increase prescriptions for epinephrine, making it more likely that patients and caregivers will administer epinephrine sooner, achieve more rapid symptom relief, and prevent the allergic reaction from progressing to a level of severity that could lead to hospitalization or even death.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from our studies of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrated nasally delivered epinephrine reached blood levels comparable to those of already approved epinephrine injectable products across single dosing, repeat dosing, self-administration or allergen challenge conditions, and produced statistically significant responses compared to injection on pharmacodynamic surrogates for efficacy even one minute after dosing with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2024, the FDA approved </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 mg for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children who weigh 30 kg or greater. As a result, we initiated commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 mg in the United States, with product becoming available for shipment on September 23, 2024. This commercialization effort currently includes a direct sales force of approximately 108 individuals targeting high-volume epinephrine prescribers that is supported by branded direct-to-consumer marketing, disease awareness campaigns with advocacy groups and non-personal promotion including continuing medical education programs in collaboration with allergist societies, speaker bureaus, peer-to-peer programs and participation in regional and national medical conferences. On March 5, 2025, the FDA approved </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 mg for the emergency treatment of Type I allergic reactions, including anaphylaxis, in patients who are four years of age and older and weigh 15 kg to less than 30 kg. As a result, we initiated commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1 mg in the United States, with product becoming available on May 7, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy U.S. Commercial Launch Initiated in September 2024</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img77826477_0.jpg" alt="img77826477_0.jpg" style="width:319px;height:319px;"/></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our launch strategy for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the United States involves direct outreach to high-volume prescribers of epinephrine accounting for approximately 55% of prescriptions in the last year through an efficient sales force. As of June 30, 2025, our sales force is comprised of approximately 108 ARS Pharma employees, who serve as sales reps, area sales managers, and national sales directors that began field operations as early as October 2024, as well as 10 virtual sales reps, and approximately 60 sales reps via our co-promotion partner, ALK-Abell&#243;, Inc. (&#8220;ALK U.S.&#8221;, an affiliate of ALK-Abell&#243; A/S (&#8220;ALK&#8221;)), who began field operations in early June 2025 and will target up to 9,000 specified pediatricians and other prescribers in the U.S. Our launch strategy is also supported by: active participation since November 2024 of approximately 2,800 healthcare professionals in our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience program that allows healthcare professionals to use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">firsthand as rescue therapy for anaphylaxis during in-clinic allergen challenge; extensive non-personal promotion including continuing medical education programs in collaboration with allergist societies, speaker bureaus, peer-to-peer programs and participation in regional and national medical conferences; engagement and contracting with payors to obtain timely coverage with favorable gross-to-net discounting; our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffyconnect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> program that provides support to physicians and patients including our $25 co-pay savings card, $199 cash price and patient assistance programs; a telemedicine service to conveniently obtain a prescription online; partnerships with patient advocacy organizations including disease awareness campaigns in 2025; and multi-channel branded direct to consumer advertising including connected television, linear television, point of care, endemic and programmatic display, social media, and paid search that initiated on May 15, 2025. We also initiated a U.S. post-marketing registry-based study for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the treatment of anaphylaxis in oral food challenge or allergen immunotherapy clinics in the second quarter of 2025.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 22, 2024, the EC granted marketing authorization in the EU for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the trade name for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2 mg in the EU), for the emergency treatment of allergic reactions (anaphylaxis), in adults and children who weigh 30 kg or greater. The 1 mg dose of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for children who weigh 15 to 30 kg is currently under review by the European Medicines Agency (&#8220;EMA&#8221;), and a regulatory decision is expected in the first half of 2026. Through our collaboration with ALK (discussed below), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was launched in Germany in June 2025. We received approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United Kingdom (&#8220;U.K.&#8221;) in July 2025 for the emergency treatment of allergic reactions (anaphylaxis), in adults and children who weigh 30 kg or greater, and commercial launch in the U.K. is expected late in the second half of 2025. Regulatory review of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is ongoing in Canada, China, Japan, and Australia with filings submitted by our partners, or by ARS Pharma on behalf of our partners, during the fourth quarter of 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been approved or is under regulatory review in countries representing approximately 98% of the current global epinephrine autoinjector sales. Regulatory decisions are anticipated by year-end 2025 in Japan, Canada and Australia, with commercial rollouts planned for the first half of 2026. A regulatory decision is also anticipated in the first half of 2026 in China.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We reported positive topline results demonstrating statistically significant and clinically meaningful improvements in treatment-refractory chronic urticaria patients at the American Academy of Allergy and Immunology medical conference in February 2024. In the second quarter of 2025, we initiated a Phase 2b randomized, placebo-controlled outpatient clinical trial involving chronic spontaneous urticaria patients, on chronic treatment regimens, who still experience flares or exacerbations. Topline data from this clinical trial is anticipated in the first half of 2026, followed by the potential initiation of a single pivotal efficacy study in 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception in 2015 as ARS Pharmaceuticals, Inc., we have devoted substantially all of our efforts to developing intellectual property, conducting product development and clinical trials, organizing and staffing, business planning, raising capital, building infrastructure, pre-commercial and commercial activities, and providing general and administrative support for these operations. We began commercial operations in September 2024 and therefore have had limited net product sales. We have funded our operations primarily with proceeds from the Merger (see </span><a href="#fn_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1 &#8211; Nature of Business</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the notes to the condensed consolidated financial statements included in this report), private placement of convertible preferred stock, issuance of common stock, licensing, supply and distribution arrangements with our commercialization partners, bank debt, and limited net product sales. As of June 30, 2025, we had cash, cash equivalents, and short-term investments of $240.1 million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses from operations in most years since our inception. Our net loss from operations for the six months ended June 30, 2025 and 2024 was $47.6 million and $15.3 million, respectively. As of June 30, 2025, we had an accumulated deficit of $202.1 million. Until we consistently generate positive net income, if ever, our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials, our expenditures on other development activities, the cost for regulatory filings, expenses for commercial activities to establish, maintain and enhance sales, marketing and distribution capabilities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the timing and volume of our product sales, and our ability to earn potential regulatory and commercial milestones under our license and collaboration arrangements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, that we can generate substantial product revenue, we may finance our operations through our existing cash, cash equivalents, short-term investments, equity offerings, debt financings and other capital sources which may include collaborations, strategic alliances, marketing, distribution or licensing arrangements or other arrangements with third parties. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. In addition, any future debt agreements may limit our ability to enter into certain debt financings without the consent of the lenders thereunder. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and may require us to delay or reduce our marketing and sales efforts, or delay, reduce or terminate our research and development programs or other operations, or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate manufacturing facilities. We currently rely on third-party manufacturers and suppliers for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates, and we expect to continue to do so to meet our nonclinical, clinical and commercial activities. Our third-party manufacturers are required to manufacture our product under cGMP requirements and other applicable laws and regulations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Collaboration Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company entered into a collaboration, license and distribution agreement (the &#8220;ALK Collaboration Agreement&#8221;) with ALK. Pursuant to the ALK Collaboration Agreement, the Company granted to ALK a worldwide (other than the United States, Japan, mainland China, Hong Kong, Taiwan, Macau, Australia and New Zealand) (&#8220;ALK Territory&#8221;), exclusive license under certain of the Company&#8217;s patents and know-how to develop, manufacture and commercialize products containing epinephrine administered intranasally, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the tradename for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2 mg in the European Union) (&#8220;Products&#8221;), for all human uses, including the immediate or emergency treatment of allergic reactions (including Type I) and anaphylaxis and urticaria, and other future indications as agreed by the parties. If the Company develops any new intranasally administered product that contains epinephrine and files a new drug application in the United States for such product (&#8220;New Product&#8221;), upon ALK&#8217;s request such New Product will be included as a Product under the ALK Collaboration Agreement, subject to ALK bearing the costs of development of such New Product for its licensed territory.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, we are obligated to transfer to ALK the existing marketing authorizations for the Products in the ALK Territory. We are also required to conduct certain development and regulatory activities for Products in support of obtaining further regulatory approval of Products in the ALK Territory, and will transfer such regulatory approvals to ALK. ALK is obligated to use commercially reasonable efforts to obtain and maintain regulatory approval for Products through the European Commission and within specified countries within the ALK Territory. Following such approval for a Product in each indication within specified countries within the ALK Territory, ALK is obligated to use commercially reasonable efforts to commercialize such Product in such indication in such countries and to achieve first commercial sale of a Product in certain countries in accordance with a timeline specified in the ALK Collaboration Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, ALK made an upfront payment to us of $145.0 million in November 2024, and we earned $5.0 million for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the ALK Territory in June 2025. We are eligible to receive additional outstanding regulatory and commercialization milestone payments of up to $15.0 million and sales-based milestone payments of up to $300.0 million, provided that $55.0 million of such sales-based milestones are contingent upon us obtaining regulatory approval for the Product in Canada by a specified time. We are entitled to receive tiered royalty payments on net sales in the mid- to high-teens, subject to certain standard reductions and offsets. Royalties will be payable, on a Product-by-Product and country-by-country basis, until the latest of the expiration of the licensed patents covering such Product in such country, 15 years from the first commercial sale of such Product in such country, or expiration of regulatory exclusivity for such Product in such country.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract will expire upon the expiration of the last-to-expire royalty term for all Products in the ALK Territory, unless terminated earlier. Either we or ALK may terminate the ALK Collaboration Agreement in the case of the other party&#8217;s insolvency or in the event of an uncured material breach of the other party, except that we may not terminate the ALK Collaboration Agreement for ALK&#8217;s material breach of its commercial diligence obligations. ALK may terminate the ALK Collaboration Agreement for convenience upon 12 months&#8217; prior written notice or for a safety or regulatory concern. We may terminate the ALK Collaboration Agreement in the event ALK makes certain challenges to certain of our patents. Prior to a change of control and outside of a set period of time after which we commence change of control negotiations, we may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area (&#8220;EEA&#8221;) upon prior written notice to ALK and payment of a termination fee that is the higher of an agreed mid-nine digit amount and the fair market value of the Products business in the EEA at the time of such termination. Except with respect to ALK&#8217;s activities pursuant to and in accordance with the ALK Co-Promotion Agreement (as defined below), we may also terminate the ALK Collaboration Agreement if ALK commercializes a non-injectable epinephrine product or manufactures such a product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Supply Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, in connection with the ALK Collaboration Agreement, ARS and ALK also entered into a commercial supply agreement (the &#8220;ALK Supply Agreement&#8221;), under which ARS will supply ALK&#8217;s requirements (and ALK will purchase from ARS its requirements) of Products for five years for a specified supply price, after which ALK may elect to transition to itself or its contract manufacturer the manufacture and supply of Products. Either the Company or ALK may terminate the ALK Supply Agreement in the event of an uncured material breach of the other party.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Co-Promotion Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, the Company and ALK U.S. entered into a co-promotion agreement (the &#8220;ALK Co-Promotion Agreement&#8221;) to co-promote </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to up to 9,000 specified pediatricians and other prescribers in the U.S. Accordingly, we granted ALK U.S. a non-exclusive, royalty-free license to use the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to the terms of the ALK Co-Promotion Agreement.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Co-Promotion Agreement, ALK U.S. was obligated to start its promotion activities in May 2025 and meet specified ramp-up milestones and minimum detail requirements, using sales representatives that meet specific qualifications. In addition, during the term of the ALK Co-Promotion Agreement and for 180 days thereafter, ALK U.S. will not market, sell or manufacture any injection product containing epinephrine in the U.S.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record all sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. and, subject to the terms of the ALK Co-Promotion Agreement, continue to have sole responsibility for all U.S. commercialization activities, including marketing, medical affairs, market access, production, distribution, pharmacovigilance, quality and safety.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will pay ALK U.S. a base fee to compensate ALK U.S. for its promotion activities. Payments for the first year of the partnership will be deferred and paid in the second year of the partnership. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from us starting in the second year of the partnership equal to 30% of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a 50% market share threshold during years three and four of the partnership.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ALK Co-Promotion Agreement expires on the fourth anniversary of the commencement of promotion activities thereunder. Either party may terminate the ALK Co-Promotion Agreement in the event of an uncured material breach of the other party or for either party&#8217;s change of control. We may terminate the ALK Co-Promotion Agreement in the case of ALK U.S.&#8217;s insolvency, if ALK U.S. fails to meet specified ramp-up timelines, or if ALK U.S. markets, sells or commercializes any non-injection product containing epinephrine in the U.S. After the first six months, we may terminate the ALK Co-Promotion Agreement if minimum detail requirements are not met for a consecutive three-month period. After the first year, we may terminate the ALK Co-Promotion agreement for any reason or no reason for a fee (as described below). After the first year, ALK U.S. may terminate the ALK Co-Promotion Agreement for any reason or no reason, and we may terminate the agreement in the event ALK U.S. restructures its sales force.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the ALK Co-Promotion Agreement by us for convenience, so long as ALK U.S. has met specified performance thresholds during the term, we are obligated to pay ALK U.S. a specified mid-to-low double-digit percentage of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified mid-quartile market share threshold that increases over time up to 50% for a specified period after termination, which period decreases in duration the later that the termination occurs. Upon termination of the ALK Co-Promotion Agreement by us in connection with a change of control of the Company, we are obligated to pay ALK U.S. a one-time mid-seven digit to low eight-digit termination fee in an amount that increases the later that the termination occurs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have recognized limited net product sales in the United States since the commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in September 2024. We have signed collaboration and license agreements for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for all geographies outside of the United States. The terms of these agreements may include payment to us of one or more of the following: non-refundable, upfront license fees; clinical, regulatory, and/or commercial milestone payments; clinical development fees; and royalties or a transfer price on net sales of licensed products if </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receives marketing approval in these regions. We expect product revenues to fluctuate in future periods as we continue with the commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We expect revenues under collaboration agreements to fluctuate in future periods based on our ability to meet various regulatory milestones, and contingent on successfully obtaining regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the licensed regions, commercial milestones, royalties or transfer price earned from our partner&#8217;s net sales and the supply of commercial product as set forth in the agreements described earlier.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold consists primarily of direct and indirect costs related to the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, excess or obsolete inventory adjustment charges, inventory write offs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, and royalties on product sales. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, costs incurred for the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will initially reflect a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers. We expect the cost of goods sold for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to increase in relation to product revenues as we deplete this inventory. As of June 30, 2025, we had $9.8 million in zero-cost inventory remaining and based on our current forecast, we expect zero-cost inventory to be depleted by mid-2026.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically evaluates zero-cost inventory for obsolescence. This evaluation considers the shelf life of raw materials, work in process, and finished goods as well as estimated sales trends. As of June 30, 2025, no zero-cost inventory was determined to be obsolete.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our research and development expenses have been related primarily to clinical development, process development, and manufacturing costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries, payroll taxes, benefits and stock-based compensation charges for personnel engaged in research and development efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">external research and development expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), investigative sites and consultants and other third-party organizations to conduct our clinical studies and development activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to manufacturing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates for clinical trials and process validation studies, including fees paid to third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to compliance with regulatory requirements and regulatory filings; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">indirect expenses including insurance and facility-related expenses.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our external research and development expenses for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates consist primarily of fees, materials and other costs paid to CROs, CMOs, consultant and contractors. Our clinical, regulatory, manufacturing, and non-clinical development costs for the periods presented below reflect an allocation of expenses associated with personnel costs, stock-based compensation expense, and indirect costs incurred in support of overall research and development, such as facilities-related costs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to remain relatively consistent in 2025 based on our planned clinical development and manufacturing activities. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials and the manufacturing costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates due to the inherently unpredictable nature of clinical development and manufacturing activities. Clinical development and manufacturing timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast to what degree our licensing, supply and distribution arrangements would affect our development plans and capital requirements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The duration, costs and timing of clinical trials and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates for the treatment of additional indications will depend on a variety of factors that include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per patient trial costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients that participate in the trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of sites included in the trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tariffs and international trade relations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time required to enroll eligible patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of doses that patients receive;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the drop-out or discontinuation rates of patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety profile of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost to seek regulatory approvals for our intranasal epinephrine technology product candidates in additional indications and any product candidates that successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing or maintaining commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation and regulatory guidance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations or to those of the third parties with whom we work; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we establish additional strategic collaborations or other arrangements.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates could significantly change the costs and timing associated with the development of that future product candidate. The process of conducting the necessary clinical research and manufacturing to obtain regulatory approval is costly and time-consuming. The actual probability of success for any future candidates may be affected by a variety of factors. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product&#8217;s or any future candidates&#8217; development, which could increase our research and development expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses consist primarily of salaries, benefits, stock-based compensation for personnel in executive, finance, business development, sales and marketing and other corporate administrative functions. Selling, general and administrative expenses also include pre-commercial launch activities prior to product launch, the initiation of commercialization activities in September 2024, legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax and administrative consulting services, and insurance costs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our selling, general and administrative expenses to increase substantially in 2025. The increase in expenses is due to our sales force which was established in the third quarter of 2024, the development and commencement of our marketing campaigns and initiatives, the ALK Co-Promotion Agreement, the hiring of additional sales and marketing personnel to support full commercialization activities, and the addition of infrastructure and programs to support commercialization activities. We expect to continue to incur audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, board of director fees, investor relations costs associated with operating as a public company, patent costs and defense, and general and administrative personnel.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net consists primarily of interest income from our cash, cash equivalents, and short-term investments, and net amortization and accretion associated with our short-term investments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended June 30, 2025 and 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the three months ended June 30, 2025 and 2024 (in thousands, except percentages):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50.37%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.182%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.182%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.942%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.662%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,800</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,800</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,594</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,094</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,717</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,217</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,984</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,984</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,035</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,896</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,861</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,312</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,944</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,368</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,331</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,840</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,491</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(47,614</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,340</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,274</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,731</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,824</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(93</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(44,883</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,516</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,367</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(118</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(97</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45,001</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,537</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,464</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">______________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Not meaningful</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes stock-based compensation expense as follows (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,707</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,452</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,371</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Revenue for the three months ended June 30, 2025 was $15.7 million, as compared to $0.5 million for the three months ended June 30, 2024. Revenue for the three months ended June 30, 2025 includes $12.8 million in net product revenues for sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$2.6 million in revenue for the achievement of the milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and for the performance of development and regulatory services performance obligations under the ALK Collaboration Agreement, and $0.3 million in revenue under supply agreements. Revenue for the three months ended June 30, 2024 includes the recognition of revenue for the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how under our license and distribution agreement with Seqirus.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Cost of goods sold for the three months ended June 30, 2025 was $5.0 million, as compared to zero for the three months ended June 30, 2024. Prior to August 2024, costs incurred to manufacture </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, and product sales subsequent to August 2024 primarily utilized zero-cost inventory. Cost of goods sold consisted primarily of product costs, the establishment of an inventory reserve, and royalties.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Research and development expenses for the three months ended June 30, 2025 was $4.0 million, as compared to $6.9 million for the three months ended June 30, 2024. The decrease of $2.9 million was primarily due to decreases in in-process research and development (&#8220;IPR&amp;D&#8221;) expense of $2.1 million, personnel-related expenses of $0.3 million, stock-based compensation expense of $0.3 million, and other research and development expenses of $0.2 million.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended June 30, 2025 and 2024 (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and regulatory</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,647</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,849</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing and non-clinical development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,388</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,047</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,035</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,896</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Selling, general and administrative expenses for the three months ended June 30, 2025 was $54.3 million, as compared to $8.9 million for the three months ended June 30, 2024. The increase of $45.4 million was primarily due to increases in marketing-related expenses of $28.2 million, personnel-related expenses of $9.0 million, stock-based compensation expense of $2.3 million, outside services and consulting fees of $1.8 million, travel and meals expense of $1.3 million incurred by our sales personnel, conference and seminar expense of $1.2 million, legal fees of $0.9 million, audit, tax and valuation fees of $0.3 million, and other general operating costs of $0.4 million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net for the three months ended June 30, 2025 was $2.7 million, as compared to $2.8 million for the three months ended June 30, 2024. The decrease of $0.1 million was primarily due to a decrease in net accretion of discounts on short-term investments of $0.5 million, partially offset by an increase in interest income of $0.4 million from our cash, cash equivalents, and short-term investments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Six Months Ended June 30, 2025 and 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024 (in thousands, except percentages):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50.37%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.182%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.182%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.942%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.662%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,563</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,563</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,804</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,304</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,690</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,190</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,078</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,078</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,987</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,130</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,143</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,416</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,902</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,514</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,481</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,032</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,449</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(84,791</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(28,532</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56,259</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,968</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,724</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(78,823</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,808</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56,015</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(266</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(194</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(79,089</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,002</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56,087</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">_____________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Not meaningful</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes stock-based compensation expense as follows (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,824</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,342</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,856</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,669</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Revenue for the six months ended June 30, 2025 was $23.7 million, as compared to $0.5 million for the six months ended June 30, 2024. Revenue for the six months ended June 30, 2025 includes $20.6 million in net product revenues for sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$2.8 million in revenue for the achievement of the milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and for the performance of development and regulatory services performance obligations under the ALK Collaboration Agreement, and $0.3 million in revenue under supply agreements. Revenue for the six months ended June 30, 2024 includes the recognition of revenue for the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how under our license and distribution agreement with Seqirus.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Cost of goods sold for the six months ended June 30, 2025 was $6.1 million, as compared to zero for the six months ended June 30, 2024. Prior to August 2024, costs incurred to manufacture </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, and product sales subsequent to August 2024 primarily utilized zero-cost inventory. Cost of goods sold consisted primarily of product costs, the establishment of an inventory reserve, and royalties.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Research and development expenses for the six months ended June 30, 2025 was $7.0 million, as compared to $12.1 million for the six months ended June 30, 2024. The decrease of $5.1 million was primarily due to decreases in IPR&amp;D expense of $2.1 million, clinical trial costs of $1.7 million, personnel-related expenses of $0.7 million, stock-based compensation expense of $0.5 million, and other research and development expenses of $0.4 million, partially offset by an increase in outside services of $0.3 million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the six months ended June 30, 2025 and 2024 (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and regulatory</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,233</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,264</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing and non-clinical development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,754</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,866</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,987</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,130</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Selling, general and administrative expenses for the six months ended June 30, 2025 was $95.4 million, as compared to $16.9 million for the six months ended June 30, 2024. The increase of $78.5 million was primarily due to increases in marketing-related expenses of $45.7 million, personnel-related expenses of $18.0 million, stock-based compensation expense of $4.5 million, outside services and consulting fees of $2.8 million, travel and meals expense of $2.7 million incurred by our sales personnel, conference and seminar expense of $1.8 million, legal fees of $1.3 million, audit, tax and valuation fees of $1.0 million, and other general operating costs of $0.7 million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net for the six months ended June 30, 2025 was $6.0 million, as compared to $5.7 million for the six months ended June 30, 2024. The increase of $0.2 million was primarily due to an increase in interest income from our cash, cash equivalents, and short-term investments of $0.7 million, partially offset by a decrease in net accretion of discounts on short-term investments of $0.5 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity and Capital</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant operating losses and negative cash flows from our operations. We have recognized limited net product sales since the commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024. We have funded our operations to date primarily with proceeds from the Merger, private placement of convertible preferred stock, issuance of common stock, licensing, supply and distribution arrangements with our commercialization partners, bank debt, and limited net product sales. As of June 30, 2025, we had cash, cash equivalents, and short-term investments of $240.1 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Cash flows</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the six months ended June 30, 2025 and 2024 (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents used in operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,334</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,989</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents provided by (used in) investing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,635</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,159</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash and cash equivalents provided by financing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,422</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">803</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(34,345</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, net cash used in operating activities was $80.3 million. This consisted primarily of a net loss of $78.8 million, an increase in our operating assets and operating liabilities of $28.3 million and $16.8 million, respectively, and non-cash charges of $10.0 million. The increase in our operating assets was due to increases in accounts receivable of $14.4 million, inventories of $13.2 million, and prepaid expenses and other assets of $0.7 million. The increase in our operating liabilities was primarily attributable to an increase in accounts payable and accrued expenses of $17.0 million, partially offset by a decrease in contract liability of $0.2 million. The non-cash charges consisted primarily of non-cash stock-based compensation of $10.7 million, establishment of an inventory reserve of $2.2 million, and depreciation and amortization expense of $0.6 million, partially offset by $3.4 million in net accretion of discounts on short-term investments.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2024, net cash used in operating activities was $14.0 million. This consisted primarily of a net loss of $22.8 million, an increase in our operating liabilities of $4.4 million, a decrease in our operating assets of $1.6 million, and non-cash charges of $2.8 million. The increase in our operating liabilities was primarily due to an increase in accounts payable and accrued liabilities of $4.4 million. The decrease in our operating assets was primarily due to a decrease in prepaid and other assets of $1.6 million. The non-cash charges consisted of non-cash stock-based compensation of $6.7 million, partially offset by $3.9 million in net accretion of discounts on short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, the cash and cash equivalents provided by investing activities was $77.6 million. This consisted of maturities of short-term investments of $143.5 million, partially offset by purchases of short-term investments of $65.7 million and purchases of property and equipment of $0.1 million. During the six months ended June 30, 2024, the cash and cash equivalents used in investing activities was $21.2 million. This consisted primarily of purchases of short-term investments of $151.0 million, maturities of short-term investments of $130.0 million, and purchases of property and equipment of $0.1 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, the $3.4 million of cash and cash equivalents provided by financing activities was attributable to proceeds from stock option exercises and issuance of common stock under the employee stock purchase plan. During the six months ended June 30, 2024, the cash and cash equivalents provided by financing activities was $0.8 million, which consisted of proceeds from stock option exercises and issuance of common stock under the employee stock purchase plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents, short-term investments, and revenues from product sales and cash proceeds from collaboration and out-licensing agreements will be sufficient to meet our anticipated cash requirements through at least the next three years. In particular, we expect our existing cash, cash equivalents, short-term investments, and revenues from net product sales and cash proceeds from collaboration and out-licensing agreements will allow us to fund commercial manufacturing and sales and marketing activities, general operating activities and working capital requirements, and proof of concept clinical trials of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional indications. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our intranasal epinephrine technology for additional indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and costs of clinical and commercial manufacturing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining marketing approvals for our intranasal epinephrine technology for additional indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of additional indications for our intranasal epinephrine technology that we may pursue and their development requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of commercialization activities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates, to the extent such costs are not the responsibility of any collaborators, including the costs and timing of building and maintaining product sales, marketing, distribution and manufacturing capabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue received from commercial sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any milestone and royalty payments under the ALK Collaboration Agreement, ALK Co-Promotion Agreement, Pediatrix Agreement, Aegis Agreement, Alfresa Agreement, Recordati Termination Agreement, and the Seqirus Agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we in-license or acquire rights to other products, product candidates, or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our employee headcount and building and maintaining a commercial infrastructure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a combination of our existing cash, cash equivalents, short-term investments, equity offerings, debt financings and other capital sources which may include collaborations, strategic alliances, marketing, distribution or licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, our current or future debt agreements may limit our ability to incur additional debt. If we raise funds through additional collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, development programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to raise additional funds may be adversely impacted by macroeconomic factors that may result in worsening global economic conditions and disruptions to and volatility in the global credit and financial markets, including due to tariffs, trade wars, inflation, high interest rates, recessionary concerns, recessions, bank failures, geopolitical conflicts, and general economic uncertainty. Because of the numerous risks and uncertainties associated with product development and commercialization, we cannot predict the timing or amount of increased expenses and cannot assure you that we will generate profits or positive cash flows from operating activities in the future.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to the supply of raw materials is $57.6 million as of June 30, 2025. Our estimated remaining payment obligations by year are as follows: 2025 ($0.9 million), 2026 ($10.5 million), 2027 ($11.8 million), 2028 ($13.8 million), and $2.9 million per year thereafter through 2035.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to hosted software license subscription fees is $2.5 million as of June 30, 2025. Our estimated remaining payment obligations by year are as follows: 2025 ($0.6 million), 2026 ($1.5 million), and 2027 ($0.4 million).</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we entered into a corporate sponsorship agreement with Food Allergy Research and Education, Inc., which was subsequently amended in May 2025, pursuant to which we have payment obligations of $14.0 million over a 43-month period. Our remaining payment obligations as of June 30, 2025 are $10.0 million. Our estimated remaining payment obligations by year are as follows: 2025 ($4.0 million), 2026 ($5.0 million), and 2027 ($1.0 million).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2018, we entered into a License Agreement (the &#8220;Aegis Agreement&#8221;) with Aegis Therapeutics, LLC (&#8220;Aegis&#8221;), a wholly owned subsidiary of Neurelis, Inc. In November 2024, OrbiMed Advisors LLC (&#8220;OrbiMed&#8221;) entered into an agreement with Aegis, to purchase the rights, royalty interests, and related sales milestone payments on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our remaining payment obligations to OrbiMed under the Aegis Agreement are contingent upon our achievement of certain commercial milestones and have been reduced to $11.0 million as of June 30, 2025. Under the Aegis Agreement, we are also required to make royalty payments to OrbiMed based on a mid-single-digit percentage of net product sales. Future royalty payment amounts are indeterminate since they depend on future revenues, which are uncertain.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023, we entered into a termination agreement (the &#8220;Recordati Termination Agreement&#8221;) with Recordati Ireland, Ltd. (&#8220;Recordati&#8221;) to reacquire the rights to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Europe and certain European Free Trade Association, Russia/the Commonwealth of Independent States, Middle East and African countries (the &#8220;Recordati Territory&#8221;). Pursuant to which, we are obligated to make milestone payments to Recordati that are contingent upon our achievement of certain regulatory and commercial milestones. Our remaining milestone payment obligations to Recordati have been reduced to &#8364;5.0 million (approximately $5.9 million in U.S. dollars) as of June 30, 2025. Under the Recordati Termination Agreement, we are also required to make royalty payments to Recordati of up to &#8364;5.0 million (approximately $5.9 million in U.S. dollars) in the aggregate from sales of Recordati Licensed Product(s) in the Recordati Territory. Future royalty payment amounts are indeterminate since they depend on future revenues, which are uncertain.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, we entered into the ALK Co-Promotion Agreement with ALK U.S. to co-promote </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to up to 9,000 specified pediatricians and other prescribers in the U.S. Pursuant to the ALK Co-Promotion Agreement, we will pay ALK U.S. a base fee to compensation ALK U.S. for its promotion activities. Payments for the first year of the partnership will be deferred and paid in the second year of the partnership. The total remaining payment obligations under this agreement are $26.8 million as of June 30, 2025. Our remaining payment obligations by year are as follows: 2025 ($0.0 million), 2026 ($4.4 million), 2027 ($14.2 million), 2028 ($4.6 million), and 2029 ($3.6 million). In addition to the base fee, ALK U.S will be eligible to receive performance-based payments from us. Future performance-based payment amounts are indeterminate since they depend on future revenues, which are uncertain.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the normal course of business with third-party contract organizations and vendors for clinical studies, manufacturing and other services and products. These contracts generally provide for termination after a notice period.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we have not recognized any reserves related to uncertain tax positions and had no accrued interest or penalties related to uncertain tax positions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, accrued expenses, stock-based compensation, and valuation allowances for deferred tax assets. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, there were no material changes to our critical accounting policies or estimates. Our critical accounting policies and estimates are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Significant Judgments and Estimates&#8221; in our Annual Report on Form 10-K filed with the SEC on March 20, 2025 and </span><a href="#fn_ssap"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to our unaudited condensed consolidated financial statements appearing in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><a href="#fn_ssap"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to our unaudited condensed consolidated financial statements appearing in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will remain an emerging growth company until the earlier of: (i) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year period; and (ii) December 31, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, on June 30, 2025, the aggregate market value of our common stock held by non-affiliates exceeded $700 million, based on the closing price of our common stock on The Nasdaq Stock Global Select Market on such date. As a result, effective December 31, 2025, we will be considered a &#8220;large accelerated filer&#8221;, as defined in Rule 12b-2 under the Exchange Act. We will be permitted to continue to comply with the scaled disclosures rules applicable to smaller reporting companies until the filing of our quarterly report on Form 10-Q for the quarter ending March 31, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="parti_item3_marketrisk"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not required for a &#8220;smaller reporting company&#8221; as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="parti_item4_controls"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. The term &#8220;disclosure controls and procedures&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partii_otherinfo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II &#8211; OTHER INFORMATION</span></p><p style="text-indent:-48.95pt;padding-left:48.95pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="partii_item1_legal"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. See </span><a href="#fn_commitmentscontingencies"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9 &#8211; Commitments and Contingencies</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the unaudited condensed consolidated financial statements in this Form 10-Q, which is incorporated by reference in this Part II, Item 1, for any required disclosure.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="partii_item1a_riskfactors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our results of operations and financial condition. The risk factors set forth below that are marked with an asterisk (*) did not appear as separate risk factors in, or contain changes to the similarly titled risk factor included in Item 1A. of our Annual Report on Form 10-K, filed with the SEC on March 20, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on the successful commercialization of neffy in the United States and in the EU for its currently approved indications in those jurisdictions. To the extent neffy is not commercially successful, our business, financial condition and results of operations would be materially adversely affected, and the price of our common stock would likely decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is our only product that has been approved for sale and it has only been approved in the United States for the emergency treatment of Type I allergic reactions, including anaphylaxis, in patients who are four years of age and older and weigh 15 kg to less than 30 kg (in the case of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 mg), and in adults and children who weigh 30 kg or greater (in the case of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 mg), and in the EU (under the trade name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and only in the 2 mg form) for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis, for adults and children with a body weight 30 kg or greater. We are focusing a significant portion of our activities and resources on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and we believe our near-term revenues are highly dependent on, and a meaningful portion of the value of our company relates to, our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States and the EU (under the trade name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Successful commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is subject to many risks. Prior to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we have not, as an organization, commercialized any product, and there is no guarantee that we will be able to do so successfully with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than we have. The commercial success of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> depends on the extent to which patients and physicians accept and adopt </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a treatment of Type I allergic reactions, including anaphylaxis, and we do not know whether our or others&#8217; estimates in this regard will be accurate. For example, if the population of patients who may suffer a Type I allergic reaction is smaller than we estimate or if physicians are unwilling to prescribe or patients are unwilling to use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any reason, the commercial potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited. It is too soon to tell how physicians, patients and payors will respond to the pricing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Physicians may not prescribe </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and patients may be unwilling to use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost. Additionally, any negative development for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in post-approval trials or potential additional indications, including urticaria, or in regulatory processes in other jurisdictions, may adversely impact the commercial results and potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Thus, significant uncertainty remains regarding the commercial potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is unsuccessful or perceived as disappointing, our stock price could decline significantly and the long-term success of the product and our company could be harmed.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to fully develop and maintain our sales, marketing and distribution capabilities on our own or through collaborations with marketing partners, we may not be successful in commercializing neffy.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have built a sales force and entered into the ALK Co-Promotion Agreement to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States. In order to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we must, among other things, continue to build our sales, marketing, distribution, managerial and other non-technical capabilities. Factors that may hinder our ability to successfully market and commercially distribute our products include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability of sales personnel to obtain access to or educate adequate numbers of physicians on the benefits and safety of prescribing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to recruit, retain and effectively manage adequate numbers of effective sales personnel, including ALK U.S. sales personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen delays, costs and expenses associated with maintaining our sales organization and receive the intended benefits to be provided by the ALK Co-Promotion Agreement.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to maintain an effective sales force, including through the ALK Co-Promotion Agreement, for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we may not be able to generate significant product revenue in the United States. In addition, until the commencement of our commercial launch in September 2024, no one in our sales force had promoted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are required to expend significant time and resources to train our sales force, including through the ALK Co-Promotion Agreement, to be credible in educating physicians and pharmacists on the benefits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, we must continually train our sales force, including through the ALK Co-Promotion Agreement, to ensure that a consistent and appropriate message about </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is being delivered to our potential customers. We currently have limited resources compared to some of our competitors, and the continued development of our own commercial organization to market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any additional products we may develop or acquire will be expensive and time-consuming. We also cannot be certain that we will be able to continue to successfully develop this capability.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into the ALK Co-Promotion Agreement with ALK U.S. for the co-promotion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to up to 9,000 specified pediatricians and other prescribers in the U.S. The commercial success of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the United States, will be influenced in part by the efforts and allocation of resources by ALK U.S. Currently, ALK U.S. has limited experience promoting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and while we will continue to work with ALK U.S. to optimize their commercialization activities, we cannot guarantee that such efforts will be successful. We also depend on ALK U.S. to comply with all applicable laws relative to the promotion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Because we do not control the individual efforts of ALK U.S., they may take actions or fail to take actions in a manner that is inconsistent with our interests. As a result, we may not realize the full potential benefits from the ALK Co-Promotion Agreement, and such actions or inactions could result in more limited or reduced sales, reputational harm, or regulatory or other adverse legal implications, any of which could adversely affect our business and results of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into exclusive licensing and collaboration agreements for the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with Alfresa Pharma Corporation in Japan; Pediatrix Therapeutics, Inc. in China, Macau, Hong Kong and Taiwan; CSL Seqirus in Australia and New Zealand; and ALK in all other unpartnered geographies outside the United States. If these third parties do not effectively engage or maintain their sales force for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if approved in the applicable territories, our ability to recognize milestone payments and royalties from the sales in such territories will be adversely affected.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to continue to expend significant time and resources to train our sales forces to be credible in discussing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with the specialists treating the patients indicated under the product&#8217;s label. In addition, if we are unable to effectively train our sales force and equip them with effective marketing materials our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> could be diminished, which would have a material adverse effect on our business, results of operations and financial condition.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy and our current and future intranasal epinephrine technology product candidates may fail to achieve the degree of market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or profits.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product before our U.S. commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may fail to gain sufficient market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community. Physicians may be reluctant to prescribe </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in place of well-established epinephrine intra-muscular injectable devices or other available treatments. Further, patients and caregivers may be reluctant to switch unless their physicians recommend switching products or are required to switch due to lack of coverage and adequate reimbursement. In addition, even though </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been determined to be safe and effective by the FDA and the EMA, safety or efficacy concerns in the medical community may hinder market acceptance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of market acceptance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any future intranasal epinephrine technology product will depend on a number of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to provide acceptable evidence of safety and efficacy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential advantages of the product compared to competitive therapies and our ability to successfully publicize these advantages or highlight them in any marketing materials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of the approved indication(s) for the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inclusion of any warnings or contraindications in the product label;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative convenience and ease of administration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of alternative treatments and products from our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing and cost effectiveness, which may be subject to regulatory control;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the standard of care for the targeted indications for the product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectiveness of our or our collaborators&#8217; sales and marketing strategy; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain sufficient third-party insurance coverage or adequate reimbursement levels.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market for neffy and our intranasal epinephrine technology may be smaller than we expect.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have focused our development of our intranasal epinephrine technology initially for the emergency treatment of Type I allergic reactions. We base our market opportunity estimates on a variety of factors, including our estimates of the number of people who have experienced severe Type I allergic reactions and are at risk of anaphylaxis, the continued growth rate of our patient population, the number of those in our patient population who we expect will fill a prescription for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those that currently do not fill prescriptions for epinephrine intra-muscular injectable devices or whose prescriptions have lapsed, the estimated increase in per patient device acquisition of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as compared to epinephrine intra-muscular injectable devices and the net sales of epinephrine intra-muscular injectable devices. These estimates are based on many assumptions and may prove incorrect, and new studies or market research may reduce our estimated patient population and potential sales. If our market opportunities are smaller than we expect, our future product revenues may be smaller than anticipated, which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to achieve and maintain adequate levels of third-party payor coverage and reimbursement for neffy on reasonable pricing terms, its commercial success may be severely hindered.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful sales of any approved products, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, depend on the availability of adequate coverage and reimbursement from third-party payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Even with coverage for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients may not use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost of those products.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payors may require documented proof that patients meet certain eligibility criteria in order to be reimbursed for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payors may even require that pre-approval, or prior-authorization, be obtained from the payor for reimbursement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Patients are unlikely to use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the market for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may depend significantly on access to third-party payors&#8217; medical policies, drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies, and we will be required to offer discounted rates to state Medicaid programs to ensure Medicaid coverage of our drugs. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available, even if not approved for the indication(s) for which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is approved.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. The current environment is putting pressure on companies to price products below what they may feel is appropriate. Selling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at less than an optimized price could impact our revenues and overall success as a company. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to each payor separately, with no assurance that coverage will be obtained, or that payment levels will be adequate for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any other products we may market. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or more products for which we receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, physicians may limit how much or under what circumstances they will prescribe or administer </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or any other products we may market, and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or any other products we may market, and thereby adversely impact our profitability, results of operations, financial condition and future success.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy has only been studied in a limited number of patients. neffy is now available to a much larger number of patients, and we do not know whether the results of neffy&#8217;s use in such larger number of patients will be consistent with the results from our clinical studies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to commercialization, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had been administered only to a limited number of patients in clinical studies. While the FDA and European Commission granted approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based on the data included in the NDA and marketing authorization application (&#8220;MAA&#8221;), respectively, we do not know whether the results when a large number of patients are exposed to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including results related to safety and efficacy, will be consistent with the results from earlier clinical studies of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that served as the basis for the approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. New data relating to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may result in changes to the product label and may adversely affect sales, or result in withdrawal of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the market. The FDA and regulatory authorities in other jurisdictions may also consider the new data in reviewing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s marketing applications for additional indications and/or in other jurisdictions, or impose post-approval requirements. If any of these actions were to occur, it could result in significant expense and delay or limit our ability to generate sales revenues.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive products may reduce or eliminate the commercial opportunity for neffy or our current and future intranasal epinephrine technology product candidates. If our competitors develop technologies or product candidates more rapidly than us, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize neffy and our current and future intranasal epinephrine technology product candidates may be adversely affected.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical and commercial landscape for the emergency treatment of Type I allergic reactions is highly competitive and subject to significant technological change. We face competition with respect to our current indications for our intranasal epinephrine technology, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and will face competition with respect to any future indications of our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other product candidates that we may seek to develop or commercialize in the future from large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. Based on the initially approved indications for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we anticipate that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will compete primarily against epinephrine intra-muscular injectable products, for the emergency treatment of Type I allergic reactions including EpiPen and its generics, which is marketed by Viatris, Inc. and Teva Pharmaceuticals, Inc.; Adrenaclick, which is marketed by Amneal Pharmaceuticals, Inc.; Auvi-Q, which is marketed by Kaleo, Inc.; and Symjepi, which is marketed by Sandoz, Inc., a Novartis division. Several other companies are also clinically developing larger dose intranasal epinephrine product candidates that may compete with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including Bryn Pharma, Nasus Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Orexo AB and Belhaven BioPharma. Aquestive Therapeutics is developing a sublingual candidate based on a prodrug of epinephrine. If our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are approved for other indications, they would also compete with a range of other therapeutic treatments that are well established such as antihistamines or in development.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our potential competitors have substantially greater financial, technical, commercial and human resources than we do and significantly more experience in the discovery, development and regulatory approval of product candidates and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#8217; products may be more effective, safer, or more effectively marketed and sold, than any product candidate we may commercialize and may render </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obsolete or non-competitive before we can recover development and commercialization expenses. In addition, our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less costly than </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current and future intranasal epinephrine technology product candidates, which could render such products or product candidates obsolete and noncompetitive.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face competition based on many different factors, including the efficacy, safety and tolerability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current and future intranasal epinephrine technology product candidates, the ease with which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can be administered, the scope of regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our competitors may obtain patent protection, regulatory exclusivities or regulatory approval and commercialize products more rapidly than we do, which may impact future approvals or sales of any of our products that receive regulatory approval. We will also be competing with respect to marketing capabilities and manufacturing efficiency for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as an early commercial stage product. We expect competition among future products, if any, will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payors, regulatory exclusivities and patent position. Our profitability and financial position will suffer if our product or future products cannot compete effectively in the marketplace.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early commercial stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our activities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the FDA, the European Commission or other comparable foreign regulatory authorities approve generic versions of neffy or our current or future intranasal epinephrine technology product candidates that receives regulatory approval, or such authorities do not grant our products appropriate periods of non-patent exclusivity before approving generic versions of such products, the sales of such products could be adversely affected.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, once an NDA is approved, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the United States. In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and adequate labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Moreover, third-party insurers require, and many states allow or require, substitution of therapeutically equivalent generic drugs at the pharmacy level even if the branded drug is prescribed. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be lost to the generic product.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may not finally approve an ANDA for a generic product or a Section 505(b)(2) NDA of a competitor until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the listed drug is invalid, unenforceable or will not be infringed by the generic product. In that case, the applicant may submit its application four years following approval of the listed drug and seek to launch its generic product even if we still have patent protection for our product unless an infringement suit is timely filed by the NDA or patent holder in which case the FDA cannot approve the ANDA or a Section 505(b)(2) NDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon receiving a marketing authorization in the EU from the European Commission, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity. Comparable regimes to those in the US and EU exist in some other major markets, including the United Kingdom.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining regulatory approval of neffy or our current or future intranasal epinephrine technology product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval in other jurisdictions.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even though we have obtained regulatory approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the United States and the EU, there is no guarantee that we will be able to maintain these regulatory approvals or obtain or maintain regulatory approval in any other jurisdiction. A failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even though the FDA and European Commission have granted marketing approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comparable regulatory authorities in other foreign jurisdictions must also approve the manufacturing, marketing and promotion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">before it can be marketed in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States or the EU including additional nonclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States including certain jurisdictions in the EU, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have submitted and plan to submit additional or supplemental marketing applications in the United States and in the EU. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions and such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and compliance with other regulatory requirements could result in significant delays, difficulties and costs for us and could require additional nonclinical studies or clinical trials, which could be costly and time-consuming and could delay or prevent the introduction of our products in certain countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. We have one product approved for sale. We have limited experience in obtaining regulatory approval in domestic and international markets. If we or our collaboration partners fail to comply with the regulatory requirements in international markets and/or obtain and maintain applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will be harmed.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop our current or future intranasal epinephrine technology product candidates, or neffy for additional indications, or experience significant delays in doing so, the commercial potential of our current or future intranasal epinephrine technology product candidates or neffy will be more limited.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful continued development and ultimate regulatory approval of our current or future intranasal epinephrine technology product candidates and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional indications is important to the future success of our business. The future regulatory and commercial success of our current or future intranasal epinephrine technology product candidates and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional indications is subject to a number of risks, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of nonclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful data from our nonclinical studies and clinical trials that support an acceptable risk-benefit profile of our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the intended populations and indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfaction of applicable regulatory requirements, including to satisfy applicable rules governing combination products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unforeseen safety issues or adverse side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt and maintenance of marketing approvals from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">remaining in compliance with post-marketing regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our intranasal epinephrine technology;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements or maintaining existing arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our intranasal epinephrine technology;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entry into collaborations to further the development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in other jurisdictions or for additional indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continuing to grow our sales, marketing and distribution capabilities and commercializing any approved products, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully commercializing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by patients, the medical community and third-party payors of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current and future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining third-party coverage and adequate reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products, following approval, maintaining a continued acceptable safety profile;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensuring that we promote and distribute our products consistent with all applicable healthcare laws; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing and defending intellectual property rights and claims.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory submission and review process, maintaining regulatory approval, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any current or future collaboration partner. If we or a collaboration partner are unable to develop, receive regulatory approval for our intranasal epinephrine technology for the additional indications we are developing it for, including urticaria, or if we experience delays as a result of any of these risks or otherwise, our ability to grow our business will be limited.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the FDA does not conclude that our current or future intranasal epinephrine technology product candidates, or neffy for additional indications, satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates or additional indications under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates or additional indications will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hatch Waxman Act added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if available to us, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for any additional indications by potentially decreasing the amount of nonclinical and/or clinical data that we would need to generate in order to obtain FDA approval. This pathway does not, however, expedite the FDA review process timelines.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA does not allow us to proceed under the Section 505(b)(2) regulatory pathway for our current or future intranasal epinephrine technology product candidates, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional indications, we may need to conduct additional nonclinical studies and/or clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for any such product candidates or additional indications, including for urticaria, and complications and risks associated with such product candidates, would likely substantially increase. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in new competitive products reaching the market more quickly than any product candidates we develop, which could adversely impact our competitive position and prospects. We cannot assure you that our current or future intranasal epinephrine technology product candidates or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional indications will receive the requisite approval for commercialization.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2), certain pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its Section 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to certain requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of a new product. Even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. Finally, a competitor might receive FDA approval and obtain non-patent market exclusivity before we obtain approval of any such product candidates or additional indications, including urticaria, which could delay approval of potential additional indications, including urticaria, for our intranasal epinephrine technology.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, further development and the commercialization of our current and future intranasal epinephrine technology product candidates.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals to market and commercialize our current and future intranasal epinephrine technology product candidate, including for urticaria, we must demonstrate through extensive nonclinical studies and clinical trials that such product candidates are safe and effective for their intended use in humans. Nonclinical and clinical testing are expensive and can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays in completing our clinical trials or nonclinical studies and initiating or completing additional studies or clinical trials. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize for our current and future intranasal epinephrine technology product candidates, including for urticaria, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, ethics committees or other reviewing bodies may not authorize or issue positive opinions permitting us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not reach an agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a delay in receiving study or clinical trial material from outside the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of subjects or patients required for clinical trials of our current and future intranasal epinephrine technology product candidates, including for urticaria, may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors, including those manufacturing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may have to amend clinical trial protocol(s) submitted to regulatory authorities or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to resubmit to an IRB or ethics committee and regulatory authorities for re-examination;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen safety events may occur during the course of a clinical trial and these events may result in the temporary suspension or termination of a clinical trial, or require urgent safety measures or restrictions to protect human subjects during the conduct of a clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, ethics committees or other reviewing bodies may fail to approve or issue positive opinions or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we have entered and may enter into agreement for clinical and commercial supplies, or the supply or quality of our current and future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other materials necessary to conduct clinical trials of our current and future intranasal epinephrine technology product candidates, including for urticaria, may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential for policies or regulations of the FDA, the EMA, the EU or any other applicable foreign regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulators, IRBs and ethics committees of the institutions in which clinical trials are being conducted, or data monitoring committees may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to appear to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Negative or inconclusive impressions of the results from our earlier clinical trials of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the emergency treatment of Type I allergic reactions or any other clinical trial or nonclinical studies in animals that we have conducted, could mandate repeated or additional nonclinical studies or clinical trials and could delay marketing approvals or result in changes to or delays in nonclinical studies or clinical trials of our current and future intranasal epinephrine technology product candidates, including for urticaria. While data from our studies of our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrated nasally delivered epinephrine reached blood levels comparable to those of already approved epinephrine injectable products, we do not know whether any future clinical trials or studies that we may conduct will demonstrate adequate efficacy and safety necessary to result in obtaining regulatory approval to market our current and future intranasal epinephrine technology product candidates, including for urticaria. If later stage clinical trials do not produce favorable results that meet regulatory authority criteria, our ability to obtain regulatory approval for our current and future intranasal epinephrine technology product candidate, including for urticaria, may be adversely impacted.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to successfully initiate and complete clinical trials of our current and future intranasal epinephrine technology product candidates, including for urticaria, and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market our current and future intranasal epinephrine technology product candidates, including for urticaria, would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our current and future intranasal epinephrine technology product candidates, including for urticaria, or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize such product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of our current and future intranasal epinephrine technology product candidates, including urticaria.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline by identifying additional indications for which to investigate intranasal epinephrine technology in the future or by developing or acquiring new products or product candidates. We may expend our limited resources to pursue a particular indication or formulation for our intranasal epinephrine technology and fail to capitalize on product candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is approved in the United States for the emergency treatment of Type I allergic reactions, including anaphylaxis, in patients who are four years of age and older and weigh 15 kg to less than 30 kg (in the case of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 mg), and in adults and children who weigh 30 kg or greater (in the case of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 mg), and in the EU (under the trade name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and only in the 2 mg form) for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis, for adults and children with a body weight 30 kg or greater, as part of our longer-term growth strategy, we are evaluating and plan to continue to evaluate our intranasal epinephrine technology, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for use in other potential indications. We may evaluate opportunities to in-license or acquire other development programs, product candidates, as well as commercial products, including for the treatment of other indications like Type I allergic reactions. Other than our intranasal epinephrine technology, we do not currently have any other programs in development. Our development of our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for other indications remains at an early clinical development stage and will require significant further investment and regulatory approvals prior to commercialization in such indications. Because we have limited financial and managerial resources, we are focused on specific indications for our intranasal epinephrine technology. As a result, we may fail to generate additional clinical development opportunities for our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for a number of reasons, including, that our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may in certain indications, on further study, be shown to have harmful side effects, limited to no efficacy or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. In addition, we may forgo or delay pursuit of opportunities with other indications that could have had greater commercial potential or likelihood of success. We may not be able to develop our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any additional indications based on resource allocation decisions and other reasons. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development activities for specific indications may not yield any commercially viable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research activities to identify additional indications for our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require substantial technical, financial and human resources. Additionally, any future potential indications for our intranasal epinephrine technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will require the selection of suitable patients for our clinical trials and additional clinical development, management of clinical, preclinical and manufacturing activities, obtaining regulatory approval, obtaining manufacturing supply, continued build out of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product sales in such additional indications, if approved. We are not permitted to market or promote any future indications before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval. By such time, if ever, as we may receive necessary regulatory approvals for any potential additional indications for our intranasal epinephrine technology, including urticaria, the standard of care for such treatments may have evolved such that it would be necessary to modify our plans for full approval and commercial acceptance of such products may be limited by a change in the standard of care. Additionally, if we receive the necessary approval for any additional indications for our intranasal epinephrine technology, we may not realize the full potential benefits from the sale of our intranasal epinephrine technology for such indications due to our existing collaboration and marketing arrangements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Even if we develop, license, or otherwise acquire potential product candidates or development programs, and obtain the required financing or establish a collaboration to enable us to conduct pre-clinical and clinical development of such product candidates, we cannot be certain that such development would be successful, or that we will obtain regulatory approval or be able to successfully commercialize any other product candidates and generate revenue. Further, even if any product candidate we develop or acquire was to receive marketing approval, we would continue to bear the risks that the FDA or similar foreign regulatory authorities could revoke, vary or suspend approval of our product candidate or that safety, efficacy, manufacturing or supply issues could arise with such product candidate.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The results of early-stage clinical trials and preclinical studies may not be predictive of future results. Initial data in our clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. In addition, initial data in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our ongoing, planned or future clinical trials will ultimately be successful or support further clinical development or regulatory approval of our current or future intranasal epinephrine technology product candidates. There is a high failure rate for drugs and biologics candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy or our current or future intranasal epinephrine technology product candidates may cause undesirable side effects, adverse events, or have other properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects or adverse events caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current or future intranasal epinephrine technology product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay, denial, or withdrawal of regulatory approval by the FDA, the European Commission or comparable foreign regulatory authorities. Although our clinical studies to date have demonstrated that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is well-tolerated by patients with no serious treatment-related adverse events, and reported adverse events generally no more severe than grade 1 and comparable with injection products, and with no meaningful pain or irritation based on formal scoring, results of our ongoing or future clinical trials for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates could reveal a high and unacceptable severity and prevalence of side effects, adverse events, or unexpected characteristics. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects or adverse events that prevented further development of the compound.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable side effects or adverse events are observed following the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, including for urticaria, we, the FDA or comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, or the independent safety monitoring committee could suspend or terminate our clinical trials or regulatory authorities could order us to cease clinical trials, restrict us or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current or future intranasal epinephrine technology product candidates, including withdrawing the marketing approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates or deny approval for or all targeted indications. Treatment-emergent side effects and adverse events that are deemed to be drug-related could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims, an unwillingness of physicians to prescribe </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for approved indications, patients&#8217; unwillingness to purchase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, or payors&#8217; willingness to cover </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Undesirable side effects or adverse events resulting from the use of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates (whether by patients in our clinical studies or through the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates) could adversely affect enrollment in clinical trials, regulatory approval and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates. Additionally, there may be negative findings regarding components of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates by other parties. Any negative findings by third parties may impact </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for its initially approved indications and labeling, or the future approvability or labeling of our current or future intranasal epinephrine technology product candidates, including for urticaria. In addition, all side effects and adverse events may not be appropriately recognized or managed by the treating medical staff. Inadequate training in recognizing or managing the potential side effects and adverse events of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, clinical trials of our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are and have been conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, our intranasal epinephrine technology product candidates are comprised of epinephrine and Intravail that is delivered via an intranasal device. Intra-muscular injection of epinephrine has been approved by the FDA and other regulatory authorities for the emergency treatment of Type I allergic reactions. In addition, Intravail has previously been included in the formulations of FDA approved products such as VALTOCO and TOSYMRA nasal sprays. The intranasal apparatus we use to deliver our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been used to deliver several drugs approved by the FDA and other regulatory authorities, including VALTOCO, TOSYMRA and NARCAN. Even though </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has received marketing approval for its initial indication, we are subject to the risks that the FDA, European Commission or similar regulatory authorities could revoke approval of intra-muscular epinephrine injection products, other drug formulations containing Intravail or utilizing the same intranasal apparatus, or that efficacy, manufacturing or supply issues could arise with epinephrine API, Intravail or our intranasal apparatus. This could result in our own products being removed from the market or being less commercially successful.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We received Fast Track designation for neffy in the United States and may in the future pursue Fast Track designation for other product candidates that we may develop, but we might not receive such future designations, and Fast Track designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the FDA may grant a product candidate Fast Track designation. Fast Track designation is intended to expedite or facilitate the process for reviewing new drug products meeting the specified criteria and gives the sponsor of a Fast Track product opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. We were granted Fast Track designation for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the emergency treatment of Type I allergic reactions and may in the future request Fast Track designation for additional indications for our current or future intranasal epinephrine technology product candidates, however, we cannot assume that any such applications will meet the criteria for that designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development activities.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek priority review by the FDA for potential additional indications, including urticaria, for our current or future intranasal epinephrine technology product candidates, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may in the future request priority review designation for potential additional indications, including urticaria, for our current or future intranasal epinephrine technology product candidates, however, we cannot assume that any application for priority review will meet the criteria for that designation. A product is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a serious condition compared to marketed products. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to standard FDA review and approval. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us or any of our current and future licensing and collaboration partners could divert our resources and attention, cause us to incur substantial liabilities and limit commercialization of neffy or our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, commercialization, and use of pharmaceutical products. Currently, we have one product, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that has been approved for commercial sale. The sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the use of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by us and any current and future licensing and collaboration partners in clinical trials may expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers, pharmaceutical companies, our current and future licensing and collaboration partners or others using, administering, or selling any of our future products, if approved. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination of clinical trial sites or entire trial programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant litigation costs, including with respect to potential class action lawsuits;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to, or costly settlements with, patients or other claimants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls or a change in the indications for which they may be used;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management and scientific resources from our business operations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the commercialization and clinical testing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Although the clinical trial process is designed to identify and assess potential side effects and adverse events, clinical development does not always fully characterize the safety and efficacy profile of a new drug, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates causes adverse events or side effects, we may be exposed to substantial liabilities. Physicians may not prescribe or patients may not use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for its approved indications or in accordance with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s our current or future intranasal epinephrine technology product candidates&#8217; instructions or any warnings that identify known potential adverse effects, side effects, and patients who should not use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. We are highly dependent upon consumer perceptions of us regarding the safety and efficacy of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage in the amount of up to $10.0 million in the aggregate, including commercial product liability and clinical trial liability, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we and the third parties with whom we work collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;process&#8221;) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information (collectively, &#8220;sensitive data&#8221;). As a result, we and such third parties face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, which could materially disrupt our systems and operations, supply chain, and ability to conduct our business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as a fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. We also rely on our licensing and collaboration partners, our CROs, third-party logistics providers, distributors and other contractors and consultants to utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities, including in connection with our clinical trials.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could, and in certain cases have, experienced adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats have in the past and may in the future cause a security incident or other interruption that have in the past and may in the future result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. For example, we have been the target of unsuccessful phishing attempts in the past, as well as successful phishing attempts that did not have a material adverse effect, and expect such attempts will continue in the future. In addition, we have become aware of certain security incidents whereby vendor email accounts have been hacked and the bad actors impersonate our vendors in email communications with us. None of these incidents have had a material adverse effect on our business. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our business.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations have required us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We have not and may not in the future, however, detect and remediate all such vulnerabilities, including on a timely basis. Vulnerabilities could be exploited and result in a security incident. Any unremediated critical or high risk vulnerabilities could pose material risks to our business. Further, we have and may in the future experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to operate our business. For example, the loss of clinical trial data from completed, ongoing or future clinical trials for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.*</span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and for the advancement of our clinical development programs. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We source raw materials, active pharmaceutical ingredient (&#8220;API&#8221;) and other important components related to the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates, including Intravail and our nasal sprayer apparatus, from international suppliers located in the European Union. Although we anticipate that our current supply of materials for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our product candidates will be sufficient for at least the next 18-24 months, tariff policies, particularly those affecting the Europe Union and pharmaceutical products could materially increase our costs and reduce our margins, including as a result of our inability to adjust pricing in formulary-based markets. Recent and potential future changes in international trade policies, particularly regarding pharmaceutical-specific tariffs, present material risks to our operations and financial performance.</span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent policy discussions have included potential targeted tariffs or other trade measures specifically aimed at pharmaceutical products and ingredients as part of broader healthcare cost control or national security initiatives. Unlike consumer goods, pharmaceuticals face unique regulatory constraints that make rapid supply chain adjustments particularly difficult and costly. Should additional tariffs be imposed, including those specifically targeting pharmaceutical imports, our production costs could rise significantly, and it would be difficult and costly to qualify alternative sources within another country with a lower tariff rate or within the United States, as developing and qualifying alternative sources typically requires at least 18-24 months and substantial investment and regulatory approvals. Moreover, the dynamic and unpredictable tariff and trade landscape creates substantial uncertainty and significant planning challenges for our operations. Changes in tariff classifications, country-of-origin requirements, or customs procedures can occur with limited notice. This uncertainty complicates our long-term investment decisions regarding manufacturing facilities, supply chain optimization, and research and development locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unlike many industries, our ability to pass increased costs to customers is limited by the structure of pharmaceutical pricing and reimbursement systems. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is included in formularies with pricing established through annual or multi-year contracts with commercial, third-party payors and pharmacy benefit managers, and reimbursement methodologies established by government programs, such as Medicare. These arrangements typically include fixed pricing terms that were negotiated prior to the implementation of the recently announced tariffs. As a result, and depending on the timing and scope of the implementation of these tariffs, cost increases due to tariffs may be difficult or impossible to pass through to customers until the next negotiation cycle, which could be up to 36 months away.</span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current or future tariffs may also result in increased research and development expenses, including with respect to increased costs associated with raw materials, API, laboratory equipment and research materials and components. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence and negatively impact our business, results of operations, financial condition and growth prospects.</span></p><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:22.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described elsewhere in this report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business, including our nonclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to risks related to public health crisis and any efforts to halt the spread of any public health crises. For example, COVID-19 and policies and regulations implemented by governments in response to its outbreak, such as directing businesses and governmental agencies to cease non-essential operations at physical locations, prohibiting certain nonessential gatherings and ceasing non-essential travel had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages occurred, supply chains were disrupted, facilities and production were suspended, and demand for certain goods and services, such as medical services and supplies, spiked, while demand for other goods and services fell. We experienced certain impacts of COVID-19, including inability to conduct clinical trial site monitoring for certain earlier phase clinical trials and delays in completing clinical trials, bioanalytical sample analysis and study reports. There can be no guarantee we will not experience other impacts from other pandemics, epidemics or infectious disease outbreaks, such as being forced to further delay or pause enrollment, experiencing potential interruptions to our supply chain, facing difficulties or additional costs in enrolling patients in future clinical trials or being able to achieve full enrollment of our studies within the timeframes we anticipate, or at all. Additionally, pandemics, epidemics or other infectious disease outbreaks could have extensive impacts in many aspects of society and could result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Other global health concerns could also result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have been working closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to the production of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine product candidates as a result of pandemics, epidemics or other infectious disease outbreaks, if such a public health crisis were to persist for an extended period of time, there could be significant and material disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine product candidates. Any such supply disruptions, including disruptions in procuring items that are essential for our development activities and securing manufacturing slots for the products needed for such activities, could adversely impact our ability to initiate and complete nonclinical studies or clinical trials and generate sales of and revenue from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine product candidates, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COVID-19 affected and other public health crises may in the future affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. If any future public health crisis is not contained, we may experience disruptions that could severely impact our business and clinical trials, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in our commercialization efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of sites or facilities serving as our clinical trial sites and staff supporting the conduct of our clinical trials, including our trained therapists, or absenteeism that reduces site resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state or national governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk that participants enrolled in our clinical trials will acquire a virus or illness while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events or patient withdrawals from our trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations in employee resources that would otherwise be focused on conducting our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in receiving authorizations from regulatory authorities to initiate our future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption in global shipping that may affect the transport of clinical trial materials, such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">used in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in local regulations as part of a response to the public health crisis which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or the discontinuation of the clinical trials altogether;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays in nonclinical studies due to restricted or limited operations at research and development laboratory facilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA, the EMA or the other regulatory bodies to accept data from clinical trials in affected geographies outside the United States, the EU or other relevant local geographies.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any negative impact a public health crisis has on patient enrollment or treatment, or the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the development of any additional indications could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for potential additional indications, including urticaria, for our current or future intranasal epinephrine technology product candidates, increase our operating expenses, which could have a material adverse effect on our financial results. COVID-19 caused significant volatility in public equity markets and disruptions to the United States and global economies and any future pandemic, epidemic, infectious disease outbreak or similar public health crisis could lead to market dislocation. Any such volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial conditions. To the extent a future pandemic, epidemic, infectious disease outbreak or other public health crisis adversely affects our business and financial results, it may also heighten many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate about our clinical development activities and the indications our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been approved to treat and is being developed to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Advertising and promotional materials must comply with FDA rules concerning the advertising and promotion of our intranasal epinephrine technology product candidates and are subject to FDA review, in addition to other potentially applicable federal and state laws. Failure to comply with these regulations can result in warning letters and further liability if off-label promotion is involved. The FDA&#8217;s Office of Prescription Drug Promotion has sent warning letters to sponsors for alleged violative labeling and promotional materials, including those disseminated through social media. Social media practices in the biotechnology and biopharmaceutical industries continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities and heightened scrutiny by the FDA, the Federal Trade Commission, the SEC and other regulators. For example, patients may use social media channels to comment on their experience in an ongoing clinical trial or to report an alleged side effect or adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about any potential additional indications. There is also a risk of inappropriate disclosure of sensitive or confidential information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding us, our management or our current or future intranasal epinephrine technology product candidates. Moreover, information communicated on social media must take into consideration applicable rules governing the advertising and promotion of medicinal products. In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;), which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Results of Operations and Financial Position</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect that our timing of sales and our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating results have fluctuated in the past and are likely to do so in future periods, especially in the near term as we continue our ongoing commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Some of the factors that could cause our operating results to fluctuate from period to period include the factors described elsewhere in the &#8220;Risk Factors&#8221; section of this report as well as in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that comparisons from period to period of our financial results are not necessarily meaningful and should not be relied upon as indications of our future performance.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have one product approved for commercial sale and have generated only limited revenue from product sales to date, and we will continue to incur significant expenses related to our commercialization activities, clinical development and ongoing operations. As a result, we have incurred significant losses in most periods since our inception. Since our inception, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, performing research and development activities, pre-commercialization activities, the commercial launch of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and providing general and administrative support for these operations. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net income was $8.0 million for the year ended December 31, 2024 and our net loss was $54.4 million for the year ended December 31, 2023. Our net loss was $44.9 million for the six months ended June 30, 2025. As of June 30, 2025, we had an accumulated deficit of $202.1 million. We expect to continue to incur significant losses for the foreseeable future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that our expenses will increase substantially if and as we:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain and expand our sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure to support the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any other product candidates for which we may obtain regulatory approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop and conduct nonclinical studies and clinical trials for our current or future intranasal epinephrine technology product candidates and for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on a post-approval basis;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals in the United States and in other geographic regions for our current or future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, negative or mixed clinical trial results, safety issues or other regulatory challenges, the risk of which in each case may be exacerbated by tariffs, trade wars, geopolitical conflicts and a health epidemic or pandemic;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add clinical, scientific, operational, sales, financial and management information systems and personnel, including personnel to support our product candidate development and commercialization efforts and help us comply with our obligations as a public company;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses could increase beyond our expectations if we are required by the FDA, the EMA or other regulatory authorities to perform clinical trials or conduct nonclinical studies in addition to those that we currently expect, or if there are any delays in completing our clinical trials or the development of our current or future intranasal epinephrine technology product candidates, or if we choose to develop or acquire any future product candidates. Our expenses could also increase significantly as a result of tariffs, trade wars and geopolitical conflicts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development activities or commercialization efforts.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations have consumed significant amounts of cash since inception. Based upon our current operating plan, we believe that our cash and cash equivalents will fund our operating and capital expenses for at least three years. We expect to incur significant expenses related to commercialization, such as product sales, medical affairs, marketing, manufacturing and distribution of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, we expect to incur additional costs associated with operating as a public company. We may require significant additional amounts of cash in order to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for its currently approved indications in the United States, or for our current or future intranasal epinephrine technology product candidates which receive regulatory approval. In addition, other unanticipated costs may arise in the course of our continued development and commercialization efforts. Because the outcome of our commercialization efforts and continued development of our current or future intranasal epinephrine technology product candidates is highly uncertain, we cannot reasonably estimate the actual amounts of cash necessary to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for its approved indications in the United States, or any other indications we are pursuing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of commercialization activities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for its approved indications and our current or future intranasal epinephrine technology product candidates that receives regulatory approval, to the extent such costs are not the responsibility of any current or future licensing and collaboration partners, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue received from commercial sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any current or future intranasal epinephrine technology product candidates that receives regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our intranasal epinephrine technology for potential additional indications, including urticaria;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approval for the marketing of our current or future intranasal epinephrine technology product candidates and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of potential royalty and milestone payments to our current or future licensing and collaboration partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of licensing fees, royalties and potential milestone payments under our current or future out-licensing arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our personnel, including personnel to support our product development and commercialization efforts and help us comply with our obligations as a public company;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ongoing costs of operating as a public company.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. The global credit and financial markets have experienced extreme volatility and disruptions and have been adversely impacted, and may continue to be adversely impacted or further adversely impacted, by macroeconomic factors such as tariffs, trade wars, inflation, high interest rates, recessionary concerns, recessions, bank failures, geopolitical conflicts and general economic uncertainty. If the equity and credit markets do not improve or further deteriorate, it may make any necessary debt or equity financing more difficult, more costly or more dilutive.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing cash and cash equivalents will be sufficient to fund our planned operations for at least three years. This estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no committed source of additional capital other than potential milestone payments and royalties under our collaboration and licensing agreements. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We may need to seek licensing and collaboration partners for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for commercialization in additional indications on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the above events could significantly harm our business, prospects, financial condition, and results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase in connection with our planned operations. Based upon our current operating plan, we believe that our cash and cash equivalents will fund our operating and capital expenses for at least three years. However, unless and until we can generate a substantial amount of revenue from our current or future intranasal epinephrine technology product candidates, we may seek to finance our future cash needs through public or private equity offerings, royalty-based or debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. On January 31, 2025, we entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) pursuant to which we may from time to time offer and sell our common stock to or through Cantor Fitzgerald &amp; Co., acting as sales agent, in any manner deemed to be an &#8220;at-the market offering&#8221;. We have filed a sales agreement prospectus with the SEC pursuant to which we may offer and sell up to $200.0 million of our common stock pursuant to the ATM Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, stockholders&#8217; interests may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect our stockholders&#8217; rights. In addition, new debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that further limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, which could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect their ability to oversee the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the development and potential future commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our intranasal epinephrine technology product candidates for additional indications.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax law could adversely affect our business and financial condition.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, the U.S. Treasury Department, and state and local taxing authorities. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, legislation informally titled the One Big Beautiful Bill Act and the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to new and existing legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition, realization of tax assets or results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history. Unused federal net operating losses (&#8220;NOLs&#8221;) for the tax years beginning before January 1, 2018, will carry forward to offset future taxable income, if any, until such unused losses expire. Unused federal NOLs generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely, but the deductibility of such federal NOL carryforwards is limited to 80% of taxable income. In addition, both current and future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the Code if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. The Merger resulted in an ownership change of our company. The NOL carryforwards of pre-Merger, privately-held ARS Pharma may also be subject to limitation as a result of prior shifts in equity ownership and/or the Merger. Additional ownership changes in the future could result in additional limitations on our NOL carryforwards. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California recently imposed limits on the usability of California state NOL carryforwards and certain state tax credits in tax years beginning after 2023 and before 2027. Consequently, even if we achieve profitability in the future, we may not be able to utilize a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our business, cash flow, financial condition or results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Legal and Regulatory Environment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy and our current or future intranasal epinephrine technology product candidates are subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. neffy and our current or future intranasal epinephrine technology product candidates could be subject to post-marketing restrictions or withdrawal from the market and we, or any current or future licensing and collaboration partners, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates, as well as, among other things, the manufacturing processes, post-approval studies, labeling, post-approval pharmacovigilance monitoring, advertising and promotional activities for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is subject to ongoing requirements of and review by the FDA, the EMA and other applicable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA and comparable foreign regulatory authorities of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States or relevant territory. We and our contract manufacturers will also be subject to user fees and periodic inspection by regulatory authorities to monitor compliance with these requirements and the terms of any product approval we may obtain. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indications or uses for which the product may be marketed or to the conditions of approval, including the requirement in the United States to implement a Risk Evaluation and Mitigation Strategy or the inclusion of a Boxed Warning, which highlights a specific life-threatening safety risk, or comparable foreign strategies and requirements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or other regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. For example, the FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Regulatory authorities impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. However, companies generally may share truthful and not misleading information that is otherwise consistent with a product&#8217;s approved labeling. If we, or any current or future licensing and collaboration partners, do not market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current or future intranasal epinephrine technology product candidates, for only its approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing if it is alleged that we are doing so. Violation of laws and regulations relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, including the False Claims Act and any comparable foreign laws. In the EU, the direct-to-consumer advertising of prescription-only medicinal products is prohibited. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public, and may also impose limitations on our promotional activities with health care professionals.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown side effects, adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the manufacturing of such products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of such products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on coverage by third-party payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusion from federal health care programs such as Medicare and Medicaid or comparable foreign programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension, variation or withdrawal of regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently enacted and future legislation may increase the difficulty and cost for us to commercialize neffy or our current or future intranasal epinephrine technology product candidates and affect the prices we may obtain.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including cost-containment measures, that could reduce or limit coverage and reimbursement for newly approved drugs, prevent or delay marketing approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for potential additional indications, including urticaria, restrict or regulate post-approval activities and affect our ability to profitably sell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for which we obtain marketing approval.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), was signed into law. The ACA was intended, among other things, to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA and subsequent regulations increased the Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program for both branded and generic drugs and revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could further increase the amount of Medicaid drug rebates to states. However, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, effective January 1, 2024. Further, the ACA imposed a significant annual fee on companies that manufacture or import branded prescription drug products, increased the number of entities eligible for discounts under the 340B program and included a discount on brand name drugs for Medicare Part D beneficiaries in the coverage gap, or &#8220;donut hole.&#8221; Substantial provisions affecting compliance have also been enacted, which may require us to modify our business practices with healthcare practitioners.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been amendments and judicial, executive and Congressional challenges to certain aspects of the ACA. For example, on August 16, 2022, the IRA was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges, and the healthcare reform measures of the second Trump administration will impact the ACA and our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to two percent per fiscal year pursuant to the Budget Control Act of 2011, which went into effect on April 1, 2013, and due to subsequent legislative amendments, will remain in effect until 2032, unless additional Congressional action is taken.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Presidential executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the IRA, among other things, (i) directs the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for at least 7 years covered under Medicare (the &#8220;Medicare Drug Price Negotiation Program&#8221;), and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs under the law, and (ii) imposes rebates with respect to certain drugs covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs as implemented. These provisions took effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the price of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions include, for example: (1) directives to reduce agency workforce and cut programs; (2) rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending; (3) eliminating the Biden administration&#8217;s executive order that directed HHS to establishing an AI task force and developing a strategic plan; (4) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing &#8220;Most-Favored-Nation&#8221; pricing for pharmaceutical products; and (5) directing certain federal agencies to enforce existing law regarding hospital and price plan transparency and by standardizing prices across hospitals and health plans. If implemented, a &#8220;Most-Favored-Nation&#8221; pricing policy that is determined to apply to us and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> based on a reference to the lowest ex-U.S. list price for our intranasal epinephrine product could significantly reduce the U.S. list price for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and likewise reduce our annual market opportunity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could, among others, impact the drug approval process, modify the Medicare Drug Price Negotiation Program, expand the orphan drug exclusion in the IRA, and reduce Medicaid enrollment and funding.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. As an example, the regulatory landscape related to clinical trials in the EU has evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresaw a three-year transition period which ended on January 31, 2025. Since this date, all new or ongoing trials are subject to the provisions of the CTR Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation and on April 10, 2024, the Parliament adopted its related position. The proposed revisions remain to be agreed and adopted by the European Council. Moreover, on December 1, 2024, a new European Commission took office. The proposal could, therefore, still be subject to revisions. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our current or future intranasal epinephrine technology product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following Brexit, the UK and the EU signed an EU-UK Trade and Cooperation Agreement (&#8220;TCA&#8221;) which became provisionally applicable on January 1, 2021 and entered into force on May 1, 2021. This agreement sets out some aspects of the UK and EU&#8217;s relationship post-Brexit. The TCA primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Among the changes that have occurred are that the UK is treated as a &#8220;third country&#8221;, a country that is not a member of the EU and whose citizens do not enjoy the EU right to free movement (Northern Ireland continues to follow certain limited EU regulatory rules, including in relation to medical devices, but not in relation to medicinal products). As part of the TCA, the EU and the UK recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2023, the UK Government and the European Commission reached a political agreement on the so-called &#8220;Windsor Framework&#8221;. The Windsor Framework is intended to revise the Northern Ireland Protocol to address some of the perceived shortcomings in its operation. The agreement was adopted at the Withdrawal Agreement Joint Committee on March 24, 2023, and the arrangements under the Windsor Framework relating to medicinal products took effect on January 1, 2025. As it relates to marketing authorizations, the United Kingdom has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland continued, until January 1, 2025, to be covered by the marketing authorizations granted by the European Commission but the Windsor Framework provides that the UK MHRA is the sole regulatory body responsible for granting marketing authorizations for Northern Ireland as of January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant proportion of the regulatory framework in the UK applicable to medicinal products is currently derived from EU Directives and Regulations. The potential for UK legislation to diverge from EU legislation following Brexit could materially impact the regulatory regime with respect to the development, manufacture, import, approval, and commercialization of our product candidates in the UK or the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of these changes could increase our costs and otherwise adversely affect our business. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the UK and restrict our ability to generate revenue and achieve and sustain profitability in the future. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws and the regulations and policies implementing them, as well as other healthcare reform measures that may be adopted in the future, particularly in light of the upcoming U.S. presidential and Congressional elections, may have a material adverse effect on our industry generally and on our ability to successfully develop and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, including due to a reduction in the FDA&#8217;s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies.*</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products or review other regulatory submissions can be affected by a variety of factors, including statutory, regulatory and policy changes, inadequate government budget and funding levels, a reduction in the FDA&#8217;s workforce and its ability to hire and retain key personnel. Disruptions at the FDA and other agencies may also increase the time to meet with and receive agency feedback, review and/or approve our submissions, conduct inspections, issue regulatory guidance, or take other actions that facilitate the development, approval and marketing of regulated products, which would adversely affect our business. In addition, government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. For example, the recently established Department of Government Efficiency implemented a federal government hiring freeze and announced certain additional efforts to reduce federal government employee headcount and the size of the federal government. The reductions in the FDA&#8217;s workforce and budgetary pressures could significantly impact the ability of the FDA to timely review and process our regulatory submissions or take other actions critical to the marketing of our products which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governments outside the United States may impose strict price controls, which may adversely affect our revenues, if any.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some countries, including certain Member States of the EU, the pricing of prescription drugs is, in part, subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. The EU provides options for the EU Member States to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for drug products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our current or future intranasal epinephrine technology product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval, which is time-consuming and costly. This Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and began to apply on January 12, 2025 through a phased implementation, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and permits EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that such prices and reimbursement will be acceptable to us. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our current or future intranasal epinephrine technology product candidates in those countries would be negatively affected.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws of other countries in which we may operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in one or more countries and could materially damage our reputation, brand, international activities, ability to attract and retain employees, and business, prospects, operating results and financial condition.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, or our failure to obtain any required import or export authorization for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates may create delays in the introduction of any additional indications in international markets or, in some cases, prevent the export of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates by, or in our decreased ability to export </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates to existing or potential customers with international operations. Any decreased use of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates or limitation on our ability to export or sell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates would likely adversely affect our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare professionals and third-party payors will play a primary role in the recommendation and prescription of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Further a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws, including the False Claims Act, prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. Over the past few years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, including: allegedly providing free items and services, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to government healthcare programs for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Drug Rebate Program to reduce liability for Medicaid rebates. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, of any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless or the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; like the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal price reporting laws require manufactures to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal and state consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations of each of the laws described above, such as anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; laws that require biotechnology companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; laws that require biotechnology companies to report information on the pricing of certain drug products; and laws require the registration or pharmaceutical sales representatives. For example, in the EU, interactions between pharmaceutical companies and healthcare professionals and healthcare organizations are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities, particularly any sales and marketing activities from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates that have been approved for marketing in the United States or elsewhere, could be subject to legal challenge and enforcement actions. If our operations, or those of our partners and collaborators, are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs, a corporate integrity agreement or other agreement to resolve allegations of non-compliance, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.*</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we process sensitive data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 ("CAN-SPAM&#8221;) and the Telephone Consumer Protection Act of 1991 (&#8220;TCPA&#8221;) impose specific requirements on communications with customers. The TCPA, for example, imposes various consumer consent requirements and other restrictions on certain telemarketing activity and other communications with consumers by phone, fax or text message. TCPA violations can result in significant financial penalties, including penalties or criminal fines imposed by the Federal Communications Commission or fines of up to $1,500 per violation imposed through private litigation or by state authorities.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide any product that receives regulatory approval. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we are subject to new laws governing the privacy of consumer health data, including reproductive, sexual orientation, and gender identity privacy rights. For example, Washington&#8217;s My Health My Data Act (&#8220;MHMD&#8221;) broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states are considering and may adopt similar laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the EU&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) (collectively, &#8220;GDPR&#8221;) and Australia&#8217;s Privacy Act, impose strict requirements for processing personal data.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR. 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we also conduct clinical trials in Asia and have operations in Japan and are subject to new and emerging data privacy regimes in Asia, including China&#8217;s Personal Information Protection Law, Japan&#8217;s Act on the Protection of Personal Information, and Singapore&#8217;s Personal Data Protection Act. China&#8217;s PIPL imposes a set of specific obligations on covered businesses in connection with their processing and transfer of personal data and imposes fines of up to RMB 50 million or 5% of the prior year&#8217;s total annual revenue of the violator.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered individuals (i.e., individuals and entities located in or controlled by individuals or entities located in those jurisdictions) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to transfer data in connection with certain transactions or agreements.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data, including clinical trials. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demands.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We publish privacy policies, marketing materials, and other statements, such as statements related to compliance with certain certifications or self-regulatory principles, concerning data privacy, and security. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are contractually subject to industry standards adopted by industry groups and, we are and may become in the future, directly subject to such obligations. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal or sensitive data on our behalf. In addition, these obligations may require us to change elements of our business model. We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to incur significant legal, accounting and other expenses associated with being a public company, including public company reporting requirements, costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as new requirements implemented by the SEC and Nasdaq. These rules and regulations are expected to continue to result in meaningful legal and financial compliance costs and to make some activities more time consuming and costly. These rules and regulations also may make it expensive for us to obtain directors&#8217; and officers&#8217; liability insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely completely on third parties to manufacture and warehouse both our domestic and international supply of neffy and our current and future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to manufacture or warehouse commercial quantities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Our ability to commercially supply </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates depends, in part, on the ability of third-party manufacturers to supply, manufacture and warehouse the raw materials, API and other important components related to the manufacture of our intranasal epinephrine technology product candidates, including Intravail and our nasal sprayer apparatus. We also rely on third parties to label and package the finished product. These third-party manufacturers currently have limited experience manufacturing our intranasal epinephrine technology product candidates, the raw materials and API for our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be supplied to patients. While we will continue to work with our third-party suppliers and manufacturers to optimize the manufacturing process for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates, we cannot guarantee that such efforts will be successful. If we fail to develop and maintain supply relationships with these third parties, we may be unable to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, we rely on third parties for the supply of our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unit dose nasal spray devices and glass microvials. We have entered into a manufacturing agreement with Renaissance Lakewood, LLC (&#8220;Renaissance&#8221;), which has been actively involved in supporting the manufacture of our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in our clinical development, and we will continue to rely on Renaissance as the primary source for drug product manufacturing and final packaging. We have also entered into a supply agreement with Nuova Ompi S.r.l. (&#8220;Ompi&#8221;) pursuant to which Ompi has agreed to supply glass microvials to support the Company&#8217;s manufacture and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We will rely on Ompi as the primary source of glass microvials. Unless and until we can secure alternative sources for microvials, drug product manufacturing and final packaging, our dependence on Renaissance and Ompi will subject us to the possible risks of shortages, interruptions, and price fluctuations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience supply interruptions or delays, or if a supplier discontinues the sale of certain products, we may have to obtain substitute materials or products, which in turn would require us to obtain amended or additional regulatory approvals, subjecting us to additional expenditures of significant time and resources. In addition, changes in our raw material suppliers could result in significant delays in production, higher raw material costs and loss of sales and customers, because regulatory authorities must generally approve raw material sources for pharmaceutical products, which may be time consuming. Any significant supply interruption effect on our business, condition (financial and otherwise). For example, drug application processes require specification of raw material suppliers, if raw materials from a specified supplier were to become unavailable, FDA or comparable foreign regulatory authority approval of a new supplier would be required. The amount of time required for the FDA or a comparable foreign regulatory authority to qualify a new supplier and confirm that our manufacturing processes meet the necessary standards could cause delays in the manufacturing and marketing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and could, depending on the particular product, have a material adverse effect on our results of operations and financial condition.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the third party to manufacture </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the delay or interruption of the production of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">due to a third-party contractor or supplier discontinuing the sale of certain products, requiring us to obtain substitute materials or products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reduction or termination of production, raw materials, or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the breach by the third-party contractors of our agreements with them;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements, whether related to our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or another product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the third party to manufacture our intranasal epinephrine technology product candidates, or the raw materials associated therewith, according to our specifications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications, including without limitation due to a change in raw materials supply, and the strict regulatory requirements of the FDA and other foreign regulatory authorities, this could affect the sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. In addition, other than to conduct audits, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, and/or raw material suppliers, which would significantly impact our ability to develop, obtain or maintain marketing approvals for and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, application review delays, suspension, variation or withdrawal of approvals, license revocation, import alerts, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates and harm our business and results of operations. Our current and anticipated future dependence upon others for the raw materials associated with, and the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates may adversely affect our profit margins and our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates on a competitive basis.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on international third-party licensees and assignees for the development and commercialization of neffy and our current and future intranasal epinephrine technology product candidates outside the United States. If these third parties are not successful in their development and commercialization efforts or if these third parties fail to meet their contractual, regulatory or other obligations, our business and results of operations could be adversely affected.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into exclusive licensing and collaboration agreements with third-party partners for the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">worldwide, excluding the United States. As a result, we are dependent on these parties to, at times, achieve regulatory approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates for marketing and, if approval is obtained, commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates outside the United States. The timing and amount of any milestone and royalty payments we may receive under these agreements, as well as the commercial success of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates in those regions outside of the United States, will depend on, among other things, the efforts, allocation of resources and successful commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates by our licensing and collaboration partners. We also depend on such licensing and collaboration partners to comply with all applicable laws relative to the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates in those countries. They may take actions or fail to take actions that result in safety issues with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates in their licensed territory, and such safety issues could negatively impact </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates in countries outside of the licensed territory. We do not control the individual efforts of our licensing and collaboration partners and have limited ability to terminate these agreements or have assigned assets returned to us if such licensing and collaboration partners do not perform as anticipated.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure of our licensing and collaboration partners to devote sufficient time and effort to the development and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates; to meet their obligations to us, including for future royalty and milestone payments; to adequately deploy business continuity plans in the event of a crisis; to adequately respond to the adverse impact of military action, sanctions and market disruptions; and/or to satisfactorily resolve significant disagreements with us or address other factors could have an adverse impact on our financial results and operations. In addition, if these third parties violate, or are alleged to have violated, any laws or regulations during the performance of their obligations for us, including with respect to safety, patient and data privacy, antitrust, and bribery and corruption, it is possible that we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences and liabilities. We may not be successful in enforcing the terms and conditions of our licensing and collaboration agreements in court or via agreed upon dispute resolution mechanisms, and even if we were to prevail in any such dispute, the remedies may not be adequate to compensate us for the losses. Any termination, breach or expiration of any of these licensing or collaboration agreements could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive license fees, milestones and royalties. In such an event, we may be required to devote additional efforts and to incur additional costs associated with pursuing regulatory approval and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. Alternatively, we may attempt to identify and transact with a new assignee or licensee, but there can be no assurance that we would be able to identify a suitable partner or transact on terms that are favorable to us. For example, in February 2023, we terminated the Recordati License and Supply Agreement, which eliminated the potential for us to receive milestone and royalty payments from Recordati under the Recordati License and Supply Agreement. Although we found a partner for the regions previously licensed to Recordati, under the Recordati Termination Agreement, we are obligated to pay certain milestone and royalty payments to Recordati.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy and our current or future intranasal epinephrine technology product candidates are developed and produced at a few locations, and a business interruption at one or more of these locations or within our supply chain could have a material adverse effect on our business, financial position, and results of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are developed and produced at our third-party&#8217;s manufacturing facilities in Lakewood, New Jersey. Disruptions of these facilities or within our supply chain can occur for many reasons, including events unrelated to us or beyond our control, such as fires and other industrial accidents, floods and other severe weather events, natural disasters, environmental incidents or other catastrophes, utility and transportation infrastructure disruptions, shortages of raw materials, pandemic diseases or viral contagions, and acts of war or terrorism. Natural disasters and adverse weather conditions can be caused or exacerbated by climate change, and the spate of extreme weather events experienced during 2021 presents an alarming trend. During 2021, for example, Tropical Storm Ida brought extreme rainfall and flash flooding to New Jersey that caused damage to local businesses. Such events could compromise our inventory, resulting in significant costs. Furthermore, work stoppages, whether union-organized or not, can also disrupt operations. Business interruption could also be caused by compliance failures. A significant disruption at any of these facilities or otherwise within our supply chain, even on a short-term basis, could impair our ability to produce and ship products to the market on a timely basis or at all, which could have a material adverse effect on our business, financial position, and results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to commercialize neffy and our current or future intranasal epinephrine technology product candidates may be delayed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on third parties to conduct our nonclinical studies and any clinical trials. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our nonclinical studies and past clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these studies and trials. While we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for any products or potential products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or studies or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials are expected to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or a comparable regulatory authority concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit or of comparable applicable submitted to foreign regulatory authorities. Any such delay or rejection could prevent us from commercializing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates for potential additional indications, including urticaria.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, know-how and other proprietary information, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we currently rely on third parties to manufacture </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates and to perform quality testing, we must, at times, share our proprietary information, including trade secrets and know-how, with them. We seek to protect our proprietary information, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our current and future licensing and collaboration partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our proprietary information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets, know-how and other proprietary information increases the risk that such proprietary information become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. We rely, in part, on trade secrets, know-how and other proprietary information to develop and maintain our competitive position and a competitor&#8217;s discovery of our proprietary information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our commercial success depends on our ability to obtain and maintain sufficient intellectual property protection for neffy, our current and future intranasal epinephrine technology product candidates and other proprietary technologies.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. If we are unable to obtain or maintain patent protection with respect to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates, and its uses, our business, financial condition, results of operations and prospects could be materially harmed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generally seek to protect our proprietary position by filing or in-licensing patents or patent applications in the United States and abroad related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates that are important to our business, as appropriate. Our pending and future patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to obtain the intellectual property rights relating to our product could have a material adverse effect on our financial condition and results of operations.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our intellectual property by obtaining and defending patents. Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Recent reforms and changes at government agencies of the United States and those of non-U.S. jurisdictions could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications, and the maintenance, enforcement, or defense of our issued patents. For example, the ability of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain key personnel and fill key leadership appointments, among various factors. Termination of employees or delays in replacing or hiring for key positions could significantly impact the ability of the USPTO and other applicable patent authorities to fulfill their functions and could greatly impact our ability to timely and adequately prosecute or maintain our patent applications, and our ability to timely and adequately maintain, enforce, or defend our issued patents.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, independent contractors, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek adequate patent protection.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.*</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including United States Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we may not be aware of all third-party intellectual property rights potentially relating to our research programs and product candidates, or their intended uses, and as a result the potential impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the potential impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of any future product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that any future product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patents or pending patent applications, or the patents or pending patent applications that we license, may be challenged in the courts or patent offices in the United States and other foreign jurisdictions. For example, we are currently a party to an opposition proceeding at the European Patent Office with respect to EP 3678649, and we may be subject to third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) or become involved in post-grant review procedures, derivations, reexaminations, or inter partes review proceedings, in the United States or oppositions or similar proceedings in foreign jurisdictions, challenging our patent rights. The legal threshold for initiating such proceedings may be low, so that even proceedings with a low probability of success might be initiated. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents are of national or regional effect. Although as of July 11, 2025 we co-own or exclusively license eight issued U.S. patents, granted patents in each of Australia, Canada, China, Hong Kong, Israel, Japan, Mexico, Singapore, South Korea, and member states of the European Patent Organization, including the United Kingdom, directed to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and its uses, among other things, three pending U.S. non-provisional patent applications, one pending international patent application and over fifteen pending foreign patent applications directed to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and its uses, among other things, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These competitor products may compete with our product, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in all of our expected significant foreign markets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various countries outside the United States have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current or future intranasal epinephrine technology product candidates in all of our expected significant foreign markets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and unpredictable.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, geo-political actions in the United States and in foreign countries (such as, the Russia and Ukraine conflict and the conflict in the Middle East, including U.S. involvement therein; retaliatory measures by foreign countries in response to actions by the U.S., in particular, tariffs) could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. Many foreign countries could impose retaliatory measures that may adversely impact our intellectual property rights in those countries. For example, on March 14, 2025, Brazil enacted Law No. 15.122/2025 (known as the &#8220;Economic Reciprocity Law&#8221;), which provides a framework that allows for the suspension of obligations related to foreign entity&#8217;s intellectual property rights. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law in the United States. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before we could therefore be awarded a patent covering any of our inventions even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology, or the technologies we license for our product, and the prior art allow the technology we use for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either file any patent application related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or invent any of the inventions claimed in our patents or patent applications.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Leahy-Smith Act also included a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including Post Grant Review, Inter Partes Review, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect neffy and our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents relating to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current or future intranasal epinephrine technology product candidates. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws, rules and regulations in the United States and other countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in the patents we own, co-own or license from third parties. In addition, U.S. Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce the existing patents we own, co-own or license and patents we or our licensors might obtain in the future. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce the existing patents we own, co-own or license and patents that we or our licensors might obtain in the future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an example, beginning June 1, 2023, European patent applications and patents may be subjected to the jurisdiction of the Unified Patent Court (the &#8220;UPC&#8221;). Also, European patent applications will have the option, upon grant of a patent, of becoming a Unitary Patent, which will be subject to the jurisdiction of the UPC. The UPC and Unitary Patent are significant changes in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2012, the European Union Patent Package (the &#8220;EU Patent Package&#8221;) regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European UPC for litigation involving European patents. The EU Patent Package was implemented on June 1, 2023. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We may decide to opt out our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates due to increased competition and, resultantly, on our business, financial condition, prospects and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the USPTO and various foreign patent agencies at various stages over the lifetime of our patents and/or patent applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. In addition, the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these provisions. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. If we or our licensors fail to maintain the patents and patent applications covering our product, our competitors might be able to enter the market, which would have a material adverse effect on our business, financial conditions, results of operations and growth prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position for neffy and our current or future intranasal epinephrine technology product candidates for an adequate amount of time and may adversely affect our anticipated future revenues and operating earnings.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on patent, trademark, trade secret and other intellectual property protection in the discovery, development, manufacturing and sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. In particular, patent protection is important in the development and commercialization of our approved product candidates. Patents covering </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">normally provide market exclusivity, which is important in order for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates to generate profits.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review, patents protecting any future indications or any product candidates might expire before or shortly after commercialization. Even if patents covering any future indications or any future product candidates are obtained, once the patent life has expired, we may be open to competition from generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patents we currently co-own or exclusively license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates are expected to expire as early as 2038, absent any patent term adjustments. The API in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is epinephrine, a generic API that is used in FDA-approved intra-muscular injectables. Since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approved by the FDA under the 505(b)(2) regulatory pathway, our U.S. patents for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not eligible for patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984. While we are planning to seek additional patent coverage for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there can be no assurances that such additional patent protection will be granted, or if granted, that these patents will not be infringed upon or otherwise held enforceable. Even if we are successful in obtaining a patent, patents have a limited lifespan. Without patent protection, we may be open to competition from generic versions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We co-own or exclusively license patent applications in our portfolio relating to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates that are pending at the patent offices in the United States, Europe, Japan, and other foreign jurisdictions, however, we cannot predict:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and when patents may issue based on the patent applications we own, co-own or exclusively license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection of any patent issuing based on the patent applications we own, co-own or exclusively license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the claims of any patent issuing based on the patent applications we own, co-own or exclusively license will provide protection against competitors,</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether or not third parties will find ways to invalidate or circumvent our patent rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether or not others will obtain patents claiming aspects similar to those covered by the patent applications we own, co-own or exclusively license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the patent applications that we own, co-own or exclusively license will result in issued patents with claims that cover </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our intranasal epinephrine technology product candidates or uses thereof; and/or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we may experience patent office interruption or delays to our ability to timely secure patent coverage to any potential additional indications or any future product candidates.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that the claims in our pending patent applications directed to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates will be considered patentable by the USPTO or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim relevant to our business. There is no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. Even if the patents do issue based on the patent applications we own, co-own or exclusively license, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to any potential additional indications or any future product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, any additional potential indications or any future product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market neffy and our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the pharmaceutical industry expands and more patents are issued, the risk increases that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current or future intranasal epinephrine technology product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe existing or future third-party patents. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to our operations or necessary for the commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates in any jurisdiction.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. patent applications that will not be filed outside the U.S. can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents that will prevent, limit or otherwise interfere with our ability to make, use or sell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our research programs, product candidates, their respective methods of use, and manufacture thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are sued for infringing on the intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing neffy or our current or future intranasal epinephrine technology product candidates.*</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. For example, on March 25, 2025, Aptargroup, Inc. and Aptar France SAS (collectively, &#8220;Aptar&#8221;) filed a suit against us in the United States District Court for the Southern District of New York, alleging that we violated the Defend Trade Secrets Act (18 USC &#167; 1836), misappropriated trade secrets under New York state law, and committed various breaches of contract (the &#8220;Aptar Litigation&#8221;). We dispute these allegations and intend to vigorously defend ourselves in the Aptar Litigation. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Additionally, delays caused by the federal agencies may increase the time period that we are subject to such claims.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the pharmaceutical industry, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The pharmaceutical industry has produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, or of use either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity of third-party patents may be difficult and uncertain. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in defending our rights in these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and could result in a court or administrative body finding our patents to be invalid or unenforceable.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the patent applications we own, co-own or license are issued, third parties may challenge or infringe upon our patents. To counter infringement, we may be required to file infringement claims, which can be expensive and time-consuming. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness (or inventive step), written description or enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our current or future products or provide any competitive advantage. The outcome following legal assertions of invalidity and unenforceability is unpredictable. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose part or all of the patent protection on one or more of our current or future products, which could result in our competitors and other third parties using our technology to compete with us. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, cash flows and prospects. Additionally, we may be subject to claims of patent infringement during those proceedings, and delays caused by the federal agencies may increase the time period that we are subject to such claims. For example, administrative changes, including reduced staff and budgets experienced by the USPTO Patent and Trial Appeal Board, could further delay our ability to timely challenge any such patents.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently a party to an opposition proceeding at the European Patent Office with respect to EP 3678649. We may, in the future, be a party to other intellectual property litigation or administrative proceedings that are very costly and time-consuming and could interfere with our ability to sell and market our products. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us, especially as we gain greater visibility and market exposure as a public company.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an infringement proceeding, even one initiated by us, there is a risk that a court will decide that our patents are not valid and that we do not have the right to stop the other party from using the inventions they describe. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe our rights to these patents.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property that relate to our research programs and product candidates, their respective methods of use, manufacture and formulations thereof. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent that we own or have licensed is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of our patents is upheld, the court will construe the claims of our patents narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention at issue. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks and pay for damages.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement by competitors, a court may decide not to grant an injunction against further infringing activity by competitors and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such infringement claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy or our current or future intranasal epinephrine technology product candidates may face competition from generic inhalable epinephrine products sooner than expected, and our patents may be challenged.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend in part on our ability to obtain and/or maintain patent protection for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates and related technologies and to prevent third parties from infringing upon our proprietary rights. We must also operate without infringing upon patents and proprietary rights of others, including by obtaining appropriate licenses to patents or other proprietary rights held by third parties, if necessary. Moreover, the patent applications we have filed or may file in the future may never yield patents that protect our inventions and intellectual property assets. Failure to obtain additional patent coverage and/or maintain existing patent protection for our formulations, methods of treatment, and/or technologies would limit our protection against generic drug manufacturers, pharmaceutical companies and other parties who may seek to copy our products, produce substantially similar products or use technologies substantially similar to those we own, co-own, or exclusively license.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not received U.S. non-patent marketing exclusivity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which was approved by the FDA under the 505(b)(2) regulatory pathway. Without non-patent marketing exclusivity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we may face competition by third parties seeking to market generic versions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as early as our approval by the FDA. Upon approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the FDA, we listed 7 patents with claims covering </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Orange Book. An eighth patent with claims covering </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was subsequently listed in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or an NDA submitted under the 505(b)(2) regulatory pathway referencing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">must make one of the following certifications to the FDA concerning the patents listed in the Orange Book for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: (a) the patents that are listed have expired; (b) the date on which such patents will expire; or (c) such patents are invalid or will not be infringed upon by the manufacture, use or sale of the generic equivalent version of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or the drug product submitted under the 505(b)(2) regulatory pathway referencing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This last certification is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to us for each patent to which the ANDA or 505(b)(2) application refers. Following receipt of a paragraph IV notice, we may bring a lawsuit for patent infringement against the paragraph IV filer, and we may be entitled to a statutory 30-month stay of approval of the proposed product of the paragraph IV filer. Although we expect to vigorously defend our patents from infringement by third parties, there can be no assurances that we will be successful with respect to such defense or any other legal proceedings which may arise in the ordinary course of our business. Such a failure may have a material impact on our business, our results of operations, and our financial condition in the future.</span></p><p style="text-indent:28.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we received non-patent marketing exclusivity for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which received marketing authorization grounded on Article 8(3) of Directive 2001/83/EC by the European Commission. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> received an eight-year period of data protection whereby another applicant cannot rely the data submitted as part of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketing authorization application, and a ten-year period of marketing protection during which a generic, hybrid or biosimilar cannot be placed on the market in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing any one of our issued patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such an infringement claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. Such announcements could harm our reputation, the perceived value of our intellectual property or the market for our existing or future products, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an owner, co-owner, inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have registered and pending trademarks in the United States, as well as in several foreign jurisdictions, including but not limited to the United Kingdom, EU, and Japan. We may not be able to obtain applicable corresponding health regulatory approval to use these trademarks for our product. Our trademarks or trade names may be refused, challenged, infringed, circumvented, declared generic or descriptive, or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. We may not be able to register or use our trademarks in all relevant jurisdictions. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to or appeal those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to register or use, or obtain corresponding health regulatory approval for, a particular trademark in a given jurisdiction, we may need to adopt a different trademark in that territory, which could entail additional costs and diminish our brand equity. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make formulations that are similar to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates but that are not covered by the claims of our patent rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of third parties may have an adverse effect on our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patents or pending patent applications that we own, co-own or exclusively license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we may own or co-own or that we exclusively license in the future may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties performing manufacturing or testing for us using </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates or technologies could use the intellectual property of others without obtaining a proper license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patent protection for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets and unpatented know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, potential trade secrets, proprietary know-how and information. We further seek to protect our potential trade secrets, proprietary know-how and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors and outside scientific collaborators, these agreements typically include invention assignment obligations. Although we have taken steps to protect our trade secrets and unpatented know-how, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of skilled personnel from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. Because from time-to-time we expect to rely on third parties, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who previously worked with other companies, including our competitors or potential competitors. We are and could in the future be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of current or former employers or competitors, including, for example, the Aptar Litigation. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we are, and may in the future, become subject to claims that we caused an individual to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged intellectual property, proprietary information, know-how or trade secrets of a current or former employer or competitor.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we are, and may in the future, litigate to defend against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies that are essential to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our current or future intranasal epinephrine technology product candidates, if such technologies are found to incorporate or be derived from the trade secrets or other proprietary information of the current or former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be required to license technologies relating to our therapeutic programs from additional third parties to further develop or commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters and Managing Growth</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current executive officers and our other highly qualified personnel. We have entered into employment agreements with each of our executive officers but they may terminate their employment or engagement with us at any time. The loss of their services might impede the achievement of our research, development and commercialization objectives.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical, sales and marketing personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry has experienced a high rate of turnover in recent years. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, which includes entities owned by our executive officers and directors, may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our current or future intranasal epinephrine technology product candidates will be limited.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, current and future licensing and collaboration partners and CROs may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, current and future licensing and collaboration partners and CROs may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA regulations or similar regulations of comparable non-U.S. regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing standards;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws that require the reporting of financial information or data accurately.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of product materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or comparable foreign programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expanded our organization following FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024. Specifically, we increased our sales force and made additional hires in the areas of general and administrative, medical, commercial, sales and marketing, and operations. As a result, our headcount has increased from 23 full-time employees and 5 part-time employees as of July 31, 2024 to 162 full-time employees and 5 part-time employees as of June 30, 2025. We may need to further expand our headcount in the future to support our growth strategy. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of our attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such recent and anticipated growth, we may not be able to effectively manage the expansion of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. If we are unable to effectively manage our recent and expected growth, our ability to generate revenues or achieve future profitability could be reduced and we may not be able to implement our business strategy, including the successful commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Securities Markets and Ownership of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock could be volatile.*</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or obtain regulatory approvals for additional indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates, to achieve commercial success;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us to maintain our existing third-party license and supply agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any inability to obtain adequate supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or our current or future intranasal epinephrine technology product candidates or any of its components, or the inability to do so at acceptable prices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory authority decisions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introduction of new products, services or technologies by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or our current or future intranasal epinephrine technology product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general market or macroeconomic conditions, including as a result of actual or threatened tariffs and trade wars;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or our stockholders in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity generally, including with respect to other products and potential products in such markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the introduction of technological innovations or new therapies that compete with potential products of ours;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of health care payment systems; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a decrease in the stock price of our common stock may cause our common stock to no longer satisfy the continued listing standards of Nasdaq. If we are not able to maintain the requirements for listing on Nasdaq, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law (&#8220;DGCL&#8221;) may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of us more difficult, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chair of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement for the affirmative vote of holders of at least 66-2/3% of the voting power of all of the then-outstanding shares of our voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a Delaware corporation, we will be subject to Section 203 of the DGCL. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving us. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation designates the state courts of the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, and the federal district courts of the United States of America to be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on behalf of us; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These exclusive forum provisions may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate paying any cash dividends in the foreseeable future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales of shares by existing stockholders could cause our stock price to decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after any applicable legal restrictions on resale lapse, the trading price of our common stock could decline. We are not able to predict the effect that sales may have on the prevailing market price of our common stock.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Geo-political conditions may have serious adverse consequences on our business, financial condition and stock price.*</span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International and geo-political events could also have a serious adverse impact on our business. For instance, in February 2022, Russia started a war against Ukraine. In response, the United States and certain other countries imposed significant sanctions and trade actions against Russia and could impose further sanctions, trade restrictions, and other retaliatory actions. Additionally, in October 2023, Hamas initiated an attack against Israel, provoking a state of war and which has resulted in a larger conflict in the Middle East that has included U.S. involvement. While we cannot predict the broader consequences, the conflict and retaliatory and counter-retaliatory actions could materially adversely affect global trade, currency exchange rates, inflation, regional economies, and the global economy, which in turn may increase our costs, disrupt our supply chain, impair our ability to raise or access additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="partii_item2_equitysales"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:-48.95pt;padding-left:48.95pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="partii_item5_other"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other Information</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecd341b6-0340-4b23-bbc1-78f04ec18803" contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated trading plans for the orderly disposition of the Company&#8217;s securities as set forth in the table below.</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.46%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:11.2%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:11.2%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:11.2%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:10.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:11.2%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Adoption /</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Termination</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Position</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10b5-1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10b5-1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">to be Sold</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d9da9546-e0e1-4e71-b3d8-a6442c0cbd91" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020*<br/></span><span><ix:nonNumeric id="F_9ca178c5-5668-4082-9871-26855d3b2acf" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3cd75323-389e-42cd-aada-a541827aa79a" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_35efb4c1-590e-4c91-850c-6d68c18e4e0c" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d9205b96-8cbc-4781-b224-bd1aae21dd4e" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_665207ef-3c22-4ab7-be7a-036893bd1f4a" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3211695d-a961-42e9-ab7c-5031d37e43fc" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21c9466f-2b7c-4cf0-a781-d24ee778cb1e" contextRef="C_f04745e7-fc61-4f44-a90e-0375301533ee" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,050,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_576d3583-2ca7-4054-8965-7ee825681307" contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_94a0cda7-780e-4fa0-ab6d-227368d88e3d" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*<br/></span><span><ix:nonNumeric id="F_773d8bd2-8686-4c5d-b6f7-f8e37f198c67" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aaa60f08-3751-4f4a-af26-49a55144f69e" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_bb9b391e-9910-4a7b-9459-6d2428842f85" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2632de7b-f5dc-4775-b09a-cdb99270c54f" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_8501f2a2-8191-4253-b98c-f5a5962b296f" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_52a43fd7-8aa7-47a3-8f8e-25bb8f80ce7e" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf1b5e7-e203-4508-aebc-fe4ebbcafc73" contextRef="C_98d3f585-f5dc-49db-8505-5f7d6f4a006b" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,050,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c8921960-8657-44ce-8b26-613dc88e0f75" contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6d842c07-b023-4c84-ae68-321c4b27df5e" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sarina Tanimoto</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020*<br/></span><span><ix:nonNumeric id="F_4edd1ea6-edc8-4562-a4d4-84e1e9c0c535" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_99ee36fa-ee74-4b33-a0ff-f02d213ca913" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_4bf12e38-ae40-4c1c-8885-b69c7e2017e2" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d2a2c55b-baf0-413d-be71-37a9589eb3df" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c14dc822-d557-4132-9a4f-f236b6785853" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b534b469-908d-45aa-8897-ffeb97835cd9" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63ea5fe-2a77-4e74-adb0-9cd1f65d3b47" contextRef="C_460d3d8c-ddbf-4c5d-a288-dca013f2b32b" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,050,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_80012983-538c-4bbe-b167-5cca81dd98c4" contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cd97b874-9f76-4648-8664-e614150204c9" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sarina Tanimoto</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*<br/></span><span><ix:nonNumeric id="F_6a4d119e-e8a4-4873-9366-701e9ab91e4d" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_669418e3-41c9-416d-8cb8-c5f8896d3ba4" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_f8100502-bb77-455d-9c75-6180a2dfe765" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_0d8e7587-3bf7-451d-8e66-2f16157a346d" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f2e88704-9f0c-44af-a1e2-26ad6677ec48" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b86c445f-4922-49ec-a054-438306029287" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59bae225-3a4b-44f3-b344-a9aa5a44d876" contextRef="C_238c6043-2b99-4906-9c2c-f32a420101fd" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,050,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b783df73-0f16-48ce-b302-09180e632357" contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_919e6b9c-c742-402e-a3c7-47cd50136e99" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laura Shawver</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_5c020f57-dc99-4971-b381-eb184083c979" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_449d1e40-870a-4bd1-8b4a-42545bcacb98" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_7f7df22d-8368-4e1d-9ed6-1994bf9fd3f4" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_45cebe39-df64-4b05-ac59-bc97f7d8f07e" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d7916ae0-be4a-49dc-b60f-e83685eefb8d" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_30cf89f4-1595-4dfa-a03e-7827b50fc9e1" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_462fe3ed-09f3-4549-91fb-94a24c5d8547" contextRef="C_eaee139f-06ad-4880-b611-5bd0dea21a98" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">128,562</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6e3cb662-57b8-43a1-abf5-d899d8d95f9b" contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d0ff14b5-970c-4d8f-9e24-da99c39481a8" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kathleen Scott</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_c1335290-0111-4608-9cb6-1579976a12da" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8985669b-d41c-4dfe-84df-cdc94996d7c6" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_591f3f1d-ef8a-42fd-8fda-14cd656e7def" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_06938b15-b0f2-46f9-85d2-c6db8750b132" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_077b5576-1e60-4be2-9578-7b5abb59a083" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8eb2c820-6159-4f9c-bcef-9afa93b81ba7" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 22, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1f56ce5-8639-4ccd-af77-ef6ba822a76e" contextRef="C_1becd9ce-e5df-4cc7-96cc-1fff890d77d3" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0e7fe17f-1c30-4e8a-a476-adcec94f21dd" contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 22, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0efa8b37-d894-47de-abc6-ce9c45d0eb3f" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Fitzpatrick</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_cc4a98e5-dbf7-4aee-bd78-bd2921cdd99e" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6fa1c6d6-d18a-4b64-81b5-75657e25e321" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_4a017509-6860-41d9-99e0-828065f21f46" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_98927921-dbd4-4573-bca5-2330acdcc8ac" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_90170264-56ba-447d-96b5-54e3c0c288a7" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Termination</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a178e7c5-6cee-4441-b8fc-4770afb55a51" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 29, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6534f0f3-a257-4dd3-ad3c-f6bdc5961317" contextRef="C_b6c4e388-e63f-477d-add2-c9ae15d79bd9" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aab0af8f-04df-41ad-8c68-7164c6a5fba5" contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f3b7fde1-f121-4c71-acea-4601736b3c69" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Fitzpatrick</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_82797aa2-da95-4b0f-8318-cf77019f366d" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_11c89d5b-2897-422d-8b80-b7b1eda16577" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_370e42c5-bb83-44a0-b0f2-47b6d4b680b4" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d2515e37-a69e-4383-a937-5817d6847558" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_1b902da7-7ba7-406f-ae8e-ab82d6548432" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_97859351-7d41-4fc7-a40b-694d782e6c76" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 29, 2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142c1e6b-8edd-4736-a3ee-079c03e1e33f" contextRef="C_99ec2511-459f-4c45-8f1e-cd91504cd76d" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_befd85ab-f529-4193-b281-036bf252fadb" contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 30, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on November 27, 2024 and amended on December 13, 2024 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div></div><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	This plan, together with the other three plans marked with an asterisk in this table, are treated as a single &#8220;plan&#8221; because the individual constituent contracts with each broker-dealer, when taken together as a whole, meet all of the applicable conditions of Rule 10b5-1(c) under the Exchange Act and remain collectively subject to the provisions of such rule, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including that a modification of any individual contract acts as modification of the whole contract.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="text-indent:-48.95pt;padding-left:48.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="partii_item6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Exhibits</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:92%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000095017023009491/spry-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2023).</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 8, 2020).</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1&#135;*</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Co-Promotion Agreement, dated May 2, 2025, by and between ARS Pharmaceuticals, Inc. and ALK-Abell&#243; Inc.</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000095017025070900/spry-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025).</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3&#135;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment, dated July 10, 2025, to Manufacturing Agreement, dated as September 9, 2020, and as amended July 26, 2023 and September 17, 2024, by and between ARS Pharmaceuticals, Inc. and Renaissance Lakewood, LLC.</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1#</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document&#8211;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover page formatted as Inline XBRL and contained in Exhibit 101</span></p></td>
     </tr>
    </table><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#135;	Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.</span></p><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	Certain information in this exhibit is omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.</span></p><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+	Indicates management contract or compensatory plan.</span></p><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">#	The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.76%;box-sizing:content-box;"/>
      <td style="width:33.02%;box-sizing:content-box;"/>
      <td style="width:3.12%;box-sizing:content-box;"/>
      <td style="width:45.1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ARS PHARMACEUTICALS, INC.</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kathleen D. Scott</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kathleen D. Scott</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>spry-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CO-PROMOTION AGREEMENT</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Co-Promotion Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of May 2, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals Operations, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a corporation organized under the laws of Delaware (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), with offices at 11682 El Camino Real, Suite 120, San Diego, CA 92130, and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK-Abell&oacute;, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Delaware corporation with offices at 135 Route 202/206 Suite #16, Bedminster, New Jersey 07921 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each of ARS and ALK is sometimes referred to individually herein as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ARS has developed </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an intranasal epinephrine product for patients with Type I allergic reactions, including anaphylaxis, and has obtained FDA approval to market such product in the United States;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ALK is engaged in the research, development and commercialization of pharmaceutical products;</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ARS wishes to engage ALK for certain promotional services related to </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; in the United States, in accordance with the terms and conditions set forth herein; and</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ALK desires to perform such promotional services, in accordance with the terms and conditions set forth herein.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, ARS and ALK, intending to be legally bound, hereby agree as follows:</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE I<br><br>DEFINITIONS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whenever used in this Agreement with an initial capital letter, the terms defined in this Agreement shall have the respective meanings ascribed to them herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.1 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party, but for only so long as such control exists. As used in this section, &#x201c;control&#x201d; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights, or corporate governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK Commercialization Support Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 2.6(b)(x).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.3 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK House Marks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the ALK trade name and logo.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.4 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK Personnel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Sales Representatives and any other personnel employed by ALK (including supervisory personnel overseeing the activities of the Sales Representatives, and legal, regulatory and other support personnel) who are or may be involved with activities under this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.5 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the laws, statutes, rules, or regulations applicable to a Party&#x2019;s activities to be performed or other obligations under this Agreement, including the FDCA, the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Federal Civil Monetary Penalties Law (42 U.S.C. &#167; 1320a-7a), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Law (42 U.S.C. &#167; 1320a- 7b(a)), the criminal Health Care Fraud laws (18 U.S.C. &#167;&#167; 286, 287, 1347, 1349), the PDMA, the Patient Protection and Affordable Care Act of 2010 (42 U.S.C. &#167; 18001 et seq.), the Federal Sunshine Law, the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167; 335a et seq.), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the exclusion law (42 U.S.C. &#167; 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), state and federal licensure laws, the regulations promulgated pursuant to such laws, the FCPA and other laws relevant to fraud, waste and abuse, anti-corruption and bribery, racketeering, money laundering or terrorism, and any other state or federal law similar to the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.6 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Compliance Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the requirements set forth in ARS&#x2019;s policies and procedures with respect to [***], as such policies and procedures are shared with ALK in writing and updated from time to time. ARS Compliance Policies as of the Effective Date are attached hereto in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and incorporated herein by reference.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS House Marks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 1.79.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.8 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.1(a).</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.9 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a day other than a Saturday, Sunday or any day on which banks located in California, United States are authorized or obligated to close. Whenever this Agreement refers to number of days, such number shall refer to calendar days unless Business Days are specified.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.10 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall, with respect to either Party, be deemed to occur when:</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any &#x201c;person&#x201d; or &#x201c;group&#x201d; (as such terms as defined below in this Section 1.10) is or becomes the &#x201c;beneficial owner&#x201d; (as defined below in this Section 1.10), directly or indirectly, of shares of capital stock or other interests of such Party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers, or similar supervisory positions of such Party representing more than fifty percent (50%) of the total voting power of all outstanding classes of voting stock or equity of such Party,</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such Party consummates a merger, consolidation or similar transaction with another Person (whether or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction the Persons that beneficially owned, directly or indirectly, the shares of voting stock or equity of such Party immediately prior to such transaction do not beneficially own, directly or indirectly, shares of voting stock or equity of the surviving Person representing at least a majority of the total voting power of all outstanding classes of voting stock or equity of the surviving Person,</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such Party sells or transfers to any Third Party, in one or more related transactions, properties or assets representing all or substantially all of such Party&#x2019;s assets, or </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holders of capital stock or equity of such Party approve a plan or proposal for the liquidation or dissolution of such Party.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of this Section 1.10, (i) &#x201c;person&#x201d; and &#x201c;group&#x201d; have the meanings given such terms under Sections 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term &#x201c;group&#x201d; includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the United States Securities Exchange Act of 1934, (ii) a &#x201c;beneficial owner&#x201d; shall be determined in accordance with Rule 13d-3 under the United States Securities Exchange Act of 1934, and (iii) the term &#x201c;beneficially owned&#x201d; and &#x201c;beneficially own&#x201d; shall have the meaning correlative to that of &#x201c;beneficial owner.&#x201d;</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.11 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.4.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.12 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Codes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the applicable general and industry-specific Department of Health and Human Services Office of Inspector General compliance program guidance (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OIG Compliance Guidance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (b) the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical Research and Manufacturers of America (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PhRMA Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (c) the American Medical Association (AMA) Guidelines on Gifts to Physicians from Industry, and (d) the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, as any of the foregoing may be amended from time to time.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.13 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of Collaboration Year 1, Collaboration Year 2, Collaboration Year 3 and Collaboration Year 4.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.14 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Year 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period commencing on the Promotion Commencement Date and ending on the last day of the month in which the first anniversary of the Promotion Commencement Date occurs.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.15 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Year 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the twelve (12) month period commencing on the first day following the end of Collaboration Year 1 and ending on the first anniversary of such starting date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.16 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Year 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the twelve (12) month period commencing on the first day following the end of Collaboration Year 2 and ending on the first anniversary of such starting date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.17 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Year 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the twelve (12) month period commencing on the first day following the end of Collaboration Year 3 and ending on the first anniversary of such starting date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.18 &#x201c;[***]&#x201d; means, [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.19 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means activities directed to the preparation for sale of, offering for sale of, or sale of the Product in the Territory, including activities related to marketing, advertising or Promoting the Product.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialize</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to engage in Commercialization.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.20 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the written plan setting forth Commercialization and related activities to be conducted by ALK and the budgeted costs and expenses therefor, where applicable, as such plan is more particularly described in Section 2.6 and as may be amended or updated in accordance with this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.21 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competing Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.5.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.22 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.23 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all statutory and common law copyrights owned or controlled by ARS in and to the Materials, Training Materials or Labels for the Product used in the Territory.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.24 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.3.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.25 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debarred/Excluded</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.2(a).</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.26 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***] discussion with [***] (excluding medical convention exhibits and displays) during which a Sales Representative makes a presentation of the Product&#x2019;s clinical attributes, benefits, prescribing information and safety information in a fair and balanced manner strictly in accordance with the Materials, the Labeling, the terms of this Agreement and all Applicable Laws, and in a manner that is customary in the industry in the Territory for the purpose of promoting a prescription pharmaceutical product. For clarity, [***], a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; can include [***]. [***]. A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall not include [***]. When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detailing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to conduct a Detail.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.27 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distributor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person appointed or engaged by ARS or any of its Affiliates or its or their Licensees to distribute, market and sell (or resell) the Product, as applicable, with or without packaging rights, including wholesalers, in the Territory in circumstances in which such Person purchases its requirements of Product from ARS or its Affiliates or Licensees on an arm&#x2019;s-length basis but does not otherwise make any royalty or other payments to ARS or its Affiliates or its Licensees with respect to intellectual property with respect to the Product.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.28 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dollar</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a United States dollar, and &#x201c;$&#x201d; shall be interpreted accordingly.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.29 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epinephrine Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any [***]. The Epinephrine Products existing as of the Effective Date are set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.30 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executives</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) with respect to ARS, its [***] or a senior executive of ARS designated by its [***] and, (b) with respect to ALK, its [***] or a senior executive of ALK designated by its [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.31 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Collaboration Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Collaboration, License and Distribution Agreement, dated as of November 9, 2024, by and between ARS and ALK-Abell&oacute; A/S, as the same may be amended from time to time in accordance with its terms.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.32 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78dd-1, et. seq.) as amended.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.33 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration, or any successor thereto.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.34 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDCA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), as amended, and the regulations promulgated and guidances issued thereunder from time to time.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.35 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal Sunshine Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means 42 U.S.C. 1320a-7h, as amended, and the regulations promulgated thereunder from time to time.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.36 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Quarter in (a) Collaboration Year 2, thirty percent (30%), and (b) Collaboration Year 3 and Collaboration Year 4, fifty percent (50%).</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.37 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means generally accepted accounting principles in the United States.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.38 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Compliance Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 5.5(b).</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.39 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gross Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Product, [***] of the Product in the Territory [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.40 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gross-to-Net Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the quotient of (a) Net Sales, divided by (b) Gross Sales, expressed as a percentage.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.41 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Organization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any entity that may, directly or indirectly, purchase, prescribe, recommend, refer or arrange for the prescribing, purchasing or formulary placement of a health-related product or service in the Territory including, but not limited to, hospitals, pharmacies (including specialty pharmacies), physician groups, nursing homes, group purchasing organizations, insurers, and health plans.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.42 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Professional</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any individual who is licensed to prescribe or dispense drugs in one or more jurisdictions within in the Territory, or who is in a position to recommend or refer a health-related product or service in the Territory, or who has significant input or influence on prescribing, purchasing or formulary decisions in the Territory, including physicians, physician assistants, nurses, nurse practitioners, pharmacists, medical directors, pharmacy directors, and formulary committee members.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.43 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the total compensation paid, on an annual basis, by or under the authority of ALK to a Sales Representative involved in Promotion of the Product under this Agreement based on the performance of products (including the Product) being promoted by such Sales Representative in the Territory, including any target bonus, award or other incentive, but excluding salary.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.44 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Label</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Labeling</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (a) the FDA-approved full prescribing information for the Product; and (b) the FDA-approved labels and other written, printed, or graphic matter accompanying or upon any container, wrapper, or any package insert, utilized with or for the Product.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.45 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party other than a Distributor to whom ARS or any of its Affiliates grants a (sub)license under its intellectual property to import, promote, distribute, offer for sale or sell the Product in the Territory (either independently from or in cooperation with ARS), beyond the mere right to purchase Products from ARS and its Affiliates. In no event shall ALK or any of its Affiliates be deemed a Licensee under this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.46 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.4.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.47 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any Quarter or month, as applicable, the quotient of (a) the total number of units of the Product sold in the Territory in such Quarter [***], divided by (b) the total number of units of Epinephrine Products sold in the Territory in such Quarter [***]; expressed as a percentage.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.48 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Share Threshold</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) with respect to any Quarter in Collaboration Year 2, forty-five percent (45%), and (b) with respect to any Quarter in Collaboration Year 3 or Collaboration Year 4, fifty percent (50%); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that [***</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.49 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all written, printed, graphic, electronic, audio, video or other materials to be used in connection with any Promotion activities, as developed in accordance with Section 4.1. For clarity, Materials may include materials such as detail aids, reprints and disease state materials, as applicable, as developed in accordance with Section 4.1.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.50 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Detail Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 0.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.51 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Product, the gross amount invoiced by ARS or its Affiliates or Licensees for sale or other transfer or disposition for value to Third Parties (including Distributors), less [***]:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; </font></div></div><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***];</font></div></div><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon any sale or other transfer or disposition of the Product that should be included within Net Sales for any consideration other than exclusively monetary consideration on bona fide arms&#x2019;-length terms, then for purposes of calculating Net Sales under this Agreement, the Product shall be deemed to be sold exclusively for money at the average sales price during the applicable reporting period generally achieved for the Product in the Territory in which such sale or other transfer or disposition occurred.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no event will any particular amount identified above be deducted more than once in calculating Net Sales. Sales of the Product between or among ARS and its Affiliates or Licensees for resale shall be excluded from the computation of Net Sales, but the subsequent resale of the Product to ARS, its Affiliate or (sub)license to a Third Party that is not a Licensee shall be included within the computation of Net Sales.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><h2 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales will not include Products transferred at no profit for use in connection with clinical trials or other development activity, promotional use, compassionate sales or use, indigent programs, investigator initiated trials, or on a named patient basis.</font></h2><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.52 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 2.4(a).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.53 &#x201c;[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">***</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]&#x201d; means any HCP who is [***]; provided that [***]. For clarity, [***], unless [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.54 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person that provides a health benefit program for health care products and services, including, any government payor (e.g., Medicaid, Medicare), commercial health plan, and any Person acting on behalf of any government payor or commercial health plan by contract or otherwise.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.55 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PDMA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Prescription Drug Marketing Act, as amended, and the regulations promulgated thereunder from time to time.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.56</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrician</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a physician that is permitted under Applicable Laws to prescribe the Product and who is board certified in the United States to treat pediatric patients.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.57 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a given Quarter in which the Market Share for such Quarter equaled or exceeded the Market Share Threshold for such Quarter,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a bonus fee equal to the product of (a) the Fixed Percentage of Specified Net Sales for such Quarter, multiplied by (b)(i) the Market Share for such Quarter minus (ii) the applicable Market Share Threshold for such Quarter.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.58 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an individual, corporation, partnership, limited liability company, trust, business trust, association, firm, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority, or any other form of entity not specifically listed herein.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.59 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PhRMA Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 1.12.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.60 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prescriber Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the prescriber data, in sufficient detail to identify (a) [***] and (b) [***], in each case supplied by [***] or an alternative nationally recognized prescription data provider reasonably agreed by the Parties.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.61 &#x201c;[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">***] Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Detail in which the Product (a) is [***], (b) is [***], and (c) is [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.62 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an intranasal epinephrine product approved by the FDA.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.63 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 1.79.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.64 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Product-specific training program conducted in accordance with the Commercialization Plan, Applicable Laws and Codes, which may include, as set forth in the Commercialization Plan, training concerning (a) [***], (b) [***], (c) [***], (d) [***], (f) [***], and (g) [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.65 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promote</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Product, promotional activities to be conducted by Sales Representatives in the Territory that are set forth in the Commercialization Plan or approved in writing by ARS. When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promote</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to engage in one or more of such activities, including the following (as approved by ARS or set forth in a Commercialization Plan): (a) Detailing; and (b) utilizing Materials during Details; in each case, solely within the Territory.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.66 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.2.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.67 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Commencement Timeline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.2.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.68 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 7.2.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.69 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each three (3) month period in a given Collaboration Year, with the first Quarter in such Collaboration Year commencing on the first day of such Collaboration Year; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the first Quarter for Collaboration Year 1 shall commence on the first day of such Collaboration Year and end on the last day of the first full three (3) month period within such Collaboration Year; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the last Quarter for the Collaboration Year in which expiration or the effective date of termination of this Agreement occurs shall end on such expiration date or effective date of termination, as the case may be.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.70 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any United States federal, state, commonwealth, territory, or local government, or political subdivision thereof, or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body with responsibility for granting approvals necessary for the marketing of the Product in the Territory, including the FDA.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.71 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an individual who (a) is employed by ALK (and not by a Third Party contractor, unless and to the extent permitted under Section 3.4) to conduct Promotion and other Commercialization activities with respect to the Product in the Territory pursuant to and in accordance with this Agreement and the Commercialization Plan, and (b) has been sufficiently trained in accordance with this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.72 &#x201c;[***</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">] Detail</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Detail in which (a) [***] and (b) [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.73 &#x201c;[***</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.74 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a given Quarter, [***] the product of (a) the [***], multiplied by (b) [***], multiplied by (c) the Gross-to-Net Percentage [***]; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.75 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Target Prescriber</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each Pediatrician identified in the Commercialization Plan as being a suitable target for the Promotion and Detailing of the Product in the Territory.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.76 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 11.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.77 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America excluding its territories and possessions, including Puerto Rico.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.78 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person other than a Party or any Affiliate of a Party.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.79 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (a) any trademarks that are owned or controlled by ARS and are used, or intended to be used, in connection with the Product in the Territory, including all word marks, logos, trade dress and/or indicia of origin, including applicable branding, color, palette, typeface, tagline and icon (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and (b) the ARS trade name and logo (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS House Marks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and including, in each case, all registrations and applications for registration of any such Trademarks in the Territory.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.80 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Training Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the materials (which may include written or other recorded, videotaped or Web-based training materials or on-line training programs) to be used in Product Training for the Sales Representatives regarding the Product pursuant to Section 5.5(a).</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.81 &#x201c;[***]&#x201d; means, with respect to the Product and a given Quarter, [***].</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE II<br><br>GRANT OF RIGHTS; GOVERNANCE; COMMERCIALIZATION PLAN</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant of Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, ARS hereby grants to ALK the right to Promote and Detail the Product to [***] in the Territory during the Term, in compliance with all Applicable Laws, Codes, the terms and conditions of this Agreement and the Commercialization Plan. Such right shall be non-transferable and non-sublicensable, and ALK shall not grant any rights to, or permit or authorize, any other Person to Promote or Detail the Product, except with respect to permitted subcontractors in accordance with Section 3.4.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, ARS hereby grants to ALK a non-exclusive, royalty-free license to use the Product Trademarks, the ARS House Marks and Copyrights in the Territory solely in connection with Promoting and Detailing the Product to [***] in the Territory in accordance with the terms of this Agreement. Such license shall be non-transferable and non-sublicensable and shall automatically and immediately terminate upon the expiration or earlier termination of this Agreement for any reason. </font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retained Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as specifically set forth in this Agreement, ALK shall have no other rights with respect to the Product. ALK and its Affiliates shall not Promote, market or otherwise Commercialize the Product except as ALK and its Affiliates is expressly authorized to do under this Agreement or the Existing Agreement. ARS and its Affiliates reserve and retain, for itself, its Affiliates and for any Third Party, all rights in and relating to the Product not expressly granted to ALK and its Affiliates under this Agreement or the Existing Collaboration Agreement, including all rights to, and ALK and its Affiliates shall not, Promote the Product (a) outside the Territory, except as set forth in the Existing Collaboration Agreement, or (b) in the Territory to any Person other than [***]. For clarity, ARS and its Affiliates shall continue to have the right to, and to grant to one or more Third Parties the right to, Detail and Promote, sell and market the Product throughout the Territory to any Person other than [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS shall book all sales of the Product in the Territory. ARS shall have the sole authority for accepting and filling purchase orders, billing and returns with respect to the Product, and for establishing and modifying the terms and conditions of sale of the Product, including the price at which the Product will be sold, whether the Product shall be subject to any discounts and/or rebates, and the distribution of the Product. ALK and its Sales Representatives are not authorized to, and shall not, discuss or provide any price concessions on the Product in the Territory or enter into any contracts with respect to the Product in the Territory.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Oversight Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***] after the Effective Date, the Parties shall establish an Oversight Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which shall operate during the Term. The OC shall be responsible for facilitating communication between the Parties with respect to the Promotion of the Product to [***] in the Territory and for reviewing and discussing performance and strategic direction with respect to such Promotion. The OC will have an advisory role only and will not have any decision-making authority or any power or authority to amend, modify or waive any of the terms or conditions of this Agreement. For clarity, ARS shall have sole responsibility and authority for establishing the overall marketing and Promotion strategy, messaging, and positioning for the Product.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OC Membership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The OC shall be comprised of an equal number of representatives of each Party, including [***] permanent members from each Party. Each Party&#x2019;s OC representatives will be appropriately knowledgeable regarding commercialization of pharmaceutical products. Each Party will designate one of its representatives as the co-chairperson of the OC. Each Party&#x2019;s co-chairperson will be responsible, on an alternating basis, for scheduling meetings, preparing and circulating an agenda in advance of each meeting, preparing and issuing minutes of each meeting within [***] days thereafter, revising such minutes to reflect timely comments thereon, and overseeing the ratification of such revised minutes.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OC Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The OC shall meet on a regular basis, no less than every [***] for the [***] of the Term and thereafter every [***] (unless mutually agreed otherwise), either in-person or by any means of communication as the members deem necessary or appropriate, including by telephone, videoconference or similar means in which each participant can hear what is said, and be heard, by the other participants. Each Party may, upon prior notice to the other Party: (a) have representative(s) from its organization attend OC meetings as regular participants and (b) invite other subject matter experts to any OC meeting on an as needed basis, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such attendees shall be bound by obligations of confidentiality and non-use equivalent to those set forth in Article 8. Each Party shall bear its own personnel and travel costs and expenses relating to its participation in the OC and attendance at any OC meetings.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alliance Managers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall, as soon as possible after the Effective Date, appoint a single individual to coordinate all daily, ordinary course of business interactions between the Parties that may be necessary to administer this Agreement effectively and carry out the intent and objectives of the Parties (for each Party, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alliance Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Alliance Managers shall meet with ALK commercial leadership (including sales, marketing, and head of ALK commercial) on a regular basis, no less than [***] for the [***] of the Term and thereafter every [***] (unless mutually agreed otherwise), either in-person or by any means of communication as the members deem necessary or appropriate, including by telephone, videoconference or similar means in which each participant can hear what is said, and be heard, by the other participants. Each Alliance Manager shall be experienced in project management, and be knowledgeable about the marketing and sale of branded pharmaceutical dosage products in general. Each Party may change its Alliance Manager effective upon written notice to the other Party.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties shall cooperate to develop and update, from time to time upon either Party&#x2019;s request, the Commercialization Plan setting forth the Promotion activities and other Commercialization activities, if any, to be conducted by ALK with respect to the Product in the Territory. [***].</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Plan; Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties have agreed in writing to the initial Commercialization Plan as of the Effective Date. Upon either Party&#x2019;s request, the Parties agree to discuss in good faith updates to the Commercialization Plan, taking into consideration, among other things, ARS&#x2019;s then-current brand strategy for the Product in the Territory. Any amendment or update to the Commercialization Plan shall be subject to review and approval by ARS and ALK. Subject to the foregoing, [***]. Further, [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Content</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Commercialization Plan will be transparent and specific so that ARS and ALK can coordinate and objectively measure performance. At a minimum, the Commercialization Plan shall contain: </font></div></div><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) list of [***];</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) number of [***];</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) number of [***], broken out by [***], and timelines for deployment, broken out by [***];</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) number of Details to be performed by the Sales Representatives, by [***], broken out by [***], on a [***] basis;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) promotion-related key performance indicators that may be used to evaluate the effectiveness of Promotion activities under the Commercialization Plan;</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi) product Training, including schedules and topics, consistent with Section 5.5, and training-related key performance indicators;</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii) anticipated use of Materials and quantities therefor;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(viii) Promotion activities (other than Details), if any, to be conducted by the Sales Representatives in the Territory and any costs therefor;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ix) other Commercialization activities, if any, to be conducted by ALK in the Territory; and</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x) detailed budgets for all [***] (this Section 2.6(b)(x) collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK Commercialization Support Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.231%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE&nbsp;III</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br><br>COMMERCIALIZATION RESPONSIBILITIES; RESTRICTIONS</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Throughout the Term, ALK shall, through the Sales Representatives, Promote the Product in the Territory to the [***] in accordance with the then-current Commercialization Plan, Applicable Law, the Codes, and the terms of this Agreement. Without limiting the foregoing, ALK shall: (a) employ a sufficient number of Sales Representatives and ensure that such Sales Representatives devote the necessary time Promoting the Product to [***], in each case as necessary to meet the Minimum Detail Requirements; and (b) perform Details in accordance with the [***] set forth in the Commercialization Plan. Subject to the terms of this Agreement, ALK shall be responsible for and have decision-making authority with respect to the manner in which it conducts its activities under this Agreement, including communicating with [***]. Each Party shall be solely responsible for all costs it incurs to conduct its activities under this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Commencement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall commence in-person Detailing activities with respect to the Product in the Territory to the Target Prescribers no later than [***] or such later date as may be agreed by the Parties in writing (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). ALK shall [***] pursuant to the Commercialization Plan (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Commencement Timeline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that [***]. Notwithstanding the foregoing, [***]. For clarity, [***].</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Detail Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], and (f) [***]. The &#x201c;Minimum Detail Requirements&#x201d; will be, collectively, the requirements set forth in each of the foregoing clauses (a) through (f), assessed each [***] during the Term; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, [***]; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, [***]. For clarity, [***]. The Parties agree that the Minimum Detail Requirements can be updated from time to time upon written agreement of both Parties. For clarity, any amendment to this Agreement shall be subject to Section 12.7 and any update to the Commercialization Plan shall be subject to Section 2.6(a).</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Commercialization Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If and to the extent set forth in the Commercialization Plan, ALK shall conduct other Commercialization activities in accordance with the then-current Commercialization Plan and the terms of this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subcontracting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK may not subcontract with any Third Parties (including any contract sales organization) to perform any of the Promotion or other Commercialization activities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be performed by ALK under this Agreement, unless such subcontracting has been approved by ARS in writing in advance, which approval shall be granted or withheld in ARS&#x2019;s sole discretion. ALK shall provide all reasonable information requested by ARS related to any potential subcontractor in order for ARS to evaluate ALK&#x2019;s request to subcontract. In all cases, ALK shall: (a) ensure that all permitted subcontractors are bound by written obligations as protective of the Product and ARS as the terms and conditions of this Agreement, as applicable to such subcontractors; (b) oversee the performance by its permitted subcontractors of the subcontracted activities; and (c) remain responsible and fully liable for the performance (or non-performance) of any activities by any of its permitted subcontractors in connection with this Agreement as if such activities had been performed by ALK itself.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusivity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall Detail and Promote the Product in the Territory to the [***] during the Term in accordance with the Commercialization Plan and this Agreement and shall not and shall cause its Affiliates not to, during the Term and, in the case of expiration of this Agreement or termination [***], directly or indirectly, (a) market, promote, sell, distribute or accept orders for the sale of any [***] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competing Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in the Territory, or (b) assist or cooperate in any way with any other Person in connection with the marketing, promotion, sale, distribution or acceptance of orders for the sale of any Competing Product in the Territory;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, however that [***] ALK acknowledges and agrees that the restrictions set forth in this Section 3.5 are reasonable and necessary to protect the legitimate interests of ARS and agrees not to contest such restrictions in any proceeding.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grants; Charitable Requests; HCP/HCO Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, ARS shall have the right (in its sole discretion) to determine participation in free goods program plans, patient assistance programs and indigent access programs, if applicable, as well as to determine funding levels for grants, sponsorships and other charitable requests (including in support of professional symposia and continuing medical education programs), with respect to the Product in the Territory (including on a national, regional and local level, if applicable). If, for any reason, ALK receives any requests with respect to any of the foregoing activities, including any request with respect to the Product to support any of the foregoing activities, that have not been approved by ARS to be performed by ALK and included in a Commercialization Plan, ALK shall promptly forward such requests to ARS as soon as practicable for ARS&#x2019;s consideration. Unless explicitly authorized by ARS in writing, ALK shall not enter into any agreements with Healthcare Professionals or Healthcare Organizations relating to speaker programs, advisory boards, consulting arrangements or similar arrangements related to the Product. ARS shall have the sole authority to develop, host and enter into, as the case may be, speaker programs, advisory boards, consulting arrangements and similar arrangements related to the Product in the Territory; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that upon ARS&#x2019;s reasonable request, ALK shall provide commercially reasonable support to ARS with respect to each of the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.7 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development and Regulatory Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, ARS shall have the sole right to conduct, and ALK shall not conduct or sponsor (directly or indirectly), clinical trials or other development activities with respect to the Product in the Territory, including providing support or assistance for investigator sponsored trials, cooperative studies, clinical studies, including post-approval studies, or other studies, including health economics and outcomes research and phase 4 studies, or any other research or development activities with respect to the Product. As between the Parties, ARS shall be responsible for reporting of, and shall report, regulatory matters regarding the manufacture, distribution, promotion and safety of the Product (including adverse events and product quality complaints) to or with the FDA and/or other relevant Regulatory Authorities in the Territory, as applicable. For clarity, the foregoing shall not limit ALK&#x2019;s obligations under Applicable Laws to report its relevant Promotion activities under this Agreement, including ALK&#x2019;s reporting obligations under Applicable Laws with respect to transparency reporting, as described in Section 5.4. If a Sales Representative receives any inquiry regarding any such matter described in this Section 3.7, ALK shall refer the Person making the inquiry to ARS, in a manner directed by ARS from time to time.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Price Reporting and Processing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS shall be responsible for all government price calculations, reporting and rebate processing in the Territory relating to the Product. However, ALK shall, to the extent it has in its possession relevant information, cooperate with and assist ARS in complying with its Product-related government price reporting obligations in the Territory, including by providing to ARS or its designee, promptly upon ARS&#x2019;s request in order to satisfy reporting deadlines, all data and other information required for government price reporting that is collected or maintained by or otherwise in the possession or reasonable control of ALK and by promptly responding to ARS&#x2019;s questions and requests for information or assistance.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.9 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">***]</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.10 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that either Party has been subject to a Change of Control, the affected Party shall provide written notice thereof to the other no later than [***] thereof.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV<br><br>PROMOTIONAL MATERIALS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preparation of Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS will (a) develop and produce all Materials to be used by the Sales Representatives pursuant to this Agreement, and (b) provide the Materials to ALK in quantities set forth in the Commercialization Plan. For clarity, neither ALK nor any of its Affiliates or any Sales Representative shall produce any Materials without the express written consent of ARS. All Materials to be used by the Sales Representatives pursuant to this Agreement shall at all times be in compliance with all Applicable Laws and the Labeling. All Materials shall include the Product Trademarks and the ARS House Marks, [***]. As between the Parties, ARS shall own all Copyrights and other right, title and interest in and to all Materials, and ALK hereby assigns to ARS any and all interest that ALK may have in the Materials; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that [***]. ARS shall be responsible and have the sole and exclusive right for submitting all Materials to the FDA in accordance with applicable FDA requirements.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submission; Use of Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK and the Sales Representatives shall: (a) use the Materials solely for the purposes of conducting the Promotion activities for the Product to the [***] in the Territory, in the manner for which they are approved by ARS, as contemplated by this Agreement and for no other purposes; (b) ensure that the Materials are not modified, changed, misbranded or altered in any way by ALK or any Sales Representative; (c) in conducting Promotion activities hereunder, make only those statements and claims regarding the Product, including as to efficacy and safety, that are consistent with the Materials, the Labeling and Applicable Laws; (d) in Promoting the Product, use only the Materials that are produced in accordance with Section 4.1 and approved by ARS; and (e) promptly notify ARS, and provide ARS with a copy, of any correspondence or other report or complaint received by ALK or any Sales Representative from any Regulatory Authority, including the FDA, or any Third Party claiming that any oral or written statements about the Product or any Materials are inconsistent with the applicable Labeling or are otherwise in violation of Applicable Laws or Codes or that any Sales Representative is making statements or claims regarding the Product that are inconsistent with the Materials or the Labeling. If any Materials provided to ALK by ARS are withdrawn from use for any reason, ARS shall promptly notify ALK of such withdrawal in writing and ALK shall promptly effectuate such withdrawal.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE V<br><br>PERSONNEL MATTERS; COMPLIANCE; TRAINING; PHARMACOVIGILANCE</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualifications</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall conduct its Promotion activities (including Details) using Sales Representatives who meet the following requirements and any other requirements of this Agreement: each Sales Representative must: (i) except and to the extent permitted under Section 3.4, be an employee of ALK and a member of its sales force; (ii) possess skills, training and experience that are consistent with industry standards applicable to the promotion of a pharmaceutical product; (iii) have completed the product specific training and other required sales training approved or conducted by ARS; and (iv) have become adequately equipped and knowledgeable with respect to the Product, as determined by satisfaction of criteria approved by ARS in its reasonable discretion. ALK will manage its Sales Representatives performing Promotion activities hereunder in accordance with Applicable Laws and Codes, and shall ensure that no Sales Representative is, has been or shall be Debarred/Excluded. In advance of engaging any Sales Representative to perform Promotion activities or other Commercialization services under this Agreement, and at least [***] thereafter, ALK shall check the debarment/exclusion status of each such Sales Representative and confirm that such Sales Representative is not Debarred/Excluded and, upon ARS&#x2019;s request, provide ARS the results of such status checks. In the event that any Sales Representative becomes Debarred/Excluded, ALK shall remove such Person as a Sales Representative immediately upon learning of such Debarment/Exclusion.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall be solely responsible for recruiting and hiring all Sales Representatives at ALK&#x2019;s sole cost and expense. ALK shall be solely responsible for: (i) all salaries, wages, benefits and other compensation that the Sales Representatives may be entitled to receive in connection with the performance of the services under this Agreement, including Incentive Compensation, and all taxes, excises, assessments and other charges levied by any agency on, or because of, the services to be provided by ALK under this Agreement; (ii) maintaining all necessary personnel and payroll records for all Sales Representatives; (iii) ensuring that its compensation of the Sales Representatives complies with all Applicable Laws; and (iv) providing workers&#x2019; compensation and unemployment insurance coverage for the Sales Representatives in amounts as required by Applicable Laws. ALK shall indemnify, defend and hold harmless ARS from and against all Losses to the extent incurred by or imposed upon ARS in connection with or arising from any Claims (including by any Sales Representatives) relating to any of ALK&#x2019;s responsibilities enumerated in the preceding sentence (including any Claims relating to ALK&#x2019;s payment of or failure to pay Incentive Compensation). Each Party acknowledges and agrees that the Sales Representatives are not, and are not intended to be or be treated as, employees of ARS or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any &#x201c;employee benefit plan,&#x201d; as such term is defined in Section 3(3) of ERISA, that are sponsored by ARS or any of its Affiliates or that are offered from time to time by ARS or its Affiliates to its or their own employees. [***] </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">***]</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Conduct</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall be solely responsible and fully liable for: (i) the compliance of all Sales Representatives and ALK Personnel with all Applicable Laws, the Codes, and [***]; (ii) the acts and omissions of the Sales Representatives and ALK Personnel while performing any activities under this Agreement; and (iii) all disciplinary, probationary and termination actions taken by it, as well as for the formulation, content, and dissemination (including content) of all employment policies and rules (including written disciplinary, probationary and termination policies) applicable to any Sales Representatives or ALK Personnel. ALK shall ensure that its Sales Representatives and ALK Personnel are familiar with, trained on pursuant to Section 5.5 and understand [***] and all other procedures, obligations, rights, and responsibilities imposed by the terms of this Agreement as applicable to the performance of Promotion activities and other Commercialization hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Removal of Personnel from Product Responsibilities. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK shall immediately remove and as soon as reasonably practicable replace any Sales Representative or ALK Personnel from having any responsibilities relating to the Promotion or Commercialization of the Product under this Agreement if required by any Applicable Laws, including if ALK determines that such Sales Representative or ALK Personnel is Debarred/Excluded. Further, upon ARS&#x2019;s reasonable request, ALK shall promptly remove any Sales Representative or ALK Personnel from having any responsibilities relating to the Promotion or Commercialization of the Product under this Agreement if such Sales Representative or ALK Personnel fails to comply with any Applicable Laws, the Codes, ALK&#x2019;s compliance policies, procedures, standards and practices ([***]), and shall replace such Sales Representative or ALK Personnel as soon as reasonably practicable.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws, Codes and Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  ALK shall: (i) perform all of its obligations under this Agreement (including Promotion and all activities under the Commercialization Plan) in compliance with all Applicable Laws and Codes and the terms of this Agreement; (ii) instruct the Sales Representatives not to, and shall use reasonable efforts consistent with industry practices to ensure that the Sales Representatives do not, make any representation, statement, warranty or guaranty, oral or written, with respect to the Product that is inconsistent with the then-current Labeling of the Product, the applicable approved Materials, the Commercialization Plan or Applicable Laws; or that is deceptive or misleading in any way; or take any action that disparages or may jeopardize the good name, goodwill or reputation of the Product or of ARS or any of its Affiliates; (iii) maintain and enforce a corporate compliance program consistent with the OIG Compliance Guidance ([***]), including maintaining a mechanism for its personnel to report, at any time and anonymously if they choose, any concerns about potential non-compliance with Applicable Laws, Codes, [***] or ALK policies, procedures, standards and practices, and that requires ALK to promptly and diligently investigate and take appropriate corrective and disciplinary action with regard to any such reports, as applicable; (iv) ensure that all ALK Personnel are trained on pursuant to Section 5.5, understand, and comply with all [***]; and (v) [***]. [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall at all times cause its Sales Representatives and ALK Personnel to comply with [***], ALK&#x2019;s compliance program, policies and procedures, to the extent related to ALK&#x2019;s activities hereunder, which shall be substantially similar to ([***]). Promptly after the Effective Date, [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Verification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each year during the Term upon the written request of ARS, ALK shall verify to ARS in writing that it has enforced, and continues to enforce, a code of conduct and compliance program for Sales Representatives and ALK Personnel that is consistent with Applicable Laws and Codes. Without limiting such verification obligations, if there is any material change to ALK&#x2019;s compliance program (including applicable policies and procedures) that relate to or may affect ALK&#x2019;s performance of its Promotion or other activities under this Agreement, ALK shall promptly notify ARS of such material changes.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></div></div><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font></div></div><div class="item-list-element-wrapper" style="text-indent:126pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1.75in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.462%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">***</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. [***] </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments to Healthcare Professionals/Healthcare Organizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall not directly or indirectly provide any payment, remuneration or other transfer of value to any HCP, HCO, or Payor in connection with Promotion or Commercialization activities, except as provided in accordance with all Applicable Laws, Codes, ALK&#x2019;s policies, procedures, standards and practices, and the Commercialization Plan and subject to ALK&#x2019;s tracking and reporting obligations under Section 5.4.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transparency Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall be responsible for tracking and reporting all of its direct and indirect payments and transfers of value provided or directed by such Party to HCPs and HCOs in connection with this Agreement in accordance with the Federal Sunshine Law and similar transparency laws required by any state and local government in the Territory that requires such reporting. Without limitation of Article 7, upon ARS&#x2019;s reasonable request, ALK shall timely cooperate [***] with ARS and provide ARS with all relevant information, at ALK&#x2019;s expense and in such form as required by ARS or its designated service provider, relating to reporting of such payments or transfers of value [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Commercialization Plan shall include a Product Training schedule, including timing, location and number of training sessions (including refresher programs), as well as the topics for such Product Training sessions. ARS shall be responsible for planning and conducting all Product Training, consistent with the Commercialization Plan. ALK shall ensure that each Sales Representative and ALK Personnel completes all required Product Training prior to commencing any Promotion or other Commercialization activities under this Agreement and continues to participate in Product Training at least [***] thereafter. ARS shall develop and provide all Training Materials for the Product Training hereunder, and, as between the Parties, shall own all Copyrights and other right, title and interest in and to all such Training Materials.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall be responsible, at its own expense, for providing, and shall provide, to all Sales Representatives and ALK Personnel a broad general training program (including refresher programs), including training on proper promotion and marketing techniques, ethics, compliance with Applicable Laws and substantial compliance with the Codes,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the compliance with ALK&#x2019;s policies, procedures, standards and practices (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Compliance Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). ARS shall have the right, at its own expense, to provide to all ALK Personnel a specific training program (including refresher programs) related to the ARS Compliance Policies (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Compliance Training</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). ALK shall provide copies of such General Compliance Training material to ARS upon request. Notwithstanding the foregoing, at ARS&#x2019;s election, ARS shall have the right to conduct or supplement General Compliance Training and ARS Compliance Training for Sales Representatives and ALK Personnel. [***]</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Testing and Certification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with each Product Training and ARS Compliance Training, and at other times on reasonable prior notice, ARS may provide testing that verifies, whether through ARS&#x2019;s learning management system or otherwise, that each Sales Representative and ALK Personnel has satisfactorily completed and understood the Product Training and ARS Compliance Training, as applicable. Results and documentation of testing through ARS&#x2019;s learning management system will be provided by ARS to ALK as soon as reasonably practicable after such results are available after testing. Each Sales Representative and ALK Personnel also must certify at the end of each Product Training and Product Compliance Training session, as applicable, that he/she has completed, understood and agrees to comply with such Product Training and ARS Compliance Training.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recordkeeping</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall maintain records related to Product Training, General Compliance Training and ARS Compliance Training sufficient to show the Sales Representatives and ALK Personnel in attendance at each Product Training, General Compliance Training and ARS Compliance Training session, as applicable, including sign-in sheets and computer records for Web-based training. ALK shall maintain all such attendance records and Product training records, including testing records, certifications, and copies of Training Materials used at each Product Training session, in accordance with Section 7.4. ALK shall provide copies of such Product training records to ARS upon request.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Requests for Medical Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS shall have the exclusive right and obligation to respond, in accordance with Applicable Laws and the Codes (as applicable), to all questions or requests for information about the Product that are outside of the Label made by any Healthcare Professional, Healthcare Organization or any other Third Party to the Sales Representatives (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Medical Information Request</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PMIR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in accordance with the ARS Compliance Policies. The Sales Representatives shall promptly refer such PMIRs to ARS&#x2019;s call center for response in accordance with the ARS Compliance Policies. For clarity, PMIRs shall not be proactively solicited by Sales Representatives. For any PMIR received by ALK&#x2019;s call center, ALK shall promptly transfer such PMIR to ARS&#x2019;s call center.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse Events, Product Quality Complaints and Pharmacovigilance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall follow the requirements set forth in the ARS Compliance Policies with respect to adverse events and product quality complaints, including ARS&#x2019;s Policy for Reporting Postmarketing Adverse Events &amp; Product Quality Complaints.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.231%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE&nbsp;VI</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAYMENTS</font></h1><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to this Section 6.1, ARS shall compensate ALK for its costs of employing and maintaining ALK Personnel to conduct Promotion and Commercialization activities and support thereof hereunder, as well as its Detailing costs, (i) for each Quarter during the Term in Collaboration Year 1, in the amount of [***] per Quarter during the Term in such Collaboration Year; (ii) for each Quarter during the Term in Collaboration Year 2, in the amount of [***] per Quarter during the Term in such Collaboration Year; (iii) for each Quarter during the Term in Collaboration Year 3, in the amount of [***] per Quarter during the Term in such Collaboration Year; and (iv) for each Quarter during the Term in Collaboration Year 4, in the amount of [***] per Quarter during the Term in such Collaboration Year (in each case, such Quarterly payment, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that [***].  </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Fee Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Commencing in Collaboration Year 2, on a Quarterly basis during the Term, within [***] after the end of each Quarter, ALK shall promptly issue to ARS an invoice for the amount of the applicable Base Fee for such Quarter; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that for each Quarter in Collaboration Year 2, such invoice shall also include the applicable Base Fee for the corresponding Quarter in Collaboration Year 1. Within [***] after receipt of the invoice from ALK for a given Quarter with respect to the applicable Base Fee, to the extent that ARS does not dispute in good faith the amount set forth on such invoice, ARS shall pay such applicable Base Fee due to ALK for such Quarter. ARS shall make each such payment to an account designated by ALK pursuant to Section 6.4. For clarity, no Base Fee shall be payable during Collaboration Year 1 and the earned but unpaid Base Fee for Collaboration Year 1 shall be paid in accordance with this Section 6.1 or Section 11.5. </font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Bonus Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Commencing in Collaboration Year 2, on a Quarterly basis during the Term, ALK is eligible for a Performance Bonus for any Quarter in which the Market Share for such Quarter equaled or exceeded the applicable Market Share Threshold for such Quarter. Commencing in Collaboration Year 2, on a Quarterly basis during the Term, ARS shall, within [***] after the end of each Quarter, provide ALK with a report showing [***].</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Bonus Invoice and Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Commencing in Collaboration Year 2, on a Quarterly basis during the Term, in the event that the Market Share for such Quarter equaled or exceeded the applicable Market Share Threshold for such Quarter, then, after receipt of each report provided by ARS under Section 6.2(a) above, ALK shall promptly issue to ARS an invoice for the amount of the Performance Bonus set forth in such report. Within [***] after receipt of the invoice from ALK with respect to the Performance Bonus for a given Quarter, to the extent that ARS does not dispute in good faith the amount set forth in such invoice, ARS shall pay to ALK the Performance Bonus for such Quarter to an account designated by ALK pursuant to Section 6.4. For clarity, no Performance Bonus shall be earned or payable during or with respect to Collaboration Year 1.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK Commercialization Support Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***] after the end of each Quarter during the Term (and after termination of this Agreement with respect to costs incurred prior to termination of this Agreement), ALK shall provide a written report (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to ARS setting forth in reasonable detail any ALK Commercialization Support Costs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurred by ALK during such Quarter in accordance with the Commercialization Plan and the budget set forth therein. Each Cost Report shall enable ARS to compare the reported out-of-pocket costs against the budget for ALK Commercialization Support Costs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set forth in the Commercialization Plan, on both a quarterly basis and a cumulative basis for each activity. With each Cost Report, ALK shall also provide to ARS copies of Third Party invoices and other supporting documentation for all out-of-pocket costs detailed in such Cost Report.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All cash payments made under this Agreement shall be made by wire transfer from a banking institution in Dollars in accordance with instructions given in writing from time to time by the Party receiving such payment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes on Income</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall be solely responsible for the payment of all taxes imposed on any payments it receives under this Agreement.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of payments made under this Agreement. To the extent a Party is required by Applicable Laws to deduct or withhold taxes from any payment to the other Party, such Party will remit such amounts to the proper governmental authority, promptly transmit to the other Party the best available evidence of such payment and remit the remaining amount of such payment to the other Party. For clarity, to the extent amounts are so withheld and remitted in accordance with this Section 6.5(b), such amounts will be treated for all purposes of this Agreement as having been paid to the other Party. Each Party shall provide the other Party any tax forms that may be reasonably necessary in order for such Party to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, or other Applicable Laws, including an Internal Revenue Service (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Form W-9, or an appropriate IRS Form W-8, as applicable. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such tax. On request of the paying Party, the payee Party shall refund to the paying Party any amounts received from the paying Party or its Affiliates under this Agreement which should have been deducted or withheld under Applicable Laws, but which were not deducted or withheld in full or at all, plus any interest and penalties imposed on such amounts (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Later Imposed Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and following receipt of such Later Imposed Withholdings, the paying Party shall remit such Later Imposed Withholdings to the appropriate government authority.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VII<br><br>REPORTS; MAINTENANCE OF RECORDS; AUDIT RIGHTS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Account Management and Reporting System</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall apply its existing electronic account management and reporting system to document and report its Details and other Promotion activities hereunder, including all of the information that is required to be reported in the Promotion Reports, and to document and report its compliance activities and comply with the transparency reporting requirements under Section 5.4. [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall keep ARS regularly informed regarding the conduct of its Promotion activities under this Agreement. Without limiting the foregoing, ALK shall provide ARS with a report (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotion Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) within [***] after the end of each Quarter which shall set forth the efforts of the Sales Representatives in conducting Details and other Promotion activities under this Agreement during the preceding Quarter (and in the case of the Promotion Report for the fourth (4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Quarter in a given Collaboration Year, during the preceding Collaboration Year also), in a form mutually agreed by the Parties, including the following information: (a) the number of Sales Representatives; (b) the number of Details made and recorded by Sales Representatives broken out by region, position of Details and [***]; (c) a written verification by ALK that [***]; (d) all documents and information relevant to the transparency reporting requirements described in Section 5.4; and (e) such other information as may be required in the Commercialization Plan; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, for the first [***] following the Promotion Commencement Date, ALK shall provide ARS, within [***] following the end of each calendar [***], with a report including (i) the number of Sales Representatives, (ii) the number of Details made and recorded by Sales Representatives broken out by region, position of Details and [***], and (iii) [***]. Each Promotion Report shall be provided in an electronic format or as agreed by the Parties and shall include all applicable information from ALK&#x2019;s account management system.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS&#x2019;s Audit Rights Relating to ALK&#x2019;s Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right to Audit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Term, and upon no less than [***] prior written notice from ARS, ALK shall afford to ARS reasonable access during normal business hours (and at such other times as the Parties may mutually agree) to inspect and audit the relevant books, records and other information of ALK in order to monitor ALK&#x2019;s compliance with its obligations under the Commercialization Plan and the terms of this Agreement and to verify that ALK&#x2019;s Promotion and other Commercialization activities were accurately reported and conducted in compliance with this Agreement, [***]. Such audit shall occur no more than [***], except that ARS may conduct more frequent inspections and audits for &#x201c;cause&#x201d; at any time that ARS learns of any material non-compliance (or of any condition that ARS determines is reasonably likely to result in material non-compliance) with the Commercialization Plan or the terms of this Agreement. Subject to the limitations set forth in this Section 7.3(a), ARS may conduct such audit (i) itself, or by an independent certified public accountant or other applicable consultant appointed by ARS at its expense and reasonably acceptable to ALK, by auditing the relevant financial and compliance records of ALK and its Affiliates at ALK&#x2019;s [***] facilities as related to the Product; (ii) by conducting surveys of the [***]; and/or (iii) by direct observation of any such Promotion activity. ALK shall keep and maintain complete and accurate records of all Promotion and other Commercialization activities conducted by ALK pursuant to this Agreement in accordance with Section 7.4.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Results</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All records made available for audit pursuant to this Section 7.3 shall be deemed to be Confidential Information of [***]. In the event that an audit establishes that there was an error in Promotion activities reported by ALK hereunder, ALK shall promptly (but in any event no later than [***] after ALK&#x2019;s receipt of the audit report so concluding) provide a corrected Promotion Report to ARS. ARS shall bear the full cost of such audit unless such audit discloses a downward adjustment of the number of [***] of more than [***] of the number reported in such statement, in which case ALK shall reimburse ARS for the reasonable out-of-pocket costs incurred by ARS in connection with such audit.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance of Books and Records</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall maintain complete and accurate books and records in sufficient detail, in accordance with all Applicable Laws, to enable verification of such Party&#x2019;s performance of its obligations under this Agreement, including with respect to ALK, all Detailing, Promotion and Product Training, and with respect to ARS, all Prescriber Data, Material and ARS Compliance Policies. Such books and records shall be deemed to be the Confidential Information of the respective Party that is maintaining such books and records and shall be maintained for the latest to occur of: (a) a period of [***] after the end of each calendar year in the Term, (b) longer if required by Applicable Laws or the respective Party&#x2019;s document management program, and (c) until the final resolution of any audit or dispute as to which such records relate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right to Audit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS shall have the right, no more than [***] in the Term, to audit the relevant books and records of ALK in order to verify ALK&#x2019;s reports of ALK Commercialization Support Costs. ALK shall have the right, no more than [***] in the Term, to audit the relevant books and records of ARS in order to verify ARS&#x2019;s reports of Specified Net Sales and Market Share. Upon no less than [***] prior written notice, the Party subject to audit (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audited Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall grant reasonable access to members of a nationally-recognized independent certified public accounting firm selected by the Party conducting the audit (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Auditing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (but not, in the case of ALK as the Audited Party, the auditor that conducts or has within the past [***] conducted the audit of ALK&#x2019;s financial statements, or, in the case of ARS as the Audited Party, the auditor that conducts or has within the past [***] conducted the audit of ARS&#x2019;s financial statements) to the relevant books and records of the Audited Party in order to conduct a review or audit thereof. Such access shall be permitted only during normal business hours. The auditor will execute a written confidentiality agreement with the Audited Party and will disclose to the Auditing Party only such information necessary or relevant to verify the Audited Party&#x2019;s reports of (a) in the case of ALK as the Audited Party, ALK Commercialization Support Costs, and (b) in the case of ARS as the Audited Party, Specified Net Sales and Market Share. The accountant</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall report its conclusions and calculations to the Parties; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that in no event shall the accountant disclose any information of the Audited Party except to the extent necessary to report inaccuracies in reports of (i) in the case of ALK as the Audited Party, ALK Commercialization Support Costs, and (ii) in the case of ARS as the Audited Party, Specified Net Sales and Market Share. Such examination shall be conducted at the facility(ies) where such books and records are maintained and without disruption to operations of the Audited Party. Except as set forth in Section 7.5(b), the Auditing Party shall bear the full cost of the performance of any such audit. All inspections made under this Section 7.5 shall be made no later than [***] after the reports that are the subject of the investigation were made.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Results</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If as a result of any audit of books and records under Section 7.5(a), it is shown that the Audited Party&#x2019;s payments to the Auditing Party under this Agreement with respect to the period of time audited were less than the amount which should have been paid, then the Audited Party shall pay to the Auditing Party the amount of such shortfall within [***] after both Parties&#x2019; receipt of the auditor&#x2019;s report. If instead the audit shows that Audited Party&#x2019;s payments to the Auditing Party under this Agreement with respect to the period of time audited were more than the amount which should have been paid to the Auditing Party pursuant to this Agreement, then the Auditing Party shall refund such overpayment to the Audited Party within [***] after both Parties&#x2019; receipt of the auditor&#x2019;s report. In addition, if any amount of underpayment by the Audited Party is more than [***] of the amount which should have been paid pursuant to this Agreement with respect to the period in question, then the Audited Party shall also reimburse the Auditing Party for its documented, reasonable, out-of-pocket costs and expenses incurred in connection with the audit.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VIII<br><br>CONFIDENTIAL INFORMATION</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At all times during the Term and for [***] thereafter, each Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall, and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose, and not use, directly or indirectly, for any purpose, any Confidential Information of the other Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), except to the extent such disclosure or use is permitted by the terms of this Agreement or is otherwise agreed upon in writing by the Parties. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any non-public technical, scientific, regulatory, commercial, business or other confidential, proprietary, or trade secret information provided by or on behalf of the Disclosing Party to the Receiving Party pursuant to this Agreement, and the terms of this Agreement, which are the Confidential Information of each Party; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that Confidential Information shall not include any information that the Receiving Party can demonstrate by competent written proof:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) is in the public domain by use and/or publication at the time of its receipt from the Disclosing Party or thereafter enters into the public domain through no fault of the Receiving Party; or</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) was already in the Receiving Party&#x2019;s possession prior to receipt from the Disclosing Party or is developed independently of information received from the Disclosing Party, in each case as demonstrated by contemporaneous written documentation; or</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) is obtained by the Receiving Party from a source (other than a Party or its Representatives (as defined below)) which is not bound by a confidentiality agreement or other contractual restriction that may prohibit the disclosure of such information.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Disclosures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Receiving Party may only disclose Confidential Information of the Disclosing Party to the extent that such disclosure is:</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made by the Receiving Party or its Affiliates to its or their employees, agents, attorneys, auditors, advisors, consultants or contractors (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on a need-to-know basis and solely in connection with the performance of the Receiving Party&#x2019;s obligations or the exercise of its rights under this Agreement, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that each Representative must be bound by obligations of confidentiality and non-use equivalent in scope to, and no less restrictive than, those set forth in this Article 8 prior to any such disclosure; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made in response to a valid order of a court of competent jurisdiction, Regulatory Authority or other governmental authority of competent jurisdiction or, if in the reasonable opinion of the Receiving Party&#x2019;s legal counsel, such disclosure is otherwise required by law, including by reason of filing with securities regulators; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, to the extent legally permissible, the Receiving Party shall first have given written notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that such Confidential Information be held in confidence by such court or governmental authority or, if disclosed, be used only for the purposes for which the order was issued; and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further, that the Confidential Information disclosed in response to such court or governmental authority order shall be limited to that information which is legally required to be disclosed in response to such order. </font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Announcements; Agreement Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limiting the restrictions set forth in Section 8.1, a Party may not use the name of the other Party in any publicity or advertising or make any public announcement or issue any press release concerning the existence or terms of this Agreement or activities hereunder without the prior written consent of the other Party, including approval of any press release or other public announcement. Notwithstanding the foregoing, (i) a Party may disclose information relating to this Agreement (including any termination hereof) as required by Applicable Laws, including to the United States Securities and Exchange Commission or any other securities exchange or governmental authority as required by law or regulation, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the disclosing Party shall (1) if practicable, provide the other Party with reasonable advance notice of and an opportunity to comment on any such required disclosure, and (2) if reasonably requested by such other Party, seek, or cooperate with such Party&#x2019;s efforts to obtain, confidential treatment or a protective order with respect to any such disclosure to the extent available at such other Party&#x2019;s expense, and (ii) each Party may use the name of the other Party in connection with its Promotion of the Product in accordance with the Commercialization Plan. This Agreement shall be deemed Confidential Information of both ARS and ALK and may only be disclosed by a Party: (A) as may be permitted under Section 8.2 or clause (i) of the preceding sentence in this Section 8.3, (B) to potential or actual investors or acquirers of such Party who are bound by obligations of confidentiality and non-use equivalent in scope to, and no less restrictive than, those set forth in this Article 8 prior to any such disclosure or (C) with the prior written consent of the other Party, which shall not be withheld unreasonably.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Injunctive Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party acknowledges that damages resulting from disclosure of the Confidential Information in violation of this Article 8 may not be an adequate remedy and that, in the event of any such disclosure or any indication of an intent to disclose such information, a Party (or its Affiliates) owning such information will be entitled to seek injunctive relief or other equitable relief in addition to any and all remedies available at law or in equity, including the recovery of damages and reasonable attorneys&#x2019; fees.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX<br><br>INTELLECTUAL PROPERTY RIGHTS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership of Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, ARS shall own all right, title and interest in and to the Materials, Training Materials and Labeling, in each case including all content contained therein and all applicable Copyrights and trademark rights (but excluding any trademark or other rights in ALK House Marks). To the extent ALK (or any of its Affiliates or other agents) obtains or otherwise has a claim to the Materials, Training Materials and Labeling, ALK shall assign, and hereby does assign, to ARS (or its designated Affiliate) all of ALK&#x2019;s (and its Affiliate&#x2019;s and other agent&#x2019;s) right, title and interest in and to such Materials, Training Materials, Labeling and all content therein (excluding, in each case, any rights in ALK House Marks). [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Trademark</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All Materials shall include the Product Trademarks and the ARS House Marks. [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Dispute</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party shall, and shall not knowingly cause another person to, contest or dispute or otherwise impair or endanger the validity of, the exclusive rights of, any of the trademarks (including the Trademarks and ALK House Marks) owned, licensed or maintained, as the case may be, by the other Party or its Affiliates, or any part thereof, or the registrations thereof. Neither Party shall undertake any action in respect of the filing, registration or renewal of any of the other Party&#x2019;s trademarks (including the Trademarks and ALK House Marks) without such other Party&#x2019;s consent. </font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall promptly inform the other Party of any material infringement of, or challenge to, any Trademark or any other intellectual property relating to the Product owned or controlled by ARS in the Territory, in each case whether actual or threatened, which comes to the attention of such Party. As between the Parties, ARS shall have the exclusive right (in its sole discretion) to take (or not take, as applicable) action in respect of the defense or infringement of the Trademarks and/or any other material intellectual property relating to the Product, and ALK shall, at ARS&#x2019;s expense, provide reasonable assistance and cooperation with such activities as ARS may reasonably request.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X<br><br>REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mutual Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK and ARS each represents and warrants to the other, as of the Effective Date, as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action and will not violate: (i) such Party&#x2019;s certificate of incorporation, bylaws or other organizational documents; (ii) any agreement, instrument or contractual obligation to which such Party is bound in any material respect; (iii) any requirement of any Applicable Law; or (iv) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions (subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Applicable Laws affecting the enforcement of creditors&#x2019; rights generally).</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations, Warranties and Covenants of ALK</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, ALK represents and warrants to ARS, as of the Effective Date, and covenants to ARS as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither it, nor any of its Affiliates, nor any of their respective officers, employees, agents, representatives or other Persons used in the performance of its obligations under this Agreement has been debarred or suspended under 21 U.S.C. &#167;335(a) or (b), excluded from a federal health care program, debarred from federal contracting, or convicted of or pled nolo contendere to any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug products or fraud (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debarred/Excluded</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). ALK shall notify ARS within [***] if it, any of its Affiliates, or any officer, employee, agent, representative or other Person who is performing any activities under this Agreement is or becomes Debarred/Excluded; </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) it and its Affiliates have promoted its products in the Territory in compliance with Applicable Laws and Codes in all material respects, (ii)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of the Effective Date, neither it nor any of its Affiliates is being investigated by any Regulatory Authority or other government authority in the Territory relating to the promotion of any product in the Territory, nor has it or any of its Affiliates received notice that any Regulatory Authority or other government authority in the Territory intends to conduct any such investigation, and (iii) neither it nor any of its Affiliates (x) is a party or the subject of any action, suit or other proceeding (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is pending as of the Effective Date or was pending or filed at any time during the [***] period prior to the Effective Date, that alleges that it or any of its Affiliates have violated any Applicable Laws in the Territory in connection with the promotion of any product in the Territory, nor (y) has it or any of its Affiliates received any threats in writing of any such Proceeding as of the Effective Date or at any time during the [***] period prior to the Effective Date; </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither it nor any of its Affiliates has [***], nor will it or any of its Affiliates, pay, offer or promise to pay, or authorize the payment directly or indirectly of any moneys or anything of value to (i) any government official or employee, or any political party or candidate for political office for the purpose of influencing any act or decision of such official or of the government to obtain or retain business or direct business to any person, in each case with respect to the Product; or (ii) any HCP, HCO or Payor if any one purpose is to encourage, influence or reward the prescribing or purchasing of any Product or recommending the prescribing or purchasing of any Product, except in either case, as permitted by Applicable Laws (such as payments under applicable safe-harbor provisions). </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is, and shall remain, and it shall cause its Affiliates to remain, in material compliance with all Applicable Laws and Codes; </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is no action, suit, proceeding or investigation pending or, to its knowledge, threatened before any court or administrative agency against ALK or its Affiliates which could, directly or indirectly, reasonably be expected to materially affect its ability to perform its obligations hereunder; </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it has implemented, and shall maintain, a compliance program designed to comport with all Applicable Laws and the Codes; and </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it has and will maintain appropriate technical, organizational, and physical security technologies, processes, procedures and controls aligned with the standard in the industry in which ALK operates that are designed to protect its information technology systems, operational technology systems, networks, internet-enabled applications and/or devices and the data contained within such systems, including Confidential Information, from any unauthorized loss, destruction, alteration, disclosure thereof, access thereto, or loss of control thereof and has in place appropriate plans and procedures to allow it to respond efficiently and effectively to any data loss or unauthorized destruction, alteration, disclosure, or access thereto. If ALK becomes aware of any such incident which it reasonably determines has materially affected or is reasonable likely to materially affect the Confidential Information of ARS, it shall notify ARS within [***].</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties of ARS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, ARS represents and warrants to ALK that, as of the Effective Date:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither it nor any of its Affiliates is being investigated by any Regulatory Authority or other government authority in the Territory specifically or primarily relating to the Promotion of the Product in the Territory, nor has it or any of its Affiliates received written notice that any Regulatory Authority or other government authority in the Territory intends to conduct any such investigation; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS has all rights necessary to grant the rights set forth in this Agreement to ALK.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defense and Indemnification of ARS by ALK</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall indemnify, defend and hold harmless ARS, its Affiliates, their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Indemnitees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against all liabilities, damages, losses and expenses (including reasonable attorneys&#x2019; fees and expenses of litigation or investigation) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the extent incurred by or imposed upon the ARS Indemnitees, or any of them, related to claims, suits, actions, demands, investigations, proceedings or judgments brought or obtained by Third Parties (including any Regulatory Authority or governmental authority) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), arising out of: (a) a breach of any covenant, representation or warranty of ALK under this Agreement; (b) a negligent, reckless, willful or intentionally wrongful act, error or omission on the part of ALK (or any of its Affiliates), or any officer, director, employee, agent or representative of ALK (or any of its Affiliates), including any Sales Representative, in the performance of this Agreement, including in the performance of Promotion activities hereunder; or (c) the Commercialization, Promotion or Detailing or any other activities with respect to the Product in the Territory by ALK (or any of its Affiliates), or any officer, director, employee, agent or representative of ALK (or any of its Affiliates), including any Sales Representative, in violation of any Applicable Laws, Codes or this Agreement or otherwise not in compliance with the Labeling and Materials; except with respect to any Claims or Losses under the foregoing clauses (a), (b) or (c) to the extent resulting from a Claim for which ARS is required to indemnify ALK under Section 10.5.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defense and Indemnification of ALK by ARS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ARS shall indemnify, defend and hold harmless ALK, its Affiliates, their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK Indemnitees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against all Losses to the extent incurred by or imposed upon the ALK Indemnitees, or any of them, related to Claims arising out of: (a) a breach of any covenant, representation or warranty of ARS under this Agreement; (b) a negligent, reckless, willful or intentionally wrongful act, error or omission on the part of ARS (or any of its Affiliates), or any officer, director, employee, agent or representative of ARS (or any of its Affiliates), in the performance of this Agreement; (c) the Commercialization, Promotion, Detailing or medical affairs activities with respect to the Product in the Territory by ARS (or any of its Affiliates), or any officer, director, employee, agent or representative of ARS (or any of its Affiliates), in violation of any Applicable Laws, Codes or this Agreement or otherwise not in compliance with the Labeling; or (d) any product liability claims arising from the Product; except with respect to any Claims or Losses under the foregoing clauses (a) through (d) to the extent resulting from a Claim for which ALK is required to indemnify ARS under Section 10.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.6 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to Defense and Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A Party seeking recovery under this Article 10 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to a Claim shall give prompt written notice to the Party from which indemnification is sought (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall permit the Indemnifying Party to control any litigation relating to such Claim and the disposition of such Claim; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Indemnifying Party shall: (a) act reasonably and in good faith with respect to all matters relating to the settlement or disposition of such Claim as the settlement or disposition relates to such Indemnified Party; and (b) not settle or otherwise resolve such Claim without the prior written consent of such Indemnified Party [***], </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Indemnifying Party may settle any Claim or otherwise consent to an adverse judgment with prior written notice to the Indemnified Party but without the consent of the Indemnified Party where the only liability to the Indemnified Party is the payment of money and the Indemnifying Party makes such payment. The failure to deliver written notice to the Indemnifying Party within a reasonable time after the commencement of any action with respect to a Claim shall only relieve the Indemnifying Party of its indemnification obligations under this Article 10 if and to the extent the Indemnifying Party is actually prejudiced thereby. Each Indemnified Party shall cooperate with the Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present in person or through counsel at all legal proceedings with respect to such Claim. For clarity, if either Party or any of its Affiliates is entitled to indemnification for a Claim pursuant to Section 10.4 or Section 10.5, as the case may be, such Party shall seek recovery for such Claim under this Agreement and not the Existing Collaboration Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.7</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ALK shall, at its own expense, maintain and keep in full force and effect during the Term and for [***] thereafter insurance policies that are reasonable and customary for the industry that are underwritten by a reputable insurance company or self-insurance and providing adequate coverage for its respective obligations and activities hereunder. A certificate of insurance evidencing the coverage described in this Section 10.7 and naming ARS as an additional insured shall be submitted to ARS by ALK within [***] after the Effective Date and shall bear a certification that the coverage specified therein will not be cancelled or materially changed without at least [***] prior written notice to ARS. Such notices of cancellation or material change shall be given in accordance with Section 12.4 hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.8 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warranty Disclaimer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.9 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (A) ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES, WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND WHETHER OR NOT SUCH DAMAGES MAY HAVE BEEN REASONABLY FORESEEABLE, OR (B) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY. NOTWITHSTANDING THE FOREGOING, THE LIMITATIONS SET FORTH IN THIS PARAGRAPH SHALL NOT APPLY TO: (I) ANY DEFENSE OR INDEMNITY OBLIGATION OWED BY ONE PARTY TO ANOTHER PARTY FOR THIRD PARTY CLAIMS PURSUANT TO SECTION 10.4 OR 10.5, (II) DAMAGES AVAILABLE FOR BREACH OF ARTICLE 8, OR (III) LOSS ARISING DUE TO FRAUD OR WILLFULL MISCONDUCT.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE XI<br><br>TERM AND TERMINATION</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall commence as of the Effective Date and shall expire on the last day of Collaboration Year 4, unless extended by mutual written agreement of the Parties or unless earlier terminated pursuant to the terms of this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For clarity, the Parties may negotiate to extend the Term during any day of the collaboration provided that neither Party shall be obligated to enter into any such extension.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties shall have the right to terminate this Agreement under the following conditions:</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either Party shall have the right to terminate this Agreement at any time upon written notice to the other Party if the other Party materially breaches this Agreement and such other Party fails to cure such breach within [***] after written notice is given to such other Party specifying the breach. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS may terminate this Agreement, effective immediately upon written notice to ALK, in the event of any material breach by ALK of Section 5.2(a).</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From and after the date that is twelve (12) months after the Promotion Commencement Date, ARS may terminate this Agreement immediately, upon written notice to ALK, upon [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS may terminate this Agreement, effective upon [***] prior written notice to ALK, in the event that [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) ARS may terminate this Agreement, effective upon [***] prior written notice to ALK, in the event that either ALK or ARS has been subject to a Change of Control and (ii) ALK may terminate this Agreement, effective upon [***] prior written notice to ARS, in the event that ALK or ARS has been subject to a Change of Control.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS may terminate this Agreement, effective upon [***] prior written notice to ALK, if ALK or any of its Affiliates, directly or indirectly through a Third Party (including via a license to a Third Party): (i) markets, promotes, sells, or otherwise commercializes in the Territory any pharmaceutical product that [***] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distracting Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) manufactures in the Territory any Distracting Product, or (iii) obtains rights from a Third Party to conduct any of the activities described in the foregoing clauses (i) and (ii) with respect to any Distracting Product for which [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS may terminate this Agreement upon written notice to ALK in the event of the bankruptcy or insolvency, or the filing of an action to commence insolvency proceedings against ALK, or the making or seeking to make or arrange an assignment for the benefit of creditors of ALK, or the initiation of proceedings in voluntary or involuntary bankruptcy, or the appointment of a receiver or trustee of ALK&#x2019;s property that is not discharged within [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From and after the date that is [***], ARS may terminate this Agreement, effective upon [***] prior written notice to ALK, in the event that [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From and after the date that is twelve (12) months after the Effective Date, ARS may terminate this Agreement, effective upon [***] prior written notice to ALK, for any reason or no reason. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From and after the date that is twelve (12) months after the Effective Date, ALK may terminate this Agreement, effective upon [***] prior written notice to ARS, for any reason or no reason. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either Party may terminate this agreement pursuant to Section 12.10.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Termination of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the expiration or early termination of this Agreement for any reason, the following provisions shall apply.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK shall conduct an orderly wind down of ALK&#x2019;s Promotion activities as agreed by ARS, and ALK shall provide to ARS such Product-related information as is maintained by ALK and is reasonably required to transition ALK&#x2019;s Promotion responsibilities to ARS. For clarity, commencing reasonably in advance of expiration of the Term or, if applicable, upon notice of early termination of this Agreement pursuant to Section 11.2, ARS shall have the right to engage one or more Third Parties to facilitate the smooth transition of ALK&#x2019;s obligations hereunder to ARS or its designee. </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise agreed by ARS with respect to any wind-down activities, all rights of ALK to perform Promotion activities hereunder shall terminate immediately and be of no further force and effect, and ALK shall promptly cease all Promotion (including Detailing) activities, shall promptly discontinue the use of any Trademarks and Copyrights in the Territory and shall promptly return to ARS, or dispose of in accordance with instructions from ARS, all Materials and Training Materials in its possession or the possession of its Affiliates or any Sales Representative. ALK will provide ARS with a certified statement that all remaining Materials and Training Materials have been returned or otherwise properly disposed of, and that neither ALK nor any Sales Representative are in possession or control of any such Materials or Training Materials, and will not be using any such Materials or Training Materials as of the effective date of termination (unless otherwise agreed by ARS with respect to any wind-down activities).</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party shall, at the other Party&#x2019;s request, promptly return to such Party or, at such Party&#x2019;s option, destroy all Confidential Information of the providing Party and provide that Party with a certified statement that all Confidential Information of the providing Party has been returned or destroyed; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the receiving Party may retain one (1) copy of the Confidential Information of the providing Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The OC shall cease operation and be disbanded.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.4 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Surviving Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following provisions will remain in full force and effect after the expiration or termination of this Agreement: Sections 3.5, 3.9, 5.2(d)(i), 5.4, 5.7, 6.1 (with respect to any payments that remain due thereunder), 6.2 (with respect to any payments that remain due thereunder), 6.4, 6.5, 11.4 and 11.5, and Articles 1 (to the extent necessary to give force to, or otherwise understand, surviving provisions including Section 11.5), 7, 8, 9, 10, and 12.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Rights; Payments on Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination or expiration of this Agreement for any reason will be without prejudice to any rights which will have accrued to the benefit of either Party or any liability incurred by either Party prior to the effective date of termination or expiration, and will not preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement or prejudice either Party&#x2019;s right to obtain performance of any obligation. Except upon termination of this Agreement by ARS pursuant to [***], within [***] following termination of this Agreement, ARS shall pay to ALK all unpaid Base Fees and Performance Bonus payments that have accrued prior to the effective date of termination; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that any such Base Fee or Performance Bonus shall be pro-rated for any partial Quarters within the Term. For clarity, upon termination of this Agreement during Collaboration Year 2, all accrued payments relating to Collaboration Year 1 pursuant to Section 6.1(b) that remain unpaid as of such termination shall accelerate and be payable to ALK within [***] after the effective date of termination pursuant to the immediately preceding sentence. Further, upon termination of this Agreement by ARS pursuant to Section 11.2(i), so long as [***], ALK shall be entitled to receive, for the duration of the Extension Period (as defined below), the Accrual Performance Payment (as defined below) for any Quarter during the Extension Period in which [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Section 11.5, (i) [***], (ii) &#x201c;Accrual Performance Payment&#x201d; means, [***] and (iii) &#x201c;Extension Period&#x201d; means [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of this Agreement by ARS pursuant to Section 11.2(e) in the event of a Change of Control of ARS, ARS shall pay to ALK a one-time payment in the amount of: (i) if notice of such termination occurs [***], (ii) if notice of such termination occurs [***], [***], (iii) if notice of such termination occurs [***], [***], (iv) if notice of such termination occurs [***], (v) if notice of such termination occurs [***], [***], and (vi) if notice of such termination occurs [***], [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Quarter for which an Accrual Performance Payment is due pursuant to this Section 11.5, on a Quarterly basis during the Extension Period, ARS shall, within [***] after the end of each Quarter, provide ALK with a report showing [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Quarter for which an Accrual Performance Payment is due pursuant to this Section 11.5, on a Quarterly basis during the Extension Period, [***] then, after receipt of each report provided by ARS under Section 11.5(d) above, ALK shall promptly issue to ARS an invoice for the amount of the Accrual Performance Payment set forth in such report. Within [***] after receipt of the invoice from ALK with respect to the Accrual Performance Payment for a given Quarter, to the extent that ARS does not dispute in good faith the amount set forth on such invoice, ARS shall pay to ALK the Accrual Performance Payment for such Quarter to an account designated by ALK pursuant to Section 6.4. </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE XII</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the application of principles of conflicts of law.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.2 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Objective</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties recognize that disputes as to matters arising under or in connection with or relating to this Agreement or either Party&#x2019;s rights and obligations hereunder may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 12.2 to resolve any such dispute if and when it arises.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resolution by Executives</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If an unresolved dispute as to matters arising under or in connection with or relating to this Agreement or either Party&#x2019;s rights and obligations hereunder arises, either Party may refer such dispute to the Executives, who shall meet in person or by telephone within [***] after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such officers within such [***] period, or such other time period as the Parties may agree to in writing, such dispute shall be resolved in accordance with Section 12.2(c).</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Parties do not resolve a dispute as provided in Section 12.2(b), and a Party wishes to pursue the matter, each such dispute that is not an &#x201c;Excluded Claim&#x201d; (as defined below) shall be resolved by binding arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as then in effect (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which ICC Rules are deemed to be incorporated by reference into this clause, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The decision rendered in any such arbitration will be final and not appealable. If either Party intends to commence binding arbitration of such dispute, such Party will provide written notice to the other Party informing the other Party of such intention and the issues to be resolved. Within [***] after the receipt of such notice, the other Party may, by written notice to the Party initiating binding arbitration, add additional issues to be resolved.</font></div></div><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) The arbitration shall be conducted by a panel of [***] arbitrators appointed in accordance with the ICC Rules, none of whom shall be a current or former employee or director, or a then-current stockholder, of either Party or their respective Affiliates. The seat, or legal place, of arbitration shall be New York, New York, and all proceedings and communications shall be in English.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) It is the intention of the Parties that discovery, although permitted as described herein, will be limited except in exceptional circumstances. The arbitrators will permit such limited discovery necessary for an understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than [***] after selection of the arbitrators, the Parties and their representatives shall hold a preliminary meeting with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration will be concluded within [***] from such meeting. Failing any such mutual agreement, the arbitrators will design and the Parties shall follow procedures to such effect.</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other non-compensatory damages, except as may be permitted by Section 10.9. The arbitrators shall have the power to order that all or part of the legal or other costs incurred by a Party in connection with the arbitration be paid by the other Party. Each Party shall bear an equal share of the arbitrators&#x2019; and any administrative fees of arbitration.</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</font></p><p style="text-indent:126pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) As used in this Section 12.2(c), the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relationship of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The status of the Parties under this Agreement shall be that of an independent contractor. Neither Party shall have the right to enter into any agreements on behalf of the other Party, nor shall it represent to any person that it has any such right or authority. Nothing in this Agreement shall be construed: (a) to create or imply a general partnership between the Parties; (b) to make either Party or any of their Affiliates or its or their respective personnel the agent of the other for any purpose; (c) to alter, amend, supersede or vitiate any other arrangements between the Parties with respect to any subject matters not covered hereunder; (d) to give either Party the right to bind or act on behalf of the other; (e) to create any duties or obligations between the Parties except as expressly set forth herein; (f) to grant any direct or implied licenses or any other right other than as expressly set forth herein; or (g) that the performance of ALK or any of its Affiliates hereunder is by or on behalf of ARS or any of its Affiliates.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.4</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All notices and communications shall be in writing and delivered personally or by nationally-recognized overnight express courier providing evidence of delivery or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated from time to time:</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="elzik1o">&#160;</p>
    <table style="margin-left:0.5798611111111112in;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:24.78%;box-sizing:content-box;"></td>
      <td style="width:75.22%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If to ARS:</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals Operations, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11682 El Camino Real, Suite 120</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">San Diego, CA 92130</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Email: [***]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cc: [***]</font></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">With a copy (which shall not constitute notice) to:</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10265 Science Center Dr.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">San Diego, CA 92121</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: Charity Williams; Ken Rollins</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Email: crwilliams@cooley.com; krollins@cooley.com</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If to ALK:</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ALK-Abell&oacute;, Inc.</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135 Route 202/206 Suite #16</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bedminster, New Jersey 07921</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: President</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">With a copy (which shall not constitute notice) to:</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;text-indent:108pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="text-indent:-108pt;padding-left:108pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ALK-Abell&oacute; A/S</font></p><p style="text-indent:-108pt;padding-left:108pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">B&oslash;ge All&eacute; 6-8</font></p><p style="text-indent:-108pt;padding-left:108pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2970 H&oslash;rsholm, Denmark</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-108pt;padding-left:108pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: Vice President, Corporate Affairs &amp; Legal</font></p></td>
     </tr>
    </table><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise expressly provided in this Agreement or mutually agreed in writing, any notice, communication or document (excluding payment) required to be given or made shall be deemed given or made and effective upon receipt.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.5 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Section and subsection headings are inserted for convenience of reference only and do not form a part of this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.6 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed simultaneously in counterparts, each of which shall be deemed an original and both of which, together, shall constitute a single agreement. Signatures to this Agreement delivered by electronic transmission will be deemed binding as originals.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.7 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment; Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be amended, modified, superseded or canceled, and any of the terms of this Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party waiving compliance. The delay or failure of either Party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.8</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Third Party (including employees of either Party) shall have or acquire any rights by reason of this Agreement.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.9 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment and Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall not be assignable by either Party to any Third Party without the written consent of the other Party; except each Party may assign this Agreement without the other Party&#x2019;s consent to a Third Party that acquires substantially all of the business or assets of such first Party to which this Agreement relates, whether by merger, acquisition or otherwise, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Third Party to whom this Agreement is assigned assumes this Agreement in writing or by operation of law. In addition, ARS shall have the right to assign this Agreement to an Affiliate upon written notice to ALK; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that ARS shall remain directly liable under this Agreement for the performance of this Agreement by such Affiliate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.10 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party shall be liable for any failure or delay in performing its obligations under this Agreement when such failure or delay is beyond the reasonable control of the Party seeking relief from its obligations, including without limitation any of the following causes (but only if such cause is beyond the reasonable control of the Party seeking relief): any act of God, flood, fire, explosion, pandemic, epidemic, earthquake, breakdown of plant, shortage of critical equipment, loss or unavailability of manufacturing facilities or material, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion, terrorism and acts of public enemies, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any subdivision, authority or representative of any such government, inability to procure or use materials, labor, equipment, transportation or energy sufficient to meet manufacturing needs without allocation, or any other cause whatsoever, whether similar or dissimilar to those above enumerated, beyond the reasonable control of the Party seeking relief (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In the event that either Party is delayed in the performance of any obligations under this Agreement for reason of any Force Majeure Event, the time for the performance of said obligations shall be extended for the period required by reason of such delay, up to a maximum period of [***], after which, if such delay in performance would constitute a material breach of this Agreement in the absence of such Force Majeure Event, the non-affected Party may terminate this Agreement immediately upon written notice to the other Party. The Party affected by the Force Majeure Event shall inform the other Party of the beginning of and, if possible, the anticipated ending date of the above causes and the circumstances thereof in writing within [***] after the occurrence of such Force Majeure Event.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.11 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless a context otherwise requires, wherever used: (a) the singular shall include the plural, the plural the singular; (b) the word &#x201c;or&#x201d; means &#x201c;and/or&#x201d; (regardless of whether the words &#x201c;and/or&#x201d; are used on some places and not in others) unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive; (c) the word &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall require notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other communications contemplated under this Agreement; (d) the word &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be construed to have the same meaning and effect as the word &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;&#x201d; (e) the word &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (and words of similar import) is used without limitation and shall mean &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including without limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;&#x201d; (f) the word &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean a calendar day or calendar year or calendar quarter, respectively, unless otherwise specified, and (g) provisions that require that a Party or the Parties hereunder &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agree</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter or otherwise.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="x__cp_text_1_366"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.12 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Integration; Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, together with the Exhibits attached hereto, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sets forth the entire agreement with respect to the subject matter hereof and supersedes all other agreements and understandings between the Parties with respect to such subject matter. For clarity, the Existing Collaboration Agreement shall continue in full force and effect in accordance with its terms; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that no activity of ALK or any of its Affiliates with respect to the Product pursuant to and in accordance with the terms and conditions of this Agreement shall give rise to the ability of ARS (or for clarity any acquirer of ARS following a Change of Control of ARS) to terminate the Existing Collaboration Agreement pursuant to Section 13.5(b)(i) of the Existing Collaboration Agreement or, for clarity, be deemed a breach of or prohibited by the Existing Collaboration Agreement. If any one or more of the provisions of this Agreement are held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, such provisions will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement, as evidenced by the terms of this Agreement, may be realized.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of page intentionally left blank; signature page follows]</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have caused this Co-Promotion Agreement to be executed by their duly authorized representatives.</font></p><p style="margin-left:202.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS PHARMACEUTICALS OPERATIONS, INC.</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:57.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.035%;box-sizing:content-box;"></td>
      <td style="width:85.965%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Lowenthal</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
     </tr>
    </table><p style="margin-left:202.5pt;font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALK-</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Abell&oacute;, Inc</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:57.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.035%;box-sizing:content-box;"></td>
      <td style="width:85.965%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Hans Lindeberg</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hans Lindeberg</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President</font></p></td>
     </tr>
    </table><p style="margin-left:202.3pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:57.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.035%;box-sizing:content-box;"></td>
      <td style="width:85.965%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Claus Steensen S&oslash;lje</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Claus Steensen S&oslash;lje</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board Director</font></p></td>
     </tr>
    </table><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:28%;box-sizing:content-box;"></td>
      <td style="width:72%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibits</font></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit A</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARS Compliance Policies</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit B</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Epinephrine Products</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit C</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit D</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Page to Co-Promotion Agreement]</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Compliance Policies</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epinephrine Products</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>spry-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.3</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIRD AMENDMENT TO MANUFACTURING AGREEMENT</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Third Amendment to Manufacturing Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), effective as of July 10, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), is made by and between ARS Pharmaceuticals Operations, Inc. formerly known as ARS Pharmaceuticals, Inc., a corporation organized under the laws of the State of California with an office at 11682 El Camino Real, Suite 120 San Diego CA 92130 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPANY</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Renaissance Lakewood, LLC, a limited liability company organized under the laws of the State of Delaware with an office at 1200 Paco Way, Lakewood, New Jersey 08701 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RENAISSANCE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECITALS</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reference is made to that certain Manufacturing Agreement, dated as of September 9, 2020, by and between COMPANY and RENAISSANCE, as amended July 25, 2023 and September 17, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Capitalized terms used but not otherwise defined herein shall have the respective meanings given in the Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPANY and RENAISSANCE desire to enter into this Amendment for purposes of modifying the Agreement as set forth herein.</font></div></div><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment of the Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Agreement is hereby deleted in its entirety and replaced with Schedule B attached hereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly amended herein, the Agreement shall remain in full force and effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This validity, interpretation and effect of this Amendment shall be governed by and construed under the laws of the State of Delaware without reference to principles of conflicts of laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment may be executed in counterparts, including electronic counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same original.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(The remainder of this page is intentionally left blank. The signature page follows.)</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the parties has caused this Amendment to be duly executed on its behalf as of the Third Amendment Effective Date.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS PHARMACEUTICALS OPERATIONS, INC.</font></p>
    <table style="border-spacing:0;table-layout:auto;width:55.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.545%;box-sizing:content-box;"></td>
      <td style="width:85.455%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Lowenthal</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Renaissance Lakewood, LLC</font></p>
    <table style="border-spacing:0;table-layout:auto;width:55.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.545%;box-sizing:content-box;"></td>
      <td style="width:85.455%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Serge Maltais</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Serge Maltais</font></p></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>spry-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Richard Lowenthal, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.    I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 of ARS Pharmaceuticals, Inc. (&#34;the registrant&#34;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.    The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.    The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.76%;box-sizing:content-box;"></td>
      <td style="width:33.02%;box-sizing:content-box;"></td>
      <td style="width:3.12%;box-sizing:content-box;"></td>
      <td style="width:45.1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>spry-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Kathleen Scott, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.    I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 of ARS Pharmaceuticals, Inc. (&#34;the registrant&#34;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.    The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.    The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.76%;box-sizing:content-box;"></td>
      <td style="width:33.02%;box-sizing:content-box;"></td>
      <td style="width:3.12%;box-sizing:content-box;"></td>
      <td style="width:45.1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kathleen D. Scott</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kathleen D. Scott</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>spry-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of ARS Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the quarter ended June 30, 2025, to which this Certification is attached, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.76%;box-sizing:content-box;"></td>
      <td style="width:33.02%;box-sizing:content-box;"></td>
      <td style="width:3.12%;box-sizing:content-box;"></td>
      <td style="width:45.1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 13, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kathleen D. Scott</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kathleen D. Scott</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img77826477_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img77826477_0.jpg
M_]C_X0S117AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(U+CD@*$UA8VEN=&]S:"D ,C R-#HP-SHQ," Q,SHP-#HP,
M  .@ 0 #     ?__  "@ @ $     0  "R*@ P $     0  "R(
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   +EP        !(     0   $@
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M54KF -"LK*OMNR\=]DD!CQNVP 26>TD?G>U;."WV$I*<GJHU<J7U)$=1ZO\
M^@_Y+UH]59!=)A8'2#U.G,SGXCOL[+#6?5LKW,?L%GZ-I(]WT_\ !I*>[26(
MWJ.8QK39<'.[_HX!/[NX$IW=8RFQ]#7CVNU^>_:DIVDECCKKVD"RD.TD[7;7
M0!+MK;=M;O\ MY:>-D4Y5%>12[=7: YIXT*2DJ2222E))))*?__4]522224I
M))))3G]9UHI:?HNN8'2)$#<[_OJY;'^M6&]T/Z46MGVNKNUC\W<W:S_JEU'6
M_P"C5?\ &C_J7KB*,.(T\%/@A"7%Q"]J8<^24.&C5V])C]4Z5D<4Y%1=.D@C
M7^V5H5T8=FK'6MGM[8_ZERP\''@A;^(R $S)&(/I1AR3EO3(858X?:T'MM!_
M[Z4XQ@/HW6C^R?\ R*EDLSG64_9WL% =^L-(.\C\WTWSM_K^U8MF1]:&O:)>
MRN\EVXTAPJ<7WMQ\?937;8ZEU;,?[599_P!OXOK_ * 1AQ=1]64RUJBZYQ =
M3;:?BS^]B%9BUS[GW.^31_U2PW8W4,"UW4W5OMOK>7LJL;6!9;E9+\5U;7[!
M9ZOV3[.RM^_^8].G^;_1K=JH./CMJ<\VV"76V'3?8[W76;?S&V6;G^FWV5I3
M@(_I ]$@WTIKNKQVSI:?$%S /R+G^H?6_I&!EWX?V/)MLI>:[/>P,)_D^[Z/
MN]OL70W+S/ZR"/K!U#_CI^]C'*7E<4<DR)"ZC?XK<DC$ CN[+OKK1:]E(Z?Z
M5#WMW.=:7N'YGJ;-FUSF;_WEV_U9+OV4&N,EEU[?D+;%X^WZ;/ZS?RA>O?55
MV[I.[QR,C_S]:G<WBAC,. 5=WK>WFC%(RN^E.PDDDJK(I))))3__U?54DDDE
M*22224YW7-,6H_\ #,_&0L2O%&FBVNO:8;#X75?]4L7&R;G];RL%SF"FG'IN
MK8 "[](7,<\OEKOI,_F]G_7$Z,B+KJLGC$JOHW\>D"%I4-TT'S[(&/7N,=AS
M_<IUF_+UI/I8_ M@%SHT_0M/M:S_ (5__;?^$0)M=&(":ZL.+7.M-8;H0PD3
M/B4#=C,(W9;B1S-D3\=45_3\1M3W.9ZK]I]]GO/'\O=M_LH?3O3V-;M:/:.P
M'9*RFD?Z!\ 9;G:R/>"I!L5AH?OC\X\GYK.ZX6N9=[1P8T"V']-Q':M9Z3OW
MJO8?^A[7?VTK)4T+VD"3QXA>:?6<1]8<[^NT_P#@=2]/OHOQR/4/J4DP+8@B
M= VUOT?^N,_Z"\Z^NF#9B]<?>=:LUC;:CX%@;1=4?ZCFM?\ U+59Y$@92.\3
M7VQ8\WR_5PV?39_6;^4+USZHZ]#8?&[)_P#/]R\C9_.,_K-_*%ZY]3M?J_2?
M&W)_]N+T_G]\?^%_W*W!^E]':2225)F4DDDDI__6]522224I))))3F?6#^@
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M_^T5+E!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @
M #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M     0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300        "   X0DE-! (       (  #A"24T$,
M     0$ .$))300M       &  $    ".$))300(       0     0   D
M  )      #A"24T$1       $     (   )    "0      X0DE-!!X
M  0     .$))300:      -I    !@             +(@  "R(    : &X
M90!F &8 >0 @ #( ;0!G "  1 !E '8 :0!C &4 (  R #  ,@ T $H 50!.
M #$ .0    $                          0             +(@  "R(
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  "R(
M    4F=H=&QO;F<   LB    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     !X-5G6%="FHS6TL*,$2,RY@
MBXLDQ/)=MV;N.RZ;U+@
M
M
M       UN>OI>E,NJ"_6Y/">%HE,J I'D%,I)B2,+)4[IV>RM.R(
M
M
M                                     !"SU<3+IB3%949TR177REP%
MX):E \%(LRQ,>8HP"1,@2ZO3MA9[J4[#@
M
M
M                 Z0KZJ)98NP25$D,X7Y<E^5EKI;+1+)+<L"Q,.8=<2D>
M(R1 @!JI-26>V)/=470
M
M
M *9ZE9ETJ-RKL$EJRLSIG4R*Y=,FN0.)1+5,:M@8Q,21\PQ@5CK&,D36&$ 3
M5!H4[)6?3(DT
M
M                                                     !0/2VO7
M*9;H-B+.$E1*"3$C7-DE3*&9."VYC#!F/3 K@$BY'"/+%DCA%B($$-;FITZZ
M&Q+/JZ398
M
M                                                 !Z>UZ>S+>!L
MI9VDQ)>2M9<DK68))2_N-P#B6JXR7!K$R*)#B(K%DC)&2)$0(.0<UBFEK.LT
MN[K/KX3.@
M
M                                                'KZ7U&R]A#:Z
MSTG!,5FA-2;$T20W'D@  '!<',H,L%(.1%(F1,B)$B(D&-<&IS0B=5[/:$?4
MD@
M
M                                         UF?./,MR+N,V.3LF:S5
M)L3M=C)F[AY    /!'IGKP@!!R'$/(>14B!"C7B:R--+UV3I[9]?J>SX
M
M
M                                   ]$*]>IEO4VB3XG9,UF9.TV&L[
MN%5     +690)EK\UVD,6')#B*$/(000UP:H301U6,'9]^J9@
M
M
M                           Z\GSA3+LL;@78Y.R:DS6;$^-C$INF
M ."P:9ZY37I"5AA$4BA#R%$#37JZL329UN.DUGU(I] (
M
M
M                     !Z#%ZV2[\7:I/R;DR68DX)Z;(3/W      <5A$S
MUPFNB#D/(L1%8:D,2"K TU<:>.OYU,LB9^C(EX
M
M
M               0$^5F9=BC="[,)V3))DLO)F3Y=BI(K@     ."P:9ZX->
M$'2(D2(D1 A:0I8*:P341HTZRV="S[?T]PH
M
M
M           !ZFCU,3+L<NW389."8DN66$T)Z;")1=,     4E@4RUT:^(,1
M,B!#TB1#%B! 36R:J-('7*SI5+[$+/NX0
M
M
M         #YCYE#S>Z[3)\30EY+"6DR6=$^)A<.2     6LRUVNOS7A#2($/
M(B1(AZ0X@RZW35QI4Z^G4@Z?7']1HG0
M
M
M      !K,^2^9=G#<QLA9\2TERRQ)63%9PDY)PEQ<0    +&9:Y77IKPAQ$B
M&$4(B1%(<L,37!K TX:%LZN'K\/N+3WQ@
M
M
M        'K+7T92]DS<*[ )T2Y9:DH62I,B9DY)\7]P     Q,RURL -?$+(
MD0\BJ1!8D0U(::\-9&GS1IUG.C=GND3[D0
M
M
M         #YZEZ<S+?R;678*35E*TE:R9),3$F!.2?F6N     &#F>N37I B
M$$56(I$4B:Q(AA$$U\NM$U&:2LZX2],[+0_433R
M
M
M              >#Y'%DTN\EV:3\ER2Q942,DQ+R6$W)T2:X>0    1R9ZZ-
M>D!(01$BI$2*D1N,.EB9KXUJ:G-,'7>SJ&>O-/U5#M
M
M
M                  :[/C[F7: W,NS"<$N)02DD:R8ER2Q9LDW);<>2
M>%B<RUX:](,0@AY%DB1$UB*0]8:D%77*:J-.&@#J?9Z]C[VD]_0
M
M
M                         !T'7YP)>T!MI=FDW):2HDBR!)(LN)4DV)N3
M!*MQ    XK$9EKPUZ0(A9#B+$3(J1$AR0\@RZ[35AIPT,=6;.@I].R?9V
M
M
M                                >D\]2LR[&KM=-BK-"5DL)(2 DQ*2
M4$W)J31+NX@   45A,RU^:\(.0PAR1=E$R()%2'K$$@J:_-6&H#19UE.BUGL
M53]'4
M
M                                        ^;)>I,N_%VTD]68K+$E)
M(R0DC)22HF9-2;&2N    %M,H,NOB!$$(80U(NL32*+$B)$0(*D!-7&HS1YU
MGLZ6D:/UBT\@
M
M                                              ^2=<-+O(VHL\)<
M2Y),LC,^2%98DG)DLS29KG[I@   6,R@:P0@!!2&$+2,+$UB:10B20XA=FOY
M=8FI32-G7 Z='1@_7D39P
M
M                                                      !;'Q6+
MOB7>!LXG#*6I,21&?) 2 DI*B8K-$F:R>X>4   &,F4"6!$#(.0LAA&$B:Q4
MB:1%8@D,->FLC5)I8Z['4*SH.?IVI[0
M
M
M     #3!\=<R[2&ZEV4DV67$M)$2 SQ("2+*TEA-"9$L2K<0  !A)G!B $$(
M00U(6L8(HL42+)$5AQ"U@2:T35!IHZ]'4ZSH0?>ZGT<
M
M
M                 '14^8&9=FS=!L4F3*6I,"0$@,\9TDRRHE9-"8),$KW$
M   1^9P4@9!"%$+(6D76+D3(HD36'D0N.OY=:FJC31U^LZL'0\^NM/L1
M
M
M                              /4NOH3E[(FY2?$T)8LK)$2$SAGR4$H
M64DT26DR2[N(  'A8U,H*00@Q"2&$,(R11(HL6(@D36'7& 2ZY-5FG30!U;L
MZ,GT")]\(
M
M                                          !Z&U]4,O8@VZNPB9$K
M).2 D)G3/DG)22@F9+5F*9&X   <%BTRA) R#D+(20TC1$B,D1(F1 AQ TUV
M:P-.6:'.KTO2&SV-I^ED
M
M                                                      ?-:O1Z
M7L ;978),24DI,^2 SQGR0DM).2XF!,#+W   "FL3F4)(&08AQ#"&D5(JD76
M*$52%$26"IKHU>:C-"V=:#I8;#/U<$
M
M
M    ^4A=)2[X-L$]68V2>64D@,\9TSJR1)22HE9,B8&:N   %&91%8200A!"
MR&D,(N1@B9%2*D+N,2F4'379J\U)9HJ7K=9TN-/'Z^R7P
M
M
M                  /CG7E+O$VJL[)@2<DY(#/F>,Z2%962DEB2]9>F=N/E
M  !;S*&K#2!$+(80@B!&",)$R*D0(>1-80:Y36QJ4T99UN.GIU+3]<@WN
M
M
M                              4SXD)EN@W:NTDG2RLE9)C/&>) 9PD)
M*"4DK)F2Y<_</*  "RF<-(800AA"B&D-2-+%2+$6(@1%(C9"9=>&LK-4RZ..
MNEG4(ZA'ZBZ>R
M
M                                               AY\1TR[/FZC9Q
M.%EI*4DZYXSQG3/F>64I*R6++DEZY^X<T  &/FI#DA1"%A:0PAA#$C:Q18LD
M92(D3(:0NXZ^F6K359I.SKP=13IJGZ/1[O
M
M
M       #KV?'3,NT1N<V6LY)22A)0N<,Z9TSJR%),LJ26+,$E1)KC40  8Z9
MPLAQ!B%D-(80XC"158JD76)$3(<D+($:P-6&DSKW9U0.EY]Z*?2N
M
M
M                         =&#Y6IEV<7<*;+6<+*DE!)S.F<,V9XSY*%E
MB2E9<2A)0E>X@ #%S.'D'(40TA1"R(D:(H15(LL4(BD/(<L N.LI=6FE[.OD
MO56SIF?90GUW
M
M                                             'J\7YQ9>RIMU=F$
MU)02<E!FS.F;,\2 DRRDE9,23I*"XN   Q$SA9"R&$*(<0XAQ%R,$4(N14AY
M$$AUD#EUF:N-+F@CJG9TT/J-3[?@
M
M
M#TQGHKF79$VVNQB;))R3+*#.&;,X9TD)(R7$G)BDK63%Q<  .*X291$@Y#B%
MD-(<D/6+D8(JD6(J1$B)#"#FM#5UFF#09U8.FI[_ !/T @
M
M
M                  #T)+ZBI>Q)MTV&LR24K)B0&?,X9\S9(B0$M)22Y94D
MH+NX  <5P$RB!#2&$+(@0PB!%B-)%5BQ$R)I#R$V0B77!JTTU9H0ZP'3T]K:
M?I'@
M
M                                    'S?KZ[9=_KM@V&3$E)*"1F<,
MV9TSIGB1DI66I*B5DL+JX  <5C<RBJPI(<0PAQ"R)+&&,6(N198JD16()!R&
M&N+-72Z?-"6=8Y>G]G<\_4.0
M
M                                                        #Y<5
MZBR[[-K&PB9)*&4D)&9PS9GC,DB)(2TDY*B5$I+^X  4IE@EB)""&D-(>0Q8
MDD6(RL48QI8F1!(B0PA)KHU@:>LT0=9CJ$;$/UB4\@
M
M
M              ^2Q=+R[U-K$^)<LI)(2,SAG#-F?) 2)98DH)22DE*Y&Z8
M%&91Q8J0DB!#2'$.(@1<C*14BZQ4BI$TA:P9-<&L#4EFB3K,=1"%'Z\Z9$
M
M
M                              'QSKA9=YFUB;K,24DG,\9PS9G#.DA6
M1)*TDRRQ9.DH,G<?* "C,HVL1(81 AI$4A:Q(C1%R*I%UBJ1-8P0JXP<US+J
M\U":.LZVG48T:?KM)LP
M
M                                                   'Q4K+9=WF
MTEG=QE\LE64&?,X9@D!G#/$C)8DF92PDQ*DR5Q\H +>91I8H0HB1#2&$0(B1
MM(LL4(V15(H1=8802XZYEUD:D-&V=<#J4=>S]6U.WP
M
M
M             !2/AM7>LRW:FT5G2RU)220SYF3.&=,X9TDI+%DQ+"2)*#+7
M'R@ MYG&2*$,(<0\AJ0\BBQI(H1=8PD86))&"%$%LUY+K,U&:1LZWG4\ZZ'Z
M?B>RL
M
M                                     CY\-LR[-F[#9*S@F!)R3&<,
MR9\S)G3/$C65))B7$E)*N9N'E !:3.-$4(:0XAY#B'D4(RL68QDBQ%5B9&;C
M#)8*NNTUL:C-)6=<SJH=:#])%/<H
M
M
M:E/BCF7:<W4;&)LLR)69\SIF3.&;,\9XDA*"3DJ).24RZ5+B +69198J0U8@
MD,(>1%8FD:(N18BQ&$BA&2$D*LU\NLXU*:2.NQU1.LUGZ$J>_P
M
M
M                       .LI\=4R[5FXEV.DU69DG) 9PS1G#-F<,ZLE24
MDE65I)B2F92I<0!8S.+$96&I#B(D/2'K$UC214BY%TBQ&EBQ#"#IKI=;IJ8T
MK9UZ.JAUA/NW3Z8@
M
M                                               #I ?)_,NT1M\V
M.3PE9)%SYGC,&>,R9TSZR%)02LDQ*"2F9N-1 !CYG%B+D/(@1 B!#R)I&UBI
M&"*I&%C9%$AED&EUZ:U-7&D+.OQU6.L"?:0?60
M
M
M          >N4^8N9=ES;ILI9O<93,I.9TSAFS-F<,V9XD!*B4$I)22(S25;
MB ,7,XR198>D0(D0XAQ%DC1%5C:198J1Q(FL-6#&OF.MS5AI6SK\=6#K"?7&
M?9&@
M
M                                   'JG7YTY>RAMDV23=902<SQFTS
M2YHSAGS/&>)02990DI)"9TKW #PN,F49(N0XB)#B)+#F,66,D5(P1<C1&4B:
MPQ(2NO+CKF75IIBSKX=7CJZ?4"?;^@
M
M
M 'IQ7T*R]D+-M2[$6:I*5D9GC.F9,R9TSQFR1$H63DG24+(DSI7N '%<9,HJ
M1E(8L5(@1 B)$DC:Q@BY%$C)'%BB0T@YKTUR:M-,G7^SK&=6D^B%?O70
M
M
M                           #T:'I:F79 VL;#)F2=9(9XSAFC-&;,Z9T
MD1)R4K)"3))S-%S< .*X>91TB9$B)$-(FD/(JL9(J1I(L1@CRQ(AZ0DURNO4
MU6:>-!6=7CJT>[]/T-
M
M                                                  #T"+ZFI>Q"
M[3382S E1(C.F=,R9LS1GC.D@)0LG)&DJ,^9XN[@!3F6(6.$4(D1$A:Q9C$%
MBI&B+$92,+%TC9%%A]QA,RU[<=<2ZQLTR:'.LIU3/;$?I%H
M
M
M                  !\YQZVYEV -I&P5F1+20F=,Z98S1F3.F=)$28E"R-)
M2N?3.EY<?*"A,\*1U8FD8(<0Q8ND3(D1PBI&R+)%B.$76%W&&3* 7'7,NJS3
MMF@Y>MEG5>7V&6?IK(
M
M                                                 !\SJ]$9=^KM
M--@,INDI)*9HSB91<T9@SAG20DJ)(LC)4DA,R7]Q\H+>9X0CY$R*$-6(I$EB
MY%$CB118RD66-)'2)$1(59 #6\NM#3%FACK4G5E>UA^I>@
M
M
M                 'RVKU*EWR;3-A+,R3DC,\9TR1E3-F=,^9\E*R5)&2I<
M^F:,A< *$SP:QM(L14A9$2)+&2)I'2*D9(P1I(RL32(+#C7MQUS,M9IITT,=
M;K.JQN _5S3R
M
M                                           #Y05T!+O0VJL]28K*
M$D:YPSQDC-&8,V9TD1*%DJ2,DYGS-&1N/)/"VTRP9'EBB10AY$2))&&412-D
M8(T1DBY'4B:P](:L -<7'6<NGK-$2]:#J]9D3];)+H
M
M
M             'R,+J^7>1M99TDQ64DB,X9TRQE3,F=,T9]94DE)(2<SAFC)
M%2X<5MIEA".$6(@1$B*1)8ND691E(R1@C)&R,I%UB%QA,R@*:^-8&G#1%G6\
MZOD6/URTD(
M
M                                         /CG7"R[R-J+.$F2R@D)
MG3.&5,L9HS1G3/K)B4)(24&<,ZN18U+CP6WF6"(XL:2&$2(DD291=(L1=(XL
M9(R1E(\1%8D0M(":Z76=QT^:+.MIUC-=GZUR;/
M
M
M         !\7BY>7=YM-9TDP62I(USAG#++G$RAF#/$@)(2=9$DF,\9LRR<K
MC36VF6"(X1DB2Q!(D1 BY&"+D:(VD:6+$?2*$/6&W& IKJ9ZS34-FBCKD=8C
M5Y^K4G9@
M
M                                       'Q-+L"7=2[32<V3"64+G3
M/F<,N9HRAFES:2!90DE60I*3/F47*)5N/"6S7"$=(T0Q8HD2(B10CI%R-$;(
MP1M(T1,B1#""+KQ-9FHC1EG6\ZRFHS]3).Z@
M
M
M      !P/ATF6\#<AM8G1+%DQ(C-F=,J9TRQEC-DA63$E3/K)TD)FC)+48\%
ML3#D;(JL2(HD.(J10CA%2/$9(RD:(ZL62'$+L@LRUX:R349HNSKO+UB-/V?I
M[)[#P
M
M                                   "P/AFF78PW0;3)P2M929XS9G#
M+F>,N94S1GB4+)DD2R4SZ9@RAY!9F&(P18BA%R$$76+$:2*I@%C!'",)'%BB
M1$A=D$F6O36R:@LTD=<3K*:?/TICVLH
M
M
M !&SX=%[,S+=";,6=DL24F:7.F<,H9LS)F3/KFDDRR=,^259"F5,HM=C16S,
M.1E8TQB*P\AY%EC"1M(HL>(ZD8(T1I8RD/(:08UPNM4U)9I,Z\'6$TL?HW)[
MD@
M
M                                #6A\2Z]H9=T&S2=$I63&>,\9DRQF
MC,F7,V2$DZR))&24SAE5RZ53B6"X1(V1DB)#B*$3(P1@C9'".$9(P1TC*1 A
MED$-?2ZS-4&CK.O)UE-('Z&J>\H
M
M                                                          TB
M?&!,NT)N4V2L[25$E61&9,T9<SAF#+F;61))"0DC)$9]<N9)+A>*8XQ!&2)K
M&4AJ1(BJQ@BZQQC'UC*1LBRQXBR1$A9"#7RZT34YHXZ^V=9C1A]^!]!B
M
M
M                           =;#X[9EV?-RFQUFBRU),2(S!FC*F>7,IE
M3-$@)02(D!(B0&8,@72\4QAB2,$6(F1(B1$R+D86/I&B.$:2,+@B(I%B&+ T
M@!K,U*:4.O9UELT8GW:GTB@
M
M                                                     '4 ^1Z9
M=H#<QL(FZRLDA(#-&;,L9LS)EC-F>)*20D*R!)$94RI7.!C3$D8(P0XBI$R*
M$66,)'B-& (R1DP!$$BBPQ(,NODUN:J-)'7ZSK(:*/N"3Z<@
M
M
M                  #I"?*-,NSAN1=@DV)22<D)F#-&8,T9DS1ES/+)4DJR
M!)"2 R9DUN$&),81HBY#TBBQ$BJQ4C*1XP!'2,I&#!+$DB!"[(/,M?IK6S5<
MNE[.OLO66S09]H*?5H
M
M                                                 >OL^729=FUV
MZFQ5F9*TDJY\S1F3,F9,P9HS!GB0$H)"2$D1DERB79;F/,*1LBZQ$B+&*+$D
MC3*-)'4CBQ\C*1Q8^D3(F0L@Q +CK69:I-*V:".LQH8^PD^N1
M
M
M                    /6N?,_,NS1ME=AI-5E9)#/&<,T94S*YA,Z9<SI(B
M3+(DD)(S(&2+@H&/,,1XBY%"'$/(N1M(VL:2.+@2-$92-+&2+)#R!FOC7!J@
MTM9U\EZTV=?CZW3[%D
M
M                                                 ]69\YLR[(KM
MA-B+."6DA)"9@RIES-&<,P9PS)(23DA)"2 R9E"Y*!CC"D?(HL42(D0(F1PB
MZQ]C'3 K&DC*QXC"1)8<D)LUU+K@U;9I<Z]'6DT ?5"?:6@
M
M
M                 'J6/GVF78LVR;$)J2Q9(2(S!D3+F:,R9HS1F"1K*$SY
MGR0F4,H5BB8\PQ'B)D4(B1(BI&B+D>(\8$C!&3")%%B:0RR#RZ]77::MLTO+
MU\LZVG7T^F<^W]
M
M                                             /3ROH9E[&KM(V2D
MS65DA,^9LRYD3,+FTS9F3-$C)&LE3/&>,L90YG!<>F%(Z1(B2Q(B:1<BQ'%C
M:1TPI&B,I'"-K$$AA"B +KE-5FF3KW9UO.O:?1HOW8(
M
M
M             !Z55](,O8DVP;%68DK)&9XSAES)&:,J9PSIE21$C)*N;20K
MEDR!<'$Q:X1(ZL82'D46))%EC"1M(\N (\1PC*1Q8R1-(BL,371KA=7V:4CK
MY9US.O)] Y][2
M
M                                            >C=?3/+V*7;"3]9@
MDK62&?,R9@RAE3*F>,X98D1(ED:9TD)ES)%1>*8TPI'%BJ1(B:Q)(N14C)@3
M $?(X1E(T1M8LD/L@TNOS7AJRS31UZ.NAU]/>:?H%(
M
M
M            !Z'3U#3+L6;278*3 E*R(SYFC-&6,F9@S1FS,$@)*2(SBR(R
MID4N2B8\PA&"+D2(H0](VL4(T8 P21U8\D86/$=2)$.6#$"36YJ\TU9U[.NI
MUY/<ZGZ'0
M
M                                       !Z!#U33+L0;2-@+,23$D,
MZ9PRYES(F87,IGS-&<)"2(D"YQ,R7Q=%N61B%C*1@AY$R(D82,K&2/F"(\1L
MC:1I8Z1-(>L*2 FMS5QIXZ^6==#KX>VA/T9@
M
M
M      #YYE]9DO8%=I)L!9D2<D!(#-F6,F98S!FUS29DSI(B2F>,\9<O"Z.)
MC3$$:(NL/2)D-6.)%R.& (^1\CZ1M8PD;(F1$A=D EUR:O--&@#KE9H4]GA^
MD.@
M
M                                 'SC+Z\I=^FSC8:S5)(LA,\9HRYD
MS+&:,P98SAGR1$E,^9U<H9)+HHF.,*1PBI$")D.6.,8LL=,"F!6.F!(T1E(X
M10AQ#37QKHU<:<-"6=<SK\>PU/TM0
M
M                                                           #
MYM5Z%2[Y-I$^69$E),9LS2YE,B94RYFS+&:)$N>23&?7-IF#(+43P8XQ!&5B
MK&(K%2'D72-+'"/I@5P!'R.D4,"14AA#DUZ:\-76:<ET'9UR.OYWB/TWD
M
M
M                            ^9M>E,N^#::SPEQ*21&?,P90RIDC/+ET
MRAGS/F?)*9\SJY=,B5"B8]<.D=(H1)(B1-8J1U(X8!<$1Y,$L7(N1XBR0Y8;
M<=?2ZX-8FFS0EG7<Z_';H_4!0
M
M                                                       #YB%Z
M?2[Y-I$])<LF)&9PSAEC)F3,T9@RIG3/D@61)(C,F;+];A+<QIAR.+%R*)#R
M)D4(\1LP)'S &"2-K%3 $52'D,LU^:WEUF:8LT0==CKT=E3]29
M
M
M                     /EP7K!+O,V:L^28,I"DI,T9PRQDS)F;,H9<SQGR
M0&?)&9DS1D3FM),<N'3 $1(J1 BA%".D?(ZF#6.F"(RD86-)%R'K#R!&N4UB
M::-!V=>SKX;X/U.T\@
M
M                                                ^55>OLN]39Q/
M%F)(R2F67-IF#)&6,N9@RYG3/&?) LD3,&9,@5UXIBR/F"(L10B)$B,I'EC1
M@3 F (Z1LCA%R,$-2&$%->FL#3)HHZZG7^S:)^JNE4
M
M
M            'RE+HR7>!M%9T2])*LD,R9HRQDURR9DR:YM,R2,SA(20+FDS
MA=+=I;F.7#)'EBR14B2Q)(P1PCA@3 I'5P)&2-D8(Z0Y(406S74NL#2YHBSK
M\=?"6GZN27@
M
M                                         /DU74TN\EV43E)H29<X
M9TS1F#)KE$S*Y=,L9\S:R%,\9]<VF<+LN%IIBS"&"(L118@D32-K&DCS+ )@
M"/D?(T1<C28!8;<83+!#7)K4TL:)LZ]FA3,'ZO"9(
M
M
M           'R2+K^7=:[,2<K,22$B,V9@RZY1,H9HR9F3.+GDD1G#/+G4S*
MWQ<I1,880CY&")$3(L1@C)@3 +'4P)@2,$>(VD4(B0U8"FNC61I@T=9U\ET%
M96/U=TD
M
M                                      /D86%&[)=FK-R9$B)$9XS)
MEC)F4,R90RYGS/KFTD1GC-+FTOBX6S2Q,(1\CI#2+D2(\1LC)@3 F!(\1DCI
M'4B:Q!(>L"37!K4TO9HXZ_F@"V/U=DE@
M
M
M  /D'F4?-U+LXFY+R3$C,L9PRYD3,&8,F9DSA(#.$A7,IG3,%ZMV6I9IA2-D
M96+I#B*I'%CA'3 F!(\1XC9&"/I&5AZ0L@!KPUJ:CLT/+UULT*8\_5O2<@
M
M
M                            ^/-;29;M39*SLEA)B1&;,R9@OS,F5,L9
MDS"YI)&L@,ZF:7,)DRH4RP,&L:2-D2(L10CJ1M8Z8 P)@"/)'5BQ'2,I$R%$
M 77J:T-0&A[.O1H4QA^JZFR0
M
M                                                      ?'2J7=
M9LQ9P2TDY(C,F8,R9$RAFC(&=,T98D"R=,T9XRQ>+?)8EF80CY&5BB1(C!'B
M.$=(\L=3 F (T1TC1%TAQ$B FO#5YJ$T19U]ET#9C#]4--R
M
M
M                  ^.=>4N]%V*DZ67DC) 9HSAE5R*90RYDC/&6,XN=21&
M?7/IEB[+E>"8XPI'",$1(P1<CY&B/& (^1Y,"L82/+'"+I#"(D#-=&LC3AI(
MZ^6:$,"?J9IO4
M
M                                           'QOS*^-U+LPG),21&
M?,T9HS)?F57*IEC,F57/)(3/F>,ZN5+Y+LM2R,*1PBY&%B21HCA&B/&!, 1\
MCY&#")&%BA$2(&ODUX:V-.FD#K]9H4PY^HNG88
M
M
M        'QHKG9=UFRUG)+R3&?,R9@RY?F8,H95<TF9,P2!<X2),Z98O2H4B
MT,*1HC:Q=(H1DCA'%P"1\P)'B.F (\18BJ1%8<D&-9FN#4AH@Z_6:',$?J()
MV1
M
M                                !\9:R*7=B[,)JLQ22D@,T9DRY?F6
M7+)DES"9A<ZF?,X2 SIEUO$NBW+0P9'2+D<(BL:2/D=(XN!2.F!(X8 CI&2*
M)$2&K!C72:S-2&BCKY9H>7!6?J$)V7
M
M
M!\7JS.7>:[%)J2\DI(#/&9,B9(RZY-,LN33,F=,\L@3/KF4SJW!63P61@ECI
M%TCA$".K&F,>6/D?,"8 CA@",I&",K"R)) EU^FM%T\FB[- FB"/'Z>R=J0
M
M
M                             ?%ZLTF6[399.25DB)"9I,VN2,J9<R!E
MS(F:) 9]<ZF9) 94R"\S@EH84CA%B-D2(RL?2.K'4PA@2/D7(^1TC)&B'D.(
M$:\36AJ T>=?;-$RX,_3FN/;,
M
M                                                       'Q>3*
M=FZUV23DE1)3.F;,X7ZY1,L9$S)D3,F?,ZN?,VF<7.&03PM%+8PJQLC"1LB9
M'2.$9,"N"3 D:(^1\CQ&$C"P](BL 37AKHT^:*.OYHNS R_IMW'MV
M
M
M                       #XNIEL!=UFQB<DL)$9XSQFEO4RYE3(&5,FN:3
M/&=) L@3,KFDO"J4BQ,.L>2-+%4BY&".$?(^8$CA@B/D<, 1<BR10AQ 37AK
M0U+9HTZ^FCY8[9^FLG;T
M
M                                                  'Q>3*=F[%V
M234EI)C/F:,L9,RQD3*KE4S"Y4S)GDDJYM,XN;2Z*I06S,(81(J14C!&5C:8
M$P!@B-F!(V1\P)%R+$6(:FOS7IK@U :,LT++HLC]GZ::=O
M
M
M                 ?&#,IT;G79Q-B5DE,^9HR1DC-&1,J9)<N9<S*9]9&9D
MD*9=;].106S3"K@"*D<2+D66.D=2/F%(X8$CI'R/D8(J19(40,UV:W-4FC3K
MY9H\P9^F8G;P
M
M                                          'Q@+.9ENA-DK.TE*R<
MD)FC(F47,I?KETR1?KFS.IGS/+GS-IG%NTK%NMNF!6/I%"/$3(RL?8QQ8^80
MCQ@R.D=(Z1@BY%"'I 37ZZT34AI$T'9I$CA^F0G;P
M
M
M           'QA3*<FY5V:LZ25)*%SAF#)F97*)D%R"9=<F9DSQFS/$@,V9Q
M+I:Z4%MDCY@"-D6(R1=8\D<, 81, N#(T1PP)&$BZQ0AQ!4U\:P-1FC30YI*
MR.GZ9*=N@
M
M                                       ?&$L^EW(NQB<I*UD9GS+F
M<,JN2,D91,F9(SAFS/+GS.IG3,%Z5"FM@F)7 D42,$7(P8 CQ'3!F ,*1HCI
M@B,D5(D1!("NN$UX:F31BZ#LTD8$_3"3MV
M
M
M    #XPIE/%W,;$)Z2HDAG3.&7,N7IEEOTR)F5SIF3/IG5SQGS+I?*/!9F"(
M\D;6*,8TL<6-I'R/&",(1\CI'#"$7(JD3LATR@B:\-=FIZT7&@+-)&#/TOD[
M=@
M
M                                ^,293I=SIL8G)+V4A3/F<,J9<OC)
MF07-)D%S:9U<ZD@7-F>,P7B<CPMDF$7 $5(RD;(R1XCQ'3 F%,"1@CQA2+D4
M2(+%2!IKI=<W'4,NDS0UFD3&GZ6*=N
M
M
M ?&!,MB+N$V*3HE9)C/F=,J9,R9?F3,F94S"YQ) 2 SQG3+%^5%I):K@DCJQ
MI(R10CA@"/D:7")A# $>(\8$BY$B*D/2"KK\UHFJ#21H8T<8BS]+).W
M
M
M                          /B]F6Q%W,FREF9+"2F?,V9,RBY<O$RRY(R
M:9A<\2 D"9LD!ER]6N44LUQ"1HCZQ,BZ1=8^1], 8$P1@2/F (\1=(PL52$$
M'->KK5-4FDC0EFEY<?9^E(G;<
M
M                                                       'QB3*
M=KNTV$3Q)6LD,X9\RADUR)>F82^7+IEB2+F$SRR(SIF"^2JM LTPA'ECQ%R+
M)&2-F!2/LL$F!,$1TP)'B-D52)K#$@YKPUH:E-+&B33%F+/TI$[:
M
M
M                       ^,293Y=T&S"<$F).9I<\F1,L9$OC*+DTRIEUS
MA(B2&4) 9TNBJE,QZX=(\L<(R10C!@B/I'3!F ,01LP1'B,D52&D1((:]76Z
M:G-)&C33-F*/TH$[9@
M
M                                                ^,Q9_+N9=CDT
M)420SRYE+\RZY(R9>&8,B9U,^9LD2Y\SJ91<@G-::8TQ!AR,$:(HL7(\1],*
ML>2/KA$CAAR.D8(P0](80<UX:Y-2FE31)IFS'2_I0W'M8
M
M
M               #XTYE-5W6;#2;K*B2F=7+IDURAE4OER)DDRJYM,VLD,^2
M,S!EB\*J42T7$I'B,D:(V1I8T1Y(\L?3!&((T8 P)%2-)%%AQ!$UZNN$U.::
MLT*:3+$_2E3M,
M
M                                           #XTYE-UW,;*2:K*B1
MF:,JN93*+DC(ID%R295<X2(SIGB3F8,L7J%IE PB1Q8VD:(T1HCBX!(Z8,CA
MAR/F"(X1<BY$B'$&37IK@U&:6-'V:7,?+^E'<>T8
M
M
M          /C9F4S7;YL\G1)B1&6,\9=<DF17))D%R)F#.D@,V2!),N9,F7I
M7*"62X@P1&4C!%UC:1LP)'UCZ8$P9'3!D>(T19(BL.2#V:\F6N#5":6LT<:6
M,<?I3IV;
M
M                                      !\:\RFB[D-DDX23K(3-DA7
M*ID#*F0,@MZ9U,XN?,\DA61&>+XR)6+<MDP2X1(VL82*$:(T8)8XF%,"8(CI
M'S $;(PD3(6L&37YK@U6:3-%6:=*)^DNG9@
M
M
M     'QRS*5&WUV*3LEI(#/F97+I?KETNER)E#-&=,^9PD1)#-F5+\YE QQB
M#!I&UC)%DC*QI,"8 P:X!,"1XPI'"+D;(FD-6")KY=;IJDTL:,-0%F?I37'L
M0
M
M                               #XXYE+5W&;%)PDH925,TN=3*K>IEC
M(+E"^,V9HSI(B3&?,T9TKE0HF-,28=(RL8(JD86.)'S &!7")@R.&&(X18BZ
M1A88D&->KK9-3FEC1QJ,M3])^X]B
M
M                                                           ?
M'7,I&NZS8*SEC*F4G,RF;+]<J90O#*&43*KGR1F8)&2),\N1,D$\+C##F"(\
M14C)&$CJQXCJ80P"X1, 1XP)'$B2Q8B20)=>IKDU2:6-(&F#P?I-7'L,
M
M
M                          #X\9EG%W2;&)T2A9&9U,T91<N7Y?&5,@98
MSI("0$A,^9Q,NMZ<S@8PQ!@C $12.+&B-)&#"F$, 8(P9'2/$;2,+$4ARQ!-
M=FKS5AJ T0:5.%?I/,>P@
M
M                                                   /CQF6;7=)
MLXFA*23KG4S)?+E#*%^98OC+&?,Z2$D)(#.&4+\\G@L4PY'%CY%R-$92,D8,
M.8$PIA"/$?(Z1DC!%2'7&&2Z^76::G-.&BS3ME*7])BX]@P
M
M
M                 ?'S,LRNYS91-R5$B7.IF3*E^9E;U,JM\98SQGTD2R S
MY(#)ER>3P61BR.&!(DD46-I&UC:8,PRX%,"84P9&B,$9(D0LB*:Z76J:J732
M:+-.G$_2:N.^P
M
M                                           ?'O,LVN[38I-"5K*$
MS:Y@SA>F1+\S!<&=,\9LD1)#-&?,N5SD<4M5PA@R,D6(J1E(XL=(\F)7"F(2
M.F 6,)&B,$6(61(UTFN%U6FE#1AJ$'Z25QWT
M
M
M      #X\IE(S=2[)6<I)R2+GC+&6,D9(R1E#*&8,R9PD!(C.D@,B7I7*!9F
M$,"1LBR198LD;6/I@S!F$,08 P!'# +$TBY#5AC'71K@U2:4-#FJCP?I&W'?
M0
M
M                               /CYF697=ALM9VDG)&N?3,KE$RJWIF
M2^,F9<S9GB0F>) 9HRQ<E<IEB88P!&B,)%5BY%DQ!'3!+A4PQ@C!$;(X1DAY
M%D@JP%-;+JE-,&C33YQ/TD;CO4
M
M                                                        'R!S
M+*KNLV.3<EA(S.KF3,F5+TR1?F6,N9<SY("1$C,N9@N$J+P,>8DP)&"-)%"+
MD9(ZN#,"F+,*L?3"D;(\1<B1#R%&O$UH:L-,KH^XZCEHGZ2EQW<
M
M
M                     #Y")ED%W2;/)P2I9 9\RYF#-%P9DOR^,X9HS9("
M0D@,Z9 ORZ*1C#%$>(X19(NL82++&DP*X),28@P2QY(^1LBY%$B*PM( NM35
M2:6-)&I++.7])FX[G
M
M                                               !\@DRRJ[I-E$W
M6;&=,^94S)EC)&1,H7YEC,F?,^9\D!(2^,@712,:88CQ&TB:Q,BQ'DCRQ],(
MN%,4F",$1PC1&"*)$B$$!76B:M73::2-1EF?I)7'<X
M
M
M            /D&F607=QLPFQ*UDI(#-F9,@9,R)D3*F6,V2 SIGC.D@,@94
MY'$Q)AS D<(F1 C!&4CI@3!&/7$$?3!F!(X1$C!$"$$"-9FK4TJ:3-0G"S](
MU-R@
M
M                                  ^0*99%=YFR">+)R5&<,P9PRQ?F
M0,J9,S1ES-F=)$9\SI?E^<R@43!$>(V10B9&4C*Q4PY@C")C5PB8,P!&B-$6
M(L04@1K,U0FG#1)J N;/TADW$
M
M                                                       #Y!YE
M=+NM=I).R5$I60&9,Z7QE3)&1,J9LRIFB0D@) 9LR)7+LMRW,$8 C9%R)$2(
MR1HP)AC&&(3!& ,$1LC)%R'$,-?FM4U.NG4T2NH$\V?I+)M@
M
M
M                  'R"S*\7=R[-2=$P)&L@) 9DR)E2^,J94S1EC-$D,R9
M\SQE2\.90+4Q!%R,D8(J1 CA&#"F%3#KB3%D;,.1A(V1,BA"2!FKC5II5-+&
MD2X/TE;CM0
M
M                                        'R 3+)+NXV63I9D28S9G
M#-&;,@9 RIE3*F;,T20S9(3.F0+@N4H+9&),"1<B!%B*D3,$1XP!BDQ*X=,"
M8DC1%",D3(,0%-;&JET@FFC3AY/TDKCM$'@\@
M
M
M     'Q^3+(+O4V43M9@2HRYFS-&;+\R9DS,&:,T9LSY)#.F9+XOT\G!;4Q9
M'2,$4(<18C)&B/&'3"KBC#)@R/KA$BY%B*D&(":W-3II@TJ:7.)^DS<=A'H8
MF7J47>2=^+/8D=SDR(     .MJZBE['V;>3D
M
M                                  #5YHM>Q"3P    &&/6),NOB[Q3
MM39NM,&8M8^8@QAB##RV1ARU,>88MEQZ4EX%N>"F72W4M.ST<)L W@;1-@++
MB4F?,P9@RIE3,&1,R98S!G"0F?)"9@OC(,:EQ\+:S+!+A"*D5(D18C!'2-F"
M,28LQ!@TC1@ECR0\B1"R!FKS5::5-)FIC"GO\6U-4&*6S,:89)6=LDR!)"1D
MPLF1L,G).28DQ-:G4^9SJ7&V94WLQ[(6=DTS(     - +U^.PQO=.8
M
M                                   !X.GJ];)>QMG;9,F   #K$OJ,
MF6.7#&WT[37&;&"EQA'#!&!7!&#(RN%*I=EH1XPY3) 2M9 EU+YLKRW=ER59
M:Y=671REO++^6Y,F5C)&0/0-<9,N\TVL3Y9B2$DAGS,&5,J9(R)G3+&7,\2
MSI(#,F5+NZ8XK9S/&D=(L1DBA%"+$>,"8$PR8Q<"88CR8$BQ%2(K"$@1J\U8
M:=329I@L#Z 66)2'K#TCBUC+DE/!:$F+DPQA"5IL%983 EQ.S9$LM,N26SP8
MV6(V81,05B3DI20DE)$26R2DG-<'3*9WY&C)'8UCVKL[&)<
M
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M<@4B(V:O($4R0E0I%4H%]+D"YLE<N5.-D>,0;M8R4E-FT39J;1)*>0
M
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ML[5)M,
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M628HD&-1D'+DM2-$>-A)VQ3OU9VO3F
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MUQ]HZ9L
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MC!.381>2U++F6P(N65DE)R2 Q!J\T@1XOS$D+-<)-CWG7'O.@
M
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M9A;,:9DF!>D?-.&E$Q*WB14B)KE?>G</:>@
M
MB)Z$9G=+8F-,T4B/DC,\52.$#)C+.+)7+<ER5CP>3F:R--69XV63HE)CC49@
M2;2R(R)=',R0(":6LYFRC8!,I:Q!S6=E>6:%^71?%R"*&C[(P3TV9+/"1F+-
M=67$LD+4]"UD@3LRN\#8Q/"6$B)"9HS49=<W9EY<T9TSA(R4$BLD,MYEI>0
M#PN.F<7EA]D7EC5D>,&8LCI&S%D8(N80CA%B+$+(0D 76::9-,&@$T"88]YC
M+M;+VA-T$K.!J@A-F<-@$KEDYQ-;FCK+<GLMY9?RW97.)KDUM9D39DNPK)++
M?D1LTX1\KDDEO+,C+>E(UP:FLO#9!L<D)Y( :?*Q)C+%\7)<R\+,01<EY-3(
M%Z:L.G1>I#UT8GU"7'ND@
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MS
M                         ,8?-Q-2W,(4#(F<,V7YDBL8PM"7DZ)*6AJ
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MG3'DC*IX.$M6R0'?]-A)Z@&7KQ3<QBS3A]9-P[B@
M
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M7.V5I;FRO+7.-E@8<R),28&>+8U :&,$94HE(M2U,:1](V84C1I\]Q5Q]_"
M
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M'#4Q/T^R&X@
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M-G,]-FW2S,4ELM%,:8LUH=4$^["XS,
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MC)K/G;F7JM.]Z\BX2J6Y9F%-4G3T^KJX>R<
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M9DWVO@K%%.:TB\.9?IEEV@:Q(LF1*:VA:)BC D%--G4<][MQ]_R
M
M              >KI?3U,^VYN@V23PE1F#/&1*A6BTJD8DPA@3#F ,,8,Q1A
M2J;+*R:.7$G(\% YGDI%T#F>3F<2]ESEF:E[%V=^KI]()GZ&%]FAF 5);@%
MOSR6Y4,N2HRYB"/6:8(_+O8SJ^4N2J>5J)36DEJ7JR1,T8HTN:8-J&V2_6X.
M1S.253@MJ44N5\%(N$L"H>#P<S@O@I'@II76FE$+:)3.!;%0H%,H+;IP/!;K
MQ2@52V*Q8EJ<#P4#D6Y3/)X+2RVEJEN>#@6]EH69X)#+N ]DMPUL?.@O8M>!
M7.)Q+DX%0H%8NC;1M%.N"Q@OS,F7+\OB]+XO2X*Q0+$QY@#$D<(N1,AB:O--
MG4L]F=Q^L!
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M$F*,28 BY%2+D3(60%-=FCSJ>G<:S[4T
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M+(Q1AC'&",,8(CY&R*$/(ZD4(0:Q-%G51.S!]T=Q
M
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M,>8<QIA3$F ,08,P)%2/)A5BZ0XUR:0.I*=B#[P[B
M
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M4XXW'I'".$077R:'3JZN]$^\FX@
M                                                 ?.G,NJ3+L<;
MG-C$Y)$:]U\.B_/..^BSUMTGJ[D.S>U'H_L;%[I\'9CB6]=VNON5=F>*[SM;
M:_LE?RZV6T\LKAEE(R"W<7!6.)7.2UDK@KEW9SEN#R52J75E0K%1*YSN/)
M                     !X "\3D@\@'@\G@  'D\*0O$\E&9\)>!X+8X%,M
MBL6A;G$MP6A0+=?">"U+$K%D6Q:%N6UEM+2LH2TB@6!X+0XEH6)CK**V\6]E
MO+:649;!*%<2T,.6-8?*6>2(?1AKK<=#5V]?)H;DVW:-Y1MVDN4;9JGD>W:2
MY1MFG>3;?K/??CR?P:G:SI;FGM5\Q=B=L^,?=A5CY"DUV:..L2;8L^]-
M
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MV*?>G<0
M                             /G.F77!EV1-PFQR8'27DFV?,9[\\N];
M^;<;[H=:<Q@VZ[?H;EVP7&&,G^++:NQ_=58:3Y/Q_LYPKD'L@Z9[&].GI+HG
M9&T?5[^O)/H_TN>F_.NG>2\7]T'F;T- MYV+K5SC@'=SK/L?MOU]V!"MSV3<
M?&N3[RXSRR0:6K-/@W&7:6KG-/5DNC].4C,XY95ED#(Q<E[9<RU3(&0LR3&[
MLYH                                ."V6.IBS$F.,<6!B3&EL69Q+
MMR@4"T.%E"7P61:G"RVELK*$MJ6%ED8U;".%6L80M"TKIMV!LW7'E^U0+>_D
MU)O_ ,&J=^^#4?(O@U!R/;]5<@^#76\_#$MT^; ?;H6NIAQM\R>,GG&^,B3G
M'"N,5C@<XI97E)QJI'&Y>)CVCZ=YE]+W@'O#-_+G#36B:&.LI.4^\ZX@
M
M                  ?.A,NM[+LF;C-B$W/G+]<]#^I3T'U3$=T^'V,],=B<
M;AZXNZNM^SW!N0^V/S]VMZ*?5_0E?3Q]H71O9_03M_K3"?7M^XN.[EC_ *MO
MWMQ7>]+<JXES?/[)>F>V(UN&S=#>V^F_9!TSV_[$.GNXO1KZM\9[?X_N_O/\
MJ^R_4WZ&\D:FY!P?W)^:/9VH-^X7U4YMU#W%Z\[EWMP[LW1.^\*GNS<HWIQ_
MGM&)3\FZ9K3UY?IZ\@T]>2DJ92N65DE8Y:RX2N>3R
M         >"FMA,K-<++A3%&&,.8PM3&EH4RD6!B3&V6BXR,.ML8U+$LJQ4N
M-LQQC2W."<BXKF5BJE %AJX?)G^A/1'0WMOBRSQ!>&4YQRCP>!'C(.4<:\'*
M.0/%<3R#RR\,?,>*\RD5>_-J?0W^?_?'L Z=Y3"DU<: .MI,T^\VX@
M
M                ?.9,^O2]CC;QL4FQ\C?O;ROIGENQ]ZNJ.=^K3OOJJK&Y
M.-;QK??=G["</W[K9S;B]YA/=EYD[M]7'?73VH^1<=]V/F3O>"[QLOJO[\Z.
M[L]9\\]A_3_:'IO]+>;);\.7L<Z:[@Z6=H]/;#VG[+F?'>9?'[&.F>].DO:_
M0< WKA?N4\T^SM=[]P;UL]Z>./:'T-Z^[G]8>@_4%Z(\#;_X?VG[3^CO:/0O
MLGS;KK[>.^QSJ_U% OHV?0NY</[ ['V')?CWO1OU;!-OFW.9?/O>$OS8?'4D
M./UW<N.9WJW[*R9YP*,VM4SIGTR1+R0EZ91,F7A<EV5SR#P>0 >0     #P<
M3P<3@<3B4R@42@42U7&3*-KB9<&1I8V8A,:N"K!Q'[,.L?+,HE@E:RHM:.=E
M4RIS,BF1D\U?E$O2[+N*E4RW+<MHMZMBWBU+>L5J8_)/^@'1GKC[EXB."\SB
MG,\1QR<L7BN.67+''P#FO%.,<SP4\K4DXW+G,>%>3SB\#*\I/)[+/,O97T$^
M,.V]=R:R70J=;2<)]W]Q
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M_P \N^8[H9ZE31AUK2;GW@W$
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M[P[B
M                          !\Z<RT"R['FUS9LO7K?]GZ(]Q];>I+T9TQ
MUAY[Q/V]^<.ZO&6/J/\ 172W8KAG)O9-TEV=ZC/1O27#+0[K=9\YZW\VX;L/
M:?LB6Y;1>XZ/>;JSL;JIV%UW =ZXY[4.A>\LSI3U3^@_-'L+Z?[D]H71/?\
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MRCP<UXR<:\UXA7.!QI'BI#MVO]5/Y@^D95L?V:J-$G6@FR?>7<0
M
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MY1=?/J_53^7GI/86P?9J(T =<2<)]YUQ
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M.NA/4^\VX@
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MIUV-D)]Y-Q
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M3Q'FO%>8Y1QKR9O;/J^GC\QO2&T=A^O1":).O!LM/O5N(
M
M       'SRS+J^R[)FWS8AZ_>U>MO2OZT\QQ+<_@E6V[CLO8MYG&U;CT2[=Z
MO[(<)Y;[@/-??WHV]8^8<9]/Q_0KXU]:>K7T!T-T>[8ZH]M'GCOJ7;?]GJU]
M ^=]V<:W[OUU#V]T5[<Z2D7S-M[!OT;W#C_<'KGM+J#V=T>SVWV]^;O8_4OL
MKH;ISVEYU]M/G/VQMKCW,/4_Z&\&=PNL_0OLCZ6]>^M;N+R'89?+[1.FO8>D
M-^Z]Z^\@ZR[A\,[MF/Q[SI'=.!S[X>0;8^#E<6SVC*8?3*M'<;G#+,X_3SQ7
M\U,^^NO+QQPS>7T7UR\E[;7N54J%63G;53F5%YIQRQU!O?#=A[7R+67W\<DO
MR;EF]#[)-I;A>S5JLAY  !X.)X.)Q*9X*9P-5;K\WYMWZ6^>>VO$-U^^K\^N
M\]4;M\NO]PT95\>K^=1^D?G[V=]6<E^XOP=W7Z?.Y>)>LOM+C7U2>2>TLQ\^
M=%:*45HGI/[UX7ZZ^R^.[*VKZ>W?"=Y]SG1/-*%42W*$4*MRA%O5N6\6]6ZV
MZ6Y;+;EO);K;V6T6]6TMM5N6\EM;;R6RVU6Y;1:U\^_K?JWT$^L>KAY%>%\I
M3JKB\4/!Q%J3F<5(CS7A2>('*AQR>8IE67Q9(-I^SZ=OS*]'S[C_ -6B4T(=
M>3;"?>[<0
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MS/%OFO$GB.=>5X'FQ#*^(J2<5SVU_5]-7YG^CM@<:^O0\=?CKN;I3[X;B
M
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M\-Q
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MIY:^W#0U1N_R]C.-;ALO:_I]Y/0O-OF0]3=:^WKIKEWW >#>[+C3MEE/D/\
M9G4OSQ>D^O?M^\$=W>WWI7E]!:*4%MTH+0*!;E MRW+<MRA%O5L6Y;Q;U;2V
M]ELMN6\6Q;U;1;);VVQ;%N6Q;RVUGH\].]<?.![,ZCK1PR>3P>8\6\L93KD>
M+?*#Q#(Q<;:DGB/-I.-O.3@>,@YQYQ<;?*9C;_K^DO\ -ST-L7A&YZ'-%FAC
M=Z?>_<0
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M@_F]Z%VAP3=]#&B#KR=BD^]:X@
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M;R/*<*Y1RCBN3^74^C_\WO0FS> ;WH<T,==#LHGWMW$
M
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MTH_FQZ'G_ M[Z^FADZX':=/O8N(
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MC$Z[';)/O2N(
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MYIX.%>8^F'\U?1.>Z_WSKVFASKN=OD^]JX@
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MVO;5*A52H52HM1*AR.9T,['Z9]:';/EONKUQW%OWC/8&M-39>RW&NQY!-Y^
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MYG$\5YE\V>9>(DY5Q.4<CP4LW/%XR(^EK\U?1&7Z^WW0":&.NR=TS[T+B
M
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MMY'[1^E;S/V'\ 7Z!]&>L#M#C?N,Z;Y;[<.HN4ZPW3Y_2+W?PW7FY?/^B/\
MG+W]*/EU/S9_TN\\]O>';K]^_P"?'>V9^?.F=>N1;?\ G0?I+Y^]DO6/(_NB
M\$]VU<+26DGJ [EXE\)/O_HZ^PR^Z'P#WA[:.G.6T2@E H+12@M MR@6Z4%H
M1;E"K8MR@6Y;%N6ZVZ6RVZ6\6UML6Z6RV\6]6T6Y;%L6Q;EN="^U>,_'I^BO
M07@\Y7GC!P594CB<3R*Y2\:\5RQ@\1XRJ3S<O$Q\55Q#AD2\4Y7+C,>>-^ES
M\T_17C@>\Z'702=>COFGW>W$
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M+GYH>B\7P;=]&&ACKX=]T^[^X@
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M?$G(\KP.9X3Q27C94CBM33OTM_FAZ-PG"-VTJG7XZ]G?Y/N_N(
M
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M2!'"O)X6H<$Y+Y3P>%\IYCAFN_FS^E7\TO1T9X3N>E#KX:$/8FGW7W$
M
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MV6=RRNBYRRK%1*I56K%4J)4MYI4CG7-:B<CD<CDMEEH76.I9-.[FI4M\1SM
M XG$\'&N,<#@<#@4S@4RD4RF4BF4BB45]</9?'/@#_1'H;ZB/*'9WT\^4^S>
M$45H%$H%$MRB6Z4%HQ;U0BW+>J!;% MRVBWMMXM[+>+:K>6VLH2VI;V6\MM5
MM%O5O%L6Y:EN6U=8.;;-\6'Z7>>;/4T^-*\RDY0.!YH>3C7.*9Y.1YBGDY2^
M4X+YLYXJ=<K>4G&WBGBKOY]3Z2_S8]%X;@6ZZ57KXF@#V/I]TEQ
M
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M$\QXJ[T,_H\_-[T5;=>;OI8Z^'7T]F"?<G<0
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MYR>A^'6^\Z3.NYU[/:&GW%7$
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MGE?%>$2DXV^9*D>*\+=_/G]%_P"='H6VZTWO2)UW.N9[7$^X:X@
M
M             >GN9>I9EV.-X&SB!;_POU=^N_S"W9P7N'OMY\]P] ?0_A?3
MW->IO:)Y8_1R \BX)ZV_2WY[=Z.B_979KK/T)ZTO37YYYWX-W[_=">U^M_8O
M0FK.3];]C>ON\<M\VXP;>>'5]/7FVT\FN-+.;;7R;6.^<%E'P[UV2X;W'H;D
M_56#UML[9<,[PL,_CZZ\CZE[&<=[4VUM?,^MV]]4270W/L9M'9<&UN.ZWU^+
M]B?A[%O\<]4Y\4V/AO\ -<-TC,V[E,9UEN_B:=ICHR#+ZKVWR7:W=RK55*I5
M*I4*I5*B53U9]K<9WEL?V]3^6[5&_JT^O7(O@[$<=^Z>_!KQ7Z]/KUR+;]O[
M1]>ZMD^SJMRK;.UO$]SZ0\YV:<_!KRWY-6 ;A\_;'B6Z=-^9[3V+XYN&J=U^
M6!_?H>V7J3E/K9[*X]M3:?J]RO3'+O2)WAPS1N^_'[2.JN3>N+LGCVL]S^?N
M9PG>(3]VCG/FU-,[W\<P^'6[0<4W/L]Q7<_2[W9P[L%QW<-);W\<I^35U[N&
MAM#:/JC?TZ>D-^^+L]Q+=>\W7V^=4N6[5M;9_L[M\ WR@4(H5;I06W*!;EO%
MO5N4(MZMEMTMRW+9;=+:+>VV+<MXMJMXMBV+8MZMXMBV73_(-O\ B8_3CSG#
M-R^=;XA7BSSB'DXGD\4/,OBSG'@\E.N4*Y1X.%M2"<*\QXM%Y\^?T4_G7Z!L
M>L-_T@O7I.NY[:T^WVX@
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MO**1PH<I?*<:YQX/ JZTLOHK_.OO["]6\DT0=?C1![=[C]MZ
M
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M13JSDNDTZ]G7X]R%Q^V1
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M*RUBJ5I*E52JM0JI5.:^K/M;C'<_A>[^L#M/C7;7B.Z]!.P-BV-MWT=_.O\
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M?T-ZJY-I$Z_'7D]V5Q^TY
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M/VDH
M                          !ZI5]),S[-F\S9A'-[X7%-WXI@=WXA >0<
M"E&W<DD>W;[AONV-9;:ORY7Y_NV7Q_G^DN8]/W&&IV1X'WOKW?.!Z8Y3U5V?
MX%WW.-KY1U&[#\X;,V3FO:'A7>F@^4=1:TW;A'<K@OHFSU/CZU<FZ9WUL/9N
MUMKYII'=NM^4G8/:.S(UK;-!M;C>V_DYAFM/ZXAGL>?Q^V7X[K8X_-<1F7TW
M,RNV5TRNF5^SNK:BW)?6UEK65I:M5HJU5BK55*A26() EB%8'*<,<L?J84?H
MPE_Q:O*O)0,"M0K&H-Y^/<&T_5DM/*K96*A5.10*L5*J%0YQ4.1P*!;U0+8H
M% HQRJD4#1._?%N;8OMX2T(MZMRWC56[?+N#;/IL<I>:>5".-O%*<6E4B]C.
MU*9,C%M5N6ZV\EO5N6Q;EN6Q;K;26ZV]6T6U6\ENMM5L6T6Y;%NNN]V^3XIO
MTS\ZZEY#\'$+X3G'$X6D5X.<+4GD\5X!RCP<3F>3Q'&N1Q/*J1YCZ1/S>]"Z
M\ZWW_1R: - 'N]N/VA(
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M.L>O-ZT8=>SKV>]ZX_9F@
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MO">5\XSAD\2\D\GD \'"N4(9/$>:YX7Z3?S6]%ZHX!O&C%Z\)UZ3W\6?9 @
M
M                     'J^7T53/LN;F-F'/ZMJZT]F>6IWMG*-^\'[UTSS
M'IK67(NMNTO7/I=EI=4^R?,6^.']R[DXSVKUNYUY^L=;X.T?!/0D+W/B.E^2
M]4[XXOVW+OAY!IS?NL<[\^X[4VCG47^OCW!IR3Y]VNI;_3U^+2KS*0:6X973
M^O :FT9[3^Z9:6\8/+;:..C/9OE6(UCM<Q;GF<OIQ6G\=\SD>?UI.&.&4SU:
MR7USKUC3K];=1M!.QB7H     !Q6A,N)P6F6TRY%H<"B68*!4*:6ZTSF<$I%
M<M5Q)6*J#BHH'-,>L=*9DDSJT4K+R2U7DE)>*%HG(LCBERMNE(XG$\%JM Y)
M1*:^4H5<%IB@=:ARF 8S2,E5N6Q;R6UMO%LENML6Q;EL6Y;$-^_0^+#],/.V
MAN5[9Y/%#B>8Y6\,9SM40OA!Y@>:Y1P6G95CB<CD<%\5SDX6\Y.>.?TF?FMZ
M*T_P#=])'78T"GT'V?8,@
M                                           'K*7T'3/M(;K-CE_K
M?)@-QXK0^[C^N]_ZYF6V<ME.W<DAN[</YW'._+N]OJ?)*O@Y!#=TXES3:VP]
MAX#[-CU]NO"-O;'V+-/@Y)HKD/4DE^;=][[#VIKS<>%:XW#A?9'C_;]>9:.W
M7K':WP<TV3\7*M:?7PZPOQ[O^3GN/?'!,^.;*PY+()]L5QV;*37EN>YT<-&E
MCIR#+Z;IESDO<LKIESDO\LH;;I&Y3J7M3+)6/$N+@   !X6E,J1S+696A:+2
M*)Q2B4UI)2*:T3@<BW2JO(QI<E ',\').2T044MUYEJG@I%-;I.*VR<U)S/*
MVR4EYA/!26DG)>!42F43D<%LTIE4H+13B"B6-O)C;KIPUU<9$F;+8MY+:K>6
MV2W6V+8MBW+98I]FA\6_Z7^>.O/,=JY2<3P<SBO*3S'#(KS'B&3EBX+YKS(C
MCE?,G->-GE6,Y'&TG@\K6PR^D#\W/1.G^N]XTN=?3KL?0_<?K_0
M
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MZ)T[USO&FCKD=?3Z+KC]?"
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M'TYUQO.FSK>=>D^D"SZ[$
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M/FU?HZ_.7T+I?K?>M+'7(Z_GTG7'ZWD
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M459YBF>:O/GU?H?_ #H]!:FZSWW2IUW.OQ]-%Q^LQ
M
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MY5)QCQ;>:5^A7\YO06LNL^0:#-!G7X^GFX_6 @
M
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M:IC&1'A>4>9.%7&GE]$WYQ>@M.];<@T@=>SKF?4;<?JZ0
M
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MN-<Y?">3R<*\'F/)PJKBXUY.4?1O^;GH;177._:/7KVG7M/J6L^JY
M
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M^4IG,XG,\5Q/)SQ*X5YCZ//S6]$:#Z^WS21UP-$'U57'ZFD
M
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M7G"_1]^:?HKK[P/>=&'7<Z]I]9MGU#(
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M.=#P%\IY7C9RQ<<B/!R/!Y7EC?HT_-;T7U]X!N^CDZX&B#ZZ+/IL0
M
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M@ZYFAT^O2SZ9T
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M-!'V#6?2V@
M                                '5,^46:G:HWD;2)47RRB?#3?/<M6
MYFI''R_)#<_4#E]?19CW<C4C+[CII^W?'Y+IEF[]_":%IC\6>SW*[98_#X<G
ME]&3NOXQT_$T\QJ?3<+3PT<AEJ7!5C1^IGVSF4LMI)2Q>%\KP.!;F+3B43#F
M),008TT:).HMFXD]WEP[,@        Z7S+U]3/<"[ 22F<6_,N5C*&=3-DF)
M2LDN-S=, >%P^.I$" D"(B1HP!'#$&*(^1TP)$C79KFS5TOLQN'N[N(
M   UP>EV9=&67:4W<;#)7+?%Z9 XGDYG(Y' J%(IUX3C;\=WO7H_U4=Z<)XT
MCROE$>*\*L\G%?*>#R>8XUXCR>%93E"/$<3SDYQ3*D<,E3&_0Y^;OHK1?7&\
MZ2.N!H$^Q2X_2<@
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MR6X_2"@
M                             '6<^2.:G:LWZ;3)27C*7X_)SF-8]';Y
MO1%<]E$VFGLB7=-S^FW&R6W+77KK0Q^;(9?1>99L='EC,GG]%<IXZ.2SUK@Y
MX87-MUEG<VC2^67>3!SJE!E03B6)8UQBQ,.8PBQ #7)U4LZQGMRN'M(2X
M       .H<R]<$SV^NP23F0,PE^79E#(KGTSA,"1&>RT^2 49E$)G"B D0(P
M1$PIA#$F+,"1HP!""&&NC7%>SIC[J;@          .D"^C"9;A7LF3J64&8,
MB>2L7A5+.SA+Y/)2.&4^*;]%.@?7EVMQGPG&.=O*3@+?"#E'BWRGB/%>1'F%
MJSS'@\5YA7*4>+.6*MIZGT(?G'Z'T9UMO.BSKB:%3[/K/HJ0
M
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MT,_H+_.CT+HKK/>]$G7)-"'VJ6?0V@
M                                                    &@#X]9GV
M[7>)MDFI7B:XZ%>YU$J3&JOSX8?)\_&KKSF39DP^UK&[>U/HJ8RLQN\M6K)S
MQPO,LZ]O/#"YJXN5S5Q<ZZ7!7,/2Y=DY:L<"Y+:.!9&/,<1(CI$:UFG5 ZE'
MN0N'L\3D           #I^OKAQU-N+/DD!EURJ5S(&57*F7,RDF)J9ZR^NF+
M>9XR91$A1"2)60V7"D=,"8PQ!@B.&!(B0NS6\NN+/9NQ]U]Q
MZ7KZ!)EV(7M4L\C/%R98YE8Y LK/,M HK\B7O'I#U$]]<'\'@YG \9*N+@#C
M53%3R5)>*>#R>*Y1Q.<>*\6^(\R<<KSD\%QI:GT$_G5Z!T1U?R#1*==4T8?:
MU9]"*
M                            :0/CAFIVX-\&VR7ESCC-L=*[SUJB<=/Y
MZ>6I^<YF[W8X;9B#99?8WIZ>Z65YJ:U:*F.%QE:\5ZN+E7+FVNM<KI7+A:Z:
M-RO>C#*[*95/*\$YF',40\A)!C4YT@LCJ?1!<-W@            Z>+ZWL=3
M<Q+EEB9DOB[7()>&8,@2 D!,B1&5N-6X8['5QA"")$,(61HCY@##&$,99AI8
MR1PBY S7MFN9?9O<?=C<            !%CYZ9EKYEW3EV29HS1E#R5#@<"F
M4BW.G?/]C^&K]*?.]EGCYCE:3R<;6,Y5X!P%,7*WDG&O!YE\R>3C7BD<RE56
M*^GE] ?YV=_:)ZLY'HU>NJ:%/MQL^@%
M                                                      -*GQIS
M/N$N\C:I,S(LIU-.I)5DJU3D^%S.:+PT>\&&&PE^J^:F\L]6O5>KAE7JX6OE
M:\5TKK72N5[:\7"8"LU<NP^&7DJ)X.8+0Q9'#79K0ZX'K@L[EL??_<9
M         =267K2QSV^LS)"F=7)I5+\OC(F3),9XE))S,65BTEPQ"2)$0(81
M8C9AC"&*,:1TQ1%2+$"-9FO3VG7#W07$            #B>GY?5Y,^\QON6:
MF9*9>%J4@<+,=')?CZ]]=&^J#O#A?,\9/!R.)R@>#C7*/)Q/*K/,>+>!YD\G
M@YG&O,#RM3%]"?YT>@.O/5W(]%G7%-'GW"V>^U
M
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MGC,E')$#R<;?,GDXU]$7YQ^@NMG6'(M(G6Y-'GW/6>]1
M
M       -6GQ8S/MV=@%VL3DNF<_852JE4K'2A/EX:< KWJ34][BY%:R5RL5R
ML7!7*Z5BX*U7$5JHQC[EV?Q<2HMP5BLMHF,(.:G-1GJ\LWNQ^C.X@
M      #J7,O61,]ODQ)&9DRBW27A5,L9TSQG25F=,K94E\$<(@1(AQ$K(S+'
MK,-+A;,/+C3!V8:6/V0\@DNM2"6>TEC[G[B              /5HOJNF?LDE
MV.94KG$J59Q:%,I,;2SX</TI\\].^P=B6D'&*AQ7P>$\@Y+3LYQX/)XCS7&T
M>8\5YD\@YQ]$GYO^A>LO6V_Z).N!HY/NVL]XB
M
M0,^)Z9]P%WH;;)F7K/8+3JE4K%L?!A<((G9I?3@GW^S/V:+7*Q7*Q7*Z5BX6
MNE=:Z5RN:@RO<S#+,V55IQ5*A>E$CQJDTP=&;.D3'ZXKC(P
M =35]8^.IMTF9GC,&6+HYF3,B7QGC/$O,^90NBV,$0^HI$0LBDL3(^8<Q)C3
M"F+,(1>R(2P\UE9KT]J+'W.7$              #YZIE>LNWA*9<@4;+B+>K
M>6TK'2>+?0_Z;ZW^8OVAU#YCPO).-O*.%GF.-O(\QY.,G*N%OF3D<:\QQ/-O
MA/*^#D>,7T0?F]Z&ZS=;[[HLZX)HX^\:SW<H
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M7+%QR,;]#/YO^A>L_6V_:).NQHA/O=L]U:
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MW_1!UT31Y]\%GN@0
M                                      ",GPXS/MTO8 VZ3LR#/8S"
MH5BJ5BJE@1\FQDBL5BN5BN5ZKR5EN$KK72N5S45O=''*Y%7<6YF3(&%(4:!L
MZEGJJ3[$;AG0               =45]76.IN,EAGS*F3,@52[+@S!EC-U,8S
M)?V9,M9<%9$Y8S9"B(&", 8F7$V826RLP)AB/$7(8:Q-=GMB8^Y"X@
M         ?/],MK,M]D@EXV6LM(QJ4*Q992^DWTAU[\O?MSIOB>#G'F/%#RO
M&SE'"O,>:\0*LM]IYY;2U8W]/S\*\)QKRJ3G+]!'YQ^A.N_66_Z'.NAI5/ON
ML]QR
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MHX5YBKCE]!'YQ>A.MW6F^Z*7KF:83] NSVZ(
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MR<HIY/3;W)L'PI^[.D-9[I\3)YQ5]//Z!_SD]"=:NM-]T4=>DT:?H,7'VV@
M
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MS2J?H2V>V-
M                                 +<^&"9]HC?:[?)V9=GLUA52J5BJ
MO2]C\0-P]?EQ[_3+[U)J=I"L5RL5RN5TKE<KE<KFJ,KW#QS(*L<B0DE+*SK'
M+U0L]-B?9=<+L                '6-?4MCJ;C)H2$S!<ER7!Y+TNR2&?3/
MU)2]EJE(P=D<(@1DBQ@3#&$C$UAS&%B1LPA%B$&M"!GML8^X:X@
M       >AF9;L9;IEOC$66DN#,<8A,17J/[[X/\ *[[OZ2YG$Y1X/%<CZ'/.
M_9/VO^)>T+[3RC?U8]!>P-K@WWZ'L(ZZWF<?#G\K'JKAW43F/'OJI\J=A]S^
M%;CZ _0'#_AS]R]*<4\%UI9^_P#_ #J] =9^K^0Z,.N2:9/T-+C[4P
M
M                "D?"Y,^S9V$-KK.S.,]GM.JM4K)5/6PG:(]3MFA#Z19E
ML(K%<K%P5BM5Q)6*]M=+B-<Y9=K,7*6Y/!5)$30AIU!/5M9V2N'OC0
M          #K.OJ8QU-P$J)(9PYER7)7+HR!F"1V9XD$N0LN2WEQ%D;(F1 B
MQ'S!EB8XP)C"QEP=D;(H0\U<:[/<&Q]O=Q                 ZB'JTFIWE
M)(8Z,8L?,59BS&G5[F.T_$5^G/G#S7F!X/"^;-I;3]_W)^&>[O;3U)O7QD>S
MNL/0=W_U[993W3=*\Y^XKPYVUZ^>P=H_/E_0GH;W-],<V^[/PAV[ZX.Q]H_/
M"_1'H+!_1H>2OI:GO]_.WOSK'U9R32*=>C3-GZ)">SH
M
M      IGPK3/L^;^7;I.S.L]H-.HM9*JD^(=AW27Y6+AN6OL F?T)3*L5BX*
MY5+A*RW%5XKI7M@B]G)>14CR71*2;FC;.GL>A>SZYKANL
M  ZR+ZF\=3;A,S.&7*I5+P\F2K,)DUS<9^S/2Y6RL4S"D6EC-D2(J84P9BC&
MF,,28<PQ@".D"-<FMSW",?;S<0                !\V4S]BLRV*8HQ-D8,
M3+B+,21_.?"A^J7F:";M\B7QE$)64]B77')_T//SO[P]+'=7%OAE]T])V.>/
M*,CI:GZ!WY]]\>SOJ_?/SF?T;Z+UKN6G^EA^:7>_2GFOQ?G4?HQY^B?V?/Y2
MXT\OH#_.[OKJUU5RC1YUZ321^C1<?9(
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M\FT:=?32A^CQ<?8J
M                                       #X9IGOP[#+MPV(9AJ;3:=
M9*L5JJFNT^9"XP:._%ONLEW:5EK%<KI66NE>JY7EKI9GBY[QDHRW=E>43,SI
MU!/6%9\Q[']+*XUP                #K&OJ1QU-O$O)&7Y=E\52L7=E^9:
M7-V20SL96KDLS&$:(D1@C)'C F+,<8DQYBS#D9(V0<UR0@]O3'V[7$
M           ?'[,O94R[JRW-D;(X8 P9AC#1\N_NOI7U1>@>">5\XSS7"WRG
MV1^-NVOII\P]@_,;Z?X3\=7L;ING7%-N;1N'Z-_YQ=^=L^(_;^>A^A_1VM-R
MOZ-'YQ]X>I;MKCOP$_H!T99Y:?FO)]$/YP^@.H'6?)-%G7LTLGZ05Q]AH
M
M                    /A[F>[5[#FUB>F<:FU6G6*I62H?*8Q^<*X=VU]>2
M?;>S][$RKE<K%<KE=*Y6MKR5UBB2FY[9Q>2]+HJ$TL'24]&9Z'&/Z>%Q
M             '65?4CCJ;=)99(9E>ID"_!7*UF3,M+FK) 2$S14+$Q9&"-$
M9(F8$P9B2S,"6QB3#$:(V0<UX00]P3'VY7$                 ?)BNTIE[
M9IE+R%D9LCAA5CJ8H^?'U]U1Z+_5O67%.4<H5PR?3EYB[1^Q[QGV5UUY)\WP
MU>Y^H_6SV3QK9NV?7]6?E#LSZ._.',].[SH_FP?I7T#[V.B.<?9=XQ[,^5#U
M=U_\D?K?J2H>#B?1!^</H'I]UGR/19H$TO<?TF$[[
M
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M!=1.M.1:*3KNNFT_2FN/>T
M                                             'P\3+<2]@5W,3\S
MC4VPTZI62L53K.?&=</6HQ[Q+]N\U.X!62LM8N"L5RNE<KK7-25V1F>52NG.
M6X,B; -2G0&SY74UM<?THD                 '6Y?3UCJ;8)T20O2Z+DNB
MI9>%]+EC.V9LSAF2J4#$D6(R1DC9'C"F*,28LL#"&",.1<@9KLB![CF/MHN(
M                 ^7A>NTR]VB[[EA%D6EBMF#(\8T]2WH'@GS'^Z>E?*D\
MGD\5G?FU_MX\0=U^_+H+E/.3S,B#J#S#XOS]OT%Z.Z>\PV*:?%]?=_@V_= .
MPN-XC5TN(KE'T-_F]Z$Z?];<@T8=>#4*?I;7'NR
M
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M/7QV'QGRG@Y1XKPJSA%69?0]^;/H7IKUYONCDZ]+II/TT;CW%
M
M            !\2DRFB]C%W&FPUS[4VXTZI5,.GQ;W3T4O7=CZTJU.?:Q,OJ
MYFI72O%:JQ<%8KE<KE=-'Y.U&&=:RLM_'DS)-#K2>I&SY76/?6S]!U
M           !UT7TQS/<4LT)*9LY5=Q5*Y>67)E20&=,^9$JED88CI'R(F",
M"8$QAAB@8LP1BB,D?(4:^(:>Z1C[3KB                 /G17UWS/VK'?
MLP$L.(39'C 1A:]=7<?$OE._0?H?E7C%QKR>0+<IH:G<?AW(.U7%/HT5OOR=
M(.<;1#_M^0#Q7F*9SHO"2ZPOT2?FOZ)Z8\ WK0Z==C3Y^F[<>W(
M
M              /B<F4I7L6;E6?$D:FWFG5*IR3HDGSOW#TL)W87Z*)G[F5V
M05RNE9:Y7*Z5EN$KE<U#E>R.&2LI%4X&;)A9U1/22GS3'M=N/WL(
M         -!KZ3IGN.6=&:,NEXMZ5[*A6+LS1GC,&=+\N3@88CI%R)& (\8<
MQIABS+0P)AS $5(&0 AQ[M[A[1D                 'H 7UAS+V"+[0S'$
M#(:1B,!6&/7OV_Q3Y2/T+Z&(A7@XY.>#E7@Y+DM+4D7S:DC^;4WWL'V]F.-;
MAZV^R=AUIN7QJYQ3HO*2XT\OHG_-?T5TAX#O&ECKH:63]/"X]K@
M
M              ?%#,I&O8I=PIL-9(SV^PJI5,,OY@=TNF*=_P!>U1.#Z!IE
M]%C*LE9:Y<%8KE=*Q<%>M0KV1F7F+TYE=+]9174%/GR3T('NQN/W)H
M           -+'H[FIM^6<&=,K9=%[+7%EX7YE9<S9F20F1*A2,.1PP!$B/F
M!,&8\QIB3'F%,<1\B9"#7I!T]Y*>SNX@                #T:KZC)EW)7V
MVR\S7MD/(^1<PAT%[:XM\H7Z(=">)/%%\G%.9Q.U'%-]^AOSOS_V ]?<@[<\
M4^_8.W:O8KC>O-/BU/A1]V]1^C+O3@)/!PMJR>"Z^?5^B/\ -ST/TCX!O&BC
MKX:<3]/^X]G
M                                   ?$[,I*O8TV\;#62M3<#2JE4\G
M1A->D:(U4;CMZ>PE:Q7*Y7*Q7+@K)7*]:B7LA,JT<2[+JR\ESUG3$^:)/3@G
MT$V?:.@                 U(>AB:F[Y9J2*S(F1.4MT7)?65S(F<,R9LSQ
M5*1BB.D7(N18P1@3$E$PA8F(,48 BA B!D4/>E</92@
M]-*^CN9=K3W,+GS6!"8P51PCIT/[6XQ\G?Z*= \3E7B/*^9/%=[N!<G^[_P;
MW-W:X5]]7&>$XY9).)\/GN7J;Y^?0'7W(\G!.9Q+[Y]7Z(OS=]#='^O]XT6O
M7I-/GZB]Q["
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M:>3]3*X[L
M                                !\7LRX+V(-QFPUE;4W&TJL5:JE8T
M\?+4PTE7UIS/2J>Q]:Q6*Y7*Y6*Z7"UBO9J%>P>.56R[E\ER9DY)T;KY3$]<
MR?6'9]3Z                 "-GSI34W>3,E,9*KN6^LYR\K+XR9F"1F?)0
M9<NBW,(8(AY&2,D7,(8,Q)BC&F*, 88AI!S7QBCZ$KAWE0
M   >NH^9R9]B%]WDNP;-3D2(F1TP!TK[,XY\E'Z/>?N)S3@>%YIOOCV\?I1_
MFKWYNK9=?UO=D[/\Z/HWA72OFVVZZ^_YNO/(MMU+N^W0'</@IV<CR<#RO@N]
M+/Z&OSC[]Z4];<CT4G7HU,?J87'<P
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MHE_./O\ Z1];<BT&=>+-2R_J?7';X
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MOT6?G!Z Z)=;\CT:G70U ?JKW':(
M                                                   /C=F417L:
M;>78I-&>XF%9*I6*I2/GUL]&['LW'U/L^X16*Y6+@KE<K%<KI7--7/L#BJ%2
MRYBLN0LLSUW'R6)U*3[M[/=L@                 'S\3.V789)3,%_&8JZ
M,R9DS1G22$F)$9TK%D8,CI$2+$5, 10P!B3 & , 1PBQ!2*$82^7ZJKIR\
M               $&/B6F>^SWD+NLTW+$;(D1DQAU5YWLGR!?I?YUY'&ASE\
MI=X9?<3X<[P]^70'*?0GWWQ?Y[/0_ LMAELW;/K]C'6^Z]S.%[G\Q'IW@?JF
M[8XCXI)Y/%OB3F?1A^;OH+HKUOR+0R==#4Y^J_<=C@
M
M     ^-N90E>QJ[F-C$R:FYFG6DJU56LGJ<3X%;IXFLE+[]9?N 9UBX2L5RN
MM<KE9*ZW":7NIV%QG)*RW%G(R)C)?7)9\D#'JF?H-W'VT
M   'I!F6C66TR4&7ER-F9,X9B7,69LSYGR4$A,L7):F'(R1<C!$R-$;,&8 P
M)'R,$7(@0]((8DW>?3W</(                 +(^%Z9[Y/><N]S4I!"%D=
M,,=:N:[/\>_Z:^<E>#S'A?-@[9\1W[[]O '=_>+@WW1CZ9S3(:5R.G><?(9Z
M\Z[^6;U5U0KS'&TGF/"_1=^;7H+HKUUR'1!UZ-.W']7A)J
M
M         #X])EK%>PYN==DDR:FYVE5*I8'6P]25Q^;EC]4\RHG9M?:2M<K'
M@KET797+@KI772S/L$QJE<\'.7.68&7UGV?(^QZOGZ05Q]B8
M     !ZVE]9LSVL30SYF"0KFDS9GY<Q9G20DD) 9,Y%D6!&R-D,, 1,PA&#"
MD:(T1DC9"B"I%C(GL23W<W$                 #P?#=,ME+[T5[!&H2!$7
M(^80Z]<NVKXY?T\\X#D@+X3A7M+ZLY=]\/@3N;<&SZXY2>+D1'QK^R^M/F<]
M.=7^(\G@Y'DXGT9?FMZ'Z*=?;[H0Z[II\_6&N,H
M
M  !\>DRU2O8TW*NR2:M3=#2JK631I^;U=+J96KHWK9F(]YTS^]!G6.B;+Y9V
MKUL7/GMH8_0TTNTR5TKFEVIOR2J5SG9>%Z8(]8Q\C3'K4?IKW'N.
M          :M/FVFIN<GY+21DF) 9PS!G20&8,R9PO"]+(Q1@B-D5(V8,C9&
M3!D;(J1LAI!$AQ76?GNTN'=%                  !\1TSDI[Q%[*&HR!D-
M(^8TT#RC;?C:_4/S:.2#Q'FVI'W<>#N]/>?T5R:GE.OO(=/J_P G^/4F[:'3
M'FFT]+.:[+Z!O0/7FCM\V\%Y'A%O/!]&/YJ>B>A? MZT0==DTV?K)W&1
M
M                    ^029:07LF;A799-V>[&G5*I0.L1H--65MJ(D3^WV
M;Q;GQFM;W7M/OTGSIS4F->O9E];[1[YL:YIFY[QQ7]E:7FEVMS9&CUEGR&L>
MOA^I!<>P(                  /2',NF#+<9-2:DM,U+(;,P9,SAES-E^90
M\%J8LPY'R-D;,*8 P)&"/D4(8D6(F6A/U[2)[R;A<@
M^+V96*^[I>T)J"6"61,C1A#4'(/@^,K]2O-7%.)Y/(,CI9?IJ?F1Z([1\7W+
MYV/1?$?E:]5]6Z)WWXL%]&A@=;2M-3'EC/!P.1X/-<+:VG?HT_-+T3T!X+O.
MASKPFJC]96XY<
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MP_-7T3T"X)N^A#KF:W/UEKCD
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M-W^/S"2K%/*^8N]#/Z)?S:]$=". [QU^3KVL-3]8FXUP
M
M       ?(LRZ[R]G#;IL99Q-3>5TJI6*I3.G9Z^T]K:V9N<V"5BJ52S,O5[)
M6*Y<+734#5VVPOB\+J7F7EF+/64?'$QJ'ZGEQ                    '6]
M?79,NI2X$MS)F2+LYET<"L4BT.1;'DM"V/ +Y,ZL@)T3LW,G:].QEQN
M               #Y7)EU*7W;+V=-3$$(N1XP1&/ITOBP_5;S)@OJTF0#S+P
ML[I<*Y)]^7@#N[:FUY^EWNKBD<^J[QV/[/97UANV_=A^OX_/8/6_S*^G.K^4
M>3B<[?,7.AJ?1!^;OH7H5U]O.@CKF1\_6"N/,
M
M'R7S+JZO94W,;(6:,]YM.JM9*JUDK%8K+62L5RJGH/:OIRF<]2:63F6>5V>8
M?0\PS1J1GM!CF"N5BM+>V8D];A\8+'?9^FQ<0                    !#3
MK3,NM"]>#7"Q,C)'3%ELGA:Y>F3,\2,E!."5$W)D;<-S,=PV;!0
M            ?,S,N@"^\1>S9JL@9#C"&!,'J8_%A^JWF2,;C\_$'DYR\Y?L
M \>]O_3MYAYUD=.>%\QXH#Y+_6_7?RA^KNJ/)R7Q23C60^;5^AC\X_070?KG
M?=$'75,0?J]7'R
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M/XK/:_5GH,[]Z[Y8N.3G*D\%[I:GT'?G-W]T0ZTY#H(Z[%$_5QN(
M
M               'R>KU%F79M=QILQ9LSWHTZQ5*Q5.G"?F?73]J[+!)LME^
M@-,I16/CTBM3WF-/,I<%<K%<N#534V QS!DBK+XLRY"SU1GQIL?>+9]YZ
M                                                    #T>KZ,9E
M[J5[QFKB D0(Z8,Q)\:?ZD^:=8<B^#PO@\G+&>;?J<\K=K_09Y]YMK3=?GZM
M\F^/I[R[;M&;[\G07G^P]0.8[-T^YGQJTRQ\'A?-G+%X+O3S^A+\Y^^^AG67
M)M IUR+NS]69
M                                    /E!7IS,NSAN,V6L^F>]+IURJ
M5:JQHX_.(NE[J6>VI-U+]0C*1IS72"]$%UF;W3MP=HDO4K6ZOFI,V,C2Y+R7
MQ9?&NCU!GQVL?JHL^PQ
M              !ZMSYEYG[G%]AAKDU^1 C)@#$GQU_I_P";M,<KVL>55XD9
M)A\/T2;YM2,?5HX+7PQVKAQKS'D'F.)R.%<XXEUIY?0Q^=/?70;J_E&A$ZZ&
M</U5+B
M                             !\J2])IEV5-V+L@V U-[-.J5DJKC4T&
M?%5=/3:Q0ELGZ&S/8"^N9E\>[6[8)3(HFNV7N(8?4,TLH:Q:DN82F6J7%ER7
MYJ4])2?)=<?NP/H*0
M            =<CXB)E[P67LU-=&O"'D9,.88^0O]-?.?7[FNS*'*!QHO%.<
M<3B<P#PM23P4\G*/)XBK+]#GYU=]=!.K.4=?3KH3P_4]N(
M
M         'RN+T9F79@W4NR#8+/>[3JE8\+\G[3GEOSKL8R2Q-\1^@ZU=D'S
MAM7 GTI-+-(779\3<U_LKRT.U,FM9J2.XS&7S966M&1LU$>BM/F)N/Z>*=E@
M                                                       <3X5Y
ME[-%]LRZ\-?D),"1\QI\D'Z5^=^LO/\ 8O)YCQ7&O)QCD*\5RQ>*XJ2I'F.&
M3E'F.&1+Y3Z(_P X^_O7UUCR7K^==#9-GZFJ
M
M?+%,NA:]G#>!LI9ZSWNTZQ5*ITM2S7H>FIY(-E,?+]-C*:&@5^0-K:)7L^DR
M- 1RK[AWS[377#/.L9D>"N71E)=(6>@=*=Q^T=
M                                  !Z0%Z 3/W1D+-?$/(J8 PY\H7Z
M/^?.I?9G'?!R@>#S"N)YKR)>**J1XCQ:3PO*3A0\GT$_FYZ"Z)]<<BZ]IU]-
MI6?J4H
M                             !\MR^OB9=@3L8;+783/?#3JK52J5UJE
M9.97+DKE9,<OJ\9]-EWC)Z[+G CZ66EW98W!KIJY-A,B[+HIF:- GST)]@5P
MW>                                                        #B
M>@J9]VUBAK,@Y'B.&)/E?_13H'ICVOQ@OFWQ(KGC.-<L7')X.<ODIV>8\GA>
M2<8X9.2DY2^_G\V?0G1OKO?^O*=>S<EGZD2
M                                                           ?
M+NOKYF6T5[5ILE=E,]\M.J55K%5*D>GJST2L?H'78J^Q!96>IAG\SS4[ F,C
MK<O>6SK.OVVOGW>FOYJ7-QG)5*I4,H==#YVD^WNX9@
M                                       ])\R[%LHV:V(21TC1C3Y<
M?T*Z&Z.=P\3Y8AX.-<JX2\DYE,\UYCR5,<N-<+B/,4ZY5YCEC??M^:_H;HKU
M_OG7Q>OJ;_L_4)0
M                                      #Y?U]<LRW"O:A-F&Q;J;YF
MG6*Q5*QK _-Q:?>:O;.OI)D^[UGVU/3"U>D:^Y=A\/D^CZR;H>[AA\MS5]LS
M#VFL8(SJL9G%PMS96,L=7#Y\F/W&7'R
M                            >FJ9;L98@U@0$C1@3%GS)^_^B^@'=?#N
M!XKS'D\KQ3Q7D\P.-NS=K^WZ@/+?:?JT[7XEZ?>X.%\SB*Y1X*FGE[^?S8]#
M=$N ;YUY3KL=H;/T[T
M                                          ^8U?6A,MX+V?39)LAJ
M;[:=6JL5BL1\_/4NG@2 '6]/TN&IVKEB!\IK5]>,S^@)I^GJZFJ"/'W.70[&
MR0AG08SHJRWUE0R1U2/0NQ^W:X@
M                       #T_S+:+*P-6D((H8$Q)\UWO3I#UR=[\)1X/%5
M(\Q)?E^W+:.I"OO^"WRQ\G%?;_U!S3] +\^^YOF^](<*^,'VETUQRGB7PE4\
M%73S]^7YL^ANB?7^]=>#KP=M3]-ZX@
M                                                     ?-"OJ\E
MWFO9LV,;+9[\8U4K%4K%8ZKGS/W#J(>^N7WULLF52&G3%EKY9 :M/8<P[+E<
MAK/&L=AEP<RH7IU'/2^Q^T.X@
M                     #U-S+/LKDUJ:Z(P80PZ?.1[HZ6]97H/@B/!RC,:
M6M[VNANP/I+\U\YWQL/V>K#M;8_EJ]3=8]+.:\>'NEZ7YS]\/@/N'YRO1O$?
MBO\ :_2G@Y2*XKY2ZT=3WU_F[Z%Z%=>[UUZ7KPG<"S]-U
M
M         /FN7U83+>2]F#9:;(:F_FG5*JU4K$=7Y+;I_2&S^)5I]D%^VV9;
M)7K^OQ,->;!(HMI)[-[C]7S2F*1%J1]CL8NBH71<G2\]2;'[*;B
M                                                /5TMI,\\:I(&
M1$CQACYY_;G3?JO]']?U,8*B_1;YR[,^S;QCV9(_ERXT8]*.;?'\&'O7I/H[
MSGCWM<ZIYI^A1^>7<WSA^CN(?%Q[6Z4X"O,>*\EY\^I[Z/S@]!="^N]^ZZIU
MW.[%GZ9:
M                                ?-JOJEEW>R[-)L==GW+?\QK25:K%
M4B9^<VT\C6S#6I]ODR]EK+U1,_1E,_L/NC)TXK!3Y16M[F&'N0:<4FI',L=D
M1<%<YE8Z+GK/8_89<0
M              !ZSUA,SF1J\@!&",F /0/[1Z@]2OIKKKQ'A-L;3N'Z2?YL
M>@>T7%OIQ&LMLV?^>^+?5KVELOP6>]NC^Y_"^0_HE_G7W1\\OH7BGQ(^W^C_
M "<@<*\XKW2U/?!^<??_ $+ZWY!UZ.N9WG/TP[B
M
M  !\VZ^IJ9;W7LZFS#8[4[ -.L5BJ1E=9IZR4]%S'ZM&7I33WF+W76#+\@S5
MZMKVP-K,=1LND,OVEW1[^,(S-6(Y8;-BZ/)DC&GKH.D-P^O=
M                                             !ZXETI,]K&L#79%
M".D=/1-[&ZE]/?J3K3C527VY]1<R_0%_/ON>'?9A\>/L7K/J]RK:OJ(\M]E>
MV3J7>R?--Z6X9Z"._P#AGZ)7YU]S>@CO[C/P[^Y>C"<#DO@\I>:.?O;_ #H[
M[Z'=9<EZ^G6P[^U^EFQ
M                                           ^<M?3_,M^KV3-JFQ[
MEV#F-5*I6/3@GP;W3S1(8V"OO9M^OB9SP@!KL@C+U@,O2<SV6?3HT?9&ETD=
MFK!\L-EQ>EQ+?61<]92=<[C];2
M                       #H"O4V9]@#6AKD@Q@C"GI!]<]5>EWUCU?X,MH
MZOT9^<>R_M#\6]E>@;O_ (K\.WN7I&A<=^\?W3[Q/!O>'M(ZLW:-?5/EV]1<
M.^I[RQS+T$=^\6^'KW+T=Y$O&SE"+C3S][WYU=\]!^K^3]?[.N\OL1L_2:0
M
M                      #YUE].TR[.F\S:*[)N78.852L5C59T!8QA8F:S
ML^.EC]S\R]S++IFR^;QJ?80T?C*:\9B?UU8C[&;H][V."FKKW+#:T5SD9(BY
MZMR%7#ZF$
M      '2\Z(34[&FMC7Q#",&"/2UZMZO](GKWJKS<I-\NK]3'EGM'ZSO)'8G
MR2^M^ ?*9ZPZBY8O%=[."<B^^7P)W;VZXA]D*^W&:?%EZ%N_.,?#%[HZ+\5Q
MMY2<05=/+WN_G7WUT-ZMY1UY3K<>R2S])1
M                                                          /G
MB7TS3+M$;S-FFR[EV$F-8JK63H0?(M<)W$^MB*>B>8_H,-7W#&+/CH:WLX8^
MMF7ZP;I[W3T#,["7Z)[I8B:NLLL-L1<ER7)%3U:F68_2I<0
M                                           !UE/63-3L\:W-=D0(
MP88]./J+K7T3^R>I/,9_0U?I8\T=G?8IXX['^9?TYPSXV_9/3'(\'(]V'2//
M?ND\+=MS;X,AZ8NZ^._ E[ZZ(IV<SP>:1RF7O@_.'OWH=UIR3KD=:3V=6?I$
MH
M                        !\]:^EV9=HS=IM-=DUV%BJE9:R=;$^>.8P7)
M!B$R^S4^BIE*BN:A7Y;YJ^D]GN"NQ":P/M*:'?)CCIJ:ERQV_%Z5RX((>K8W
M3</H00
M   :7/3W-3MZ:S-?D-(L8 ]2?I7KKT'>UNG_  7^GG[T>B>P/NG\*]L=7N4?
M)\)/N_IWUK=F<2MZJ29+2U?K"\G=L?5)Y4Y[DM-Z9^Z./? A[\Z'HY3G'&WP
MG.*^GE[O/S2]$=(.#;SUT7KHGM)L_1Y0
M                                                       #Y]%]
M)4O:A=Y&QUV5-7LC=*J52L5DK2U;*Y6*Q7*Q7*Q1-.+U)7F=QF._DNK;''4T
M[EAM^,B<B_-8GJK3MA<??*@
M                    A)Z-9J=T2 &MB&$2, >K#T3P#Y\?<73/F/)V\XAO
MGZ0GYN=\[)VS6Z_<@^?\V?\ 2GSWHW?/@Y'$GVW_ %_;GXB[I]ZO1/*/2!WE
MQCX/?>'1?"SR!%.IIQS<_;U^9GHGIEM?T=<TZYV>W$_1:0
M
M         #T%+Z-IEV?-Y&T"?X_5V9R^:LE4K+6*R55KR5JK%=*RW!6*Y6*Y
M7+A*Q<%M-32N6.Y8O"J7IJD]09[)[A[GT
M                              &-/G[FIWE(.:O(21@C1ZTN_>#?.K[M
MZ3\@O]//[<_$'=GT"^?N6V^6/YCGZ=>=^LG)]MX9.1QE[(<:W;ZWO)/;7H'[
M\X+ZB^W^$#E'$97BG9?I?F?=3\_>\.ND==#K@>Y"S]#U
M
M        /1,OH3F7:4WD;/-@+OPDB5BJ5BLM9*RUDKE8KE8KE<KI7*Y76N5Z
MI8ZFC<L-TQ>G(O33!Z94]SUP]K(
M                        .)\^\S[L+!S7) B*D:/7CWAPSYM_?71O(\'A
M>RW&=V^Q[QOV_P!X^#;O^>M^AG0&DMZ^%:3B5"ZPRLM2>"I(CQ7@8WV*>&>[
M9CY]YKI,ZW'7FSW1'Z%J
M                                            >DA?GDF7:XWF;178
M1-JW/)<%4K%8K%8KE8KE:J\5BX*UE>6X2LM<N$X,M$6[IDO2H7QH(](:?1'<
M/86
M >@J9]O%BIK4@1%2-1T)[EXC\SGZ#=$\T%,\K)?FU]J[5]FBM]VWA<>!QKG'
MFN)YQ>:\G"*@)3PG??:-^;OH&%[=JZ6.MAUX/?'9]^B
M
M       >H1?F,E[>KO<VF;#6=$@K:$E<JK62L5BN5BN5BN5RNE8KE=:Y72X,
M36N66S8OBL79UN/0TGU<7#MB
M                      >AN9]H5PAK,@)%"-G3#M+C7RX_HSY_Y*KSBXIR
M/!XH<H\'D\+X3R*'*7PE31UNYOA3NSN-T-S'4RZ03K0=>#Z3K/N20
M
M                #H4?'-,^XYV -O&P%F9*C,$VK(25RJ5RL5UK)6*Y7*Y7
M*R61"5XF=K%5-<;E#(E0\'5H^?1/MGN&R0
M                               #T;3+>[+@:Q-=$7(T:LWOX_C[_4WS
M/3RGBO!Y7E)PKBODY)XCR>+?,>)/&1',JZ.IV8\D=M>Q#RIV-'L6GDT4=<#1
MEGV$GUIH
M                               !@CX!)EVI7L4;B-GK."6$B*IB*OIE
M-&$A+@KE9*ZUBN5RO)6RM>*Z53F:AMVIC:]7I4*)TX/0<GW97"X
M                                                 /2Q,MBLLF:O
M-=D5(H8]/E\_13H+IUVMQ@<,G/&^$\+QLYRDXQYKR<5J1PRF2^#6VEU]R'NM
MY.[3[9=,\JP.FUBFGEZ])U[-46?H\I[6@
M                                                         ?*N
MOK,F7;@WV;6789*B5$@,N53#UC"L5DRA,8SI<%=*RW"5[:\5TUS5U,IJ7)='
M@M#H\>G%C]O-Q
M           'I\F7EE.#6YK$B!'#%'1?MSBOS2_H5T-;ZF/DXT7Q%3%6QM;#
M*_\ CU+W;+OW@>_=E>N^0;UZ_P!_W)P#?]D\0W:WVOZ<+B@R:Y742:-.ORZ@
M3O;9^D,F0
M                                 !KL^%6924[;+O@VF;!68$A)$9DR
MY5+\O"D1>L<<CRG,S)(#&+ EF";(BX*I>%4BQZ^#HPQ^Q2X@
M                                             #U8+J"9[E-=FMB&
M$6,68@]9/H;@7I"]?]4WVW?1MWB&Z[CXK]LJV?#=W$MUVIQK<]I\7W38O'MT
MVGQ_>*VAG@Y<.F"(^18A:P)-5FDC0EQU3+.+/T"#V!(
M
M        ->'RX3+U4KV_.S)N5=@DZ).20D)>F1,F7Q<E<%P>3%D9K*Q+078+
MLK'DUH>JPW3</H\0
M              =/U]4\S[:D4->$-(@8HPY9)A]2>#&?5I6/U[7.-GWK$QCR
MB43'&.(\8$P!&"%FN4U(NGDUDL/3V76?8TG;(
M
M    Z=GH@7UERR1>RQOQ=JD\)H2(SIF"^,P795+DJEV<CR7!2+@O#F<RS.M!
MZ/$^N*X=F@
M        43YKYGVN7(D$(.14PR81; XE)+(X%@O$L$L#&F/, 1@CQ C7)K,U
MB01+X]L5GOB3VD%0
M                                            %@=#5]9)TQEZPF<7
M>Z[B3;BS@D)+3,F8,N53)EP5SF71<%8N2S(">JM/9%<?=J@
M                                              Z?+Z1YEV:7&D/(
MP1XPZ8U;-+9<8EH6!B%PJ1\C!&B&D (60<Y)W0.^=GLT3V4$N
M
M                     +4ZV'2I>JYUO-(2ZR7RNQ$G9L!9*25)*N:,J7Y5
M+\M#5YK]/:1<?9P@
M                ZMKZ8)>O:\S!+@$Q"X<PB8LP9BC"$9(^1@S:;M.QYVEL
M[8'=8[<)G0
M                                              "F04T0:@74Y B,
MF'*!>F<)H3<W";W-])<
M                     \&HCK(NF#5Y%".EM+7LSA+R;&US;Z;P-GER
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                        ?__:  @! @ !!0#_ /,/
MI_\ N^3_ /P%,?A=/_NY1^ E^FSR_2:/_IMR_2X?_ILR_P#L&1^$,']* _\
MMFC_ /;.C_Z7@_\ L1A^F,\?/]'G+]/)_P#IIS_^\"'Z4!_]M0/_ +6WR_\
MN^!^4C__ $+P'_\ @4\OU,3^?\^$_@3B<3B<3B<3B<3B<3XS_P !S\4_@S_
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M$6Q;X%B[6*5ALU"*;5LB.D 1+00=(E*!I$X(!&;X1;LE99EB3W&KA\M,?;U
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MR@YQETERU%.V4:K^@Y1<FBQ5ME!2:BZR2FX(/4@'J0H!+F)PCDN4$QY&!K!
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M5G3=V)\CH><=>&V#)%"G;\JN[]MD.97.UV;<RV-TM_@'AI^"\A X#GVZK)$
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MUTK[9JZL. GPZ8(XZF!PD(\A!@B43$I1RX:\!QG! D)0-# E#L_\+N8)9/\
M+$<VCI-&BYJ"LDTU38GT@MPE:'()6WF*M.JD(?DDS,V*OH<D="R>INH]<DE#
ME1FE1BF M-:2!UJG35U0:8$+5J%F.D&"91U0=>'/A.7 "43@ZQTB!!$H(G $
MHZ8G+@><_P##?F"#!CSY^)K_ *^UNN&\ 8',Q*4<HD8EK*/(:'SYD$3(UX3
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M\9Z<)'@3.)RCRT@2!@B4 RCRW4,\Y^6(YC0H5 "2%F HB$CJ!2$P5F HJCH
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M4?B!^2@2C0Q2_P!794SPOAY2T@03.):F4$QRB9\4]./G CF8$3)X+_;N2/\
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M@8X3:6:Z:*=,<B>&G&O_ *.ZO_R[Y9']\#PCEXYP->(''_U>?R#P9?7AT<N
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MTG'D9090!.-)S@<C$HY1*47>YM[0RR+?-HJKM?GARVAY#@.7/A5TI;B?]_\
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M1Y^?F 028TB<N/.-/T;"#P$&<#X,M?/P'GX!R,'7CRX:1SCR.D>42U&H)CR
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M(TC3CRCE'EX?*!.)Q+AK^C0>#E$]/Q&D"#SX'GX^0\C.-1'D.'/A.7Z,1P'
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M2,2,=)CI,=)CICICICI@)$=(CI$=(B0B0B0B0B0B0@_AR>'. )#XTOA\^$H
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M96ZHMG==S<7+AE7;'#<NILJ.;Y&W?A5,F-L+A0;U,M>LJMLOY0+A@-"DYO\
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M5)@*HIR$.#*E8J9II  B0/&0@@$)IH2;G-=:A20:(2$B0G$@(  B0@) @@$
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M94?M+AC16\>,6=!-#+F"4M:=V=FIC=N16;OK0U52<W1U:W%J<5KO638&QIO
MNT+_ *B562ULP=IJVHLE4;T@)JJ-U4;'T0V<AK%5ZA:?XU58M::FI#A!#I)<
M*H,S072J#IK*ZD_;%2F^@F)5D=44$R,*F0E)!/ :<.9E&D3^. 3'2(Z1'2("
M1\$\/.#..?P>4><^&G@/AE/C+P<^!UX3@QYGAY1Y2$<X $2@@")?%\N?!Q/T
MKP)7+Q'@(/#R\7EX9:>42GP3SL?_ &SP'Y4#GX'] .&=OL[5%#(K72;4D96^
MH1CUK-Y2_P 48^B+^XLE>MD#B^+I8(@T*5->,U3F#-5"M9G60N:6/.;.XM]]
M:>CD+]+ZA_3+E$8ZZ%&@[>411N;"I<'&.42R<4ZB2C(R*B63.K0<6Y22W?@&
M@\IU?7QY Z"-+NGI5;NJI4II 2]3]/K+"V*)H6A)37J&DILLU#T)BI]$)JDP
ME,P4@QURB<XE*! $" (EK*)&)'X4C'1'1'1'2(Y<)Q.-?@2CEPD?%RXCP>7E
MXM/!RCRU^$9Q*?"7@EQ!CS\OIB7P)^$17_TKV)7/R^*(/'R@P((XSTXH_=8C
M.V\90?E0.?@4)IHNJ 5D3FFMM7LCBM7PZL@-'*TIHY524X<8C1-!ZF73EZ$*
MIMTU2ZQRBA%NN=%-1I<UK:NL2H)K5S2IE.14BUK,GE=Y5M[!NEO=V%-%$7EQ
M25;&Y?Q6M#5:"^JV^HFXK>FG9J12:1M:_P"6IE(:EX3;31-)[3E6JBO'\=.&
MRO2!JIDN@:RJ-,TCU)E5^J$42"G]OD4S*=!SA,X @B!],3\!F8"3$A'3'28E
M*)"  (GX9#Q:#AY2E^" '#7CIPG&I\9GPY\/.-?@2X\^(XSG $><M9<)1YQR
M\.G"MJB_B5U GQ.G$F?C$N!\ EP GPY^*GJNQ_\ ;N.L'Y4#GX#RR!_58W2S
M+7<:J;0VZ+NA=HKHR"NY+*QT7:7UAILQ0RBI222N]E>*("&%R_B8=WNFY0K&
MZCM3!K4L]9-W:E%TI+N51O9JS.HP=TC0NCA"Z%2UU:E6QGT@5"5WI*<5;305
M06CZD70 TJ%.J*S$#TU":7G4FK;Q. !)XF0;K4M2  E:9@U2A5(=0D(4>F$J
MG $^ 3J!!$&/*7@Y\9>$^'SX>?@UB9X\CPTX\H\HTCRE/PGQ^?X.<_!K\'R\
MB(E'/P\^(BJ/HR(2NWP!P\^)^/2_U;$9V_P'Y4#GX<@LZWURLS5=OJH=4E)R
M?_BUM+96;N+4M'VUU4C[-VUK5'&,I"04@IRE!%>RBHJNV0@4;U106_W%9->R
MT4&C6H(*+C66SKVE:G=1+6GTW"G]O%.YKJ%JT14IUF:$@7!5$TE*>G["F *A
M;G[SK@,PN$TO0(<B%#UH2U"(0L %4P:(5"!TQS"D]4)3* F$@#AK$XY? Y_
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M$*0 /4U'U1TB#(0)& F)^+SX:>'3P:<9Q+PSX3E$Q'5'5 ))TC3PB)^!6H^
MD3/PAPUX2@S ZHZHF(F/!/PC2.<'EX3PGXI<.<:1I!)*I&4&#%35&5B5WX2^
M ?AR^#C(_P"B\_ ?E=62##Q -.L]J4:MKI>HE="DI+RLIHML[J/%(944I<T0
MVA-U,Z#;[N*EO0F ]]&"X^Z@6Q)")M"7B2%-2Y--H6ZDN$ 5B*H# I-!72%K
M24U6YJEL@TC,2K)*HIT2A2>2N2D$E D(5K"$ZRX&.9UC24<OB3@:>*8CJCJ,
M3/A3S\&D^.O%0F/@)Y>"?PU<O!,QU&.J)CX<^.L<_!R\,N$H\B(EK"_VY:)7
M?E\">D"7X3'!TV;P'G\IQS\-70.*Z:@7:#54S_X:#5IR?-E.BS9J9K"DD/9*
MI_85?58D&E4ET/J*ZB[8@H(T#\?3034]2A]**OU(K*6E;,3$X=?0:"U+4E(Z
M:B=/5(53$Q(0I704*ZHY08G. !.0@3EX>7 ^(\-?',1U1.?P4\_#IX9G@H2/
MC EQU^!,\?.%<O@]1@*B?P.?A\^/EX//4P8(X5/VY<97?PS'P#^ '.P"5HX#
M@?E0.?AJ":6R3ZX3#],DTG"UU&R!T5:8*:KE5%;0FK!HTY."6YIO%5BAN@BI
M1"(^\(*$EQ!:)@5?2CUQ4C[0*A*/1CU4&%4_5*6XIE*A)<B/0U0)"%HZH2GI
M$HE"1$@0#QE\;SXD@1U1/XB><N/*-?!K$N*N7B'/R\,N.ACGP'@5\69@&?&?
MPI3^!Y0>?.%ZIS 2O'#6)&.42GQY\1I\&?P4Z*L/_:N&O _*@>)4+HA%4.$Q
M7_X@!@$J0KI26RB73-,V933@*28>H]6&[95):#--7]E2@LU&NB1S>(*H:)4"
M!%0 I^KKIB23RJDI-'6!"AHDDD""!+6!I&D2$XY<9<1\&?&8$3/QT\^/,\)^
M(CQI$^,_C*Y?&F1 (_"R@) A8^G,A_U?X9^*3PE $^ YV#_M7 <#\J!XE17
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M@T\_"/@*$_".<:?"\O"K\(%0/C:\2(E,9P@HNO&?@\N$Y? TE\)/.P"5LB?
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M&D<HT^50T\*O]*/*-8D(D(($2$=(B0G\ \)Z0)P9>,\H/+\D'/AI$_R%7/\
M)!XN?@S+_P".>#GQQRSKN+AI;Z#2G+0\N<>4HUC._P#6 G$O#0_UK,9MM>/+
MY5"//GQ5_I>#R^#R\$_#K\$_X*5S_)!S^#EXGCGB2@J5C;%#5GH(\NH2*D@F
MH@0IU0IBM=V=)&3W.G<7/BH_ZM@,V7*.7RL'+P$?Y7+PSE!5KU&#RG'G\(1/
MQ:<-.!_P4>?Y=EHGCL_!Y18J*:]P:H2BAI%SN]"W4W&;TE!>95#"\O<$5\B>
M5C5N;JJDDD^'SIZ5,:,[=PU^58\*O]+C+@J$B<&#R2?'(P.1U'"0EIXS'E.#
M_@H\_P E/P<J$\>\6/?]RH#_ "ZRPBGD#VO6N,'4\#IP(EP.G@1^[&!_TSAK
M\JQR\!_THG+P*Y3E!,R53A(X:QY<^'/PR@?LT^ >!_)AR_(SS_)?/X&3B=@C
MRG*)RXV:N*#YFL5&[E'71OK:K1?_  CP&AQD$6N)_*P>$_Z<3\!C2):].O@\
MI^'3@/V?"/Y,.7^$LD$[#X/*$**%8S<DNFIY7JP4K@FMAK[U484[,(P>H30P
M-K)&&6NG&4VFG;J\'C.?'&A*VZ<3\JAX3_I<#RB<$F748G(S$ F#Q/P!_IZ?
M"/Y,G\C\OR_(1.Q>.RW:LPK6]R7+:9$=*22E, ")"#K&; >GQ'@QO2W1I$OE
M6/"K_1U@\/,F4'6!(1I&D2\9U\(_9$R?$8\](//\E3S_ "(Z#\F'P;[K9( G
MQY<<7M)?.*%!#>E*<"/(ZCS'/-W%+X%@$F$""#\JQX3_ *4><$P28\N4&<3U
M$^*4SCH  2)="8-,P4D> ?L!E$YQY>(_X*)_)QR^!>1.S\C/7B)PD35C;.FW
M9>6L+<4Z<&Y-DE5Y;(%?)Z%,O,Q(IW"X5[C7X'B1 U-C$F?E$OE6/"K_ $HY
M\=(D)R$2$=(EIQ1()4HF.HPA4R5%)T4%"7%(^CX!C7\H!_(29#\G\O@74=5L
MGKX4?OM('\>8R&_(M]*MD-SK%5R>KA3MRJ"M:HU^ @?59O\ E8G'E\JAX5#_
M "N,XG!,X&D=4$B0,E1/5$C!03!0J$)Z869E)D:@!$3A(_R_@:?E0,_QYT@F
M?Y0(Y? ?CJ8J_=/PT_WVE:3;YB635JE2Z?" X4_]2S_\L3QY_*H>$S]+SX>9
M@@B-3&LY0F?$&4)J05B:J@D9DB"KJ'!/^GXS'*#^5 _C20()G^4CX+H=3:H)
M+\$C T5BERI.6I$XRRSU/66A5-4=*H2V<+BE9KE5#I@X9D"<<N/E%+_5LW_+
MSX&7RK'A/^EQEP(G$I&0B6H''RCG$^,N*?\ 3_- 91,?B9R@J/Y6/@UA.C7$
MJW@GPQU;E#II554IUF]*NEQB%OJ5:>)6Y)1C;!!I6YG1 0A,9PW0BEX#KPH?
MZUE/_#<?+Y4B)&!KQ,_2\1X>?%"9QT""@1Z>GIB#3@HEQ3^S\WZC'4(T^-+C
M,05""J)G\M3\%>J'0DZ\ Y@35A]NITF@  !B<&-2><&,[_Y3B>-'2K85=32.
M<<XE\JAX5?Z7AG'5'5'5 ,><(4$PHF768ZS!7'7!62.<3E"/V?!/YE,Q,QU&
M.J.J.H1U".H1U1U".J.HQU&)G\R'/X!A^)/N.DH1^[%O^2D(E!T@<O.8$+KT
MD#,[E0=(\5/_ %,;4%,3&L3'RK'A494N(CR,3UZ8Z3( QSX]>G ^%'[?@G_&
M(X#X%T'3<H\O+R@&1PVYA393]NF%W9JF*^0,Z05E3415S!L$N<O4HN<D<54J
M4I1X'P(_?B__ "'./*#I\JAX3_I>+D0J<=4Q./+A(F/3,=!CH4((/@1^WX)_
MQB(EK\"]#INW&>G"B[<-PI^\5!<5S!74(Y_ /%/[L5,[=Q.ORJ'A/^E!X>7+
MATS@ P4Z2/"<)3,_2 *@ ]01U@P"E4+0(E+A3_;!/#3P'@?\9#7X.0CIO?X4
M<\4_[:=>'E\JAX3_ *?#0\#SF93,"<=4=7#S1I"TF?'40DS!YPB?3X#Q/^-!
M ^!DPZ;]\0Z'X.+B5NX:P?E4/"?]+RXR@".D".D3Z1!3Q!D4J"HZ4F/3$>F(
M%,""0D<X\Z?+QF"?\9B!\#+$].1?'\HGX<;$F$>4'Y5#AY<#_IZQ(\=(Y\1.
M/+@-8"53(4(ZS *C!"@53XTSIXS_ (U3R\>9#IR2"!! $$2CR\1^!+2)1CXD
MRXS^50\)EZ?B)E'5,B)\#*$"94H)CKCIG!(2/4E!DL$$$0CX!_QJGX&;"62>
M(>,)4J"DI/B3J;$)-8$2U/RJ'"?$_P"G,^$P=8E()A6I&O!&A6F #"1(+F#%
M.<+YQ3^ >7^-$_ SH2R+PCQ PP957U>W8HBE3RFRIMZ_$C]]D_Y<<-(/RJ'A
M/^GP\N)$B53B8@S,#@#"5P2)%< A4= @R0"9F*?/QG_&J?@9\)7_ ,5!@X<"
MK;'-)/0OP80A*KB)RS*DA;,\)^"F)KLDO0GP,'Y5#AKP\S_IQY\?.4XZ8*1$
MM>'G*<!$="C'2H1-0!)@\YQ3Y^,_XU3\#<%)%Z\%*@NO4LN))K(:V)BU2JU,
MEIN.--J].ZV&NP5PP8 W!,9?(L3S\-+6K9#.A\K1 \!_TYB-.,^'49\AU:A1
MX@3,D@%:1 J""L02DPJG$I<*7[O&?\:IY^/<42N_EP ).)V$$)"4I'*7!\QI
M/:-^LU2VUXPM90_UC+Q_P'BH_P"K8C.AY1I!^50X>7 _Z<3B7@5!,)$'F.4(
M,+G+C,Q3),5!(Q2_=XS_ (U'/Q[CI_ZC+0B7"V-5.W;&@ENW,3 "5!0E$XN]
MKI/Z%RM]1@YPS_GIB,LI]=O\5+_4QTE360XGE\J1SCRX?_\ /P3GP(!CI$Q!
M$X&D2@&12H&"E)@TX]/7TA&B(49F*/[_ !G_ !J.?CW''_$\""(PUHJI<TR
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M,B&)T:+)AL9I\-7D[.KU4H?KF7QD7YF7JH?C1[S<P\,X>IT><W@F72>J'E,
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MH$T$B="8(,BLS3%><5!HXIB'H'4[2"EZF'2)EV)15Y.%=0<2 K S=3FY,5E
M4W920\"8?)24OT_2\!(N<HN:!%U(E?DDJO\ 2D,A3*+K33UVD3N'8P@([./T
M7;U$?^2V-%13:$S3;]"QFE+,&&Q,-Q**2I"DL3I:FD  G5-! ,4IB*!AN)%L
MDJB@!)F  WHA2: (-%,X D"1TJ!(J:PZ3TEU4F7BM7AT="'0F7:8< B',Q%<
M&*Y,.1H[09N$E2':/I>@B'AU?CZ7LA%SIQ=% 1=9&+X0%9&M,9&F<71)IKLP
M*KCV/IZ.S[]%V] '_DKC>B;*J<,0"68F&:@(HC5NOIBB%10"1%#G0)@32F@9
M&GK%#DV&K82BB 89B<-B>FBJ&\I)((4F0BL!)T#-X@]3D2#WDX5)+DP[U#H=
M(<_5#@!*' D7),.E#JK:)>'1\)AXF'Q^E[^VXK)%UIZ742%\F%9#(G)" +MT
M$V,I%Q[(TJ1V@_HNWG2$=R>. !%G/U6W4M!#)(G2J250F31,A12#%(2B@#"5
M:4@(H&<4$@Q0  :K!%+DRF V49(I]2:">D)2%0I$TE( J\W:NE3O4.TD!T)P
M]$H< 0Z^F'*9PZT#F936_<Z!,.AK6_TW1T>RD^$TO@ AXD2N,HNAG%U3(7X=
M47VD%G)$I!NJ$BI:$J#_ ++@4]I'Z+MZR?\ R3QL?1:.@BVB9:+!AJ20T3JV
M!BBGJ-&0%+4TN02 :,NEOS;Z0W ,-:1G1 AM+IH ]+=)":(ZHIIA?[0F1<H2
M [ *G7)X0(>$=3S]SE.KN'9AQ.583%5/U.S(.DS-9)D[Y.Y2=_M>I2H7$2BX
M<KK3BZB47X$C(!*,A,U7F0J6-"5ONS$2[3/T7;]:]TF-E/1:4"5O41#"1#52
M2EJ/JH@)--1G02(I*^JA"3U&E.*($4.3>0#6H8HI*H9HZ8IJ$J"^I--,@@"4
M*^F*Q*BZ3,NP>EXDD/!J\TAP)0\F0YY.9D5M!6("GFH<S,5D!(=)E#Q(4'0^
MEXG1ZF:KDCZKH2HW><7Q9C(M1?0D1>$BJJP_Y;_M&E_XM_HNW_G_ .4F-!/I
M6=)E;P##)/TLQ)+9)AO,Q23,T3%%),4Y]% 3*$_30!$-YQ00HPV!3#8RAH 8
MI)G#>G(( Z*84.%0DBJ"F'"I%P1)\25/) ODE0<PZF(<G1P016,50"IT-'1,
M5U P^4).P0EVJ0=F8>D]5TBY(TNZ%RO=,RR&FH"_$&'R)5++1/\ (=H__P"E
MO]%W<)333[IL:F$V@21;TPRG-KJIK*5$?703((,-TGI3](HJZ8II411$@W/4
M6Q,-T@11250U3T"@910((HD]7 B8<:0\3-%<P]A[.;K5+K0O1#A(*:Z9&N@$
M5ST*KK!#E,TU@"' 3)V!TO4CI<Z!^D3NB.E5T)$7=14+X9IR)*R+_22(NE7I
M78:B2^[2!+M<_1=W"$#NIQLD"RS*;=-,,I=+, PU!$49]5%1G3 DW^F!%%()
MIS*:0D&R1#?2&RYK;Z%N9FE(10T%&4ARD9*U%=,.3--<B'J9P\)*G(!2[(,.
MM(KK(57YU1,NDZU40Z^D5I$.!U0[D [(D]&CR95<0#%W3%X!(O*9)R#I";\1
M.[4O\S':,[EVECI[7_T7=QB33[J\:4"BQDIBV_4&"=6HFIJGJ2VBD $I&M)?
M5%-)(HC2B!)&H;33%#5+1 !H_7#:1BD.HT4](IB< 1J(.@K:ATD=-<:/$JAX
MB'('2ZZ0'NL5]"X$A6)ZG (+G53A(5#A&KH%)=B8=(AYH7\IOTF+NH1=I!-[
M/4,BI]0OJ9&\"=7'D#[_ +34*I]L/Z+NXXC_ ,L\:0E2;.F88)Z R$@T2!#8
M$!JJ1HDJ"$:41(TM12'TT$&5)/U4 06QG% ";61#:GK0'2JC**(F8U/!PF*X
M"@[1TP]'5#W2'JH<RDZAX!#A4H<$=3F94Y*@5)ZDNM(<D$N1.'4X>#5]+JN"
MC*[25%VIDQ?D=*<A2KIR %,78]53&TC^1[5Q+MI_1=W'R5W9XJ#%I21%N'53
M9 DM>;4F&Z"(H\J0!31*>JB?J1I#91(0H]38F374-P0IM(!J8I J50G%'0)G
M,I( UAQRK:!R 4N"8?B<.I]+L=)<*AV 2Z$5Q(N@ MT 8JD)+P@PX29N@J;J
M</$F'M,]5Q$HNNHNA 3?"DT\A44B_P!1*S=D2J8VB5R[61+MJ_1=W(31W;8S
M40(M9"S:J9*6-,0U2!#;G045)H)F*74313TQ12812)B@)0WII)HA$-QHW08;
M)(B@!#8:T$Z450B4NA*DKIE(JZBLB<5](>:%Z2(=J$G)!+N14Z"IND:.9 NN
M;J*Z=7*='1!4]2!#I,B[6(N47$#IN291>$!(OJ0*>1(*DWZD0JZB2L=_[CVL
M?_II_1=W*:=V&-TP4VBD0+4LI%OF0V&C4"*$@EN1#?\ <E/4&ROJIJZ8I*G%
M$]);H!- B;8:-90V2"6J)Q24H&F@  !$)ZA%0+ K$!-8=,.)PZ ,/4RAV0(=
M@ .04EP)ARHA+@$PZ3)+C6*ZNHN1]+T2+D+,/!*'B?JN""I%Q02+BF<7E("K
M^1TY"E2DWY(B[DA6.D&Y=KX [</T7=S5%-'NXQH?19E&5O$RPG)H/I; PW$Q
M0D"W DW$Q30$JHH5U4A)3<3-($Q0IF;:<FVH:),VHG%+2$2(E.$DR4217Y54
M&'*2@O"J;T$AZ@P[3]+P?36)FX$BX7.*\I.0.FN!ZCF:0[$X=F1?_N?(G#Y2
MDBX:BZ)5*YHJ$WRDHQD$^F])D;O+JQT3N?;31]#MX_1=W1=/_F!C$RFS#I4P
M*2FWH IM)*+>?53UBB(:B0IC5.JJ'[4HDF@H M5!4-X:"<-D3AM4 AFJ<-T0
MA/3%%,XZ4Q40(JTP8< B'?U+>2D\(AXH%+KHAU*'23-V8KB*VL.)%#S0.5'I
M> D.TRAX3U7"?5<AH_(2BYJ$KNHI%\4KIOR9QD"0M=YI=)QT%5R[<A+M_P#T
M7=T)'_E[C!2E%F'66"2#;U*DSZ &J>HT4:T00&X)30,BA *J0(%!04*=-,-P
M 6Y!+40U!BA3F6>@; J"1,TDZ#I(JI,53(N 8="2WH ATE4.SJ]AV#TNC(.)
M*%<@&J/JK) #J4W 2 ZF4NP9O3J_YW%0(N$BFZ(DBZI^F[:F_I3*^I"57;5>
M/IZ;IVY3_P#'_P#1=W/()[O\<_;9IA%N5-+(Z,U$AHHQ0$S12!%$)A"=::@D
MTOJ301TQ2'4F@D2H($FX2(;RZF\Q#4B*)/31F5(0F01%58E629UPH0[3]3U(
MF^6!#OZB]"3#I4@X4%%P"8JI(BMTB*LBIVD16D0XZ9.PDI?I$WZ0H/D"3] E
M=R4INLU"\) .0\[^"HW687C 0FZ]NO\ _0']%W=#56.[[&RJ5D3U)MJDIAB$
MR::*8@%-$'JH]1%%) H "$("DT4$0A)ANG1K2 B@(;\FIDJ@"8:(DEL=*9 A
M*RD!962"#6_:X)5#D&;I))>TB2[24J=),WJ1#CZ%N-#7,5PI0<!0+A),./I+
M@32Z29/J<P]2 'H3T/D2-VZ5BZB47KGD%,!-_J?7=@34QJBC^1[>2#L+^B[N
MG2D=XN.+FBS553MB0H,I!#/FS(26HZC1DE=$ Q13.*,@FF1U4]0W$E4!(-TZ
M49 M:8!:* -*4J* $TZ:1"9E10 DE(BHGJ363TET/J<:*?*^I\)P[61#N9+R
M''U)K2$50 *JATN?K#H:U^3Z<G95TO$]2+A,!_J+LF+J#TW=)GD<Y7^G(W=6
MN.*)N>PU-%+9#]%W=7TI[Q\8'TV1 $6Q>EO2DPT3*&R2HM"J&P!51&E :4:0
MBD 54"$FC*=&4J8(#9$RW2J;=($-TDB@/IIIG":2029!8"X42 YD8<!<W2E(
M+M0(? JAVA1+F4G253JI #G055'JJIU<I2E+HS+H)3#M(5#I(*'23)ZCZ;@4
M@7.01=DDQ>$@1D) 5DB H70?YF+TPJ[;%R&ROZ+NZH@]Y.*KDBT3E;0!# $P
MR,TMC%)<H;5(HK)+9!F5]$-Y&*(!520!%&44-"UGU45@EN@J-#Z303TD3F@5
M(Z)BHCI"P)5M8=("3<4 PYI$I=S27>@<D*57ETN"D%SU$UIR<*(BJN<.I17*
M2ER 2]*DIKD]-P"C#ZDHF[33%T5I?$=49&"I60@A%RI KQOI%RV00:>S/#J2
M#^BONP0I/>3BHG3LBI!B4E%M_:SY-@.EMK#9)*J(E#>K(J_S%-TD1329T?VM
MT@FC*;0 EK3 +4@%O*=(A4)F(IF<+*P5)4L5:93#A $/@9/I=+M4X?Z)>?4E
MU0"(< "'(BJCJBNDI%>D8<4P5.42ATOI+D3AVB'<H>3!N/5U73ZA=4I$7WZ8
MR% (OR%=-WIK"\6I*5<]F$E&T#QXUM[3NS]RS,K_ '6^;H;WW*\X#[AO>3M<
M=M?>PHBMM?[BO:-NK5MEWM-Z;?$W%[I]K]O;C;._3!:[G#M^MJ,YIH6BHCYW
M;@[S;;;7AOWT;!U7F'[H;>9_1^%D.06C%;+N;W@;@9,]I;]]Q-G>XIW];BVA
M6'][>R63U*F^&SE&@X[D=B6T+[J-@4(<]Y&P3<5.]G8])J]\NT BMWV[?B*W
M?OC*!5[[C4#COKR+KJ=\.;F''>ONBM*^\C>NLBKW9;[UT+[J-_UH1W)[^/(7
MOMOI5C_>#?"L#N;O+5%/,MU7!1?=P:T%YE]:%T\A<QO$VJM-_P#%EE*++5D+
M0GK%N 3#9*@&2DE- #J;3BBDRI $T1K0&E$ZT*<HHB*  +?Z8;F:6PZBT(1#
M?ZBD$E"9"#I%?ZPZ!!=R*7JJ<G20J'],I#NG(.P8<( #M,HJ),5IF'8(BN!-
MR-7@$W&A=I)AZ.F'W40\()NQ3.[#ZKV08OY*8R*JLQ=E"5DK+%PMN;[JL;?=
M]R]Y7=O*Z5"FLTJBG+>BL5+(WK0\PMH\&%Y'O%M.YL_NA=]6&6RC[S/>:T+#
MWM>Y^BEI[YF^U(L/?/W"5%M]\:X5A;?>MQRO%M]X_;1X;=[MNQKP,?=-[;G2
M6?N0]L[L[X]Z^,9MC5C8MZZ:=A85D.<"9E5@O.ZF KQSO)W9QY>*]X^S5]-E
MR/'\C;_$W)[CL V[6KOYQYH^P?N8V9SU-.I3JH^9JE)2G<OO#P[$GE+W ]P6
M#W ^^79'+HM%[LV0,?@=S>_5+9O&GS]U?W=3'63H'$:S*MB_<%W';=C#O<-]
M(O/<1VF0H^XA8:JG7?\ 7NJFOWV;KJBOWL;[/$+[L^Y%S%7N3[F7ZWF\7<$X
MJ7/*MS,H;%E7$(I5$PELSK0XQ=DZ2ZV_I5$5,+N;,44U&2VE2R.U,;&QK)H8
MXS0$8^VZJEB;=5*V4TQ0M%$+7::'4+-3DBU4EPBT4TQ3M3<A%DIH6FV4S%"W
M4DPE@E*J;.D44VR!%)F(;L4 ]PRZB>YC&#,65!7%I/TLC*&2PL-!TPVUB@@A
M-!,XHI A">D43(-Q]5"9- 3-!$X;('0UIS2T0H+;\J,@: !'!0FD_1#H32YY
MOD)3#D@!\KJ+U8,.TF'"=':2J*P2D54S4X2)US-5<$+>A/4[1.')(4\$/P##
M^GTQ=T]:;ND@7I/TWNF <C  NZOKM52G3=VIFA-G>-@J']LI*4]M9IJJ?<T3
M0N*1#9RA2J(H*15MK1PAGAC.K5I;0VQ^A7;8R<TW7;E?695M@_MM6W832,6[
M VZTL-O:2E,=N6G5;MLZ"UVO RQJ,6-=G%!TNBEM<PLT*C:LA=N95X=XE;7*
M*VW]5FX=4]]K8MWNCW26 ,>ZGN4MI9]Y7<>A3+O?W_H"CW\[P)+?W!<NH(:>
MX<W7#3W!]OR&O?SLA7##O<[>7JMZN[O$;GC5O^W4BM9K>^0]P-A6./9'O!MS
M5Q'ODS^R5<.[M]B<P0T=M'[;YE=Y6^SC'ZK&K1Z*K5LXBX87;K@FSV?+\%N&
M&]Z&_P!AJ_\ ]QG:%LR>>Y!C-47'W!<X<H>=\F_K]3WNO[F;@MYO-W#W@5LD
MW<NR:UBN+URNR/*"$5';2&UP0L(11<"I8FCE#C +>X-7;RK2)L]\8K%WJ-C:
MKQ9GJTM:=5-"WTY_QM,J5;4FI_%HIPJW(4:]AF%TGS9;1\DE%6@LJL[)VA[@
MC1V:N'7JVU*=YR&UH896P=(I/VKF*--"@EM3$&E024@+%*B(-+J(0*<4 )5$
M@111%+IJ%+0@4J*>H4"(Z>B.XU4^YK$QTHLRB$V@'I8IZDL1T!H@R: 3IK$-
MYRI!0B@282=6ZA.BDB* E%!.E $0V*A#8A5-LGI-*EI1F!QK("DN!]#Q!ZWL
ME%TF0?(!AU24"Y28<TIAR"F'")BHF1=)*35IS2Y Z*R$K+PRAR"5ONCJN"8N
M"P3<R0+H9F])ZQD8D,C"S2N:%+59Z 2]L%]IU+-6<-JH> $NTF3FBD"K;Z:E
M./7:J9W>LA+2[HJ&R.D+5C56@I./MF[A-AQ=F[4-HK#<&]_[;L=JHN&RM_LJ
MVEOJ6Y=MM[.N&ELH(!;I!HMZ:TK;H*EV\TX35KT8HW2HDT+TD&C=Z*R:[:M#
MAHS<BZ8#;GZ;IM 0:^+Y':%M+DWI5*;5D['\'0A6.T*D(Q5FI(PYGUT,<H-R
MFE6;AO<:Z5L[BA4&O05!8M'47/#K:\39K)E6$U<;[L-^\02?<?\ XHVKW+=D
MGHM/?AVV746CN>[?KVFU9KAU\2%!0^8.1YMAV'M\I[XMA<>7NCGUTW*W5:9'
M7HEADB*H97FG430JT:B:=O;.D7+!;;<4O]K5,U4TW>QKMUTM+V&C2@109IFA
ME3$(MZ%+7:T+A5F;U0_Q5NL5K9<[>JA>*M(-+PCKHO:-6$TJ%9-?'&+JG>-K
MVCB"WRW'$6O.6U5;1ZU=)303*K235(H=12V4B%6RFI3W'Z%6*ULN#15.[U6J
MF=^2N$NJ#A)MK5TA[AS)PAQ@#YBID_R6T*99PQ<EL];5H0L3!-("1A?*@L@)
MYH&@2FC%"JHQ35-=%4D] J([DJ*:'=!B]25.PGJ%J48MRB5-N38E0H3"6\X;
M5$RHJG"%$Q1^F*"DSH*430*>FC*3,A2Z"8;4TF&X'51(A*0!QJ?MJ)BX),/$
MA(KIG#Q,X=@3=)F7((BO3)+FE,5J/0JNF<.@8K]4WM(2<(G#]$BZI_4_2F=V
MII"[DB:;E1UO2>F+Y(JR8 (N2RE5MKK#IIC;:K:;EB+BDE[3OML6N_-ZD+<4
M:X6A)*T(45,DJ2TL+BI%@M3RFFP-'=*,9N%9L<0O5)*K=?*-1O0=T7$5+>V<
M&ZX':;O%SV;0WK.\?R>RQ0R+TJK>ZT')I*"R"(53"X0SI]56VA9<-G3=5.[.
MFY9Y F&5\I$4GC>L*]I:.XN6 6JX(NFU)I!Q:LLLR6N3T*-6C<FCHTE)( 0L
M&DD)2R0L5&BZ4%;M!;WBM3BG?4JBC<J=:/2:.$W'%K8\1D.R5N=JN6W-ZL=0
MV1C5J_TP4"U97NQC";!WC]TN)JQSW,\U9#$/<:V*OL85O=M%N*CY=;A;_P"T
M.UXSSW$ZJJ^4]SO<'GBJEEN-X<-<2HTPWQNB$U\/9.H>;=+I1587RTU;;D51
M*K?DM-<-;TBJ:=2A70XL3)VFZ[<MG*JF.919%L,P^U5;[JPN 091+H--*%0M
MNBH1;*-077$6SU5PQ.]VU5&_UFAM>34:D,KO16J@]I54JM;=T+E@C!XA]@5X
MM"FN3WYE2M-]MMP0A:"436I*4I-5*3"F@(N..-7]-[BUT810N[EHMID:%HM]
MZ0I5-U2JC^-9.4/<+8. [PAY06N[Y+8Q:,QMUQ10>(4FDI*XZ1U(0HPB:8"9
MBBOIBD$*122"H+DCND)1W4XFLRL"DA-IZ5(9)Z4LR.AHM,FR3)L@@T$S-/Z(
MH2BD"N*"  V!!HI"H;(D&Q #7DR *6Z"54:?4? 0"*LD%V2J'J='.D.1#U(F
M[1I7HE(KIBO2(BO2D7  BNF:G:)0Y1#LS#RFJ3^+A^ZY$]5R)5%TE%[*99$J
M1R1<A=:@"[6OJ=6KH%N52I5X<6%LZ3<MLV5SK,NW6H\3<>VW.VJ;U@F36*O:
M+%4*[-C05%GQ-$K7B16;7A1*K7B%1L$JN# MLJ716SR<5BPO5)4??4*L!@Q=
M"_;?V^X)NFU#AH%-\KLJVF3L%K#Q"PBM J$#H2LUV3>N']F)41<F,-<I536P
MR@%#:_4U0E[0K*_CV;H7G +;=(N6TR&L.V64V*HTR=LLTWHJQ16"GJ3UIH(K
M!5MI*+VUJ*E5[BSJ-+^L&WWNE5/\@WJHKVQD_IW?;.T/T7?;2Y6]52HZM=6G
M]@]2ZL3>HFOBE)</<5+5>(=P'<)MJG"/<\W L]7;+O;[=-SS2JTZU/Y9U:M.
MC3W@[Y-L]O7&?]TV^>Z"Z-KI&HUM[4J;L$HABTD:;= %.B)IH 0WH)J1484*
MT7C;^VO4.\2O=KJ-KVY;&TY-]5NO=*H*#VE5A=*C5BZXBQN%"YX Y:5D9A>L
M?JV3*++D#<#I"5A0;K4(I@*4I%-<7K";3=A<=M[HQBB[N=OKVO(4H3;,AIU(
M;W&FN$TJ+FF\QMDX3?\ ;] KN+AD^-IQW/K/<5(KA<)J=1H#ICH3U"BE8N.,
M,+DFZX&_;057*U56F2SAADTX:7JG72UKT*H>VID^3>L#9N:9&38XNU;C6]:T
M/6]>DWJCH0H%1JZH^N*:28H)Z(04='=154GNMQ)P%"Q*BTK"8MQ*X9ID&@Z2
MTJS-'44DE444$Q00 EN!U!73%"4F_P!2FU,F&B1.A(PR21#8IDW)/A,Y.*.C
MA&CNFE0=T?J=ID7=-4W%,IBLA1#FD#%9$P]D8<:Q52.FN)*>P\007RR4/%&=
MQ3]=R;HZ+H@2N8Z8N_2#D:03D=(%-Y**:K=5]9Q:7BZ%NHO0HT*X4G'&(=.<
M'Q^A5IV'";:&N:;-X]?J&:]L#2W5*.*NK%7QNRLGA86!NVAFWHTR%J2L&E42
MYL;&O#NP/6T4+T^85&66I(89*A2&%ZIUDBJW<AU8V3I.0;86I^+EM]?;&NIE
M%VM#FU95;+HE#E(%*L5$%*XJ(I*#G'F+HO;$_;*4_N3%=ORA)AGD2 &V14BF
MBXHN0XMC-VG(=N[>_3<,&O=F"LNN%GJ6C)+7>$MW2:0^X"H*Q-=)O42[L;.K
M3KVQ^U70O+AFIAD5-:6-WI5 4M7@NV(6U_3R#:)=.O7MV0V$T;FR<HK-Z5=+
MJV(4']DHF+GAU"LK;O?S?;9.MLS[HF(WESCN26#+K/\ +#>3?'!]DK'O)W+[
MH;RU6-FIH79L7:KHW/!Z#@/<4O%JJT<K>VJI9LKLETALKU4MZ84>A(30"T0A
M0*&YT6SH5!<\2MMR1=-LWK,!Q=K54MF55!4MV0(KAI<*:T.*S5:;Q96KY-ZV
M]6WJ--PLVQBIC&>X]DHH5$J32J+2M2PA*/\ -0@R5<+!;+JB];;5:9J4[[9*
MMHRDI%NRGJ+._4X=OVE87%DV>HR' &ST+=9GAZ\>W4M+\MW=*M30I7537TPF
MH ?H"7EG8W&E>-L::TOK5?[$JV9-6I5+;D2?399%2,*O%"I#^@V=)NN+LWB7
M%CRC':EDW6<,HLN16>]T?408I D404*"E FLE".[&K__ '78@H]..U1%H63%
ML7(,ES#98AH 8;+"$H*IT%*Z*)64M@0H%)#='TM0*:FU0DMTS+9"9T!]+1)4
M*20$>&JCK2[ICI<_0'BU2=]14XY.QU%Q3)APF4/)2< JBM2$WJ?3BMJIXDJA
MP(==)-P1*'X BY+ 1==$W<!8OR.DY"K3(IF+Z 56M?IU;=6HU[2NLBE#*Z4D
M4\0N:?N, ?4^IC=T(;5;Q1E=:C9VF]8C;;E3O>V3EG6H9;F^,18]R,9O!;/J
M:TI<&HM%0A--SI5;,W8N.(TE*J-[S:XMN65Z:FF7@!GE*5)3>T5P[=-7";YC
M[&X'(-KFM554YYA]>R[KV=R6MVI54!P:L-JA3'J)J179M*J7V&-ZX<V>]VJ*
M&05FZK5F$X8Y-U+I7FE4#RLU<HO>.6]^C(MK4^NC(L]QBI8]T,?N*T.Z;A%-
M1(*R"I5-2'-I:.D.[!7;Q2>W%@;9DZT%C?J58)KMG27]D9OT7[:VWNTWS'\B
ML%2AD+6LNL:-85V8E=K8A</[)2JG:;?G=OMYO7:SWT[=]Q=;Y7;_ &_E@V0Q
MO)KWD>X634J%&BD.Z!?6^\!*:=S0M+QVWJF[V9G<$W/;^BJ&-VS_ !)5AWEL
MM8L;K;[I0I("D(5TP>H);Z@36$S3#VUVZXM[OME0J&LSO]@K4<J70IMLRIU2
MTO:',)]*O%RQEH\3D&VE.H6669QAM7&=Q\>R0)JBI"*BTI02F$J)":"(<VUF
M\1=ML6KF'=@R"P5OZHJ4$TLS/5;\BIN44WE&L'-J:/*=\V^8/44[;F>(U,9W
M9:UJK1^TN*4R"@N<4%(DI29N&;=U2NNV-H?FYXA?K'"+PX; 9BA*F62FNEF_
MIU$H0W<"Z8LQN ?X$YME:V9[D-C79,GM-YH4J@$57  >OS1I=S=Q17[IL1K
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MLE;;(L;5:LB9OQ3*%A*22E$PM"IT&\J::!6JZ8S;KD7F%W)I6;W-_;:MJRM
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MLAIU!0<-W-%W:F;A&<[26B]4GV(9?@;JSYW;WU=J\0M=.J"2KK!/22E*T=(
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MWKMCO.4(O5;/MI'&,YG:\F:,33JH732%*2A)4Y3.DM"XK@32A"$E2U"D]JH
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M"0*> GII[?A8H[?J"D[?A51.W*2JG@E"5+!:$Z6$MZ2CB%"H58?2IH1C%"G
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M?T%4)3@=2:L J IP"L5*P6HHHV^)-3;T@U, J)","4(_H(@_[?+64[=K2?\
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M[">X]2A6R?N44X5M![F*(J[8^YXW2RQ#W/+=0-H]SJF*37W-*8)]S!$%U[F
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MN\?NUJNC2LVW KTW#:WVQU2=8>XI*M=T*/M+A2K*>81(1TI*;V"E=B7474I
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MK[31K-KM8V;II6O3VQ.L<<N;[7H8U;DT;EZN..F^45WQM]CH.$UK6BWPWO\
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M*CW**/J[!A(,)D"OFD$A7-0,PHQ,2GJE1)2(5S)(/3*.4#4*3*-2"I,:2!2
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MJ%:PN%0N%0J%:PJ%PKFN%PO2%Z0J%B%&%PJ%0J4+A<>XO2-38!)T"I%$3,B
M3-2H/[9")" "DD&!(P HP#,$R$^B"2J .D% D9!/2.E$@%2(,PD+!,=/U?\
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MA4+A9A4*C>03P/<P%&?A4PDR3+J)T 4$A1ZH F2 D'J)UZ4F<2,A,0G0J$X
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MFL8V)[==WMPL[.Q.1L>Z[-63I_CEDV(R]E=>U?:ZZ[:X'A^R>8M\HV#VCO\
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MZ@1TF@?\WL2I$=O=]1(9 $KC*D]!R%505/[9A155^4_N:4TU.R7 E)31QI0
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M;D;7M_MA8QCFWP($)"9!:D&E7)4WIZT L(13I6YIF5R'3D]P**?>;N<&%O\
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M?8URO'\DVMVWL.VF,Y19T7_';'[:J,:[D,;9U&%G3*-\A_[0MB>I@D=,)FJ
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MFS_;QL_MVW3"9QN0)X-ME5']#I6E4!28 "BE9IJ=5C]INBX"6^$M$9![D?\
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M[YLOG7M6@'N/H:M_?ZL-.Z;5$&)],=0E,*A'[@2J+<>M_LTOJ[4,DJJ5&53
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M1DKL]R&HE*<JJ>HG)4J*O939*=>Z!\J??C0D7W!B2G%$E&560J4+2@*C&/\
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M_HD>PI[HR]J'S%T#VI]3== W'DW4J6,W:LL-)#VA2LVK,+;C^$*6JT<S*?0
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M,0 IFWO8H^([U$7B^Y&2-F#L"A9N.7*C=N0!)1E'P@+R;DWB_2HW)$5"-ZA
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M'<Z!CTJ)ET(1C1EF=$3JB61":6#!-LOC78;9?$&,<T"O.T\/$ A?OQ((JO\
M;H0)BCK #TE9I1+!>6''4GD""JJUH+1:5PLHSN3#R'4I68G-5J54=1,F Z#3
MO0AJ(1D1V(QM6H@GL4_J&G+QCP"E9N@@QZ<1:LQ)?J=1U,CX3P(0&JMB1]B:
MW9B#[%*YH (LYX(V-3$GK; &)H5;U\F:" "(< +[P7WPOOA0UD9 F)?#S;TF
M=??"EH<_W2H@RX='4K=W25$SL0TDXYHFJA"=GQ !]V_W*U<^G6\ES-7=^Q>5
M]/OFW$="-O5:F4@5GG4GT%BJ\NRO1_!\"GQJGV&.W1/@W(-@^%\=,"K\>L\V
M0NP#Y+<S]C(FH\2%NZ[-Q6<*5F!H"A:N%W4;LH@N$\?#2B\F<Z=J\S>X1NL*
M+Y:XQ]JS6P[A>884="S=EE"G:LS!<(F()#H7;F["=V(H2HL#O^*MYM^4*,K+
MAWW+,#5_BOZM6 WJ[>A$.(D[E*4)F+'AVH:?5>)Z57FFV'WHZ/1G*W!?+ZF5
M)+S^)JO.AP620HZ\ZW0E9I[@A:=B*+^G4IF1,J(@%&F&5.=JN+<A7"@)3$*<
MI!I J7F;B*I['W5$2^^0IB;,05X&("!!"#,A'I6DN;Q"?Q60"BE&\&B").=U
M"HVXQC;$0 2S;EDGJ( ]H7_VUV,^PHV;T1('I1^H6(M&Y(T'#".GLQ)S'@H:
MW6Q$S)BTMX66V!"(37+\(]I":.H@?^()[<A(=2N0C; N$4*N:&Z"T3O0GJ;D
M82$CO+4JB--=C,CH.'EZJ]&!/25__:A[TQU,/>O_ .S'WHPT%T7#'>R<[EY6
MKO",DYU(^S]J\_0W,UN3!U;O#]Z(*C=9S %2B>!; 1'%?[E=CXXG>W!2OSW1
M#JYIX2>V#0<,:\A7"O*/M-@^Q=CTP^!384VJX4VF'(,J;-YOX2M0.OFRO^8:
M^6P]I"\V WE"=S@O)B:[D=1:B^8J,Y@A1@9"@0^7.X%"G%#S!5E<E$,6*+DB
MJ%NZ25YC51T\"P0L7"XD>E"]*()-491&5EY<KGA?I0NRJ]5YX&Y"P&+)@Q++
M.U%DO4HKEFS-S($>]2\N)()="[<\+'C191(>]?,QJ&43$;BHQEO4O+3<4,R)
MBI.LO!9BLH6].RHG5=AL6PJJ[+XBS'>4-9J@")C<>"\ZP (]"$=-X1Q;BC"T
M:D%'3RG2J&J)K'=O6:X7BW6C9M;EFG]Y W$!T*&I.^,OCA+67R(L-ZG]/T!$
MQ4.$;IG(/T2*AI=1(F!XDJ&JC43#J,R*Q<HVQTLA]2U<69B'&]$EH1B/8I:'
M0M/K",Q=G!^@D(7//F6_$5;^E:ZD9?O%1O6SFC)2^L68^(RJP1%BY*'865^%
M^<I96-2B1T*,;$R&<4)5;DO>5]^7O*^_+WE7I7R2)14NP]RG;C(^&1&]?>/O
M4+X-01WK33!<Y ZO0(=H2[E?M2X3D/M.%NQ:WY@?8ZM6H1RO$/VJYF-;D2!V
MLIWKDG)D>_TE\:;%-DCI@WV'"J;D'3I\&3XOM4P;"JHK@ZBM2.OFRMPM_OAC
MWH&8'N4O+IV($R+9E"[=JX1NVVHO+B68LO)GXBR\[(W%>5$LRE8)%0R\VV*&
MJ$[H9>0]4=19#H7)@ABHPE(.I>0?<LO%^A0%W>RE*.]3$G%2O*N.0W%9FX(V
MH%@HQD:2("C=F 7 *)M,*<$^<LZ\RX,Q1NB+,O*MF@7R]T[UG&YUY8X+)+BO
M-AQ7F365Z+-"JJ$Q5,']"L>;]W-5U;%EF;@FXIBBRS<41=4K8W,491'%08((
M=H6H%L/D((3J?TBW-KDHN C=G4R+E.5"['>"%H[QXP'P4C+@Z&B9Q*9[U9TH
M#&,0%*/T\9IEPW:I7[EN1,B3O/2O\(K_  BA?M6R#$K3#5!IB-75R,AN+_8K
MMOH)5R\WWX? H@]!5VV?W)D8NAJ6WAE*1W,5JX/03.%%\E*3^7$*Y;Z8D?8I
MD!A.4C]N$/J-R+P!:NY"(I&*E]'M2I;D[CC5.?T)10'3'!L7QJFV:8-R-$$Z
M?&8ZEJQT2YLM+FH"3W%>3G%$96R[A  <5"S>HP4H6BY1+'>CYSLW%%NA2R[G
M4(EZD*$YQ!H$]JE."K*CI[U5<O6@S!T80- 4-/=J3TH:@1&]UY$#E9?+W)."
MOF+0?-5>?<#4XKR2W1O7GV _%1,XTB74+-R3, $?(+TX(PRE2C=+=JF(&K%2
MS*)&Y'I1940S<$<JH4TDX5$Q3IALUP?"O(QNPWQ*&CU#-$;RA:$08GC1"<8T
M(WKS! R1U!MD <&0LVK<HY36A7ESC('I8J1FY!/05G!-"LI*9U?NW-\XJ1'
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M_''O"LD;I1B?L6HTT-]R'Q1B53"-MGXJ$.B(5NW_  %0OVRQ!!^U0LSF,]L
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MDP&Y4H4ZR&A1CQ5$\DR<<A7DWVF&,(RW$U5 -WP1C*H!*>WTJ$STCO6EMQD
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M\LV%<9M_">Y:D],Y=_-E:RFDSE/M0N3%>Q'RJ(2S%G4;\X@DHZC*S57R]J5
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M05,7;?C@6+E?)?1H^7<(:3<0I?3I?XADZC.YN!5FW_VR"K>HM[@!]BTUN'
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M3OWK-:+.LUTN5FM%BGN2=9B=R<IPLDI.$9#_ *D48PD0'3E,5193(MT+>O\
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MQ=:/ZD"_S%FU<?\ /",CWJF%<'3K4:F!\8%/<5<UEXUF74[M^+QM@2"C"/
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M&=Z #] "\Z_ R/L3Z:SW+)IXY0GQK@VP>PK4'IN3^'-F>2ILTYB_IWY=1_\
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M,=S]2OZNU D2D30(7-3$@%MX4;L31AW*T=,03$L5:E=H,P[U;-IG8;NQ79R
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M'Y1LTYK=9/>ULH"[, MN=2L6O%V568@MV*&EF?%$*43(;E<G#<Z,-0 S<4Q
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M92JC"U5T+S50C.A19$@+RY8,$\D-A^0?D;\[1\0B6[5XI2^\.G<ZC<M$BX8
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MB9992ZH,-Z9D\:+*$Y3A,4R=,G3E4Q<8OQ5<&_33X5]/JJ<I78IL%'L]&;D
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M[X:.50H67A.  -WQ.$-SPR5.^&E"@]^^ \CAO PG""0'^*0X07 ;I#N[X<"
M1G(#-08<4S/;*4.EW8;H)[?K@XYK[C]<.'$?&"4WS"2@RS(PR(AW:/C#I8@]
MI!ARB9"'.>45,5"RW=L506K(Y11U73:]Q8WVGW%.[L[RTJU+>ZM;JWJ"M;W5
M"O2(<Q['!KF.:000HBWT;J?4: ]:/2ZVL= ZZLJE4?B]>L*5$6^C];TJ90EM
MZ&EERGW;AK\&N8O\S^P](]"NS6Z7]-*KGZTZ@_FH7_6-U3 NFOY9.%E2(H!5
M1[JD4?E0 ! !B>R&2G)3#21L[$A@(P )XXRAI]I3PAJ#&> [%ANP>RRALIF&
M@C8!V9B&@;/\89+]DX=V[>R'"' ?TD[)B#QAP3AV P[,(/M@CB.S&';VK#MB
MKV0[C[RB0_<I^$5!N,5);8J_*LG9'9NCH3U9M*UT>FJ>I-T+K_2Z#W\FL=#Z
MS4;:ZY;NH!S&U*E!G+>6P<4%:C3."QHW4W3]_;:KH74&EV&M:/J=G597M+_3
M-3MFWEC>6U:F2US*E-[7-<"A!_F?=4=;.J4CKM2W.B](V50MYK[J;4V.HZ>&
ML/WFT?FN:O\ 0IG;%SJ^I5ZM[J6J7=;4-1O*[G/K7-Y>5C7N*]6HZ9+G.)*G
M.*<L -HGE#)2EPE)(:.'UPU,T"YS^R!PV8DPWLV8"9AJY!>*XP)8"?N^$-*8
M?6G^-<##AP[9%8=VP[L,^U8(V)X(8<?95,/FLH/$^,$?T3X80[A/LQA_?[XJ
M':O=!ED?=%3MBL$R=X16J-;-JNEL$\8UW^&3K+5?/Z[]#F,O.D?QEQSW>L>E
M^IW/);4:/FO<^H='NW&T>@#:="K:-&!_F?:)Z6:5>FOH7IE9>9JU*D]:#^KM
M9:VM=!_+(NMK84:4YM<ZH-L40D_E4#N3VV0P 3EVY_5#1.2=^$-*%<MFP0-V
M?"0@8XC'NAO$P$W<43[8!7$$>*QV#_&NX0=Q^!@RF(<%^O PZ:*2.Y1! P*J
M=PV09S(*_7!_6AQ&P^^';V^^'C:%V[8<$ERGC,P2GL##\\8J2V\(K(%D\3'M
MFD>DGK&;N[M>F])ZHH:/UW1MG52V_P"@^HS^Z.IJ-:WID><*-"J;NE3<H\ZC
M3("@&++5-.N*5WI^I6EM?V-W0>VI1N;2[HBXMKBC4:H<U['!S2#,'^9YUCZ@
M:Q4I4['I30-0U9S:S_+;<7%O0/X*S:Z?S5ZQITF@!27"-?ZVUVHZXUCJ?6M0
MUS4J[E)==:E<NN:C0OYK>;E:,@ (82, !(9F&'( &&IM'8$F8#>&/?#1M [U
M6!Q^(AIX^^<-XMAH[H"[)?YW^-=PAVPH?"'; O@A@_UOL@IOW#&4.]LI1V"$
M.)/Q2#MG[X/ZL5. \%@[VGW+#P-IA\MN^*@3;%:61/PBK6:Q' DX8)@8Z1T/
M7=7M[_U"]"KC_95U/0-:D=0?HFD6[7]"ZO<V[3S\E;3#2MO.</VE6VK%2X._
MF>=$>D]A<.9>]>:\[6=6ITWH[]P]-@&E2K-:5Y:MW5ID A#Y9V10:&H@&6*Q
M3"3EA*>.<,X>\1P40TYJ(:X3,D3;G /$]BPN8G+;C#> /<L-XGZH:=WV_P"-
M<=@AZY*.X2AR;^XB'8*A]\H.9)=O2'!9SQX)#I[.S=!'$P?U8=P]TC%3A*#P
M^$/XGW+#N$5,,XJR50[PF(N2&A#S<=R1=>C^J7]6ATQ_$-TEJ?3#;5Q:VV_O
MKTK1J=3]+7=4O<.4FA2U*U80I<ZNUJ3!'\SOK(VU47&B]!"VZ#TEU-W/2)T8
MEVJU6H2"77M2N%&0$4R6X<LCMP5(I[)'L64-X-[R8"R)W;YP)_G0)J<?9(&Z
M7Q$)N^$#;AXPQ#CC[A#5,O8?" ?\89[?JAY ]OR0Y9#[8,Y+\8/ D8\ L%-I
M7M=#@3-<=B0?U8?#\TE%0?T?C'!J^$/XGOAW;%0IMBI+,_&*X+<0X$)V8]D>
MG'J[TX6C7/3;KSI?KG2FOYBRK=]+ZW1UBE;5@P@FG5-+RW@&;21'07J=TO<B
M[Z<]0>C^G.L]#N6@CSM+ZDTFEJ]DXM,P?+JM!!P,OYG7J!Z@W3Z3&]*=*ZQJ
MU 5B RK?T+1PTZW()"^9<&FP!9J@B]UJ_>:U]JVH76HW=5REU2YO*[KFN\D[
M7N)BF$P 3N6<,*30=R0U/Z,-)V#Q*1VCWQWP!P/A#1M$ ?EF(&X^Z&]GUB <
MD'N_QG88=/V,.X^\?7!)V+X01N3ZL.$%=W@%@I[ E(=[8PX;2D.WF*BG$1V?
M"*G&'2_2[)P_MBJ2A_+%:61&$YSBO4#<"9X%%C1^@=8OFW74W\._6.M>F-=E
M2Y;5O'=*W'+U/T;<5*1<7MI4[>\J:?0+@ 1:$-^Z4_F<VW2%O<^5?^H_5FF:
M0:37 /JZ1I"ZSJ110>7GIV[723Y@#C%"0D&\9PQ/8&2PP;)?"&H)J/ )#> \
M# V\WVPW:?>DO= .YOOAG;PEA .&!_WT<N[W0W/#\D-!V>[_ !CI_FR'OAQ7
M].7 PXX3/@8(W'W"%QR\(=M"KW)!7=WF''>/M@[W'N@_K0[VR,$;OA**G;]D
M/[?=%3MBJ-SO=%5!D5[B(N"6Y/PEA@NY8]=/0.^O*-'3O5CTSMNKM)MZU4L=
M6ZF]-=7#/(LJ;G %]33]5O:M0!A<6T 5 :5_F<] ^FUK<-J6G0_2O[TOK=I)
M\O6>J+KSDJ9<PM:%N1+!V^*(1"$5!L"&*93]$?9#>#??&8Q/Q$!-@]\#]9>Q
M4AIWCN2!P([H 0;#[X;E+X?9#3NGVPW:OO'VPW@/=]G^,<%]C#NWQ@\5\)PX
M[_<8*'/NFGPAV&!@]GA.#_6^J/\ .^,'>2>[&'$9N,'@? 0^'K@KO=#TWQ4V
M3$5$QGX%8N 1-'!$[X_AA]2ZMS3LM)H>JVB])]1UJ];R+9G37J&7=#:Y7NJA
M+1R4;?4'W'S% :8)P@.!!! ((F"#,$'^9P7$H "23D!,F/5KK1M8W%E=]8ZC
MI^E5#@-(T-XT730Q<!Y5!I[8I!,A--IADA*<I8#%(;NY5[E,-&XXPW@)]L8X
MR@ E9@?" DT.'&$,P?R0T;T[I0PJ<EF8$\AVKGXP 2<O<I@?XL[?J*PY5/V%
M8<,_#!/A#AD?MAV_/O,.&9S[H=VYKNAW >,']6,<B>^'$;8*9 ^Y%AYX^Y8=
MQ,/[8>>,55&'./"*Y3]/(YK%._MRZC<6UQ3N*%1A<U].M;U!5IO:X8$$ @K'
M\.OK;3KVU>X]1?2+HCJ#5S9OYZ%#J&KH=*AU)9-*D@T+^G<47-)4%I!F/YG'
MJ'UI7J"DSICHWJ+66O.5:RTNK6MP-YJ!H&\Q<W]<E]>\NJUS6>9E]6XJFK4<
M2=I<289*0Y?=#9;^\PWCX)#>"_&!P'O@G,)V=D=@[]L#BT^"0/;. =^/"&[!
M\"GQAG?V0T'^C]4#A_BC#A/\[ZH=O^I(><)GX&#Q\$G#B-_B(/%. E.'<#XE
M8=P'NA^X)!GEX;(3^D??#IS1=\/[?=#^V']L/!WQ5E)2>^*RB0!]THJ.#50N
M64R,$(CI7I&I4+]0]%/4OU"].[GGK"J\VM_J;>OM+<&("QC:.LBBQJG^S)7(
M?S-^OJ-.N:%WU?=Z%T?:\H)=4&IZDRXOJ<C(&VH5@3%*4SRDRQ*K%,=_9MAO
M!OOAG]:&KL'OAH&X[D2 1L\ 8 R^7ZH48R'<B0V?MC 4[/$0T;QXSAD-X!,\
M"90/;'_%'A!(.W_2AQV+X%(?/:G  0[<LO;LAPX_ "/\[XPY-P[A.'?K&'P[
M<$C'/[8?NEWSAYWF'A-ONA_ P_M]T5>$5FD9'P6*Y:%0N(R3;'\7/H/>ZF *
MU#H'U5Z=TA[G*Y]"I=]*]67]!B($#]'94*_H[/YG'HSZ=T+D-&L]0:YU3J%J
MT*]]+1K.GINGU'%<.>ZK($F1NB@4V"&2R/C#0A3Y<-TX;QRPWPWA[H"; 80[
M/9("9A>Z<#>T'N@%1^490)S3Q!4P!MEPG#$R([%@27+MQ@'<._\ Q1/$]PF(
M<OA#SQ/><(=[9SAR^TX)WGWQM^]+BHAQVF7:(,LR>Z#C-WNA_MA'8?=#CAL[
M)0[B?=#SL)AR[X>1OBJHR)[A%8(GWO';%T#F'S&(SSCHGI=U9M.P]8^@?4?T
MWO6/<X,=5I:1_?K3'-:V1?Y^C,8U<GG^9QTQTQ3>'T^C/3_2:%9@+D9>:W?5
M]5JAP,E\IU&8[8H;$'PA@3\T"&>_L24,&PD?;#>!]T!,AX8F&KF 3L[( [(:
MF03NG#0N*#A.4-GN/; [<-I"P=Q^*" >!\<N^&C9+_%'A\##N'N$'BGVPX^V
M*P[B/=#MQ'O@[V^^.T]PE\(3B>^)XKX*L._6,#A\(?NE#N)A_$P\<8?VQ4_5
M/&:F*O SW(#%P3L?+X@Q_"CUZV]_=MOH7\0/IE^\KQU9]!E#1M4ZIM]&UWS:
MM-"*;K2O7;4&!87 J# <TJUP#FD8$$*"/YF_K)?4WN?0TSJ6CTY1+GEX#>G=
M.HZ34#"I0>92>0!MBG^H(9+( X3SAHQ3E&_!(9O)AG& NQ,(:>SO,+GS?DA1
MD1 .PA%X0%VA>Z9[X"\?%#"=O&&]W;@ONA-H7ZS+_%'A\8<1_2[A$]J_$P[V
M_-AR[5[A.'>TT)AVX@0/ZWQ@_JPF:$]X@[5/V05R7N2'I@4A_$^Z'[R8<>,/
M[3#]B'NVQ529*^XB+A 2@=NBPU:T>^E=:;J5IJ%M582US*]C=MN*3F.$P06J
M"L>E/J-ICGNT_KSTYZ+ZOLG5 E0VW473EMJU$U I1W+5"A<?YFUW>52&TK2V
MKW-1QP#*%(U7D]@CKKJNY?YM;J'J_J'6:E0#E#SJ6KUKOF#<I.P6&2R;QRAA
MX >!AOZWNAD,XPW"<H;[;(3<#VQP ^$=@, #@2HQ[(:5Q^HK#. 'Q@<1^7PA
MO CX0"-G^)(R*0[9]<S!0KC[D$.[9<(<<OF]QAW$^Z')MQX3B6*./>8>NQ!&
M])]T&6WWPX;C#QNAW$I[H<>/UPXY3AYX^Z4.08\T5"AP/>#.*RC)V.^<.</^
M,<-\\(_A"ZA?4%2OH_IC0Z!NG!SGN\[TXU:ZZ&!>7$GF++!CBNW^9MZQ]34Z
MGE5=']-^K[JA4#N0LN?W)6I6Q:Z:'S'-3?'F.4N<]2XXDDJ23#.($MT4TS(6
M&\5AGA#>V&>W&!L6"=P]T#A[H VC[! * 8?6IAO%.Z&$S,-W@>Q[X:9XCC,+
M _Q/+Q/Y8=[90[M]X$$C:?$A8=_6[Y0_:A^$$[W>Z/ZOMC#S!X>XP1M7ZH<1
ML,5"<<!\8/;[X<-YGV0Z'IL,._K3BJ#M>9\8K%!^<DA#R!(/3'$$\JQK/2-W
M<&JSTO\ 7?KOIW3Z10?AM-UW3--ZS;3"30W.H7+@NT_S-O5QX<&U-9M="Z>I
MJ4).K=06U&H&R*GRP\I%(IBA\89Q"=T,&_W13]MD,A@,@H]I0SC#5VE8[![D
MAJ;(8>P]D#@#\(!&T^^&\4AO"&[)'X1V#W?XD\'#ZH)_I'N6"OM\T'@/>(=_
M6,=I\70[B8=N7XP^'[4/OA-_O*P[@??%3C#LIF'\3#X?\>^'?UAX?9%27Z<5
MB1@'%-Y,A%8R)!<Z0GBN/C'\8WIK4JN-KI6O^E?6]I0/W&5]<L-6T+4*C1M<
MW3[8&>0_F;=,:!3J!K^J/4S1Z51G,CJEMI.EW>H/EF!4%)>R*(3)L4O;9#-P
M7M2&0W>!XPV&\0! .UR]T#A]D-[H;N)AJ[-N4#B?>L-.\^^&$&4A[U@#V Q@
M?J_X@\(,LBO&#/(]^<.W*(/;[X.^7BD%<C\5AQW.\#!QQ(W3.4.VDI]</79V
M8PO9XI#^Z'RS/NAW;#N)]T.[5A_;#^.'9%4;57M$5I&8([A%:2?>P&T;8]:O
M3X7-5FG=:^@5]K->T#R*-?4>CNLM,%C6>S NIT=0NPTY![MO\S;T$Z/94^_7
MZOZBKTER:+/3;9[F]M4 \8I2_-&";(I#"64LI133(+WPU?T8;N ]\-!$DW^"
M0@VC[(X 'MAD-&^ )S/P@   JT\90J^R#ZX&R7PA@ECEQE [/]&&\..[_$'A
M#O:2&#N!^,/XGW&'>'B8E[3@[9>XP>T=Y@IM';/&'<2(?P,=T/A\T58/;[X?
MQ/NAW;#EAYV*8J'-%^$55&3CAV16/+F[+ 1Z$65.O5HV_6^E^I71-^RG4+&7
M-"]Z$O\ 5[>C7;^<W\394'@'\YK3E_,V]/\ 0&.7]P>FEE5>WG)#:VKZ[=W!
M5J2)939F8I#^B/JBG^J(;^K\(;^K _5AFPX=V,XWRCL;#?;)8!7.!N(A@/?V
MQNR_S8'9XA(3<,N!@=G^E '#_$>W"'+M/@(?P7WPY,)_5!3*7^]@Y)\3!7=[
MIP4VR_SH=^M!_6AQW?E@=W;#N!]\..\PNX[Y+G#^WW0[MAZ[XJ>V<5=A'=/*
M*P&_LF=D5Y8+]0$?PA=24:[[;R/X@_3C3:U5CBUPL^H>HZ/3U_3)V/HW51CA
MF"1_,VZZH!Q>S0='Z/T1@)<0PT- I7E5H#I#YZYPBG_5]\,V?++;V0W]40W]
M4>^%W?"&(,]FZ N*B%V)WRAO'[(&\CWPOZHAI]L8!X?D@'</"< 8RG [$]\=
MOV?XCVXP^<_F]TO?#^WNAW:GO^,%.WN@\.S"#/;_ *,.XCWPX;U[E@_K0_VV
MQVK#MP2'<3'%??#N)A^R</38??%3M]\5!M:?C%8_K_5%=Q"@\R\(],NL[2N;
M6[Z4]1.C>I+:Y!/["XT3J*WU*E5E^B:0,:?>L<'LN[&TNF/&#VW%NVJUPX@K
M_,U]=]4\[SF,]0]8TVC4"D>3HSVZ13:%R:**=D4A^J(;-</= .YOP@'8!";0
M/= !&.<#C\80[N])PWC]L#C[HPS![5@>PGP@37#WS@<![T@*)D"?A#2-GN A
M.WXP.'^&>'P@[U"\3#^!\1'9[TAW:/ 0[?\ 4IAVY?J@_P!6#Q(APVDP\^V$
M=\.3;\%@A-LX.XG?O^,.3>/C#AE/LAR[\HJ<'0]-CQX15"X\V2"<XK2E\PPE
MPBE484=3JM>#@A8]6X;X] >OR^E4?UGZ-^FW4M1]&5(UM8Z0M+VMY8V!SR!_
M,TJU7?=I4WU#P8TN/NCU'ZBJD.J:UUUU5J3G $*;S7:]<$!Q) 0RBDN[W0U-
ML#^K[A'^;\('ZL#<B=_VP./VP88N:>$#C.-TN\S,">[MB8/';.&C^C QE]<-
M&[X1+8/$) ]L_P##<NPP>\;LX< <5\)"#PP[3#MBF'<3[H=L^:.SW"%4XGW1
M/,_&'\3[HXK[H=+ F#N)]R0\9S\)0\=O?#CQAT5!N=#M_-X[XK#B>X*(K*,W
MF>W PW)*CIX+./X/=;:7%UEZ/:'TI5+RKC6Z)K5ND:KE4XFR4;MG\S3K?6WE
M&:1TEU'J;CL%CH]:Y7_>Q<W;E+KBZJUG$DJ35JFH3/>8I0WC\8!VD#N$?YOP
MCP\(&TX;M\#B#!X PV?M..T ]\)L([L(:3M!\)P![;X!&R?;G#4SQ[X:N8 [
MX&\!.Y([O&?^&[VS,=GP@I_2^,.X?$P[B?\ 22''B>\+#AQ,'VQ$H3>Z.TP[
M>3[H[O"9AY$/^.V#Q(\)0^'[@8=#OZT.*2^:?&*IV Y\1%8; 5V;#"#$5#AB
MNR/16T;=-N+GI?JCU3Z>O*8<7.M*C>OKW5Z%L]24_8W=)X'Z+A_,T]=]6\QM
M)UKZ6]8MIO=@*MUHU6TI"69=4 &^ Y,72]T4^ 2&!-A6&_K+ )VCP$*/91#5
MR&"^*0WL7X0> 'P@<1X0?#BLX&,Q\(;/9[H[X XS[)F&\3#03FG=#$G).Z.[
MPE_ANG[*8)WI\8/;\46';_M,'8">[FAW:.Q$AR;_ 'I'M^C!3:<H[70Y-I@C
MC[H=QAW$PXC$$P_X8)E#NV'=O=#\\8?Q/NBJ-TQVQ6(&/,?J@O3"H';U6/4S
M0ZF'3/\ $1U)2I3)2EJO16AZ@D_Z9?(?S-/6JJ'.:Z_TG1M'86A5.I]26EJY
MIG@6DK%(IGLWQ238%[X9+9[P(;^MX0!_2@]GA#=\#B/L@]L-/M..[ZX";/%$
M@#]7'OCO@?UH;Q/O@<?B($L_?'MQ_P ,D^Q2"F7BDH<,N7'?!X?"#L4]RP[C
M\1#CN)/88/$^Z"FT^Z.]/&'<2.Z#VPZ'<3#N)]T.PPRW0[;.'0_?]45%R6*I
MS^;WQ64+\I^P15*8G/(K^0Q_%QT&^Y>ZAI/5?IGU7;VA7DIU==TG4])O*[,E
M<-/H-=^J/YFFH6--Y9_>#K[H[2Z@ '[2E1KUM5<PJ<%MVGLBCM0+CG.!P'NB
MGN SVRBGO^,,.TK!7=#$V?DAO$#NC@![H;Q$=@]R0/U?R0T\/JC<I@<1[H"[
M1[H''XB =_NCL^ _PSM^R''*?Q@C8$[X/M^;#AM^V'<?C.'<'>^#V_Z,'9/W
MF!Q/O@\3!W+[H>!#N/PAR[X?+#X_DAQXPX)F8?P,5>)]\52DD=[EBNF$QW14
M.SF/:J1_%%T*6*>I?2SH_J6F_F^X>D^J*MA48&_TOWL#_5_F:>EVA<Z5=7]3
M77@9/YJ6D]/7(J'L=<-B@DARL]T-VR'PAARY1-%[A%/@GNAFY?""-_O,,X0W
MB/&# XB$W!>Z&[VK#>(^N&S_ #H;Q]TH$TP/A#>/Q$-5<3[X\>\?X1A,\>\K
M!'ZWQAQ&9@_K0>WW&"-Y]\.X.]\'B[W0Z67C 7)8=O*=\%<9GXP](=E,P]=L
M.&T$?&'&'=IA_"*J[_KBJ$V_Z,50GZ1,5,1B#V'&.K-$=793I]1_P^=;VXIN
M*&O7T[J/1=1ITZ8S<&TZCDV _P S3^'S0%5M2^ZWU=[>;.E1L+.F2W^NZ<4-
MS6;LI0%VCWP/U3QP"+#. A@XK"YDCZX$TD?"!V?9$\@("[1[X)S7WP-S4AIX
M>WA W$>Z&SS&/"!Q'N@'.7@(:F*@]\!=GP_PNV,I!8=P/MXPZ'<21V)!]I<L
M.7/ZX=P/OAPVD^ ATI$./C'$_&'[C!XGN3&'I#QQ\(>NV'?;MAP6'=L/[?"*
MHXGQ6*@VK[HJG% >*G,14*"1>N7 B/0VU\QS6=2Z/ZF]./#2 *@K] :CJ--C
MP<N>V84V@?S-/1?0^<NHZ?T!J6H>5+E;5U/J%]%S^UMN!V100?FLEV0WB!
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MR_J-K<6=(]#,<LI_N</D>!$4@B2;* @V>^&=D,XCW1O0>Z&EHS$#>GC![?A
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MOC.!Q]\'?CP2&K^E[X3<1W0%V>^ DL3W80PD[?" F9Q3%8&\S^$>V<2[3Q$
M++/OA<_:4&93#A!79!"&9^,'C]4%=I2%."K!3#YCXP1L^ G!3QW+#MRC">"P
M=J%((EA[)'8O;!XGZH'<>Z')L,.) ,R?98?!X&"N^#M3;#CQAQ&]8<!OBH,)
M)WE##T&9[R%,/E[2$. 7/W?EB@-M:D1N/.%*QZ*7*<HK^E/I_5#55 _I6U<
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MAJ%-J0-R'QAN]/JA=L=DN$%)%(X!8,=J>,=L&2?-G':??!38<.,&>2;LL(X
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M=F>.R&EQQ.6/C V?7#5,B5'#(0!E(>$9*9^,#*&M)4C@DPD-W!1[X X ]LS
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M@"%1)SWS2#[;81,%^J,/8E?A"_TCX"#P/OAR;8[ /&"=_P!D$9K!R$$#A*'
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MEQ2?;#P=JC@B0$V'MV+#QO'N@H,>7A(0XGA#DFJ 1LD>^,9%??#T@A$Q]T.
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MMX0U=GVQ/VRA<QAV0T#PVXQ/<#V0$P"GZH8>WP@#%0(:<N*#(!88OLLX;W?
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MDTU6 Y9B/0@"0'I)Z?@#% .E[8#^9?Z_T"[FY?4_J.H"9%:UWYA W E(8DT
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M .(, !K6>I.KE!M?R.=WE3# ,N4C<.988DON_41#2<"1,[YPU-R=T(DT$\H
M,B2.&TS@3DH^L0)2P2.'O@G8?=A 3<3#>*> @#?/WP =A^N&]_@DX&\KQ2 %
MS'AA /OX8<("[3XPU-OY(7VP@'VEMAO=W1O@DB>S%?H<""H,NV.Q._A#A_1@
MF0 W[EQ,..8"XIC!)V8RS$'&93#)/L@GAX2,+O\ >$$'@#/NAXW<VX+L@2S/
M<,X)&]>Y(7%1AV0[?]4.3%3[H3VWPJ[1\8.Y?KA_Y(<1O_+#U19]R0\'?%4
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M="5&$A4*B$>QH,\1AO@K39/^B#FN<%M(U&3/*65"-X*0#1+ZB2"KS(3@2-T
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M$\WFT@&G<"ULC"VA=<4FA5;*H@.')GV0&5PYCFR*@@@[P8:XO!W*O#&&N!"
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M%-U1H<CJEN_![1GRS$E$X/*1/-=N<(#( 3C8F:XD!5C(E>S9!E@N28A()Y9
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M<H\RUNZ=1S4\RF'CS:9,B'TS,(1L@ /!38>Z$;PS@SG &1E*&N4'!1BA.:0
M,  J)/(DQR@+B.Z"YKD2>.<*UQ*83[9P.9TL\)#;%&BT\Q>]HVR)S^,6E_\
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MPC2^I-"N!7L-5MFUJ8/+YMO5'RW%I<L:3RU:3P65&K(C9',XA2%Q18*NEE!
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M=*@*--@^5C*8:QL\FM 3;*.7RC) J;2DS#3Y))E^;CE),H"4<?Z. X[Q"&B
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M>Q?BD!#[" ,0/JG :A7W0 /;A$P",Y!(   &S'WQRH.X;84 <QR]Q"02C1+
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MQ)WC"A\N,3<>^)F4*UTN, A_C"AZGCMW0KGX[\%@D.E//;O@#G15S,<Q=XB
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M',4KRH01S*L5+.TOZ;Z_X%C SY2XN%-$,7%2G\P<\N! WF++\0UA;Y]$.#Y
M@OWQ^UM+<UOPC4<QS"Y?*7"+_P# ,+&_BJ@'*$DJ8MBUIBXKL#ZU-IY:M1H
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MZFHT_P 6+2F"QS@3SALQ%9UK1?7#JH<UU,<V)W1;W5S97%-E.M2>2ZFX!&5
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M0<_-;M=50 X(\J)RPA*W19I<P1+CK2U..T4:#H2WT7INTK.>U7ZEU%J%Y2#
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MJAN-0?IYN TC^S_U%]NSE"2^19E29)+6M+=O#:9WX_BX ?J.FU'%2IH!P_\
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MTG%-U<)5(^81NV_X6?QX1]N$;/M^C?A@L)B> V;OH7<G"+J[J'E9;4*E=YP
M%-O,Z*OIQTYJ1KZ'7H/I7?E5N0T[BB.4M(:<HL=)L@^O?ZE<LM[<.)>Y]:HY
M&C/;%#7:G2U1]M<T>:G4\FJ1\S.9AD/C J=4Z'4LK9S'5F$4:P')BJD;(Z!U
MSIFA5;2TW7[.XN7<E8 4Q4!*\I$4;S67)=VFBLKU'*DZ%H'*KMX,7W36DZFY
M]CIE>XTZ^H%[B.:D_EP$LC&G=/:93?4NM1NJ5M3+:;J@:^L[E!([8M]8NV4.
M:[MFUF%U$-<&U*?,Q>8[XM+'J@!]+5'5'VW)3Y6AH)Q11'0533ZM6DRMU-IC
M*XI@S8ZN 0Y(Z;N5)-?1=.J$G,OM6N,+E+9X1L[\/H/LLHV2C2?0NC6K4:?7
M=D&M?;U'4*_.6(E.I3(<OS' Q^Z?5+5Z]E2MZ[6&I=/JU:B./YSZCE..<6=A
MZ>U:FK]!V]F;D7=(.')>T!YK06M)&(S,>HWIKK58NM>B;]VE:53+W.<VWMW!
MC X'"4+E'CWP?'XQENA?;?\ 3X[UCV'NCPCVVQ+9'M.-OY(]L(^N#[<(]IQL
M6/BF&R/=]L>QC="_$1[#?'Y9[XV;/RQM7'WY1]4L(XQ\?LA8(.;43<D=(UDG
MYSV@G'%WUP!G/ZX(_3\(S)6 =D?+C\(39#AL,-0+B80A._9!62F6^<$&83""
MN!P3)(+MHPX"%V'X0T;3 '= 143"'#](IPG"=L.7)8'&"I7M,)L2% SWF204
MA7&7Q[(!& E]',9$RG(>,8S24:&,W:G:#_NPCIT25C+%IW?L"9+PC4@TF5=P
M[0 "D.#E) /?#P-^_.*CU) !5<L9Q_#T0Z7^V#H*2Y?WCM_Y*.B:A#/*K^DF
MD%I4AP?1ZIU5A:G:"(IG]7[!#"1-![D$-W !(:BHO9QC4#3;S/M+'0KL)B!2
MUBL"[Q@Z0UU<4V4O)!#S((FV)/N*GGD#!S@"YR+#M<?SNH,I,K$&F9!P69A]
MA>7?E4:9:RF"\A "F!BK;T*S;AM1J#E+73(0Q6NVV-=S*CW/+FTW$3*Y"*(U
M-KJ?G7-(?-\I!YD_.CE_%,!?;D?,6E2::"+FM9O:]CJ]4JT;2N C31<AKJ3K
MJD'!Y :6\V9,41^%MBMJ?N.81.FL7;["@UBOJD<O+BJ22*3"7(7HBG,[HH7]
MQY;JE2FCA4:#EBIA^H6AHTW4J!<C UI^ZJQ7M+6^J4Z=-W)R@R39*+=M<?B:
MCW,+^8<Q(+IXK#K^UT]S;MMJQX2FBNY%,VQ<VM)E9OEU>0T^<R0["8IV+C78
MYY:"%*?,0(?J-*F5/SGG9,\P51%2G6<ZW8V[#:IFP%K<?=#;>AJ#7UW4BSD+
MAB6I#K^A:U:Q+Z@'EMYE!.Z-(U.]M*])MM=4ZA-2FYH1IVF*%5U:FUPH(1YH
M#E:V>)BO;6I\Q[@X?*0Z8PPAE1U(AB@JC@$X&+'2JU5C:]%J%I191=T"^DZH
MZF2 >59MB\J4Z9+#6<X$"2+E')=L:":03G0%1(8PYE3D-(TD )&'*<S%R;10
M/Q#T+2F)V"+2G7>Y/-IR<XG\X91;-92I/#[>DY>4+-DHHW=H6T7GF<>24PL,
MM77%0@/ F2B$I NKI@J/5I#I%5GG%6YMV 5*%)SVR"JNWP@VU1SF\JA"3MY4
MA@KD\KW<LYC%!"-:Q0U, "JI*'V9+N2F4&S$B1@46.7FE+<-D"L]K2:@5<23
M'G#Y&&4I9_; ^:9WKEM^$<Z*"5!3+MAKF-P*F1"0UI(42G/+P@!J$X2]M\<Z
M)AELGE "'+'.280OP!7="X!?:4)N&")'P^C?V[(]DC9\.[Z-JX_7*._Z'UZU
M1M.E3',][BC6C!23#M'%W:/(>QC7BJU"7.Y4^$?O.I7H&CR->?G" /;S"</_
M !=I:W5:Q^1KG/82%_1!BGHU&G0MFDBW-,5&! \\J)#==;;TQ<.8"*P+ $=\
MV,/MZ+FN92'(0' R'"!3#FM D 7 &%4)MRB1!X0F?^&F,9'ZS-/IRV+XY1/O
M7Z#F.[NCJ#4KNIY5,Z7J%,.42>ZT=R8[XZ^J:A<&NRTZFU2E9DN+DHFN>0*8
MMZ%W9"\_<-W:7Y:6<Q:RF_F<1E&F:-I5N*%O1L[=KJ?*T /;2 =A#J/6VA4M
M4JMI.IT^9M- TC[OS Q;7/3O2-&QU&BYK_-:VBT\S"K?N-'OCJ#6*50T*5M8
M5Z +3R\K'4"P".M]2J534IW6M7=:F563ZA*K%7]\6%*\M[.A3O:!N& M:^D[
MF!8XQ9Z79T64:-M;4J')3DT>6P,E'3]SI#A;7.FT*C:E1H:'$D?>5THTGJ;4
MM?6GIU_;7K:=5])O]A4YP $!RVQH^D/<'OTZPMK1S@00[R:09S CA!]ECVXP
M8GC'OG[X]!.M',(TW3KMC;VL#\K*:M4N;AEG&NMIC\3;U* K6AIB7G<JA&MW
MP.A.K"^RUC5;BY=IC'%K&OMW$M;]]#@1A'K_ $K4<UO4U>I7I.1&D.(/RG X
M0%W;=D'A&*]GQC:9K]!V^V4>WA'MA'U+'?[2C+=LGLCM]DCV[?H^SMCV[U^C
MM@^WC&R/J&V,OC'?CXXQ[+'LD?E6,-_T_7G'&/9=L'>NR.DJKO\ PM[>]YCY
M9';.&C%900D@,=\ "<Y[H.Q(WF"-Y@#8(YOR;(!/9C\(48]L/6:*BY8X0JRR
M@#=$SAO]\!)XX1R@(3@?MAW&)#MB7]?X^PCE;\>,%5QS[(!QYAP2!V^^$/W<
MS]L)^;ECC'*W/C]"%4QEM@'("??.-!_0_>EI_P!]';&DS7RVT#_F6CC&K%"
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M!!I\A<XA"4(18IZYKU 7+'O+75"U9F9F8.J:-:EM2V87JUJ?,)JHA^F $LI
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MI7>GW5O49496M:AIU&\K@Y Z+?H'6[Q]?4NG-+HTW7%S46K6+6IS.+C,J-D
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MQD,\8:"=F4="^0Q[F?O*^J52U0.6DQCPO; LJ]5',M^0\SIR$5:-N7O%1ZA
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MC;NBT;6)%,O:O,9??$6+J8H/+[>ES!&J#R[H9>VHHLK&M\QIIS9XP&><2WS
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MVB6A!%<K\QJ5"LS^<4,X94Z>KNHEN!#G,(79RP -1J\H/_A-4?" #J->4_\
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MOY>U,?Y*/X>:KF@.J:3ZA46U,W\EYI3_ "^SF4<99Q1(S $S*&*3-,UXRAJ
M$RWP$DJ14 #35O+JI:TR4YOVML[G:"9H4!(X;(J7M+2[FK2J?.',8YP(,UD(
MMJ6HVSK<AX!%5I8A5,X-\:U$L_#EY#:K5^[*-1O;533J5"AQ_.G.+"I7(;3#
MVJ7 $8C$19BB^@]+=O,C6A/E$B8\RW%K^*%P%+$\U$S2&H!]YN'&+2Y?2;YI
MHTW$_*3S()Q=LK4V@TZ%1S3R!0YM)1.-4M;6ZKTF6][58T,JO:"&NV QY5[<
M/K!E2F2VL>90NUT>2_3;5U8T95 UI<O)C%.II=7\-YE5[Z7($ 28$DBSTV_O
M'5Z=6K3I!I<Z?.4P)BG>ZO;$5*S>;F#2?O#F!6#JNCTJGEVY-56@@ -G'[IJ
MV[W-;3-,5%4X(I(C\2M4"LYP4J6A2J*>R&:FUY>VFP5 @F$X0-&UNLYHH-Y
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M%&I6;YCRR;CB98PY].GRN&!ELA])SR!S$-"QS5OFI$ B:I")D)#W0.7[JS[
MJ& QAYE*$;ERAKC/F ,YXS,<S</L18 SWS79 <?'[8D,-AW0AP&/",<^R$6-
M_LL9QNQ@1EWY_1VRGE]';A]'Q[(JZ9KEG3NZ7EU/+#P"&O<V1"P[4Z.ETJ5P
M*]1U-[6M'R.>7 819U;NQ;4-J,3RCE$YDGC%;I:SIMIUC:U+>JSGIHZG4IFF
MX(-RI UVUM?+K&I4JEQ#0%JU/,))BQHZHSG%A3\NB0 4;/%.,=2Z%IC3Y-'I
MG6Z5%J 'YM->T#P$=54N8O?8Z[KEI5YB#R.9?N'*.Z.C-4NVDTM)UVG4>\-7
MDYZ7)(]L6]M1<M)UO3(.Y],0_P MQ(>XO0[25, [(U#414\H<U:BYRI*I3+4
M6-:N >87&I5JJ[>>KS+'45_R$,U2PIU%(0%W+S2C6-#OJ-.M3O-.NZ ;48'C
MFJ4'-$CQE&M:O:Z5<,TG6M2OK\52QPIM94J&H.6+:_TV[N+2XH56U&/H574W
M!S"HFV+'0C1JZM;4"QGG7E7SSR_=(/F'9%*YU%FGV]=U-CG4SR AQFX<JQ<V
MVBZ997OG,J4BZFUA+0Z7,"#LB[?<7VIZ*RX<5IVMU4I,"N4_*PQT5<Z1?ZS?
M.9K%-M8LN*KBXO>)NG'3S-;IUV:@VW9YPN"355U-I^8NC7+]S@UHL;FFXE,'
MT'-2<>J-92YM;J2\K-G("I4)E%K8\G.ZD*%R BH:=55C1Z.=+3[:FF]M,"/L
MW9&/8QU-J;7^7Y%K65V[RBHCKC40X$W>K7%95"$FH9Q09<,6A6LP6R4<S2N^
M*%!LA2IM8,ON@  +]&_W1M[-\6U=MKY[]%HW=T"&!SF!@+L?C&I6;@AMKVXH
M(@']G5+?A&GZ)8M<ZYOZS:%+E;S'G<40#MCI_7[C3VV^N7UDVE>U^0,J5/D!
M',$7Z/CM^C/VR2.S[8Q^,?E,>WA!CVRE]'"/='MV1O@_#QCOX P>[COA-F/T
M<>Y([_H*^R09YQ[=L>W;"?8D&/#CO2/;WP?;+Z,(]EC\DOH]I\8^S9'7#0%3
M2GN]X@MP<"0>PP$$C+ ;<8/&,<)P2#--HA&R)D?AC"?G9\.R%A L$[XG(\##
MCEC"P$"=@@S1#!*802,2%3&>*0)37!(&7= (RQ@#;+OQCE&!G#5VA,/A$XP'
M=!RY5[8! 6?& <SCQW1N.,+)/LAK4Q(&,=(T=FBW#CQ^1(UB_>T4WWNI7]VY
MC?F:Q]Q=.JN:TNF0"4!,5 $D"J8RAX:2)E8J=I7!)SD8] 6/8UP;J75KVAP#
M@'LZ%U-S'A<""A!_DH_AXK"9%MZBM1!(-JZ,5!.WF\(H\QG\N9QP4I%/YEP6
M:PUJ+@F/9#3@)1T/T\XCDO\ 5+NX<T$S%O:D*0/UHM ;>@_S+2D0:E%I)YJ0
M=GQBMJEARVY85 I#E3/*/P7[RN#2+>0L+BA:1@8I:KJUNVYHW *N+02NU3!U
M/2;)U-U%G.$;RH0,5$5M+Y26T1Y?*7J0DL^$'3FBK^U+26,/,T3Y500-2I5G
MN::;:A86*0"%PANF:I6=3IT2VF026B1G(\(JT=,O ^M4I%A:7C\ZFAPC4=2L
M=.JW+*US4J\S%P>Y=D"IJ=D^V#JC&N\P( %F3#:QO+8/%$ L+VAQ^1??%NZR
MI&IY#WL)IM+U[!&FUZ]"HQM.[H/)=3>)->JSBTI4Z@YFT:;2)2(8A$:C;NJ,
M\YUL\-"-4GE*I#RGR\[L?UHY*PHFX;70<Z*>$7+*S*;F"@Y%(PW1J%.V8UM,
M%0&F4WY)&E4+MJL>_E*F6(R,,M&TJ9I&CR(6-,L)15O;-[J3S5']DK/SOZ,"
MV_>%R&%&H:CG!!(8QI^H:A:TKM]W;L<7/ +B[:8JZEI5I3MGM+B"P#\V>45[
M!E\X-94<QK2YV#'(!C%9^M#SV4G-J@S<B@+CQCFMJ9%:FKP U""T+(P;.FT^
M4QY:.8Y-P,X98"D[EKN\LN8D@Z2RCS:E57O5_P ^(Y@H586HYU2DY_-)4032
M4!H"/<SE[QLC\;2;SVY!:6D'LQBA=LI\M*FX.J(-F)2&LJ50'M;,%,4W[(=0
MM'>8YT@T3W0V\%%_,T\Z 13HUTIO:$Y7_*?&"CVN)&16>R*CF-(1RC'X0VWJ
M!"&XG#& 01@N.$HY6[T3C#7U&D-)W[98PPJ$+1WB,1@84*BXKAQ@3RV;LU@>
MTN,8X^TX7V[(]MD=D81LX@0(W]T#V$88"9E';[HP/L<(_+"X3V1W\(]NZ-<J
MVI<+BGI]5U(L!YN<(1RI'*ZYU #\33INYF5)TVW!5O=%M=V;ZU._JZ7;U/-8
MUR^9Y'S*D\8O*.L5JM9U*BUS34:]J&2IS1K?3A-3S:^DWM-H <1^UMG,& WQ
MZAZI<6EQ4L]6ZHU:_LGLM:SEHW%RZJ, F<7NM:E8/%LSR+RB^I1J4RTTR'$_
M/PBVT]ZBK2H4J>X\C V4 C _1U%8=,T36U*E6;48QH<XEO*29-G#],=IU;]X
M&X\M[?)JH:B[2-L:'K>MV1MJ]W8"E5):6DD,S40D7]OK]@VMJEM8U:5@64&.
M>Y[F( <UC6+[1>FJG]U:=2HZVK>75^X'DE$&S?%6PU.TJT;BD\M<WD>$+2CL
M1#DJ7+0F3Z@$MPAEI;>?6N'D-#'&HY>8REW19?N+IFXOK.N]@<X4ZQ4.("2&
MR-)ZOZMTVM8]2V[:%X^E7H$\MS3(<@#]\4K:B&LITF,IM#&A@ 8WED!'4]II
M+#4OG6C_ "6!02XA$^6<=;-O-->VM5U)SR.2IBY[ABD6'6NLZ4ZGT_5LWTGU
MRQTJ@>HF9913HL"-IL#&\!A';)-N4'\D=:Z3I06^KZ;6% (2K^0\LA&N6U]I
MURZYJ7=17-MJY;\U4@3 BP]0=1LW4J-$NHU'NI/IN0S'WP(X;]D?7Q@^V4=X
M^$=4_OYENZC4T34Z=+\0YK6MJNMG!J<T=8T[<-_#CJ#4O*#4Y>4W+BWE(XQH
M5^R@]]ET_JMI=75-U+F94HBH'.',1A&FZ/IMLRTMZ%I;CRJ81H?Y #I<8]IP
MOLJ1FD)[#891AX[-L;<(Q]MT=V]3C'LNR/MQC='A'@LH,>_=&4>'U1GA!\??
M'?WP?90L8>V^-W=C"9>PCOR^,>QG"_DC+?GNC'#MC'VWQN^$>[V$)!V?9"^P
MX)&7Q2#\=\?;MCX+[XZX8F.C53A.4\(K-("MK51AL>0D'^B?C'-FO9 )Q)0[
MQPB2@^'C +IJA&[C!21S/P@;-F(B2*L_81B?" !FL-&V1@C),,NZ ,5FL.X_
M&%G[&"N20.4YXPCIDR:F1WP00N'",.$C. 3]L%9\IENG$BD;3!5 <A"F0PPS
MA1-,.,-"YS[XD%G%(;:E,=[TCIFFJ\O3]8H44$^7.+K-:];,R/F&'D+F9+V3
MBJF)6>45"4XRRVQZ"@'E\N\ZSJ[5Y.@M3*?R4?PZ/<" 3ZC-#R/DYDT<\B[<
M"D4<40>,,*R*3\(81,R/U"&@[I?ECH+7Z35I:?J-Y;U=G^L4 0?][%G2N;QK
M*E*TI-0D("RB D7%G8AMP7 H6-:L@@G'FU+*Y:W%31=RIM4"+/3JX:RXIE"'
M$,*X8&+IE5PYG42DVG*-2?07RW5G$$24$DQ1I7Q9Y)H_\,%:O-+&#2+*)IFB
M , WE3**M2R%-A-P9L(*_,N46U&JXN8ZK3!"G-X$65SY#"ZZMJ=1W-3:5)&T
MB*FIVK!2>KGJQO+,3RBK;4[RZ:QM1S)5"B ID8==Z@&W(HU&O>VL.90<56'U
MK'3J%*O0INJ![&-!5K5V15L;6Z?293J/:&@D <I081;V%W5-9M9XIN',XKS8
MP+FJQ].Y--ST1WWN5091Y%)M7R!4<X!W,&D!TH;I[:);4?3-+F:N)E.'ZK3>
M[]NT_?:N9,6.KUR12MR*A<UI;FIF.$,;=W1%RRB05</O=L5:&EM_$M<\.:&S
M*+N@7;M-K\K0'D\IS"Q8:7>5*=O6M: 8YM1S6D',3BK;4JM*NYS7$>6]KC-J
M8-BYN:5"H&&L]W]F2H)7%(N;6Y!IO?3#1S#E4E-L.JN<WD+'3434;8>;?YCY
MCP$BV-R$!JT_O3SWQ;NI%O+Y3#\J;)80#RMY^0IM$!KN8T^<  CY<4@.8&AW
MRF4L<3%P'A?V9&S+.'LH$AO,0B_TDBE5J+S*,?F\(Y?+86IARB8XPZM1<6C8
M)"&L<]P'/RS,4W.8TN+0I2<LX-:@T,>#B,4Q/"/)+CS+RB9\(#ZOS%,=XXPG
M+A,(DY06O/RB0GD,)1@"W(S'B(!\4[S$A)?@L?F_&)3P0#@LD@#</J@<?#A]
M'LD3GE]"1]D3FD?7'M\?I]ECVX14H56AU.HTL>UR(X.'S @P-7;IMDLR?V35
M+N;F6'Z=7M:+V>5Y=,.:"&-3 +'):TK>WKN;RN+$:YPWP;^_L:5Q7<PL-1P!
M):0B80Z\U_H:PO;A[W/=4>VFI<XJ3-I@U>A^G;?1GEGEGR0T*Q$3Y0(%=S :
M@P="#Z+C0NH+1EYIUR$JT7AI#LL' P=7_N3;"]-3S34Y**\Y*\WW8H:#T[:B
MSTZWE2HM#0&A$3Y0/H^'A%32^IM/I7EI54.8]C"2'#E,W!9Q<7CNC+=U[5+W
M\XHT%<YWS'%L.-/I"C^'YLJ%*8!X12NKWHZBVY8AYA0MU)!6<HI#I'2:=F*/
M)R?LJ34+$V#=$@!D$"1^7**MI<-YJ-9J/:0"".V+SJ7J#I>A<ZI>U/-KUC1H
MJY_,7+,;X9;=%:2S3J=-W,T-8P(N:M ^CPP67&-D5K*\I-K6U=CF5&."AS3(
MJL5-6U?H?3[N^JGF?6?387$JJX1^#Z2T2WTJW7F%.B !N,'(INX1PCL$$RWJ
M(U'HO3;YMMJREQ%&IRUWTZC.5P(7"*M6FRI<7>H79J\H!=4J/J/YCVQI_J3J
M-HW\3U)I@6A<4E?1J,H@J.82QQ7*       , !@$C+MSC9X1["-G9[S''ZX_
M)'L.,>WPCV\(/P6#'ML^COQCVE$OJ3A]!WQGG[2B4&/;"/;PCORQG&SVR^CV
MEG]"Y^$9<3'M\8V[\I[HSV1[9QVS]_T?&64>/L82.MA*6A710_T6DQ=L1/\
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MZLZP8:@YD9SZ59D G"9$EV2SBBY9. 12ID)80Q4,AMQ1,!#4,O880%R39AE
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M*H@(,>=7N:%"DG-YE6JQC"-O,XI!IV>I6-RYI((H75&J1O(83'F7MY:VM/\
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M'N#2Y$F @C\)9UCYERPTP"1,N'*(==.MG.:\EX(!,G%01#'7-%U*F*@)+I
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MU2,%B[](O577[W7KBSM1RZC=.>:50N)9)Y*&<-N&$<M2B:C"#*;%!!BZ]/-
MO[ZC>ZOJ7[KMJUOSO_"U:KS3IO=RX)&G^HEQZGZI=:.;RVKU; %Q6@YXKEA
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M7=/IOJ#Y.;GJ &8VK'2?I2Q_FW6KZ?INHT::\P<13:XE(U#3*S>2KI/37EO
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M9^8:H!VH:<7#EGYM4_[\I#TR7[(J IRSW80\RSEO2 X."4?2/U J$;0Y]E2
M_P!\O\E'H_(\O^U9X+D4-)Z5O>4D]DHHB9DW?LSACE603&&S]A#91J)5>6M:
MN[JN21IE,UJ3'4]/M&%O,T%66[1A%Q1I\KR6$#D/-.<?B0QP8O,?D. ,,H&5
M05<TR4%8N!40+2)&$73K=7#F7Y<44[(LOQ7*JX/3:-L!C0WD( DB)N,5:M%C
M0_FQ:BXPRA4+BPO 0$[=T6-;RV.=4I!>9@.0S(BK=,8QE1JS8T-(DN0BK;TK
MNX#"\@!KS)(#[]QN6\@?RUCS3$R9P:3;"B'^7B@$PW+;%6G95S1ILJ$!K50
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MPQ$@-N^%=([,)=L$;D;OA"?=\(X#OE%-_P#3$N$-J?I.N0?\ZG%PU5'F5/\
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M;,*@7"+=U=LO-&,HM^1%Y4.&R+PN(#PV4@N!A&.?R%TR"4$4GU@USB!]X*>
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M"?U=)I?_ ">"C^I#LY=)HD?^Y$!E&CU77>A(IT=$IU'D"9(:RN3'RZ5UN?\
MZG2/_CL2T;K<\.GT[)U81NA=;%?_ '@@+N3S8U'J]NB=<5+G4*HJNI'0U#7
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M4;)"0YTP<<X>VO:VM=M1KFU65K:C594:\(]M1M1I#@1(@XX&$/272Y)!!/\
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M>'T=I[.R,NZ"D?E6,>,L/H]CA'MV0O"-6'_B=S_WDQUXW]'7+Q/_ &:8'MG
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M)#&7!YZ;G(DS(\8Y>5"6D?=GA I6[7&B5<2J +NAML ?VGR%-\"ZJH><+\P
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MRM#4'*)3Y&X[/Y**U5KFM%IZE=#UW*LP:MS0")FKP9Q1#L/E3B-T-DJIE#'
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MW&_8L.!V.7!#*":*ABE0T2QW0KOOEH4[40%8(*$!I]V9@NI_>F9;<088*ZD
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MG@N8ZJ7. )!6*5&A3IT*%%@IT:%%C*-&E3:$;3I4J8#6@)(  0F?9C ;GO\
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M3#J]0!W-\P*83AM2H.6B-DH#N=% S]\.%$<],G'MAM5M,H"I[UE#*=2H ]@
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M4#%03 2LQ9(CA[;H -5J\<5E :*K3AGLC[X^&V)O &[[8^]P@'F\8F[ =PA
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MFN5OZ2_]]U[^2CUJY@3Y=ITG5:@)(<SKG32"@V1;(B%E,R210*#%,MQ('9#
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M?,3Y7-"/N7#=3""+31]%L:&G:784A0M;2V8&4Z3&XDC$N<9N<XDN,R87L@[
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MF=P^R"2[Q[X<TNW8^,._:@&?YR<1!!K H3/FP,.8*H!:%)Y@)HF'OAXI7+6
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MF<@:/J;U[0:WINTJ/=H&AW#'^1?-8'"V%*W=A;4G$5"]P/FO$^8$F!R@
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MD]D_\,\(<A4C9E!YI3,UP0S6'%9!9_;#PJX[Y;902F<I[HGQSFDXV 89YKG
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M 2Q@E9\1"G;#EF%E+*"<C--T-*1DJX&-Z^Q@!R 8P@7"4<RJLD@=OOA5PE#
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MQ3PS$$)@GOA=D\_CVP0$)F?K6'A9*4(@NF?O$A9+A!:F>*YDY[8]1@1/^XU
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MU6S^5S4<:)==4J590'T7U 'A<"!G#!3>"J9Y'" I"]D(N/U0#D8E[X0$GO$
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M9)VSFL-YOE<  1CV0T+CBIGM),2Q&(&4H:Q$RV=L)CS(9C;MA%G,S*IM@?*
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MNLG@ Q<-**V^N@Y$ 47+@=T4BTI)J_68825,OMAH.2#ZHJD8>2_?^9&JA?\
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MR1']:-+Z?H]"=+W-73Z0INNJFDVU2K4( ',Y[@N4 6W2'3M%,/+TFS:FS\V
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M?;-(7?LC7[^E_:6.A:U>4YHM2UTRK6IA=[F@1HU2FU7ZC>ZQ>52G_",U.I8
M?YE!L3EQ2 !,Q\P4B<'9L2!+.&$CLBH[ AAXJDHKDRFXR4S6>,:@WSRUQH5P
MVGS$.?4%-SF@<N:[MFV.DZ(<&-N>O-!LF-,BSGUBE1J<X .;B3+LBWHM #:-
M"C2 & %.F& #N_R)U^45&Z Y% ^[U+:'$Q2=FC%GF4(@.* 9##'. B >PF!
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M>],H8'#.7:8"X"2"62S2 #++=-)_5 (S/:D#FQY8PS0+-5P$$F2GOFL K*<
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M5>B4@TE2Z]I($X&"=5]0-"IN:"K&737.ECBD:A=OZVMKFK;T:O(VA4I%7<I
MSC4-9TN\?=Z39ZA=_N]Q<J4'/^4J)3@]D..T80W?]Z!RR\"G9&"S2';9GAE%
MA.?XRW*C=5!CUBJ$KS=":J%V\N@:F%AZ9K%52F.<5"9X[XIIAY@[/FCT$#0
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MZ.ZA1IT@2]SB]I0 1U;IVMZ=<6AI:@^BPU@0YQ:\[1!48;81-\T^B0GLW;8
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M_FE#\3&I)4%-WEU2UR@_FGF4&07#&.M7$?-_>'4 XIBYK^4N"$A"BXPT#-P
M1,2X )'\+E@5YF^C/1ET]6\A#]1TUNHO'*IP-4C_ "-UIZ?7%3R']1:-7M["
MZ7E_":M0(N]*NB0#\K+BG3+PDVJ,XU'IO7:-2QUC0]1N](U.TK?+4M[ZPN'6
MUQ2<-SFGLAB.54Q.6Y8 .!P,#E7+BL<H"8!5Q!&,H:#()+\L-4IC),(:5&6P
MX8P)IB=TQC &"@>_)8"']$#<LX!)& VXK 3#/=LA0Z8S[8FXP"7(HVF"5SEL
MWS@M)4 9[1MAP7&"5DA(5,I09Y[,\E@I,;\$PAQ5,9C$2P*00,M^>4H*8X#O
M@GFFD\,8/,9KX;X(!1=_9!!1-G'*"5"D]W&" 5$SQ$$*<=JB XM4&28J<T2.
M<A.4! BC';%?J;4J)I:KUQ<4[ZG3?3+*E#1[,.I6(=S@.!JN+ZA"D%O(1C_D
M?^)/1*=)M%NG^OGJO1I-YVO2B>L;M]) TGE'*1+\L3)YO+*;_F!GW1I9:WE'
MX2T(12#S4FE 3CQ*P&DX-VRPE#VC(G(KN2'$Y+!!4(4^*PBRSSQCE"'?'KO1
M',M7T;]3Z<@I^?HF^ 0;9P[]4P.,!3M._&/FEG*$.)P&Z%..>,6[$45*]*FF
MWG>&)XP>H[G26TKW6K>SO:%P^D&N(J,#N9I(@-QEC%2J]R,8TN<=@$5Z?4&K
MMHU+<.\Q@?2!"?K.&^'BEJ K%A(^:M2"D8X&*S[2G1K>6QS@TW /,0%R,5[?
MIOIRT<&<P94<6$*) J]T7UMT[2L;*I7IUJ30TT5:VHTMD6*<XN.L^M[PW>H5
M#4:P\SG-:QS^;E'-"@27"6*8P.'UP250>,()0)H@FF9C&9AC/TW >,>H5)5%
M/T;U,;IZ-J9,/*J)_7%0H 9Q4G*<6+1_X?:?^Y#8Z7_^EW1/_P VTOY*?4U[
M6M:7:3T YQ  )<>C;(<QVF0BB5V8Q3!W)C#","G9#<L(N9XZ8X)M_P!8:91C
M\<XX>Q^BK8W]"G<VMPPLK4:@5CVNQ:X15U7J/TGZ:U&_KDFK<UK.D7O)*DN)
M;MBZU?J#TAZ3MK:VI^;4J5FV]!H:)N5[F14MM!]*^D[VLUG.6V-Q:5T E+E8
M8/F^C6GMY@5+'VPQE):)A]6X]*K*R8A+GU+BQ8QHQ+E?1 BT]0O1[1-*TWJR
MS8:=)]MJ&G5:H9S*6\MNCOHO:]/^TI6U:HW]9C"X1T3Z<:]=W-MI5]JSM+>*
M-5S0^F:GECG:TA9;8T;4J]&UU.XJ4*3WT[VT%9>9@=RN-18\FMT3TW4/)Y9<
M[2Z&&"J!\(Z-]4]!L]/98W_4U&XN].H6S*=NVA3N%?3<T 2(,XJ=7]&T]&Z3
MU"UI4[1SK*FRF1<6]'DYE<LR6J8TFJSJ3J;5.CJ&L-_%4;1M1UG5M*-1"UQI
M 201I/4]G4IV]\ZG2HU[.I62Z\UK4>33>5QCVSC?[918[!K=N?\ S2L/C%$@
M@K2IGO8(YO:4?,(!$X :/;L@*,?B-AA^?RG*6$XU-Z->E*LC2<PTD$M]NZ.L
M75"'//4>K D!!\MPYB 9(B)%"F)E]9C1N+G@)'\.^F<O)^#]%/3*F6RD3T=9
MU'*F\S_R/;>M/3NFU'=-=9FE;=5OMJ1-+3>J;>F*5*[KFFT!C;RBT.YG%75&
MU%BF/, D")JB#&<-$D034]ZP$!60.\^V< D;%XB<-W)F.XP#S8%")8^THD<@
M=X)C'89IAE F98\("$Y+Q3.)D# ."G;(0@<AF,92EE$W*W&?=C','(?'?C"#
M8,')NV1(S.,\)3@ESD&969,.<TKB"1,@8G&#\QP4[<9 ?&"CLYC([H+>9<4*
MR[8<USBB9\4$$ J#OEO,2. D<9G?#@3+*?C#E=CBNR"5G,C9VF'!YP)(F%)2
M'N62$"<$B!(XRV8YF&DL)[QO3#"-&T:E;5':?2KT[S6;H,)IVVG4'M?7<XHD
MY- =(EP;B0(M;&SI,H6EE;T;6VH4P&TZ-O;TQ2HTF-& :T #_(_\3M@U.5OJ
MYU-J 67,-8J,U<.0 ?\ 'PXG\RB]V<^5JY1T\^HXE]32K N#E+F?ZLTAKB)*
M 8)7\P]Y$H<X',X\56" <5P,$'$K^6#,H5[8,]GNG'J_00D5_2[K^D@Q/F=)
MW=-&[YPX(A#G ]A2$1$D-\%,?LB6*?&%., &:J1AA&D-,VNU33VD' @W; 1'
MI!^"M*-L:_16C5*KJ3 TU'.M6GF<<X79%QT/Z9=0&SZFMW7%GJ+!5+#3J_-R
M >65R$7-WU%U=<5G71<7_M:[_O%?SW0YU;J*[^8SY7.$\93@MKZY?U Y5'G/
M"KC@8+J]U7>YQGSU7E=\S".)(."DDDG.$$(<$Q^$350LMR00<5\(2;EG]D&4
MQEC .$N$409K6I#':\1ZF,/YGH_?M[]!U**C3A.*@VK#TPG]L:+3>T.:_6=,
M:YK@H(=>L!!$:(QC0UC-(TUC&M"!K6V; UH&P#^2GU&:JBIH7I]4*C!QZ/M
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M02(((.\X[L8ZOI*4K=+=04D 4GS-*K-(3MC468%E_>-..+;AP@*%)*+CCQC
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M;'+LG"G/C\(5Q1)>"Y19<TDNJ)EN>(];'F:>G>I-[!TYJOU0\)*>45%_I14
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MU&TNK:G=,N*;Z"UZ!ICYVJ(ZMZCT?KGH^M;ZSK-W?V]&IJEEYK&5W\S6O!J
M@P?P.L])7:?=Y-0MRO\ F5H/X;3M NVA2M&_0H/U:ACH+J34NEK;]VZ+U-IM
M[>5:5W7J<MM;W+75" ",!'1NDZDSR[_3^GM,M+QB_=KT+<,J">\1]OQC7=;L
M*U*MKUN"VE8\[15<VI1/*YH[1&KZMI%]UI::-J%\ZO29;U;A]M2H57RY6@HB
M'A%.XU7K;4K>I7:'.9>ARAQ',5YA#G6W6U&J0O*7L86X?=F.V.?3>K*-6G3/
M,QK:5+[PX'=!U;2.H;XML/VS3:6M=RBG.7DKLBAZ=>O>MWM76N2A8T1=MK47
M?C*R,:"*X_2BSU&U<'V][;4KJ@X$%:=9@J,,MQC/VV1J.Z[TT_\ GS L=..&
M>@Z.>_3Z9C#M\(X&!\QWA?&!(>&,$+AG%1'2#7'B2<XZEKG&GHNJN0O<TEQM
M78F<B.S;#J;02#4(VG'='6?J#?6SK:KZJ>I-6K8BHSEJ5M(Z2TMFGVURTYL?
M7N+EK?U3_NQ]>?3^RH_B-1ZC]+^K+?2J'+SFKK%II;]2TBFUJ&9N:-(-0*N$
M,IO<YM2B\4GM)(<Q[#R.8X'">46/SBH*.MZPPG%S2;PO#25V.6 5/]F !V0]
M-_C!&P[-T%H,EP01,G?[H^:?A"M4 8I+W1ZRT41.NM8. _X5XJ?]=!$T22X1
M@/=& /=$\>SX0.;'VV0$"RR@8#''$01D25/U02-B^$H!S)G&W=LWQS GLX1,
MS,M^,<K9).!ES239"06I,!9X0GYV9^V%(11$C@"3 59&*9!F'M)X+'J.\SYO
M3GJ!W$?W?U2*B2,XJ#/YH>';Y\(_A98YK7TW_P 0_HXU[' .:YI]0=/!:YIQ
M'\E70#@2?-]&M <F :6]6:NR1[(HA<FQ3)G@88 -GC#1F4BU&1HU_P#W&K?1
ML]YC%(K/8%>RF]S1M+0H$:%IVC6-U:V5>LZBRXMZ[J/.P.(:0B06ZS;WAJ-M
M;U[=1?7+ZG.RV>X(_&21U_HUEU9U%1M]-ZDO[:C3IWU3D9380 UK>:4-Y>M^
MI&D;+QZ#@IAJ=>]2!,6FN2)!,XZ+TB\ZYUNM;:CK^F6=:G5<2',K736.:9;#
M'1&O7+S4KZOTYIE]6J'[SZE>W#W.)XQL]LHUGJ2WHU*FF4*=OYW('I\K 7*U
MJC 1:].7=>Q_?[;&C;W%&ZM[<O%;E 0^85QBG7T^ULO)J-#V&E2I <IF/N\8
MG;43,?\ !MX1R5;&UJ-V.I,,53UET_H-6TY#YKK^WI&F&$3YN8'&+'6/22ZT
MNQI'K73";317-:&TOQOW>2F!))1T?=W[:[:K= TP%U9J%W^JM&??]&K;KC3#
MW:A36.EW!?FZ>T4G,*=-IK&!GCQB0F3XQS*>&'?'RDI+8!AA!!,5A)"QTI9#
M%8ZN!J\CJ>B:F^FA:@)M'M<23/'B!OPC3-%TNUJWFI:KJ-KIUC;TF.?4KW=Y
M<BVMJ5-C%+BYSF@  G9'HKZ0FU99WW2'0ND6^MT&(>7J&_I?O37FO>/O%MW7
MJLYC,AHF?]V+F/:',>TM<UP4.:X(YI!R(CUI]+KK3ZFEZ,>K=1ZHZ+#F%EO=
M]&]3W;]6T"M8N:UK74V4JOD.Y C:E-[,6F-1I<P>ZGU?J;0%0-#K&UJ(>))[
MX )ER+,[1(I%1 <3@(>3C/+N@\HDN<)GA\(3M6"5ELV[,8]::0"!O5]6H!+"
MK84*_P";+\Z)IA".QRX=D(3,E1PA3,31(D2!"":SC#.??"9]L$3P2!.7ME&,
M_;*"))XS$?Z)WY0<Y0#]!EB0.Z4$KEA"P=A$ =\LE@D"8"X#*/4"DF/I;K]0
MD[]"U80]W&*G;#P-\?PI4B>4/_B*]'07 *0G7]@53^2KTXK%J4ZOHUHPIN.#
MBSJ[5VO 0Y+%$G/ESR2*?.9$@(<R1A#4PEW0U,?&+1/^+K?^XE9(]OC ]NV<
M>WC!;D0F6!$6?^U7I_\ >3K)Q=0>QE(N:KE/WQ#^C.B]+KV>CO%8>66TE JL
M+'@)N<8UKJB_HZM0U'7;VM?W9I,: :]8JXA'COAWX?5M<MN9?NBJW'";*L._
M!]8Z]1)VU;P(NP"K+LC0^IM)]0=9\[1-2L]1HTZE>[Y7/M:PK!K@YQV1TSTC
M1JFO1Z=TBSTFG6<5-1EI3\MKB3M2/=G&L=':S8VUW^\*)8TUVAS>;RRUI*C)
M1&M=<^DFNU+'2;BZJ7%G;:=;5*WEL:[F:$HN&Z&:-U/U)KM0VK^0E^G:DT<M
M(H 27$91;C5-=O\ \0QC15\VC=M^820\ZPXV6L^;=-^ZU_FC"<U$7'3&FV;;
MQMZ#:@TG5&O1TFD$-SXQ8>H7JGH.J6>BU+RUU*G>/J5JM(U:-?S@"'2G'3O3
MMLUK1IFF6MFXAJ$FC1%/YAV?1JV^KIY[KYA^$=*__2_H[>ZPIB$,MG?!=C,I
M]< Y=D  J?KAQS0YQ6!*CE(CJNV+W%U:QJVW-S$"F*]44@"1,+S8819?Q&]7
M].O=Z6^D%[5O-#O;^@/P74_J52IL.CV5DVJ/VS-++_Q]P]JM95;089O('^[+
MI_\ B"]-- KZMZC>B].[9U-8Z;1\S4M>]+ZP??ZBYE&F.>O4TFNW\53IM!(I
M5;@@% (UVY8\.<.M+MKI(YKAI-F2/FSVI\8;BO+X)#^8(23M^$&?9(""1CV=
MT':8)PD<8,\\X]:&X<VOZ95R3_6.F+"OE^M"-,TQQELA3,[8!3)<!G .28;5
M@ [%5=L<Q!!$H=RXYXXQ@5S._-(F%YC+=QA<L$P A=TL,85P]NR #BH.X"".
MPQN$*#+%)S3*#)$PWQS8$R.Z%W+X1S#.2;/9("%0)G/L@D;$3MCK6I:>6VI5
MZ#TVP>:C ]OX;6K^YTB] :"/F-&O4#2LG(9HD5&I(+A%3+'=%0KMV?"/X3J%
M%KJE1_\ $7Z/!K&S)3KVQ)\!_)5Z6!)_['=/(X_WQU5(HK(?)E%KI](J*!8Z
MX</T^4EK .&,-*[,X!"<-O;%GMY:PW_\SKB/8\(S&,>V$?7G&!^GFJ5&4VC-
M[VM'>8!:]KM[2"O!(G@</JC[(_)%;4]7N6VEE;M+JM:HG*QH"DN)BMI.HW?2
M/5-S0J.IW%A?MH52Q"A:6.<L4M-U'I'TVT&M=O-/\4ZA;T4<X_>YESC]]]/6
M72%QIU2F;C\3:^0Z@*/WC4+P$ WQ6L^I=#Z7U\4 'U#87%M5=M+2UHQ&<65+
M4?3C\)J3ZK&MKTO*#6U% !4MVXQ8/]*!96VFEK?)MW5+4UFJ @(:A^V 6X;L
M"-LHS^N-8W.M'=UTTQTPXY:'IP"_T;5K?A 3%%[,H0[ F6,&<(8<[-#[I1</
M)"AKE"% FV.HJ3&'S+EUBQ6N"ASK^FRFHQ10,-^R/1[H+I;0;#IO2>G_ $[Z
M3MQI6G4FTJ%._K:+1NM6N'D3?5KW3ZU:M5<2Y[W.<XDG_=FZG4:U]-[7,>Q[
M0YCV.'*YKFND01(@Q_$[T+T)H]MT[TTWK[ICJRUT*QIMI:;8776GIYI6MZH+
M*W8 *5*I=NN*C*30&L!Y6@ "&% G)[QG#W)@?A#LT@C$3[C[+"F4S]<<K"3M
M0D1[SV)'K%20HZ[Z0KC +Y_I_I-1QE_2)A52>.[9]"\3'-GL436.P+N@;PL$
MC!3& [H"3QA ,,9'C"\?H4A2J!?KCF1"[MG ),L]\\X6<C+8F4(4G@F[;"8<
ML*, <=T2PQ@'(!>T&" IYB/$RCK2E^AT7TF>"]1.=%3F 2:15205V<HJ<JYK
MCPE'\(G_ /T=Z0K_ /7Q9_R5>DSN4<Q]'[0%R30=8ZIRK%$C8T[]L:@3^9=^
M!; ' P%*JD67"H#VVM81[>_Z.[ZXP3LCV&Z'O)DUKG'@UJF+VRT35='UC7].
M-:G=Z76--U6E7IJE(AQQE!T.EZ<6M -NVM%[;,MVN+6U$4$%9B<7^HWNB'2Z
M^D63*C@4!> Q29$P?3SJ"MI]"_%6E3Y*U<,J$5:C:8=RD[XT3J:Q<UUGK5C1
MOK=S#S-=3JA6H1E'ME*.I;+1;IUKJ-QI[WVY!(^;D0%01#O4S7[:]U"QUSS*
MK:M&K=(7.>7$2<F$5M;Z&TSJ :G9L%6E3HW%_35S/F0<I.Z.I/0[KC2JM&]L
M=&N]"H/O;AYN6UZE$T6<IK#F51*<7'4FLW'4MMH-_?W(==BXN*U"FRK7+V
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M>8!S2"GS"*US6J/J5:]1]2HY[G.)<XJ9N^C2>H-&U6[M;2SO65[FWH5',%8
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M5\[\(S5*[6$DFGY9J$-0881@L:X-NEW@[Z)BU:)D:AJ X?MN91WPI$L]O&
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MC4-!ZBT>POGW=!U&G7NJ#*KZ:CE1I<#&J^I'H_U/>Z9YU1]>G8Z0PM+"UQ>
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MP>8Z!I0*MY2@LV-#FC8<1"@?F#OQAY<)*<H.V:01V"6Z"F*_9'MQCTVN#/\
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MNHP\JFIKW5%_K#JGRR1_G<PW'_=MZR:6XD5+'U6ZVHH'"3#U!7>O+L(( AO
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M6L ';$MI2< G<,9<3 ]MRP""F>, '$"/CNXQ4:7!0UQQ(W1J-:YJL:QMO7<
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@W:5:) K 9:VEM;,: &MMZ%*BUH$@ VF !_\ =W"__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>spry-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-12T20:18:04.2310+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ars-pharma.com/20250630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:spry="http://ars-pharma.com/20250630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>75000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2" id="DisclosureInventoriesScheduleOfInventoryDetail2">
        <link:definition>75020 - Disclosure - Inventories - Schedule of Inventory (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>75030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3">
        <link:definition>75040 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4">
        <link:definition>75060 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail) 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>75070 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>75080 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>75090 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995455 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>995475 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995485 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureMergerAndRelatedTransactions" id="DisclosureMergerAndRelatedTransactions">
        <link:definition>995495 - Disclosure - Merger and Related Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995505 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails" id="DisclosureBalanceSheetDetails">
        <link:definition>995515 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet" id="DisclosureIntangibleAssetsNet">
        <link:definition>995525 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements" id="DisclosureCollaborationOutlicensingAndRelatedAgreements">
        <link:definition>995535 - Disclosure - Collaboration, Out-Licensing and Related Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995545 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply" id="DisclosureInlicensingAndSupply">
        <link:definition>995555 - Disclosure - In-Licensing and Supply</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity" id="DisclosureCommonStockAndStockholdersEquity">
        <link:definition>995565 - Disclosure - Common Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>995575 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
        <link:definition>995585 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions" id="DisclosureRelatedpartyTransactions">
        <link:definition>995595 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995605 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995615 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" id="SummaryOfSignificantAccountingPoliciesPolices">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Polices)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>995645 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995655 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables" id="DisclosureBalanceSheetDetailsTables">
        <link:definition>995665 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables" id="DisclosureIntangibleAssetsNetTables">
        <link:definition>995675 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable" id="DisclosureCollaborationOutlicensingAndRelatedAgreementsTable">
        <link:definition>995685 - Disclosure - Collaboration, Out-Licensing and Related Agreements (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995695 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables" id="DisclosureCommonStockAndStockholdersEquityTables">
        <link:definition>995705 - Disclosure - Common Stock and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>995715 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995725 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>995735 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
        <link:definition>995755 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail" id="DisclosureInventoriesScheduleOfInventoryDetail">
        <link:definition>995765 - Disclosure - Inventories - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" id="DisclosureInventoriesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Inventories - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>995785 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995795 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995805 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail" id="DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail">
        <link:definition>995815 - Disclosure - Balance Sheet Details - Schedule of Other Long Term Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" id="DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail">
        <link:definition>995825 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail" id="DisclosureIntangibleAssetsNetAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail" id="DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail">
        <link:definition>995845 - Disclosure - Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail" id="DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail">
        <link:definition>995855 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail" id="DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail">
        <link:definition>995865 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD" id="DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD">
        <link:definition>995875 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail">
        <link:definition>995885 - Disclosure - Commitments and Contingencies - Additional Information (Leases) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995895 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail" id="DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail">
        <link:definition>995905 - Disclosure - Commitments and Contingencies - Summary of Supplemental Lease Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail">
        <link:definition>995915 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail" id="DisclosureInlicensingAndSupplyAdditionalInformationDetail">
        <link:definition>995925 - Disclosure - In-Licensing and Supply - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails" id="DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Common Stock and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" id="DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>995945 - Disclosure - Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" id="StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
        <link:definition>995955 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail" id="DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail">
        <link:definition>995965 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" id="StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail">
        <link:definition>995975 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
        <link:definition>995985 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail" id="DisclosureRelatedpartyTransactionsAdditionalInformationDetail">
        <link:definition>996005 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" id="DisclosureSegmentInformationAdditionalInformationDetail">
        <link:definition>996015 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail" id="DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail">
        <link:definition>996025 - Disclosure - Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/CoverPage" xlink:href="spry-20250630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="spry-20250630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="spry-20250630.xsd#DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="spry-20250630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue" xlink:href="spry-20250630.xsd#DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories" xlink:href="spry-20250630.xsd#DisclosureInventories" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureMergerAndRelatedTransactions" xlink:href="spry-20250630.xsd#DisclosureMergerAndRelatedTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements" xlink:href="spry-20250630.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails" xlink:href="spry-20250630.xsd#DisclosureBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet" xlink:href="spry-20250630.xsd#DisclosureIntangibleAssetsNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements" xlink:href="spry-20250630.xsd#DisclosureCollaborationOutlicensingAndRelatedAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies" xlink:href="spry-20250630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply" xlink:href="spry-20250630.xsd#DisclosureInlicensingAndSupply" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity" xlink:href="spry-20250630.xsd#DisclosureCommonStockAndStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation" xlink:href="spry-20250630.xsd#StockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans" xlink:href="spry-20250630.xsd#EmployeeBenefitPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions" xlink:href="spry-20250630.xsd#DisclosureRelatedpartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation" xlink:href="spry-20250630.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="spry-20250630.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" xlink:href="spry-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolices" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="spry-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables" xlink:href="spry-20250630.xsd#DisclosureInventoriesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables" xlink:href="spry-20250630.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables" xlink:href="spry-20250630.xsd#DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables" xlink:href="spry-20250630.xsd#DisclosureIntangibleAssetsNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable" xlink:href="spry-20250630.xsd#DisclosureCollaborationOutlicensingAndRelatedAgreementsTable" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables" xlink:href="spry-20250630.xsd#DisclosureCommonStockAndStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables" xlink:href="spry-20250630.xsd#StockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="spry-20250630.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:href="spry-20250630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail" xlink:href="spry-20250630.xsd#DisclosureInventoriesScheduleOfInventoryDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureInventoriesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="spry-20250630.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="spry-20250630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="spry-20250630.xsd#DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail" xlink:href="spry-20250630.xsd#DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:href="spry-20250630.xsd#DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail" xlink:href="spry-20250630.xsd#DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail" xlink:href="spry-20250630.xsd#DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD" xlink:href="spry-20250630.xsd#DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureInlicensingAndSupplyAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails" xlink:href="spry-20250630.xsd#DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="spry-20250630.xsd#DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:href="spry-20250630.xsd#StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail" xlink:href="spry-20250630.xsd#DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:href="spry-20250630.xsd#StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="spry-20250630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="spry-20250630.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureRelatedpartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:href="spry-20250630.xsd#DisclosureSegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail" xlink:href="spry-20250630.xsd#DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2" xlink:href="spry-20250630.xsd#DisclosureInventoriesScheduleOfInventoryDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3" xlink:type="simple"/>
        <link:roleRef roleURI="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4" xlink:href="spry-20250630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LauraShawverMember" xlink:label="spry_LauraShawverMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldMember" xlink:label="spry_CostOfGoodsSoldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SeqirusAgreementMember" xlink:label="spry_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IntangibleAssetsMember" xlink:label="spry_IntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestrictedStockUnitsGrantedAndOutstandingMember" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontPayment" xlink:label="spry_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OrbiMedAdvisorsLLCMember" xlink:label="spry_OrbiMedAdvisorsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_KathleenScottMember" xlink:label="spry_KathleenScottMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedGrossToNetAdjustments" xlink:label="spry_AccruedGrossToNetAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RemainingRegulatoryMilestone" xlink:label="spry_RemainingRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseDecreaseInDonationOfEquipment" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SegmentOperatingExpenses" xlink:label="spry_SegmentOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpirationDate" xlink:label="spry_SupplyAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanEconomicAreaLicenseMember" xlink:label="spry_EuropeanEconomicAreaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ScheduleOfInventoryTableTextBlock" xlink:label="spry_ScheduleOfInventoryTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidSupplyAgreementFee" xlink:label="spry_PrepaidSupplyAgreementFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseFeesPolicyTextBlock" xlink:label="spry_LicenseFeesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PacificLinkConsultingLlcMember" xlink:label="spry_PacificLinkConsultingLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryAndCommercialSalesMilestones" xlink:label="spry_RegulatoryAndCommercialSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CollaborativeArrangementAbstract" xlink:label="spry_CollaborativeArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PediatrixAgreementMember" xlink:label="spry_PediatrixAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseCommonStockMember" xlink:label="spry_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerThreeMember" xlink:label="spry_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ContingentSalesBasedMilestones" xlink:label="spry_ContingentSalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseToTheFinancingLiability" xlink:label="spry_IncreaseToTheFinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestructuringPlanMember" xlink:label="spry_RestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationsPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SanDiegoCaliforniaMember" xlink:label="spry_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NewDrugApplicationMember" xlink:label="spry_NewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneAllocatedToTheEEALicense" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerTwoMember" xlink:label="spry_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrentAndNoncurrentNet" xlink:label="spry_InventoryCurrentAndNoncurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedCommonStockMember" xlink:label="spry_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NoticePeriodDescription" xlink:label="spry_NoticePeriodDescription"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquitySalesAgreementMember" xlink:label="spry_EquitySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SilverbackMember" xlink:label="spry_SilverbackMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TerminationAgreementMember" xlink:label="spry_TerminationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SalesBasedMilestones" xlink:label="spry_SalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_HeadquartersAmendmentMember" xlink:label="spry_HeadquartersAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCo-PromotionAgreementMember" xlink:label="spry_ALKCo-PromotionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeAllocatedToTheEEALicense" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NumberOfPediatricians" xlink:label="spry_NumberOfPediatricians"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueInputsLevel1AndLevel2Member" xlink:label="spry_FairValueInputsLevel1AndLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyTable" xlink:label="spry_InLicensingAndSupplyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedGains" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LiquidityAndCapitalResourcesMember" xlink:label="spry_LiquidityAndCapitalResourcesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentMember" xlink:label="spry_DevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneMember" xlink:label="spry_CommercialMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MarlinspikeGroupLlcMember" xlink:label="spry_MarlinspikeGroupLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ClinicalMember" xlink:label="spry_ClinicalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentDueOnAchievementOfAnnualSales" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RecordatiAgreementMember" xlink:label="spry_RecordatiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCollaborationAgreementMember" xlink:label="spry_ALKCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateSaleOfRecordatiLicensedProductMember" xlink:label="spry_AggregateSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMileStoneAmount" xlink:label="spry_RegulatoryMileStoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:label="spry_LicensingSupplyAndDistributionAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingandsupplyTextblock" xlink:label="spry_InLicensingandsupplyTextblock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RenaissanceLakewoodLlcMember" xlink:label="spry_RenaissanceLakewoodLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Share-BasedCompensationMember" xlink:label="spry_Share-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SarinaTanimotoMember" xlink:label="spry_SarinaTanimotoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityOfferingsMember" xlink:label="spry_EquityOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentAndRegulatoryServicesMember" xlink:label="spry_DevelopmentAndRegulatoryServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlfresaAgreementMember" xlink:label="spry_AlfresaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKFinancingLiabilityMember" xlink:label="spry_ALKFinancingLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePaymentsMember" xlink:label="spry_CapitalizedMilestonePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IprDExpenseMember" xlink:label="spry_IprDExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="us-gaap_OtherCommitmentDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontLicenseFees" xlink:label="spry_UpfrontLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2018Member" xlink:label="spry_EquityIncentivePlan2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanTwoMember" xlink:label="spry_PlanTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FoodAllergyResearchAndEducationIncMember" xlink:label="spry_FoodAllergyResearchAndEducationIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="us-gaap_OtherCommitmentDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestonePayment" xlink:label="spry_RegulatoryMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentsEarned" xlink:label="spry_MilestonePaymentsEarned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PerformanceBasedBonusPaymentsPercentage" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PatentsCostsPolicyTextBlock" xlink:label="spry_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ZeroCostInventory" xlink:label="spry_ZeroCostInventory"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFiveMember" xlink:label="spry_CustomerFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2016And2020Member" xlink:label="spry_EquityIncentivePlan2016And2020Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsMember" xlink:label="spry_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ArsPharmaMember" xlink:label="spry_ArsPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MedicalAffairsMember" xlink:label="spry_MedicalAffairsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedInventory" xlink:label="spry_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlansMember" xlink:label="spry_EquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanOneMember" xlink:label="spry_PlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ROWLicenseMember" xlink:label="spry_ROWLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationClaimsDescription" xlink:label="us-gaap_ContractTerminationClaimsDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeNotRecognized" xlink:label="spry_RoyaltyIncomeNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerOneMember" xlink:label="spry_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfRecordatiLicensedProductMember" xlink:label="spry_FirstCommercialSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePayments" xlink:label="spry_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SoftwareLicenseSubscriptionFeesMember" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RedTeamAssociatesLlcMember" xlink:label="spry_RedTeamAssociatesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OmpiSupplyAgreementMember" xlink:label="spry_OmpiSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanMedicinesAgencyMember" xlink:label="spry_EuropeanMedicinesAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LegalPatentFees" xlink:label="spry_LegalPatentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyLineItems" xlink:label="spry_InLicensingAndSupplyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKAgreementMember" xlink:label="spry_ALKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfNeffyMember" xlink:label="spry_FirstCommercialSaleOfNeffyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementMember" xlink:label="spry_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldOperatingExpense" xlink:label="spry_CostOfGoodsSoldOperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestonePayments" xlink:label="spry_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlexanderFitzpatrickMember" xlink:label="spry_AlexanderFitzpatrickMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFourMember" xlink:label="spry_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementExpirationTerm" xlink:label="spry_LicenseAgreementExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="us-gaap_OtherCommitmentDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InitialTransactionPrice" xlink:label="spry_InitialTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestone" xlink:label="spry_RegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiabilityIncludedInAccountsReceivable" xlink:label="spry_FinancingLiabilityIncludedInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesTable" xlink:label="spry_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsGrantedAndOutstandingMember" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="us-gaap_OtherCommitmentDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiability" xlink:label="spry_FinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingandsupplyAbstract" xlink:label="spry_InLicensingandsupplyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderSupplyAgreementsMember" xlink:label="spry_RevenueUnderSupplyAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerSixMember" xlink:label="spry_CustomerSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidMarketingExpenses" xlink:label="spry_PrepaidMarketingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ThresholdPercentageOfValueChangeInEquitySecurities" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrent" xlink:label="spry_InventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedRestrictedStockUnitsMember" xlink:label="spry_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TitleAgentMember" xlink:label="spry_TitleAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpense" xlink:label="spry_SupplyAgreementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="spry_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RichardLowenthalMember" xlink:label="spry_RichardLowenthalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AgreementTerminationDueToMaterialBreach" xlink:label="spry_AgreementTerminationDueToMaterialBreach"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OperatingRightOfUseAssetsAndLeaseLiabilities" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LauraShawverMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laura Shawver [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LauraShawverMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laura Shawver.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LauraShawverMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laura Shawver [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Common Stock Reserved For Issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligation, transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods Sold [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of Goods Sold [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Goods Sold [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seqirus Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seqirus Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seqirus Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Including Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncancelable lease agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Amount Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense capitalized to inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted stock units granted and outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units granted and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Granted and Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JAPAN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OrbiMedAdvisorsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrbiMed Advisors LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OrbiMedAdvisorsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">OrbiMed Advisors LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OrbiMedAdvisorsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OrbiMed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_KathleenScottMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Kathleen Scott [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_KathleenScottMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Kathleen Scott [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_KathleenScottMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Kathleen Scott.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedGrossToNetAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Gross to Net Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedGrossToNetAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued gross to net adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedGrossToNetAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued gross-to-net adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RemainingRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RemainingRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RemainingRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValueLiabilitiesLevel2ToLevel1TransfersAmount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueLiabilitiesLevel2ToLevel1TransfersAmount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities transfers from Level 2 to Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) in Donation of Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Donation of Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Donation of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Donation of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life of Finite Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SegmentOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total segment operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SegmentOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SegmentOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Segment operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply agreement expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EuropeanEconomicAreaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">European Economic Area License [ Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EuropeanEconomicAreaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">European economic area license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EuropeanEconomicAreaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EEA License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfInventoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfInventoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of inventory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ScheduleOfInventoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidSupplyAgreementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Supply Agreement Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidSupplyAgreementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid supply agreement fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidSupplyAgreementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid supply agreement fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseFeesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseFeesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Fees Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseFeesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License fees policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PacificLinkConsultingLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacific-Link Consulting, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PacificLinkConsultingLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pacific-Link Consulting, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PacificLinkConsultingLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacific-Link Consulting, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining noncancelable lease term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryAndCommercialSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory and Commercial Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryAndCommercialSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and Commercial sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CollaborativeArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CollaborativeArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants To Purchase Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments, available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PediatrixAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatrix Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PediatrixAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatrix Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized under the ALK Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ContingentSalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Sales-Based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ContingentSalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent sales-based milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ContingentSalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Sales-Based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseToTheFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase to the Financing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseToTheFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">increase to the financing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseToTheFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase to the financing liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IncreaseToTheFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial milestone allocated to the EEA License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional purchase obligations, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities, Gross unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments upon achievement of certain sales milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments upon achievement of certain sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate milestone payments upon achievement of certain sales milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March Restructuring Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligations amount made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligations Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecorded unconditional purchase obligations paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">San Diego California Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">San Diego California Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Drug Application</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Drug Application [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Drug Application [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Options Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Subject to Options Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future awards or option grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone allocated to the EEA License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Allocated to the EEA License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone allocated to the EEA License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Options Exercisable, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) gain, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncancelable lease term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period for First New Delivery Method of Epinephrine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for first new delivery method of epinephrine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for first new delivery method of epinephrine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrentAndNoncurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Current and Noncurrent Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrentAndNoncurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory current and noncurrent net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrentAndNoncurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net unrealized holding gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gains and losses on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice Period Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notice Period Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice Period Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquitySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquitySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquitySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long Term Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Capitalized Computer Software, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Capitalized Computer Software, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Capitalized Computer Software, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized software implementation costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SilverbackMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silverback [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SilverbackMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silverback [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SilverbackMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silverback [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter through 2035</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecorded unconditional purchase obligation to be paid after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_TerminationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_TerminationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-Based Milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-Based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SalesBasedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales-Based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_HeadquartersAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Headquarters Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_HeadquartersAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Headquarters Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_HeadquartersAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Headquarters amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Options Outstanding, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCo-PromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ALK Co-Promotion Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCo-PromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ALK Co-Promotion Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCo-PromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ALK co-promotion agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based royalties earned in the EEA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Income Allocated To The EEA License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty income allocated to the EEA license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NumberOfPediatricians_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of pediatricians</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NumberOfPediatricians_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pediatricians</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_NumberOfPediatricians_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of pediatricians</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueInputsLevel1AndLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 And Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueInputsLevel1AndLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level 1 And Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueInputsLevel1AndLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value inputs level 1 and level 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingAndSupplyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Licensing And Supply [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingAndSupplyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about in-licensing and supply.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents gross unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash And Cash Equivalents Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annualized payment of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash paid for leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional purchase obligations, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued under the employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share purchased under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price Exercisable , Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration, Out-Licensing and Related Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss and comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and Capital Resources [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Capital Resources [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product revenue, net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MarlinspikeGroupLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marlinspike Group, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MarlinspikeGroupLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marlinspike Group, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MarlinspikeGroupLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marlinspike Group, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold expenses related party amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of goods sold (including related party amounts of $866 $0, $1,354, and $0, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ClinicalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due On Achievement Of Annual Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due on achievement of annual sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Noncancelable Operating Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RecordatiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recordati Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RecordatiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recordati Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options forfeited in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ALK Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A L K Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A L K collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional purchase obligations, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss), Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateSaleOfRecordatiLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate sale of Recordati Licensed Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateSaleOfRecordatiLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate sale of Recordati Licensed Product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMileStoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Mile Stone Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMileStoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory mile Stone amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMileStoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised and restricted stock units released shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised and Restricted Stock Units Released Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options and release of restricted stock units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Life (Years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Commitment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicensingSupplyAndDistributionAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Supply And Distribution Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicensingSupplyAndDistributionAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing Supply And Distribution Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingandsupplyTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Licensing and Supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingandsupplyTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In-LicensingAndSupply[Textblock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingandsupplyTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In-licensing and supply [Textblock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Income, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based royalties earned in the EEA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Lease Weighted Average Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RenaissanceLakewoodLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renaissance Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RenaissanceLakewoodLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renaissance Lakewood, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RenaissanceLakewoodLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Renaissance Lakewood, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Share-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Share-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_Share-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger and Related Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventories [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue under collaboration agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Under Collaboration Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue under collaboration agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue under collaboration agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Account Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CapitalizedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CapitalizedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CapitalizedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Lease Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SarinaTanimotoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sarina Tanimoto [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SarinaTanimotoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sarina Tanimoto [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SarinaTanimotoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sarina Tanimoto.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including related party amounts of $582, $518, $1,245, and $1,245, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses related party amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Options Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation number of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Offerings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity offerings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Offerings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentAndRegulatoryServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentAndRegulatoryServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_DevelopmentAndRegulatoryServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AlfresaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alfresa Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AlfresaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alfresa Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKFinancingLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ALK Financing Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKFinancingLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ALK Financing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Administrative Fees Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CapitalizedMilestonePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Milestone Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CapitalizedMilestonePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IprDExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPR&amp;D Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_IprDExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IPR&amp;D expense .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Revenue under collaboration agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses related party amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative (including related party amounts of $107, $114, $231, and $208, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potentially dilutive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Incentive Plan 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate offering price of securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and Cash Equivalents Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Plan two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FoodAllergyResearchAndEducationIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Food Allergy Research and Education Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FoodAllergyResearchAndEducationIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Food Allergy Research and Education Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FoodAllergyResearchAndEducationIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Food Allergy Research and Education Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock reserved for future employee stock purchase plan issuances [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future employee stock purchase plan issuances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved For Future Employee Stock Purchase Plan Issuances [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional purchase obligations, 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentsEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentsEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments earned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePaymentsEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance based bonus payments percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Bonus Payments Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based bonus payments percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of credit risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Marketing Costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued marketing related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents costs policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ZeroCostInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zero Cost Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ZeroCostInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zero-cost inventory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ZeroCostInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zero cost inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Commitment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total segment operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized holding gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds and Available For Sale Debt Securities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money Market Funds and Available For Sale Debt Securities Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2016And2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan 2016 And 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2016And2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Incentive Plan 2016 And 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlan2016And2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan 2016 and 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">common stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted common stock, vesting in equal monthly installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ArsPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARS Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ArsPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ARS Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ArsPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ARS Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Shares Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets transfers into (out of) level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MedicalAffairsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medical Affairs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MedicalAffairsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medical affairs member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MedicalAffairsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medical affairs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued inventory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Incentive Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Plan one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ROWLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ROW License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ROWLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ROW license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ROWLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROW License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationClaimsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Termination Claims, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationClaimsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Termination Claims, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash And cash equivalents And available for sale debt securities amortized cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Income not Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty income not recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales-based royalties earned in the EEA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RoyaltyIncomeNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty income not recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FirstCommercialSaleOfRecordatiLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First commercial sale of Recordati Licensed Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FirstCommercialSaleOfRecordatiLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First commercial sale of Recordati Licensed Product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses, Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Life (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock reserved for future awards or option grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future awards or option grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved For Future Awards or Option Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related parties, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software License Subscription Fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software License Subscription Fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software license subscription fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RedTeamAssociatesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Red Team Associates, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RedTeamAssociatesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Red Team Associates, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RedTeamAssociatesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Red Team Associates, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OmpiSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ompi Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OmpiSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ompi supply agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OmpiSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ompi Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EuropeanMedicinesAgencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">European Medicines Agency [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_EuropeanMedicinesAgencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">European Medicines Agency.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Patent Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Patent Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal Patent Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingAndSupplyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Licensing and Supply [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingAndSupplyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represents in licensing and supply.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock , shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net change in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ALK Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ALK Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ALKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ALK Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 (remaining six months)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution totaled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FirstCommercialSaleOfNeffyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Commercial Sale Of Neffy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FirstCommercialSaleOfNeffyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Commercial Sale Of Neffy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FirstCommercialSaleOfNeffyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First commercial sale of neffy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AegisTherapeuticsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aegis Therapeutics Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AegisTherapeuticsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aegis Therapeutics LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AegisTherapeuticsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aegis Therapeutics LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash Equivalents, and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Options Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods Sold Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of goods sold operating expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CostOfGoodsSoldOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold (including related party amounts of $866, $0, $1,354, and $0, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Product Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Goods Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional&#160;paid-in&#160;capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AlexanderFitzpatrickMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alexander Fitzpatrick [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AlexanderFitzpatrickMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alexander Fitzpatrick.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AlexanderFitzpatrickMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alexander Fitzpatrick [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">U.S. Treasury securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less lease liability, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less lease liability, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseAgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_LicenseAgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiration term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecorded unconditional purchase obligation paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligations amount made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InitialTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InitialTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial transaction Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiabilityIncludedInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Liability Included in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiabilityIncludedInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing liability included in accounts receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiabilityIncludedInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing liability included in accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options Granted and Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Granted and Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options granted and outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, 2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecorded Unconditional Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecorded Unconditional Purchase Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional purchase obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 (remaining six months)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_FinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash adjustments to reconcile net loss to net cash used operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingandsupplyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In-LicensingAndSupply [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InLicensingandsupplyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In-licensing and supply Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Under Supply Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue under supply agreements member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue under supply agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RevenueUnderSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue under supply agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_CustomerSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Guarantees, Commitments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidMarketingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Marketing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidMarketingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid marketing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_PrepaidMarketingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at June 30, 2025 and December 31, 2024; 98,697,658 and 97,954,172 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Future Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Percentage of Value Change in Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold percentage of value change in equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_InventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Reporting Provided to the CODM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Rights and Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction under agreement with A.L.K U.S</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_TitleAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Agent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_TitleAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Title agent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_TitleAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title Agent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SupplyAgreementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply Agreement Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion on investments, net of amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset obtained in exchange for operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RichardLowenthalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Richard Lowenthal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RichardLowenthalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Richard Lowenthal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_RichardLowenthalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Richard Lowenthal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AgreementTerminationDueToMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement Termination, Due To Material Breach</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AgreementTerminationDueToMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Due To Material Breach</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_AgreementTerminationDueToMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination, due to material breach.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Right of Use Assets And Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Right of Use Assets And Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset and lease liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable and Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities (including related party amounts of $1,091 and $656, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of short-term investments, available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LauraShawverMember" xlink:to="spry_LauraShawverMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:to="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CostOfGoodsSoldMember" xlink:to="spry_CostOfGoodsSoldMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SeqirusAgreementMember" xlink:to="spry_SeqirusAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_IntangibleAssetsMember" xlink:to="spry_IntangibleAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RestrictedStockUnitsGrantedAndOutstandingMember" xlink:to="spry_RestrictedStockUnitsGrantedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UpfrontPayment" xlink:to="spry_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_OrbiMedAdvisorsLLCMember" xlink:to="spry_OrbiMedAdvisorsLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_KathleenScottMember" xlink:to="spry_KathleenScottMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AccruedGrossToNetAdjustments" xlink:to="spry_AccruedGrossToNetAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RemainingRegulatoryMilestone" xlink:to="spry_RemainingRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" xlink:to="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_IncreaseDecreaseInDonationOfEquipment" xlink:to="spry_IncreaseDecreaseInDonationOfEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SegmentOperatingExpenses" xlink:to="spry_SegmentOperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SupplyAgreementExpirationDate" xlink:to="spry_SupplyAgreementExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EuropeanEconomicAreaLicenseMember" xlink:to="spry_EuropeanEconomicAreaLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ScheduleOfInventoryTableTextBlock" xlink:to="spry_ScheduleOfInventoryTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PrepaidSupplyAgreementFee" xlink:to="spry_PrepaidSupplyAgreementFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LicenseFeesPolicyTextBlock" xlink:to="spry_LicenseFeesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PacificLinkConsultingLlcMember" xlink:to="spry_PacificLinkConsultingLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RegulatoryAndCommercialSalesMilestones" xlink:to="spry_RegulatoryAndCommercialSalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CollaborativeArrangementAbstract" xlink:to="spry_CollaborativeArrangementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:to="spry_WarrantsToPurchaseConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="us-gaap_RegulatoryAgencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PediatrixAgreementMember" xlink:to="spry_PediatrixAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_WarrantsToPurchaseCommonStockMember" xlink:to="spry_WarrantsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerThreeMember" xlink:to="spry_CustomerThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ContingentSalesBasedMilestones" xlink:to="spry_ContingentSalesBasedMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_IncreaseToTheFinancingLiability" xlink:to="spry_IncreaseToTheFinancingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" xlink:to="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:to="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RestructuringPlanMember" xlink:to="spry_RestructuringPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UnrecordedUnconditionalPurchaseObligationsPaid" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationsPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SanDiegoCaliforniaMember" xlink:to="spry_SanDiegoCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_NewDrugApplicationMember" xlink:to="spry_NewDrugApplicationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommercialMilestoneAllocatedToTheEEALicense" xlink:to="spry_CommercialMilestoneAllocatedToTheEEALicense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerTwoMember" xlink:to="spry_CustomerTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" xlink:to="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InventoryCurrentAndNoncurrentNet" xlink:to="spry_InventoryCurrentAndNoncurrentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UnvestedCommonStockMember" xlink:to="spry_UnvestedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_NoticePeriodDescription" xlink:to="spry_NoticePeriodDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EquitySalesAgreementMember" xlink:to="spry_EquitySalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SilverbackMember" xlink:to="spry_SilverbackMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_TerminationAgreementMember" xlink:to="spry_TerminationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SalesBasedMilestones" xlink:to="spry_SalesBasedMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_HeadquartersAmendmentMember" xlink:to="spry_HeadquartersAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ALKCo-PromotionAgreementMember" xlink:to="spry_ALKCo-PromotionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RoyaltyIncomeAllocatedToTheEEALicense" xlink:to="spry_RoyaltyIncomeAllocatedToTheEEALicense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_NumberOfPediatricians" xlink:to="spry_NumberOfPediatricians_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FairValueInputsLevel1AndLevel2Member" xlink:to="spry_FairValueInputsLevel1AndLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="spry_InLicensingAndSupplyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CashAndCashEquivalentsGrossUnrealizedGains" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LiquidityAndCapitalResourcesMember" xlink:to="spry_LiquidityAndCapitalResourcesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_DevelopmentMember" xlink:to="spry_DevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommercialMilestoneMember" xlink:to="spry_CommercialMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MarlinspikeGroupLlcMember" xlink:to="spry_MarlinspikeGroupLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ClinicalMember" xlink:to="spry_ClinicalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MilestonePaymentDueOnAchievementOfAnnualSales" xlink:to="spry_MilestonePaymentDueOnAchievementOfAnnualSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RecordatiAgreementMember" xlink:to="spry_RecordatiAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ALKCollaborationAgreementMember" xlink:to="spry_ALKCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AggregateSaleOfRecordatiLicensedProductMember" xlink:to="spry_AggregateSaleOfRecordatiLicensedProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RegulatoryMileStoneAmount" xlink:to="spry_RegulatoryMileStoneAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" xlink:to="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:to="spry_LicensingSupplyAndDistributionAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InLicensingandsupplyTextblock" xlink:to="spry_InLicensingandsupplyTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RenaissanceLakewoodLlcMember" xlink:to="spry_RenaissanceLakewoodLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_Share-BasedCompensationMember" xlink:to="spry_Share-BasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoriesMember" xlink:to="us-gaap_InventoriesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RevenueUnderCollaborationAgreementsMember" xlink:to="spry_RevenueUnderCollaborationAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CapitalizedMilestonePayments" xlink:to="spry_CapitalizedMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SarinaTanimotoMember" xlink:to="spry_SarinaTanimotoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EquityOfferingsMember" xlink:to="spry_EquityOfferingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_DevelopmentAndRegulatoryServicesMember" xlink:to="spry_DevelopmentAndRegulatoryServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AlfresaAgreementMember" xlink:to="spry_AlfresaAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ALKFinancingLiabilityMember" xlink:to="spry_ALKFinancingLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CapitalizedMilestonePaymentsMember" xlink:to="spry_CapitalizedMilestonePaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_IprDExpenseMember" xlink:to="spry_IprDExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInFourthYear" xlink:to="us-gaap_OtherCommitmentDueInFourthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UpfrontLicenseFees" xlink:to="spry_UpfrontLicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EquityIncentivePlan2018Member" xlink:to="spry_EquityIncentivePlan2018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PlanTwoMember" xlink:to="spry_PlanTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FoodAllergyResearchAndEducationIncMember" xlink:to="spry_FoodAllergyResearchAndEducationIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInThirdYear" xlink:to="us-gaap_OtherCommitmentDueInThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" xlink:to="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RegulatoryMilestonePayment" xlink:to="spry_RegulatoryMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MilestonePaymentsEarned" xlink:to="spry_MilestonePaymentsEarned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PerformanceBasedBonusPaymentsPercentage" xlink:to="spry_PerformanceBasedBonusPaymentsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PatentsCostsPolicyTextBlock" xlink:to="spry_PatentsCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ZeroCostInventory" xlink:to="spry_ZeroCostInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerFiveMember" xlink:to="spry_CustomerFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:to="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EquityIncentivePlan2016And2020Member" xlink:to="spry_EquityIncentivePlan2016And2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommonStockOptionsMember" xlink:to="spry_CommonStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ArsPharmaMember" xlink:to="spry_ArsPharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" xlink:to="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MedicalAffairsMember" xlink:to="spry_MedicalAffairsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AccruedInventory" xlink:to="spry_AccruedInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EquityIncentivePlansMember" xlink:to="spry_EquityIncentivePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PlanOneMember" xlink:to="spry_PlanOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ROWLicenseMember" xlink:to="spry_ROWLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationClaimsDescription" xlink:to="us-gaap_ContractTerminationClaimsDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RoyaltyIncomeNotRecognized" xlink:to="spry_RoyaltyIncomeNotRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerOneMember" xlink:to="spry_CustomerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FirstCommercialSaleOfRecordatiLicensedProductMember" xlink:to="spry_FirstCommercialSaleOfRecordatiLicensedProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_MilestonePayments" xlink:to="spry_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" xlink:to="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SoftwareLicenseSubscriptionFeesMember" xlink:to="spry_SoftwareLicenseSubscriptionFeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RedTeamAssociatesLlcMember" xlink:to="spry_RedTeamAssociatesLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_OmpiSupplyAgreementMember" xlink:to="spry_OmpiSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_EuropeanMedicinesAgencyMember" xlink:to="spry_EuropeanMedicinesAgencyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LegalPatentFees" xlink:to="spry_LegalPatentFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_InLicensingAndSupplyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ALKAgreementMember" xlink:to="spry_ALKAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FirstCommercialSaleOfNeffyMember" xlink:to="spry_FirstCommercialSaleOfNeffyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LicenseAgreementMember" xlink:to="spry_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AegisTherapeuticsLlcMember" xlink:to="spry_AegisTherapeuticsLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CostOfGoodsSoldOperatingExpense" xlink:to="spry_CostOfGoodsSoldOperatingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommercialMilestonePayments" xlink:to="spry_CommercialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AlexanderFitzpatrickMember" xlink:to="spry_AlexanderFitzpatrickMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerFourMember" xlink:to="spry_CustomerFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AggregateMilestonePayments" xlink:to="spry_AggregateMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_LicenseAgreementExpirationTerm" xlink:to="spry_LicenseAgreementExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitmentDueInSecondYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UnrecordedUnconditionalPurchaseObligationPaid" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InitialTransactionPrice" xlink:to="spry_InitialTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RegulatoryMilestone" xlink:to="spry_RegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FinancingLiabilityIncludedInAccountsReceivable" xlink:to="spry_FinancingLiabilityIncludedInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="spry_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CommonStockOptionsGrantedAndOutstandingMember" xlink:to="spry_CommonStockOptionsGrantedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInFifthYear" xlink:to="us-gaap_OtherCommitmentDueInFifthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_FinancingLiability" xlink:to="spry_FinancingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InLicensingandsupplyAbstract" xlink:to="spry_InLicensingandsupplyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RevenueUnderSupplyAgreementsMember" xlink:to="spry_RevenueUnderSupplyAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_CustomerSixMember" xlink:to="spry_CustomerSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_PrepaidMarketingExpenses" xlink:to="spry_PrepaidMarketingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_ThresholdPercentageOfValueChangeInEquitySecurities" xlink:to="spry_ThresholdPercentageOfValueChangeInEquitySecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_InventoryCurrent" xlink:to="spry_InventoryCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_UnvestedRestrictedStockUnitsMember" xlink:to="spry_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_TitleAgentMember" xlink:to="spry_TitleAgentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SupplyAgreementExpense" xlink:to="spry_SupplyAgreementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="spry_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_RichardLowenthalMember" xlink:to="spry_RichardLowenthalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_AgreementTerminationDueToMaterialBreach" xlink:to="spry_AgreementTerminationDueToMaterialBreach_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="spry_OperatingRightOfUseAssetsAndLeaseLiabilities" xlink:to="spry_OperatingRightOfUseAssetsAndLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiability" xlink:label="spry_FinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrent" xlink:label="spry_InventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="spry_FinancingLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="spry_InventoryCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldOperatingExpense" xlink:label="spry_CostOfGoodsSoldOperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderSupplyAgreementsMember" xlink:label="spry_RevenueUnderSupplyAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="spry_CostOfGoodsSoldOperatingExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderSupplyAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiabilityIncludedInAccountsReceivable" xlink:label="spry_FinancingLiabilityIncludedInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseDecreaseInDonationOfEquipment" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OperatingRightOfUseAssetsAndLeaseLiabilities" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="spry_FinancingLiabilityIncludedInAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="spry_IncreaseDecreaseInDonationOfEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="spry_OperatingRightOfUseAssetsAndLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanOneMember" xlink:label="spry_PlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanTwoMember" xlink:label="spry_PlanTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RichardLowenthalMember" xlink:label="spry_RichardLowenthalMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SarinaTanimotoMember" xlink:label="spry_SarinaTanimotoMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LauraShawverMember" xlink:label="spry_LauraShawverMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_KathleenScottMember" xlink:label="spry_KathleenScottMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlexanderFitzpatrickMember" xlink:label="spry_AlexanderFitzpatrickMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="spry_PlanOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="spry_PlanTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_RichardLowenthalMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_SarinaTanimotoMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_LauraShawverMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_KathleenScottMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_AlexanderFitzpatrickMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureMergerAndRelatedTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingandsupplyAbstract" xlink:label="spry_InLicensingandsupplyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingandsupplyTextblock" xlink:label="spry_InLicensingandsupplyTextblock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingandsupplyAbstract" xlink:to="spry_InLicensingandsupplyTextblock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PatentsCostsPolicyTextBlock" xlink:label="spry_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseFeesPolicyTextBlock" xlink:label="spry_LicenseFeesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="spry_PatentsCostsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="spry_LicenseFeesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ScheduleOfInventoryTableTextBlock" xlink:label="spry_ScheduleOfInventoryTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="spry_ScheduleOfInventoryTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CollaborativeArrangementAbstract" xlink:label="spry_CollaborativeArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_CollaborativeArrangementAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestructuringPlanMember" xlink:label="spry_RestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ArsPharmaMember" xlink:label="spry_ArsPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LiquidityAndCapitalResourcesMember" xlink:label="spry_LiquidityAndCapitalResourcesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SilverbackMember" xlink:label="spry_SilverbackMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="spry_RestructuringPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="spry_ArsPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="spry_LiquidityAndCapitalResourcesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="spry_SilverbackMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringPlanAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TitleAgentMember" xlink:label="spry_TitleAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesTable" xlink:label="spry_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="spry_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerOneMember" xlink:label="spry_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerTwoMember" xlink:label="spry_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerThreeMember" xlink:label="spry_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFourMember" xlink:label="spry_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFiveMember" xlink:label="spry_CustomerFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerSixMember" xlink:label="spry_CustomerSixMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_TitleAgentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="spry_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerFourMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="spry_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerFiveMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerSixMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseCommonStockMember" xlink:label="spry_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsMember" xlink:label="spry_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedRestrictedStockUnitsMember" xlink:label="spry_UnvestedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseConvertiblePreferredStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseCommonStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_CommonStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockOptionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_UnvestedRestrictedStockUnitsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrentAndNoncurrentNet" xlink:label="spry_InventoryCurrentAndNoncurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrent" xlink:label="spry_InventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="spry_InventoryCurrentAndNoncurrentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="spry_InventoryCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ZeroCostInventory" xlink:label="spry_ZeroCostInventory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="spry_ZeroCostInventory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedGains" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueInputsLevel1AndLevel2Member" xlink:label="spry_FairValueInputsLevel1AndLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="spry_FairValueInputsLevel1AndLevel2Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidMarketingExpenses" xlink:label="spry_PrepaidMarketingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="spry_PrepaidMarketingExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InterestReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidSupplyAgreementFee" xlink:label="spry_PrepaidSupplyAgreementFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="spry_PrepaidSupplyAgreementFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedGrossToNetAdjustments" xlink:label="spry_AccruedGrossToNetAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedInventory" xlink:label="spry_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="spry_AccruedGrossToNetAdjustments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="spry_AccruedInventory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TerminationAgreementMember" xlink:label="spry_TerminationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePaymentsMember" xlink:label="spry_CapitalizedMilestonePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RecordatiAgreementMember" xlink:label="spry_RecordatiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_TerminationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="spry_CapitalizedMilestonePaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="spry_AggregateMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AegisTherapeuticsLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="spry_CapitalizedMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RecordatiAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="spry_CapitalizedMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementMember" xlink:label="spry_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanMedicinesAgencyMember" xlink:label="spry_EuropeanMedicinesAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfRecordatiLicensedProductMember" xlink:label="spry_FirstCommercialSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlfresaAgreementMember" xlink:label="spry_AlfresaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:label="spry_LicensingSupplyAndDistributionAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKFinancingLiabilityMember" xlink:label="spry_ALKFinancingLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontPayment" xlink:label="spry_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TerminationAgreementMember" xlink:label="spry_TerminationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateSaleOfRecordatiLicensedProductMember" xlink:label="spry_AggregateSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RecordatiAgreementMember" xlink:label="spry_RecordatiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementExpirationTerm" xlink:label="spry_LicenseAgreementExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IprDExpenseMember" xlink:label="spry_IprDExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfNeffyMember" xlink:label="spry_FirstCommercialSaleOfNeffyMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PediatrixAgreementMember" xlink:label="spry_PediatrixAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanEconomicAreaLicenseMember" xlink:label="spry_EuropeanEconomicAreaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SeqirusAgreementMember" xlink:label="spry_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePayments" xlink:label="spry_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ROWLicenseMember" xlink:label="spry_ROWLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCollaborationAgreementMember" xlink:label="spry_ALKCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentAndRegulatoryServicesMember" xlink:label="spry_DevelopmentAndRegulatoryServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCo-PromotionAgreementMember" xlink:label="spry_ALKCo-PromotionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneMember" xlink:label="spry_CommercialMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InitialTransactionPrice" xlink:label="spry_InitialTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneAllocatedToTheEEALicense" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseToTheFinancingLiability" xlink:label="spry_IncreaseToTheFinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeNotRecognized" xlink:label="spry_RoyaltyIncomeNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NumberOfPediatricians" xlink:label="spry_NumberOfPediatricians"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PerformanceBasedBonusPaymentsPercentage" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ThresholdPercentageOfValueChangeInEquitySecurities" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestonePayment" xlink:label="spry_RegulatoryMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentsEarned" xlink:label="spry_MilestonePaymentsEarned"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RemainingRegulatoryMilestone" xlink:label="spry_RemainingRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryAndCommercialSalesMilestones" xlink:label="spry_RegulatoryAndCommercialSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestonePayments" xlink:label="spry_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SalesBasedMilestones" xlink:label="spry_SalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ContingentSalesBasedMilestones" xlink:label="spry_ContingentSalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiability" xlink:label="spry_FinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="spry_EuropeanMedicinesAgencyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfRecordatiLicensedProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AlfresaAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="spry_ALKFinancingLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_TerminationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_AggregateSaleOfRecordatiLicensedProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RecordatiAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_LicenseAgreementExpirationTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_IprDExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfNeffyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_PediatrixAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_AggregateMilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_EuropeanEconomicAreaLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_SeqirusAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_MilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_ROWLicenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCollaborationAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_DevelopmentAndRegulatoryServicesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCo-PromotionAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_CommercialMilestoneMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_InitialTransactionPrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_CommercialMilestoneAllocatedToTheEEALicense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_IncreaseToTheFinancingLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RoyaltyIncomeNotRecognized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_NumberOfPediatricians" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_PerformanceBasedBonusPaymentsPercentage" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_ThresholdPercentageOfValueChangeInEquitySecurities" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RegulatoryMilestonePayment" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_MilestonePaymentsEarned" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RemainingRegulatoryMilestone" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RegulatoryAndCommercialSalesMilestones" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_CommercialMilestonePayments" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_SalesBasedMilestones" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_ContingentSalesBasedMilestones" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_FinancingLiability" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCollaborationAgreementMember" xlink:label="spry_ALKCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:label="spry_LicensingSupplyAndDistributionAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKFinancingLiabilityMember" xlink:label="spry_ALKFinancingLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseToTheFinancingLiability" xlink:label="spry_IncreaseToTheFinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeAllocatedToTheEEALicense" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_LicensingSupplyAndDistributionAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="spry_ALKFinancingLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_IncreaseToTheFinancingLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RoyaltyIncomeAllocatedToTheEEALicense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SanDiegoCaliforniaMember" xlink:label="spry_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_HeadquartersAmendmentMember" xlink:label="spry_HeadquartersAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="spry_SanDiegoCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="spry_HeadquartersAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCo-PromotionAgreementMember" xlink:label="spry_ALKCo-PromotionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FoodAllergyResearchAndEducationIncMember" xlink:label="spry_FoodAllergyResearchAndEducationIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SoftwareLicenseSubscriptionFeesMember" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="us-gaap_OtherCommitmentDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="us-gaap_OtherCommitmentDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="us-gaap_OtherCommitmentDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="us-gaap_OtherCommitmentDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationsPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="spry_ALKCo-PromotionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_InventoriesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="spry_FoodAllergyResearchAndEducationIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="spry_SoftwareLicenseSubscriptionFeesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInSecondYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInThirdYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInFourthYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInFifthYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationPaid" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationsPaid" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OmpiSupplyAgreementMember" xlink:label="spry_OmpiSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfNeffyMember" xlink:label="spry_FirstCommercialSaleOfNeffyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyTable" xlink:label="spry_InLicensingAndSupplyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember_0"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NewDrugApplicationMember" xlink:label="spry_NewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyLineItems" xlink:label="spry_InLicensingAndSupplyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontLicenseFees" xlink:label="spry_UpfrontLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingandsupplyAbstract" xlink:label="spry_InLicensingandsupplyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IntangibleAssetsMember" xlink:label="spry_IntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RenaissanceLakewoodLlcMember" xlink:label="spry_RenaissanceLakewoodLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestone" xlink:label="spry_RegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePayments" xlink:label="spry_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentDueOnAchievementOfAnnualSales" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMileStoneAmount" xlink:label="spry_RegulatoryMileStoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NoticePeriodDescription" xlink:label="spry_NoticePeriodDescription"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LegalPatentFees" xlink:label="spry_LegalPatentFees"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpense" xlink:label="spry_SupplyAgreementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationClaimsDescription" xlink:label="us-gaap_ContractTerminationClaimsDescription"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontPayment" xlink:label="spry_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpirationDate" xlink:label="spry_SupplyAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AgreementTerminationDueToMaterialBreach" xlink:label="spry_AgreementTerminationDueToMaterialBreach"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_OmpiSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfNeffyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AegisTherapeuticsLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="spry_AegisTherapeuticsLlcMember_0" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="spry_NewDrugApplicationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_UpfrontLicenseFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingandsupplyAbstract" xlink:to="spry_InLicensingAndSupplyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="spry_IntangibleAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RenaissanceLakewoodLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AggregateMilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_RegulatoryMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_MilestonePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="spry_InLicensingAndSupplyLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_MilestonePaymentDueOnAchievementOfAnnualSales" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_RegulatoryMileStoneAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_CapitalizedMilestonePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_NoticePeriodDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_LegalPatentFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_SupplyAgreementExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_ContractTerminationClaimsDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_UpfrontPayment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_SupplyAgreementExpirationDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AgreementTerminationDueToMaterialBreach" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquitySalesAgreementMember" xlink:label="spry_EquitySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityOfferingsMember" xlink:label="spry_EquityOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_EquitySalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="spry_EquityOfferingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsGrantedAndOutstandingMember" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestrictedStockUnitsGrantedAndOutstandingMember" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseCommonStockMember" xlink:label="spry_WarrantsToPurchaseCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockOptionsGrantedAndOutstandingMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_RestrictedStockUnitsGrantedAndOutstandingMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseCommonStockMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedCommonStockMember" xlink:label="spry_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlansMember" xlink:label="spry_EquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2016And2020Member" xlink:label="spry_EquityIncentivePlan2016And2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2018Member" xlink:label="spry_EquityIncentivePlan2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="spry_UnvestedCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="spry_EquityIncentivePlansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_EquityIncentivePlan2016And2020Member" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_EquityIncentivePlan2018Member" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PacificLinkConsultingLlcMember" xlink:label="spry_PacificLinkConsultingLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OrbiMedAdvisorsLLCMember" xlink:label="spry_OrbiMedAdvisorsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MarlinspikeGroupLlcMember" xlink:label="spry_MarlinspikeGroupLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RedTeamAssociatesLlcMember" xlink:label="spry_RedTeamAssociatesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_PacificLinkConsultingLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_OrbiMedAdvisorsLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_MarlinspikeGroupLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_RedTeamAssociatesLlcMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RoyaltyExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKAgreementMember" xlink:label="spry_ALKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SegmentOperatingExpenses" xlink:label="spry_SegmentOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldMember" xlink:label="spry_CostOfGoodsSoldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ClinicalMember" xlink:label="spry_ClinicalMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderSupplyAgreementsMember" xlink:label="spry_RevenueUnderSupplyAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentMember" xlink:label="spry_DevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MedicalAffairsMember" xlink:label="spry_MedicalAffairsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Share-BasedCompensationMember" xlink:label="spry_Share-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="spry_SegmentOperatingExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_CostOfGoodsSoldMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_ClinicalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderSupplyAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_DevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_MedicalAffairsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_Share-BasedCompensationMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldOperatingExpense" xlink:label="spry_CostOfGoodsSoldOperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderSupplyAgreementsMember" xlink:label="spry_RevenueUnderSupplyAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="spry_CostOfGoodsSoldOperatingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderSupplyAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" xlink:label="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" xlink:label="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanOneMember" xlink:label="spry_PlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PlanTwoMember" xlink:label="spry_PlanTwoMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="spry_PlanOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="spry_PlanTwoMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RichardLowenthalMember" xlink:label="spry_RichardLowenthalMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SarinaTanimotoMember" xlink:label="spry_SarinaTanimotoMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LauraShawverMember" xlink:label="spry_LauraShawverMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_KathleenScottMember" xlink:label="spry_KathleenScottMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlexanderFitzpatrickMember" xlink:label="spry_AlexanderFitzpatrickMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_RichardLowenthalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_SarinaTanimotoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_LauraShawverMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_KathleenScottMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="spry_AlexanderFitzpatrickMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" xlink:label="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestructuringPlanMember" xlink:label="spry_RestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ArsPharmaMember" xlink:label="spry_ArsPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LiquidityAndCapitalResourcesMember" xlink:label="spry_LiquidityAndCapitalResourcesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SilverbackMember" xlink:label="spry_SilverbackMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="spry_RestructuringPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="spry_ArsPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="spry_LiquidityAndCapitalResourcesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="spry_SilverbackMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="spry_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SummaryOfSignificantAccountingPoliciesTable" xlink:label="spry_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TitleAgentMember" xlink:label="spry_TitleAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerOneMember" xlink:label="spry_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerTwoMember" xlink:label="spry_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerThreeMember" xlink:label="spry_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFourMember" xlink:label="spry_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerFiveMember" xlink:label="spry_CustomerFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CustomerSixMember" xlink:label="spry_CustomerSixMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="spry_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_TitleAgentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="spry_CustomerSixMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="spry_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseCommonStockMember" xlink:label="spry_WarrantsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsMember" xlink:label="spry_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedRestrictedStockUnitsMember" xlink:label="spry_UnvestedRestrictedStockUnitsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedGains" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueInputsLevel1AndLevel2Member" xlink:label="spry_FairValueInputsLevel1AndLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="spry_FairValueInputsLevel1AndLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" xlink:label="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" xlink:label="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TerminationAgreementMember" xlink:label="spry_TerminationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePaymentsMember" xlink:label="spry_CapitalizedMilestonePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RecordatiAgreementMember" xlink:label="spry_RecordatiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_TerminationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="spry_CapitalizedMilestonePaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="spry_AggregateMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AegisTherapeuticsLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="spry_CapitalizedMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RecordatiAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementMember" xlink:label="spry_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanMedicinesAgencyMember" xlink:label="spry_EuropeanMedicinesAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfRecordatiLicensedProductMember" xlink:label="spry_FirstCommercialSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AlfresaAgreementMember" xlink:label="spry_AlfresaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKFinancingLiabilityMember" xlink:label="spry_ALKFinancingLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontPayment" xlink:label="spry_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_TerminationAgreementMember" xlink:label="spry_TerminationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateSaleOfRecordatiLicensedProductMember" xlink:label="spry_AggregateSaleOfRecordatiLicensedProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RecordatiAgreementMember" xlink:label="spry_RecordatiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LicenseAgreementExpirationTerm" xlink:label="spry_LicenseAgreementExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IprDExpenseMember" xlink:label="spry_IprDExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfNeffyMember" xlink:label="spry_FirstCommercialSaleOfNeffyMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PediatrixAgreementMember" xlink:label="spry_PediatrixAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EuropeanEconomicAreaLicenseMember" xlink:label="spry_EuropeanEconomicAreaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SeqirusAgreementMember" xlink:label="spry_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePayments" xlink:label="spry_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ROWLicenseMember" xlink:label="spry_ROWLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCollaborationAgreementMember" xlink:label="spry_ALKCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentAndRegulatoryServicesMember" xlink:label="spry_DevelopmentAndRegulatoryServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCo-PromotionAgreementMember" xlink:label="spry_ALKCo-PromotionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneMember" xlink:label="spry_CommercialMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InitialTransactionPrice" xlink:label="spry_InitialTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestoneAllocatedToTheEEALicense" xlink:label="spry_CommercialMilestoneAllocatedToTheEEALicense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseToTheFinancingLiability" xlink:label="spry_IncreaseToTheFinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeNotRecognized" xlink:label="spry_RoyaltyIncomeNotRecognized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NumberOfPediatricians" xlink:label="spry_NumberOfPediatricians"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PerformanceBasedBonusPaymentsPercentage" xlink:label="spry_PerformanceBasedBonusPaymentsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ThresholdPercentageOfValueChangeInEquitySecurities" xlink:label="spry_ThresholdPercentageOfValueChangeInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestonePayment" xlink:label="spry_RegulatoryMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentsEarned" xlink:label="spry_MilestonePaymentsEarned"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RemainingRegulatoryMilestone" xlink:label="spry_RemainingRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryAndCommercialSalesMilestones" xlink:label="spry_RegulatoryAndCommercialSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommercialMilestonePayments" xlink:label="spry_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SalesBasedMilestones" xlink:label="spry_SalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ContingentSalesBasedMilestones" xlink:label="spry_ContingentSalesBasedMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiability" xlink:label="spry_FinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="spry_EuropeanMedicinesAgencyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfRecordatiLicensedProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AlfresaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="spry_ALKFinancingLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_TerminationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_AggregateSaleOfRecordatiLicensedProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RecordatiAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_LicenseAgreementExpirationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_IprDExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfNeffyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_PediatrixAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RegulatoryAgencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_AggregateMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_EuropeanEconomicAreaLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_SeqirusAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_ROWLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_DevelopmentAndRegulatoryServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCo-PromotionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_CommercialMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_InitialTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_CommercialMilestoneAllocatedToTheEEALicense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_IncreaseToTheFinancingLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RoyaltyIncomeNotRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_NumberOfPediatricians" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_PerformanceBasedBonusPaymentsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_ThresholdPercentageOfValueChangeInEquitySecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RegulatoryMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_MilestonePaymentsEarned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RemainingRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RegulatoryAndCommercialSalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_CommercialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_SalesBasedMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_ContingentSalesBasedMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_FinancingLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCollaborationAgreementMember" xlink:label="spry_ALKCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKFinancingLiabilityMember" xlink:label="spry_ALKFinancingLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseToTheFinancingLiability" xlink:label="spry_IncreaseToTheFinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RoyaltyIncomeAllocatedToTheEEALicense" xlink:label="spry_RoyaltyIncomeAllocatedToTheEEALicense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="spry_ALKFinancingLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_IncreaseToTheFinancingLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="spry_RoyaltyIncomeAllocatedToTheEEALicense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SanDiegoCaliforniaMember" xlink:label="spry_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_HeadquartersAmendmentMember" xlink:label="spry_HeadquartersAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="spry_SanDiegoCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="spry_HeadquartersAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKCo-PromotionAgreementMember" xlink:label="spry_ALKCo-PromotionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FoodAllergyResearchAndEducationIncMember" xlink:label="spry_FoodAllergyResearchAndEducationIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SoftwareLicenseSubscriptionFeesMember" xlink:label="spry_SoftwareLicenseSubscriptionFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="us-gaap_OtherCommitmentDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="us-gaap_OtherCommitmentDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="us-gaap_OtherCommitmentDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="us-gaap_OtherCommitmentDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationPaid"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnrecordedUnconditionalPurchaseObligationsPaid" xlink:label="spry_UnrecordedUnconditionalPurchaseObligationsPaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="spry_ALKCo-PromotionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_InventoriesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="spry_FoodAllergyResearchAndEducationIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="spry_SoftwareLicenseSubscriptionFeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInSecondYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInThirdYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInFourthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OtherCommitmentDueInFifthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="spry_UnrecordedUnconditionalPurchaseObligationsPaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyLineItems" xlink:label="spry_InLicensingAndSupplyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InLicensingAndSupplyTable" xlink:label="spry_InLicensingAndSupplyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OmpiSupplyAgreementMember" xlink:label="spry_OmpiSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FirstCommercialSaleOfNeffyMember" xlink:label="spry_FirstCommercialSaleOfNeffyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AegisTherapeuticsLlcMember" xlink:label="spry_AegisTherapeuticsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NewDrugApplicationMember" xlink:label="spry_NewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontLicenseFees" xlink:label="spry_UpfrontLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IntangibleAssetsMember" xlink:label="spry_IntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RenaissanceLakewoodLlcMember" xlink:label="spry_RenaissanceLakewoodLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AggregateMilestonePayments" xlink:label="spry_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMilestone" xlink:label="spry_RegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePayments" xlink:label="spry_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MilestonePaymentDueOnAchievementOfAnnualSales" xlink:label="spry_MilestonePaymentDueOnAchievementOfAnnualSales"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RegulatoryMileStoneAmount" xlink:label="spry_RegulatoryMileStoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_NoticePeriodDescription" xlink:label="spry_NoticePeriodDescription"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_LegalPatentFees" xlink:label="spry_LegalPatentFees"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpense" xlink:label="spry_SupplyAgreementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationClaimsDescription" xlink:label="us-gaap_ContractTerminationClaimsDescription"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UpfrontPayment" xlink:label="spry_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SupplyAgreementExpirationDate" xlink:label="spry_SupplyAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AgreementTerminationDueToMaterialBreach" xlink:label="spry_AgreementTerminationDueToMaterialBreach"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_InLicensingAndSupplyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_OmpiSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_FirstCommercialSaleOfNeffyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_AegisTherapeuticsLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="spry_NewDrugApplicationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_UpfrontLicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="spry_IntangibleAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_RenaissanceLakewoodLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AggregateMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_RegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="spry_InLicensingAndSupplyTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_MilestonePaymentDueOnAchievementOfAnnualSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_RegulatoryMileStoneAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_CapitalizedMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_NoticePeriodDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_LegalPatentFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_SupplyAgreementExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="us-gaap_ContractTerminationClaimsDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_SupplyAgreementExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="spry_InLicensingAndSupplyLineItems" xlink:to="spry_AgreementTerminationDueToMaterialBreach" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquitySalesAgreementMember" xlink:label="spry_EquitySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityOfferingsMember" xlink:label="spry_EquityOfferingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="spry_EquitySalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="spry_EquityOfferingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockOptionsGrantedAndOutstandingMember" xlink:label="spry_CommonStockOptionsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RestrictedStockUnitsGrantedAndOutstandingMember" xlink:label="spry_RestrictedStockUnitsGrantedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" xlink:label="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" xlink:label="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_WarrantsToPurchaseCommonStockMember" xlink:label="spry_WarrantsToPurchaseCommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockOptionsGrantedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_RestrictedStockUnitsGrantedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_UnvestedCommonStockMember" xlink:label="spry_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2016And2020Member" xlink:label="spry_EquityIncentivePlan2016And2020Member"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlansMember" xlink:label="spry_EquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_EquityIncentivePlan2018Member" xlink:label="spry_EquityIncentivePlan2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="spry_UnvestedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_EquityIncentivePlan2016And2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="spry_EquityIncentivePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="spry_EquityIncentivePlan2018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PacificLinkConsultingLlcMember" xlink:label="spry_PacificLinkConsultingLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OrbiMedAdvisorsLLCMember" xlink:label="spry_OrbiMedAdvisorsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MarlinspikeGroupLlcMember" xlink:label="spry_MarlinspikeGroupLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RedTeamAssociatesLlcMember" xlink:label="spry_RedTeamAssociatesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_PacificLinkConsultingLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_OrbiMedAdvisorsLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_MarlinspikeGroupLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="spry_RedTeamAssociatesLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ALKAgreementMember" xlink:label="spry_ALKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="spry_ALKAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SegmentOperatingExpenses" xlink:label="spry_SegmentOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldMember" xlink:label="spry_CostOfGoodsSoldMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderCollaborationAgreementsMember" xlink:label="spry_RevenueUnderCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_ClinicalMember" xlink:label="spry_ClinicalMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_RevenueUnderSupplyAgreementsMember" xlink:label="spry_RevenueUnderSupplyAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_DevelopmentMember" xlink:label="spry_DevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_MedicalAffairsMember" xlink:label="spry_MedicalAffairsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_Share-BasedCompensationMember" xlink:label="spry_Share-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="spry_SegmentOperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_CostOfGoodsSoldMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderCollaborationAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_ClinicalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="spry_RevenueUnderSupplyAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_DevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_MedicalAffairsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="spry_Share-BasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InventoryNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="spry_FinancingLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="spry_InventoryCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_FinancingLiability" xlink:label="spry_FinancingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrent" xlink:label="spry_InventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="spry_InventoryCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNoncurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_InventoryCurrent" xlink:label="spry_InventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="spry_CostOfGoodsSoldOperatingExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CostOfGoodsSoldOperatingExpense" xlink:label="spry_CostOfGoodsSoldOperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="spry_IncreaseDecreaseInDonationOfEquipment" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="spry_OperatingRightOfUseAssetsAndLeaseLiabilities" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="19" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_IncreaseDecreaseInDonationOfEquipment" xlink:label="spry_IncreaseDecreaseInDonationOfEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_OperatingRightOfUseAssetsAndLeaseLiabilities" xlink:label="spry_OperatingRightOfUseAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="spry_CashAndCashEquivalentsGrossUnrealizedGains" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CashAndCashEquivalentsGrossUnrealizedGains" xlink:label="spry_CashAndCashEquivalentsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="spry_PrepaidMarketingExpenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidMarketingExpenses" xlink:label="spry_PrepaidMarketingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssets" xlink:to="spry_PrepaidSupplyAgreementFee" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_CapitalizedComputerSoftwareNet" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_PrepaidSupplyAgreementFee" xlink:label="spry_PrepaidSupplyAgreementFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="spry_AccruedInventory" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="spry_AccruedGrossToNetAdjustments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedInventory" xlink:label="spry_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_AccruedGrossToNetAdjustments" xlink:label="spry_AccruedGrossToNetAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="spry_CapitalizedMilestonePayments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_CapitalizedMilestonePayments" xlink:label="spry_CapitalizedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="spry_SegmentOperatingExpenses" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="spry-20250630.xsd#spry_SegmentOperatingExpenses" xlink:label="spry_SegmentOperatingExpenses"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_HeadquartersAmendmentMember" name="HeadquartersAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CustomerFiveMember" name="CustomerFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CustomerOneMember" name="CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CollaborativeArrangementAbstract" name="CollaborativeArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MilestonePaymentDueOnAchievementOfAnnualSales" name="MilestonePaymentDueOnAchievementOfAnnualSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_RegulatoryMilestone" name="RegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_IntangibleAssetsMember" name="IntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SilverbackMember" name="SilverbackMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember" name="CommonStockReservedForFutureAwardsOrOptionGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_PerformanceBasedBonusPaymentsPercentage" name="PerformanceBasedBonusPaymentsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_UnvestedCommonStockMember" name="UnvestedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_InLicensingandsupplyAbstract" name="InLicensingandsupplyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RenaissanceLakewoodLlcMember" name="RenaissanceLakewoodLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CostOfGoodsSoldOperatingExpense" name="CostOfGoodsSoldOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_AggregateSaleOfRecordatiLicensedProductMember" name="AggregateSaleOfRecordatiLicensedProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ALKFinancingLiabilityMember" name="ALKFinancingLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_CapitalizedMilestonePayments" name="CapitalizedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_RemainingRegulatoryMilestone" name="RemainingRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_CommercialMilestoneMember" name="CommercialMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_PrepaidSupplyAgreementFee" name="PrepaidSupplyAgreementFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_CapitalizedMilestonePaymentsMember" name="CapitalizedMilestonePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MarlinspikeGroupLlcMember" name="MarlinspikeGroupLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_FirstCommercialSaleOfRecordatiLicensedProductMember" name="FirstCommercialSaleOfRecordatiLicensedProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ContingentSalesBasedMilestones" name="ContingentSalesBasedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_LicenseFeesPolicyTextBlock" name="LicenseFeesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_RegulatoryMileStoneAmount" name="RegulatoryMileStoneAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1" name="Fairvalueliabilitieslevel2Tolevel1Transfersamount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_ScheduleOfInventoryTableTextBlock" name="ScheduleOfInventoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_TitleAgentMember" name="TitleAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CashAndCashEquivalentsGrossUnrealizedLosses" name="CashAndCashEquivalentsGrossUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_EquityIncentivePlan2018Member" name="EquityIncentivePlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_EuropeanEconomicAreaLicenseMember" name="EuropeanEconomicAreaLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_AegisTherapeuticsLlcMember" name="AegisTherapeuticsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_TerminationAgreementMember" name="TerminationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_IncreaseToTheFinancingLiability" name="IncreaseToTheFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_RedTeamAssociatesLlcMember" name="RedTeamAssociatesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_LegalPatentFees" name="LegalPatentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_RegulatoryAndCommercialSalesMilestones" name="RegulatoryAndCommercialSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_DevelopmentAndRegulatoryServicesMember" name="DevelopmentAndRegulatoryServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ALKCo-PromotionAgreementMember" name="ALKCo-PromotionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ROWLicenseMember" name="ROWLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RichardLowenthalMember" name="RichardLowenthalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SupplyAgreementExpense" name="SupplyAgreementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_RevenueUnderSupplyAgreementsMember" name="RevenueUnderSupplyAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SanDiegoCaliforniaMember" name="SanDiegoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_InventoryCurrent" name="InventoryCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_DevelopmentMember" name="DevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_EquityOfferingsMember" name="EquityOfferingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_FirstCommercialSaleOfNeffyMember" name="FirstCommercialSaleOfNeffyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_UnrecordedUnconditionalPurchaseObligationPaid" name="UnrecordedUnconditionalPurchaseObligationPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_SegmentOperatingExpenses" name="SegmentOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_UnrecordedUnconditionalPurchaseObligationsPaid" name="UnrecordedUnconditionalPurchaseObligationsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_SeqirusAgreementMember" name="SeqirusAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_LiquidityAndCapitalResourcesMember" name="LiquidityAndCapitalResourcesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_PacificLinkConsultingLlcMember" name="PacificLinkConsultingLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RestrictedStockUnitsGrantedAndOutstandingMember" name="RestrictedStockUnitsGrantedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SarinaTanimotoMember" name="SarinaTanimotoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_LauraShawverMember" name="LauraShawverMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_AgreementTerminationDueToMaterialBreach" name="AgreementTerminationDueToMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_NumberOfPediatricians" name="NumberOfPediatricians" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RestructuringPlanMember" name="RestructuringPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_FairValueInputsLevel1AndLevel2Member" name="FairValueInputsLevel1AndLevel2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_FoodAllergyResearchAndEducationIncMember" name="FoodAllergyResearchAndEducationIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_KathleenScottMember" name="KathleenScottMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_AccruedGrossToNetAdjustments" name="AccruedGrossToNetAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_AggregateMilestonePayments" name="AggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_AccruedInventory" name="AccruedInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_InventoryCurrentAndNoncurrentNet" name="InventoryCurrentAndNoncurrentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_ZeroCostInventory" name="ZeroCostInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_CostOfGoodsSoldMember" name="CostOfGoodsSoldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SalesBasedMilestones" name="SalesBasedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" name="CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CommonStockOptionsMember" name="CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CustomerThreeMember" name="CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_AlfresaAgreementMember" name="AlfresaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_NewDrugApplicationMember" name="NewDrugApplicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_PediatrixAgreementMember" name="PediatrixAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CommercialMilestoneAllocatedToTheEEALicense" name="CommercialMilestoneAllocatedToTheEEALicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_RoyaltyIncomeAllocatedToTheEEALicense" name="RoyaltyIncomeAllocatedToTheEEALicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_IncreaseDecreaseInDonationOfEquipment" name="IncreaseDecreaseInDonationOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_LicenseAgreementExpirationTerm" name="LicenseAgreementExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_FinancingLiability" name="FinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_InLicensingAndSupplyLineItems" name="InLicensingAndSupplyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CustomerSixMember" name="CustomerSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" name="MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_PeriodForFirstNewDeliveryMethodOfEpinephrine" name="PeriodForFirstNewDeliveryMethodOfEpinephrine" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" name="UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_SoftwareLicenseSubscriptionFeesMember" name="SoftwareLicenseSubscriptionFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MilestonePaymentsEarned" name="MilestonePaymentsEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_EuropeanMedicinesAgencyMember" name="EuropeanMedicinesAgencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_AlexanderFitzpatrickMember" name="AlexanderFitzpatrickMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_RegulatoryMilestonePayment" name="RegulatoryMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_FinancingLiabilityIncludedInAccountsReceivable" name="FinancingLiabilityIncludedInAccountsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_InLicensingAndSupplyTable" name="InLicensingAndSupplyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_NoticePeriodDescription" name="NoticePeriodDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" name="AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_SupplyAgreementExpirationDate" name="SupplyAgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_CommonStockOptionsGrantedAndOutstandingMember" name="CommonStockOptionsGrantedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_EquitySalesAgreementMember" name="EquitySalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ArsPharmaMember" name="ArsPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_OmpiSupplyAgreementMember" name="OmpiSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_InitialTransactionPrice" name="InitialTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_RevenueUnderCollaborationAgreementsMember" name="RevenueUnderCollaborationAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_InLicensingandsupplyTextblock" name="InLicensingandsupplyTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_PrepaidMarketingExpenses" name="PrepaidMarketingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_PlanOneMember" name="PlanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_ThresholdPercentageOfValueChangeInEquitySecurities" name="ThresholdPercentageOfValueChangeInEquitySecurities" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="spry_ALKCollaborationAgreementMember" name="ALKCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_OperatingRightOfUseAssetsAndLeaseLiabilities" name="OperatingRightOfUseAssetsAndLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="spry_LicensingSupplyAndDistributionAgreementsAbstract" name="LicensingSupplyAndDistributionAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CustomerFourMember" name="CustomerFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_UpfrontLicenseFees" name="UpfrontLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_Share-BasedCompensationMember" name="Share-BasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_CashAndCashEquivalentsGrossUnrealizedGains" name="CashAndCashEquivalentsGrossUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_OrbiMedAdvisorsLLCMember" name="OrbiMedAdvisorsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ALKAgreementMember" name="ALKAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_EquityIncentivePlansMember" name="EquityIncentivePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_ClinicalMember" name="ClinicalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RoyaltyIncomeNotRecognized" name="RoyaltyIncomeNotRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="spry_EquityIncentivePlan2016And2020Member" name="EquityIncentivePlan2016And2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_MedicalAffairsMember" name="MedicalAffairsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_PlanTwoMember" name="PlanTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_RecordatiAgreementMember" name="RecordatiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_WarrantsToPurchaseConvertiblePreferredStockMember" name="WarrantsToPurchaseConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="spry_IprDExpenseMember" name="IprDExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARS Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11682 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">771-9307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,826,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,540<span></span>
</td>
<td class="nump">$ 50,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">188,590<span></span>
</td>
<td class="nump">263,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">25,126<span></span>
</td>
<td class="nump">8,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InventoryCurrent', window );">Inventories</a></td>
<td class="nump">8,738<span></span>
</td>
<td class="nump">5,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,442<span></span>
</td>
<td class="nump">6,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">281,436<span></span>
</td>
<td class="nump">334,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Long-term inventories</a></td>
<td class="nump">13,374<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">12,972<span></span>
</td>
<td class="nump">7,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">313,472<span></span>
</td>
<td class="nump">351,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (including related party amounts of $1,091 and $656, respectively)</a></td>
<td class="nump">44,264<span></span>
</td>
<td class="nump">22,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability, current</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,599<span></span>
</td>
<td class="nump">23,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_FinancingLiability', window );">Financing liability</a></td>
<td class="nump">71,959<span></span>
</td>
<td class="nump">69,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability, net of current portion</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">121,151<span></span>
</td>
<td class="nump">94,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at June 30, 2025 and December 31, 2024; 98,697,658 and 97,954,172 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">394,485<span></span>
</td>
<td class="nump">379,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) gain, net</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(202,128)<span></span>
</td>
<td class="num">(123,305)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">192,321<span></span>
</td>
<td class="nump">256,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 313,472<span></span>
</td>
<td class="nump">$ 351,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_FinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_FinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties, current</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock , shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">98,697,658<span></span>
</td>
<td class="nump">97,954,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">98,697,658<span></span>
</td>
<td class="nump">97,954,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 15,717<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 23,690<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CostOfGoodsSoldOperatingExpense', window );">Cost of goods sold (including related party amounts of $866, $0, $1,354, and $0, respectively)</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including related party amounts of $582, $518, $1,245, and $1,245, respectively)</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="nump">6,896<span></span>
</td>
<td class="nump">6,987<span></span>
</td>
<td class="nump">12,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including related party amounts of $107, $114, $231, and $208, respectively)</a></td>
<td class="nump">54,312<span></span>
</td>
<td class="nump">8,944<span></span>
</td>
<td class="nump">95,416<span></span>
</td>
<td class="nump">16,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">63,331<span></span>
</td>
<td class="nump">15,840<span></span>
</td>
<td class="nump">108,481<span></span>
</td>
<td class="nump">29,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(47,614)<span></span>
</td>
<td class="num">(15,340)<span></span>
</td>
<td class="num">(84,791)<span></span>
</td>
<td class="num">(28,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,731<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">5,968<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,883)<span></span>
</td>
<td class="num">(12,516)<span></span>
</td>
<td class="num">(78,823)<span></span>
</td>
<td class="num">(22,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains and losses on available-for-sale securities</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (45,001)<span></span>
</td>
<td class="num">$ (12,537)<span></span>
</td>
<td class="num">$ (79,089)<span></span>
</td>
<td class="num">$ (23,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, Basic</a></td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted- average common shares outstanding, basic</a></td>
<td class="nump">98,361,771<span></span>
</td>
<td class="nump">96,827,687<span></span>
</td>
<td class="nump">98,212,035<span></span>
</td>
<td class="nump">96,656,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">98,361,771<span></span>
</td>
<td class="nump">96,827,687<span></span>
</td>
<td class="nump">98,212,035<span></span>
</td>
<td class="nump">96,656,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,563<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember', window );">Revenue under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember', window );">Revenue under supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CostOfGoodsSoldOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold operating expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CostOfGoodsSoldOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses related party amount</a></td>
<td class="nump">$ 4,035<span></span>
</td>
<td class="nump">$ 6,896<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="nump">$ 12,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses related party amount</a></td>
<td class="nump">54,312<span></span>
</td>
<td class="nump">8,944<span></span>
</td>
<td class="nump">95,416<span></span>
</td>
<td class="nump">16,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold expenses related party amount</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses related party amount</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses related party amount</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss), Net [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 230,760<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 362,004<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (131,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,414,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares', window );">Exercise of common stock options and release of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(10,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(10,292)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">223,868<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">365,577<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(141,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,574,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">230,760<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">362,004<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="num">(131,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,414,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(23,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">215,241<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">369,487<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(154,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,939,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">223,868<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">365,577<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(141,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,574,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(12,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(12,516)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">215,241<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">369,487<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(154,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,939,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 256,798<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">379,873<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="num">(123,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="nump">97,954,172<span></span>
</td>
<td class="nump">97,954,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares', window );">Exercise of common stock options and release of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(34,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(33,940)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">228,974<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">386,137<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(157,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,129,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 256,798<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">379,873<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="num">(123,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="nump">97,954,172<span></span>
</td>
<td class="nump">97,954,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (79,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 192,321<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">394,485<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(202,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2025</a></td>
<td class="nump">98,697,658<span></span>
</td>
<td class="nump">98,697,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">$ 228,974<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">386,137<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(157,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,129,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units</a></td>
<td class="nump">2,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(45,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(44,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 192,321<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 394,485<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
<td class="num">$ (202,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2025</a></td>
<td class="nump">98,697,658<span></span>
</td>
<td class="nump">98,697,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised and restricted stock units released shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,823)<span></span>
</td>
<td class="num">$ (22,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments to reconcile net loss to net cash used operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,669<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion on investments, net of amortization</a></td>
<td class="num">(3,428)<span></span>
</td>
<td class="num">(3,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory reserve</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(14,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(13,232)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(697)<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_IncreaseDecreaseInDonationOfEquipment', window );">Donation of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">16,981<span></span>
</td>
<td class="nump">4,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_OperatingRightOfUseAssetsAndLeaseLiabilities', window );">Operating lease right-of-use asset and lease liability, net</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="num">(240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents used in operating activities</a></td>
<td class="num">(80,334)<span></span>
</td>
<td class="num">(13,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments, available-for-sale</a></td>
<td class="num">(65,723)<span></span>
</td>
<td class="num">(151,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Maturities of short-term investments, available-for-sale</a></td>
<td class="nump">143,500<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents provided by (used in) investing activities</a></td>
<td class="nump">77,635<span></span>
</td>
<td class="num">(21,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">3,422<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents provided by financing activities</a></td>
<td class="nump">3,422<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">723<span></span>
</td>
<td class="num">(34,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">50,817<span></span>
</td>
<td class="nump">70,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">51,540<span></span>
</td>
<td class="nump">36,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Intangible assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">5,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_FinancingLiabilityIncludedInAccountsReceivable', window );">Financing liability included in accounts receivable</a></td>
<td class="nump">2,576<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_FinancingLiabilityIncludedInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing liability included in accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_FinancingLiabilityIncludedInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_IncreaseDecreaseInDonationOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Donation of Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_IncreaseDecreaseInDonationOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_OperatingRightOfUseAssetsAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Right of Use Assets And Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_OperatingRightOfUseAssetsAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (44,883)<span></span>
</td>
<td class="num">$ (12,516)<span></span>
</td>
<td class="num">$ (78,823)<span></span>
</td>
<td class="num">$ (22,808)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated trading plans for the orderly disposition of the Company&#8217;s securities as set forth in the table below.</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.46%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.2%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.2%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.2%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:10.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.2%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Adoption /</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Termination</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Position</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10b5-1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10b5-1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">to be Sold</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020*<br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Lowenthal</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*<br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sarina Tanimoto</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020*<br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sarina Tanimoto</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*<br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2027</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laura Shawver</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 21, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128,562</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kathleen Scott</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 22, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 22, 2026</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Fitzpatrick</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Termination</span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 29, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Fitzpatrick</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 29, 2025</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 30, 2026</span></span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on November 27, 2024 and amended on December 13, 2024 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div></div><p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	This plan, together with the other three plans marked with an asterisk in this table, are treated as a single &#8220;plan&#8221; because the individual constituent contracts with each broker-dealer, when taken together as a whole, meet all of the applicable conditions of Rule 10b5-1(c) under the Exchange Act and remain collectively subject to the provisions of such rule, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including that a modification of any individual contract acts as modification of the whole contract.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=spry_LauraShawverMember', window );">Laura Shawver [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Laura Shawver<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">225 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">128,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=spry_KathleenScottMember', window );">Kathleen Scott [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Kathleen Scott<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 22, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 22, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanOneMember', window );">Plan One [Member] | Richard Lowenthal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard Lowenthal<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 14, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">723 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanOneMember', window );">Plan One [Member] | Sarina Tanimoto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sarina Tanimoto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 14, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">723 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanOneMember', window );">Plan One [Member] | Alexander Fitzpatrick [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Alexander Fitzpatrick<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">May 29, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanTwoMember', window );">Plan Two [Member] | Richard Lowenthal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard Lowenthal<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 14, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">723 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanTwoMember', window );">Plan Two [Member] | Sarina Tanimoto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sarina Tanimoto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 21, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 14, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">723 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=spry_PlanTwoMember', window );">Plan Two [Member] | Alexander Fitzpatrick [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Alexander Fitzpatrick<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 29, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">January 30, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=spry_LauraShawverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=spry_LauraShawverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=spry_KathleenScottMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=spry_KathleenScottMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=spry_PlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=spry_PlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=spry_RichardLowenthalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=spry_RichardLowenthalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=spry_SarinaTanimotoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=spry_SarinaTanimotoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=spry_AlexanderFitzpatrickMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=spry_AlexanderFitzpatrickMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=spry_PlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=spry_PlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p id="fn_business" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARS Pharmaceuticals, Inc. (&#8220;ARS&#8221;, &#8220;ARS Pharma&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the commercialization and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (currently identified in the EU by the trade name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the first and only FDA and European Commission-approved needle-free epinephrine product, and the first new delivery method for epinephrine in more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incorporated in Delaware in January 2016 and is located in San Diego, California. The Company has a wholly owned subsidiary, ARS Pharmaceuticals Operations, Inc., incorporated in Delaware in August 2015, through which it conducts substantially all its operations. ARS Pharmaceuticals Operations, Inc. has a wholly owned subsidiary in Ireland, ARS Pharmaceuticals IRL, Limited, to facilitate the filing of regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in European countries.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses in most years since its inception and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. The Company had cash, cash equivalents, and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and has not generated positive cash flows from operations in most years. To date, the Company has funded its operations primarily with proceeds from the merger with Silverback in November 2022 (the &#8220;Merger&#8221;), private placement of convertible preferred stock, issuance of common stock, licensing, supply and distribution agreements, bank debt, and net product sales. The Company&#8217;s currently available cash, cash equivalents, and short-term investments as of June 30, 2025 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date these financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From August 5, 2015 (inception) through June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has devoted substantially all of its efforts to developing intellectual property, conducting product development and clinical trials, organizing and staffing the Company, business planning, raising capital, building infrastructure, pre-commercial and commercial activities, and providing general and administrative support for these operations. The Company has a limited operating history, and the sales and income potential of the Company&#8217;s business and market are unproven. Management expects operating expenses to increase for the foreseeable future, and there can be no assurance that the Company will achieve profitability in the future, or if achieved, that it will be sustained on a continuing basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="fn_ssap" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s financial statements are presented on a condensed consolidated basis, which include the accounts of ARS Pharmaceuticals, Inc., ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#8217;s functional and reporting currency is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income in the condensed consolidated statements of operations and comprehensive loss. All adjustments considered necessary for a fair presentation have been included.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, the condensed consolidated statements of stockholders&#8217; equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, are unaudited. The balance sheet as of December 31, 2024 was derived from the audited financial statements as of and for the year ended December 31, 2024. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of June 30, 2025, the condensed consolidated results of its operations for the three and six months ended June 30, 2025 and 2024, and its cash flows for the six months ended June 30, 2025 and 2024. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2025 and 2024 are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed consolidated financial statements are revenue recognized under collaboration agreements, accruals for variable components of product revenue, accruals for research and development expenses, and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash readily available in checking, money market mutual funds, and short-term investments with remaining maturities when purchased of 90 days or less. The Company considers all highly liquid investments with remaining maturities when purchased of 90 days or less to be cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable and Allowance for Credit Losses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable includes trade accounts receivable from product sales to customers, partner receivables for reimbursable research and development costs, royalties, license fees, and milestone payments under the Company&#8217;s collaboration agreements, and partner receivables for supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the Company&#8217;s supply agreements. Trade accounts receivable are recorded at wholesale acquisition cost (&#8220;WAC&#8221;), less purchase price discounts, prompt pay discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company&#8217;s estimate of losses over the life of the receivables. The Company determines the allowance for credit losses for accounts receivable based on each customer&#8217;s or partner&#8217;s accounts receivable balance and age, their financial condition, and the general economic environment. The Company must also use professional judgment for its allowance for credit losses on trade accounts receivable as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was commercially launched in September 2024 and historical data is limited. The Company is currently operating under the Title Agreement (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with its Title Agent (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the Title Agent retains all credit and collection risk on product sales to the Company&#8217;s wholesale distributors and pharmacy customers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was deemed necessary at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 or December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests excess cash in investment grade fixed income securities. These investments are included in short-term investments on the condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss) gain, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Realized gains and losses on the sale of securities are recognized in net loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and short-term investments are carried at fair value. The carrying amounts of all accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, and contract liability are considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its financial instruments portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also subject to credit risk related to its accounts receivable from product sales and revenue under collaboration and supply agreements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is distributed primarily through wholesale distributors and pharmacies. These entities are not obligated to purchase any set number of units and they distribute </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on demand as orders are received. The Company enters into collaboration and supply agreements with pharmaceutical companies under which the Company is entitled to receive payments for royalties, license fees, milestone achievements, reimbursable costs for research and development services, and supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company extends credit to its customers and partners in the normal course of business after evaluating their overall financial condition. As stated above, the Company is currently operating under the Title Agreement with its Title Agent and the Title Agent retains all credit and collection risk on sales to the Company&#8217;s wholesale distributors and pharmacy customers. The Company&#8217;s Title Agent accounts for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s accounts receivable balance as of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. One additional customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of accounts receivable as of June 30, 2025. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, four and six customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, with each individual customer ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, respectively. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025, one customer accounted for all revenue under collaboration agreements and supply agreements. For the three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, one customer accounted for all revenue under collaboration agreements, and there was no product sales or revenue under supply agreements. Historically, the Company has not experienced any credit losses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process, and include labor and overhead. Inventories are stated at the lower of cost or net realizable value, and are determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered. Such impairment charges, if any, are recorded in cost of goods sold on the condensed consolidated statements of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes inventory costs after regulatory approval, when future commercialization is considered probable, and a future economic benefit is expected to be realized. Prior to regulatory approval, the Company records inventory costs as research and development expenses. As such, when regulatory approval is received, this may result in zero-cost inventory which does not have a carrying value. This inventory is available to the Company to utilize for commercial operations as well as ongoing research and development activities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally five years. Repair and maintenance costs are charged to expense as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate, including its eventual residual value. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. The Company has not recognized any impairment losses from inception through June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the initial classification and measurement of its right-of-use (&#8220;ROU&#8221;) asset and lease liabilities at the lease commencement date and thereafter, if modified. The Company recognizes a ROU asset for its operating leases with lease terms greater than 12 months. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The lease liability is calculated by using the present value of all lease payments, with the present value determined by using the incremental borrowing rate for operating leases determined by using the incremental borrowing rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment as well as a review of peer companies. Variable charges for common area maintenance and other variable costs are recognized as expense as incurred. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues consist of product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and revenue derived from its collaboration, out-licensing, and supply agreements. See </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on product revenue, and </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on revenue from collaboration agreements, out-licensing agreements, and supply agreements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). The provisions of ASC 606 require the following steps to determine revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, determines whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold primarily consists of direct and indirect costs related to the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, supply agreement fees, and royalties on product sales. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, costs incurred for the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initially reflects a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, external research and development costs incurred under agreements with contract research organizations, investigative sites and consultants to conduct clinical studies, costs related to compliance with regulatory requirements, costs related to manufacturing the Company&#8217;s product candidates (including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prior to FDA approval in August 2024) for clinical trials, and other allocated expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for research and development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company uses judgments and estimates to determine the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Costs</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative costs are expensed in the period incurred. Selling, general and administrative costs primarily consist of marketing-related expenses, salaries and related expenses for personnel, including meals and travel-related expenses incurred by the sales team, stock-based compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax, and other consulting services, and insurance costs.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for producing advertising are expensed when incurred. Costs for communicating advertising, such as search engine marketing, banner advertisements, social media advertisements, and print advertisements, are recorded as prepaid expenses and then expensed when the advertisement occurs. For the three and six months ended June 30, 2025, advertising costs were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advertising costs were incurred for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Fees</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred to acquire technology licenses and milestone payments made on existing agreements are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes expense for awards subject to performance-based milestones over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and recognizes forfeitures as they occur. In the event that stock-based awards are granted in contemplation of or shortly before a planned release of material non-public information, and such information is expected to result in a material increase in the share price of the Company&#8217;s common stock, the Company may consider whether an adjustment to the observable market price is required when estimating the grant date fair value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss typically consists of the change in unrealized gains and losses on available-for-sale securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, stock options, warrants, and unvested restricted stock units, are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:66.967%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of June 30,</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,436,432</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,318,828</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,484,651</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
          </table></div></div><div></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280)&#8211;Improvements to Reportable Segment Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-07&#8221;), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 was effective for the Company on January 1, 2024 for annual periods and on January 1, 2025 for interim periods. The adoption of ASU 2023-07 resulted in enhanced disclosures as included in </span><a href="#fn_segments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 15 &#8211; Segment Information</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and did not impact the Company&#8217;s condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8212; Not Yet Adopted</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards, other than those noted below, and any issued but not yet effective standards will not have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Income Taxes (Topic 740)&#8211;Improvements to Income Tax Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-09&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The amendments in this update are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company does not expect to early adopt the new standard. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2023-09 on the financial statements and related disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2024-03&#8221;). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the income statement within continuing operations of public business entities. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact of adoption of this ASU on the Company&#8217;s disclosures is currently being evaluated.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p id="fn_revenue" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Revenue</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues consist primarily of product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue derived from its collaboration and out-licensing agreements, and revenue from its supply agreements. See </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for further discussion related to revenue from collaboration, out-licensing, and supply agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was approved by the FDA in August 2024, and the Company began generating product revenue from sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024. The Company uses a third-party logistics provider (&#8220;3PL Agent&#8221;) to fulfill orders of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Company&#8217;s customers. The 3PL Agent provides services to the Company that include warehousing, distribution, order and accounts receivable management, and data management.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a title model agreement (&#8220;Title Agreement&#8221;) with an affiliate of the 3PL Agent (the &#8220;Title Agent&#8221;) so that the Title Agent may purchase and take title to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and then sell it to the Company&#8217;s wholesale distributors and pharmacy customers that have contracted to make a purchase. Under the Title Agreement, the economic substance of the transaction is such that the Company does not recognize revenue until </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is sold and title has transferred from the Title Agent to a wholesale distributor or pharmacy.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into sales agreements with pharmacies that are not subject to the Title Agreement. Under these agreements, the pharmacy holds </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under consignment. Under the consignment model, the Company recognizes revenue when </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is sold to a patient, at which point title transfers from the Company directly to the patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product revenue is recorded with each sale at the transaction price, net of reserves for variable components, including but not limited to distribution service fees, prompt pay discounts, product returns, chargebacks, rebates, and co-payment assistance, which are collectively referred to as &#8220;Gross-to-Net Adjustments.&#8221; Estimates for Gross-to-Net Adjustments are reassessed each reporting period, and adjustments are recorded on a cumulative catch-up basis, which would affect product revenue and net loss in the period of adjustment. Trade accounts receivable due to the Company from contracts with its customers are stated in the condensed consolidated balance sheet, net of various allowances as described in the Accounts Receivable and Allowance for Credit Losses policy in </span><a href="#fn_ssap"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components. Variable consideration is included in the transaction price only to the extent it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain Gross-to-Net Adjustments. The specific considerations that the Company uses in estimating the amounts related to Gross-to-Net Adjustments are as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distribution Service Fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchased amount. These fees are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial Pharmacy Discounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides discounts to its pharmacy customers. These discounts are a contractually fixed percentage of WAC and are a direct reduction from the WAC price they are charged. They are calculated at the time of sale based on the purchased amount. These discounts are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prompt Pay Discounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company incentivizes on time invoice payments through prompt pay discounts. Prompt pay discounts are typically taken by customers, so an estimate of the discount is recorded at the time of sale based on the purchased amount. Prompt pay discount estimates are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chargebacks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain government entities and covered entities (e.g. Veterans Administration, 340B covered entities) can purchase the product at a price discounted below WAC. The difference between the government or covered entity purchase price and WAC will be charged back to the Company. The Company estimates the amount of chargebacks based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rebates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides commercial rebates to pharmacy benefit managers and managed care organizations and is subject to mandatory discount obligations under the Medicare, Medicaid, and Tricare programs. The rebate amounts for these programs are determined by contractual arrangements or statutory requirements. Rebates are owed after the product has been dispensed to a patient and the Company has been invoiced. The Company estimates the amount in rebates based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-payment Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company offers co-payment assistance programs to commercially insured patients whose insurance requires a co-payment to be made when filling their prescription. The Company estimates the amount of co-payment assistance based on the expected volume and the average buy down rate associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment programs estimates are recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Returns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Customers have the right to return damaged product, product that is within six months or less of the labeled expiration date, or product that is past the expiration date by no more than twelve months. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was commercially launched in September 2024 and due to the lack of historical sales and returns data, the Company used professional judgment and industry data to estimate returns. As time passes and historical data becomes available, the Company will use historical sales and returns data to estimate future product returns. A r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserve for potential product returns is recorded as other current liabilities on the condensed consolidated balance sheets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p id="fn_inventories" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Inventories</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company began to capitalize the inventory costs associated with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon FDA approval in August 2024 when future commercialization was considered probable, and it was determined that the inventory had a probable future economic benefit. These inventory costs consist primarily of purchased materials, third-party manufacturing costs, and packaging and serialization services. Noncurrent inventory consists of inventory anticipated to remain on hand for more than one year from the balance sheet date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized inventories consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,784</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in process</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,826</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory reserve</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,160</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,519</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reported as:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,738</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,212</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,307</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,519</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to FDA approval in August 2024, costs incurred for the manufacturing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which upon approval resulted in zero-cost inventory. The Company held </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in zero-cost inventory as of June 30, 2025 and December 31, 2024, respe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ctively, none of which was determined to be obsolete as of each period end. The Company expects to fully utilize its zero-cost inventory in future periods.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="fn_fv_measurements" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Fair Value Measurements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:3%;box-sizing:content-box;"></td>
        <td style="width:86%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
        <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unobservable inputs in which little or </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></p></td>
       </tr>
      </table><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table identifies the Company&#8217;s assets that were measured at fair value on a recurring basis (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:8.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,248</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,248</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,636</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,590</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,884</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,838</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,382</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,387</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263,205</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,878</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,098</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods present</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed. During the three and six months ended June 30, 2025, the Company purchased </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in short-term investments and there were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in maturities of short-term investments. During the three and six months ended June 30, 2024, the Company purchased </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in short-term investments and there were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in maturities of short-term investments.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is less than one year from the respective balance sheet date. The Company's money market mutual fund holdings are highly liquid and invest primarily in cash and U.S. Treasury securities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net unrealized loss on available-for-sale securities for the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0276b15-2565-43a7-b2cc-bff166e8c881;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immaterial</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unrealized loss on available-for-sale securities for the three and six months ended June 30, 2024, respectively. Management determined that the gross unrealized losses on the Company&#8217;s available-for-sale securities as of June 30, 2025 were primarily attributable to current economic and market conditions and not credit risk. As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was recorded. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell any investments prior to recovery of its amortized cost basis, which is expected to be at maturity.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest on the Company's available-for-sale securities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and is included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheet.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any liabilities that were measured at fair value on a recurring basis.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p id="fn_bs_details" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Details</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid marketing</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,447</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,169</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,261</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,027</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,469</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,442</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,886</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid supply agreement fee</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,863</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,800</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized software implementation costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">314</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,051</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,114</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,559</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,870</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,341</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,179</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued marketing related expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,855</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,306</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued inventory</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,145</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,264</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,841</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets, net</a></td>
<td class="text"><p id="fn_intangibleassetsnet" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Intangible assets, net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_inlicense_supply"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10 &#8211; In-Licensing and Supply</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Aegis Agreement the Company capitalized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment in August 2024 and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment in September 2024. Capitalized milestone payments are amortized on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Recordati Termination Agreement the Company capitalized the achievement of a &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) milestone in June 2025. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized milestone payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are amortized on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in June 2025.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net, all of which are finite-lived, consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized milestone payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,360</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">388</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,972</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortization expense for the three and six months ended June 30, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> int</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">angible assets were held as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amortization expense recognized for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, estimated future amortization expense for capitalized intangible assets for the next five years is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.823%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,544</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, Out-Licensing and Related Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, Out-Licensing and Related Agreements</a></td>
<td class="text"><p id="fn_collab_outlicense" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Collaboration, Out-Licensing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Related Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into collaboration and licensing agreements, including supply and distribution, to license certain rights to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; clinical, regulatory, and/or commercial milestone payments; payment for clinical and commercial supply; and royalties or a transfer price on the net sales of licensed products.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, revenue is recognized from non-refundable, upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If the license is subject to repurchase by the Company, at its option, control of the license is not considered transferred to the customer, and in such case, the Company would account for the proceeds allocated to such license as either a financing obligation or a lease in accordance with ASC 606. Future amounts received related to the license which is subject to the Company&#8217;s repurchase, such as royalties or milestone payments, would be accounted for as additional financing proceeds and would increase the financing obligation on the Company&#8217;s condensed consolidated balance sheet. The Company would record such financing obligation as revenue when the right to repurchase has lapsed or was exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If the license is not a distinct performance obligation, the Company evaluates the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the inception of each arrangement that includes clinical, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within the Company&#8217;s control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized when the underlying performance obligation has been met.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction Price Allocation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of each arrangement, the Company identifies its distinct performance obligations and allocates the transaction price to the performance obligations based upon their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. The best evidence of standalone selling price is an observable price of a good or service when sold separately by an entity in similar circumstances to similar customers. Since the Company typically does not have such evidence, the Company estimates standalone selling price so that the amount that is allocated to each performance obligation equals the amount that the Company expects to receive for transferring the promised goods or services. The methods that the Company uses to make such estimates include (1) the adjusted market assessment approach, under which the Company forecasts product sales in the appropriate market, considers probability of commercialization success, and estimates discount rates; and (2) the expected cost of satisfying the performance obligations inclusive of a reasonable margin, also known as the expected cost plus margin approach.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For arrangements that contain research and development commitments, any arrangement consideration allocated to the research and development work is recognized as the underlying services are performed over the research and development term, if the criteria for over time recognition are met. If the over time recognition criteria are not met, research and development performance obligations are recognized at a point in time, when the research and development work is completed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical and Commercial Supply</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered customer options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. Revenue from product sales to the Company&#8217;s collaboration partners is recognized at the point in time that the collaboration partner obtains control, which is typically based upon the terms of delivery of the product.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty/Transfer Price Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For arrangements that include sales-based royalties or transfer price, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alfresa Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, the Company signed a Letter of Intent (&#8220;LOI&#8221;) with Alfresa Pharma Corporation (&#8220;Alfresa&#8221;) for the right to negotiate a definitive agreement for the exclusive license and sublicensable right to develop, register, import, manufacture and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan in exchange for an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In April 2020, the Company entered into a Collaboration and License Agreement for the rights pursuant to the LOI. Under the agreement, the Company delivered a license to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">technology, completed a required clinical study, and remains obligated to use commercially reasonable efforts to develop and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Japan. The parties agreed to share the cost of any additional clinical studies required for approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan. Alfresa is solely responsible for regulatory and commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use in Japan. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in Japan; or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received under the LOI, the Company was initially eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain clinical and regulatory milestones. Further, the Company is eligible to receive a negotiable transfer price expected to be in the low double-digit percentage on net sales subject to the regulatory approval to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Japan.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified the following performance obligations: the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and research and development services, both of which have been completed. The Company determined the initial transaction price to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which includes a clinical milestone as it was deemed not probable of significant reversal at the inception of the agreement. Due to the uncertainty in the achievement of the regulatory and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon the completion of a clinical milestone in Japan. In November 2024, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon the completion of a regulatory milestone in Japan. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments that the Company was eligible to earn, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has been earned and a final $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million regulatory milestone remains. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue related to the Alfresa Agreement. As of both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contract liability recorded for the final regulatory milestone.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recordati Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2020, the Company entered into a License and Supply Agreement (the &#8220;Recordati Agreement&#8221;) with Recordati Ireland, Ltd. (&#8220;Recordati&#8221;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Europe and certain European Free Trade Association, Russia/the Commonwealth of Independent States, Middle East and African countries (the &#8220;Recordati Territory&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the terms of the Recordati Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and a regulatory milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified the following performance obligations: the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Recordati Territory and the research and development services. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, at inception of the contract, the variable consideration associated with future milestone payments was fully constrained and excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation. In November 2020, the Company earned a regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 22, 2023, the Company and Recordati entered into a termination agreement (the &#8220;Recordati Termination Agreement&#8221;), pursuant to which, among other things, the Company and Recordati agreed to terminate the Recordati Agreement. Pursuant to the Recordati Termination Agreement, the Company reacquired all of the Recordati Rights, paid Recordati a one-time upfront payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars), and has agreed to pay additional payments upon achievement of certain milestones including: (i) an EMA regulatory milestone payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (ii) a milestone payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory, and (iii) royalty payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate from sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory (collectively, the &#8220;Recordati Rights&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the Recordati Rights at the time of entering into the Recordati Termination Agreement had no alternative future use and therefore recorded the &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment to Recordati as an in-process research and development (&#8220;IPR&amp;D&#8221;) expense presented within research and development expense. The Recordati Termination Agreement ended the Company&#8217;s performance obligations pursuant to the Recordati Agreement and consequently the existing contract liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million previously received from Recordati was recorded against IPR&amp;D expense presented within research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. Accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue has been recognized subsequent to the Recordati Termination Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the EMA regulatory milestone was met and a &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) expense was recorded in research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company paid the EMA regulatory milestone to Recordati in July 2024. In June 2025, the first commercial sale milestone was met for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory. As a result, the Company capitalized the &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Recordati Territory to intangible assets in the accompanying condensed consolidated balance sheets. The Company paid the first commercial sale milestone to Recordati in July 2025. The intangible assets will be amortized through the cost of goods sold in the accompanying condensed consolidated statements of operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive loss on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty expense from the sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Recordati Territory as cost of goods sold in the accompanying consolidated statements of operations and comprehensive loss.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatrix Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, the Company entered into a Collaboration and Distribution Agreement with Pediatrix Therapeutics, Inc. (&#8220;Pediatrix&#8221;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the People&#8217;s Republic of China, Taiwan, Macau, and Hong Kong (the &#8220;Pediatrix Territory&#8221;). Under the agreement, Pediatrix is responsible, at its sole cost and expense, for all ongoing development work that is necessary for or otherwise supports regulatory approval in the Pediatrix Territory, including all clinical trials, and activities related to post-approval commitments and commercialization tests. In addition, Pediatrix is responsible for commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use. The Company is responsible for the manufacturing of product for clinical studies as well as commercial supply, all at a negotiated transfer price. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in the Pediatrix Territory, (ii) the expiration of all regulatory exclusivities that cover </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Pediatrix Territory, or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Pediatrix Territory.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In addition, the Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain regulatory and commercial sales milestones. The next eligible milestone is a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million regulatory milestone. Subject to regulatory approval, the Company will earn tiered royalties in the low double-digits on annual net sales in the region and will receive a per unit supply price for the sale of commercial supply to Pediatrix.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified performance obligations related to the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Pediatrix Territory and manufacturing of product for clinical studies and commercial supply. The Company concluded that the license was distinct from potential supply obligation. The supply provisions are effectively options granted to Pediatrix to purchase future goods and did not contain a material right. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. The Company recognized revenue of the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2021.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Seqirus Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a License and Distribution Agreement (the &#8220;Seqirus Agreement&#8221;) with Seqirus Pty, Ltd. (&#8220;Seqirus&#8221;) for the exclusive license to commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Australia and New Zealand (the &#8220;Seqirus Territory&#8221;). Under the Seqirus Agreement, the Company is responsible for the transfer of know-how, which includes regulatory materials, regulatory data, and commercialization data, and also for the manufacturing of product for commercial supply which is available to Seqirus at a negotiated price. Seqirus is solely responsible for all regulatory and commercialization activities in the Seqirus Territory. Either party may terminate the Seqirus Agreement for certain breaches. Unless terminated earlier by either or both parties, the initial term of the Seqirus Agreement is 15 years from the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Seqirus Territory. The Seqirus Agreement will automatically renew for two-year periods unless either party gives a notice to terminate at least 12 months prior to the end of the initial or any renewal term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Seqirus Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in May 2024. In addition, the Company was eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments upon achievement of certain event milestones. Subject to regulatory approval in Australia and New Zealand, the Company will also receive a per unit supply price for the sale of commercial supply to Seqirus.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the commencement of this collaboration, the Company identified one performance obligation which is the delivery of the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how. The Company determined that the option to purchase the commercial supply does not represent a material right. The Company determined the initial transaction price to be the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment. Due to the uncertainty in the achievement of all the regulatory milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The variable consideration will be reassessed at each reporting period. In May 2024, the Company delivered the license for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Seqirus Territory in combination with the transfer of know-how and recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue. In August 2024, the first milestone event was met and the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Collaboration Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company entered into a Collaboration, License and Distribution Agreement (the &#8220;ALK Collaboration Agreement&#8221;) with ALK-Abell&#243; A/S (&#8220;ALK&#8221;). Pursuant to the ALK Collaboration Agreement, the Company granted to ALK a worldwide (other than the United States, Japan, mainland China, Hong Kong, Taiwan, Macau, Australia and New Zealand) (&#8220;ALK Territory&#8221;), exclusive license under certain of the Company&#8217;s patents and know-how to develop, manufacture and commercialize products containing epinephrine administered intranasally, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the trade name for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the European Union) (epinephrine nasal spray) (&#8220;Products&#8221;), for all human uses, including the immediate or emergency treatment of allergic reactions (including Type I) and anaphylaxis and urticaria, and other future indications as agreed by the parties. If the Company develops any new intranasally administered product that contains epinephrine and files a new drug application in the United States for such product (&#8220;New Product&#8221;), upon ALK&#8217;s request such New Product will be included as a Product under the ALK Collaboration Agreement, subject to ALK bearing the costs of development of such New Product for its licensed territory.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, the Company is obligated to transfer to ALK the existing marketing authorizations for the Products in the ALK Territory. The Company is also required to conduct certain development and regulatory activities for Products in support of obtaining further regulatory approval of Products in the ALK Territory and will transfer such regulatory approvals to ALK. ALK is obligated to use commercially reasonable efforts to obtain and maintain regulatory approval for Products through the European Commission and within specified countries within the ALK Territory. Following such approval for a Product in each indication within specified countries within the ALK Territory, ALK is obligated to use commercially reasonable efforts to commercialize such Product in such indication in such countries and to achieve first commercial sale of a Product in certain countries in accordance with a timeline specified in the ALK Collaboration Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Collaboration Agreement, ALK made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment to the Company in November 2024, and the Company earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the ALK Territory in June 2025. The Company is eligible to receive additional outstanding regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and sales-based milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, provided that $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such sales-based milestones are contingent upon the Company obtaining regulatory approval for the Product in Canada by a specified time. The Company is entitled to receive tiered royalty payments on net sales in the mid- to high-teens, subject to certain standard reductions and offsets. Royalties will be payable, on a Product-by-Product and country-by-country basis, until the latest of the expiration of the licensed patents covering such Product in such country, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the first commercial sale of such Product in such country, or expiration of regulatory exclusivity for such Product in such country.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract will expire upon the expiration of the last-to-expire royalty term for all Products in the ALK Territory, unless terminated earlier. Either the Company or ALK may terminate the ALK Collaboration Agreement in the case of the other party&#8217;s insolvency or in the event of an uncured material breach of the other party, except that the Company may not terminate the ALK Collaboration Agreement for ALK&#8217;s material breach of its commercial diligence obligations. ALK may terminate the ALK Collaboration Agreement for convenience upon 12 months&#8217; prior written notice or for a safety or regulatory concern. The Company may terminate the ALK Collaboration Agreement in the event ALK makes certain challenges to certain of the Company&#8217;s patents. Prior to a change of control and outside of a set period of time after which the Company commences change of control negotiations, the Company may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area (&#8220;EEA&#8221;) upon prior written notice to ALK and payment of a termination fee that is the higher of an agreed mid-nine digit amount and the fair market value of the Products business in the EEA at the time of such termination (the &#8220;Repurchase Option&#8221;). The Company may also terminate the ALK Collaboration Agreement if ALK commercializes a non-injectable epinephrine product or manufactures such a product in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ALK Collaboration Agreement, the Company and ALK also entered into a commercial supply agreement (the &#8220;ALK Supply Agreement&#8221;) in November 2024, under which the Company will supply ALK&#8217;s requirements (and ALK will purchase from the Company its requirements) of Products for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a specified supply price, after which ALK may elect to transition to itself or its contract manufacturer the manufacture and supply of Products. The contract term for the ALK Supply Agreement is coterminous with the ALK Collaboration Agreement. Either the Company or ALK may terminate the ALK Supply Agreement in the event of an uncured material breach of the other party.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Assessment</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the ALK Collaboration Agreement and the ALK Supply Agreement qualify as a contract with a customer under ASC 606 as one combined arrangement. The Company identified the following performance obligations: (i) exclusive commercialization license in the European Economic Area (the &#8220;EEA License&#8221;); (ii) exclusive commercialization license in the rest of the ALK Territory (the &#8220;ROW License&#8221;) and; (iii) five separate development and regulatory services performance obligations. The Company also evaluated the (i) promise to add a New Product and new indications to the ALK Collaboration Agreement, and (ii) the promises under the ALK Supply Agreement, and concluded that these promises did not meet the definition of a performance obligation nor did these promises convey a material right to ALK.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is the estimated transaction price at contract inception. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outstanding regulatory milestone payments (totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) were fully constrained at contract inception and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a result of the uncertainty of whether any of the milestones will be achieved. In making the assessment of the constraint utilizing the most likely amount method, the Company considered the stage of development, and the risks associated with the remaining development required to achieve the milestones, as well as whether the achievement of the milestone is outside the control of the Company or ALK. The Company determined that the commercial milestone ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and the sales-based milestones and royalties will be recognized on the later of when the related sales occur or when control of the associated license has been transferred, as the Company determined that such sales-based consideration relates predominantly to the licenses granted to ALK. The Company reevaluates the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and will include regulatory milestones in the transaction price if it is probable that a significant revenue reversal will not occur in future periods.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At contract inception, the Company determined the estimated standalone selling prices for each performance obligation in order to allocate the transaction price among the performance obligations. The standalone selling price for the licenses was estimated using the adjusted market assessment approach. Under this method, the Company forecasted future cash flows expected in the ALK Territory, the probability of commercialization success, and a market discount rate. To estimate the standalone selling prices of the development and regulatory services, the Company forecasted its expected costs of satisfying each performance obligation inclusive of an appropriate margin for that service.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the total transaction price to each performance obligation on a relative standalone selling price basis and determined whether revenue should be recognized at a point in time or over time. The Company allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the EEA License performance obligation; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the ROW License performance obligation; and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the development and regulatory services performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue should be recognized when, or as, an entity satisfies a performance obligation by transferring a promised good or service to a customer, i.e., when the customer obtains control of the good or service. The licenses granted to ALK are being accounted for as distinct performance obligations. The licenses relate to functional intellectual property for which revenue is recognized at a point in time. In the case of the EEA License, the Company evaluated the impact of the Company&#8217;s Repurchase Option, and determined that, as a result of the Company&#8217;s ability to repurchase the license, control of the EEA License has not been transferred to ALK under ASC 606. The Company determined that the transaction price allocated to the EEA License should be accounted for as a financing liability, due to the repurchase price being greater than the original selling price of this performance obligation. Control of the EEA License will not be considered transferred to ALK until such time that the Repurchase Option lapses, which under the terms of the ALK Collaboration Agreement, will occur upon the expiration of the contract, or exercise by the Company of the Repurchase Option. In November 2024, the Company recognized the transaction price allocated to the EEA License of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a financing liability.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of the ROW License, the point in time for recognition of revenue was shortly after the inception of the contract because the customer obtained control of the license and was able to use and benefit from its right to use the intellectual property at that po</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">int. In November 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue for the transaction price allocated to the ROW License.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and regulatory services performance obligations under the ALK Collaboration Agreement each represent a separate performance obligation. The development and regulatory services, which are transferred to the customer over time, were provided to ALK from inception of the agreement and are expected to continue through 2028. Revenue related to the development and regulatory services performance obligations was initially recorded as contract liability and is being recognized as services are performed based on the costs incurred through the end of each reporting period, as a percentage of the estimated total costs to be incurred for these performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In November 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the development and regulatory services performance obligations. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the development and regulatory services performance obligations, respectively, which is recorded as revenue under collaboration agreements in the accompanying condensed consolidated statement of operations and comprehensive loss. As of June 30, 2025, the accompanying consolidated balance sheet includes a contract liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million classified as current and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million classified as noncurrent associated with these performance obligations and based on the expected period of performance for the development and regulatory services.</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, ALK completed the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EURneffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the ALK Territory, and the Company began generating revenue from product sales to ALK, earned royalties from the use of the EEA License, and also earned the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commercial milestone. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million commercial milestone, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized as revenue under collaboration agreements for the three and six months ended June 30, 2025 in the accompanying condensed consolidated statement of operations and comprehensive loss. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the EEA license and recognized as an increase to the financing liability, along with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to royalties earned in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had accounts receivable and contract liability balances of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associated with the ALK Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Contract Liability</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the contract liability from the ALK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"></td>
          <td style="width:1.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.68%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,089</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized under the ALK Collaboration Agreement</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,849</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Financing Liability</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the financing liability from the ALK Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"></td>
          <td style="width:1.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.68%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial milestone allocated to the EEA License</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,435</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales-based royalties earned in the EEA</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,959</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Co-Promotion Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, the Company and ALK-Abell&#243;, Inc. (&#8220;ALK U.S.&#8221;, an affiliate of ALK) entered into a co-promotion agreement (the &#8220;ALK Co-Promotion Agreement&#8221;) to co-promote </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specified pediatricians and other prescribers in the U.S. Accordingly, the Company granted ALK U.S. a non-exclusive, royalty-free license to use the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to the terms of the ALK Co-Promotion Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ALK Co-Promotion Agreement, ALK U.S. was obligated to start its promotion activities in May 2025 and meet specified ramp-up milestones and minimum detail requirements, using sales representatives that meet specific qualifications. In addition, during the term of the ALK Co-Promotion Agreement and for 180 days thereafter, ALK U.S. will not market, sell or manufacture any injection product containing epinephrine in the U.S.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is the principal of all sales transactions of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. and, subject to the terms of the ALK Co-Promotion Agreement, continues to have sole responsibility for all U.S. commercialization activities, including marketing, medical affairs, market access, production, distribution, pharmacovigilance, quality and safety.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay ALK U.S. a base fee to compensate ALK U.S. for its promotion activities.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Payments to ALK U.S. for the services performed during the first year of the arrangement will be deferred and paid in the second year of the arrangement. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from the Company starting in the second year of the arrangement equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% market share threshold during years three and four of the arrangement.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ALK Co-Promotion Agreement expires on the fourth anniversary of the commencement of promotion activities thereunder. Either party may terminate the ALK Co-Promotion Agreement in the event of an uncured material breach of the other party or for either party&#8217;s change of control. The Company may terminate the ALK Co-Promotion Agreement in the case of ALK U.S.&#8217;s insolvency, if ALK U.S. fails to meet specified ramp-up timelines, or if ALK U.S. markets, sells or commercializes any non-injection product containing epinephrine in the U.S. After the first six months, the Company may terminate the ALK Co-Promotion Agreement if minimum detail requirements are not met for a consecutive three-month period. After the first year, the Company may terminate the ALK Co-Promotion agreement for any reason or no reason for a fee (as described below). After the first year, ALK U.S. may terminate the ALK Co-Promotion Agreement for any reason or no reason, and the Company may terminate the agreement in the event ALK U.S. restructures its sales force.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the ALK Co-Promotion Agreement by the Company for convenience, so long as ALK U.S. has met specified performance thresholds during the term, the Company is obligated to pay ALK U.S. a specified mid-to-low double-digit percentage of the portion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net sales generated from the ALK U.S.-targeted prescribers in excess of a specified mid-quartile market share threshold that increases over time up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for a specified period after termination, which period decreases in duration the later that the termination occurs. Upon termination of the ALK Co-Promotion Agreement by the Company in connection with a change of control of the Company, the Company is obligated to pay ALK U.S. a one-time mid-seven digit to low eight-digit termination fee in an amount that increases the later that the termination occurs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated the terms of the ALK Co-Promotion Agreement and determined that it is a vendor arrangement with ALK U.S. During the three and six months ended June 30, 2025, the Company has recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in ALK-related selling, general, and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss, and the corresponding liability was recorded in other accrued liabilities in the accompanying condensed consolidated balance sheet as of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="fn_commitmentscontingencies" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> noncancelable office space lease for its current headquarters location in San Diego, California. Under the terms of the agreement, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is no option to extend the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company is subject to additional charges for common area maintenance and other costs.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Monthly rental payments due under the lease commenced on December 6, 2021 and escalate through the lease term. The Company prepaid the first month&#8217;s rent upon execution of the lease, and the lease agreement provided full rent abatement for the second and third months of the rental term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there was not an implicit rate within the lease, the discount rate was determined by using a set of peer companies incremental borrowing rates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the Company entered into a lease amendment to its headquarters location lease (the &#8220;Headquarters Amendment&#8221;), pursuant to which the Company will relocate to a new office space located in the same building. In May 2025, the Company took possession of the new office space upon substantial completion of the landlord&#8217;s work. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term of the new office space is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. Monthly lease payments increased when the Company took possession of the new office space and will escalate through the lease term, resulting in an annualized payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company remains subject to additional charges for common area maintenance and other costs. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has one option to extend the lease for an additional term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the monthly payment amounts would be determined by the landlord at the then-prevailing rate.</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon entering into the Headquarters Amendment, the Company remeasured the right-of-use asset and lease liability pertaining to its current headquarters, and as a result recorded an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to both its right-of-use asset and lease liability on its condensed consolidated balance sheet. Upon possession of the new office space, the Company recognized a right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on its condensed consolidated balance sheet. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there was not an implicit rate within the lease amendment, a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% was determined using a set of peer companies&#8217; incremental borrowing rates.</span></p></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes supplemental lease information (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.9030000000000005%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">219</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">______________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs in each of the three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were immaterial.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, future minimum non-cancelable operating lease payments are as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.823%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">318</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,864</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,661</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less lease liability, current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,072</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 24, 2023, Aera A/S, an IP consultancy firm in Denmark representing an unidentified opponent, filed a notice of opposition with the European Patent Office (the &#8220;EPO&#8221;) in respect of EP 3678649 (the &#8220;EP &#8216;649 Patent&#8221;), which is a patent directed to a nasal spray formulation of epinephrine, and uses thereof. The Company filed a response to the notice of opposition on December 15, 2023. The EPO scheduled oral proceedings on October 7, 2025, and the Company will continue to vigorously defend the EP &#8216;649 Patent. The results of any notice of opposition are inherently unpredictable and uncertain and could result in the EPO finding the patent to be invalid or unenforceable.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 25, 2025, Aptargroup, Inc. and Aptar France SAS (collectively, &#8220;Aptar&#8221;) filed a suit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. in the United States District Court for the Southern District of New York. Aptar alleges the Company violated the Defend Trade Secrets Act (18 USC &#167; 1836), misappropriated trade secrets under New York state law, and committed various breaches of contract. The complaint was served to the Company, and the Company filed a motion to dismiss on June 12, 2025. Aptar subsequently filed opposition to the motion to dismiss on July 28, 2025. The Company intends to vigorously defend itself in this matter.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of the outcome, involvement in legal proceedings may have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. The Company cannot predict the outcome of these suits, and failure by the Company to obtain favorable resolutions could have a material adverse effect on its business, results of operations, and financial condition. The Company&#8217;s chances of success on the merits of these suits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of June 30, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as described above, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or other body pending or, to the knowledge of the Company&#8217;s executive officers, threatened against or affecting the Company, the Company&#8217;s common stock, any of its subsidiaries or its subsidiaries&#8217; officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unconditional Purchase Obligations and Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unconditional purchase obligations and commitments are defined as agreements to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, the Company enters into arrangements with suppliers, manufacturers, and various other companies that supply goods or services. These arrangements can include unconditional purchase obligations and commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to the supply of raw materials is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payment obligations by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2028 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year thereafter through 2035. During the three and six months ended June 30, 2025, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under these agreements, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under these agreements during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of commitments related to the ALK Co-Promotion Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025. Payment obligations by year are as follows: 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2029</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made under this agreement during the three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of commitments related to a corporate sponsorship agreement with Food Allergy Research and Education, Inc. is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payments by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). During the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under this agreement, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under this agreement during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total amount of unconditional purchase obligations related to hosted software license subscription fees is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025. Payments by year are as follows: 2025 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), 2026 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), and 2027 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). During the three and six months ended June 30, 2025, the Company made </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in payments under this agreement, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made under this agreement during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts above do not represent the entire anticipated spend in the future but represent only those items for which the Company is contractually obligated. For this reason, these amounts do not provide an indication of the Company&#8217;s expected future cash outflows related to purchases and commitments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-Licensing and Supply<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingandsupplyAbstract', window );"><strong>In-LicensingAndSupply [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingandsupplyTextblock', window );">In-Licensing and Supply</a></td>
<td class="text"><p id="fn_inlicense_supply" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. In-Licensing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Aegis</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2018, the Company entered into a License Agreement (the &#8220;Aegis Agreement&#8221;) with Aegis Therapeutics, LLC (&#8220;Aegis&#8221;), a wholly owned subsidiary of Neurelis, Inc. Under the Aegis Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable, rights to certain proprietary Aegis technology, patent rights and know-how to develop and commercialize epinephrine products. The Company utilizes this technology in its sole commercial product, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As consideration for the license, the Company paid an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which was recorded in research and development expenses in the condensed consolidated statement of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of certain regulatory and commercial milestones. Regulatory milestone payments under the Aegis Agreement are recorded upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, regulatory milestone payments were recorded as research and development expenses in the condensed consolidated statement of operations. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Aegis upon the achievement of a regulatory milestone during 2019, and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Aegis upon the FDA&#8217;s acceptance of the Company&#8217;s new drug application submission for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which occurred in the third quarter of 2022. Since the approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory milestone payments have been capitalized as intangible assets in the accompanying condensed consolidated balance sheets. Amortization expense has been recorded to cost of goods sold, in the accompanying condensed consolidated statements of operations and comprehensive loss, on a straight-line basis over the estimated life of the intellectual property of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In August 2024, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was met for achieving FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was met for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a result, the Company capitalized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as intangible assets in the accompanying condensed consolidated balance sheets in the third quarter of 2024. The Company paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone for achieving FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in September 2024 and paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone for the first commercial sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in October 2024. The next milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is due upon the achievement of certain annual net product sales.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also pays royalties based on a mid-single-digit percentage of net product sales on its or its sublicensees&#8217; net sales of the Licensed Products (as defined in the Aegis Agreement) on a product-by-product basis. Royalties are recorded to cost of goods sold in the period the related product revenue is recognized.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, OrbiMed Advisors LLC (&#8220;OrbiMed&#8221;) entered into an agreement with Aegis, to purchase the rights, royalty interests, and related sales milestone payments on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will make all future payments under the Aegis Agreement to OrbiMed. As described in </span><a href="#fn_relatedparties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14 &#8211; Related Party Transactions</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a member of the Company&#8217;s Board of Directors is a General Partner at OrbiMed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is responsible for reimbursing Aegis for patent costs incurred in connection with prosecuting and maintaining patent rights that are specific to epinephrine or epinephrine </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expenses were recognized in connection with legal patent fees for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Aegis Agreement with 30 days writt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">en notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the Aegis Agreement, the Company also entered into a supply agreement (the &#8220;Aegis Supply Agreement&#8221;) with Aegis that allows the Company to purchase materials for preclinical, development and commercial use at predetermined prices. The Company may elect to have Aegis supply minimum quantities but there are no minimum or maximum purchase obligations under the Aegis Supply Agreement unless this election is made. The parties may terminate the Aegis Supply Agreement at any time by mutual agreement. In addition, the parties may terminate the Aegis Supply Agreement in the event of certain breaches of the Aegis Supply Agreement or upon the earlier of the expiration or termination of the Aegis Agreement or June 2028. The Aegis Supply Agreement term may be extended by mutual written agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Aegis Supply Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payments were made to Aegis in each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreement with Renaissance</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2020, the Company entered into a manufacturing agreement with Renaissance Lakewood, LLC (&#8220;Renaissance&#8221;), which was subsequently amended in July 2023, September 2024, and July 2025 (the &#8220;Renaissance Agreement&#8221;). Pursuant to the Renaissance Agreement, Renaissance agreed to manufacture for, and provide to the Company, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nasal unit dose sprays (&#8220;Renaissance Products&#8221;). The Company is obligated to provide Renaissance with certain supplies to manufacture the Renaissance Products and to purchase from Renaissance a mid-double-digit percentage of the Company&#8217;s annual aggregate Renaissance Product requirements in the EU, and a high double-digit percentage of the Company&#8217;s annual aggregate Renaissance Product requirements in the U.S. The Renaissance Agreement contains conventional commercial pharmaceutical manufacturing provisions including certain minimum purchase amounts to be determined in the future based on forecast needs and minimum batch size projections. The Company may also request Renaissance to perform certain services related to the Renaissance Product, for which the Company will pay reasonable compensation to Renaissance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the amendment in September 2024, the amended initial term of the Renaissance Agreement commenced on September 17, 2024, and will terminate (a) for Renaissance Product designated for commercial sale in the U.S., on December 31 immediately following the fifth anniversary of the initial U.S. launch date (&#8220;U.S. Initial Term&#8221;), and (b) for Renaissance Product designated for commercial sale in the EU, on December 31 immediately following the fifth anniversary of the initial EU launch date (&#8220;EU Initial Term&#8221;), in each case unless earlier terminated by one of the parties. The U.S. Initial Term and EU Initial Term automatically renew for successive two-year terms (&#8220;Renewal Term&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Supply Agreement with Ompi</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company entered into a supply agreement (the &#8220;Ompi Supply Agreement&#8221;) with Nuova Ompi S.r.l. (&#8220;Ompi&#8221;), pursuant to which Ompi has agreed to supply glass microvials to support the Company&#8217;s manufacture and commercialization of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the Ompi Supply Agreement, the Company has committed to purchase, and Ompi has committed to supply, specified annual minimum quantities of glass microvials, which may be increased with prior notice by the Company or through the rolling forecast process, subject to a specified annual cap. Ompi is obligated to establish the relevant manufacturing force, assets and capabilities needed to comply with its supply obligations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, as partial consideration for the supply arrangement, the Company made an upfront payment of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in U.S. dollars) to Ompi. The supply price for the glass microvials is specified in the Ompi Supply Agreement, subject to an annual adjustment that is capped at a specified percentage except in the case of material and extraordinary increase in Ompi&#8217;s cost of manufacturing the glass microvials.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ompi Supply Agreement will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and may be terminated (i) upon the parties&#8217; mutual written consent, (ii) by the Company for any reasonable business reasons (in which case the termination will become effective at the end of the following calendar year), or (iii) by the non-breaching party if the other party is in material breach of the Ompi Supply Agreement and fails to cure such breach within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after receipt of notice thereof from the non-breaching party.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InLicensingandsupplyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-licensing and supply Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InLicensingandsupplyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InLicensingandsupplyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-licensing and supply [Textblock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InLicensingandsupplyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Stockholders' Equity</a></td>
<td class="text"><p id="fn_equity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized Shares</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.56%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.56%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,161,180</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future awards or option grants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,062,484</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,905,773</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future employee stock purchase plan issuances</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,811,182</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223,100</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,192,494</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,338,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Offerings</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the Company filed an automatic shelf registration statement on Form S-3ASR with the Securities and Exchange Commission which became effective upon filing (the &#8220;Shelf Registration Statement&#8221;). The Shelf Registration Statement allows the Company, from time to time, to offer and sell any combination of shares of the Company&#8217;s common stock and preferred stock, various series of debt securities, and/or warrants to purchase any of such securities, either individually or in combination with other securities, in one or more offerings. The Company simultaneously entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales agreement (the &#8220;Equity</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Agreement&#8221;) wit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">h Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) to allow the Company to offer, sell and issue shares of the Company&#8217;s common stock from time to time through Cantor acting as sales agent and up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities have been sold pursuant to the Shelf Registration Statement or Equity Sales Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="fn_sbc" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,824</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,707</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,452</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,342</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,669</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three and six months ended June 30, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on of stock compensation expense was capitalized into inventory, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense was capitalized into inventory during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the total unrecognized stock-based compensation expense related to outstanding employee options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted stock units outstanding, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverba</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ck&#8217;s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,918</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,679</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">25,737,116</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were authorized under the 2016 and 2020 Equity Incentive Plans, of which </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">7,765,139</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,033,358</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were outstanding. As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,634,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were authorized under the 2018 Equity Incentive Plan, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">297,345</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,240,014</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were outstanding. The Company does not intend to grant future stock options or other equity awards under the 2016 or 2018 Equity Incentive Plans.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the Company&#8217;s equity incentive plans expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of grant and generally vest over a four-year period, with vesting either occurring at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% at the end of the first year and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to the Company&#8217;s non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 is as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.11%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.662%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:8.942%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.662%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.182%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subject to</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Life (Years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,161,180</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.63</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,158,150</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.54</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">630,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">417,153</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.23</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,541</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,540,712</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.72</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,815</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercisable shares subject to options outstanding at June 30, 2025 in the table above include vested and early exercisable awards. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock for all options that were in-the-money at June 30, 2025. The aggregate intrinsic value of options exercised during the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of option grants for the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The total fair value of shares vested during the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted was estimated using a Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the following weighted-average assumptions:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.343%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.343%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of stock options was determined using the Black-Scholes assumptions below. Each of these inputs is subjective and generally requires significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The fair market value of the Company&#8217;s common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the Company&#8217;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free Interest Rate. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend Yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p id="fn_ebp" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Employee Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company adopted a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#8217;s U.S. employees. The plan allows eligible employees to defer, at the employee&#8217;s discretion, pretax compensation up to the Internal Revenue Service (the &#8220;IRS&#8221;) annual limits. The Company matches up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s pay that they contribute to the plan, subject to IRS limitations. Expenses associated with the Company&#8217;s matching contribution totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2025, respectively. Expenses associated with the Company&#8217;s matching contribution totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p id="fn_relatedparties" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Related-Party Transactions</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2015, the Company entered into a consulting agreement, superseded in July 2022, for regulatory and development services with Pacific-Link Regulatory Consulting, Inc., an entity owned by the President/Chief Executive Officer/director and his spouse, the Chief Medical Officer of the Company. The Company incurred consulting expenses related to this agreement totaling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2025, respectively, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three and six months ended June 30, 2024, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company entered into a consulting agreement with Marlinspike Group, LLC (&#8220;Marlinspike Group&#8221;) to provide management, business consulting services and business development support. The managing member of Marlinspike Group is the Chair of the Board of Directors of the Company and one of its stockholders. The Company incurred expenses related to this agreement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2021, the Company entered into a consulting agreement, as amended in April 2022, with a member of the Board of Directors of the Company for general advice and assistance with the development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any future product candidates. As compensation for the consulting services the Company granted the member of the Board of Directors </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">590,950</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options that vest over a four-ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ar period. The Company incurred less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in stock-based compensation expense related to this agreement in each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in </span><a href="#fn_inlicense_supply"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10 &#8211; In-Licensing and Supply</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company is required to make milestone payments to Aegis upon achievement of certain regulatory and commercial milestones, and royalty payments to Aegis based on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2024, OrbiMed entered into an agreement with Aegis to purchase the rights, royalty interests, and related sales milestone payments on net product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A member of the Company&#8217;s Board of Directors is a General Partner at OrbiMed. The Company incurred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty expense payable to OrbiMed during the three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="fn_segments" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reports segment information using the management approach and views its operations and manages its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_626c3f50-1884-4203-bf7b-50eea6c01f4f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;), who is the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_84bd9e86-c4c0-4576-8d3c-cc8e99b6414a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, allocates resources and evaluates the performance of the operating segment based on historical and projected product sales, segment operating expenses, and condensed consolidated net loss, as reflected in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accompanying condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated statements of operations and comprehensive loss, which is the segment measure of loss.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The segment reports that are provided to the CODM are tracked against the Company&#8217;s internally budgeted expenses. The segment operating expense categories consist primarily of the Company&#8217;s functional departments: Clinical, Development, Medical Affairs, Sales and Marketing, and General and Administrative. The CODM does not review assets when evaluating the operating segment&#8217;s performance; therefore, this information is not presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment reporting for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,800</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,563</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,804</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,717</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,690</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment operating expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,984</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,078</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,226</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,454</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,042</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,151</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,591</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,252</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medical affairs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">421</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,018</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">754</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,925</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,694</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,682</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,145</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,118</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,505</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,837</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,195</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,669</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total segment operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,331</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,481</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,614</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,340</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,791</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,532</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,731</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,824</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,968</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,724</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,883</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,516</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,823</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,808</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.  The Company is currently evaluating the provisions of the new law and the potential effects on its financial position, results of operations, and cash flows. As of the date of these financial statements, the Company has not completed its assessment, and therefore no adjustments have been made.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Polices)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s financial statements are presented on a condensed consolidated basis, which include the accounts of ARS Pharmaceuticals, Inc., ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#8217;s functional and reporting currency is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income in the condensed consolidated statements of operations and comprehensive loss. All adjustments considered necessary for a fair presentation have been included.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, the condensed consolidated statements of stockholders&#8217; equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, are unaudited. The balance sheet as of December 31, 2024 was derived from the audited financial statements as of and for the year ended December 31, 2024. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of June 30, 2025, the condensed consolidated results of its operations for the three and six months ended June 30, 2025 and 2024, and its cash flows for the six months ended June 30, 2025 and 2024. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2025 and 2024 are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed consolidated financial statements are revenue recognized under collaboration agreements, accruals for variable components of product revenue, accruals for research and development expenses, and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash readily available in checking, money market mutual funds, and short-term investments with remaining maturities when purchased of 90 days or less. The Company considers all highly liquid investments with remaining maturities when purchased of 90 days or less to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable and Allowance for Credit Losses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable includes trade accounts receivable from product sales to customers, partner receivables for reimbursable research and development costs, royalties, license fees, and milestone payments under the Company&#8217;s collaboration agreements, and partner receivables for supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the Company&#8217;s supply agreements. Trade accounts receivable are recorded at wholesale acquisition cost (&#8220;WAC&#8221;), less purchase price discounts, prompt pay discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company&#8217;s estimate of losses over the life of the receivables. The Company determines the allowance for credit losses for accounts receivable based on each customer&#8217;s or partner&#8217;s accounts receivable balance and age, their financial condition, and the general economic environment. The Company must also use professional judgment for its allowance for credit losses on trade accounts receivable as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was commercially launched in September 2024 and historical data is limited. The Company is currently operating under the Title Agreement (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with its Title Agent (as defined in </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the Title Agent retains all credit and collection risk on product sales to the Company&#8217;s wholesale distributors and pharmacy customers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was deemed necessary at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 or December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests excess cash in investment grade fixed income securities. These investments are included in short-term investments on the condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss) gain, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Realized gains and losses on the sale of securities are recognized in net loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and short-term investments are carried at fair value. The carrying amounts of all accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, and contract liability are considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its financial instruments portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also subject to credit risk related to its accounts receivable from product sales and revenue under collaboration and supply agreements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is distributed primarily through wholesale distributors and pharmacies. These entities are not obligated to purchase any set number of units and they distribute </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on demand as orders are received. The Company enters into collaboration and supply agreements with pharmaceutical companies under which the Company is entitled to receive payments for royalties, license fees, milestone achievements, reimbursable costs for research and development services, and supply of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company extends credit to its customers and partners in the normal course of business after evaluating their overall financial condition. As stated above, the Company is currently operating under the Title Agreement with its Title Agent and the Title Agent retains all credit and collection risk on sales to the Company&#8217;s wholesale distributors and pharmacy customers. The Company&#8217;s Title Agent accounts for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s accounts receivable balance as of June 30, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. One additional customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of accounts receivable as of June 30, 2025. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, four and six customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, with each individual customer ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s gross product sales, respectively. For the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025, one customer accounted for all revenue under collaboration agreements and supply agreements. For the three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, one customer accounted for all revenue under collaboration agreements, and there was no product sales or revenue under supply agreements. Historically, the Company has not experienced any credit losses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventories</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process, and include labor and overhead. Inventories are stated at the lower of cost or net realizable value, and are determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered. Such impairment charges, if any, are recorded in cost of goods sold on the condensed consolidated statements of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes inventory costs after regulatory approval, when future commercialization is considered probable, and a future economic benefit is expected to be realized. Prior to regulatory approval, the Company records inventory costs as research and development expenses. As such, when regulatory approval is received, this may result in zero-cost inventory which does not have a carrying value. This inventory is available to the Company to utilize for commercial operations as well as ongoing research and development activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally five years. Repair and maintenance costs are charged to expense as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate, including its eventual residual value. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. The Company has not recognized any impairment losses from inception through June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the initial classification and measurement of its right-of-use (&#8220;ROU&#8221;) asset and lease liabilities at the lease commencement date and thereafter, if modified. The Company recognizes a ROU asset for its operating leases with lease terms greater than 12 months. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The lease liability is calculated by using the present value of all lease payments, with the present value determined by using the incremental borrowing rate for operating leases determined by using the incremental borrowing rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment as well as a review of peer companies. Variable charges for common area maintenance and other variable costs are recognized as expense as incurred. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues consist of product sales of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and revenue derived from its collaboration, out-licensing, and supply agreements. See </span><a href="#fn_revenue"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3 &#8211; Revenue</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on product revenue, and </span><a href="#fn_collab_outlicense"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8 &#8211; Collaboration and Out-Licensing</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more detail on revenue from collaboration agreements, out-licensing agreements, and supply agreements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). The provisions of ASC 606 require the following steps to determine revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, determines whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold primarily consists of direct and indirect costs related to the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, supply agreement fees, and royalties on product sales. Prior to the FDA approval of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in August 2024, costs incurred for the manufacture of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initially reflects a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, external research and development costs incurred under agreements with contract research organizations, investigative sites and consultants to conduct clinical studies, costs related to compliance with regulatory requirements, costs related to manufacturing the Company&#8217;s product candidates (including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prior to FDA approval in August 2024) for clinical trials, and other allocated expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for research and development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company uses judgments and estimates to determine the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Costs</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative costs are expensed in the period incurred. Selling, general and administrative costs primarily consist of marketing-related expenses, salaries and related expenses for personnel, including meals and travel-related expenses incurred by the sales team, stock-based compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax, and other consulting services, and insurance costs.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for producing advertising are expensed when incurred. Costs for communicating advertising, such as search engine marketing, banner advertisements, social media advertisements, and print advertisements, are recorded as prepaid expenses and then expensed when the advertisement occurs. For the three and six months ended June 30, 2025, advertising costs were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advertising costs were incurred for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_PatentsCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_LicenseFeesPolicyTextBlock', window );">License Fees</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Fees</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred to acquire technology licenses and milestone payments made on existing agreements are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes expense for awards subject to performance-based milestones over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and recognizes forfeitures as they occur. In the event that stock-based awards are granted in contemplation of or shortly before a planned release of material non-public information, and such information is expected to result in a material increase in the share price of the Company&#8217;s common stock, the Company may consider whether an adjustment to the observable market price is required when estimating the grant date fair value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss typically consists of the change in unrealized gains and losses on available-for-sale securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, stock options, warrants, and unvested restricted stock units, are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:66.967%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of June 30,</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,436,432</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,318,828</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,484,651</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
          </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280)&#8211;Improvements to Reportable Segment Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-07&#8221;), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 was effective for the Company on January 1, 2024 for annual periods and on January 1, 2025 for interim periods. The adoption of ASU 2023-07 resulted in enhanced disclosures as included in </span><a href="#fn_segments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 15 &#8211; Segment Information</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and did not impact the Company&#8217;s condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8212; Not Yet Adopted</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards, other than those noted below, and any issued but not yet effective standards will not have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Income Taxes (Topic 740)&#8211;Improvements to Income Tax Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASU 2023-09&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The amendments in this update are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company does not expect to early adopt the new standard. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2023-09 on the financial statements and related disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASU 2024-03&#8221;). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the income statement within continuing operations of public business entities. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact of adoption of this ASU on the Company&#8217;s disclosures is currently being evaluated.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_LicenseFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_LicenseFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_PatentsCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patents costs policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_PatentsCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:66.967%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:1.16%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
            <td style="width:13.357%;box-sizing:content-box;"></td>
            <td style="width:1%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of June 30,</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,436,432</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,318,828</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,484,651</span></p></td>
            <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           </tr>
          </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ScheduleOfInventoryTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized inventories consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,784</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,674</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work in process</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,826</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory reserve</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,160</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,519</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reported as:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,738</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,212</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term inventories</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,307</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventories, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,519</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ScheduleOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ScheduleOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table identifies the Company&#8217;s assets that were measured at fair value on a recurring basis (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:8.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.08%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,248</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,248</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,636</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,590</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,884</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,838</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - Money market mutual funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,382</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,387</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments - U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263,205</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,878</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,098</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid marketing</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,447</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,169</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,261</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,027</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,469</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,442</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,886</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Long Term Assets</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term assets consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid supply agreement fee</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,863</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,800</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized software implementation costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">314</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,051</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,114</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,559</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,870</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,341</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,179</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued marketing related expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,855</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,306</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued inventory</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,145</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,264</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,841</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net, all of which are finite-lived, consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized milestone payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,360</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">388</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,972</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, estimated future amortization expense for capitalized intangible assets for the next five years is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.823%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,544</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, Out-Licensing and Related Agreements (Table)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the contract liability from the ALK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"></td>
          <td style="width:1.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.68%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,089</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized under the ALK Collaboration Agreement</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,849</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Financing Liability</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the financing liability from the ALK Collaboration Agreement is as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:83.74%;box-sizing:content-box;"></td>
          <td style="width:1.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.68%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial milestone allocated to the EEA License</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,435</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales-based royalties earned in the EEA</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,959</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Supplemental Lease Information</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes supplemental lease information (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.9030000000000005%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.24%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.344000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">219</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">______________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs in each of the three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were immaterial.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Noncancelable Operating Lease Payments</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, future minimum non-cancelable operating lease payments are as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.823%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (remaining six months)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">318</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,864</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,661</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less lease liability, current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,072</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock', window );">Summary of Common Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.56%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.56%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,161,180</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted and outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,382</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future awards or option grants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,062,484</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,905,773</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for future employee stock purchase plan issuances</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,811,182</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223,100</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,456</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,192,494</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,338,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,824</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,707</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,452</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,342</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,669</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 is as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.11%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.662%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:8.942%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.662%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.182%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subject to</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Life (Years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,161,180</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.63</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,158,150</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.54</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">630,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">417,153</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.23</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,271,990</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,541</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,540,712</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.72</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,815</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted was estimated using a Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the following weighted-average assumptions:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.343%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.343%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Provided to the CODM</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment reporting for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,800</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,563</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under collaboration agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,804</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue under supply agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,717</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,690</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment operating expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,984</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,078</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,226</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,454</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,042</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,151</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,591</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,252</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,099</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medical affairs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">421</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,018</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">754</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,925</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,694</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,682</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,145</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,118</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,505</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,837</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,195</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,669</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total segment operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,331</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,481</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,614</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,340</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,791</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,532</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,731</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,824</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,968</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,724</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,883</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,516</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,823</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,808</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 202,128<span></span>
</td>
<td class="nump">$ 123,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_PeriodForFirstNewDeliveryMethodOfEpinephrine', window );">Period for first new delivery method of epinephrine</a></td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=spry_LiquidityAndCapitalResourcesMember', window );">Liquidity and Capital Resources [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 202,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 240,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_PeriodForFirstNewDeliveryMethodOfEpinephrine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for first new delivery method of epinephrine.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_PeriodForFirstNewDeliveryMethodOfEpinephrine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=spry_LiquidityAndCapitalResourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=spry_LiquidityAndCapitalResourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Additional Information) (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Account Receivable [Member] | Customer Concentration Risk [Member] | Title Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Account Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer One [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer One [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Three [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Three [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Four [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Four [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Five [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Five [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Six [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Sales [Member] | Customer Concentration Risk [Member] | Customer Six [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_TitleAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_TitleAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=spry_CustomerSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=spry_CustomerSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">17,318,828<span></span>
</td>
<td class="nump">14,484,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">45,456<span></span>
</td>
<td class="nump">45,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">17,271,990<span></span>
</td>
<td class="nump">14,436,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 17,784<span></span>
</td>
<td class="nump">$ 4,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">6,488<span></span>
</td>
<td class="nump">5,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="num">(2,160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">22,112<span></span>
</td>
<td class="nump">10,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InventoryCurrent', window );">Inventories</a></td>
<td class="nump">8,738<span></span>
</td>
<td class="nump">5,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Long-term inventories</a></td>
<td class="nump">$ 13,374<span></span>
</td>
<td class="nump">$ 5,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ZeroCostInventory', window );">Zero cost inventory</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ZeroCostInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Zero-cost inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ZeroCostInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 51,540<span></span>
</td>
<td class="nump">$ 50,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">51,248<span></span>
</td>
<td class="nump">6,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">51,248<span></span>
</td>
<td class="nump">6,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">U.S. Treasury securities, Gross unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash And Cash Equivalents Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and Cash Equivalents Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Recurring [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash And Cash Equivalents Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and Cash Equivalents Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Recurring [Member] | U.S. Treasury Securities [Member] | Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">U.S. Treasury securities, Amortized Cost</a></td>
<td class="nump">188,636<span></span>
</td>
<td class="nump">262,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">U.S. Treasury securities, Gross unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">U.S. Treasury securities, Fair Value</a></td>
<td class="nump">188,590<span></span>
</td>
<td class="nump">263,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=spry_FairValueInputsLevel1AndLevel2Member', window );">Level 1 And Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">239,884<span></span>
</td>
<td class="nump">311,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue', window );">Total Fair Value</a></td>
<td class="nump">$ 239,838<span></span>
</td>
<td class="nump">$ 312,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And cash equivalents And available for sale debt securities amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CashAndCashEquivalentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CashAndCashEquivalentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CashAndCashEquivalentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents Gross Unrealized Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CashAndCashEquivalentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Money Market Funds and Available For Sale Debt Securities Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=spry_FairValueInputsLevel1AndLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=spry_FairValueInputsLevel1AndLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,723,000<span></span>
</td>
<td class="nump">$ 151,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Maturities of short-term investments, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,500,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest on available-for-sale securities</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized holding gain (loss)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="nump">31,400,000<span></span>
</td>
<td class="nump">87,600,000<span></span>
</td>
<td class="nump">65,700,000<span></span>
</td>
<td class="nump">151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Maturities of short-term investments, available-for-sale</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">143,500,000<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1', window );">Fair value, liabilities transfers from Level 2 to Level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1', window );">Fair value, assets transfers into (out of) level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FairValueLiabilitiesLevel2ToLevel1TransfersAmount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_PrepaidMarketingExpenses', window );">Prepaid marketing</a></td>
<td class="nump">$ 3,447<span></span>
</td>
<td class="nump">$ 3,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">956<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 7,442<span></span>
</td>
<td class="nump">$ 6,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_PrepaidMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_PrepaidMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Long Term Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_PrepaidSupplyAgreementFee', window );">Prepaid supply agreement fee</a></td>
<td class="nump">$ 2,863<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized software implementation costs</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total</a></td>
<td class="nump">$ 3,051<span></span>
</td>
<td class="nump">$ 3,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_PrepaidSupplyAgreementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid supply agreement fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_PrepaidSupplyAgreementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 15,559<span></span>
</td>
<td class="nump">$ 9,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AccruedGrossToNetAdjustments', window );">Accrued gross-to-net adjustments</a></td>
<td class="nump">11,341<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued marketing related expenses</a></td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AccruedInventory', window );">Accrued inventory</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other</a></td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 44,264<span></span>
</td>
<td class="nump">$ 22,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AccruedGrossToNetAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued gross to net adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AccruedGrossToNetAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AccruedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AccruedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">12,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics LLC [Member] | Capitalized Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life of Finite Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AggregateMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life of Finite Lived Intangible Assets</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Termination Agreement [Member] | Capitalized Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life of Finite Lived Intangible Assets</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CapitalizedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CapitalizedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=spry_CapitalizedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=spry_CapitalizedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated depreciation</a></td>
<td class="num">(388,000)<span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total</a></td>
<td class="nump">$ 12,972,000<span></span>
</td>
<td class="nump">$ 7,371,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CapitalizedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CapitalizedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remaining six months)</a></td>
<td class="nump">$ 476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2027</a></td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2028</a></td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2029</a></td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 2,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="15">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2024</div></th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>Doctor</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses related party amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,312<span></span>
</td>
<td class="nump">$ 8,944<span></span>
</td>
<td class="nump">$ 95,416<span></span>
</td>
<td class="nump">$ 16,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_FinancingLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,717<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">23,690<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=spry_EuropeanEconomicAreaLicenseMember', window );">EEA License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation, transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_FinancingLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=spry_ROWLicenseMember', window );">ROW License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation, transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=spry_DevelopmentAndRegulatoryServicesMember', window );">Development and Regulatory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation, transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AlfresaAgreementMember', window );">Alfresa Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InitialTransactionPrice', window );">Initial Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RemainingRegulatoryMilestone', window );">Remaining regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AlfresaAgreementMember', window );">Alfresa Agreement [Member] | License Agreement [Member] | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_LicenseAgreementExpirationTerm', window );">License Agreement Expiration Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InitialTransactionPrice', window );">Initial Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AggregateMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life of Finite Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">&#8364; 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Research and development [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | European Medicines Agency [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePayments', window );">Milestone Payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | First commercial sale of Recordati Licensed Product [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePayments', window );">Milestone Payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember', window );">Recordati Agreement [Member] | Aggregate sale of Recordati Licensed Product [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_PediatrixAgreementMember', window );">Pediatrix Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_LicenseAgreementExpirationTerm', window );">License Agreement Expiration Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InitialTransactionPrice', window );">Initial Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryAndCommercialSalesMilestones', window );">Regulatory and Commercial Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_PediatrixAgreementMember', window );">Pediatrix Agreement [Member] | License Agreement [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_SeqirusAgreementMember', window );">Seqirus Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InitialTransactionPrice', window );">Initial Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryAndCommercialSalesMilestones', window );">Regulatory and Commercial Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | ALK Financing Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_IncreaseToTheFinancingLiability', window );">Increase to the financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RoyaltyIncomeNotRecognized', window );">Royalty income not recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_LicenseAgreementExpirationTerm', window );">License Agreement Expiration Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ContingentSalesBasedMilestones', window );">Contingent Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase Commitment Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SalesBasedMilestones', window );">Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | Development and Regulatory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | First Commercial Sale Of Neffy [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Collaboration Agreement [Member] | First Commercial Sale Of Neffy [Member] | Commercial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCo-PromotionAgreementMember', window );">ALK Co-Promotion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_NumberOfPediatricians', window );">Number of pediatricians | Doctor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_PerformanceBasedBonusPaymentsPercentage', window );">Performance based bonus payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementRightsAndObligations', window );">Transaction under agreement with A.L.K U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> Payments to ALK U.S. for the services performed during the first year of the arrangement will be deferred and paid in the second year of the arrangement. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from the Company starting in the second year of the arrangement equal to 30% of the portion of neffy net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a 50% market share threshold during years three and four of the arrangement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ThresholdPercentageOfValueChangeInEquitySecurities', window );">Threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses related party amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ContingentSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ContingentSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_FinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_FinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_IncreaseToTheFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>increase to the financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_IncreaseToTheFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_LicenseAgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_LicenseAgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_NumberOfPediatricians">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pediatricians</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_NumberOfPediatricians</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_PerformanceBasedBonusPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance based bonus payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_PerformanceBasedBonusPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RegulatoryAndCommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory and Commercial sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RegulatoryAndCommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RemainingRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RemainingRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RoyaltyIncomeNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty income not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RoyaltyIncomeNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_SalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-Based Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_SalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ThresholdPercentageOfValueChangeInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of value change in equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ThresholdPercentageOfValueChangeInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_EuropeanEconomicAreaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_EuropeanEconomicAreaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_ROWLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_ROWLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_DevelopmentAndRegulatoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_DevelopmentAndRegulatoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AlfresaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AlfresaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RecordatiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=spry_EuropeanMedicinesAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=spry_EuropeanMedicinesAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfRecordatiLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfRecordatiLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_AggregateSaleOfRecordatiLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_AggregateSaleOfRecordatiLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_PediatrixAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_PediatrixAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_SeqirusAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_SeqirusAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=spry_ALKFinancingLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=spry_ALKFinancingLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfNeffyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfNeffyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCo-PromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCo-PromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail) - ALK Collaboration Agreement [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized under the ALK Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2025</a></td>
<td class="nump">$ 1,849<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember', window );">ALK Financing Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_IncreaseToTheFinancingLiability', window );">Commercial milestone allocated to the EEA License</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RoyaltyIncomeAllocatedToTheEEALicense', window );">Sales-based royalties earned in the EEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at June 30, 2025</a></td>
<td class="nump">$ 71,959<span></span>
</td>
<td class="nump">$ 71,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_IncreaseToTheFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>increase to the financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_IncreaseToTheFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RoyaltyIncomeAllocatedToTheEEALicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty income allocated to the EEA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RoyaltyIncomeAllocatedToTheEEALicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_ALKCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=spry_ALKFinancingLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=spry_ALKFinancingLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Leases) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Noncancelable lease agreement description</a></td>
<td class="text">In January 2025, the Company entered into a lease amendment to its headquarters location lease (the &#8220;Headquarters Amendment&#8221;), pursuant to which the Company will relocate to a new office space located in the same building. In May 2025, the Company took possession of the new office space upon substantial completion of the landlord&#8217;s work. As of June 30, 2025, the remaining lease term of the new office space is 36 months. Monthly lease payments increased when the Company took possession of the new office space and will escalate through the lease term, resulting in an annualized payment of $0.6 million. The Company remains subject to additional charges for common area maintenance and other costs. The Company has one option to extend the lease for an additional term of three years, and the monthly payment amounts would be determined by the landlord at the then-prevailing rate.Upon entering into the Headquarters Amendment, the Company remeasured the right-of-use asset and lease liability pertaining to its current headquarters, and as a result recorded an additional $0.1 million to both its right-of-use asset and lease liability on its condensed consolidated balance sheet. Upon possession of the new office space, the Company recognized a right-of-use asset and lease liability of $1.6 million on its condensed consolidated balance sheet. As there was not an implicit rate within the lease amendment, a discount rate of 8% was determined using a set of peer companies&#8217; incremental borrowing rates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In October 2021, the Company entered into a 38-month noncancelable office space lease for its current headquarters location in San Diego, California. Under the terms of the agreement, there is no option to extend the lease, and the Company is subject to additional charges for common area maintenance and other costs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining noncancelable lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease Weighted Average Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Annualized payment of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">The Company has one option to extend the lease for an additional term of three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">there is no option to extend the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=spry_SanDiegoCaliforniaMember', window );">San Diego California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Noncancelable lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">38 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=spry_HeadquartersAmendmentMember', window );">Headquarters Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Annualized payment of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=spry_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=spry_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=spry_HeadquartersAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=spry_HeadquartersAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitments</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=spry_ALKCo-PromotionAgreementMember', window );">ALK Co-Promotion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitments</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Commitments, 2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">Commitments, 2026</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Commitments, 2027</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">Commitments, 2028</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">Commitments, 2029</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UnrecordedUnconditionalPurchaseObligationsPaid', window );">Purchase obligations amount made</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=spry_FoodAllergyResearchAndEducationIncMember', window );">Food Allergy Research and Education Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Commitments, 2025</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">Commitments, 2026</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Commitments, 2027</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UnrecordedUnconditionalPurchaseObligationsPaid', window );">Purchase obligations amount made</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember', window );">Inventories [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unconditional purchase obligations</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Unconditional purchase obligations, 2025</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">Unconditional purchase obligations, 2026</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">Unconditional purchase obligations, 2027</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary', window );">Unconditional purchase obligations, 2028</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour', window );">Thereafter through 2035</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UnrecordedUnconditionalPurchaseObligationsPaid', window );">Purchase obligations amount made</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=spry_SoftwareLicenseSubscriptionFeesMember', window );">Software License Subscription Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unconditional purchase obligations</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Unconditional purchase obligations, 2025</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">Unconditional purchase obligations, 2026</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">Unconditional purchase obligations, 2027</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UnrecordedUnconditionalPurchaseObligationsPaid', window );">Purchase obligations amount made</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecorded unconditional purchase obligation to be paid after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_UnrecordedUnconditionalPurchaseObligationsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecorded unconditional purchase obligations paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_UnrecordedUnconditionalPurchaseObligationsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=spry_ALKCo-PromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=spry_ALKCo-PromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=spry_FoodAllergyResearchAndEducationIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=spry_FoodAllergyResearchAndEducationIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=spry_SoftwareLicenseSubscriptionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=spry_SoftwareLicenseSubscriptionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Supplemental Lease Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for leases</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2025 (remaining six months)</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less lease liability, current portion</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-Licensing and Supply - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">7,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=spry_OmpiSupplyAgreementMember', window );">Ompi Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SupplyAgreementExpirationDate', window );">Supply Agreement Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AgreementTerminationDueToMaterialBreach', window );">Agreement Termination, Due To Material Breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_UpfrontLicenseFees', window );">Upfront License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones', window );">Aggregate milestone payments upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_RegulatoryMilestone', window );">Regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_MilestonePaymentDueOnAchievementOfAnnualSales', window );">Milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_NoticePeriodDescription', window );">Notice Period Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_LegalPatentFees', window );">Legal Patent Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SupplyAgreementExpense', window );">Supply Agreement Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics Agreement | First Commercial Sale Of Neffy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics Agreement | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life of Finite Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics Agreement | Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember', window );">Aegis Therapeutics Agreement | New Drug Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_CapitalizedMilestonePayments', window );">Capitalized milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RenaissanceLakewoodLlcMember', window );">Renaissance Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_InLicensingAndSupplyLineItems', window );"><strong>In Licensing and Supply [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractTerminationClaimsDescription', window );">Contract Termination Claims, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_AgreementTerminationDueToMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination, due to material breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_AgreementTerminationDueToMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_CapitalizedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_CapitalizedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_InLicensingAndSupplyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represents in licensing and supply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_InLicensingAndSupplyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_LegalPatentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Patent Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_LegalPatentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_MilestonePaymentDueOnAchievementOfAnnualSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due on achievement of annual sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_MilestonePaymentDueOnAchievementOfAnnualSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_NoticePeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice Period Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_NoticePeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_RegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_RegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_SupplyAgreementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_SupplyAgreementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_SupplyAgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply agreement expiration date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_SupplyAgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractTerminationClaimsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477623/912-405-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477623/912-405-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478685/912-310-50-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478685/912-310-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractTerminationClaimsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_OmpiSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_OmpiSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfNeffyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_FirstCommercialSaleOfNeffyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=spry_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=spry_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spry_NewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spry_NewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RenaissanceLakewoodLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RenaissanceLakewoodLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock , shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=spry_EquityOfferingsMember', window );">Equity Offerings [Member] | Equity Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=spry_EquityOfferingsMember', window );">Equity Offerings [Member] | Maximum [Member] | Equity Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Maximum aggregate offering price of securities</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=spry_EquityOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=spry_EquityOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=spry_EquitySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=spry_EquitySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">28,192,494<span></span>
</td>
<td class="nump">23,338,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_CommonStockOptionsGrantedAndOutstandingMember', window );">Common Stock Options Granted and Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">17,271,990<span></span>
</td>
<td class="nump">15,161,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_RestrictedStockUnitsGrantedAndOutstandingMember', window );">Restricted Stock Units Granted and Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember', window );">Common Stock Reserved For Future Awards or Option Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">8,062,484<span></span>
</td>
<td class="nump">5,905,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember', window );">Common Stock Reserved For Future Employee Stock Purchase Plan Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">2,811,182<span></span>
</td>
<td class="nump">2,223,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="nump">45,456<span></span>
</td>
<td class="nump">45,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_CommonStockOptionsGrantedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_CommonStockOptionsGrantedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_RestrictedStockUnitsGrantedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_RestrictedStockUnitsGrantedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 3,365<span></span>
</td>
<td class="nump">$ 10,669<span></span>
</td>
<td class="nump">$ 6,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,707<span></span>
</td>
<td class="nump">$ 2,452<span></span>
</td>
<td class="nump">$ 9,342<span></span>
</td>
<td class="nump">$ 4,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Beginning balance | shares</a></td>
<td class="nump">15,161,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Options Outstanding, Granted | shares</a></td>
<td class="nump">3,158,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Options Outstanding, Exercised | shares</a></td>
<td class="num">(630,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares Subject to Options Outstanding, Forfeited | shares</a></td>
<td class="num">(417,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Ending balance | shares</a></td>
<td class="nump">17,271,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Options Exercisable, Ending Balance | shares</a></td>
<td class="nump">9,540,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 6.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">11.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">4.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">11.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">7.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Exercisable , Ending balance | $ / shares</a></td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (Years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance | $</a></td>
<td class="nump">$ 174,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable Ending balance | $</a></td>
<td class="nump">$ 114,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options forfeited in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.70%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock compensation expense capitalized to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,271,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,271,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,161,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted common stock, vesting in equal monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair Value of Shares Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,192,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,192,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,338,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2016And2020Member', window );">Equity Incentive Plan 2016 and 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,737,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,737,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2018Member', window );">Equity Incentive Plan 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,634,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,634,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share purchased under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,918<span></span>
</td>
<td class="nump">43,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=spry_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</a></td>
<td class="text">In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverback&#8217;s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). There were 111,918 shares and 43,679 shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024, respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=spry_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member] | Equity Incentive Plan 2016 and 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,033,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,033,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,765,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,765,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=spry_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member] | Equity Incentive Plan 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,240,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,240,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future awards or option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2016And2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2016And2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=spry_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=spry_EquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=spry_EquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Contribution totaled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based compensation number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,158,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_OrbiMedAdvisorsLLCMember', window );">OrbiMed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based compensation number of options granted</a></td>
<td class="nump">590,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=spry_PacificLinkConsultingLlcMember', window );">Pacific-Link Consulting, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Consulting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=spry_MarlinspikeGroupLlcMember', window );">Marlinspike Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Consulting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_OrbiMedAdvisorsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_OrbiMedAdvisorsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=spry_PacificLinkConsultingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=spry_PacificLinkConsultingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=spry_MarlinspikeGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=spry_MarlinspikeGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;), who is the Chief Executive Officer, allocates resources and evaluates the performance of the operating segment based on historical and projected product sales, segment operating expenses, and condensed consolidated net loss, as reflected in the accompanying condensed consolidated statements of operations and comprehensive loss, which is the segment measure of loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 15,717<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 23,690<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">63,331<span></span>
</td>
<td class="nump">15,840<span></span>
</td>
<td class="nump">108,481<span></span>
</td>
<td class="nump">29,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(47,614)<span></span>
</td>
<td class="num">(15,340)<span></span>
</td>
<td class="num">(84,791)<span></span>
</td>
<td class="num">(28,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,731<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">5,968<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,883)<span></span>
</td>
<td class="num">(12,516)<span></span>
</td>
<td class="num">(78,823)<span></span>
</td>
<td class="num">(22,808)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=spry_CostOfGoodsSoldMember', window );">Cost of Goods Sold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=spry_ClinicalMember', window );">Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
<td class="nump">4,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=spry_DevelopmentMember', window );">Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">4,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=spry_MedicalAffairsMember', window );">Medical affairs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">40,925<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
<td class="nump">67,682<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">7,118<span></span>
</td>
<td class="nump">5,505<span></span>
</td>
<td class="nump">15,837<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=spry_Share-BasedCompensationMember', window );">Stock-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">3,365<span></span>
</td>
<td class="nump">10,669<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_spry_SegmentOperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,563<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember', window );">Revenue under collaboration agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember', window );">Revenue under supply agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_spry_SegmentOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment operating expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">spry_SegmentOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>spry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=spry_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=spry_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=spry_ClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=spry_ClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=spry_DevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=spry_DevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=spry_MedicalAffairsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=spry_MedicalAffairsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=spry_Share-BasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=spry_Share-BasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_RevenueUnderCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=spry_RevenueUnderSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>328</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75070 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75080 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75090 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Collaboration, Out-Licensing and Related Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements</Role>
      <ShortName>Collaboration, Out-Licensing and Related Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - In-Licensing and Supply</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply</Role>
      <ShortName>In-Licensing and Supply</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Common Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity</Role>
      <ShortName>Common Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices</Role>
      <ShortName>Summary of Significant Accounting Policies (Polices)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Collaboration, Out-Licensing and Related Agreements (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable</Role>
      <ShortName>Collaboration, Out-Licensing and Related Agreements (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Common Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables</Role>
      <ShortName>Common Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Inventories - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail</Role>
      <ShortName>Inventories - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Inventories - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail</Role>
      <ShortName>Inventories - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Balance Sheet Details - Schedule of Other Long Term Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Long Term Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail</Role>
      <ShortName>Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD</Role>
      <ShortName>Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Commitments and Contingencies - Additional Information (Leases) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Leases) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Commitments and Contingencies - Summary of Supplemental Lease Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Supplemental Lease Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - In-Licensing and Supply - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail</Role>
      <ShortName>In-Licensing and Supply - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Common Stock and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Common Stock and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="spry-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="spry-20250630.htm">spry-20250630.htm</File>
    <File>spry-20250630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img77826477_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="663">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="79">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "spry-20250630.htm": {
   "nsprefix": "spry",
   "nsuri": "http://ars-pharma.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "spry-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "spry-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 276,
   "keyCustom": 57,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 65,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/ecd/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 328,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 689,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 663,
    "http://xbrl.sec.gov/ecd/2024": 79,
    "http://xbrl.sec.gov/dei/2024": 31
   },
   "report": {
    "R1": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/CoverPage",
     "longName": "75000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "75010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "75030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "spry:CostOfGoodsSoldOperatingExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
     "longName": "75070 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3b5b2d22-53f7-4c9d-8b99-321480d17789",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "longName": "75080 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_3571bb42-9451-44e2-9e1c-0598970a2964",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_13db5f9c-2f06-4b3c-be00-958784249b0b",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "75090 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness",
     "longName": "995455 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue",
     "longName": "995475 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories",
     "longName": "995485 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements",
     "longName": "995505 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails",
     "longName": "995515 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet",
     "longName": "995525 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements",
     "longName": "995535 - Disclosure - Collaboration, Out-Licensing and Related Agreements",
     "shortName": "Collaboration, Out-Licensing and Related Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995545 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply",
     "longName": "995555 - Disclosure - In-Licensing and Supply",
     "shortName": "In-Licensing and Supply",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:InLicensingandsupplyTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:InLicensingandsupplyTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity",
     "longName": "995565 - Disclosure - Common Stock and Stockholders' Equity",
     "shortName": "Common Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation",
     "longName": "995575 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans",
     "longName": "995585 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions",
     "longName": "995595 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995605 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995615 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Polices)",
     "shortName": "Summary of Significant Accounting Policies (Polices)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables",
     "longName": "995645 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:ScheduleOfInventoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:ScheduleOfInventoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995655 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables",
     "longName": "995665 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables",
     "longName": "995675 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable",
     "longName": "995685 - Disclosure - Collaboration, Out-Licensing and Related Agreements (Table)",
     "shortName": "Collaboration, Out-Licensing and Related Agreements (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "995695 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables",
     "longName": "995705 - Disclosure - Common Stock and Stockholders' Equity (Tables)",
     "shortName": "Common Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables",
     "longName": "995715 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995725 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
     "longName": "995735 - Disclosure - Nature of Business - Additional Information (Detail)",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b8271b46-8d08-46dd-ad0b-ac8a80d68454",
      "name": "spry:PeriodForFirstNewDeliveryMethodOfEpinephrine",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies (Additional Information) (Detail)",
     "shortName": "Summary of Significant Accounting Policies (Additional Information) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18b0f553-9076-4f15-9748-2023f42761a7",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
     "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail",
     "longName": "995765 - Disclosure - Inventories - Schedule of Inventory (Detail)",
     "shortName": "Inventories - Schedule of Inventory (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "spry:ScheduleOfInventoryTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "spry:ScheduleOfInventoryTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Inventories - Additional Information (Detail)",
     "shortName": "Inventories - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:ZeroCostInventory",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:ZeroCostInventory",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "longName": "995785 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_de447bf5-c664-451c-be04-6c477bce8fb5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
     "longName": "995795 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:PaymentsToAcquireShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18b0f553-9076-4f15-9748-2023f42761a7",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995805 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:PrepaidMarketingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:PrepaidMarketingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail",
     "longName": "995815 - Disclosure - Balance Sheet Details - Schedule of Other Long Term Assets (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Other Long Term Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:PrepaidSupplyAgreementFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:PrepaidSupplyAgreementFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail",
     "longName": "995825 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Intangible Assets, Net - Additional Information (Detail)",
     "shortName": "Intangible Assets, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:CapitalizedMilestonePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail",
     "longName": "995845 - Disclosure - Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail)",
     "shortName": "Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "spry:CapitalizedMilestonePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail",
     "longName": "995855 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)",
     "shortName": "Intangible Assets, Net - Schedule of Estimated Future Amortization Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
     "longName": "995865 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)",
     "shortName": "Collaboration, Out-Licensing and Related Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e127c89b-57cc-45dd-88e0-5952c92514a1",
      "name": "spry:FinancingLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD",
     "longName": "995875 - Disclosure - Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail)",
     "shortName": "Collaboration, Out-Licensing and Related Agreements - Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_0bd8344d-6c3d-4f4c-9193-8180e76f5899",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d1c3a878-557f-48fb-9597-d12ba95d1e11",
      "name": "spry:RoyaltyIncomeAllocatedToTheEEALicense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail",
     "longName": "995885 - Disclosure - Commitments and Contingencies - Additional Information (Leases) (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Leases) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995895 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f342e672-771e-4d11-b09d-5aa31a2a64f1",
      "name": "spry:UnrecordedUnconditionalPurchaseObligationsPaid",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail",
     "longName": "995905 - Disclosure - Commitments and Contingencies - Summary of Supplemental Lease Information (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Supplemental Lease Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:LeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:LeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail",
     "longName": "995915 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
     "longName": "995925 - Disclosure - In-Licensing and Supply - Additional Information (Detail)",
     "shortName": "In-Licensing and Supply - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_18b0f553-9076-4f15-9748-2023f42761a7",
      "name": "spry:CapitalizedMilestonePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8c71eb6-d9a2-462a-9cd5-a2de07335991",
      "name": "spry:UpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Common Stock and Stockholders' Equity - Additional Information (Details)",
     "shortName": "Common Stock and Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2241ca04-d0e3-4458-81a0-72b7a112643d",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "995945 - Disclosure - Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "shortName": "Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_eda30636-7284-432d-8ca2-1f8a4dc398d4",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_952043ab-5fba-4c7d-bfff-86d859fc075f",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
     "longName": "995955 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59f4bf3a-7f8e-4ad6-a506-194c1950572a",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail",
     "longName": "995965 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_18b0f553-9076-4f15-9748-2023f42761a7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail",
     "longName": "995975 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
     "longName": "995985 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_1ef13204-b17d-483a-99d0-289ce05e08db",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1ef13204-b17d-483a-99d0-289ce05e08db",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
     "longName": "996005 - Disclosure - Related-Party Transactions - Additional Information (Detail)",
     "shortName": "Related-Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ba7df335-5578-421e-8c2a-d36e33edcb60",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
     "longName": "996015 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_869de754-f3e6-4177-9331-4ed5d47c7e01",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
     "longName": "996025 - Disclosure - Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail)",
     "shortName": "Segment Information - Schedule of Segment Reporting Provided to the CODM (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3",
      "name": "spry:SegmentOperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "spry_ALKAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ALKAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ALK Agreement [Member]",
        "documentation": "ALK Agreement.",
        "terseLabel": "ALK Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_ALKCo-PromotionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ALKCo-PromotionAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALK Co-Promotion Agreement [Member]",
        "label": "ALK Co-Promotion Agreement [Member]",
        "documentation": "ALK co-promotion agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "spry_ALKCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ALKCollaborationAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALK Collaboration Agreement [Member]",
        "label": "A L K Collaboration Agreement [Member]",
        "documentation": "A L K collaboration agreement"
       }
      }
     },
     "auth_ref": []
    },
    "spry_ALKFinancingLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ALKFinancingLiabilityMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ALK Financing Liability [Member]",
        "documentation": "ALK Financing Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total",
        "terseLabel": "Accounts payable and accrued liabilities (including related party amounts of $1,091 and $656, respectively)",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r843"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Account Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion on investments, net of amortization",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "spry_AccruedGrossToNetAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AccruedGrossToNetAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Gross to Net Adjustments",
        "documentation": "Accrued gross to net adjustments.",
        "terseLabel": "Accrued gross-to-net adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "spry_AccruedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AccruedInventory",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued inventory",
        "label": "Accrued Inventory",
        "documentation": "Accrued inventory."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued marketing related expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive (loss) gain, net",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r82",
      "r167",
      "r608",
      "r636",
      "r637"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss), Net [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r18",
      "r456",
      "r459",
      "r507",
      "r632",
      "r633",
      "r981",
      "r982",
      "r983",
      "r988",
      "r989",
      "r990",
      "r992"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r843",
      "r1110"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r988",
      "r989",
      "r990",
      "r992",
      "r1041",
      "r1112"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r400"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash adjustments to reconcile net loss to net cash used operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative Fees Expense",
        "terseLabel": "Fee",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r703",
      "r1111"
     ]
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r831"
     ]
    },
    "spry_AegisTherapeuticsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AegisTherapeuticsLlcMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aegis Therapeutics Agreement",
        "label": "Aegis Therapeutics LLC [Member]",
        "documentation": "Aegis Therapeutics LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_AggregateMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AggregateMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Milestone Payments",
        "label": "Aggregate Milestone Payments",
        "documentation": "Aggregate Milestone Payments",
        "verboseLabel": "Aggregate milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate milestone payments upon achievement of certain sales milestones",
        "documentation": "Aggregate milestone payments upon achievement of certain sales milestones.",
        "label": "Aggregate milestone payments upon achievement of certain sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "spry_AggregateSaleOfRecordatiLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AggregateSaleOfRecordatiLicensedProductMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate sale of Recordati Licensed Product [Member]",
        "documentation": "Aggregate sale of Recordati Licensed Product."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r889",
      "r899",
      "r931"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r892",
      "r902",
      "r934"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "spry_AgreementTerminationDueToMaterialBreach": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AgreementTerminationDueToMaterialBreach",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement Termination, Due To Material Breach",
        "label": "Agreement Termination Due To Material Breach",
        "documentation": "Agreement termination, due to material breach."
       }
      }
     },
     "auth_ref": []
    },
    "spry_AlexanderFitzpatrickMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AlexanderFitzpatrickMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Fitzpatrick [Member]",
        "documentation": "Alexander Fitzpatrick.",
        "terseLabel": "Alexander Fitzpatrick [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_AlfresaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "AlfresaAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alfresa Agreement [Member]",
        "documentation": "Alfresa Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r927",
      "r935",
      "r939",
      "r947"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r435"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r256",
      "r293",
      "r296",
      "r297",
      "r1077"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r316",
      "r323",
      "r814"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "spry_ArsPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ArsPharmaMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARS Pharma [Member]",
        "label": "ARS Pharma [Member]",
        "documentation": "ARS Pharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r133",
      "r162",
      "r189",
      "r220",
      "r229",
      "r243",
      "r246",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r451",
      "r453",
      "r483",
      "r603",
      "r696",
      "r803",
      "r804",
      "r843",
      "r870",
      "r1030",
      "r1031",
      "r1066"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r171",
      "r189",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r451",
      "r453",
      "r483",
      "r843",
      "r1030",
      "r1031",
      "r1066"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities, Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "U.S. Treasury securities, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r301",
      "r601"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r301"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r96",
      "r97"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Intangible assets included in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareNet",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Capitalized Computer Software, Net, Total",
        "periodStartLabel": "Capitalized Computer Software, Net, Beginning Balance",
        "periodEndLabel": "Capitalized Computer Software, Net, Ending Balance",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Capitalized software implementation costs",
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "spry_CapitalizedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CapitalizedMilestonePayments",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Milestone Payments",
        "documentation": "Capitalized milestone payments.",
        "terseLabel": "Capitalized milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CapitalizedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CapitalizedMilestonePaymentsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Milestone Payments [Member]",
        "documentation": "Capitalized milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "spry_CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Amortized Cost",
        "totalLabel": "Total Amortized Cost",
        "label": "Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis",
        "documentation": "Cash And cash equivalents And available for sale debt securities amortized cost basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash, cash equivalents, and restricted cash",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r159",
      "r784"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044"
     ]
    },
    "spry_CashAndCashEquivalentsGrossUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CashAndCashEquivalentsGrossUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents Gross Unrealized Gains",
        "documentation": "Cash and cash equivalents gross unrealized gains.",
        "terseLabel": "Cash And Cash Equivalents Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CashAndCashEquivalentsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CashAndCashEquivalentsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Gross Unrealized Losses",
        "documentation": "Cash and Cash Equivalents Gross Unrealized Losses",
        "terseLabel": "Cash and Cash Equivalents Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Member]",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash Equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "verboseLabel": "Cash, cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Total cash and cash equivalents and restricted cash",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93",
      "r186"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r93"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r163",
      "r164",
      "r165",
      "r189",
      "r211",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r290",
      "r343",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r356",
      "r357",
      "r360",
      "r363",
      "r370",
      "r483",
      "r644",
      "r645",
      "r646",
      "r647",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r705",
      "r727",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r958",
      "r985",
      "r993"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r222",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r368",
      "r370",
      "r644",
      "r645",
      "r646",
      "r647",
      "r817",
      "r958",
      "r985"
     ]
    },
    "spry_ClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ClinicalMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical [Member]",
        "documentation": "Clinical member.",
        "terseLabel": "Clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "spry_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Abstract]",
        "documentation": "Collaborative arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration, Out-Licensing and Related Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r142",
      "r152"
     ]
    },
    "us-gaap_CollaborativeArrangementRightsAndObligations": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementRightsAndObligations",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Rights and Obligations",
        "terseLabel": "Transaction under agreement with A.L.K U.S",
        "documentation": "Description of rights and obligations under the collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "spry_CommercialMilestoneAllocatedToTheEEALicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommercialMilestoneAllocatedToTheEEALicense",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone allocated to the EEA License",
        "label": "Commercial Milestone Allocated to the EEA License",
        "documentation": "Commercial milestone allocated to the EEA License."
       }
      }
     },
     "auth_ref": []
    },
    "spry_CommercialMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommercialMilestoneMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Milestone [Member]",
        "documentation": "Commercial milestone.",
        "terseLabel": "Commercial Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Milestone Payments",
        "documentation": "Commercial milestone payments.",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r125",
      "r605",
      "r682"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r334",
      "r336",
      "r765",
      "r1025",
      "r1027"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Common stock reserved for future awards or option grants",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Total",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863",
      "r865",
      "r866",
      "r867",
      "r868",
      "r988",
      "r989",
      "r992",
      "r1041",
      "r1108",
      "r1112"
     ]
    },
    "spry_CommonStockOptionsGrantedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommonStockOptionsGrantedAndOutstandingMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Options Granted and Outstanding [Member]",
        "label": "Common Stock Options Granted and Outstanding [Member]",
        "documentation": "Common stock options granted and outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]",
        "documentation": "common stock options.",
        "terseLabel": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "spry_CommonStockReservedForFutureAwardsOrOptionGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommonStockReservedForFutureAwardsOrOptionGrantsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future awards or option grants [Member]",
        "documentation": "Common stock reserved for future awards or option grants.",
        "terseLabel": "Common Stock Reserved For Future Awards or Option Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future employee stock purchase plan issuances [Member]",
        "documentation": "Common stock reserved for future employee stock purchase plan issuances.",
        "terseLabel": "Common Stock Reserved For Future Employee Stock Purchase Plan Issuances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r683"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r683",
      "r702",
      "r1112",
      "r1113"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized at June 30, 2025 and December 31, 2024; 98,697,658 and 97,954,172 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r607",
      "r843"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "verboseLabel": "Net loss and comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r176",
      "r178",
      "r183",
      "r596",
      "r617",
      "r618"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r59",
      "r60",
      "r254",
      "r764"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r59",
      "r60",
      "r254",
      "r639",
      "r764"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r59",
      "r60",
      "r254",
      "r764",
      "r962"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r144"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of credit risk",
        "verboseLabel": "Percentage of risk",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r59",
      "r60",
      "r254"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r59",
      "r60",
      "r254",
      "r764"
     ]
    },
    "spry_ContingentSalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ContingentSalesBasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Sales-Based Milestones",
        "documentation": "Contingent sales-based milestones.",
        "terseLabel": "Contingent Sales-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractTerminationClaimsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractTerminationClaimsDescription",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Termination Claims, Description",
        "label": "Contract Termination Claims, Description",
        "documentation": "General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r552",
      "r553",
      "r555",
      "r557",
      "r558"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Contract and Financing Liability from ALK Collaboration Agreement",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "periodStartLabel": "Balance at December 31, 2024",
        "periodEndLabel": "Balance at June 30, 2025",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Contract liability, noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r385"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Revenue recognized under the ALK Collaboration Agreement",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerReceivableAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Receivable, Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r374"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock [Member]",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r360",
      "r865",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "terseLabel": "Cost of goods sold expenses related party amount",
        "verboseLabel": "Cost of goods sold (including related party amounts of $866 $0, $1,354, and $0, respectively)",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r562"
     ]
    },
    "spry_CostOfGoodsSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CostOfGoodsSoldMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods Sold [Member]",
        "documentation": "Cost of Goods Sold [Member]",
        "terseLabel": "Cost of Goods Sold [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CostOfGoodsSoldOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CostOfGoodsSoldOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods Sold Operating Expense",
        "documentation": "Cost of goods sold operating expense",
        "terseLabel": "Cost of goods sold (including related party amounts of $866, $0, $1,354, and $0, respectively)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Consulting expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r352",
      "r358",
      "r514",
      "r535",
      "r600",
      "r787",
      "r789"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r254"
     ]
    },
    "spry_CustomerFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerFiveMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Five [Member]",
        "documentation": "Customer five.",
        "terseLabel": "Customer Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Four [Member]",
        "documentation": "Customer four.",
        "terseLabel": "Customer Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer one.",
        "terseLabel": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CustomerSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerSixMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Six [Member]",
        "documentation": "Customer six.",
        "terseLabel": "Customer Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three [Member]",
        "documentation": "Customer three.",
        "terseLabel": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "Customer two.",
        "terseLabel": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest on available-for-sale securities",
        "totalLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r301",
      "r302",
      "r303"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r301",
      "r307",
      "r308"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Compensation",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r109"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution totaled",
        "label": "Defined Contribution Plan, Administrative Expense",
        "documentation": "Amount of administrative expense incurred by defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r674",
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r746",
      "r747",
      "r748",
      "r749",
      "r861",
      "r863",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r119",
      "r671",
      "r674",
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r746",
      "r747",
      "r748",
      "r749",
      "r789",
      "r861",
      "r863",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1055",
      "r1056"
     ]
    },
    "spry_DevelopmentAndRegulatoryServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "DevelopmentAndRegulatoryServicesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory Services [Member]",
        "label": "Development and Regulatory Services [Member]",
        "documentation": "Development and regulatory services."
       }
      }
     },
     "auth_ref": []
    },
    "spry_DevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "DevelopmentMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development [Member]",
        "documentation": "Development member.",
        "terseLabel": "Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1109"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r402",
      "r431",
      "r432",
      "r434",
      "r829"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r209",
      "r211",
      "r214",
      "r215",
      "r216",
      "r219",
      "r446",
      "r449",
      "r464",
      "r465",
      "r597",
      "r619",
      "r794"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share Basic Line Items",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r214"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r211",
      "r214",
      "r215",
      "r216",
      "r219",
      "r446",
      "r449",
      "r464",
      "r465",
      "r597",
      "r619",
      "r794"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r218"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock compensation expense capitalized to inventory",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r154",
      "r179",
      "r180",
      "r181",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r221",
      "r291",
      "r292",
      "r330",
      "r371",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r507",
      "r615",
      "r632",
      "r633",
      "r634",
      "r652",
      "r727"
     ]
    },
    "spry_EquityIncentivePlan2016And2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EquityIncentivePlan2016And2020Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2016 And 2020 [Member]",
        "documentation": "Equity Incentive Plan 2016 And 2020 [Member]",
        "terseLabel": "Equity Incentive Plan 2016 and 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_EquityIncentivePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EquityIncentivePlan2018Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan 2018 [Member]",
        "label": "Equity Incentive Plan 2018 [Member]",
        "documentation": "Equity Incentive Plan 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_EquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EquityIncentivePlansMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans [Member]",
        "documentation": "Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_EquityOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EquityOfferingsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings [Member]",
        "documentation": "Equity offerings.",
        "terseLabel": "Equity Offerings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_EquitySalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EquitySalesAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Sales Agreement [Member]",
        "documentation": "Equity sales agreement.",
        "terseLabel": "Equity Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r889",
      "r899",
      "r931"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "spry_EuropeanEconomicAreaLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EuropeanEconomicAreaLicenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "European Economic Area License [ Member]",
        "documentation": "European economic area license.",
        "terseLabel": "EEA License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_EuropeanMedicinesAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "EuropeanMedicinesAgencyMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "European Medicines Agency [Member]",
        "documentation": "European Medicines Agency."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r479",
      "r832"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r479",
      "r832"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r478",
      "r479",
      "r481",
      "r522",
      "r523",
      "r524",
      "r815",
      "r816",
      "r825",
      "r826",
      "r827",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r471",
      "r832",
      "r1046",
      "r1057"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_FairValueInputsLevel1AndLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FairValueInputsLevel1AndLevel2Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 And Level 2 [Member]",
        "label": "Fair Value Inputs Level 1 And Level 2 [Member]",
        "documentation": "Fair value inputs level 1 and level 2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r389",
      "r394",
      "r468",
      "r479",
      "r522",
      "r825",
      "r826",
      "r827",
      "r832"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r389",
      "r394",
      "r468",
      "r469",
      "r479",
      "r523",
      "r815",
      "r816",
      "r825",
      "r826",
      "r827",
      "r832"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r468",
      "r469",
      "r470",
      "r471",
      "r479",
      "r524",
      "r815",
      "r816",
      "r825",
      "r826",
      "r827",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r471",
      "r832",
      "r1046",
      "r1057"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "spry_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net 1.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net 1",
        "terseLabel": "Fair value, assets transfers into (out of) level 3"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r478",
      "r479",
      "r481",
      "r522",
      "r523",
      "r524",
      "r815",
      "r816",
      "r825",
      "r826",
      "r827",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1057"
     ]
    },
    "spry_Fairvalueliabilitieslevel2Tolevel1Transfersamount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "Fairvalueliabilitieslevel2Tolevel1Transfersamount1",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount1",
        "label": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount1",
        "terseLabel": "Fair value, liabilities transfers from Level 2 to Level 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r304",
      "r305",
      "r306",
      "r354",
      "r368",
      "r461",
      "r482",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r616",
      "r812",
      "r832",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1042",
      "r1045",
      "r1046",
      "r1047",
      "r1054",
      "r1057"
     ]
    },
    "spry_FinancingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FinancingLiability",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing liability",
        "label": "Financing Liability",
        "documentation": "Financing liability."
       }
      }
     },
     "auth_ref": []
    },
    "spry_FinancingLiabilityIncludedInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FinancingLiabilityIncludedInAccountsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Liability Included in Accounts Receivable",
        "documentation": "Financing liability included in accounts receivable.",
        "terseLabel": "Financing liability included in accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Life of Finite Lived Intangible Assets",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Less accumulated depreciation",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r313",
      "r322",
      "r814"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "terseLabel": "2026",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2025 (remaining six months)",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r325",
      "r326",
      "r563",
      "r564",
      "r779"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r322",
      "r325",
      "r326",
      "r328",
      "r563",
      "r779",
      "r814"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r325",
      "r326",
      "r779"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1020"
     ]
    },
    "spry_FirstCommercialSaleOfNeffyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FirstCommercialSaleOfNeffyMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Commercial Sale Of Neffy",
        "label": "First Commercial Sale Of Neffy [Member]",
        "documentation": "First commercial sale of neffy."
       }
      }
     },
     "auth_ref": []
    },
    "spry_FirstCommercialSaleOfRecordatiLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FirstCommercialSaleOfRecordatiLicensedProductMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First commercial sale of Recordati Licensed Product [Member]",
        "documentation": "First commercial sale of Recordati Licensed Product."
       }
      }
     },
     "auth_ref": []
    },
    "spry_FoodAllergyResearchAndEducationIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "FoodAllergyResearchAndEducationIncMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Food Allergy Research and Education Inc [Member]",
        "documentation": "Food Allergy Research and Education Inc.",
        "terseLabel": "Food Allergy Research and Education Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_HeadquartersAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "HeadquartersAmendmentMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Headquarters Amendment [Member]",
        "label": "Headquarters Amendment [Member]",
        "documentation": "Headquarters amendment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r101"
     ]
    },
    "spry_InLicensingAndSupplyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InLicensingAndSupplyLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Licensing and Supply [Line Items]",
        "documentation": "Line items represents in licensing and supply."
       }
      }
     },
     "auth_ref": []
    },
    "spry_InLicensingAndSupplyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InLicensingAndSupplyTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Licensing And Supply [Table]",
        "documentation": "Disclosure of information about in-licensing and supply."
       }
      }
     },
     "auth_ref": []
    },
    "spry_InLicensingandsupplyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InLicensingandsupplyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "In-LicensingAndSupply [Abstract]",
        "documentation": "In-licensing and supply Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "spry_InLicensingandsupplyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InLicensingandsupplyTextblock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupply"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Licensing and Supply",
        "label": "In-LicensingAndSupply[Textblock]",
        "documentation": "In-licensing and supply [Textblock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1020",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development expense",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r473",
      "r477",
      "r480",
      "r629",
      "r631",
      "r712",
      "r779",
      "r834",
      "r1079"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r473",
      "r477",
      "r480",
      "r629",
      "r631",
      "r712",
      "r779",
      "r834",
      "r1079"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r984"
     ]
    },
    "spry_IncreaseDecreaseInDonationOfEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "IncreaseDecreaseInDonationOfEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Donation of Equipment",
        "label": "Increase (Decrease) in Donation of Equipment",
        "terseLabel": "Donation of equipment",
        "negatedLabel": "Donation of equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "spry_IncreaseToTheFinancingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "IncreaseToTheFinancingLiability",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase to the Financing Liability",
        "documentation": "increase to the financing liability.",
        "terseLabel": "Increase to the financing liability",
        "verboseLabel": "Commercial milestone allocated to the EEA License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r320",
      "r324",
      "r814"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r320",
      "r324",
      "r814"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r927",
      "r935",
      "r939",
      "r947"
     ]
    },
    "spry_InitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Transaction Price",
        "documentation": "Initial transaction Price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r951"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r951"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r951"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r327",
      "r329",
      "r777",
      "r779"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r563",
      "r790",
      "r1012"
     ]
    },
    "spry_IntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "IntangibleAssetsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Member]",
        "documentation": "Intangible assets.",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total",
        "terseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r1020",
      "r1022"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFinitelivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1020",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1114"
     ]
    },
    "us-gaap_InventoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoriesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Member]",
        "terseLabel": "Inventories [Member]",
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale."
       }
      }
     },
     "auth_ref": []
    },
    "spry_InventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InventoryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Current",
        "documentation": "Inventory current."
       }
      }
     },
     "auth_ref": []
    },
    "spry_InventoryCurrentAndNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "InventoryCurrentAndNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Current and Noncurrent Net",
        "documentation": "Inventory current and noncurrent net.",
        "terseLabel": "Total inventories, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories, net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r785",
      "r843"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail2": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Noncurrent",
        "totalLabel": "Inventory, Noncurrent, Total",
        "terseLabel": "Long-term inventories",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r158",
      "r169",
      "r309",
      "r310",
      "r312",
      "r556",
      "r791"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Inventory reserve",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r978"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesScheduleOfInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for inventory reserve",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r640",
      "r641",
      "r642",
      "r643",
      "r738",
      "r739"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r666",
      "r667",
      "r669",
      "r672",
      "r735",
      "r737",
      "r741",
      "r744",
      "r745",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r863"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r666",
      "r667",
      "r669",
      "r672",
      "r735",
      "r737",
      "r741",
      "r744",
      "r745",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r863"
     ]
    },
    "spry_IprDExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "IprDExpenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR&amp;D Expense [Member]",
        "documentation": "IPR&amp;D expense ."
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "JP",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "spry_KathleenScottMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "KathleenScottMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kathleen Scott [Member]",
        "label": "Kathleen Scott [Member]",
        "documentation": "Kathleen Scott."
       }
      }
     },
     "auth_ref": []
    },
    "spry_LauraShawverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LauraShawverMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laura Shawver [Member]",
        "documentation": "Laura Shawver.",
        "terseLabel": "Laura Shawver [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r963"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r963"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Lease, Cost, Total",
        "terseLabel": "Lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r842"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Supplemental Lease Information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "spry_LegalPatentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LegalPatentFees",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Patent Fees",
        "label": "Legal Patent Fees",
        "documentation": "Legal Patent Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r506"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r506"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Noncancelable lease agreement description",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease agreement description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Noncancelable Operating Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "terseLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "totalLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Total",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining noncancelable lease term of contract",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r1059"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncancelable lease term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r189",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r452",
      "r453",
      "r454",
      "r483",
      "r681",
      "r795",
      "r870",
      "r1030",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r126",
      "r610",
      "r843",
      "r986",
      "r1009",
      "r1058"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r157",
      "r189",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r452",
      "r453",
      "r454",
      "r483",
      "r843",
      "r1030",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "spry_LicenseAgreementExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LicenseAgreementExpirationTerm",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Expiration Term",
        "documentation": "License agreement expiration term."
       }
      }
     },
     "auth_ref": []
    },
    "spry_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "spry_LicenseFeesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LicenseFeesPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fees",
        "label": "License Fees Policy Text Block",
        "documentation": "License fees policy."
       }
      }
     },
     "auth_ref": []
    },
    "spry_LicensingSupplyAndDistributionAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LicensingSupplyAndDistributionAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Supply And Distribution Agreements [Abstract]",
        "documentation": "Licensing Supply And Distribution Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "spry_LiquidityAndCapitalResourcesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "LiquidityAndCapitalResourcesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Capital Resources [Member]",
        "label": "Liquidity and Capital Resources [Member]",
        "terseLabel": "Liquidity and Capital Resources [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2025 (remaining six months)",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Purchase Commitment Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r820",
      "r854",
      "r858",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "spry_MarlinspikeGroupLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MarlinspikeGroupLlcMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marlinspike Group, LLC",
        "label": "Marlinspike Group, LLC [Member]",
        "documentation": "Marlinspike Group, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r396",
      "r436",
      "r471",
      "r551",
      "r628",
      "r630",
      "r638",
      "r673",
      "r674",
      "r736",
      "r740",
      "r742",
      "r743",
      "r751",
      "r775",
      "r776",
      "r811",
      "r817",
      "r828",
      "r835",
      "r836",
      "r840",
      "r841",
      "r855",
      "r1032",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "spry_MedicalAffairsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MedicalAffairsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Affairs [Member]",
        "documentation": "Medical affairs member.",
        "terseLabel": "Medical affairs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureMergerAndRelatedTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger and Related Transactions",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r118"
     ]
    },
    "spry_MilestonePaymentDueOnAchievementOfAnnualSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MilestonePaymentDueOnAchievementOfAnnualSales",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment due",
        "label": "Milestone Payment Due On Achievement Of Annual Sales",
        "documentation": "Milestone payment due on achievement of annual sales."
       }
      }
     },
     "auth_ref": []
    },
    "spry_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments",
        "documentation": "Milestone payments.",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "spry_MilestonePaymentsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MilestonePaymentsEarned",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments Earned",
        "documentation": "Milestone payments earned.",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r396",
      "r436",
      "r471",
      "r551",
      "r628",
      "r630",
      "r638",
      "r673",
      "r674",
      "r736",
      "r740",
      "r742",
      "r743",
      "r751",
      "r775",
      "r776",
      "r811",
      "r817",
      "r828",
      "r835",
      "r836",
      "r840",
      "r855",
      "r1032",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "spry_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Fair Value",
        "terseLabel": "Total Fair Value",
        "label": "Money Market Funds and Available For Sale Debt Securities Fair Value",
        "documentation": "Money Market Funds and Available For Sale Debt Securities Fair Value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r820",
      "r854",
      "r858",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and cash equivalents provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and cash equivalents provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and cash equivalents used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r129",
      "r155",
      "r175",
      "r177",
      "r181",
      "r189",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r213",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r446",
      "r449",
      "r465",
      "r483",
      "r614",
      "r704",
      "r725",
      "r726",
      "r869",
      "r1030"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "spry_NewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "NewDrugApplicationMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Drug Application",
        "label": "New Drug Application [Member]",
        "documentation": "New Drug Application [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r927",
      "r935"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "spry_NoticePeriodDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "NoticePeriodDescription",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notice Period Description",
        "label": "Notice Period Description",
        "documentation": "Notice Period Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r995"
     ]
    },
    "spry_NumberOfPediatricians": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "NumberOfPediatricians",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of pediatricians",
        "documentation": "Number of pediatricians",
        "terseLabel": "Number of pediatricians"
       }
      }
     },
     "auth_ref": []
    },
    "spry_OmpiSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "OmpiSupplyAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ompi Supply Agreement [Member]",
        "documentation": "Ompi supply agreement",
        "terseLabel": "Ompi Supply Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total segment operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r796",
      "r994",
      "r996",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "totalLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Less lease liability, current portion",
        "negatedTerseLabel": "Less lease liability, current portion",
        "terseLabel": "Lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail4": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalLeaseInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Annualized payment of lease",
        "verboseLabel": "Cash paid for leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Discount rate",
        "verboseLabel": "Operating Lease Weighted Average Discount Rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r842"
     ]
    },
    "spry_OperatingRightOfUseAssetsAndLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "OperatingRightOfUseAssetsAndLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Right of Use Assets And Lease Liabilities",
        "documentation": "Operating Right of Use Assets And Lease Liabilities",
        "terseLabel": "Operating lease right-of-use asset and lease liability, net"
       }
      }
     },
     "auth_ref": []
    },
    "spry_OrbiMedAdvisorsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "OrbiMedAdvisorsLLCMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrbiMed Advisors LLC [Member]",
        "documentation": "OrbiMed Advisors LLC.",
        "terseLabel": "OrbiMed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r161",
      "r602",
      "r804",
      "r870"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "totalLabel": "Other Commitment, Total",
        "terseLabel": "Commitments",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInFifthYear",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, to be Paid, Year Five",
        "terseLabel": "Commitments, 2029",
        "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInFourthYear",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, to be Paid, Year Four",
        "terseLabel": "Commitments, 2028",
        "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments, 2025",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, to be Paid, Year Two",
        "terseLabel": "Commitments, 2026",
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments, 2027",
        "label": "Other Commitment, to be Paid, Year Three",
        "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized holding gains",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gains and losses on available-for-sale securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r174",
      "r289"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized holding gain (loss)",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r173"
     ]
    },
    "us-gaap_OtherExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense [Member]",
        "terseLabel": "Other [Member]",
        "documentation": "Primary financial statement caption encompassing other expense."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "terseLabel": "Other",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r691",
      "r804",
      "r1076"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other Receivables, Net, Current, Total",
        "terseLabel": "Due from related parties, current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r891",
      "r901",
      "r933"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r894",
      "r904",
      "r936"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r894",
      "r904",
      "r936"
     ]
    },
    "spry_PacificLinkConsultingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PacificLinkConsultingLlcMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pacific-Link Consulting, LLC",
        "label": "Pacific-Link Consulting, LLC [Member]",
        "documentation": "Pacific-Link Consulting, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "spry_PatentsCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PatentsCostsPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patents Costs Policy Text Block",
        "documentation": "Patents costs policy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of short-term investments",
        "negatedLabel": "Purchases of short-term investments, available-for-sale",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "spry_PediatrixAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PediatrixAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatrix Agreement",
        "label": "Pediatrix Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "spry_PerformanceBasedBonusPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PerformanceBasedBonusPaymentsPercentage",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance based bonus payments percentage",
        "label": "Performance Based Bonus Payments Percentage",
        "documentation": "Performance based bonus payments percentage."
       }
      }
     },
     "auth_ref": []
    },
    "spry_PeriodForFirstNewDeliveryMethodOfEpinephrine": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PeriodForFirstNewDeliveryMethodOfEpinephrine",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period for First New Delivery Method of Epinephrine",
        "documentation": "Period for first new delivery method of epinephrine.",
        "terseLabel": "Period for first new delivery method of epinephrine"
       }
      }
     },
     "auth_ref": []
    },
    "spry_PlanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PlanOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan One [Member]",
        "documentation": "Plan one.",
        "terseLabel": "Plan One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_PlanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PlanTwoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Two [Member]",
        "label": "Plan Two [Member]",
        "documentation": "Plan two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r356"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock , shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r683"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares, issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r356"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares, outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r683",
      "r702",
      "r1112",
      "r1113"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r606",
      "r843"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r813",
      "r1010"
     ]
    },
    "spry_PrepaidMarketingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PrepaidMarketingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Marketing Expenses",
        "documentation": "Prepaid marketing expenses.",
        "terseLabel": "Prepaid marketing"
       }
      }
     },
     "auth_ref": []
    },
    "spry_PrepaidSupplyAgreementFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "PrepaidSupplyAgreementFee",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherLongTermAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Supply Agreement Fee",
        "documentation": "Prepaid supply agreement fee.",
        "terseLabel": "Prepaid supply agreement fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of short-term investments, available-for-sale",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net",
        "verboseLabel": "Product revenue, net [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r562",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r781",
      "r818",
      "r853",
      "r855",
      "r856",
      "r859",
      "r860",
      "r1028",
      "r1029",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Member]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r562",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r781",
      "r818",
      "r853",
      "r855",
      "r856",
      "r859",
      "r860",
      "r1028",
      "r1029",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Total",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r505",
      "r599",
      "r613",
      "r843"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r145",
      "r149",
      "r612"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "spry_ROWLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ROWLicenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROW License [Member]",
        "documentation": "ROW license.",
        "terseLabel": "ROW License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r388",
      "r396",
      "r425",
      "r426",
      "r427",
      "r436",
      "r471",
      "r525",
      "r534",
      "r551",
      "r628",
      "r630",
      "r638",
      "r673",
      "r674",
      "r736",
      "r740",
      "r742",
      "r743",
      "r751",
      "r775",
      "r776",
      "r811",
      "r817",
      "r828",
      "r835",
      "r836",
      "r840",
      "r841",
      "r855",
      "r863",
      "r1026",
      "r1032",
      "r1046",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r388",
      "r396",
      "r425",
      "r426",
      "r427",
      "r436",
      "r471",
      "r525",
      "r534",
      "r551",
      "r628",
      "r630",
      "r638",
      "r673",
      "r674",
      "r736",
      "r740",
      "r742",
      "r743",
      "r751",
      "r775",
      "r776",
      "r811",
      "r817",
      "r828",
      "r835",
      "r836",
      "r840",
      "r841",
      "r855",
      "r863",
      "r1026",
      "r1032",
      "r1046",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "spry_RecordatiAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RecordatiAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recordati Agreement [Member]",
        "documentation": "Recordati Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "spry_RedTeamAssociatesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RedTeamAssociatesLlcMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Red Team Associates, LLC",
        "label": "Red Team Associates, LLC [Member]",
        "documentation": "Red Team Associates, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAgencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegulatoryAgencyAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Agency [Axis]",
        "documentation": "Information by name of regulatory agency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAgencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegulatoryAgencyDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Agency [Domain]",
        "documentation": "Organization that establishes and ensures compliance with rules or regulations."
       }
      }
     },
     "auth_ref": []
    },
    "spry_RegulatoryAndCommercialSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RegulatoryAndCommercialSalesMilestones",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory and Commercial Sales Milestones",
        "documentation": "Regulatory and Commercial sales milestones."
       }
      }
     },
     "auth_ref": []
    },
    "spry_RegulatoryMileStoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RegulatoryMileStoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Mile Stone Amount",
        "documentation": "Regulatory mile Stone amount.",
        "terseLabel": "Milestone amount"
       }
      }
     },
     "auth_ref": []
    },
    "spry_RegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestone",
        "label": "Regulatory Milestone",
        "documentation": "Regulatory milestone."
       }
      }
     },
     "auth_ref": []
    },
    "spry_RegulatoryMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RegulatoryMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Milestone Payment",
        "documentation": "Regulatory milestone payment.",
        "terseLabel": "Regulatory milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r395",
      "r511",
      "r512",
      "r604",
      "r611",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r701",
      "r703",
      "r734"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r511",
      "r512",
      "r513",
      "r514",
      "r604",
      "r611",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r701",
      "r703",
      "r734"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r1065"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r708",
      "r709",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r395",
      "r511",
      "r512",
      "r604",
      "r611",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r701",
      "r703",
      "r734",
      "r1065"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r515",
      "r649",
      "r650",
      "r651",
      "r710",
      "r711",
      "r712",
      "r731",
      "r733"
     ]
    },
    "spry_RemainingRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RemainingRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Regulatory Milestone",
        "documentation": "Remaining regulatory milestone.",
        "terseLabel": "Remaining regulatory milestone"
       }
      }
     },
     "auth_ref": []
    },
    "spry_RenaissanceLakewoodLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RenaissanceLakewoodLlcMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renaissance Agreement",
        "label": "Renaissance Lakewood, LLC [Member]",
        "documentation": "Renaissance Lakewood, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r352",
      "r358",
      "r514",
      "r535",
      "r600",
      "r788",
      "r789"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r1040"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r1040"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development (including related party amounts of $582, $518, $1,245, and $1,245, respectively)",
        "verboseLabel": "Research and development expenses related party amount",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r779",
      "r803",
      "r1074"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense [Member]",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r887",
      "r897",
      "r929"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r888",
      "r898",
      "r930"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r895",
      "r905",
      "r937"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "spry_RestrictedStockUnitsGrantedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RestrictedStockUnitsGrantedAndOutstandingMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units granted and outstanding [Member]",
        "documentation": "Restricted stock units granted and outstanding.",
        "terseLabel": "Restricted Stock Units Granted and Outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "spry_RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RestructuringPlanMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March Restructuring Plan Member",
        "label": "Restructuring Plan Member",
        "documentation": "Restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r107",
      "r609",
      "r635",
      "r637",
      "r648",
      "r684",
      "r843"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r291",
      "r292",
      "r330",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r457",
      "r458",
      "r460",
      "r463",
      "r491",
      "r492",
      "r632",
      "r634",
      "r652",
      "r1112"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenue",
        "terseLabel": "Total revenue",
        "netLabel": "Revenue under collaboration agreements",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r220",
      "r230",
      "r231",
      "r242",
      "r246",
      "r250",
      "r252",
      "r254",
      "r383",
      "r384",
      "r562"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r780",
      "r792"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligation, transaction price",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "spry_RevenueUnderCollaborationAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RevenueUnderCollaborationAgreementsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue under collaboration agreements [Member]",
        "label": "Revenue Under Collaboration Agreements [Member]",
        "documentation": "Revenue under collaboration agreements.",
        "verboseLabel": "Revenue under collaboration agreements"
       }
      }
     },
     "auth_ref": []
    },
    "spry_RevenueUnderSupplyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RevenueUnderSupplyAgreementsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Under Supply Agreements [Member]",
        "documentation": "Revenue under supply agreements member.",
        "terseLabel": "Revenue under supply agreements",
        "verboseLabel": "Revenue under supply agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "totalLabel": "Revenues, Total",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r182",
      "r189",
      "r220",
      "r230",
      "r231",
      "r242",
      "r246",
      "r250",
      "r252",
      "r254",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r483",
      "r598",
      "r803",
      "r1030"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_RichardLowenthalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RichardLowenthalMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Richard Lowenthal [Member]",
        "documentation": "Richard Lowenthal.",
        "terseLabel": "Richard Lowenthal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset and lease liability",
        "verboseLabel": "Right-of-use asset obtained in exchange for operating lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r842"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense payable",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments",
        "label": "Royalty Guarantees, Commitments, Amount",
        "documentation": "The amount the entity has committed to make for future royalty guarantees."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "spry_RoyaltyIncomeAllocatedToTheEEALicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RoyaltyIncomeAllocatedToTheEEALicense",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based royalties earned in the EEA",
        "label": "Royalty Income Allocated To The EEA License",
        "documentation": "Royalty income allocated to the EEA license."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Sales-based royalties earned in the EEA",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "spry_RoyaltyIncomeNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "RoyaltyIncomeNotRecognized",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Income not Recognized",
        "documentation": "Royalty income not recognized.",
        "verboseLabel": "Sales-based royalties earned in the EEA",
        "terseLabel": "Royalty income not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Maximum aggregate offering price of securities",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Securities sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "spry_SalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SalesBasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones.",
        "terseLabel": "Sales-Based Milestones",
        "label": "Sales-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Gross Product Sales [Member]",
        "verboseLabel": "Product Sales [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "spry_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego California [Member]",
        "label": "San Diego California Member",
        "documentation": "San Diego California Member"
       }
      }
     },
     "auth_ref": []
    },
    "spry_SarinaTanimotoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SarinaTanimotoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarina Tanimoto [Member]",
        "label": "Sarina Tanimoto [Member]",
        "documentation": "Sarina Tanimoto."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r991"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r397",
      "r959",
      "r991"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsScheduleOfReconciliationOfContractAndFinancingLiabilityFromAlkCollaborationAgreementD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "spry_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Issuance.",
        "label": "Schedule Of Common Stock Reserved For Issuance [Table Text Block]",
        "terseLabel": "Summary of Common Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r322",
      "r325",
      "r326",
      "r328",
      "r563",
      "r779",
      "r814"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r1019"
     ]
    },
    "spry_ScheduleOfInventoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ScheduleOfInventoryTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Inventory [Table Text Block]",
        "documentation": "Tabular disclosure of inventory.",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Long Term Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Provided to the CODM",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r114"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r103",
      "r105",
      "r106",
      "r107",
      "r163",
      "r164",
      "r165",
      "r222",
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r368",
      "r370",
      "r644",
      "r645",
      "r646",
      "r647",
      "r817",
      "r958",
      "r985"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r1021"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r665",
      "r668",
      "r670",
      "r737",
      "r741",
      "r745",
      "r752",
      "r763",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r782",
      "r819",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r857",
      "r863",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "spry_SegmentOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SegmentOperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total segment operating expenses",
        "label": "Segment Operating Expenses",
        "documentation": "Segment operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r802",
      "r810"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r799",
      "r807"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r232",
      "r233",
      "r234",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r254",
      "r797",
      "r800",
      "r801",
      "r803",
      "r805",
      "r808",
      "r809"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r249",
      "r252",
      "r798",
      "r799",
      "r806"
     ]
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "terseLabel": "Selling, general and administrative expenses related party amount",
        "verboseLabel": "Selling, general and administrative (including related party amounts of $107, $114, $231, and $208, respectively)",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Costs",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "spry_SeqirusAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SeqirusAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seqirus Agreement.",
        "label": "Seqirus Agreement [Member]",
        "terseLabel": "Seqirus Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_Share-BasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "Share-BasedCompensationMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingProvidedToTheCodmDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Member]",
        "documentation": "Share-based compensation member.",
        "terseLabel": "Stock-based compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted common stock, vesting in equal monthly installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares Subject to Options Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares Subject to Options Outstanding, Granted",
        "verboseLabel": "Share based compensation number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares Subject to Options Outstanding, Ending balance",
        "periodStartLabel": "Shares Subject to Options Outstanding, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Subject to Options Exercisable, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Exercisable , Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "spry_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award options forfeited in period weighted average exercise price.",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of Shares Vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "totalLabel": "Short-term Investments, Total",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r979"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments [Member]",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r783"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r187"
     ]
    },
    "spry_SilverbackMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SilverbackMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silverback [Member]",
        "label": "Silverback [Member]",
        "terseLabel": "Silverback [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_SoftwareLicenseSubscriptionFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SoftwareLicenseSubscriptionFeesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software License Subscription Fees [Member]",
        "label": "Software License Subscription Fees [Member]",
        "documentation": "Software license subscription fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r163",
      "r164",
      "r165",
      "r189",
      "r211",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r290",
      "r343",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r356",
      "r357",
      "r360",
      "r363",
      "r370",
      "r483",
      "r644",
      "r645",
      "r646",
      "r647",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r705",
      "r727",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r958",
      "r985",
      "r993"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r79",
      "r80",
      "r154",
      "r179",
      "r180",
      "r181",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r221",
      "r291",
      "r292",
      "r330",
      "r371",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r507",
      "r615",
      "r632",
      "r633",
      "r634",
      "r652",
      "r727"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r665",
      "r668",
      "r670",
      "r737",
      "r741",
      "r745",
      "r752",
      "r763",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r782",
      "r819",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r857",
      "r863",
      "r1034",
      "r1078",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r221",
      "r492",
      "r562",
      "r640",
      "r663",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r683",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r864"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r397",
      "r959",
      "r960",
      "r991"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r221",
      "r255",
      "r492",
      "r562",
      "r640",
      "r663",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r683",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r864"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r890",
      "r900",
      "r932"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under the employee stock purchase plan, Shares",
        "verboseLabel": "Share purchased under employee stock purchase plan",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares Subject to Options Outstanding, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r107",
      "r411"
     ]
    },
    "spry_StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Stock Options Exercised Under Employee Stock Purchase Plan",
        "documentation": "Stock issued during period shares stock options exercised under employee stock purchase plan.",
        "terseLabel": "Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "terseLabel": "Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r75",
      "r76",
      "r107"
     ]
    },
    "spry_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options exercised and restricted stock units released shares.",
        "label": "Stock Issued During Period Value Stock Options Exercised and Restricted Stock Units Released Shares",
        "terseLabel": "Exercise of common stock options and release of restricted stock units, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option Awards [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r99",
      "r685",
      "r702",
      "r728",
      "r729",
      "r843",
      "r870",
      "r986",
      "r1009",
      "r1058",
      "r1112"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock and Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r188",
      "r355",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r462",
      "r730",
      "r732",
      "r762"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r517"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r517"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r517"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r518"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "spry_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "spry_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]",
        "documentation": "Disclosure of information about summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "spry_SupplyAgreementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SupplyAgreementExpense",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Agreement Expense",
        "label": "Supply Agreement Expense",
        "documentation": "Supply Agreement Expense"
       }
      }
     },
     "auth_ref": []
    },
    "spry_SupplyAgreementExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "SupplyAgreementExpirationDate",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Agreement Expiration Date",
        "documentation": "Supply agreement expiration date",
        "terseLabel": "Supply Agreement Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "spry_TerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "TerminationAgreementMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Agreement [Member]",
        "documentation": "Termination Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_ThresholdPercentageOfValueChangeInEquitySecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ThresholdPercentageOfValueChangeInEquitySecurities",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Percentage of Value Change in Equity Securities",
        "documentation": "Threshold percentage of value change in equity securities.",
        "terseLabel": "Threshold percentage"
       }
      }
     },
     "auth_ref": []
    },
    "spry_TitleAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "TitleAgentMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Agent [Member]",
        "documentation": "Title agent.",
        "terseLabel": "Title Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1064"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r354",
      "r368",
      "r461",
      "r482",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r616",
      "r832",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1042",
      "r1045",
      "r1046",
      "r1047",
      "r1054",
      "r1057"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLeasesDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquityAdditionalInformationDetails",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury Securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r825",
      "r827",
      "r832",
      "r1075"
     ]
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r338"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Unconditional purchase obligations, 2025",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r1061"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "Unconditional purchase obligations, 2028",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r1061"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Unconditional purchase obligations, 2026",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r1061"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "Unconditional purchase obligations, 2027",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r1061"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation",
        "totalLabel": "Unrecorded Unconditional Purchase Obligation, Total",
        "terseLabel": "Unconditional purchase obligations",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r1061"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]",
        "documentation": "Information by category of product and service for unrecorded unconditional purchase arrangement to acquire product or service or both."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r337"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationLineItems",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r337"
     ]
    },
    "spry_UnrecordedUnconditionalPurchaseObligationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UnrecordedUnconditionalPurchaseObligationPaid",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation Paid",
        "documentation": "Unrecorded unconditional purchase obligation paid.",
        "terseLabel": "Purchase obligations amount made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationTable",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation [Table]",
        "documentation": "Disclosure of information about unrecorded unconditional purchase obligation arrangement to purchase product and service. Includes, but is not limited to, information about asset pledged to secure payment and payment due in each of next five years and thereafter."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r337"
     ]
    },
    "spry_UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter through 2035",
        "label": "Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four",
        "documentation": "Unrecorded unconditional purchase obligation to be paid after year four."
       }
      }
     },
     "auth_ref": []
    },
    "spry_UnrecordedUnconditionalPurchaseObligationsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UnrecordedUnconditionalPurchaseObligationsPaid",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations amount made",
        "label": "Unrecorded Unconditional Purchase Obligations Paid",
        "documentation": "Unrecorded unconditional purchase obligations paid."
       }
      }
     },
     "auth_ref": []
    },
    "spry_UnvestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UnvestedCommonStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock.",
        "label": "Unvested Common Stock [Member]",
        "terseLabel": "Unvested Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "spry_UpfrontLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UpfrontLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront License Fees",
        "label": "Upfront License Fees",
        "documentation": "Upfront License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "spry_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCollaborationOutlicensingAndRelatedAgreementsAdditionalInformationDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment.",
        "documentation": "Upfront Payment.",
        "terseLabel": "Upfront Payment",
        "verboseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r141",
      "r143",
      "r146",
      "r147"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "spry_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureCommonStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants To Purchase Common Stock [Member]",
        "label": "Warrants To Purchase Common Stock [Member]",
        "documentation": "Warrants to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "spry_WarrantsToPurchaseConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "WarrantsToPurchaseConvertiblePreferredStockMember",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants To Purchase Convertible Preferred Stock [Member]",
        "label": "Warrants To Purchase Convertible Preferred Stock [Member]",
        "documentation": "Warrants to purchase convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r216"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted- average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r216"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "spry_ZeroCostInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ars-pharma.com/20250630",
     "localname": "ZeroCostInventory",
     "crdr": "debit",
     "presentation": [
      "http://ars-pharma.com/20250630/taxonomy/role/DisclosureInventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zero Cost Inventory",
        "documentation": "Zero-cost inventory.",
        "terseLabel": "Zero cost inventory"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "275",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478685/912-310-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478685/912-310-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477623/912-405-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477623/912-405-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477866/928-440-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000950170-25-107618-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-107618-xbrl.zip
M4$L#!!0    ( &PX#5O9D5Y7#:T& %AF!P 1    :6UG-S<X,C8T-S=?,"YJ
M<&?LO =4D]G6/_S004%)0)JBD 04A!!2*!E$A! 2"(B " I*.I$> J)C042D
M"@DU**(T11$$;& 90$1*  $%L<Q($:4X,]AA1OV>8)NY,[?\UWO?^*[UN5E)
MGM/W[^RS]]G[Y(3W=]X/*?<XQG!8 .#J"A@# * (*$A! 1GP20K\ Z1T +FY
M9P"@22W^_+Q5:L7'.M+@F[GX'= '7UPI]-RS.OC*/, !9#_6/P&^;@&F+0T
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MO):S@^&1E]X=E%I]Z2*TX '=J/H%;N3NT]W?ORHYSC$XB)^\:U>3\13Q-'K
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M7C3  >C@IS@7!;ZP@#.P'G #S %KX+/:_HFD_J;_?U;A,WTQ4D!H5'#P!TB
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M/6NDN2D=A4+K65HCJ194"XRUA1751$]\'\0,A3%#69B:F^-Q:#P*I_>18."
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M'P8NTTS)S=UVR)5-1OD:DP:LV,HUC]56L)2G]1#Q!0RR(:8EN&/YRC3<>6%
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M@$R:![E-*0]## #]>"Q3]*S-P[E&-D,@8\CH'Y)'M$"*D Z@?D.-JSW0_!'
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M8OSAVNSAWU!*U_GOF(EH_D)P]S!F^=SN)()V6](*FJ7BSOPM(9&%J9'XV/W
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MV,(%SL4G_DR2(ZFOO?=__X%M+QLF]LQ6(Z9SX7/;QH"^UZJI0!;';#;&:TC
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M]/\XJXM #G&S9Q?9?P#&WQB+P;3?A-M9INK[?8)U);D:*UZ-?7BJ,0;.!G6
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M@?XV#INSYCS[(U.)25ZS_NH.6X&2.]74RJW!A$VL!1G[\EACBC?C&$#L]>B
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MC&+S0\Y%3>#5^@\3]\RUO4-K5_A>!_G@9O5H?-X[)T$D>,T1W0%-. 2(1P;
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MSRI0UL_S!++1AK'![SNOAMWPV\K9UT"VB=/@QKO9C#\(6[N_&5Y1%QI4'DQ
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M9 []SGHP1]X&1[V5:J*3_[LIS<G]*'XK@/HW2?Z<>_N9E K*M1O*D;3H_*1
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M-6CQ.X1?7TUL3KFYOLU^C4_SUR1EN?DFYLZ.@])(M0V%ZACR).)P:' :GPG
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M;$B/&B4%1*GKLQ06!_\S 7>MB'M]GDE]0$WY2I+0]:FO?'WY#D-45U5>AU>
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MC_(72"T/@")UEX*3"*98):NSA&-H53,S[TKX,B!W&5S73Z\;$%@YN(O9UBC
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MF.%QGV<364;\_K4D$QBHD;3N^,)3RZ"E<K,M(0O&C8P.SWI8)6*MUF[P[=W
M+89'N5X1#\;NFX5#(@70]Z+NQMQ\=M-PVVYQZ]][GT64>R0YL;%F2Z>"X5%,
M#_F5#U4WO(>VMQGVX3M#$4MID0_UD^:,*3"'UY?G9H[\1AE3+;=2AN%U+$8F
MR96^[CX,1;*^'BQT^QD4;Y>:N8;NZEGB9/%5JZ8I!^B3G-ARU?Q8W$C]T;W+
M29"T*[?/IB7<I"?UCNN6>CV15 FL[3F[X;0.9J-*N7YAIKOZU]%V^BI[1L6T
MU\TN&*HZ2VS- VNCOOX 9C68B-2H=S31&J/\',Y(_Y7&OX)0P$&%9[0&;W&F
M2NK.Z'(G)@"2M9Y9J^&CN1(4'T1&_Q_VWC(JKF9;%VY"@B0D!'<([BX!@H0D
MN+LU[C3N3H  P25 XP1/ PW!&H?@KHV[N[MS\^ZS[QD[YWSCGITO]\\=XWU&
MCT6/M9HYUWS6JJHYJVI6'5/HAZ/ZL0?A?S7LPPBEI/(*)+P,2M_"OY'[==5(
M(2?U":_!Z=*%<@0FWD\_7V",P!(=G<ZV1N4FD6NR>+?VCOKTMU7TF9!9'Y*N
M-ZKM0A$XC;=IKS:(/@CO70&.= V3!L):I(M8AVG7F[(\C'Z\AKY(<^&ZNK:9
M]?S#_A+$90<3>MWVE'BSMAA(5;*S5#[59JS7P:P@$ZT+WF:6V;Z)B\C/-R^A
MYJ_#$F-\__OXW4@"1GH<.22K1,TQK!$I+SCIA(VPYZ]YAD.@+7ZSZK4T@FP6
M<)B'>EFF1AVGF%L?P<AM#2^^(;]H5\Q'R@[BCD3#O@HV&N(?&$I(;U'L]^>7
M]@A^$4/Z$6^<N'>2XN8]>QM:4,SG'VKX9P<SM\IKE*>LF9\#W7A7-P+BW?A8
MI*651$\L)>ZM92^^>S<DKF@'0QN[)YWSUHX*4Y6SCF-_>IM9OOV^HD[!'P\(
M-78R<[^<'E:?5P/^",CM:#UB#:$Z+2G/C<//;YY"5%I9UY&=:@W3'@"Z8U@!
MFX0FIQH]96I::\T:Q>I2[<VZE4_/Q4S66>5,G)HT19V?"'E]&?+;[UBYH/GX
MKW*?,WF\24[QT6Q.XX#IX)5-X.KBK:L!^Y-BWQE+!5*^$$=#P*1<_ZMI(324
M<0]D;_,*B0[0C7:ZB$T?V'_UKX+0Q0JW.4QFX\]G6#EUI]!_1O\M)$_VBIF/
M Z_)A]*ICD2/[>7,L"J)E;VOB4Z:A,\1)V8#J@24#R;?N)085L_7PY='+Q4O
M;!6O.0[D'LDC/[/L7JR].O/Y_-=&5.@C0@CUYMDE0:GR\/N5J1]_1B495CD]
MPSG73$>K)J.R'5=!O#RM&)9N3!:W8O7>UBXUZ*?K\[,6K&:D=FBPI-[]U%-A
MS]);R$H]J G'6@\1Y*4=DLTPW_Q%XFAP9@BD;BTYEI&#YL,:\["#GB:P*ZF5
MP[3O2"7'\/,6'L6J1C,^%J8B6V#(9W8Q0.A+"B11= ]U=)-?1P9.1QHCUW6@
M@GTL7N./:=A4B2GSW]]HAWNEW8<ZH6/%NT4QKLOCS.\_Z;X_N"6:G9M>TO,&
MFGU:29#DS4!/7]NVS<AXZWQ!V=W,ERI]D*&^&7;B.C1'MG.W(EJB^T4^XUM#
MY_=?GOWO0XC15%-T5Z0:SP S(6_)0E6K7:5(C1$[W _X'UT@AC\#28<:NV3_
M^7;I'JVU=XO=22!^":_Z_(*V:^/RG>Y?A!&>7ATEI_2E)VTYT+RM*4]2Z<(S
M51C 1!0RE8X-"6=[+!&.X<"K'TX?R6[*U)ZH_%04!>,Q)6V3=/#W3[_(\8#J
MI;N#3=3GDCBX,; I<IR:28CV6+B/C:[9-\X<VWAGUGMG.6\Z#M4]/*NV2*7H
M@/8>Y<^+)YI\HK3=6;N/"/9?9)PM3*;J=;=[Y=.MJ"\(Y0\=_/0,:R4G/,^#
M^*\M5N]DBM_\$@+_/I#;=WO]SU_-FK9J:BO;5Q2T:Q6H<1T=C[9*JH^G#DKE
MEY[]U<7^D\!:(+-A0W*@)W*DJE4=N-O!5$YRN/9*1A[8?19L-GK]BU!*LX&X
MT;G5OK@.J>*UQO+4^J)&#E/]F*1C!9/>K-D6? I2,8EN/+8@M+;$;$+#<(0@
M\ASBB0ZZ:\QJU_A?!)'61B5U9QCBS:W6(?7+??B<1,*&+'7#&>D5YQ/E?A/2
MSTN*EVS;*%CO$^>;W'!5"]/QU9[[4GZ[>?TZT*DDQ;IVY^"J]J0+-B==MS=$
MTKJ8;T;9_>.X\5D#TWU0$^_-1:Z@==>IDO/F:.>V@?WLCS]C4H@C3\-YU[U:
MW3"V(V_%0I4!:@C-X&42\HI]ZNTB<^^9Z+W!S0C]&;M(^Q?,_M5%#)]@:97N
MH=>,3:A)9![PTSS^E(8I7UHH].77UM?<:Z9?MIEI-Q8L>FW,<%FL1]#*(8$J
M2<U)K33;@1'+(HH"(6![[-6*[_C" (T\F.(#VD00W;5$M<O:+[='PB:DL.X=
M(+A8/,K-ATJ!]"J"A'?71_CX_;7X1A.N?:3XEW:7X-"#A9S\]4XONZJ3C#O"
MS4CPB:YPQP+JP+.E9RV#M-$4&]*L67H#0@^ +3)M!V8DY^5^:=9M;_N9Q3^D
MCFM=,7<WLQIL0%596#W]C^BD!()$AL-GD+VZ6W;CFN2=Q_F/3LQVAQH=1C!2
M<LWY2PCMDZ:P+RR&19NHQ^9I#/*P,"&_7V=O"5GEY?4E>)LZ]8.'DPMC3WL(
MRMY)2/*E<.9V2T0E8C)]D$@BH@P"M,6<  P^7Q%3M&$'8G_9&EEJ_/BO4I!U
MY*,LTB\$-WX2)XE,\=--3!/?90Y>?7.:/<AP1"HG3O1:M[W.)[XIV?O*-D$O
ME7;S ?#N+#O.JGXEINV8(M*RNEX=*ZZ1J1K>))J12OIQ$ZQ]+$B8YL2-<%TX
MZ_*'HQ+H$5-QHIZ$UFN3.</IRP::#/&AN90;XX-BNYZOR91W;S[]++QA_C5_
MU8*YCK+ &\303*7>Q**:9TR#.IW=AL[T0GN[%U:_V(MP<L0)TPF2E&GV)0BM
MY:0Q[B<8D9 ,P4ACQ!5#BXS!9!*50<!F0Z+Z@8\($$<I?4+QR8 5O%VPU?OC
M7Z4\QK],2#HHGW^W7R[;BU%&)29C,*;K6N;EYP.^FHCI".;SRITG\&Z[=*P7
MO')"IC^E7?#2VR@?NGW&'*3]VNKZ+MRY<6=V *_FMLW#U>\Z;R^2<CG674![
M6<YL.'C]X&LMX_AMV'M:G>=R/H47))%_1B+BBHT)JFY'\3H/.X>EC6F:!<.8
M:E%Z/M:BVM8RB)JU2=-GD6"<!?-G9%S9LV9<7(6:NY]O8)\:6S:KV=65V.WM
MH'G\MK/ ;/.U_?FOG?K(.00)$285W2)@,*6I\0!!B".N:=]5!O7C3[UXU)!@
M2BI@. 8'EU@?P4<V*J^?C<JK]R,HAK+SWH*S K\\DF>42QYFC?+NO0W]4B(H
MFB1LG5HUQ8-'!]>@#6HW@<[ $_V]#(R%QKMZA+F[Y<4%)Z.M5#AYK@._:ZI7
MD,=)\;UF@^K8TQ-B:]K$PR;1A11=_\T2'0>2E\Z;\"JRL26:KW]&GY @C5:[
MYPL;YRFJ;DC-M*I4KM]XZVA\Y_I:U)A 3\A4Y7EL94^G?XV33GRO?ZVZ#M/@
M=QG+^$%D/L<$?9.S#+.N&]*2C!R<SLG$7\22PL#C5H,@K/="IJA/U[_PF*WU
M::91445'$W#&&&M@E/&\1T/ 8ONDWQ*3Q?4S''[Z"H++05M*=>'X:^R&CMSJ
MU&O"VH"SB_%- @./<OWES@3+=".?K[S (M\KUD]+NB/7Y6#OPTNLFBJDP6(^
MR>75#UZ@&U:HD)D@W]@]9??BJCMOAIA>\GSP9KZ>;>W+G5J+D[.@ZIX_(PW@
MY2%3*77.-5M8)EFH[,15 #4>SE\_<ZI-TJI]#4WZ?)'&>3-DIK&9PIK@4J*-
M)^1I;G3*-;+'H2ZU#K:T[6:('W#1Q<M#.0OWBF#?4;P&S7K^6@B0H$+6>7D;
MM*L5,;&&;\W0FM.HD/3[DEH.&YC"%?TIC54B$CEXQ&0(B"ARK(*B/P3CC/MX
M5E2[BOZ7FQ276<VO%]W-_-9%\)QRG6M((-OZ<OKN_8GY:D";.RS'>];M38/@
MQJDZ37[<S@$Y?/L!0'MY1K.7"2>UJ#@M3]YM]&M G$A^XS73[$Z*82M )B:<
MG!ZRJ?=HOD)DPAANMD-K_X>+Y@&N'B=9/-E-JE8W^>+B69JO4J# WV;.-18/
MRZ*2WSNWQ=WH &G/><HW29[D<]-P[TR!QV_$&ZU R:8;]?9Z4UJZ%BY5/&)1
MFF9=(-)&,LB3SN^O?A&/+N'(DL@Q:SR:' OG9@KJ:_["&03L!Z\K'&HEEK\0
M[YHB8LL#_(CQ%Q)%,13]G&0N/U$1<D"S]%_BT<N&)(V2NMP]U&_4_II8E&(O
M1XD#%B][[J1.U+&7W04"*'/!6Y"KF,W(X2/OW@VC82_Q-="8MW:6ZT+8DU-S
M?><**#?[6OBA'1\I.G?+]+3K)OQ$>E@08;%N()C_,/G;G8D-GQW@CT!&KLR,
MW1"GTV/E8.$X!W\*4041<@N!BH5JX5OW)N/85QOEI^Q)$T(*><6'):8GZ&\O
ME&<IY:LZ^P/4][@SO\CRC,YNQ4JMJ1:!.Y[J:>!Z?62'!V^GV$]^_44+RM9)
M)^<8J+P_5#K$()VSXVTO 2*%#C@?Y[N,O;X!FF006]"K" P'MACJSXEQ?46G
M<\'5SX*FWOXB W%EVP0Z,6=XG@HW?A6.3R$$(EE9O:R_DS\1A#D.*/=1KYC*
MRPN/I)Q(#S5T+M6!-XBNA8?NZV_0(R,56VI(Y; Q5K47JX=[-UM/U(<%'RVF
M-'[B7P<YGB54_V%&)L KL*]"9$IU9J>TNU79C6L[/A8R4GN[EZPC_>:QD;P[
M4^,AC2M-I5XJ4DFQR0&'MU1%'NJ68$:]6&J@TXZR76EWKH4E3M@,>WYA]LI:
M9+6P6F^DQ*\**)#S(6"))-.082ZJ#Q^[P4$?UM49L*5,(!',:)JF!C+D)!)3
M^'I(5BDIO OTNU(K%?]E-CL9-2<S4N,VN&(]^]4G_0C\6.1J<R]-GP+WV$[M
M%^(!S2TSX7HFZ>S[43D/ .X3UF!6AS/Q3)N;G1W@86%$RBW_#-SHQAGW(+/@
MM6]4'U4A]G&CX<%[X2R]_I(/3I0?#TA\Y!J*N(4U4B+^]&6DZ*L]8#5[7FME
MDBHKN^94\-.KX<PW*ZDXA\%,-WA0-0I4F?H:=+LUBH',3J//=6 ME_4LN>NZ
MFF&")F3$,I9DD+7_NDJ <\-/)[PVKAISMCN)8G==A_AI.\70JC:I]+O)PV>K
M T4?T[#*'6E!\%(PT<=?_Q-QS<%D-/?"JB&-F_TQQ:I;,T94OO1RZYEV7R)K
MH60T.L=A>2V0,=;[R@VQ#I8WD9$[O[T<,UAP0!*U>ZX^3@2[F_1IBAK4/VOJ
M*\GG;XISYTW=.\'C)\SX0);2&+BIKF?+C[*31":LP1C%]H>L49^P%)>8R/99
M!29SSEOS%VHR0(U_1F_,QD7J#/E?STORZ5//:!+D3-+5S1*]T=GZ"6/2AXP2
M&>-#1^:G0@1MR/"97*>NK?[;5A OX5!.E@I6W>=VI1P<XC*:5NFX-1[&?4>4
MU(\7X[$<C*U;'=EG>:S^6_>E5U]?+:#Q"*_<M/"5,6\+/A8R)*H]>+LJB9(H
M:K"-5,[A!+R+V-G0=+JW3NH< T_'ZW/[*B1]9SOA2^=3O!U%2WTDR3O^?GWL
M&O]VY11/Y'K#>QA91_FE3\FO$VC^?T!(3AWRA:4O)=[%GKWF0/*OL29&?.4-
MYBCUW12Q^ZJM=R;Q4;)@X0_/Y;WA<N16 D&8 9NB^2FR,F-3X1PF6_:L*9Q*
M[45GT5[ZI>=89IO_.WOH7Q"2?.<\_#2!0O^9<YX. 2=3K*&*M!4X=A0<_]]^
MBKCA[*TJTS!;8MVO]:Y+DHQ-[-5EXYWR"1/6/Y:B964RD03/1@7>="YDO',(
M;#0^LDTL'Q#QN1,.'02=F7T=N-MIU*A>W6"0?[*?D#_DNO':U^D]E.^%/_^N
MHK ZT1_&%\C=VV>X)E.5LQ;EN%:#'EP[.%+MROFH5QDZPI:[WR7+IGP^PNE%
MC59&&)7GC>0YP$_^ZJ#B5E;69^\CH"AJ9.J-+A\C.,KKG&?.<-_\G]7]$^CB
MA9L=)ONYGAV6RX\^H&P%L--V9&S+)SL'4UP*L 9T]Q*L+T &&5V:ALPRW&$5
M<SX^T&/;J/SZ.IOAE(/N(5W?[V>(B;MS0NM>EG F+U*\_M12-Y;3DVO,VXV#
MQB!G,,T0_03%_N!8TI^1 Q!24,_G9!D@"I\""24=2.<#"U0+2K.C!BBV/"%F
ML)PYZ3.4'K'4"0G6#WB:*7-O[%Q"6)4J:QLM92:[1E;KP>W@CEI!D0R2(I\"
MIANTM_^V6H\J(9-UGPV\28-B69\/*-T?V6D[];8> "D5G8S3G?'J(00T9.C#
M-%>5E&1JD<_TT%R*B4%][LB)RPZ\ZKS+.A9KI^Q7\ 4=I.U[Q4RLXB"[.U66
M5W]&!!F#](@%V$1VLN[5Y'/9W;^&P0HC9)&\5'4$>4K?:=-N6@WJLQ:;ZI'N
MV4Q2<] E[X&K@\@4^IDRB[1BUS&3+,&X0/!ZKB U;;=SY_Z/ZZ?_/A?.79>?
MDSR;379')\3JR5>-6Q.-5EE/)P:\?=;K.(+IB,WKE5/M>5-_"#!+"F ?.T31
M?BYD'=K84/=VPBKD$]>3J\5J/1/\P\VM %[%K&*F.HFOE78#],OG]_ASC5IN
M,RHV$FYW2L-CVQ8PKE]4NHB<!(W]R)"291K!T\G <M3;+6%^,=H--<V)7&$'
M]\<G5!A;C8IG55R%5-^GTT_I_]NZB>4#W<'EHN=]M8<3JU0_8DX(O:)]XJ\6
MBNH? (;'[E$X'?6I1M$E.+UXH<LY$%*C(#G%=5YCZ36ASP\ WIN;B0F-8]VF
M-"<>V0Q(P?^L[?],0ZE,+6Y#ZFN_L@2/0<^*GW5%OK12OP=I<KH$CS(9*]R(
M/O.K^NIS:)9Z^18'UV.'DFK7P8H)(.= :1+IT[7A.+"$YB8)_:S/\&],C?-X
MJ_M1YFXXNESOY3&#/AK?<>"U\,9 [KD9R:&#W^+)TV7W$@I=NH*890$M^6<]
M<M@"&2+"*>G^FQE !Y:&?#W97+-MI8]_9C89<^_.LLDD5FE0K\ZG02^N;:A*
M@;I6KO&Z.HO4FG$G:V&'-X_."FUQ;RK*M::%JTE$<W%R#0\6Q6XM?5+VVPQ!
MU/,G_YHF]3]BV>-ITH6U85#YJU6W2/PO:[ZGRE\]C*9O]1NMCRAJ5G@GF( .
M;GR]J_EFB<=NNI(=O,:K.6NL31G]&>^<;(LO[NOS=?N[S;8__*G9+#L[ZR85
MZI469>HFG O,_+E_+1(5L[4]^*'(QV_"L*3T27QZ'L'M(/>;1T:4T-YY;?Z!
M)NN2#->\IF3P:X)NE0(5CF =]+2<&\__,M'H_PQ!VKXZW!X>D"&FN,1PA!#0
M]UTM479::]N5X5^)2M72W7QQ@]SK O'LO1%VU5'L<C7JB6L1%WM7)9LVH6?W
M5Q/M.]NV-\(*<7]F/>#*5P]8SMS2\$TVT4H;TFB:9EBJ4@1"/+&WN$AN*"_)
M21(ZT#P?/6T9VR*\ 1L<7@E%%:5D[B\%]SJJSW"B6Q3IAV^7)K6WS$YI])(
MA;P2[SJ 7A__??4>EDDV'1H!&B\QN?1E-$]H#^[#-I&=#_>10T](Y1G;!=2_
M]+W@V9TKV;O^>+Q@<5VQYT.]=5'-J\?YN5AQ$9(/_ODZ1+UWDOYHF^8N5T>2
M67YZ\/;/^$!/'#O+Y)A_-G4Z1=-E:0M+TRK$"6WSNCUC27_\D<16?F0),EUC
MB-P#4I\(']Q$S=_:WK;T%_ >T'G1T8UB)A*^6<A\%H\6,T8Y5$=6]3L;S2#"
M;WO-R[YS6Z!0!#UNR^">/]U"!Z8=M"@N'JE2]DGZZ%4Q9T.>WMP_\RH]MM>S
MO1/I%W[+.MBX?M5X&OSTLOD<+&O?XP9N417 <3JY6+LJW[0).;L_FP@H0;:6
MAWO\X2Z9""?O&DNHYT%3Y49$S.FW1JJ,/QTHHX*-OKO6;\&--=YG9=WQ$A9P
M7*TK8R2H8##;;@TPJ+RC=-*DN>^;;IJX(&OIS?O?:9T$9?O*=XME+4%9; 9H
M_%ZKGMFY#28>Z/Z4S3V<A%KSY[5$WX5B;R<&7#M:SSV^[UE'K16.SAF-#( Z
M@VMUP1O"7D*(^V2I)6)'9*$/ -!I?D!<Z'*CTHZX\H+>^D&F!\Y$W80NN 1U
M]IFP[.B?,0.X*M93PV)>;4CDT;(*RKNW&&. JA2)JZ_"MN[(RR_C+<Y%?&9,
MM:D][INPGKM_E\B:EMR=7SGS&DG,$860&96&964Z =-8!25+;^A_BR$=YIQ!
M <M8I \21T%"[G<U<)_".[*),W;_K#O<J]YRH?YZHZE883 +E]%(I/71+;[G
M1,[UFP&WB\H!R'I&IO@&V-%KZ?K-9R^@IW8N[],34L9N]Y-MS\W;Q5.\=]<'
M/CL%SK/[[1EY6G](C]=T28&FJR=+/TVG3H;#P@GAB&I!NQ*-CZ.U0(15JU:&
M[1=6DZ(&1<Y3$\X;]%H.I^7ORFLXT'V#X!JD5"5+<8Y.8]%FX+H:/XO'H-$Y
MP>_LY>@QJ"$S8&QY#!#[Z5H*(MZ(?Q.4N@85UXM_FB&26[J6O+?R0*X :F^U
M@9C+S>X]EQ?4&G++;G$]9[)O,EJNT#?!5Q-S9 *-@<L9F$(+FP\ VE=V);PE
M3I6"AS[V%P^ =]<+T<Z;.TGSCJ>M?^QXS91 ( D7N@-Y?3QOE+\_YV\WA!#H
MF*:7*0\[DA6*Z<;!YPTO=/1[C]'&MJ?/?TSW.1.Q1/>>@YT\+ULXN0WY#,H-
M-X^-PRUVOFX];]V9^PW-I-5@*9GSTJ+G+J(H6R2"6)Y$$&_!ZR]0WC%)[YHS
M/(X[!%^AFW22<X.CE5W=\NT+ANG&+(&J*=TI?K G;?_KW&JSKY$/@*6,+/4-
M/4</E(-]SL.#?=UP6L382X'<]4B?\P< _YN#S#F3;H]KY^\'>SX)?[@\#T#(
M8>)G3>E38MQ?8.4)UE_G5H)HG"YF(%W(<TD8Z9<TI/@TTCBV $!E*+WCB*R2
M?>>:IYO#YV)@29+D[U[?I^P]@-+>QL"SN#3'ZCOK5_^^7L2OC*-3&?K/S4&Q
M:/KA]%O($X*J6Z[C@GJ+O>;;=P17G67W0[?:4[I^=0^ T-LWGN <<Z#K =F<
MT)$ T3SI"'^Y2X2W\MK,*/#-MF<O<>^0N,^1;7")PZEK#"L1WSL6KI.+AJNQ
M!4'D[7OYB1O^ ]92(F')G#^C"G UKB<'9QE(Z9MF++/1"4C\66U'J#D]"3<P
M-"TO7\F-FKWMG>UE22J[JK?T_L3EPY%\E)@QH4:Y:[IYT1#YU')G]OOT,'#5
M^'/-]FP@4"CO-_+?$$9.LK"42_-@W$=HE$@HIY7;\R6G(3OS!2<.7[QJFY1)
M-??(B@ZH7&B[6:&7R#UF1?QA":PX\P.H78U77JAS#;7+9,:,>QT61R:;VDV\
MG:UXM?RL[?95<:DBZO*LGDUIWF=#\] U$G>Y*M)NICOJ/\S,0]P(\>:4J?M@
MRVF:PK(V*1EA6# N]XF,8@)U5A[Z.3_+/6J3;>P"S7 P,JBJ/$@(9G+=7.LY
M)XC(^1V\F;YE2%-<UON\%(^ZVT%47BU/,VHD]S<6]T085QZ7&=T]@O:[?$!I
M#A+DO0Z#>F/=T$($.GS?JV\9]9.DG=.O1'9>@4\WT"YGSN5E' 2(HUQ(* =]
MM@289QQM \BWPFHO#WZ &VLITE('D9/%Z<&-Z .D=YNN6@YR-206@FF:UQ^^
M_AE#R(-:USI)+N%S>7"=+SJ!H1!-$*TVUD:DT9-N)'*.&VZAT"2IT/5,O82K
MPBW!],7B-IKO0B/)),=&D<G)8":76]WX7G\4#]AKV=9-D=]02P@\O>!^XP'B
MU(L>8=)'5_*)WRD1F1_?>@ \N4_W.?6@_2ZT=<LX0Z*[1D;;(E]W[3I>96K/
MZ &AD996WWG6/5=Z)KDFYQD+]S#;CQ0\)#\8",Z.VR"V/DQ=;DS7/1#F:L 8
M>?&\_FS88S-]Q.J.] _3_A$WAKVII:<#Y\4Z=>*Y/2F="N*EVHVAS-J,\7]E
MV@"+%+F6SZC=TSJ,FF*W9XB=N?8UK"^[4L-.--(+X# \,J]OOZ'L4WJ$:;Z3
M! +TLP$F&W(A^H=#] PR>Z?!Q&.7D\^V&3FTZQM>NVGEVB6S 1NW4P\ *:^+
M;-?!@)BV#.L'@-Y,QN>Z_/F2#\=1$B1K'4+HWDO#7DS'CY4A^<2S=PT^IAZT
M>=IZPQ-<.VGIL_+#?[BF($#P"6NV!=BL?]7ZD6_4V%1JHV6W2E%E:+<JJ/NG
M>SU2-OL?61S54NW-UMQ<Q1K[&O4,X#R(H$AZ]S[IQF^$T0@10C[K^>X2?(5=
MDOB4XE"6N\4%_L:]+>%73?#!O<$VDJG39QO[VK8)PHD;6Q-IU]W=Y_,$?,0F
MN\&$<XU5]5]F=/UN3OROP_;N7_*)8\0OIX&W?,SFY ?G#W=RG(=V_/;?#0Z=
M_2D96*R9?& +V56K$WV66ZJ0OWIMF8V+*F-K_DIGC>_9 A:K:ZUYY$;F1?0^
MA^/E4YS"D?-4+@3MSLM^0PMOAM")T"X3\0052FA,]D24F]U@BJ^WDRUE\Y(G
M<X>K;>D!T<^VV>V2Y^!JQR?("2EVOA$G9UF%Y7M/KY(;@T04SJ*1=ZB;69VI
MD/=ZK<R._42*X#!9IN4?VNXAH9<N"09%K%OC3'Z8KA( /U$JU?B/Y&?+$IPP
M_\KXM6JI7F"U'%J%:%V>]$BFESGE"*$WQJQ@X,=_7PO")H/93'MH\J@?AA(W
M">J^+N4)W_7S88$A98$B\/K$=)WZ5%;57%5@IU]'36?RLGO[>GTJQ5=J 5KO
M\XBKNDU\W;G"W$@8B9O@T=3%YF_H_?\":2;>.H?N?/$%3]+W<2<)1G-)8$%E
M;.D_'G7HFD/MSS_C-3HL:+*@!&T>UM#VJ?&5H1%O(/"-X6\H0<ZLR3!71P%Q
M/!)%F8*_&%G18Q'.%O)=+3@)"W40(*5SB$+^TG(I3Q%,[T4M2V*S?JE<]R9B
M:+93F25:KH+$3>A+T4WLVS^S\T4@&3%<:"7M(\_1=UQ3J?!FGJ)/\3VY#J4Z
M(.I_S-)FI(Y!U:5Q*57E[EA#"U$X=#:_.I6'>09U_\^R_Q.(PQ6]GF6+("P=
M# <NR_Z#E<N;.]D308'\T$-W726[8L;5U73*[N4%]F5Y HR^PFS(5!25RT0I
M.H,+ER=NNBRV\X_A!.]/&5I_F/>+X"^$0*,#T6TG^CRUPTO]Z7.!(<.U"9<!
M.<O3->/BRI^/M3Z^K'*Y5I4O.6@.$E&BGOLN!!XPY. ]!63Y'3VGI1R3166F
M)=Q3.!1!@D)ZPJ+\S_)UH!W(:*E'C5@M1^6I.2NDH.YV2W&T/.G%\6D=[RY/
MZ.H^? \L<UST(D4C+UVW@5:W7]%L\SA]_.,?VGQ<W%A.HU/]>JH2;!";I2*!
M5J/2.LY6I":3R1Z^9:<NU6OW5\HX'#@VVF,)!(O[#VT>;;5'S?3_SCKGR/G=
MX 3E .WDML\8K=A.>E6\)?VLF^KOM;>-5E=$CW#8U3K&6QD? %%*%U9U%WX'
M<_$[C2(-'@\ W]E41-\I@?<N5=/WJ2QT'*#X4<ELN2:6KW+G4]?O:=[^F>T
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M^!M_XV_\C;_Q-_[&W_@;?^-O_(V_\3?^QM_X&W_C;_R_#=^':0 *PB, PA/
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MT[+O2@W^ELI3:3:Z46K<BWB*R-=N)<]A-U2.:.>.C,YHY\@4T.=OG!V^6<Q
MH4_2VPRA2WEP@_ZLR">AP[*=MKLEYFO:N,//#RZA(\W::^Y'K[]6<<,V0$3,
M@1D(1E8U.$]%ALY2UGC3.BJWFR55K*7Y;42G;I[L[22[PN38@=YM)F[I3,T-
M^:3MMC9S5LYEM39OB!1KB?=Z0U5WK*T/E:%^>O1X^&O--3K0:7)9$%4R-Q8)
ME>^GLP@CO9X<HURQ)]R)SPOQ11M&EN.#5E1&VFQ5PZRKNXG?RZ;T_#P$=%FV
MZL[KQDY4P22"4G BAI_S!&-8:2]JU&GD&I0KA%IK4_"_Q6!^3$*AY)<CA_+8
M]%*TCMHDR5#>OC"X5\:[X>T!BJ-29?Y;CMN!(&%EO!Y"/7/F!NYVRXKI89!]
MUI+F"[:!RU1;XES#/!!E(6?E> U;6ZEV8..)]&:NSPX3RPL;E9+$"*WXO0&Z
M(:[RL ;<0;8>%] (R5X0Q^I:(G/H2 )^]K-<]3H15Q1'V$4"1)=GC9MA)6J+
M2BLMMLXS#G.@5B1703RO.B:$+$#XB%]<L4P?+ZS7=(;;%_K\G.9&I6KO?-F@
MRO;SRQD#IM,E6-_R*'GCM*%U.]I[8EMLJ_-::FRZKR&(?5]X5VD! SA]/T:X
MB6ES')'LQ,K\Z,6V#; /SL$1"<.#/?#E&326!:=V9BMZ;>V\!OY@AR-:<',5
M[\D./U*  %0WX@N@ZP#'IG_;>=A1>RCO > PP]6HK3=<4_F<#JZZ\\K:FF<G
MP+/0;!(DM3^C8 L"B=ZXVJ<:[+CKH78RSBR.R5RP![JB=A#69=M58)T35%I6
M6'5L+P+ML;EJ*MPCIK"DJ5W&O^P:1!2?X)S#QI0XPFT6C)DT*KR58 L-6L!E
MEF1REVN?7&E1NXS2HJ?)HS*$C!A#W^@4_+^T#GC<^_)F+'.'X,?\+"7OJ"@D
M,7(LL$+Y1Z=*)=W"/[ZRE+DD=?#7=Q18E.)+/.;P*P'0/K8H,G^%PL;WX8S&
MZ\7W[6B[!;?2MLECUOC\]C*/Q231Z=S*8L9J9]UYWUY7^;PO']1["4;LEK]X
M%N+BF]1\^5ZKHJA#[RA./C,3$!Y%:*3ZA;_%?"YH@@4*+;Y]C63$7U=35=%R
M$AQO4_$$;Y2%VUR;CG\60VI#AJ>+>:^49I<16"8&R]*I[&8>^&[V:,7 0JIO
MRC:E1LP@:B+G 8!<J9ZI/BXNME8)56K(Q?$YGH9P]8XW53*J0Z)8QZWM;=^E
MT8[%[VCW\V]#+#-I5;:&Z>BIRA,A;RF$$NE'E")>]= DCM!0RO?EMYC20M8I
M[)P.)=K"__'YJPJ1^/")X.TC+G8AK"5.+"%TNN-#$+;OZ!3.V;+'#ZR DD=F
MG=%1]!*(="]YW>U?NF$@2\1=#DIBM?I:64!L*<37# [ST\=5,JU:.;0=6*SL
M9TD+B4.R!/E?&T.L.;*=,KU;"M6@EAK1 QP3N*'5-!J%_0P1%LSJH-QGVIYJ
MIL,[A5!(PW0\;&1Z2B[O[4":]AVD82\BP'9D8'-2&21-;I5?9%M]UA*_@&2U
M!&TX;05NS4S;\@SL[\G%Q24.EJAJI"!I+'_9EM&8T])5&.\8*78[0R<<L8[7
MWC*PWBOP_3)457A%B-?SPAXLZ3"J#%,LN ^( R8SJ<(4E"Q9RJ1L4 0ED"%/
M$5@,[2*EX[!(Q9"^OXVAP,),E99G_=DP\+6M==CGHUXZA?3P=<3D6##SNA^.
M<*4Z1%!*C'#]X["4(X>6+3%"BQ5!X1 EA!5R2,P=XG8EUA20>W-.[MB>^Y5C
MJ>>QE#TS;8<I7]M7 C=T=)97<C2/I130LA0Y'MLBDC6T 2GAA<??+S5XE#MA
MM\-.!<L7HCH$Y!%4*ET.EKBYFJQ[^Z?%U;G(Q00*^=9F4DNB?6:35<>0F3X/
M:$X\ L&*UMGDBLR^BJW+?$E%(U1E4I=U\)O.84J@V:ZJ)':'$7C,3.]%#]Q!
MNL\YK+9*._X9%LC47FY%G;H=RUV..4RY7*3+.@22K#GLD@MJU_$^JX*;M[);
MZ6FGLY6(SL\K0$6@??V5#X!Q=/N",87CKY)R"NM9()A#K;,Y^8N460\B1>6>
M!A4/(%7%.XI"?Q3(-J(4^O#C 31,PW<(XW8?EBC>?SR2UT,7CA30LC\Y(B6T
M2V@B[N3=6,SX)!^^*B!0[;@B?['+D!\A<[@NX_#I:!V &1VRLXCXEA83_D.N
M+!7TB ^A2(H3*<35I"X;7N-5)$1LDP%QR0U6/V7+>VH(AU#91-#.%T]!MJ6H
M+-:CQCOF0M=M&('?'@O9;HT8R2VE*M@Z96LVK*6A6=2YOG[6\,R$YX+P==!$
M.)6ZM[Z!W.CP:Z3X%:&.;5ZH_^1L95'(4\\TT9:MR0*!?/OO=&-5QF=ATIR%
M)QE-K2P,-3#5A@:ZWN-@;-+E&HH%//S*FIX2=(@1=,KT;$ZU9F5T'V)BC)NM
M36W%H$M'LTJOS9@'?3HZHU@35_VU@IG!,#9&T\"B $6++\FI)"FU#Q^+#?J*
ME--O"4S&"CB,!QVZ7Z*C,QN!@S.B).#+@^%KC_CLX9]7O01NM2Y?^C3X 8_N
M>"7L3HC7<K!XB3\Y8BZ1_\!GXXTTR@#'8="M/R9H'P$7#%(@O%Z(#V[]."+K
M%1J1U#0SFZ%4"2LWY=)I:M0DTMF:8K_&K=99#\191?--@$W9U4:PA+_3JJJ.
MTBR6M:G.)V\1]; JN)_KKZZS:JBNYX.BYLIE<>P40"/L;SO*]N-F1FJK"D8B
MBN,[^9@7GE1U,_?;U<JFCC7 RI4*':U]JW38-E!]0]AD\V*+F0K1EOLU@'8S
MUDYO\BJNB6+$H%*RHO+598.[Q]38L$)5'ZA_;0'<499.M+OGSH5%$J)8@/,"
MO-D"++;,20ZAPVXI(,@HPNY!#<"*M(=3$G_*CGON1:K[7.BQW^6T&[*_%SH9
M"ZD>X)*O$XR*T>)#[\;GQG?)38S^V&=_8>P-$T';UTU]1%)E>'!Z=E3TJ!^B
M!&50-(J_"7+J(VK$:'^#*028] / ]\JH/.%,J&]+Y9UR^D@Q+'&D6*7D/)#>
M:O\L K?JMK;.$T;BB"=M.ZTDTEUF/*,:9AQ7W+(6_MIER]?6W&J"VF8=IA<!
MKU-L9X]:03ZVWA+3MKU7C<_&*Y$Z,I/2YNY"+NHDMSS"(ZE]@3G\TR.EY*^N
MR=E!J)]0/M.>40L?6;:.VYN2_B28:9OI4557I5 .\TP<SUG*#M7$4C&,^S;N
M[H&[F-)CH[*@D<#(D1?FS _FYP[L+HM0<U)A2(:@^L3J!V!'23$F-?/GX1"*
ME2ERRDB(4&$G'1+3MNB2+[U-+OA*512#RBG!<";S0I>9-Y'TN0QWE8";A8$[
MM<I$JP/-<IT'=*QE)@JXGQ<$7SL;N;!R2$"QFR[42F>F;CN$?UX4>+_\F11;
MOK"J,@"$Z>^\;I(7C?+R,1;IVQZ$B50$Y*#LD"$10I2-'PB4F"LY0 EIM.B!
M2_?;0B$2/]6GZF9)RW3")KJ!5V$R]'6@@-XO("VEO88IF+B_2O$# +.29:AS
MGWY4;D4K;4QM!N8ITJ4.S^"UEX0FG-C)SO<K[T,O/#Z;]APDJF7;M]E ZBID
M(RH):WAD4JQE?*GSG?& @NB@K#0T[Q1@<5A!C2DOBT7;47(XL.!T)*9_RI=6
MM#*FRSTRCJO">(W%&LR/$WV (*O"/!*<'\ORS=4"JLC"3U^<+JH,YYH=?6;Y
MLX!NQVK#M>.=%=6+<&=R1@M'O.6^T:62Y6"U2E @Q?!2V%-0=J&'K,G%;K^+
M5?+ 1J ZBKX4^'IY5.\]=K9/4'&^HVPZ/AX18U=:5CTRIP/-:@GUDVQAQ],D
MNE6W*3HW'?VFE!4\#HO:VC^?@8%$+>A4+J]08#.S0.#RS,N.[4&F*1I8WN"4
MFOXR]Y)PP$;G8"L+!5^GD,"R0KIWW>@#()!-9J4W.(;S$%4L&JT:16 1M3/6
M\$-BZL='2-'Z23\6J?&,&$U%'P!N O>J&2_Z5/3.D$2L?.4.8%L.H4BO:<[/
MRJ&UW6GJ6N;#1>%Y!W)]/<T9R*S;9=8>5BT]T^-D:_U: JZ2#5<IP!=I>$NM
M(&G+?;HYS54-ST @6YBJM E9==ZW64;/W#<M=&]R]D.;NF?S<;9X8, Y9=\(
M%70-72S1M-J5.'[TTC>QMMAR'!UIP!(J'6A[,.UKS NL]^6JV+O8=&O^4%!:
M^15@9$";I6$-NQ^>>\;6\U7;,L16=$Q%/5<IV3_9_XNB?NAB8*0C)G"CB(2R
M3^I%#"=BW"4ZRM+&4F?*ZZ+Y+:E8$E71EPMR)1R6'J$,6Q]ZO)0.W4$=R4\G
MRO"=<7<+QW.FXP]<BG O>!O=S;O@&3K042NY&#EHJUFIE%J=:O,9[O,2H@4S
M\PO4 7R3O1,UI[G)#,K,#1(WZP JA7S;GN*#&6.^^($)T]E>(Z>J2^2@#/_C
ME[POO&N+8@!R2*5"F".T+8IK@![4U!>8<0X!10Y^ T91O'%20#0$WH:7*7+_
M^0CZ:Z2]ILZIAL\\1"I#RIF&PS;<TZG%3L/EG\F6.NT,Y7'.R()R:WLC9LWG
M2J>=Z4H;( :1$O<K<F=5)6GJU@K=1#$Q?*;0QI["B8*$"""\J]C)JM_:TT\M
M=P1:6?QVK)A_NH]%L]64>XX<)F^=[3^1=92=,&XZ4/Q\OXC5;264]7N8M=C+
MJ@I5@KO:VF(WN!FJQWR!THS@F;26I9;EI"7$VF:5)JQ@#$>K%S@:VK]%_9IP
MC9NH6D\K)=->2T6\V R^3:URK5],.X8Y0HT54"2EP!7R K&%SP[\..=;5L>:
M[%9EH5)!0*&Y1M'R<ZU/!%%1)?Y]8W+[^&&$,D6>T.B"=N/JAJ*KL6#:6@T&
M7<Z4N]EEJ_Z.LPB8M#;/V<*VEI4<"-IN#1GX$EK(,#]>K/&F@+'Z>*D'+=NZ
M(*^8.7 V;9(Y)9W$V.DU@B!^/AB=%]ZZMI(1H'$BP-=\&.E=2W=]*X[I%+)%
MV.7(CVF&Y4>7M,0L@"Q'V*M!^7%(KVEWZE7\ZLF5 0Q!JF^S3WGV-?<F=YDN
M*;Q!@QC:7[N]6@[R&2 >KC;$FW;=<6!BHAMK,%&QZBY=8S[H:M*/RVB":2=/
MIBAW02LGTI9#:H=:OD^'%RI"I-($YB?4EMO3 H]9+AN>0B?U6OJ;J+7;A&>0
MBRV5"\GE!>NK<S:>=Q7"?0I!>)(]\TIE0YG)0N@$96:QVI8K?;NGQ7RQ*6I6
M]^FB(FX14L[;C=F6XL>GI+EW>2406]OSZ*I-(- \GB6>FC#DVTMPALK+#XH<
MLJJ/:'_T?@Q\NVI,KO5V7*"3C(4VHB3_ZHFB,0'G>Q&G;D0#67_MA*<H-_GD
MKTZAH&_S.=^>^F.&!GW+5FG.5A%Y[(:&LJ7B5$!E)(<946VNLPJK]8EHJD:6
MUBG*RHR2R_'@-JFTVE;I31G!-C]H]QA3/B_6?WHZJMU0$$\N(<#WXW$RCVLE
M/'2VT C\K+)A0*6C/4K/OB,E,%JAIBY*&'!DL;BVG+H,-%E>(ZEEO'_S@XM?
M0B0$ ^OCA_J.G-[6WN8!ZJ)\PL_L+$BL'M,<%4X__<!XL]:*C\3S,'O1\L)
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MHSORWX_J+]=;SE1E47@S59_5Z>R2'&.W>W>^J/UQNS&;NS8S[-%SL^CO^P-
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M]7]."!9^.GN2^$+&YTB$4OZ1_U[UJUNU*T3//4]O]#CF==OZ$L9C=FYATK>
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M3\E%A9(YF_Y7DF%_^(>ASJH8B4$,5#$PI_I06.BD6%W5L[B?S_V<:QVK#SL
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MXQSO (P.&ZE\1G56'",[5:4W47G*!*4C)N(A&>9.\4I :P()C8U9'< -\R5
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M)9U;C<1%-4F'V.G8$4M9!V $32]1@2<A:WX)N8$:C3';XHG7K)K3.@!T='K
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M=>OJ!T8R**<R?Q*BD=T+^%@L#*QFU!.PL6*]5?.1<J_\ :9N2[A2"/?JY@&
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M"H8 ^_@EYI[@N,C(OH?47&^V\!B(?Y47R=HD2Z+D%A4_J%:&RU'XBWA,\@X
MGS0B]GT')L^V^_\^[5H++<[;V""%=/%P X3+_BDX3I/DP 3%+0,#WY02B)A8
MA$VJ5N+N\\ A"0CA8N01ES/-BR37K]OW6L]Y_53"7<.^B+&VY"'0D#RPP)Z^
M#VVQ2QP@^X\,X:& -=*1JQO@T*F)UKA@]Z.(26.?L_0^%:\&Z2K)ECF5W,/7
M].]V+:1<6VB2=OU:H=N_VNI5KI+1\DT-6U\W:N<2PI# 'K7@UIU3AO[#K?'Y
M(2QT"(4T.8H');?&%/%0ED"[2B^9E5B%:FX!.R[A417MC@MW37N13S\\G;L
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M]/K45J#HZ =N8(PU>B$R8NF81V#D^!6-JQ+CU]-B* )-X[YF8YS>W1!TSN@
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M14MKP!M?#NPK[PM/TN*@31&E-!N4RM'9YF5XSK*0[V,9-"9D<BP\ VM3//"
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M-ED4T51!?S.FB*&1ND, -5^'M9VTHPGCYZ/T,=C\%C*0#%^P'"@A 91I*)+
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M-C'SG?*UJ=E'63 Y7S*AA)I5W<BX6+1RW/MZ^;A3]D;D5-*:'<\1<R>9<E5
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MC*F.EO?=L6#98-YEM,<5Q*2#AN37R%P@R5JX.;%DY<<:>1]/"=18(_NS.=D
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M7):/AX9>;6)4DQ)7<2N\^+W8F_+"%W 7'*)?FN/D=\=JPN"AEW'FP^=@8ZD
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M@FJB,L<5O)-3005!A\ZVN#$^>I!,,C%A0 4BV!7^%0,MAYC!C'"G="DE-*1
M4N5;G[@L_7#<%%GT_.!E@S7\N%"/,Q9!D=6=M6QR>D"H>)2O32ZEZWQ@%EM0
M"#P=SG,5Y?,A_*]4;QV6$K?>TE/*R6!$PPAE"!%KV"IS9Y](N-"X4BD(!860
MG6J&J-#W@A)[FW/'+LBZH:0D&61B4J?D2FV$@6O WA49$??7@">1PY9GY<!!
M#)WEA>4%1RNQ$L>\E1_%743Y7D@@V&Q2(E</"98Y):L]=8)3M:=DB/"MQ&O
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M0\-;U^XUL"@QOL#TX*$S4YW,M'!CL;X GQJM# S64(P1&T^S^AIA^^=UK-\
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M+)JD8N3<4+T54NX:QX4*ZQSU([XC$\LTOCT!L567SK)1:/GQ%FU0ZH?'P&M
MBV_KPH>O\_3;6]^,O3K+G_MUY_A-OYT&F$^3>JS:AN<^Q,5H ";'&HPB<K*;
M,6EU?V3M#"H)^VZ9BJGQ.=/+SO0FTS8P+O4>R!\UKGPN[IIEU'Z)V#6@^0Q>
M*HC"YZ)SY?3":N^?/WKV\4&R/Z*T\*E>E\*M?W:TT7!3:J-;?2B+% TI +F3
M:FJ>C$ ,3-JINK]C^#$S#>R&T,HW [Q/?.[ZJ_#45A$S!X;CH0]HP1ULS=1N
MK!R8WT<R8..Y=D(BF"V:!]WZ"[[SW/NWVX<G)\Q :$CB,!5G]Y:0_X?< 2CR
M+D;;@E'>_OPAB#=7K;AHAQ89 SO+874H21M&NUF&S02+U!RW0?L_J_1WY71"
M/&M8@ZJQ,:H[$L>]1[S>YAA/)[5?59\ Y"JXA'<YVTOD&]I+ZM;?GNY5!E6=
ML"P8;/]X)K4@?VMN91;6^2S1:'I,IKF$3:A,>GW@47.>#(^Z^!)^)\8MAES4
M/8/G,^*&Y9NX^+0$2QPLN*J5-<#!*CO +[B$=V_EY%<PC27"<>:%7"/*1BO'
M1#CA5Z?)O7G7/Z$>+W_S^[QH1&A=;7RM/W[BRGH[$#V8*F .4FF^F@N*L9)V
M2X54FJX:?KY?7=/H4*0N"+ZUQJ_QF?N&$[)]J']LR%([OSNH4V+OTL"D=/L%
M?8:&LFER9GE7V*N:BE=3TV<0J=3CS1E<Y0=1@_M_\SU/-$>/G_P6RIUY$K\B
MVB/\(&R[D:J_W=<!J2OA,.RDETF;6:L&F3*70L?[7+V4Y:TYFR*XBY2SP-_'
MYVZ^BMJ\&.J4%J>D#M!0MKQGN;):P7T4!!%3WVF#N'ZD_"2@91C.EB]1YAF)
MQ%\MY<_5-UMOVY2&/@TNE[O::H"!-!.HS,.H6E)IVJ0A["*F-;/51$BHRX:Q
MP;P]T.F";MTV][M]'.)3@4MC):M5(4AQ5/'![.HF%^LS867LY($QB_#(<LBK
MR5VYON,!5%)QCC'>Q^(&?D_=RZR1\[)<%7EY^]G[#"&IW^(LY0(/&6\UE'?H
ML/L\HHP9-.VC?%RMKBXUC.3-/=-KKGB=!6TQ^;+\R4Q/!!=?/+TV?%9._Z5T
M@ZU=6G<^H"H@)*M/;V=NK<13AU/.6_K%G)3 SRSCW&>W$J:>/;,>S=BK\!GT
M?>I[[/9GA$WZ@XV(DV)^(D_45\9;?;V4SL,%X6_>+F4_MFV0&':N+HF+OQ%5
MG=;8(K*+! ;?C"N+CUC=;@UI;66PO08(C<PN?,K"FD51!I[;D)H>[<B!J#T?
M'7_;8BF6'P:S6?'C6S%."9O82J^_MDN=)V:++,?N2TXZKQ5M)3#L\8/& E_[
MTCU ,: 8FZ9*2(7ACU?V4DN[?9]1":.RZH+J-_K!,L$WTS;%0)D3ZE[KUX#T
MT^>?OY[9L 9^WCFSX;1FL%LY]]1R[:#2W'--J:QR=.%Q/E9+;_W<8QGZF'Q%
M<?1%^S5 Z]-Z&^7@<[FNJA>LA\JOX!IU/:H)4G"9C%<ZMX\>"UC45C5,L[.I
M\],H-$C%;+J<L@A3ACAYWC?;Y#X,L3W FO=N/_4/<J;G7;($4;:%+'YJ"-+/
MH>1QM#$<=WVAF*/^\VIZ;_-CL,&Q^V]P&NS+HM--@XHD>'+%)(5>APZK"UN.
M8 E.UYMVO"X3ZDHC1(N*E(8Z.-.8R;N?![M)L0CVKLFWL?5> Q9.LX.KGK^&
MPY4Q\!QQ#273-PG%9UB]/I15.DO9@$J8<0:/KOQ](SGA]HS0)@O%9\Z_[Q,M
MFJ2.2[0;E3Y"F:?S>K)+@6.$J771 LV0V^.W<3&%;>_Z9&;OC%G,EO+7"F8*
M#70N^EQ.:,?C,I0EKAR4UX]'.!G4\?2\*SP=FX04[D0Q"+)]K'^=RH'RS"?(
MOE*Z@EJ.+Y7_/.CH&:M->];VE^]<IV)6PW9,9ZX/4J%-/G8RCC1!Q6]Y:0-;
MI&(J#&=5;K77U4-B5".*L_;MVH0&,<-R-YA9#N-QV:V<W)Q<(]PC(H=!MJNQ
M])2"A(Q[Z/3I(#%$\PY+F G+<5)")C!A.@/?.C-HT.QI849ZPG#)?I[]_1J0
M]]N=N1+V5/)60RDM;W:,1N_#XY9L6O^8-:V>VVS"N>V1O!)]5<*Y90\XE?P3
MTOZA?034CV26!(4NOO=^]T05[RFM_SZQ9)9_?FY36+*L_*K&[HAE1<8!ES)F
M1"U'%U'>^% W ?S<(RGM;/%,9G_AU*> T!!W']]0)+!(GF!DFQN5<RGLXE>$
MDN6[G7@[_6YN=5J0.C]/M_E[Z1B1\-&^]6%ZE"6.]U]*JT]P,?TPP]XX1VQ0
MM7JO?.#G?])!VO3 G25!D9),Q7? ^FI.!=A]?2L=UR68N7+^S4'WG.JEI 4B
M.OW=J#'OXC^C2I])9ES>TNA_9SC"1FO.%F._4ZI<46(7GF:!>KEPBUIBIK_3
M1!H40^I58"VD0R*>R2((RKIX ^/C/@Q]?6^:PZ!\979+J-3,%<)=>?_^=DB^
M6'5\EV3P+!L((M5'E_<'4'*"@JS]HLVMO/=W[I)MG_/K70X*,,S?>]#U\J[,
MD(61AA18%%A<".FH8NM]4$R;C)*#O^6)B=0-2'6RC8N:=%(R0+CO/P,%V?0>
MR(=DOZ!7Q9(BB;F(+:,,J+,>,1"D7]US$@?'CSFH#%CHNTP(,],4,2E??>?(
M?:G^R_5,>G_DZ!*Q>)<R9T ^_\ZC\"?D*(U(M-2XW6WM\M:881[#;-'QNG7;
M*.F\^9Q;0;V"2$SG$]P*I[A6"UB@$X.0PNYB^T#'N^MC2MBPX9VS_-Y]@TW0
M!9C%$/"A0EP8SPO6-TPC?Z:C/;H3YWD-:!H5J'ZZASAVWM<-O&)Y=T%>:*)(
MZO!X1-(C3PI,<QP3X_@61#PB7F58[X]HGT2,U^@K?=0LL1XI"T7Y=1K&XR#<
M1ZTD+&2UQ]M'KY(,A.2,TW]\)[B<I_]>./G[#;AZ(,F26J&27"FB$>,6B<_%
M9X;^4AG=;5WLG"K\\'F_O+Z1XP; \"W$VUG-V0-$TQ>I[2K<PJT;V/MDX<>K
MP,]M,1##B5>DI+D^+K+%Y\$&L=O/BUOKS99^Y'NRL^1B.WZ.<_D^+U.2%M=*
M]M/MEOG(H_D9(K8J#L7SL#MB-O.^"?)+HW:O 6Y:UJ]"3J\2+G^*0]T; F2%
MT0U".XW&DIYGMK% V=28O$5.**<%6\S9K0''5@G\*TFH ^1AR)Q;:HGS*CHE
MJ,CV-+NUTFSR&G!B25Z/)-F2DY8XM./BY'2IK. B+>O(*&#Z8XG5[L#U+^^$
M:DMF7"VM"//+EMRS^14Z%-W2.3%5^/';_.4;)IS16Q*\<WR0QGRL"S"WPFL>
MA@&.&JH4R1"I%68XF?/.4&+T%2C( MKK>GQJ-GP ^(A9W:!/*#[>\H)W7M;3
MO4'>6"I>!@7R68_H'_]W7 #LIWQ[A1V!GP>94"R0,)VR,PX=#EV<3<U[]NWF
ML?-ODZ=5:T%>NX^,&L+Q+O%^TN1Z,C1CO0&EGUM@##_4%M-=''A38V#9#M4U
M$5$=(E+TF[J-XV(:?S[!/VV><:?3*[2?%2_!X4J7^V'8=O5I-6O4JTJ18JD.
MRDZ<EGY.PD@.QADS8?;^I>EK\:5Z(H). C0G/BRI@BKM*P7,&6G -%&RW+H/
M 3,1+PGSES*4$@M>B^G6CU>2[_*QE87-^1!F+^MCL7'3JTCC;JE3IBR\Q!E7
M?\@3V^_ARYP&J)5E3$&X4./8/G+Z)R\+3O/R'CK-^,Q7QB]A-3NIY_"&W>5N
M!.4EV_/<I<Z7O].9*O'Z ^E3;@;373ILXX\W;=N=:1G47"@]E5^>W3J46-"0
MC7%0E^+%394,QPRX$F;7]W;_&&%_Y@0[V.1DU6#7[G<L]?;*!^5S^09 K(1J
MN(P!RNQ+TW:[N/ZODB':!89IC-EX085IH(?FXMES/P\ZAD/\F=3OH+W:K:#3
M&F2E(_#FXW96?39UQE(_W%VXH73,C^:P'$_;-^&OI7ENY<T?N@C2&DPK!,#R
MN6JXQK!OC]-L])]HK%RL;,D%J7]Z$BM!<-MCL"*3*^I=X??->!.EN>DD/LRS
M_EYXS!#NFXL4;IDY=Q\8=: ]_)Q_R?;DU^"__6U)/S_\.UQ_HU]QV%1!RA>-
MID)=6X$6GICUL 6C)\*34C%NLX6SM!KQX@N3X^SA1-LBE,_/"SBYP3-_N5F#
M2NG;[DF)E=,#E;%8L]RL&,UEB!C'OIJW/^!VZ]P%/P0U8)E<*8<T-)39Y_KQ
M92W]K\*9Y)M._>B5#=TW6VNNF8I\S+<^JG/I*32K2,P*4 -UPL]R!5+5U&Z[
MTS;13*O:J=#2C/(?-^9)2ZD%!HBPJ?_2_6Y0O)*GS-Z!Q:<W_($S[ UU@.D5
M/FP2W+9WO! F(W9B93K[:9I_(%(" Y80:0P)\^!%Z/OO>F9W_LY<LFXD3??>
M&H2]^+S%I<*TATMIKBR3($?U22.1Q<.=,#)SCBI:\\,G"M)Y7P\]%-XB=%7E
M72ATB(8/G_)^Y;D'_PB_EVK\B_=X?9NM8YJSMXTUP/\97<)HD=UROB>?MQ]J
M];>$>$-J!?IE.#ZWG,<257 ._,X2\+?EDO7WM^Y;=<D]:'CK-^4R<V#)=ZI;
M1S3&M:[J 4^*BC\WGKE<;2ZHNZKK/_XG:_A*$$PK=!>K$]S!/)3>UCNQ\/O5
MZ?/B%Y]/?ODY6;O3-6+S\J^V:CCUL1@EB8M+,QZ@%:/\!YPF05^*5_*E$5[V
M/LH*%')R[O'DS_[W)40IU]&;C+W+ZD?57VX;Z(B2BI::RDSH"E0)OI9C5'%5
MNXVCYMAV,^_5?YQYW B^$Q5O9)LS72A.EKSPRPC;V71 8A!X[W*B[6,&T:;E
MM^QGP[_EPO1Z'#A'G@%Q2WV6.,: ')9N@74>K0<Y--,YD+^D5M< ][J5)XKB
MEZSGR99@S[T/9"4%KP!G'ORZ=L@[::3F^NS]5+&>P"I]OT!#>(O$#$IVLH'(
ME28,YNXT_XQ!7!12V\_XZ<?2")3/A3]M'E.^@/HIMZAQZ7#1<NE[1LULZW"1
MS'KG[:N)Y=Y\TQ"L$R0E,[2!3/-EU^@_++QP_OO:)M/&K5-+>?>$Z>U>)T79
M#<4;"C?A?LUEL8X2[#6J1;MQ9#I\:EC(.J,*U5WI.& %>XW7 'O:3>E::P]F
M7NV=OD,_I&Z*]HOAG=EE;"[+Y!5'3O4T#AOAN*0DA;4WB^!T\53:1_O&O_/[
M&#F5"D%GE,&D972D9 !KY\:>NGJ_C^U_@X[O_A*GU-AY8%Q>Q-HRSN;&7L8P
ML2.C8!3'W=11]MUK 8KK-82,_FW.6W!CSV>_VK6^X>,3DB402VQ^&?YRD1(Q
MKI6DD;$]U"&@_LZ!@&M#&(\_B1J]>J;*[P>*?U-Q<NXCS+0AC)=4BQTV,MHZ
M?_@DT^(9VYGD244P].]E% _U4Z8_-W5"7@47IV3( ,DWM<*GL;-,"G*I3#1W
M)=5\7!QIHGK1M9A>#W6)H.I"TC:XE.X[9*L+EY[A(3?#S:^]O]3?_X%O$JB4
M ,2.SJ$<GJ$(-AF6DD/4B!5BK(Q94N ^3"A'4G5))&/:Q.S5?'Q[[LD4T7I;
MD'&DK=^6 ;=&].L7=PF\A7>C,IHO9X#3\XQ$XR"F4%^7QS*/99PEB>TKIK@&
M%V-O;E3([//LW+*_YX7^,3;EY-5W@S9%;N.A0&DZ#27V#ZB,3<.3DR6(YI0T
MBX2&5?C.1SZ["P$I#$!:HT;*;[S^[ZJ#[)U/:]> 4N[GV#CC/;$LG3L^\6:_
M'@%TE1^GH>0H:L($[H)B-J$^GKQMX-(JUS+IRSK;(HDE=9,</+LW&JOA]T$*
M.Y);D$,Q@'Q:G55A>#JDN+FM3\QL")=/X'G>^!,POS?<$E6RQ>(($@=M=^8,
M:).PI06MP2IAG[I;2EU.X$24SUFZS7S+D]>[A>9WG6--9*-T(E4/U*N$"\^%
M@8I'(I"B W5MLN 8)]77=R5FQN0FIR$@)WE1(SJ3VE[YI]75FPU>>8H@XV^V
M>^W6$,>AJ:]8'_1S7KKQ-S2C:W6]F7UD+#*4'_",00;X$(T!5(Z6%2H\LT+W
MKW4G/]?)':+Y84OU@HT#1H&O1B:W4J$MI+J\4'=!\E[3X3A^<X!.0KE*3K-T
M##[=M5>29WYW,5U24LU;52/C< 6#DM_<#J>/E3CPP0Y6&]@NX+ =Q"0W5^^F
MBUK9EG[^N2]*&?/%*R4^-KL-%_]ZE9!3R</N$ :39AUAG.E\_+S=^^J2F&?[
M+$SW?H/!VI0-VZ]TU*+;."4F7GGP-N3)S4$KH.%X-9^B?(LP6BID=4QP;IBN
M=ZG>C1O:S3,D8C IK/.N/]'4>O%>@I+$3V+LZ=[$\OX0*D0&GEOK$ NH<FU,
MJM=EB]6-B<SY_DMI?9W8,0"9&/+F7LAJK=FS1V,A"?>F.+ ??]O%DMS"N+I4
MEE+UZMU$RWM\?M.@D>(B5#6%9/B13[\TO[W =N@B8)%.BUKIB",V2.F2P"&3
M*=D)]%,5K)/AE4\  %MJ]H[A>$QI5W!$6_>-_GW,/7;%O&^I<GG[9#5BW,U;
MT/9$SYT,FV,M[9R$)IAD9H7._.V2O5?C Y6O1X]M]R%;^Q]6^]''7[%3+B!=
MLE)5>7=Y-R':;F3Q.'8Z5U=B :IS.XRW>C8%Y'[\LD+UM2'\;FK44;1/34CN
MX:MI4FN?H'>V6T+I-_;&%*;H%;X(]+8^K59O2SDZ@5/4'?JWXC1[T3X:J[LI
M?$=%GY+*UHMB1T&.F7B2![KU:SYCFD//XT(2%&=#3;>^)\'H]5+H7MF(!$'8
M8EV$:%5)DRK"XFR:XU"&@'XZC_321Y"A- M?-S^W*D^9Q\ TFA4M$6U( [8=
M:Z=*N*=_3,^$4L)JN00R__NPODUJ3<O).+?G=O;"X ]]FQ45H[\TBZWD"Q";
ME(9CX8<[]V==!5FL4C\8=^Y]V>YM:\&UGKC&)5>,EGB\BV%71Y>JJ3[V\V B
MK^OK9Z,LK7G5:UOJ3=,HJM#$?A=$NP5Y?T-(^T'<VO9KWA5L3<8]0XFC]&YH
MX.>9LCU46XKQ^]+2:6LW+/_%H)WF/_ +^=:0Q0PK8,DO%H+*, G&T05_Q\#H
MUU;)QM?HWG_64Z%:M_O6+143!D"D=Z:%FVE9(VFZTVV6%KSOY]/I_4.GQI&5
MZZV&Q^!C<#&XC+NFB41OI-)NEBC<T*>NI(-IFZ'3AYX+4G@1MHF=7(7F0E-@
M\;/S?#=.B.9F^-!9@9L-??697XB &!(B%J:SG]-/H!P&.H:%9Y:QNNEX<BT9
M=*;MB1_;H*UD#EFH7[3/3POJC"6*EK RW)3FF1]JFI5!^%,6%WD294<55Z8A
M(";&\+-&+CBFJQ>3]K)7J\QKEY0>OA.WC-P2BE%=4M)/'L*6>.WI<*%ZZWBG
M4IY]7D7J1O[I('W2%1\K<0W(',NQ4K"*B+)I9&.4&DE_8RY00XD(_:40*#?A
M&3KU8JYE<6&^E?[=TF.1BK%\T3!D2HY33B]&W?YX$CXY,\F.9O@F+1.5L>!P
M5T =6OQ:=OVKE;"G3N0+7J6PY>5,ZJ7\'.$3H2#U-N3?Z*D\I?6?#Y[2&W<!
M_,_S<P2'SO)KS1;ZN]@^@5ED1L2\GTG%$W838C+P+TONBQH8A4,#]S+]-+\L
M2A_;Y,C3'-#87(P6W*77*W/U)&>E?9@**1NNDE2AJP&H!_:#5(I*^+#['M.@
M'T8CC^3 HI604(SAE.A81H13&N!AW/I(>[MZ@ZPRIW @"ZGM:E3>4: D70:E
MO[P?%5U4QN^_[5)B&S/G%68D]*$>XQJ6Q_&--LS3KZ/M'@90ZQOQ-5[]GE<]
M^7YN'Q)_DM^3^_@*/-.>O:JM602^-8Q,J!C3EIV[75C>6*EE7*1115GDR&0B
M:TBN1R(QL[O@1,0MM*2420%_^6[RL+[(RX_8<(G<_]&P N$,EXO1W"WNGOW^
M=JM&?VMF#Z5(43V/O91JI>4.68QS9K&ZL9C_!VRJ!B)_ (\Q3TK;M/WQ]\#J
MYC7 8V(JU&?"=?%#8#=ZVGN2^LZJMR>2)!SD7.4F8 $ :[S :(QZEP.$5,B8
M4DBKV%Y:+AP5TSK9UF3"R<P1;;"S8INFOM5.(9ZT?8>/(-UNGNVQCR!L$</Z
ML'X3EG_[J9-5<OG460&G#:Z_*SN8&>\E%5_0\ R@^<M\76:+S4Y JC$[.(63
MN(W,;K%SX"7+2=RZ]"\;<M2 $J#2$7#;!ZG+*"BS/G=;NR*FIE1A,J^*UB)'
M4SA=_961AJRDBK:L@+JLN\;0I)%*">11*M[::WD(_A"K97A6-CK_-#NHFD(C
MX\/E^'V4/ :.,/YZK(@J7@5:"LU<&3T7A*SG>^)2/E!I'@C5\L$=D9AWP\-7
MR8AFS>WZKUG;G9V5M;9?YVBH].^F:!;SW'[VRXZWBI0]V[W$)6270D<XCF,[
M$F:Y6*HU:)JW4'-;W7;:!8E&PJ>E@"C&Z=Q1+)^K#URWBYG^/C+ B9,MJ\?P
M9WIO;7T-AX#Z6\CA"[$_V*ZP,Z]K@.&)QI+"-V3^4O\>U;I,E,,.:!0O[:5-
MU]E,OAK]]_.9^ FGC\53JTCC:X#(;8UT5U)6 >!;N.P<NT"JJJ0JQ$_!<'+J
M<H8JDX%&#CY)RJ[N-W[;ATCM?<8"FOPR46KKX <O]%^".%_8SH0%.566J/Y-
M(8QSYJCWUN8P/@BGBQ5< ?GQ_A8)PZ[:$J1:"[+;=L4Z?OL4:/@-[Z3E=4O)
M*6 1"]\O=1<14Z'M_-%R>[5D%>7&;WF*[Z;?6H8_2*4EKT-2>:+N2EDQEM/Y
M&<S\0&OHL%>:]K#_89:5HMTD4Y?W]"M_;92R8H(VTW[.9YDCN"PH3L)PL4V(
MX S9<N(<R@(@AV:_[#^5\:-0GZ7+6E?OLCV5]&:W+-FCBE]U\.%GDT4:CUX#
M_$<KOUS-5<Z2T4^%?N!??[\W"M2)N*/FVB2@V:IWA[$4&?%EETDUW2%GDEN/
MM;3X"1-YXJ=4]0<.?FXJ,4NY.GZ",&]-B,8;F#NS]JMR4LM((8>PO7'N1&LR
M(4"F$HG$+Z3$AN'Z".>1?XG5:/'7[.#L0(5[X/A<E&645<EIA+X6CB:?6\N:
MTF061A?:5+YUM7_)<MYEHJ.HT6T,,Q48,W>B;66D\:=EH"%J&[1&KQ\,RBG<
M&^*GD@FPBPLJ?N=(,^VTI',[GRW6TRX#S<L#9;5!QE4#VO3?&$P?#XO%)(^_
M&2O^NB.>,/TST_.)0,FV&T']+9Q3P.]>1L%V5H-/QIO<V^^<6?+)M;)'4$EV
MU(F?K?-#?SUKK7GY]RK^<CV?+\L]0%,B]ZX,F[F1X&/@2R@5+;C64,UBAW:(
M+]?A=C@<<$-NQE!BZ:>F\9T*OIBW"SZN"I/LTW$^/"DW-/K5H3Y.5F1"[N"
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M]7@\_O=B/\;J9"'U(:KQG+.#\82JF;&)$X6 UH%IF6+4,+L3GX"6+3C2E:H
M_\?F8G0(2%=><#=TMX5=@-48.'CU_%] XSKGNFR03',V3],*)5B1.Q+70$@
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M'!$D/6D1N24I5HU#/3G.HME-Z2%=[$J[HPJK)C:SLXZD2G4<CCEDJ8".<[3
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M(4A!KFKB#<UTPEP,TIP:%I /Q4OT:XA>-28#IH[$U5?&B3BG^_^OS.J^<Z/
M!ZJ1ZLQ0>D:J%)T'!' E3HD;+H*CTMFK,=_!1\=M/.1U^:L&&6)O)=%G,F&@
MOP!7/?- )-LLUZ?34V%M+X+.98S-MYYV%=4//#G#)1>9/#.%R\V6[U<"IP=#
M$A1A-D8PL#R\I%)'6LBB:\G-A<P?4-?.J10S4QMUH>#%*7P%5@,-7LNIR^U/
MT?J8*01I<!"#8IT%;I5<OM/=0*F&*"8_(:Y<0PZWI>G &NB\2*+XV H[P*Y)
MMO!NEN1U!<G"FRS[!B;RQ:UUF[I;.Z%[]('4)!Z>-W0+8=FVG&1Y?W3PK\*
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M+CQZ?.M$4_\ADH"W\-END%79))[I)I5QNF;2?4;9QXPPCUL?*2VZ+NI/W2@
M5IC7Z<UX69.*1,+:0<(6<'YLV,N3@^&%HU7N>8-550B$IMA)-82$L_9)7 @?
MX[ZVOVNIQ:(F!<G,&RH/V:1;H%\HMYYQ<FAR_Q36$3F\^@(S?7BR=M<0H^_I
M]^6*Q,-K]^8-P'7Q<_^:!AK)QM83NY\K=<W"VCF_$MJ]_P*:K?U._QMKQ7M
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M=9ER'_.-/!5E _V?-^*/L]O)%7W/Y"Z=I)QQ+>\_YSO(MS+(4>BX6]*Y>;N
MI5@@V&].)H:UX;?*O/P,,OFDT2K[=FSL<ZWQLF-[REZ>+=&:U<$>?O]Z5?5!
MA+3^I.Y20QW^>Z?>B<S,M,Z0X(4\8V56G1I>X>/SYX^M']I$ D]=*,$%%;&R
M5*' +!5> AG:%J=Q<=K*Q:Y5N6;I0]OK6;75()5PAU)W? 1?1P:[']KO"&R
M@LBWRZZ3F#^?[391_BSW)_[' *LNPT5:87 VB6C@0+IB'CJ0N+ZP:WY(;3M8
M\F6#<G+1'?+K).=K"-;9=U#)9Z\178Z=C8]J7;H:?^-''[<'LU653*OS%JBV
MV,EWG0'*KS<WI)F^5EMKT](98QU-<<1AH8=S;0#PV+1N2<?BA)Y>U/:/E%:7
MUE>_F0'FQ1;KB,LOZ_X"3IH7_A.30F[\>B+N-^-QR\5I+B,QPI>W,O<M66;?
M'/9[6.UYO1MAW."A+\7PB =X?6'FT8R,42E'+5M&QUC$"D[E#'(V#C8>L?!(
MI']F$CM-Q2GI3XOJ915+ACL0A]U+^ZFURPNM6Y&K)G,G9P]S[UQM_XG4Q2$+
MD4Q!RTDMW;\ 4W%C?._3"#YSJW4RE$[YVHILO<-B>3=5,$=V731Z0B_Z>)HE
MW\D&1&SJ3UW-?G!TWMEY8WX>.C%:G>!V"06N/+@B<?WJE=CJI%FU<.?/^#_/
M:H/17E3G*,?[Z"(8O/<!$.JP(UT._DQZE%2L?*9*@QLX?_40\V6!YU="BN-A
ME@30SCZ=(E%'.=ZIUK-7D-^DWW.QQL$8@?V-<8>*#:<#U #^3;T*Z=Q1+%^7
M2FD5TP7FSQ]SQD"X+?;.A%>M]E=M4_05<!!ML:2PJGH#X=WB<[9)+8BWKFYW
M75ZXQJ)*8F@.@X@G4.)$QD+-.'&&NX1D/,GVU9Z3U[T)()&?P%X[SC^YV'.<
MM0P=!]%(*_O=6W82(B<YKYL;FB .>M7:;L\,0G_?$=DZRS8G:+5X]ZOZAIDE
MEDX=C^QPZUHK+$K@!'5T&RG;##R/WO]H-1SIHT:"V2NB1ZC>IQ,-+/)TH%4W
MAAOT.X*2PT*+4U4_0+!N-V Q:^,>$MU7OD0=U)SYV(+'?2I)N6'P>7JNJ"T,
MCSFB]G"&@4K.Y2I--_.*WUQ)7ARNV XCJNX/7FT)5LRR-,<*_4)QLGJF<:0%
MR^B;=TCA;I^K0/_&$HML1E^LZSGPH^31CNE-DE0T/#XT1"CS16FV_T2;\H'I
MPOK]>3O4R_2U<IW=@M+-2ZVM"VOFKVZ!'N(8^2UU_.=Y_KXEU)DWF7V_=: U
MH6V?$G]?[TI\]-9E?EO%^T/BGE1]N!UH])B^7;"NC$9FJD%D5E2F?C]!ALZ-
M-C].7.!V3M/F%.-G=Z!9YA%_ 0KX[.L1+23U^FZA/5DT/Y/P=%4BFJ-X$34N
M&YGXF72C>QK#"3_=\T;/=:C8OC1BJ!PK^)EM>!_YV*>QZ)YB?F2U56:19YE_
M2VSYBQ=-MG0F"\044!1*D+D2E3GQD<'?52(;PSYJO#&6VA^]2J0H.I^V<?^/
M6$IQN^[T,#XL9*/\1W2)#<PZZFK.Q/-K0?5A]<>:VZN-):7*,%CM:G"4:EL"
M\G.K6?;'3SF7ZF)(?5E/@G61M$ VW[.GQE77X9JHD&34?O!_BJ5!X<$W\M^\
M#AQ<,Z<#>2)*/H"C/2:AU\QC83>%C6I/F+V/E(-2S+9<#KN@[_3!"J6GM"?]
MG4H01&.JEBX#K;E712 #CRBEN7W(0#KPM3163,*Y%\5803+>QSD_HSCDX7TA
MALOB'%DW8B!$<*@VE_YN<,QP31L66""K(WO@09K6QED2=[^YJ:JOG&V/G)/=
MQ!4=5W@G'N$=-#S)7O*(<JUSO=K4W8[OBSE!O'/E,-]+6#I>Q+E&2PW]\#2H
M95=&H6FFQ=Q,.?K ^19E$LOCX=7_)4=8]SZGA5Z/V*"JT$'=S3QP6+Q=Z(T[
M#Y/\EA[,2IZ*<M^A_D@?;1M6>#@+@@44$WP<.D^?".U>:VEX#WN^G[)$\N]X
M?0-;UZ'?L.7H00'QV=D91.K*A/.KL/$X]O:!I 'Z=GC87T#]V6GI'^06LP'A
MI-:\I/!&:,AW59DW7NL<KO]P3/_%:[%\J-GCTRDPI5Q['QWQWZR3N&B[7I^+
M$*C4M5?XJ 'W>?2#7-XY>@0CMG)L(\ZW[4HBJ>(8]0H>LMS'8U3YGBK5079X
M*V)\O.8B96_(?Q6R?]1\"+Y>>C'QD_S@QNS/U8^0L'O(SH#]UEXI. S7]EP7
MWM^ER(77HCJ?@BT&3D@YC;C%]^E_Y8[W15N\)P6O+?^4CYHOB_O&^FBBXE)T
MD1[J=)GL00?!7_&K=IY43@WJGHLN>$\PP,U[->GIA+NXLS^^+F0W&SX>Y['8
M5,)<[/-[*V]_UC]BM0R>?JRJO#91%5-Y9[%7V/+*5RY>[4/(JS+J"=.8- \#
M);<"8_\;#O]%_8[D1@R4&?E60=#V0S_IU2U>I@7N;Z;XIRZ>/C%83UJV8,Y$
MK<U7>ZG^BG4I"ON(>.6K?_YD+-2R_/H17GV"GV=39^E/V6OA^&J!,*(^;&@"
M-)FBM,]\@$>7YO(=_O,M?1KSI-:X85Q_Z$MUP\WLQOB!SY,U<[LJ=9W%?0:@
MB[-#"?N+*ZMS0/J#1$F,M.1BAR#;;.(5YQ5,,A<9<FHBB[>2]0RJ7KF_&2Y9
M:>4@FLS5!N8=S,C-;LYVZ&95KV!)^>*Q)GV-%K6;](WL=#W62)<AYAN@)H$5
M?A)Z%*R13_Z/E3U)+B  F,L4K@J16=)=B'F+'XU+R"#U#M0&@KO&%?CSM6V]
MWWYOO0KX7Y@J>Z)UZAGV%15QH4EY1+A0;U".J_NX%LF-&E(FOX"B;4?^IQS*
MK_8U71OVK3H^*Y4P+[LG2="^\);YTEFKX6W :]:=M<5[G\\#L",^$,BPAOBU
M0K?K%T#-I4V^Q@-KT+:/IC,D]ZM(7N0O:>AB5V]>@%<K@?1<*;J=M#XNJ:3G
M]^A+[,GM"Z\Y90M=<*>H9=B9#[T,RP^$_H@*ZE-+\#F7E>*Z)G4;)]5P.GBX
MA,C(^TD-=+WAQ*F/BOAR*7'];:S,SX^_\CJ=/EZJDX^<>YDP57YF*-_D=#+\
MWN<LEN"E:@/4+S(!_?R'4,?281/7^L&OZ>)\J >BM:U=V;?-X]_5]0NAURL6
MS+A)#C?J';7@_"8T;AG5X"Z5'5 ^<GH]// L?OM#IVG<R9%I^](PF6A4Z4%+
M6VQQ?@>6ZULQ);5UY,6WS2)ZY'U3Z?46;G_W1F;1@Y5)-)A2IO,'.KEE/?(:
MRV&^UWL.G6YZKG(%C9# 9JR(0: %P.0:5 B[N0R\ENIU7W_*_-9#7.MR2PC^
M4:#0*W+;*TIDD^?PW_6JY4!K]X4F]UG0\\FP 5H/<$A9@8QT-6R&$M2'Z"%*
M/.&=V0;81Y6X4,^NX=W6^EH]6^7_TDQ?)J_4T5MG#" +#]UEQPBSOZO)58=R
M<5+0X3E1<7VNA)H2D$=(5N#[,7VON'\F&W2&L#]<>N6IY[E1A9HU5@O+VI9T
M1FL+XHHO[IH'?&UK?F7=YA?YJ5WZ]I7.G\O3<4? /TCSN)(77W,QS7/[;9\.
MFQX@:S%-*E'F]G?,)0^D)^=!@R/=!"&4!O43[CF&X^7[JH[_"5(+._A\6>E@
MH<C;$W$X*TPI-=<"H\MKX"3HZ SU.F2B#82T#L9IOQ+4&=1P+ZVP<5PV/[/O
M6VIII7W!-=%3JQ)WBC@2@W,I*K?=6_Q&;7JN'0.U7Y[OOE+2I=SJ7H<-)+?0
M3G!X]?8!M],I=68)LK%."1.K_==:2U-V/R=X;U XC3W86FD_ 2_;[..#@INS
MX;Y3=QV:__TR&?*V? 9ZFC"SZ$*7-E7:TELM5U'0,>&!WQ,]&S#;4NW>+V^T
M3$UCQV@RM>[>=G;U'S-C0@4Q1][G'3FN/5,:^=3\\3&M%R^/\,JMZA<P6+1?
MB^L#@>YK["K0G&=0DLE\=\2_V Q9=8/O%>[U" +KU*WV$72,-A3:=18D/KOH
MHY@RHZ;+6Y\ONE+;%HBZ?Y1%&&VHQ'U XJ%#%\'IF59!2OK;T#7>Y;O],XNM
M14Z)$6Z$D_6G+D8GM9-IY5US=,]$:_>5P2<#,X('%Q[I_TZ8>1L/7 7QSN(6
MUK\T_CX]-SCB2;'NMH@)F^0AY3K&#Z#2PR1QP=A)?WW.*X-QNPG\BW#SC-?)
M8XF=J\^,.HAI?-TIV<:?U\0"9W$"'JFN385[>:#N]8P)1BPY\/QL/D6FA'7!
ME07$SD-5SAB/Q;C=\5J+X$;R.R+TKV5 3LZY-4#%/!SJ_#M9@9TN@H[:"SK/
MPSTWK!.> *G$R"E6I;[(0QQ$8K4& 96M/W2?\4>R&<)?3]R+^Q2>_K5GDR9Y
MDM^61F?:>];>JPQ<SUSXOFT2%^W2TEVM-L@%03"K]B&AR%0]#H5KH(^K<+O5
MME:K.Q/UD]K8@W/TBE.#G6P@\*IUJ_U*RU)J)RZ9K69ZW4AK;IW+H[YO[9S5
M<GK[3_^"YRD6K&)WXN1V3W7>#.5T/")FO-J)',S#3>P+E*&'T,+>5NMSP6KF
M2OO<5UEL LS-KIW%RCWQPE.;,6E8%<.&] W9.M"]^' )GH+64TFE*4G?NYPX
M8$D<KOT:3MN28Z6!D]L*+6Q1Z,Q#7\*+&MQ-A\VT']>,H_9/M_2N_(A*Z?B=
M.M__Y=CE&TH/$V#5$ EF*+7:R"M''J= 86TF7^'B5G5PO:/-K[4;FLAAC5=C
MV.]5N(YCM;&7.Z-0&/UI)=,##X26LI'UY2>T9EM53/Q:*[Y?X;S5XGM];KTY
MTZ+MCL=0ZHZUXUQYE6=782\3[PKYO1R<9.M"I-[_ZXO!?!'#-;H;Q(4ENTC5
M.I]O_J'!:YGGS,>4U<K7A@U&KE,JJ$PB4K(6)X5.0"A-^/=WD39[^M3^78MJ
M'6A=WNI=ZU!0DC8 AFN9<"9EOC\_55"X)J7"XU]1=3%KO2ZM5EOE*76@ X&/
ME4C$XA-\C>Y&J3_V_[/O[9]3D:U!-E\C@K8UWLYE%D7-7HVYT[<OWC/,D_"Q
M2;X"6Q-[]8W3]XFW1R=OXK;GVTUCCL[70;CN]%#@T?1"+;-*!P)(%P&FVE;!
M)(1A^60>U%/YYU;F/RE0O-J%^BV:'_SD@I;M>.4'V>]%#0742$\ES\#M5T'N
M_Z3/)D=E*BC"H!(16-Q,)3$4:^MA_P2;Z:UW@F,Q[[Y8M7T'U[OASO80<=\O
M:9HYJQJVJ.HW 7ILUO4V-F#HR]0G^QRJ(1E+=[1E-5!<-=T0AHLMDD]'K-[0
M@>ON'V:_?I8;6J;G1KJ7AT5%ZI>Y#29N54^5]RGTO-=M^QB*G+6J]KIO7U0T
MX38*R>>=J-9E-_#N"'$RC7KQSUZ_.#;K$=WM$1$Y+:FG53@!5>#ME3AK#\H#
M]1M3-:W^2(V(K(5E)9_$[4)O[.-S>H^@,XOSQL]7647F'6Y7XY!]YU?*3T X
MWMKZTMR$ON G!S@K6;MX+>K^_6Z,FB?<LT0A'#9$KW68D#LZ#$F8("_&XY/3
M='J?&D#%X^LL?1AC8 T/N,%G\(6PW#F-2JG2*KW._LJFWD<1K(N=I^?GF$;G
MHC4ZPQZ?"VI]'Z5[@(/DC:/F_@**H*+5>#:VA:&CQSA O"-YO'9\\@HC0;O=
MY/6X\PHR7"VKRPJOZ/[F]1BS.#*O>]<K[<I-I6'U3"C7M^M1(S5RF/?U@M;,
M; NQI58K<:CJ&D6/;4L/R]@L7 7C/IW&X&0BW+>9W59KW-"$=N_BD"'1Q>KU
M/,Q\Y#S[D_]>C!UY^:@35'OHD8+O(\TKL1(2.A",5C#AJ:M7,LQ4<\^MNE9Y
M;Q8:]:/^]>QO^L]#NB''"-D%74FX'/RSPK/Y9V=EA_]UL"F6NJ7AWPMEZ%W"
M>RAJ)D">?5P,A\?QJ/[CMIP',*U3(>0[];3-7;(YCI<]=)]P9J/JU=0+.PA#
MZ'*DDJV+!1_$XN9O.2>G]L5(<G#8 *HG1$D:CL3EWV,)HNB-?L/H((FDB=DH
MQ[[SN-7,1]5X\_] ;Q-JDF<^%YU=O'MSXRUV89<ZV'7<4$&Y\#P7KYX&)%NY
M!_,<,]A4R?Q.*_N\JRAJU..=7-:6%')6ZTW7(NKM>/?:Y,CSC>FRE#PGF15+
M%E<W75)4%J:MH.(X0B)0U'3VC.CUN;#OZ6NO@]R<]9C*=.=JUU-?UOZ?D(ND
MG>B3EF?U_<9HS3=<NUR:1T7ET=KC^[@F.Y6CG$Q0GFGU%JTZZ8]H9U+PKW&8
M]P.$CWD*VA]<CIN+0,]CNRXGI L_;).4O-$SKY,KOZJW/$:V;KST/+96;U*8
M_3B*YT[*/'P5]D')],9%Y;L#Z)85;(B%G=M1J@[5,E_[K(AB-B&9L2:+/O47
M$+_J97/?;1#P(9XXE(U/=N:M"J_Y569#8W%2-O,;DZT=I.:J .-/.>&SN@3]
MW4>1L[&A,V6R1\Z%.N60W:0\$-R+DT3*4,!C :_0!\<N4.*,2)N"E1%8"@((
M1 KK]'%333RDO*-NK\ *2P'33($M;CAM.9SN)#"=PZV>84KIK> PUUR:?&9*
MVYT0;6:=5*F?T\L7MX*O!R52O6P8?C8F%*PMG5MGKWN7[@4S9O(I(5.05BUP
M^IR9M]13EOZVI(%H@1,SZDVI7MZ1SF".A0'MP\7J1$O%$\^)@D88 H%MT3C-
MP+$FN!9UNNYLDM<8$+B4VK8@#S?E5U]VK_8Z.N/)A[WP]Z [79EU>7\9Z+6<
M-Q[G1;XPX>;I6#V4AIS4K;-Z290H;'VDZA _MO:V Y]8V/66:C/V\79<9T.3
MB2NS2 DJ^7,2@89B#Q K77!E#'F[)6QH]]ZI KPD&<[^I217S $7+G%D\BP8
M?O1>$C+3-&SL4,-SNKI-Y:*!;EO,J79KJ7+KHOWY2W?KU*NQF<X)PX_H)NEA
M5(%DQI@X4G=_'58D@&R+6"'6HF'ZY6JYU=OZ?>&5!TBI[>W>NI9.Z#;4>O/"
MTG4G=>SX_48OF@7L(IL71B0(+H^5P#05( /:*<[5FW0"7H+I*FU@BO'N834C
M;Q.C8S\VC!=%HKL6(W==,]H;/_PLY:GK*W&KSUWDT#CUT)HM($7.34GU_WAR
M[W"VW_][/%5:HQ.AJHH6)6K/4JU=8I-$[4V-Q*:5*D6HJ+VIO6+/#(*6%K7W
M3$)KM4:BI6BI]J>O]^?WO9+GG<?]1ZY<UWW.?1[G/,*<A(-LH.6J%0S:J/M%
M1R#4$3#5KS?GH=;@Q3!XH#>9);VQI_QH9D7M<JB4;L!,795M<:@@ZT*\*?H,
M?5VM9&YU^99W=BOB.@WJ(7B:G(7R-RW,V0\U>$S^ OP:;9-;%;-%R!<L?&3(
MUE7EGQU;/B$NB8[5=O>PHDDQB<(JP]1++.1B"@3::5+'8ZZE4[68IU/K5L&?
M.(;Q6!Z&U6^(&JM+5<NQF[20QH%7M:Y<9*T JIMFR@Y!_33-?:>@CT,\?'6U
MH'=8("E5Z6Q X)1'>%J-B.;$&>"5,EXU$19U$QZP"'O(.Q86&TEF=T,@V%BD
M\M&D2=3-+#MP"75ZXDKKV;&<P*F(WLTV]27D/E!MF)-A.J^ZQ87DX$4<?PL?
M@<;E"OFH:(]L3$5! ?SN$3"HOH@@^ AE^\HFH%*V6A\;-H8+[KI 8[*$H<5-
M@GH>DT76E=4G:A\9[GH9!#W/F0^NT*X%O1/0#R@'3:M DL[H%:;#D/KO+'4*
M=['"1:&85WVVW+D=)1_F+!HI@WU92]_%O_EX-\:7D'''*#2G"!AT;Y-9*/!"
MX0^,.7RFXF*(MN:X*)?!Q IJ#>F?)4F^<7;M@7^J;/>W6N)E!+:&XR]@E[0P
M>]NU<MKJIFF\5U A:B6=V<,)\9*C:FK"LE77PE?]"JTMU?"[;<J319"&YV92
M6+Z<@>C"%1$;]RHVI-:MN![FTUX :.DHDE+_ FXEV625Y?1^.NB(;F]$A/B%
MHHA4W.>YO=<>N6@] Z58$U%5 QG]1S79Z?QJGN6 ZMO@3W0OUO,LAQ=A#&5=
MNE%MI0YK97%'%M'3)''=2@W9KFHGKI/B$Q/B@/0FB]A'%LL-$1$P&,T<#S85
MRJG4NHZYPIH>O5]E$KV3A*D1-C<8!7K[:ENT?,J8?V$6 VM>.X@C!6&3&K 1
MPA/&$>$EF@SL(]EU9I9T'!%I0J5F56TNS4VORO^@4UI,,;DS0@/KF3_CO_!4
M>Y*_7/1H[E1XBKZ4@C%K5H)"DGCNHJ'3AB#EJ9D-IN=JQ_6F(HJ8RS4).2.E
M::VW6&E5L HH&V] 63KQ<?@78ZHKFW$27I#!,.4VS;1T A-2U<:8V/%&<&+J
MQ880R'P:D995L\$OXN-BVC:5+EX,\:SI3G.^ 43'@DLPX1YT'E!=Y@?%586
M)GJAY"NEZ6=5 T*8(2&/*B9-@1,P#WF^ZQXI&XP5FH)";Y9+4QF+TR+E@$+&
M+?OTLIOH6.AMW34//:=0J*!5T_5 AO,7R>/!'JZ?N48F+"4@!8Y<+\YMCN:1
MELP]OK/8*!6FU#48Z8J QR< .ANH2A.#@21+9^UPW&IQBVE;>:%/-"T5,=_7
MVA,ZLHU><_+:NQ^*MU"V:N( 69LRUS%>D1#1K7U:RK?H7GY.-3W=N;*"=YH]
MD]LWTW*>@L,+-:X^Q5DOYUJ[$3D#%HVI#L'KQ!0K*.1<8#JC/;:[%F1L4U,.
MDA&)&?[S.D''<&O,1MMV@I30T;,=O/8PC$OOM5Y+/*X<#?%BO^).RN9WZ(@'
M.N;+H@0^I\VDH@2-)0&86KR[)12G9U*+!5F:8TNUX/5^0"N$K1!GI'(Q$-U>
M\&.KI>)G7TLZ-)7 GC>.-N0QA7+GF5T+A<ZV44-!$)\O*KQPBEB-#24('^EZ
M'&@:_UU7N+U?ME[7^(];Z40KJD<Y1\C.U%CC@YB>KX%DI@[(X..DJ03[U!.*
M>C%JZ'I8,+A*G$/^D'Z1Z-2^QM@!&\4E]\ID+^RZOC90PMC(HD2$=<W21E+&
M"'7T$U'\@GK&I0=5@)#4BP@5]<AWCLTA<N,ONN>L-URXG6E#Z\.$'2J0BL<E
MNF.#TOLLW?33A._E)!N(&%AD:<F TH8%<Q;,Y.AEGY?F2%2*0>?Q_D9\[^8H
M*7^Z4AQHOI0I=PNX=\!6&;&[I0@*,5W6PVRH!(J:50/&9:?'LD"6]E!(N@T8
M:EFM:5;5!+6J%*F>!,+*RM.=7V[^J&FU7*$QG:_4XQ-@^"B.AXCFB*9UV8WE
M?*F$#G2W9;)@C",^5:K8TS6@*MWYID2,'^>BF\W+"^M.XY"@E'%@9!%?6E6A
MJH%FU84)>F$FAI$REYM17.APOLE*R0@4D)_91K,?G.* N,+/P@RU[)!,1S''
MTF-^]"@ GV1PV;@V>@^29F7SL7YQU/CTWGRU!J!TUL<&ZLC"./K+P38ZGN4U
MNDY'5.&*T\[&C[@RR?K5/JAGRFET =PZ:.&8[X#U<0UPDWG@*F5E;SD[90N/
M1A<?W)C8T,.];KX=]G*68&YM$K3:]UL=O:%L<LPIQ_9;#RLB?P=TECN@6>_Z
MTU=.3]I;3/WSYNMZ]U\3VK5XB,5C9N]9TR"])P*YU_3%Y^@577-</U%$# ;J
MU?U<1A04"W '3,/Q?>X/S(ZQSDOO#TBX3U,E"?55>:F0A;%T#K@[QAAO*NSI
M4EBXQ.M5^,:E)34.E[BA),<JB1NT_";?7(L?_J!, GL:&#27GLUK5HU1=DQ_
MGU>+>56/W<^\A)MI<K!ZOIZ"<<0+>3;3'FPY7418=728"^&MH,M;YD>6'>R3
MC??RD%8-(M+!.K7-Q66F070>;0SBUK<8NIMT6J'6MSZ;A@T"A:VG9W*_J[FG
M<"E\5$H8GF-+6\08%\\D!OU$U774)E@]7Q#;Q=N9:><I?ZOD[8]P)V/8#%=T
M1'H&4@H[MF3MBB3Q+?UR[VZM5C&YA6[HW8_(Z4;\2+^<BWW&/&]N,>2JS$)0
MUF_G#LI>LFTB,#<>WK*M8C+H8HHBJK\+885LYCVM4=.I-4WQ4+9TJ(YZ[YF&
M4IB:R45U$*?6<KT1;1/ YC=,(V)M')XG\ISCE@649'9/H5)(58Z+.+/[> U[
MVJS:2]N<?A^1:MIJ%4)DVN 14WG!XZN;(P55K%J06MF9E*KI" CH!W-"=QK>
M7L!\$T5(8C8QK?Y1:BZ,4MH4J@1?-+47%LAI!@++0!1W3%.$=6GW%E_*U]'9
M*Q72O 'TL+J(*',69L8-\(9@H,V$NCG,72)"M8X?T:?CR]>V8:E7RB<R)J(Q
MS'[T1N2$G_>9FI8YLRX:SYZ">*49)JKKVO%.Z.+8*YMY%?4?#7 N4K0;^V 6
MY>;GQ_M-XZY+[>*CR \*81R##;_W?EE&  ,MA G3F4NS0GGF#&#,NNYQ>KJ<
M7P-\U.VW3$Y$G'*J;RQB??OS5&* U<SZ4II,JTL"]Z<_>;(.GB:>$5\E32_>
MORIJ<(.+[P*;]L_'FW]>EZ=?L$7;/[9BK^O7N7Z -EZ>5BT+^I;>[JG#/.5>
MSLL/()K>\7_.*B'N=,NO.&_$#T(Z?B$3UK*4F/9G=]8<0E5^9A/@[E3/R*&T
M)=(TQ1*M I!Y#)&%RER<2M-P3!$I3D:S5V9=(/$)D7/>66ZDQ6D!!8.NGP,Y
ML3.;OS*UJ(WA-VX_#?Q69^% ^65TCP&^U+%SGM]8?JE0F62!)CXIY,2?$>HD
M253A2&)GD/X6GK5XJ#H4#_QBQ5"3!6.RT*YCL;AJ?M$OR?<\$V//FVO^:(+Z
MIM/.6-N%.EDHCAOK3_IB]RO8A9%"W;%=,S&\_:0B4-T:A1YQ9U?RER#6H/X"
M[MCJ$F;1P==;T@TWZ\HH$!BQ7PJV(UNU SDWS[JAH=\!-'NEJ)";+^+LZ=A$
MZ\C&DB[2$B\1F]OA?XR>MBY?W&7'O'[)5_Z#HV4Q*4+B"3]GE:E"(S-Q_\XO
MKBY"7;8!K99N5@3\N5/]S#LIR];J :)N-,2-(C_T%Z!KK1R\U.,&-7FA;]PQ
M85P=4 Y!? 0S4 #<3<Z(CU\Y!>@%]X&/=E^!IWV _)P"IFA\0$H<2A"H4LST
M-*DJDSVK],\K V13R/! 3LFO@-*Z+7T^._8RT&X2R/9*E=W@)-@$>>;A8!D4
M9#,Y^_M#VO+7E!R%EV!1VX@)8M&F#46D/+<8PODL36B;(R<S2H#[G658AH&P
M0DLET-L#O&D;ZIP[_F/63PCX5 OD3HP +3+K=*3SFPMF_7&'/-KSO%4V4C50
M,'M&HCJ%9U;J4!RBAU[C:S,]<=-C+M[0%>-A^^TY)Y^)CFIN-8L[!R40OG4B
MQ+=7O<A.]3>F_B37-!I=J#04<< "F;JJKE5$SD0Y %T>,5A^O@;T:;MVR[6&
MLW"LVQ2CR"KTYNHM80==_=N,Q81K!M<]2F+' 4YI[M5'+\)?.JH^[#$[H__D
MC$FM *@6)-!J(-MGHQ@(2S;K8_^@%*3Z] ?CB\/2^WZ,SU='MFP]VHF,%:GW
M30R7VS9+MI%A\ODGG6;'_0\JS>]U;='?OEG-[^A7]:J)*!SG_ZUI?%S']5 [
MD[X?^RY@'#EEV:H#MA,**+C*SF.@6R7D 7"?+F](F[RB=8O3\$VDI=X9+!]'
M5Q.ZUH#]8GP-RUF=^M<M&."K%DMSU#BH,LK,1%&0[X:]R0D@70A'NE1%]-7O
M"<65WL+-%U:5STTFD_C,S+U,^:TLE?+@?DE8>+QJ#M$!TD4"H5'PY+S0QJI4
M,[A'&@^Q)FV*%++.B0\<>TCZ<M6,+@ #8UP5*F?_IF4M-L8[<2E*E#5([[76
M=N7RSH868>DNMB9O #&==\_(ESLW53KTB<^?#F71#]UBXDEE))N4:*,SF&$R
MQZAZFVT@8)4>$FQXT5RSJ@0+Z@@602>02W&=]XL[BI9^(R^6/")0WU0;$>#=
M?7@>&B\VZ^!V>N@:%.U-YF-!^82EUM$53/-9BPK4GCCJ'?+<VO[T:'=:$[3_
MN/I7R!AQ6#-JT5/=^Q)[F:VG661@0),X0B!S7[?:MRZ=)?VI B=S8H=?"C&R
M+-DG %PP*UF! .BU;0IUF)PC)L$V)OJMTB]#YQ@,T\P,NE\6?U,M_YFLNR%W
MO4VRW+!-X[S'2WB 0U!F-$/1L@-'#!KUF,((DU_M^T$JOAK7BH'&MC%K"Z^F
M?YZ>9NI^(R+[S5S[TI7/#->4$UH^30L:G7F015I[1SKJ%:8N?ZS [T=@J)NO
M[P!D%)GH\NE"W*D_'Y?@-YD-EU 00W)I53Z3.J3!DJTL"E]:\LH8 XV9*(]R
M8A=YU_OURNL@U"VOX==A%^;.>!8!N13*7TQDJA9I"9NKB9K20ZH-C*LP^I"G
M2>8^.N+Y43F'[#6S!'XZ;-^4.&^1X/0[C<$<@?75"]8($9U@7TAUFV@<RB^+
M,,.@@-<L$0@H#K[8-[G]^R3HK<^IX'X//+%9?4\7W@=3:X:DP(%F0D ZV$Q;
MZ?2FNB5TZ^)66L\=5:T["Z;/V:N\P]D+ %?]U$US,R%FK0%5>4/"@M_R3MLF
MZS<!DY"<&)K9%*CPG:6^OF;?NZ1(<$X)-;?KR5PDPE6]YF"_J\GJHZUBEP=,
MRMM8,;V]1U\L)\TG.GRF"S,M%_0'/1:TGLQ,J@) 257:('A;B#GNQ]2E!:'
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M+B"WL!SX;!-E,S3['%#W:Y:%&)A.Z1!6J,-4/Q.T&RI%9SY3;<O/P6NPM!F
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M)QNU;!5O!*\LU)KH==!F/'JJVPR7=M)$=A:'I]'(Z9;]>+%Q4MMRAF^T.>.
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MZ>D?I0Z:,9]S\)7 ;"J9.IB%AX1?O55X)M-\<GJ"<4:7+SLV6V_3>)-%Z S
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MV:V_-%B%!?J?7E2LJ%3+U1&&I#"Z2]?SI)Z9RO^6F\!4( -.[LMA5?(6@7I
M$AM>8 R?7ZEF!+-FGT&S;@(@3$K"%V([S1O2O7@9,#ES%_-S*[/)%EEN@\,-
M*_A3A_XW=T<QT,I_O1M@_U06;R,2+*1*53]B[Z.I7:<-OVF8YZ1$*=N,M3[C
M]*T?43=*:<[4(HZW;G7:1'T.XRE/ZCHNO/ @%$]O=FQQAQ%_/EL.9Z/S^A+6
M^-_%R6.)^."4K8PE4M"#=2#)]+Z_U41Q3R"$'.L/6YKP>!NMB#*":J1V,W6_
M;I =HPC[@PMZ0VFF6X[3(1%+@],+?C#<4M"SQO:>G@>>A#7>\H\:H!MC6-4P
M*7+HX=AW_O&JUQGX![HG=R#+,M[IE1S1KP2?\-8FJW7^ ER!(6N_6 ^-W?<V
MBNI_\N-IT\HNFV-T*2C#*\=BK[;L[@QU1.1+!C1'QER4D9N128J)Y2QK;DRE
M;N]N%H%^LPA!;N>?/W]4O-[I&G#\X:. >;"=9/?G*#3$5+NC=NGQ/X2CP=BD
M_<Z4Q;:,IET8M65^'TG-F+NO?'O]B-JU@&#7N)F$F-CO7\(+A2_K9R11!;'Q
MNWRRZ8NE2G_A:LI46H(5NCQAS7];27<_6OC;YF9<Q/%PA[MQ,/Y.V#>3J+Z.
M\H^[B&7W2&1>)-XWZN_7SG:9<@D=U!<_-&PH"%2\8PMYH9>&/Q><3"LB/*8L
MMOS3O/=JM,EFQS%6*6.2<C($'\,#UWO4:XM,6VC?_GK+[4G[!8 [5_/3C2\3
MO(1@BZZAX@AY[46K]L\/]M][T+ZRL_74YI<H]8>J'R51ST7G]S9\+V,65 WJ
M7EN7#T3Z+\&ZM?QS#J[F6E&MRQ;0'MVOHB!9&^H+IY@]Q?"YWP-Q3I4A;?^%
ML?SOYGK_ZG]S_>!5'UY@QD?NOPZ4>'Q7K5F538BI[YF94J[4,WK%9T>GSJ&D
M0L5%K[.^KS<#Y$B N*?5PI4Y32HBC>WLWK/*Z0J+21BRJ/BU_-,"K\E+\$J.
M_ B1>U:*T;N<8"0^+W"V+G;EU I.P=K_T<P0O/_C6(L7K(^Q%BJN/&9[[+Q
M;D.,326E1QK+Y=EZNN#X+C]NC*"HC$JAOOL(3M\T59_AX-C!:51;+1+'G>&U
MM\8?WR'\,PW!X9'I*=AELMTO0,.5WK^:,NV\%.G%\)%,]YCA;4^2I7?3D.C
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M,_I3$A-&M)<B&*PG>364AR)Z6K3=Y;;BBVLU*\4L3BF14U0E@?6CB#_OB_:
MLL)-VD!.,*E\02B:BLQH7T-K=;_Q(\<NZWC)'&@7?*)=SU@;^7O^%V"$NG\N
M/"99AQYSFWDE<L&[LW4WDEN8CDU87FI^8';H]M/'$;&KPNM!UMY>.\N]C.,T
MW+5F2#ZHPUMH35)N_ *,*6  R.YV2,+RX#O.%S_V[7609:_0"<NW1]'<RWRC
MH#O?OGNSGZ?A3/I)N(7K;/1U;STYTE@19_/NOA>8U+_0!MSE]V62ZXHMYWSQ
M53WW%7EI=J&/OHX0=:;"5Q]3BK"F[1('ODF50/HTAU+S3IL*D#XDH-2SO</9
MO+WS]?Y2D.;/XL:8EH" Z?N[.WTK[(2^Y7?4O*[.PPI$SZ:-FD:2IH]S\*JO
MD?:0>SF'UN/% S]?TI%OZ%V3Q+XP<(*H4P'POU/OO$"E4Z(C."E:$&PE_PSQ
MI0QN,#:9QW)/DKC.2N[Y562&U.R!.U+EZF-%!," BQ4I7*+:I^0HF'J&BTLJ
M!%AQYI0(+2XX7:W_(BK%4 ),:HJ)EIZB-/X4?B#X45DM7AE4#HO#AW8'E']\
M6'?P\!?@QW222;6 \'5?B]JR\)3!OSOKTZ^(AU4$V9.(9@+D5DWKC%<-D +<
MNE6J;PG>BBX4MB1V "F_8QZV,&7H;;]TSTX!T]J^H?YX&]]+O.WV'1!H]8W>
MK-Z/8L]%/7RPSIZQ,8LINPB'84X&Y4/OW40G.RJ@1_BVS]89E/=*J<^'/SSQ
MD'6_C0[JOD_3_YAO:TJN1$8W-<$4(A==_)H+E@F/2NUH>HIO/FA4.Y/%]9?:
M$.CY^L)T?>C%2-VFQAB'_%-NFVYBJ"V%:=MH,B6 XE,LBEE*TP ,2J= 5!)=
MZLOH*;Q+-9M8MVBF<3^L3]^]+Y B$70OY">O_KYI)I7??X?B20N67^K=&4AL
M9)?CP.KST2C2JYSL$6(<@E*W%[KX,**FQ2P<EV3-X+,%(A^*>:09*7O]?RMT
M QL2X%MYUL'[/R[BM:(JN@F4IS:+M+Z$4U<DBG>,48/OKTA<Y@^>O#IY0V*0
M/TGB&GM_(ISP2:H/ D< FQ:>62-F9%7+P%_><V;I<7'EHM<>H1-OKU5(CB%J
M9J"C[[:@=BR6#)$LK+F5 0[Y1+(52#W@ _2-T@;/SOA,4@2-XK_<$-O%=Q[T
M@?0+X(ERO;DL?U]EI4D1%>ACG^;J@05UN)^ZE-_9(?X_<Z"!;%-\[O\)!4MI
ML$1Z4/X%:L3>>C)C"$CAOGJXE_D2;96Z]^;3V;9I,5TES5JF52F]1'<'*0]&
MP^1<M]CKLF"PCQJS%-#[W/ZPC(1<2ZMJ]'W8L;/Q, ]7V$!N,)D/%(<HG>FA
M_4Y3&O\"7%(2B[T5&@!NVLLEX)B2.ILLO@L&/XH)@F?-A#]J?JZ^M'\ LWGC
M\@O@.!O#1]7X":6&.A3OV=@?62P=;GF#7%;F*IZY')O-+Q_EX"-F<1)KJ[;G
M(4W74C;;JHLLG5?)+T8<YK<&3](6?,[+D-T:[R9NGX%I0M$-5S+-=;WW!0R?
M*/3KR\^F,6M%^LI%9EG6[4\X6ELC,[<[0I_5T4544=/1(&^KA9#Z;XT&^<<:
MIGFF//04.4_C.?-%,=V^"K_9HZ=WO< Z=2P8,LL]*(.XJ0C87:G8Q(OT)'EU
MIEE[4KU3037F#=43L3.I$4!X@B#=3&ZHYC.1?8BHO-WQU-DB^_(X6S;'/1&P
MRZ;EBL4%0/(M5K6EE*&5S/SNXJ/B"Q)HK+GY\I4TA"[SDD#LABH/L;8*#STL
ML% P: 66B :*'.9JZS!8!EB-IJ4GZ0@.5@CRSFBS6O$%V$+<;'39&E!J]6@4
M&!C0CY9IB+-BG,G%EJ04,,FP; D_JM=U2+7?8+/*)35K>_2\'XZ)II"F%G<^
MK:[+AN;2FQ7XX!-]NP-&VJ"/A/_60(MZN]-C> JX6MO<1HWJ$*U18.#-J*,C
MHFNQM766Z6,)3TT"*]-@]ODT)5YEO7X=I@*3>A:(EY2(0"(#\*RSA ZSTJ.J
M%FH#9UR87M%\6'1HS&)N:8E\ZBAG)3]9?N:$&B"G/7%*-7"405W@/^#LL[=Z
MVKP-'P.>CL-^ =IS_!M#_1]7_W, W18UI*J)3J=K$QM]"6L-LH\M2HW;NU P
MQ7T:5M0TXCWZ ?EJ6^>:2_7G_5F%]Y0;.%'V3=>K@L4IZ+S"(B$V20MDS -O
MI$?$9Y%P<UX//R?PUZUJ9<=DQZ^MQ[QMWP.M3:IRK>T#AOFNB^LI$23C,?=1
M-J6A>T3UP2V\ C_064/0X /.!J5</T74UU"S0L<-*D3"5\ ,7 _T83!X+=K2
MS%F-^T95+E^!H;7)*"!Y8%WDE>>S7>&WE"MWX+CR4;J3AW,=[8J6U0H<[^#P
M+TQ&@I^1K29>.)'OIZRIAEOI!%=V47S_BV3!%E^VB'KC%".U8:N 6A@()3*W
M9:I65T_.30E7O2'56-=K9 6JJE7S#"':R)ERPQIU&&515W+9(ZT,-VO-T947
M^$,+?'^&L9*\_>_*#?2%7"Y@GE$#06UKN6U*((UR:!WI!N4];K;Z7*Y7' %?
M9$M$U>*3Y2^Y3J'3\T7JN5 F/T;\<V 6!< 1>Q@T98;!0J*&20'RA87WZ;,L
MIC?*R82%IBQA6-!GN8$YO^&=![R\D#]#!"'5IZJ<[8\P7U<WM]&B8NX8QT!%
M>+G<>'[D9S,8,AV+>0$DJD586(LL-!/VF!7UF(;$11E B1+61S[6W%(LQ5N;
MPI9*[E8YRCR/T$M/<D./-O28/^J=R2-H/V"<*O@%@.^!U&+B?YK3WR]%QICT
MY>L,VG"6@:>8L7K/1U\V/O6P*>SM\[)!P^NGWUY5?X:8:9QR]6#7OIASL\VV
M,??&,,B*,AI0L9S[%3*D[E&[MV.NC(RXCHR25N_*R*K,=\H)13S7)JNDWC*.
MVKWZGN>:.G'.MCCR##P2C.:XW&?4E [#D6P+]45-%2LEL>,9<:1^_QKK3>&;
M8IK\6:4%5#S8&D(SDLJ]8FL:(RGBUYS+\R1R=B&*B(ZP-'C>F& @<TO..EK4
MZ$=N=NGQ=?/M+!- <AX+U[/782%='%B%=\NF\RYJB^'\S5_?!5]Y4UR?>-'B
M(6L"]\49)A"1FV$*"MU@O?H X_N)9U?_!I,4L19J DQC?IT"*;#F17/S;*="
MP_>*F+BA$:B9?&<I,%:D=%0T8AMEI)AGI#LL0=8WY,T]U]R@L&B18KL- 1V#
MFFO VPD,&[=3>G1!$2_RB<5J,U"> LG(1*ZT[XD;,'W)9$%L-+3.2&26-<$>
M9(LNAAF]2<XUA($9].W!SR-E196(E=)DD*B1DI>I@XJ5[)9C78V1+/@3BL B
MVVSCU,128FG)"M0'#0_OW[E LHT]^>QVT7UTQUZ-%[SJP0]420EW^IW<+W;R
MKD8/+<%4[CXZ9YE 5E$R-[DZ7V+(";EG^-+P>E6556(J4S:7=0/@?)NP!V^-
M7.X#:5T%:&0"@RSS'<+Y')VQ(7=>X,Y/0:9OH'AQ.1Z=81L.<QJA(FXE./]D
MQ[>NXQ8?Q$!90GZY1'UC>$/-U,F1-US//DR:Q3%@5H/7:166+7C#@?N>?$6=
M8@A1LKN_R,@@T*RT04W?8YN[TJS\U:XNK[WSUHS/][.((L4ST=X"IHPC Z\^
M;!X':F-: Q]AIU"Z-X6(;&WM)PYRGD$!5B?V Z58(;)C5=DZ#T\6]L:Q;LZ4
MU<5@&-GU+]D&?V2%Q>JH2[*=D3KY<7PG:MH^L;PA":;JP)=W7@<MTV'%LP*-
MVX2)H2R$12Z]U3C#^5>IQMN#ES$P?'>+VPU*+[@<:,WD+_D.;(F.MN+0ZR^T
MTC9BL&12K)EHMN8METBYN<V\EGVFQ8(0Y5]/D@!^DKLA*]EOJF('E=SRKW'*
MLNA,X'T!JHD=,))=J[A1[T84-HI*D33STM=EGB ?A#N4BZ 4^TT#>BIK/@[?
MV$Q<A20394PAHW9W>Y*KB%MR]+_2L*GQF\9J 3]D%1G.UE33P>>6%$+J0!#_
M&UE$0U/^6(BB7H&%+!@-):9RZ_N#4"$YD [9R3,SN7,N+R$V>4"K0DU-?7U9
M$1MS?4D(#^3=3#YJBEC82DP0$4QAJA"IJF($!P9@ U[ H#Y0<%ALX\ WS8$'
M" DT[ NQAO _K5<"U*L_ZM'NET/MODB 48K &Q2#Y8RO",1:V($9G*^[]9S3
M>_K'GLR5 %G.7!^)LU5<#;K9\>P2 5Q,7%#=8J.S#,^5A<VUF&8IT987<PVG
M1O*KKFW]V(J#5U@NM^2?;(M*MS==!%@/HB/UL^,5T(?*^N;\J!#T"+8@D$#6
M+V_37P6VSZ)RYB)J^00O<!U=K7EC\18]=>]GT=XU#IVZ0.(O -N%,)#9Y+&L
MY3=,T-;\Y>F>=M5@U0"7@/:A1LK6HNOD40QE-%)(\<T:YJ&]+F&/DSL;;SUT
M:3T@0TY=9&I8$[I0?HYAJ?B"_EUT^32Y9NTOX%2V9*1)'CS4IMOF"V.Y7F+B
M1@1:6=B?Q22_VF32M8$%K#.BW!5ST:U\D$JC/'BRWYZ$10^D"P6J7JLT;"I]
MJ@9-*1+AM551E(!^X*GJ!-9O.D/"$E/F#GL^/G5,3;)C%JSD%#[?0OQ23WNO
M5*=30ZQ_ZDA'\4MDP3Q G<]CWQ28$1D:7/2Z[5R7I/1W9/MY6=$EY.;2T(-R
M75B.J1C1EGF1$_KI):2\0BKOC1FF3UAW"GC['T!1ZF;]'HOL YEKF[F-&8H%
MMTH<_ZHH$I/3!AQ/6.A'B$A5\8&@FTG.UGM/P4Z--;96A8$\#8@9?6E&T,VS
MS"[)YP*L9CZ Y.03(/5I!8D,(= (AP!6L$WS2^L:V?$40[M)"=;,7'=8C7]3
MO8(1F]W%&; 5L,#26M8,"^9)7UZ<K+,^3,-BOXI!_H#FU",) ,[.+9=?O4=(
M,=0Q277*LL_@!00 3'C-5!,AE58OIV>D)= AD5S*1L]91\1K.'F!)H0$&2.5
M?)X\KLVDF6)\:L_^+X!VU-M%8L'O@(ZM1<U'G=\EZ9[M$>K;RR6K7- ^/)'\
M"R#-+W/1R]P!,P4<01U?-QC'[^Q@0(Z-UI'ZAB._ &LSHV1[4KJ"7BR6['?$
M_VP;,RB67*EL;N:2*+>>6$5MJXE?$4&DJ%VXC)I570)5.F/4K$DW&Q'A;FA2
M2H")S"$RX(X_S[6"1O02O,XF+]T;Y&^Z 3>&*6[IEV;I:V[A&S2";60=\J!6
M_OL^93\X._AKRSLL%;8J+EB"KGJ ^!I^)-H4.X!7I?(T'RC^0^Q<"NFA.%'I
M"HMJ;LNE*!8[YK"+$&(N%F,-21Q%-];+L("?RJ&9I%J@T'I+AGFIZLQXX4OU
M.]/.]WSJK1OT;2L2MPP:LSUW-5-L6:7IN8PO$I@_R-5O<!]]M#[[A8DM0TW?
MN%[W!*8FAAJJNE-8SQ/,6 /KKKQN]74V?^G0W997'MK=G'-B#^'9]:\-<-%,
MNQ8'OL:M1A^%V$;)71UKJ2T?,[C][Y[0F#B0N)<3)>HZ*A;8R7SZUDSK?Q"]
M\PZELZ1C=8UGB^DV9/VG(/2#D\4KYS,L2",EXLRAQ4ZE;!//HP\23UPJG=U8
MPUC8=,^V;IKJ, >4*Z6EVC56Z)MEQ\/8E&^C(0&-E1&7)8!]PL;U)I*ND(2+
M,'VE)]Q "R5LO"(N!OZU?/OB\-_7?885BK9.9<[>GRV;>E@I,>OF]T(#H!]*
M=,WR)&6+A?7Z$T0EI#3CXZV C[M%WISD#TLDBLAM6N2+;$H6/Z]TA<J8ZIF
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MU<^/NC7KR&?8:$KN*?6O_6J55LH=>J??:O,\1UO<*.JO.I_SHNP9W5#ZS&'
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MC"BNI(O5=8#&%#M*D&^A:YJ-;8AJ]7S0UX,2>P"?^+F2;QT!!KG1Z88<'N3
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M<( 4U^5'5=?B=MQG#S_ S:?T"Q1(Y11OO_)?RGQ3GJ-(-5+K'D]ZLWFY>X#
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M>G2JUVK-RB]E'GCBOQ9$QS[J)Y;3\$?#ZRNO"YU&,#'"DDZW']^< EDO$U+
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M^9WR@LZSP%SGS#S;'4GGU[\]ZZZU"?!EM167<)ZYE_T9:C:2:W-\JJAO92K
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M$PW&65_9",JKA,<:\<@N;8G>[+7=UDC?3=X#IO+S9B&NB-C;%C:8^D8<M_8
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M8_AZ9\U%OC>D:B?H.\8OB#X^B+!=05!&QZUG+_3'XN_;7!F@PT:R-_?ZV#V
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M4YO2:"7*KS7V_V;39/I3,R@HBV0)XSGT4!4^8,%G3)G4F>1?2BC9S,O> ?@
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MB0-#V;4]Q#BC!*_"_AD6TH)FK$+I9JNNZG<*\,9D<!6=CJ=T@<991['>@+4
M8:T4P2)(Q&"ZYO)2[B4I92P/H?&J(A67"5AKVCWU%=@H=V@\E"&X/[%OJ2:[
M@H%ZTJG4*)-@@IV0GEB2)XZZ?Z'TV5COLMAF6-V6M]);)B<4?^<KMY//*9X*
M C."5:U$"&FIS;>LCXZT/448?)*0@F8:M[/!OYT<(P]673CO 3D9R92A#4Q<
M2$4J*_%+0QF9CIS#H>1?9X(_C7BZU+_2ZA)+B&73?C\B_O-2E%<&1,]I;I'H
M;&/T%"0]OE3!2?5P6^J\&(CNT\NJ[2*T(LAN5)O](Q$=CXYFJX1R_=@:A01W
M68W5JNXC=J:/1*(BU*^)9A4HL9CZS+.I^YC\#SK5WBS'5/EA+162%*Y,2I"5
M>+5OAJNASNKK2P/]GFYZ)?.L6$E>&) *?6YW'JC-43Q3IX^A3+=^(BGT8R5/
M3HVI*(6'+9#3^<2>O^<N3M^L5W[R3^,O_1!\6&58RI<G["('W5P13P;^=FS8
M]J&KG,O^QCS0H7;Z7#,O@;LN#K >QATM%ELZ]KMYO9ZXE""QJ".G&1NN<Y.^
M*%-N,M@2BUMVR:=_TIB[B0^.M2MLC.5YE3GXAP@E*L+K]ZO.7/D?V]DPU<R6
MQ)GZ;7\_8U)&OW6(WU/UX\;^.?O@)K.6V<0G)G&59\J*EP(6:(I$9B)%I%\E
MG)U0TS230K'_I[=JK#'-.=_7@KK-VJ>3N=)EWF,%EQ9#V(V]_>GO%TBB./V@
M]7T6F82XOLJ44,9PBE21,3:6\IIKT=K)<6H!#J)8!Y+UW49J"H]4UFX"55RO
M,P[D<,1IWJ_.0DZ<<>=D6:\7NC6<H^IW_<Y4[#.-.<-%>K-D:X+T,8^SGFM[
MF2\]E<;(/RD-X9EJ2*Z=-"N_!^2+'+2634'^=@S5)-Q:2;)\35&W#5&U"=OQ
MR1$NPJX"GU&7*/DD!54X'2T&*/L!>D$% -&\=TU751.9@X=T9">6.9%8VFL-
MV+?$4BK1H12Y2ZOJ@(97D4+:*=FCJM=XK((5I)@QZB'Z\MV6W>XG?1JXNBX:
MRFL'R,&3Y*J:KO!3&S4DGVTB;>.GWE:AV9 ELO.%3&=E,HH< <71]*L'HMVL
M)9]=R<II\2:LZ%M)=>LS#OWI?3R!_\N"O,'=?@.KSC[W](LX&82R360U\$._
M5A_",DV^_O:$0H:3F"FU **=WGC%",)61#6XBRRIRDJSW5'!5EO<@L?#S"IE
M!):R(;F;5]K6&..;?S&ESP\-!R^K/VJ^&TLVEZ^6<"=TEL-S"V]Z;6[TY OB
M18U/*]>T>S%CXG7XPLL##(U!S^G/VG'?K=5[0)W(,>0WRYWG!V>X^#/,P;!C
M9]9YI-.O=Q5^,JW2.Z]R>-ES,[N<GP16>II&&>0L_3-Q"! '\!=#-JL.@*MJ
M!YAW6=*O+XCHP,_]JH*.L+@9-,:P?X'U#FX%9+C4E&7J%6U4,T!4B0N:E9^?
MB>&%&&<R09ORA#6?C-:G*O(,$4GV*5(F/C5>G3"LG\%>K&!@[("X).-Z![)*
M5FA.4ME&3#[6;Q(C%C*S  N*F8P^<-ZAZ4@.99KV[U3M7Q]%BKBC;#P;._RN
MMZ#NM#_)KNOHQJD)1CPX^68'/RKG8B9GN9V7=L0(QHW?S/%&0QU7L\BW/UAB
M)282A$C,:=G/F8/I)41:IJY5D]]GK?7/4$XGE^YC)LK"-U8#%$;8U3R+Z!TV
M1W:DPOD42>!-IQWO?]+!PHI"I2OEK+QBO#;L!_2I<_Z<A;[M"Q;<*T#_=JJB
MV"O[:G@*DDYB3N;2O#T&'\]ET;1,F#KAQO-9]8'6; +L)YVB:-17"]^N]>('
MD,2;$<_$GJ5AE&9MO*936/BL)&G.070>(\V...B,T+B!BD0B"YF-/AUQX)Q8
MOPZ @2&0TYTKRGI.6H1*-9%6&3'_.BNQ?5^H28&X_DS4=+6;KE=4Y"F@E<=J
M1OT5<PBH@D:=X5T.'I%$*9V&Q4'4"VJ:0\ ?<^<"B5K2V:U/ V)JL9KS/]1@
MERQ7$A(A@-/>YS8TG+1\&M'/E[.70;P[IO9AD^+;.U#F8FG-W6;+N\<=:04C
M\=KE(_:8NIWA4[2P_)N2EBI/,!8SEQ(;O:T/)L_P:UV.H[(;T8681?-4LM@:
M:/4(-P%$=0^X)@00>V."^3/N 2Z9N=D@V:&34RF7&^G/L0%^W9OA6KE!UK:)
MAZSQGX*8S=_Y=LP5;# K_J-"FE?]R8B0MK30"?!G_:O]-Y3B(BD1;XS>A9SX
MBL^BUZ]#&J&U([04%$"ZRTXA2U,#L%"76,"))3Q1M11BP/YG MXE,[D<XR@E
MK. 0B$O9Y3!?2)2"MO),-/+-'U_CFI*JU9+_5-P!4 BDEVBE'P5::G[CDJ4/
MI!2?45+&?TTA:Y0;?86P,39=];*I,*8[5V,7G\0QTZC19%Z,RM!.RE>F3&-P
M#E ]2WJ(^/6H]/RA=?S66Z54?\56H $Y!8'M"!5!XST '$N8+/N17,NBAFHT
MQ&X:%()-U-A=WF5I3LRW>#0^$\AOD?3)K,8DD)H'IWQEB,"=G8%R,]7+,I&W
MW>",T>]G!J#&^81MNH[2?4$KO,YH=>:/ 38%8Y.]QF81O"#F M17CBWT/5KZ
MJ3AO<QL^3YS5QFP1 2#1!QLS&O9C^(_ANKIB0?[XIR&>0/187H("7(!M/D$#
M! W6,I)L)^4Z+.)II"@MH\!">Z,%S>5+O;D7UN 8^MPKS+<=#67I:\M"3=KW
M@;Q++QM_7;1J_'A+]-:]S"X=3OUU)^;U'UMF,8%_H9^EE2]PCJ"2* F>JHFX
M@99/DRY$9J]=B>A:Z .9.A)%J*?'M45Y_.O<?\OTJI\3B>;U3F]W6I'MA\33
M! C!\PSKW!=&?9(2'W '@\>"[?FT4W!&#IJ_[>7PS<TGA,V+/8U(OFM^27J&
M.%%]E@3,J2$L:-_?CB\S/0@U#:G=##LYN7(1]+$5;<CE&KSC:5I,P,M23A\\
M#^!V?O\UKLZ>;Z0.5/A.HI*-QBW>Y+M[+Y3]%1^AKG))-:-B0TAQ8B.$-5!5
MYS*SEF=!R0:?C4V)0)*=);>Z;U Y@C:3B%_]AVLTU_= HK3>*>D)1=Q.L 5O
M?:1<101JPT%^+*UXF>I1#6O]RQ3UH[1'))QUG53^+$2,<$_5A8(N:%S>)D6B
MGM\_SFUEUS.VB -"Q(QFH&!F6IL(I7*+*SAZ&;CTOO;(CIUSL%L@<<4Z=>;D
M64AHTW*4''?$;3UDA5E7[OP><#&]FRI%KS;.?%&"M#%K^9&:7:J)47#_?24C
M:97]R.R2?#=10,9B 0N4]-4*BW(RHL\Z(YT7X@,:D5LF:W';Y^TA?43B,6-.
M]"NC:U-^<O-J_*NQG5[COE[MDQ@!SUWO?4%#V;\=(]\8_WK*58M*XX0H!S\3
MY>$9>+=JF?)-0+* 71U?.8H\'QBE7&+X&\_B58X*'5\?1[U5OY:-@RGS"V)<
MH5<B7*&&0WS1>D8YZF8VKUK>V-80=S2MA7P%*W^TGXVAF@<:.0YI"^9Y?EJ(
M8KD6%>&*MB:&OA!ZL^Q$Q7+]6[S>B9JRMW[*:G6P:\=P(2DY^\,@G7U'W!!0
M@-=T\\&E-%X,<RP$YSPM*B<HV'DC*OL16XY 0V__B56R6)>[DH8!_Y=Z]Z0/
MP=X6+?0I@57.Z\=%$2$XOEA+%0W 0]%TJG5;#B&9AEL%1=5)E5APX8R":G)\
MOA''ZS=9%8UIJN/U"\F3<]+3.NS7PJ\L"A*8EKDK'F?8YR4HKYP3+%B7L)9G
MQGV6=QJA-+O+;:EVPDRJ7W<628!N)@O^I#:.4MH?56Q:V,;]G;-XN5JIH9SJ
MJ1OOJVP*UMDUW\L?;!T1#3&O>9O%32LROE,'EI!GH!P*.[PT'"958C[7$WMU
M1-:JF."JTV?;+4*=B=&GN[#<*V!U:#*K>-)*<=OXS<'J'5M01^EYEI\CY);[
M9^VDM.9I3%@"4>T1L^Q;!GG1;ETFHD;!F/IFS?-O<SO"=W\<=J,*6(Y%14H3
MJ3FV<D3@3;%@F+NH"'=!QR^7 Z'!B[3)$".A.3-"6I)!F'U\O?Z)TY&<T:H%
M6=QL]./Z,1!9S1&KW_SD#0T>_**&[]*8RA<TV)2NXFM1'"U=_I)O2CV+C0]>
M@/>1KUB7?U3>;W%P/D9<_21%XE=S$=XOM/YU"3CP.)V8J[=5^HEYX=/<DT[E
MQ@IQD]%;HNEBM+_I6KM382_/04'EO R-VIJ@@S^-$^6D4C1!4%P]W?@16^Q9
MA"94NH^OEP!>JIN2<ZQ\$1Q-E_[S$.L'2.+KB6OA1"UDK92/Q(&"INKJ9Y'3
M>%"#;1]8=29[\*KU1_(]@* B?*V#1'N%U- M<6UM9@8LBA+LN2$T%Y792_A8
M2:YD[E6V4_BXGS%OET%;PY^V*69)=U_M%RC[KR_1\7#!.Q1_YF-]D *8XB9M
M9A#+':G,\2XY?QFAG7>$?+;V_)90#6OE"1/]5$./6XR?E)+L6V?9O \!.L7"
M(N[8!KXV^KZJ3IX#L8 G)D*[50]67<1(*+CJ.U"&QJI"1^2[85)H9L7S"49<
M5(,^44=5W9"IWW7Y O-CQ24:*;2[@39C%.70QCN<W/SYG>SH8?NEMVLV81]7
M#P:SX$P;9:\5:*F??>%>%=K)%L-B91MZQDE2HRVC$]20R-@.6JA4/PHU<E*5
M]-$0J-#CVC<2UR_PW'@T-ICZ?TBXZH"HNJ>]='=+=Z>4=$FSL"P+(B4IW;ET
M2H?4XA("4HMTKH!T@Y+2*2!=4I(?[^_[^]XS9\[,,S//F7ON<>T-TGPAJRRJ
M>AY=2&SE/XDS(,H*_8N.GS9#:X/2G=K@N%R<\2LZP"LQ?,_JB]T6V82ANP[N
MB.9[H^/E-<D*DBZ&;<\]P?3>8XAV,4I?%1_1<7_F:%F$U 3=$ORAG&,&"^?\
M(>X\Q3.H\YU.1F $I;,>AO_HAT.>,SH; S$F=[<ZS8UURIK/XV>V]&HD'"=&
MKH0HC@(IJY++3>XW-A),_NI^5>((M)/T,[T6XF.%ZRQE&2?Q5,Y@,_..5[:O
MM'PK/[7%?$F[N@WV*.VO'O\P[_T;\S4$!)*;MH2\!N)<L6$I_;K4_FM;BJ3_
MEY:>!J&E0CSPCA$3DC=>V0RPXU%M=^ =T\V^_VR[1>.Q9^Z3NA4E8)IL6%D^
MGQ&-!I$M(B"38(C^>$FQY#OZ$3>-1/J1APS&).7<#=03!8U.5>7,U+^LESPU
M_DM_P']ZH=_FRO>F8BG\[DOTUJI ]"*SW2P=7_ISA8FM4#UXR5?=$%_&C!>,
M)TC'H)$&A-OE)KCHU?OQS YZCO+OH%6A8,>X09$<<;+XL20DH@@B8@W:V2%*
M)D$,8OK7RJ![D*TO<)5LV1"QLGF>-.Q7RBO20)B#X3BY<4=9-+'ZH\GX.KY8
M($P7J:7EJ4*L?BWX/?C@)/-Z;@W26FU_D2UW:OP'S!*>=<8.7=\@K5FF PK'
M;2J)?UMQM)U$K38]D+U9ZB#]H7 '2>CZ;J_R$$\%\'(F6RTNR0ABZFRM?.M.
MRZ=PS?RY3I":3XU252V%65?9F7MH@1H"QAK(C118IL5:#(Z@;'M0'L_Z*/L2
M^Y\>!UOY6IOJGK$B+K0<EX(&I=\DL:4^$+U3?PS'3WE\%PRC %08Q+"Y'2CU
MGU Y_M5&*[;J'C'&DXK3?YW:*;NMN?4B840Z#R\5,%0CM8Z/5U@F8E<DSLSI
MO8F1)SLUH]^(70Y&DFB0ZB&9-9FQU@L]5_1<,]!'LI2[C: .KBK]5 J<.A0=
M$##N^GX\7$QW.$DTP00E0)P-7Y/2TCBL2YZ"W[7HUYO1.V]6QV53^L/OAA[E
M^,F?DP[DMAE*',]6]Q\FNRA"SM:X\R_U<AP4G@!(ADO7^=_4!;7<>\-W9V_A
M9L)@>F'9$2^8)3?#0VOR1^E?JN^MFMX7+1AQ^"%/!M9VZ/<7W#J(#8LXKPN9
MKWA3[O5/!DCIL.4VOR[Y"87A7A;1Q6ITC%QU@O$;HH<!#X20%0T^9E+(BHKM
M)\ZK/,2&A8+EZ-Y2&>5 J_@L&>=\D%/M/$2RUWSMFGWMV<+*-SUD2(!%A=8(
M32!QQC%="E+IZ#;R2 UDEP39,K%"<<4;@9.J;O\)._-36IG.S/AJ#&^UW=G;
MM&%_RPR]_M!D0TJXPKOC,@,H4E@.X1$J )#?([)41?R\,:8,QJ#DOUG50+4A
M>PHC3!G6[WO-L8%@-JD6Z*X7T^YR/8T_ 8I^]"8#,VUX@-YZ4LY9D?^QMKVA
MOA$<XY,63Y%-/Q@+TE-Q)DV^C=W14TCBY?X0O_6-@#@Q%*IM:'_!C=:M-/S(
M)+NM.BJF>!U=]5UB@+4CH\8;86E7X.LA[]CTSWJ9 I:RBI]8^@88+_%:)8Q'
MZH@M2 ]].E[\DEB8Z:P4G[C%;CE6%H4^((Z/'EY!/2:,^Y^QQP;V>MC-B:[7
MU>:K0ZS7$EG0;CY IQA@6/KI#1%R_>[)(I+?.HIS[HIB^XYYE(&TPEZ+W\UG
MX&.8G(LE+_MR+5*KI\]U1QPZ11"E_61)"!<(.&..Y G@:7:_\(;3IP%V1]S$
M&T;25:&ER[>2::Y%%1+M.KNR 11:+<LE@63]WG:S8M=<UJ%7Z3N1IW \&HK0
M5CUM,$Z0E,ZR7^;;'=1_*83(+QJC#MM=G!H)#VHN_Y!)-39@,EI_OJ?BO>5F
M(?$E^?+OVZX!3NBY3A>NA/>J@*C2\N?7D#:P&$H:94*%RD7F*RV/)T W";G&
M 8BU!']I5H))+S&-!(AH$+&,/">D("-4;(Y>D8'5L/U(+*'.\A8#E_N9&R1$
M:4M6&G'>>YS@#M.64!?4.8I.K'DRDEM!A)*:0WB(=V,-CYX *'J=SG7HC$U*
M8SLOEP"LKNOH#)G\REN<GT6$F[>8><^%;="M:5K4?4(DBJEOH*BMSN)&ZU5+
M!WCJ4DPD!5K1K[S3DRK5XFXJ*3MCF%BLV\EMIVNM<]I[4!,'B7$S[^#%$#]=
M'-G6;&HCQ_9TSYF%4BGP3::O4R,9Y[:TK\;;!>_E[.?=6F<YBHD>(% S;4Q9
M_5C6WJ'FIJ D8/6-M_<W8UMA95T$O//MB[2!RI_\P,SS<X"[A7 IH8Y>5A$^
MB@^![$$$&Z9.6;X='24(K;.X2MV</R=SJ"MB_4P_XP-IH1 >*H5?6>0V:T1<
MG, ^::MC-?#7:=*4X_-NXP-!?T .6L5" RL):72>2F($E3;/$($8#OZGC4)S
MRU50ZUTZ"E(_6FK('I1"H7*NG>M)L;7F$".4V$(&49 ((DE$H' ?791K7R1?
MEK30 "Q=F>9B<<7Y-<8552Y^N^Z4-VK^]<+_6OVFCA.P0>.P-<G1I-<2<G*9
M?!H]^KK;)"*@%D7KYS=6IK+BR2'-20_E[O<?FZ0[??:_VN2AAUIEQ?<] <H)
MMVRGX'A4-:ZDA(6\GO@KS%I[O[:V#A?_^7EP'1\9XK=LI7@BG0LHAE)Y^S-J
ME@4TQ*YN33P)&DKD$YF@,13=(T7!'V3@A*IJY=?\QGM(@4?GID\X;FW$:K45
MFLMX- R7M'/W?/5QD4?@3MR^<MBQC[-N(<T"QEK$V/8*]FJ59 60.18#N#3%
MEK3K4$V%;2I,^XVXR;IGHSQ*T)2#K3#DT#0UZ4X1)G6^;BXP.I9&D_9=*\PL
MJ#UF6Y9/8EBV]49#"9J"@S?Z@UX7Y$R#PX!MFLJ,K7X*RN4A0Y]6XV&ZV'AM
M0):IS=N\1'Y!PMP=H/KZ/89,.CJ_0PVLSUVGNO7]8@%)*-!SR,-<-]^SN'PF
M.^UW"KPD2Y\XK/V-+V)5<#'1$OKA:_%?+[\^H"@S@4#^'DD2 /&S.O]]=RT5
MTYLHOH7O*FH8!<8O7\XUT/O,MTM-O\#&$"Q9S.37^L!@AO2==^D0_(,K&]F&
MNSE<ZY%P/A[M 0_%.7Z;/OW*[Z^M$_>7'^ CI:W^0)+S\J@&2A_:O[%LQ>4C
MXY#SJQ(%$^@_K2A20P_D"O:R([ISUTS,:DEYW0OM;U27**G-=O2I'66O<JZY
M$K\(TY%;NI_B6BU *;A^!A;O'/MPK/9KLB^8A+''*:E!,RR1[]'+@>OH&;8
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M>_RJ"EI6(('56//S+UD.9F'-?QU Z4KU%O582:6@_J^^98;MB*GMI7^E/K$
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M0N NV0\DYCY[MRP%A;07O5Y7:Q5$MY[Y7XX:EXO?+1'L$NV_6*O._).<FQG
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M>,JVX'9PMTA/8##&%6\"SWEB$10IY3R7G6)_8MC)M5 CUF):A^12"=W!6F_
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M$@70".82DM$<V'*S8C^6+]F?OU:T\R?ZJI:JIBQ4T3'J?P*J#<D74U-WNWY
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M_7VCT@E<PUPIT,"$'RO6?04HTZW4JM PL\U#>HB@37((U=(I#=^H<)#Q/48
M7"0K)74CBHT?-621BG>[JW%8B09)35<#<^-SI:I'>#?FB(W0-==,.4X:S,RG
M;C\9]6URQU0,T/X^(A/NSK%7/C1'U;Q+V(9[Q,<T2JBX]Y^?F5WMDQ?CV,]L
M4G;CK3(*?'(Z1R$;6-5"XMC,-))9\.-P3H. LDI>AC7C#HW(UA%?UJW\&)?<
MI=W'.DCR5B)9>DZ#.-A3+?S(T$7-*VZ2DA#L9,\AS&H2]6/CB^U0N\')>C5Z
M#1^-6:Q&GH?>L:&X%H,)W9S3K:=M=;N?G.GD=!2V-_N@SIL&T@(584?&OEHW
M X2?N\&E%^>(.G/34)8WA:E5P%QL,IKO6(DW4@@,"(1>B;D-W^L$]5C/=2N]
M7.2DW"@AJL)DMLLK,\8 37P=GHI28":@0@,/RU;\3/&9OG_C1E?@[&4;D,&'
M =M00RZSTZ[</RW1P#@#:Y,023-# &@A=X7W6U;'3X^:O?;;>/HE;OPV(YJB
M@7$7KV3<MH1-X/EF? 6H3VXM)L4'*R+H8W4DR<8;!V %L)W?HID X?.6Z&-%
MVCEZ_V?4(7VD9Q84^ARV_K7VH&];8'DP&F<V1G2$$^>XCC3/NL<QQV^'ZR>^
MH_T)@[*>O3(Z?VUAM ]N1\KZ%:2DI0\>:LUO"WMHZ_6OWI0BQ7A?9C.O&CYY
M-^=HV//5ON6P#%/']-%;5/"S*0OZ'",GD"ECII17OER<<ET%Z9*A!P%DMRK%
MW>E%(3R?)1VV$KJH%C1.9D@ !YBW3.3B3*"%,DW,B;688ET[R$Z__T=5N>J!
MB2[C='Y+.+]' :MF 2LH_3)SI:8"1V=<>2!'S\*4%28,,Z0\SN\6M[K8(N:P
M-#/(D89--IH^CV:XRC=)8^Y/JCE*N(@> ^DS.=UX5,S\8NW-P"MDNJCG>D+*
M<..K1VVD7%6? \-L$ %=N3&<GEE%MX 1"6A0QC@3U2*(31^7G2D#?*.YQS-F
M(!LTG6<8<1G+TS4>C2W!I-T5FS6IB%#HK-L#EV'-DLPT,_#U\T$LFIO&F>5\
M9$C^#!34<)ST,IF__\J5;U437TNI(S3(.CR#'W]BB*'.UZ!F\9SO),W$=L!Q
MMB]1]DA@H+Q#O6J?X@F 4$$.L,[D*"/SF!NXDK GODE0S<Z']\3OVYMLL@?+
M;:(*-Q&FUOQ-CB']K80V0,GY&Y2,ZK2>PGP-,K.>AR/Y\?XIG=E1FZS7+H"2
M((E'C%-F[@,@LPE5$+(#7:$.[1DH089O7;J/3+4.^=#<_&3<1K-2N!"ZK"UH
MOD*DJ=2C*C^E$K;L?!Y<8W$O72(,4C?Y!W"T5'QM(=]^&\7@,(T[<]#?.SR0
M-:*+\K3U"29DWV@CF@F<;?. +EET=7HSL\\<E%7%<$8$8]6_+.OP;R6HE&:N
MLY8K;+(%Q$S@BA'"[0<"Y!Z"1F%*OB-6<JQ\5;K?3\A*/Y7OYJ:OX9%ET_SY
MO]TP6SK)@\W%@3R#9IC-P94JON1!3%"5!QJPD=EM9@5E$E.;G,S/LM<F2O+4
MY'._5NBEA_I[^2E,U:^)_V%NX]W4\J T[/\5_O$"#<D#D.'J(),09LX)6@SZ
M;P$E&P8YB1L.ZCF(>D=(4DC-D<V5AY#[HZQ/<#NS]Q;SN](U@^@"JM-AD$U#
M[H1Y((/+6512AI&L2I^[W'1?.)HMIDD[>ZGU; Q[CCB;^#E_!*T]*G%= 7'&
M!PXV4/JPK=?O)-Q$'ZI9X?H5/:M\UZ;Q&4GR>:N<^3=[=!D-S$^N8YF^;;/K
MSJT8'PV>T%]=9%!%ER'/TDW GH]XR(D3/S6#P$CN&&UG8UKTD0(#+V13G8^;
MQE<7/$!84=:NGC ?;TX0$E76I ^#BRX'JPYJ2M<ZPY>N,L8_0J6UG$P?7^;@
M_D% SZZZW9(*Y%IIM"(2FU&_5TP*&D"V[\4L"G9_ 8\[OG+5-ILXC'T#KWO=
MZSEV>J^&),L$9^T5?QX6HN"OF#,,]'=\!)P8/&$(^5HC?Q@K<2&KF<P <ZUY
M9DFJ&!%M0?_ QLT%;?Q@^HBI!=:LW2*JV;G-6G<SC>Y+I>,_PU@;3[4"98AH
M-.Q43"7;&"5>'L,\Y'$Q?E\%622/&'Y;0UL%P^M9?O4"UFP<C\J?W_Y46@ZX
M*KBH]J2:*U6RKO"M!ZEVKH\OIX?(2<+DFRT?&N!N0#%DR\A*-)LV0SD/M$)
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M_4[%B5_WY[105CNU+_F+O8OTX.HQ7U@4YGQ\V=#@\G(PY'5L\FB0[RO[ZK^
MO*U$_L*2]ZGWBT]_[3VI_;+>?K*@K\ J(D^A<N3D<L+UD+ W7K[A[G@S9NGY
M^4%67&UU;<&5M\JC'UN_J7R%SS_Z89QW7T[+[N/B9:#M2/;$]]_4@ !_4_[>
M;^6YWUP^%E_($SG4=HI?/>I]9M9Q*?2^[>@I;=95YX>E3O7S!>;\^X_J;IX
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M,A5:"DS _P5$,7^VFE75J2E_OXMEB4]7\.DQ4I#%4*QE*RB"A-TLC6[??DV
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MI%KHWZ,D1!#58?1R9)CNW/CL^#[*9 4AM#\8WZIQ:M/,,F 6;(2A?;3S1M+
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MY[6/+\IPDJU.A7A4%SU?@I_W/OK TNO^N_J$J;E"Q-O++P_V?=CQ?=]TX2_
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M92M@=HMS@^NE\4. ;=7'CU=FA:>)>$J&9YMX;Q)V!FL"1%A36%'V7Z5IT+^
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MD %0Q5^ /H3QN]4BDVE3[L?]4Z?D6SQP8JQ8X36@I]%!*ZS,AFAXO($=$5[
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M@<RG7Y0-%;E'1/;NCIF,1'^KV&:<V&+P!TDR-;_;GO!Y9HF['!LX46X,T\\
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M-Q5VH#-!-#E1&6LNO.U]CQ?>I/1'=21 /<S$NK;RL$=XIXU ;.Q\O[[/7\Q
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M3IJ!Q C"OXD_,,9%3D_LA-= OH*][DU%8U/\R$U!M&_4)4:\.>1@""*=N+P
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M:L7IMR:V-VPC5*JW550"O"EN=^@6!9#;MT>WO:,1=23U-N"\?$%.=G21*DV
M&WS^OB/'W':D#62*\<)UH[L.*>>CS6-Q4TC>3I8-S'8'[F.U7Z>#0B/+AF\K
M](Y]PS+_1R&HZ)5C$T(>_%5"CWHIKG=&CCE;3:ZKD'ZQXM\*G9H@?)CQ!RT2
MPJ>6W*GO=8N0^2%3A=5<<+(DZ3:[4*T@ZP0YQB2&5>N9SO;1A@/]#K\J^^Z1
M[T/NMHR0=U3UPXM/QNE/I-NCI$@#V[$/0U I;-\WHS8TT*1 SNP>B%U481^
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M$R)3IE:WB\*<#!KO31K\!9SRS[UI2H)G:9:UV?VCB:>"3!+N*-_H!W\!I2;
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MA9K_$3"3 [7G[N&K?N^O:T]X"U1.UP,3]J\AU:6 K8%V#U3 ',<<C%Z:\W;
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M1=&]H:I5"R>=%X\FK:YQ5&M?<&EY_/3]VOCT.<7YTM=SP=&%4[$&97XU)=4
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MY!*+RF2C-##34Y[=V!9<-\MR@H %D=LB8;Y55CE3\X$SF 4@8%>'P@.( '=
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MO,H5H1"2@([3'/9W%RRH1S-:6AU,OY5P,^5<8J5+"R_>C6,:X-M^857*,F%
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MD3R2>R4X4R!$^&" 02#(=N)G$\"@P[H!*8*1VPWEVKGC )P:-\U$-!X[$G"
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M7FH-@^5VWA'E5Q4:FU5[(:TU$(R+H!\P'@9Q-P/$B.1[6GN[X<SRF?,$/RC
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MV$>6XXS!$LI0VE2OQ97H#34L]1!LZP<<6L\U ]#CRF%Y@9 XY9$'"/E)0=T
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M,<EPRH $< 0<")$1RN?R936>S&%-8$NPF,#F("U 5[>V$*(0G?E#@ZFQRKB
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MQD1E")@A&R<D6"F03OE$S@2HW';!DHGNXPXY8RXIE!:<"2A]\%X28.Y-T$J
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M:[+L@5M*J.F0E%Y):T(2?V@GP40*=S0JTP /F0NIF63L#WPUM4HY4(66$H8
M_*<Q[X#B]N6?? * C@#EO@\U)KFD8$#O"X0ZXM&FE6 )!:2T2P4B"RYINJT@
MJ.Y9@ IE(KMBWU;2JE'3^N-!HU:>E7%QRT[;4[1[S7?HNHU4YF#F5]O54MIO
M<\$!M1SFUNG^H].NM*U6QJ!E>VN6<I((!;6MZDVU*;P0YE1A+7-((*&*9+D^
MZI&&V8BF.82#9J,%7"*:N"2[>V&AI!5)@R)2&D(5P GDD! !M7@L"1]V4@(
MPPW(D#%/>3(PAR*]HB8DDAX2,"0*B9\90 "LUEF<$B9[?>D*2<D"C PU-WQ@
M XD'LG,0!EMX3@.66S_$%,A\(=(X^,/)&\*%1(<1+-,%2>4$'>>W$0[-LTW
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M&R'!S63D00)J-\%UNSD>)_*)[PHG.#IW4VATM6MZ:FVNVTQ2U.RY.8AUEJ#
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M5K:H #Z3E9484FTL=.6< M(.X%87WQ/ZO= +3+V6%6/F:"=XWQYC*8I//YS
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MZOL$)#KVB%YZNXHP' J+$O2]8[=<!#;)3A4@T4/M0#Q; E+SGGZ<HC9M/:E
M)(G;#EG#B#F*1\Z%=SX78$TVXA1$IQ  9V[0)L7,G"FDT&9XDF+\A9VIF\16
MSS#\D :EAF6*LAE2'H5GF0 0A;(104*&]COQ"X&J#"(/M[B1&T'K#O79 [G.
MAP'([0Z^;.SCSV('D#GCX2WQMYT.:N5F1E,6-F-SKUXWN5S<ZE0@#RW:J#+,
MB2@X\5]ZQ;M*IFJ)@BA,EYLJPT?W5N=9A09*1YGTA"SUB-*8ZCD=T8@(=I\G
M8;7I^@H1/.A!2'*BI_JU5YRTO>(X*AV>H)SA_,T$+R!L88_US=#4:%7C'*G]
MB@T>-O/^/;5EF*,'-^9$A*A.$131!0&LJ0.QO?S15K['+NHE4(J:@,_GX@>2
M)[?TN:2X71.[*2^TQ\LAW[F/GUB>S*K+E(Z7G7XB31+B#0ZN)2$'BR2(8:!T
M:C " Q'Y>OUW.8^  . M&X(6\1P.VNH%>B0=&? IF_2'"MJA6U%\8 643M*/
MLADP'UO#",5 3*6;[XPUOSZZ$G'!XOSK6/L\L><'?9J7ZI</N[]>=" ]9MQ2
M*2S-9;0@D41! NV/4U.S:E"/RO8C*"IZ)/(&"4-!^1 F'A2F2!\2Y)-@_?N7
MG8:*.K %H:U@ =W';FD%JH_9)WS#4W9?C9#(!V*082/*VPZ\PD_N!VW]<9+X
MM5H&Y@?#[[K>?:IVWV0>U]'1I-?,()XKPI-X%I_E&2BNA/@8C'FM\G6</7+9
MZSSA2H?&8F-?P!:\+%\PL8S$H:U7XOUZ/%8Y$ J(JQ/,0T&QGP4([[$>):!H
M6*E_4%'@UI'=ISVQLT'R,.WM^E62=+6.!)'K3_Y*%7O'UVK\D\U<.Q^=BU^*
M7,>R<#+L/>)'">!"MHT"<0 -A:S<\CB8SRE"^!N>"J;^--LW!A&CHY'+KB0Q
MV85":O(+GA\E9A:.TD9'\%AXKM^K#RHTM8LC78;M":=L(55F6UG]V-#Z[R/E
M(#EH)1H>/,]+YY=#\*&7$.48&>UBO#%B,EB[<MM>7^OK*E$](>JI'V-;@+H#
M+>.V]EC(D30[M?;^*FFDJ^RY&)?(1<3I>8*OF;B%GI^Z'A6#0!P$Q;*LQJ^U
MI!0QY*:NQ'O$KFW/?95+FOBFBRY8#J++G&2>.OH\&(WTL7BI1 HDQ/+X2+*?
M7 _!^-F-$VX5*'W ;W/%R>*YB7E[@6\$8B"*94,DC@HHMFVR 4/!3);-BT4C
M5P_<Z<,SR%,7T[+2DKJ4_P0BT =UORI5-R/TG4&#(C?2*?_=ZPZT\7@QJEO@
MBX;TJE/]>7^M\FY,A-864H#-B'M6?V</E6WI3<F!A^,TD:'Y1V'*UK:M,)/(
M!,=C:6Y (,9G'8 FH$0P;Z-2A&7(7].,ZCT _C=Q,<7W,<+2=I\1V,4ZQV2C
MV6SVGJAW1Z=RI/N/(>XPTN&W9V&>Y&+X67K3?Z^99BM8*!Y:OK@=D#"<RSPP
MHN0Q<9R^'>:E8.^. F#IB4JTTB1V&!HG"4_#X;I?[C8;V[C$6!>23R- FB]#
MHU-5'CP@C(U(7Y-ABY(!MB9W(-5&3A#T_&\!,A';6-1;]XP,XYH#B6+2$)=B
M+KS,!*#$_+/:?..ZVMF14,6H0$=0+,ZRJJG2T ?MK'Z+B??N-!H9=/OQ!5GI
M+DZYM"!3SY]QN]8G6A4/;;-SF,]C.,CH*Q.8F6X*LM'X[M[<F]ZDVV0E4"WU
M(A?):EKS0.04D$($+R!@=]EA0& D&#-!857T )R=ROGY>6)[/3.&XC.0EHR2
MYG@0"K%/#[Q67HYD?TWMNU?!KJ$\.A#,.?.A?^->IUH1ZP<_BHLD=_WG>H=-
M\B^F*XA'^9O7.E)O83_R?\[FG%N^TUO^WLEBF6\4?=CIOEI>&V@;]8=XKU E
MGV90R-+H9):4+9I /9@C2Z4[1)^^*%B:30!X=&+.V@ ZNU:Z5?9F9<!?@/"A
M^4NWKC0(10+L\/!S<SZ521!#V6DM:4B;Z'C!R[[L$6%W;VM>(C[$"7XXDQUG
M:X#RUHCC*\/K9!Z'WTF.VBV3X%_%[#<@[CZ0"EZL PF;2R;@)<B0^LCD,?CJ
M$#7P@\GJV5MGDS='XZJ).7N>$\3B>P;D>*)#<\!>@(!Q&TU(LL\>7_FNR24
MIB73,(;=2ZZQM)AR4IVO])W5")U'CJ9ETAM&:&-?W$E%S!V_"K!:>/^")7OZ
MUZG$W@R^T7UZX=%3G=@5G=II]ZG>DV=N*99?T,09=*MP]L!IEX2E5-QD\'DN
M.VI2WH_O)6$<^TN=01'054 OC/GC=0H=I&#$@0'4IJ !ZXLC'$NX*9'<8^G5
M)Y%)]?1M(SM>23+G>[QVH;"<AN1BUE*?/3DP*7MBNK8Z'60].Q9?83TW27%
MG&AJL7;8;L(1B:\)D56*9R- OA?2' ;KJ_O#M+%6ATPZQP*C4GWX:ITE!(O9
M3,60S@=[$#(!$,X)P'&S*UX=1U >G?4B+7/P#5CV_B$^Q0;_83-(%SX1ES^>
MESSR"^&)L=P$BUWO4 "V! /Z%#B%DB\CVYS$1?3E-G+:LA6)"G8^OH;<G>2W
MUI0O>D2)N;8QZC_N_]B4B:<"_HNS5P'&*P_5)-,^=_)=WE/+]U;P$)_($LV^
M.(LT+;1-<VXE>?Q]8[$Q/)2HE)SR&36W;'UB&ME.Y+!1/NU7HA*8M1EA4H(]
M/. 7FR\6(R9;1VI8R4U&[IM&PJW80XZ&Y]_@ _LXVY'034FZ:Y5NWPB5,'ZK
M*"(N+$D.+?QUZ^5WC^PT(=CO=:F/%7>O3?9?2'F]8^?*:B$DG_V1[3WS0C5]
MYH5TV)/.OC/AY@^A#W,5UWPBVYH4C3F>.1!A J-(E2JT?;ZVDXC/-@03J(2N
MT,91&A82Q$GV)^LGW-Q2BG#*#=_&V"X)@4*TNJA+U2/\^$M<3B*ZR<_AEMHW
M/;XC7$[UR*==+V\4E IR"_ARU9-7UTDR"VQEOQ"F+4U"52?KJ34#[C8[<CCK
M27'U6>%CX1<];.\7@$0!6K GRLT.S&548O7RN74EU;XV4>+A(Q+XN#HL8 >G
M_?)D$*GX9 EN !U-\+E$I*["T&$?FI>X=JY4MDP-$;U*7C&D(62^1Z&C&8O@
MD%LU80&RER<G\;.*.T3J&G=<C.])1Y1WR,@;)A$:2OCH(SAXB\SE*AKIKT0X
MB,98Z3=))@,3 ]F@E-\\W.73???T@@G'%DDH!J$]&@F/&'@$VJ'CDEHA5LT9
M4O&6XFLL0P[C$VN%\X_>ZU:7&4(GBLW&G8X[)9(>?C'XQGQ11?(FEWWR8ZV.
MI>Z%=\VAY&AK4ZU(J>W;V,;3[I@P1?.<5FTGL.Y# SO 5B<OR=Z]3&NVL*UE
M8GOXG7W@+U.YZUARN_OS^(>Y:H.$S$:9=B63S@9*.?]%7G;&<T_0[,%*GVWL
MO642L,U_E:@X/CR%9*IH2XE\+&"53H9SMUA#BV^^+[/M6U(0^3#K1>:-7O;G
MXPR<:S?DJBJ@W7G )&FPNG&O-FFAMMU[R*#=8?5N5J.Y4'-'[_WB7$[\?9-?
MTM$I1IZC;Y,NWK.3L, U$?EG;8)$>T_$\CE\B;D6 Q1NK1_X;,%8!9*PW:F$
M:265O(3(\E4P8>\.!QD767J&F7\3 4)N9;N)!.:[HQU'_OJXX[^-AK;96R2S
M WJ.*2_(<&QYU[C"\FT[]/F2]]M_P<'_X+G/2P$H3BCKR5N>F;*%Q_[%JM(S
M=/7!Y,&-TW3V#=QPO?0(2D)G+6@%UO<$$M-R >8FL",^"^C+5,7W 2-O B?W
MV*MEPUGC3 WCT2S2_6L.B[IAU283;W1>A1?]H&CBN+#27:T4E^_YG!Q%5&FG
MH6UV"YL2ES#9K9[/K_0;?UL9=3][H=TFXJ3%&")"4$K&];[NK0O7"@,\PS[6
MP4$!2LO@RF$',DZ*Q)Y$_NI@4Z=Q J03I=M"2'!K97FI$>(YD=VZR"%XT<;"
MSN/P.YXB6IZ;'A9]"T>V/_W"8JXPA1&HE=(3WQ5G0]+[FU5_O/45F_,=X8ZF
M2F"GNB/W'6S<F_'IU7L^.'PS\C,E>.C$'A>F= M0WYX3\_5,,/ .K&=OJPJ%
M$<U!VPH$>GTFGZ0Q[;WO;<2.(>Q9PV>DWAG4-RL0==1\OUOQU$82%ZI^X%N)
M]A^PLEQWJ'K-U!'HWKPRI%Y?8<FCT/ZQN=RD^+E [Z:Q<M4&TS4]R_;/-(\'
M<T&Y!VT3Z#*-_MZF!!)Q[Y>;G"=)J;9&R<L@7>L@4P">ZZIL"3HN^_881ZF_
MF9K+V58ZZ',[1*X88?;R.#$SY36D5(GY1HG&1**WDO8KECCJU\QDNWY"%8TM
M/O0R)@ET-2)DY4?:[/%I\8NQ$73BWE*R;D0GCT&Q1HV3E-\*TT)3<5H!L/6)
M](H_CL@JVX3?5"94>5\O"^,U& QR\T_W\SZ5LJI]D4/Y;LZOBJ?T:=]3=S//
MAH;Y8]=-5M7BT*JHO1+;*LLYC\!0A$.^/1M&Z7R4,$X@3W!_G59LFR9H)R>3
M1Q1I3YC6:W6)(0P%RI9#JTAWL 419#Y05,0>,*#[8ET./G,=?#'&1>FBEX@)
MFTD=5Z&G\$&J[[2SJ@YI/(".\Y]RW>?CQ^XWW1<XM!1Z]2[2COZ_;]=^AW]H
MBM7W'O-%?A!(MQZ?I(]=(;JC3)UKUJ;Z4+IN[/IBG)W7^F!2?F46%-R#C+13
M9A[CB;T?4D<IM[I)K_L5Z]N*M:!!QYD]QMT5Z(%!.-3P"9R:^RO9\J..T#@-
M:Q<@?I-N+&Z+Z>QX%+QK2-O80^E@7<0?KMCU#-%<;)D&!%Q,BK13<3_L*IAV
M$^E>-28-?!+G]RDG3,Z-G'F#36)BL_XXWK)94NCB.1]U3,@#'0F$>C<H3!?T
M+W 0$_2W=R[@18?S,!,GH@EINY1-FI=X(ALN=M,G$LIM^M%[?MJ88+8PQ\[_
M6/F^<L?DI83+G5;1H^*"AF\4:-2)2IC7[ 22.+;S(1C\QD>Q5>"GD') :GXP
M&Z6#6 L#5]8C<GMZ$*=UE2A<.==X"W.M>#Q)@,82.V!I&HB19D(?16D"8W38
M@9G<SDEE+EP:WMB]%$<0/3?B* G'8Y"!11/*VX.I$F/5QM2B@I_)UL>43/-"
MQ_VZ2*&U M#Q_[\K9Z:4%3>M[&<&I4UI_W%V\[\ EAME,9#L[,_F_@UR_%&=
MG%UNL!UGF%W(%&2$#H)./L'N >(KSR+<2%[M',-NXUJO>Z/(2^IJ?)F'" GR
M-+%UF[7L=)6(@9K.@7'^9TV6GI35!HV]G3T-Z!+$0)Z6I>F\@+6!EXN-X<7A
M)4D$09XSC(TB\M&C_RST)26Z'T_L>E!HZH$0B-#EU78AJ<39',O%!_%S!\VG
MF@70_VP,A\Y)+5<.4PUJ[.QE/@Q$[3'V*:8S0,?&6E3E;DQXN\AHRLE11Q&^
M$R[,=83*<1^5ZZE[AH)OP  T: =,JI-ZAB/ ,V/[E&4&B!3=V,*3#1#BXBQU
M"^^/Q^4?G36M/Z]:@<-\9YKF*Q>=Q-B0E8U(KDJJNNJJ UUZ-[DTK<%OIF-=
M:!:#KY*2.#(!8X/NW*G8%JD&HGG-"71^(\:-Q[=L*FG$KX),?$G.5#33XZ%,
M]A2M9W'&B*A"96/)F/@M5]9K;Z2&* ;G\R>!,.$<[(KQOYAXXI/PE(L_&4,C
M:@LOPJ1HX805J*&U15/14;C[8:)LO9$ 2L6"<;IWP4 \@6IP=>_K;\H:-1SF
M0" C9HE[G8B!(%?D!)Y;P!.2I/9HY('K.K&B,PH2S=.Z6Q]U/U<.8JU^:ZH<
M4*](=D]782Q,LF]8--.FU(6>?D#S&"S];)<$H@S%.H(P:EZ)-J]8/OK^X"V7
MLFU3R*Z@\,XZ)%XU9K'H3W^:4@R@NC#X)>WJMR%/&CC/[%6U;@BT=G?[:1.?
M5Z/R)W&[BG*IH/?=BS;:';K^SQ)&I_=@#G&A0(1C@7+0@^TDR!V8$")7V>U.
M?ZU N(K5)A!+4@< B,="SD?"6[TB &AH9S\733Q-]QCCMD/:."C.J0N,9_X"
M=DO,/"*$VE'!^(-](NBZQ8:]KM3U8'IR3['!<TKQ4QI%$K_72]F2%9Q1_S0>
M0JWDBRFVQR%=43*=#0E/^ZKU$SO"Z+,5*5HLH$R=!^#_?,MIAS.C.<].*/EN
M<^IQNNNS?Q+@1:%]WU$<+\'*"@D4LJE8KP?\SAL_X'JX"Y+O/@\=,K[X;N9&
M5\+DZU'XL1;'&7I<;H&=TF1T6' Y)8%&-M<#)F^&-#*L TXWIV&@E%2GKL;C
M<G@$=<_R^\.\*$<"\\U(>U%6:]&6DUC+^/OYEHV')B%DD5G01+H-(& ?G@0]
MB5H$:H16N@U49R-"3V)-F[,)&W/XZ=:ZO85ST 'Z[2ZYT\ P=XP@A>.!:5,3
M_Y/!C8LF:LNFMC<;+QKRJ?C^)"F)<E"SD/P%A #8AYR7.:(-2[2ID5[P0LU"
MH"8;#A/>XLRW2H:E:16&LB%[52U27@H^"$UPS<N;8DZQ(UU*P932NMJ<(6V0
M<7/\2B1IVSG[0'=(:M8ZL/3;<77Z[/V%GJT-)]7P; (CAOK&EK*%UJFRG_,
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M2K3W;2WYK37T.KR=]>[#DQ#M0+UTTG4Q*N>,<BD,>T_59H\,%T=YJK_0O3F
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MM#A^TMF/:99 \8=5IU=8O@T BE:V&IU:M0J)4P^FUIVS<( _N_U4\[:ND7+
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M<(GRC#C"DR$S,Y1L7X& FX>$(1[H*YP%.4$;)0%V0578.R 0@&S?M2"5Q.R
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M<B<XY>9$7NAR@?</;D3!-$D$$X#?A#'5)O&!,HV>TXYFXX]T!CE0%,=AALL
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MP_\ %VEK=5K'Y&N<]A(7]$&*>C4:="V:2+<TQ48$#SRHD-UUMO3%PY@(K L
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MU*M<%PGS&H[F)6+S6K@TF4[_ $TMYGN:U7!<S :+NV#6A /.IY8S6)WUJ/\
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M4#FIDMWXQJUW;=6-_!U+VNZS=_K3SY+G*R?F@1U'8]>ZZ[5-"J:6QUG3=2N
MUJTU< ZH]P\(.H]<='VFM7;V@.J5VTB>WF:??%*_Z;]/M,T^ZH/;4IU:;6*U
MPF'?*!#+6SIBC0I@!E,8- " "-O>OT>W9'MG'OA/='PDJ"#XP=RP?;*/#X1X
M?",/;C!]O=''Z#N^N42C&,?=*/MCV PCZL>V%XF<H]NV/;NB7?MC/?EVP4C?
M]&V._P"I8Z=K +RZPT+L!KM'QA-OUP. @-.!&$$# 2RPA%1-\;@H(VK [3#I
M&9Q[8E][*!/#[T%R_7L@!-@58)VC"#P/NC:@3'9PB> P@C,G[8)_1\4@DB>
MR@KD)8239"37;VK#9*H^$ Y%"=RF %5)XP5^]EP[( 4P#)(3"<)EM[8:N8"1
MI#ME]0/<^*#A,-+!W6;@(UT)AJE\%797<,#%0*3)TI[)3BH229G,2E#RY$1T
MY+M5(_AOMZ=1K2?5_HQZN4RHZO3JD;9AJ#^2CTW:T_/_ +);*0<)M/5VJ?>;
ML48_5%'S,@,<Y9PP-10 GQPAJID/98;+(?5&AV]9P8+S4*-.9Q#+VC4=[H8
M+9X-HBCEV 1<75FRDUXJ*#3(P78V&T7O)82T'.2[1%K?U*0<^XMV./,SF!,L
MS%:]MF-IFF"X%C>4JT+B(N+2E=UF-IU'4T#BGRRR@->3<!M=AJ CF4$YF/Q]
M#3N6LVF'%PI_T5Q$.H*^D*54A.8A0"DA%*R;5JJ\<A )<JA$2':Q0%5K27/+
M74S@B[893N'NHMIU_P!H2"S!T?AF7X-7\,X(:BSY41%BO?6EN^Z>_G3D0J.9
M<(TZ^O[&K0\FKS(]LB!,Q296?;,>VV 1SPTKRHA!,7%E:M:ZJ7<P+'<T@=T!
M:;A,8@B-/LZE4"O3MV![7<I *3BZ#ZM#F-!R<S6F?EQJIIN')^-K%J (07;(
MNZ=^RD\-%)U/S$DZ1"+#Z+J+#3-$D#Y2/[.1G _ !U(5*M9Q+"6Y[HT>RKW%
M9U*O>T*3@ZHYS0'2P,6U.XL+:Y<^@U_/4IAQ^>F#B=\5-4TAK+/D#JH\H!J9
MB8AMD-5JF@0:?(7.(0E"$6*>N:]0%RQ[RUU0M69F9F#JFC6I;4MF%ZM:GS":
MJ(?I@!+*0-, F<I2!AFGW#:C&UD7E)0S2&75*Y_:BB'<JS#MB0--O/,?3H$,
MS Q2#;6H<RJ]@ 0G$A,8N=3\OS&5W^=3*'!T/_>#/)MCRM:XA JIG J?BZ?/
MRM!"C9A%)EI2=6IESF.?3"@ JBI%O7J4*O(ZLQI5I0?, JQ2(>T'D82 Z8^5
M)"*C05)IE "N 3*/Q;6GR^;F5,@9PUC3-I#2)"8D8J$X<N[9#O)4E1@N"[H8
MRJ#SK^<JSB79L[8>6_>"E1CC :\DCFP,,20Y904Q^S; :LER"'= .)(W8P5
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MHL,HM>"IY3GP^,"O4'S.$\]\?BZ(^:G-,-^'9 #DYD1"1B/RQSF0(SF)0K0
M<5&,"B[%@15[XY6F>(0KQQCF,RJYXPAPP3=LB4BJ$+VJD*=N><;)YPL)&]<\
MH$76J7+FLI6M/F>YY :!BI)B\Z1Z:N;BSK:->.:^YMJCN2JWF*(6F/W7K52Z
MNM45X;<E]0N +9815K]0.JW[W5'-LW5BX^52<?E:KHM+V_M ZUM[NE4Y0!)K
M3\T6NNT=-8+@.H,>Y&%Q#$YEE%7IUMJ&TKQM-MQ3)I(YR(9'C#;:SHNH:A^*
M8*,[?E\S\V*6LZ\>2NX47,>/*0@$.89Q<:?8O;4THTF-J.Y6DAC6D-=*+NGH
M55E6J]J56%C5 DAA]_<&D+E[4<UU)IX3,:CTXQ[12U#1"U@:>4.#*#L(<.7
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M@UK4'L92=IM]1IO?4#.6JZW=RD$QU1J-[>U+QEMK6H4[9U1Q=R435)8UKCD
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MZ!UKYB'<H(ZBP+A*85 8I-(0HW@IV13,P"F2=L-W@)#92BMY;27LM[H@)/\
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M65B,HZ#U!S>:V==.MZDCB7@(3'IB;1WET:]6K9O#5,IM0IP1(L[<$<UW>4*
M)P6O6;3"KO,6/4NG:?1K4+NSM;IKN1I^6O3YFE87]TT2F!%%I"Y3$%-)HDKE
M2$*='I%!_P 5/O$'_H.D?^U%=I)C_P!T5,B2_LG?&.G^KNK-#I@:7>-J<XI
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MRJE.@TN YF\Q01;7W3^L66ITKBC3J!UM6;5'S,#C-I.V.W[(=4>X-8P<SG'
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M\A]TD,5*ULK7IB-B[1%NZX<Y6U !.14I["&-Y&%0B<HSBI5H_LW JK0AE/=
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M!B[KVE-I9RHM($@SF06Q8NKTW!@JA>9I;+C%D*( >*'S(0<6A8N:K2!=-J#
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MOQ@YIC"-"9S@#9(GPB1$8S2??!6)PN6"9K";L(4R&W?%JBK^)H?]]$6S?T-
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MIJFK-I"DVXK4V%_(,E<.$,UO3>C;"UU&UK-KVEQ38P.95:!RNEO$-IL'*U@
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M(J6]V>1SV-8%03.U8J575&AKJ1Q0CYFRBXJVK><>=4/RC:8MW7--!Y])2\2
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MU-W,UR-7#;%&TIW5K0M[6FRBQKJ]-K:;6#E#221!I4]4TY]14#&7MNYQ)D@
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M6>NO=S_N.^KT:CY'D >9$QZM7=-J6VH,\UCT3G*%4RBZU+FY!1O:#2Y4 #R
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MJKRJ&.1IYGUR<YQUE5O+AM*O7T.\%J%;.H*1+08O.KKAP-9NO7=DZIM8^L6
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M\MJ(#B,QN@%!S#/9F8Y'3V=D!,Y98]D$OF#M\$A!(;(]IY91N$CF!.<(/;*
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M'TG5N4S/.4))W1U1HVAT_-U*O0!MV9EP."B-(TW4;1K>LM+T.Y-FWE*MOFT
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M4>KVZ)UQ4N=0JBJZD=#4-<#BU:L-IMZ9ZV(:T-'_ $.T8!/^,CY>E>MC_P#
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M=2Y3^B36:(M:;:R,\AG+B)(D,9<'GIN<B3,CQCEY4):1]V>$"E;M<:)5Q*H
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M-L-I.J5 "Y/O2,XI.J4F.<6#F<0I)WK#J]LUM*JV?, )]T?AS6<I/*N^!4O
M'A Z.7DF!D!+9#J!/+28>5GZHCRA-A28[I1SN0EZ.^8+C.#6:2]E0IR[$@
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M=+; FAEG'-S2RA7G=&,O;;"\Q3ZXF8W>.,8J2N8A0>R$R6%,$9'?$I9S.WC
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MGMI4:5,3+WU'H !M)@='>DFCUNK^I*]0VYOZ5)[])L7D\AK%\@YK4)+WEK
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MR@M!/*#^2&4@[Y7(TKALG 5@),]BK.<<S!R@*2DL(Y ]2B)C'XFH%4$;0JK
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M:L$@*#GOX" \-(..>*JL-IN(! SX)G'(TJ7;/C'.02I5$P[H#7"2#& 5'?\
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M(Y@<(SE)83+V$%3(P[E.T0>9W#[()+O'OAS2[=CXP[]J 9_G)Q$$&L"A,^;
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M<C))SVQJ0/\ X%6E_4BV"?\ "WP[[RI%1IR?+'; &[X;8YAB)]D<I,O8P,,
MLL3#DQ3M@LGC]D!SBJSF98[(0M:?9,(+F'E;F,E!F(#03L.V 2)^V$<[&_,
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MJNAZLX'DMJKBG*\_FM,FUJ>11PE%Y1JM#7LIO#@J@@@.:X."J"""#F"L:_\
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M#22LD'O"F&D%.!F8 1IEB9DG'W0"B8;UXP $PQ@-,SAQ&XQR@  [DC:LB3/
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M C!5D<$WQB.T1EN]T R!.<X2>'Y(J5*KV4J-)CZM6K4=R4Z5.FTO?4>]T@
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M$;=L..^/XC;HAHI5?4_I2W80?F-2VZ7JU*JMR"56H?Y*/XB"07 >E_4A(&)
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M_=938.>NDR>6F/FQT_IS2*-,4[6C3-Y=<@96U*_+ +K4+@S)=4<% 4AK4:)
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MUP]CZ56C<4ZGE5F7%*HCFN8X$/:0H*@B44JMM=4ZK7-85IN!Q"CF2&D/!:>
MQXPBR3,C9 Y#]AV+ <=BXQ(2'AQA50!/KPC& >;/!1  G&&4%P)0Y+*)89]Z
MF)2^N,)0 )[>,6_KAT3I[KGKKTDM:];7[*VI\]QKW0;CYM\]K&3=6TYZW#<S
M1-5?N-$*9.$D0]QA")[H(&>V ")GCC"#(^&,3PQ WP 53%8PDLS]D!,#"!"<
MP=D(</&,X_6^, +"9QO6"1P@ !>W."D"6$H*XN$Q Q,24'LA-Z^"0JX0)9RW
MQ/'/Z%:@B@P#[U6GXO CK?,4_3O50?\ \F5"D5",)Q4#@N.SX15E/YO:4/&
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M26ZUU_J%O0UG0.A]5MJ;]*Z,HW-,5;2KKEC6!%SJ8:6N\NI^SMR4+7U1S4P
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MP^R&JH43[H^6<#:W'<81,/JCF=+ZH)&"[XG,.^ZGQ@<1'4U(!!_<OJ%YV?\
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MO( .=_+SO*3<2<X^L1-.\'OB6'L(Y1,&/ESA<T@\V$$DR0]R0^8SSW14>H0
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M'>>R!.>9^V)#N'U0F9,%=_+&($()$2)VF  50Y1RF0/?'*<"LMT(DQ(2PX0
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M4H*D*%Q0K(;>$*Y"IQPEQC@%Q.R1@YC*>P$'",$[<()!193.!3&.<_"6Z$"
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M)?" 40\8&$Y*N$$#$]PR@M#E49(IVP2JX^Z'@3*2*2AS21,F9X;HE+ <9(H
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M7E(TKVRJ'^TMZM)Z#F2*-6F[F:YK2,,PN^ "4A4!) [N,=D;(!S@#V$*!EE
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MJS57434%1SU:.8&;YY+'M./;C [)+X1XG/'-8]DQC++9W0.WCV1]>Z![X_+
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MEF2O8<8<%&<O!?J@X ?-]<%=IQS2<DA6JB ^*PO?/$H8G,D[E7.4<P^Q!*"
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M5A^PK%1K3BJP_M[H8UH_/'OC^$Y<?]F-'&6.N7I7^2GUHY UO+ZL=?MY6@-
M_P#2JZ" "*7 13(20;#!RD\(<3+Y'(NSEC7Q_1THKV7$=GTC?!.P$]P7..EN
MFNEKN_L:U[>5=/K.T^LZBZLVI4Y0'@8C; ZVN!U \7ERYKKRI3=6'[1Y=-[F
MGC!U>CK]ZZJVW\[\,ZDPN! 4M3DQBTZE;6UK2[>PU&@NH&WJ4:-1M&J'D"J
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M/EYE99=2T+QYY1B VF2=P_R+ZE(4/[MTY$!)4ZY:H@$45)#2P'MPACBI" +
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MB8/N!@N49C#?C"E<5/V]T+-,?'&)\/"#MQE@N @!%[_A'*-JG/'#&"QL\57
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M&14I SF24PVI!.U-R)"K/<1""$,_'WPA" 3' 1,[_9(F)PPG N:1GG'73/\
MBO2'6')L71;T?"'G(+PAQ;B%6'.S"KM,,#/O<^6XKA'\)G,"''T"],B0<5/2
M]N?Y*?XBV-:&M'K1Z@@    _WEN"2(IC,IW0P\/ 0P 8#N3&%Q1I]RQK0_\
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ME!\NM<T050"U8<=I6-;U;H6[J5ZFMTA3N&/H^7R_*DDCVE'Q0881VQ[;8'9
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M-T)JH7;RZ!J86'IFL55*8YQ4)GCOBFF'F#L^:/00-  'HQZ7@    ?W)L4
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M.9WX&+=P&%9I&&141ZB578UO3_J!Y(S'[BU"</F#(X\(J-#93^J'DF4XI?\
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M&@Y@ _Y&M.H&TZE.VZOZ1TB]\U2:-:[TI[]'N6!?SFLI420,B#G%,KBF>!0
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M&DWG:]*)ZQNWTD#2>4<I$ORQ,GF\LIO^8&?=&EEK>4?A+0A%(/-2:4!./$K
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M-<IQ?^KWHA=4])TNW=7N?PUG2\Q_FU*IN'.'ESVQ_=_J/6-4=;6!_#L+[*\
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M@O;X_1P0R^A/;C$L,EB7MPCZT@=WU1[=T91[8?1\8=1OK.VO*3L67%)E9O\
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M#E"%3]BP3(F:_");X)XRWP>;W]T=*W"?\UZZM2N?[:PJTXYA(()<8F9%#$U
M^V4=*=7_ (@VQM[FC0\P/Y2!7KBGB.,=%=14Z].X.J]/:;?.<RH'E;BW#_F(
M)G/."TX$$$9%9&.H^E-0TC3A^]*#S4NFV5N^Y^6F]4JIS9[8]4>E[(%MIHW5
MFHV%!I;RD4Z+P&A!A")(A3OV09XB6X91R@*F?CA&E=3:-7JT;O2[NE=T0VM4
MI,<^D5;S<N(C2NC^J-6IU>I["RIB[94N6EK'U0&TV@O()PV0RK3>VHQX!#VE
M6D$*H,:AIUW6%.XU#2[AENQ0KSVP\@HKG?Z4$&2'E[H&Z0B>V$RY5\8!RD(T
M2P:T/=<7E-@82G,20 WM,>FWI[1?:NM^D.EZE[7ITFD5[;5.HJ[77%O<G_R:
MULZK&HJ5"5/,$J*-O9%5?Z4/"YF/1MP)_8=,^JU<H%4#TZU%D]@^;'^2K^'>
MLJ-9U9US3..-32=/<"O]4Q1P,FQ3(&*>TH9O3:,8:#M$:1<DM#;35-.NR\LY
MRRG0NV/N P#\YU+G8.,2]ECZ^Z<?DRC='#X1[=D2PCX;U@>WOCVXQ[9QQVKQ
MQCV^$>/U1W>R"/;W0/"??*,CQ.R49)]L?DCV6-1:DS8W0[Z#A%R 9MUR\:G_
M +9V[L^,3!XG//Z%)W[ L2,5.8X-.S9D(UEA<YC76EV2YCAS!*#G."Y+E'X_
MD>VKK_K-ZDZG5<XJUYHOLM*::9S %NB[5_W:ZK9O;S,N]-OK9S<.9M>U=2<U
M1M!BPL$<&V=_JEJCCS%OD:E486KC(K (FK/^M0P\&79XPY)CAX0Y=\H*8S*C
M#;"KV+X1;UB ?PO6>AOP5/->:/Q@MD$EXP@F4";XWE)9X[(M+RBXLJT*]"LU
MV;?+JAX]T4>B>I=;H_C[(VNGV5.^K@512MZ?*&T6$S' 0VK2<'TGCF:]LVEI
MF"#%Z[]&TN#/"5$F/6\YCKO6$3;YR0"@PS$ B850BE-D$G$A"-BP #*:QI'4
M6CZA<6UI0OK>O?6]!Q;^)I47**;D,:1<Z[J]EI=XVP8YU.I4I"OS-:$#BXJN
MV&Z1::T;OINQJ5J-!C*I>PT2Z4A*""9NG[+ !.'?$H3/$C/NA<@)]A5(!;DI
M(EV$B.E[I[@VSTW5+>[O*CR&TJ5"@\5'5*U1T@T("2<E,:[KKO,;2U*_K5;.
ME5Y/,MM-II;Z79O-/Y2:-LRE248\JSQBI().*I"9[(J.7!??'I^!EZ=>K)[/
M[I5?Y*O0N]!'+;^IFMV[AR_,3==,NJ-(=L'DE1G+9%!#@&]\4^R&98>Z&<J)
M+P@LP):HXB8BVK$_ZQ0;^%NFXEM:@ WF<J_>".[8]V'T>V4(D<-L88Y\(^.^
M/=&7Y<(]TD\8&_/M^CZQEPC',8QO]L(XX1[>$8?ECNXQ[=BQ?-Q+K.Y"8$K0
M,:DW_B^H+I.'[OMC[UCW<?H 50@[X)_H^\15:JGE*X=A$:^'$OY+&YJ-;3/,
M"6TW$L/'9V1Z.5V4^1^K:UZF:I6=REIJU*OJ)J5L*A!_H4F-[/\ =J]AP>US
M3P<$CJG07OYCIG6O5-KS *$H:S5I3 D">53#0 ORY<(>=YW3APS!QGLAR9+#
MMLY?7!6-<K $FTZGZ4J9(/,UJE0)_P!_!_2SQQA=@3X07':HX'"%)12H_+&E
M=7:!=7=46-5KOP+;@LMWESPKWLP*<(L+7U*U^VT_6O+MZ-&Q94H\S@UJ.4J/
M=&M:[;:C2JL98U_+(N:;2?,H. 0-/NCU-ZIM)VVM=5ZG?49JM.M65LX/](KP
M6<)LD-LH^66*XA8(,Y<??!27+G#:;[NX=28$:PUGE@&0#52%12<R9J8)$DB8
M$9 =T*1,XQ+.4 "9)3MV1U)JU6F/WEU11&E:=YC5++"M2+=8N6J,!1>:((((
M=5:X?=,.  DOAA%11M\(J-RGX0\\8Z=KL+0RP])?56ZJAP)+F/TBE9-##D>:
MJ.Q?Y*O2[43]ZS]:+"W:24"7W1VJN=([Z(BCO#=V6V*:SPQ$-0I(0Q)G+9#3
MO ,"Y>'&PN^2E?L:"?*()\N[ 'Z*_-N)S2&5*;FO8]K7,>PJUS'!6N:X2((*
M@QCM2![&)2VQ[)A&';AX1[>Z/;MG'CP.,>V'"/;NCLW1E.![91W=A[(P^S;]
M Q4^WP@?5'ME%V]WW66U=QW 4B3&L(/D/4-S/*5C;R]T -,^$+CGV0H[H>1)
M <NZ+@DH$<-N$=1.%17-M+H('3!>.4[ B2,?PR6C:)H&\Z(O=;J,/*IJ:]U1
M?ZPZI\LD?YW,-Q_W;>LFEN)%2Q]5NMJ*!PDP]05WKR["" (;P \(?+;[&'KB
M927"';UEOPAQW^ Q@D#;EV1U_5<9VVK=#U6RS=UI8T,MSX);)9\=D(9_0!QE
M!7*44]2T>Z?;W5%33J![OE)(FC3NBII%]U3>.L'@-=0:^H&%J(F,5+BX>7UJ
MKBY[B5<YQF25A A(D L<V2GW09G$YP)+C]<$C$B?$QRG!,,ML*N:PXG:%[H"
M%,$X0!,E>.7T(8L=.I!WEOJ@UZA^Y2I@*Y[W8   E3&GTJ#>6VMM.I6-HSEY
M3^'H/<37<$!6L\NJE0H!#?S1#DPG#UV&*L]L5!CC'55RZF'.TS^'KKZZHO)0
MTJE?J;0[%S@,U;5<W@?Y*F:I1#2WI3U7Z(UFY5G,X6]U;WW3ZM(P_:7M-3%N
MU5DV*95"C8:[= (W=L#F&S%1!:X @A""B$8$$9PRSOJAJ:-4J!EK=.*U+![U
M/E5TGY1*H[\T[L&N:0YK@"UP*AS3-I:6R*Q[=\X^J![90-_9E'Y8\4G]'V"<
M?5QQC;C+Q^CVXQGP[/H'MA"X8_DCVE'Y8Z@NW&5MHNJ5DP)++%[FM'$RC3JH
MI>54OJ]_>UB00ZH773K>E5<';:5*FB8@ P7'V,(=DM^R#@A/AG%1<@8N5( #
M7S&\("D=04A5:SSZ;J0#C\KW5*@IX# D$D1_"SI8HBW-OZ$>F=2I2:7.#:UY
MTK;7M=RNG\SZCG=O^[;U[T^NT-YO4?5-086R2CJW)J5)527+5!EMSAO+-6J@
MW)@!#A--N_"'@SX0XJAXA>$.&<$$3CU;MJ;5-IIFDZP[E$Q3T7J"TU2LZ60;
M2),("=TSA' "-B2@!-P*X[X3]*?=-(F4W"8.^.WX0)J9[D@20S.,CVB"%3>(
MQ\(.\)^2$3' DP",3LW"""9F4\8(,^5!LX0B9;8(7 +A")E#:3 2YY#0T N[
M915N[KF<*5S1NJ]5U+RV"E31+ *7<QYQS/*X#E29@TV@-:T<H "  ;$AX*9[
M(>AE/W15+3.?UQ4YIF<?Q%=:.I/-/IST,LM$;6#":3*_4_7-E<-INJ9.<S3G
MD#, [/Y*OX@M-TZW;<WFE]+Z?U8RF5+FV_1W4=GU-J56FGYS+6UKN S1(I(Y
M43OPBE.0Y<88 92]^R&C.6?A (7@L-*Y8?D@LK-;4IO"/8\ M<TR(<#'+:M-
MYI6)L.8_B;,)\YLWO*/:LQ2<1GRG*!7M*S*U-2UW*4?3>/O4ZK'38X9M< 8^
M'Y(^$>R1C/ZXQWRCX+N@21/?'MX0/:>Z!VQ[=YB?C+*)$CQCGL;2UNR 4IU:
M[Z+B@63D(G!9?=!:R]C25K6%:E>4R!B6\@5.R$N>F>H[8Y\UDXIX"!S4=5H.
M)PJZ?5 &04Q=V>DFM4O-<OM/T*RINIFFZM7O+@5'TAS_ *5.F]J[XT_3*+W/
MI:?8VME3>] ^HRUH-HA[P,W(IXQ\W9A[Q ((^N)*O#ZXJ$Y-/>D7G,4/)47$
M$$!5[XO:$G5;G4:%*BQI',0^L@ SP3#A'I5H+F"D[1?3CH?2GTVL%,,?I_3-
MK:/:*;9!"PR&'^[;U>H\M3_7J_2VI,)8$++GI6S)+3F.9I$4P3^:"N[&<$C$
M#'.>\0_FF4.W:L''.2RW07'W]L$ )O\ &.O^B*G*G5G1_473[2]$94U72JMG
M2J+D6N>' Y$+%>VKT7T;FVJU*%>C4:6U:5:D\TZM*HTS!:001"'8%$<NW*<(
MF$NZ%VYY#=&,3WIPRA,S-?LCE_.R.P#?!6:'\L$($!3L6!/C*)S!PW" ,Q(8
MP2!,>\P$Q,^TP"X2]MD JFW?N,-H4AS/>X-: "22>$4N5X%1YIU*E5[0UEI3
M525<OSD8#+&+;2K5E,.HTTK56-'-6J8N>]QF23F8>5G.'SVP\<\IRBHA7$F'
ME%*F/XL_5>YH/IZ;U#U=Z==!Z57<PAE>YZ6TG4-=UAM-^?EC5;/F'](?R5=0
M]*ZO19<Z5U+HFJZ!J=O4:'TZUAK%C4T^[I/8Z1#J=1P(CK[TQUUIH:OT'UGU
M#TEJ--0 ;G0M5J:<^JU5^5_EA[2LP08IH[(9PWYMF<-GL\8 !"D=L#F[-F$"
M<I" 092^$-KV]S<:;>L'RWED[RJCOEDVNUJ<[09@*#BA"F'OJ^5KNG46AQN'
M4F,JAF+C4;3=Y@(S)YAOAHU"UJ654_>\MWGTUXN#9<3 _#ZE;%SOS7U!3</Z
M/SH/& YCFO:1)S2'##$$1E[_ */;;[9Q[OKC;]'M/@8^J. $;_? @<U-CL_F
M:T^^)V]'MI,^J+*QMPW]R]!I>W;J0:VG7ZBKO!MJ"L1?)+&N.QS'M/WH 0<=
ML880-GLD)+$>QBH<N7:F291>%LE955#_ $2LC'I=T*#4=5ZO]2^ENFT8&N>&
M:OKU"P! :/O?M4$XM;2D VE:V]&WIM$@*="F*3 !P'^[:\JL IC7O3OI'5:C
MBH%2I;W%WH[B3N%NS#9%&:_*U9CA*#O;XG\D/;F%GPE."$G]1P@CVPC9V=D(
MDL)B21UC2M[5U'IWKBXJ==].U0SEH&EKU9U?5[.D1\H_#W_XBF&#[M/RS@1&
M\K]<+G"[2H[XG)9G=G W"49 X=D)^=D?M@;<XYES/C!.1*G#"&E,5QW" ,C+
MA!+<)I$VD8*2,3!<DQ@@R6 -.TS4+XDH!:6E:M/>:;2.\Q;'4="U"PM*M0#F
MKV]5M1X6?)3 ).] 4BUJU=!K6M-I8ZM>UVEMR]"IY2X?*".)@6VDV-*@0U'/
M'S/<<RYT.[8<%VQ4*SG%17;=T/&U8( S/OCT$T>[LW6FO^H>EZAZP=1BI2-*
MN^\]0KLZII K-))6GI(T^E/]' ?R5Z9_&3T-8UZW2/7][IW3WJY:T*;W4- Z
MPI6[+#0^I'EDJ=#5*%-MM5)  N:323S7 $4'LJ@L+6$%5,PJ&*?*^4L_&&#G
M"H,]T,<'!"DH:5E[80 #LV\("^TH 5<@(SG.#^-TRRN2[&I5MZ1JSG*LG,.Q
MT$T[:YLG&8-I=/ !R(;<^8.P)!?HO55];%5;3K-?R C#FJ47E?\ V7 \JOI>
MNTF8A[J;*C@-@?Y+R>^/^GNC=1H,:O-<6@>]A3-C*K43_MD!ES7N].JN_P"#
MO[2LPC(J^D'M':Z +'5M/N24^6C=T7/"Y%BJ.!$ M*C(@@@YXCZ=NU8&[&/L
M2-^<8?&*73V@EMYU9JSJ=K9T*:/&GFY/(V[N5DUP5:;3^LX<H*TK)]7\3?5J
MM6]U.\/,3=7]P5JO+GJ2&@!@.:*9DP9;$,<J!?JV02<$('U0>+?"451_0(RS
MPG%Z0Y7!E0F94[43=OC^$OHNBY:G^V7IO7KQE97L_!]+:LSJF]<6L#E2C9O
M4(IF@"_[M_1_J1PIMIZ_T%KF@!Z$/\[0=<;?D%QD1RWH08XQ11RDM;,!Z!47
MZMJB4 E3*?:-D/+>W;V?&'.FN/L((G"Y^P,.4;8>_0K9C_4'H=UWK723D J:
ME3?2'[VZ<<\Y73*;'4EPK4Z> +HN;.\MZUI>V5>K;75M<4WTJ]M<4:AI5J-:
ME4 +7-<"UP(4&!M('VP <3\(>#M^,(>#=\#E!5$,C  8XJ-FZ 0PREVF.5M%
MY4C[K'.,\$2%=;UFM "N=3<QH&$RZ4"VTZRO-3KN=R-M],MKC4:_,2@:VA8,
MJ/4G)(9^[/3#J:C2=,7&LV]+0:0!P)IZN^E6.WY:)BF[J?J#I7I:F0USF-JW
M&IW#00KF?M_P;0[+Y><+@N,,?U)U?K.O5&-'FT+6C2MK9[O^QFFRDX#_ +<[
MMAGX7HZWOJM%"ROJ=4W3^834APYNSS>Z.33NG-)LFMDW\/9T:;@FRJ!S_P"^
MAS[:PM*3W$EU046%[B9ESJC@23O)AP" 30;N$.).^''C#R2!C%0!RXP]#.?L
M8)Q58Z:Z N+>ZM_2[H]]KUIZPZ[2:]C++H_3[UJ:';W "-O-6K 65L%5H=4J
MH6TG1INB:1:4-/TK1["STO3+"V8*=M9:?I]NVTLK2WIMDUE.FQK&@8 #^2OK
M+TH]1='H:[T9UUH5[H.N:=7:TDV]VS]E=VE1P/E7-M5#+BUK-'-3JL8]LVB&
M]*=:&YZA]+>H;NYJ^FOJA:6]5FC=0Z:Q_/\ NW4N56V>JVS"!=6CG?,/VM$O
MIE6VY-PPFJ&D$.R(E%(BNT\W*1\QV88PQ*H5&YA.T0WYE5)+GM!,-/.$,N'"
M A.(GE/; *A99]\(=R+ +?J,92':((4KW>Z/F(GF3VYP2TN' IGNAPO=,L+I
M<36M*+JAG/\ :\H=XP2[2/PI.+K&XJT"NT<Y>%[(#M$ZLZATOEG3H_B#7MP$
MD',Y@"/ZL$V75&DZPP#Y*.I68HN&2.J,:U>/- %_T99ZH&D<]72;Y)9N:Q_/
M 9K/2W4FED??J.LO/HM.']HQ/ 0 -8%L_ MNK:XMR#@A+FIXPU_]X--Y72'^
ML-4KA+&'DZLVZJ4^9:5I3?5<2T*&AY1JG+YDBIIG0VE/L;=_,U^L7.-*F .=
MQKD&E2,T ',[ R.%74;^Y&K=071>;C4:O.\4A4/SMMS65RN7YWDJ>$!,D6 ,
M"0.Z!S$8>RP&^VZ-F^'M!0D2=LS,7E1[PPD5/+)PY@TD%VXQH&O5?-KVOI9T
M+Z@=9%[$?19<5]+_ +IVQJ.. -35@0F8_P!V_H3UP"6NT3U-N>F:C_S!0ZMT
M&K5^<Y?M+!@:=IBW!<9,;BF" ":]L!"IY1+%)0\8C[(<X9K+'N@J#@BIG#DS
ME]<$G!/R^^"DS.+_ -1O3 66B>H=1CJ^L:14Y;;2NKGTV_VW.T)0O2!_:$<M
M3\]'?-%ST_U%T7U#I.JVE5U%]M=Z=<4^8AQ:'T*R<E1A3Y7L<01G#:M+I/56
MT5'[>K;U&46AT@Y]4CE:-[B/".>RT,U*;B.9],BNQH.UU$E(IUNJ-7Z?Z7HN
MY4K:WJ=CI3!S?T[^I3$"E1ZBU/JJZ:X-%KT=TUKG43*[R?NT=0T^W=:'MN -
M\?ZMZ<=04Z8:.:YZVU_I[I&D'8*+6E6OKDA<O)!388H.U_JKTYZ7I%P=6HZ/
MI6N=::E2:'38*NIU=.MR],PPM7;!_?G4_7W5%10?*T]VA])::@^\/)TFT=7G
M_P"62\8IU-+]'-!U&ZHIRWG5%>]ZEKN>/^%>=<J7(YCC(#<! MNF^FNG.G[<
M2;1TS2+2W8V2*&,:&KOY8+7W58JJM8X4F3RY*/*/""3B9E,SOC''VG!./ CW
MP9I(XP?F;AF8=,]_U007#>5R.V'<KU";1LBHKT 62[(?R$GW27ZX<2"!/([8
MZ;](/1[I>]ZLZTZFNQ0MK:W:YMCIEFUP_&ZUKM^0:=I96K#YEQ<5" T2 <\M
M:ZW].]*N[7J3U!ZFNJ747JEUU3LVVU3J#J$VXI4=.L Y:C=-T]I=1L:;ROS5
M*K@'U7 ?R6:MZ>^JW1N@]==':U2\N_T/J"PHWUJYP_LKFW-0<]&O3/S4J]%S
M:C#-KA&J>IO\'EYK'J3T!:^9?ZAZ3ZC</O/4#IZAYW,]O3-R0!K%M28011?R
MW8:TI^(<0!6T;J2SU#0]7TNY?9:EI>IVMS8:C87=!W)7M;VRNVLJT:K' M=3
MJ-#@9$+%)S;ZF2H!!J_,3L2*1\T%I2?-MPACQ6:9 HH&,- J!)8.!'A#2'C$
M_G=L <V*8%9C/A ^9<,_"<(N(3ZX#@<3A *RW2@$'&,1M]DA)1*8VJ(ECNB9
M^/;'+41[/T7@/;W.6#^/T;2[I5!-2SHDS"8M @/.CMHEKN;EMKJYMV/SY7-I
M."C=%&I;].Z6VK0<'4JKK=M2H'@\S7%U15(R)@MI4Z=&F5)92ILI,)S<6L '
M;$MI2< G<,9<3 ]MRP""F>, '$"/CNXQ4:7!0UQQ(W1J-:YJL:QMO7< XM!?
MRA2P%VV0[8_B3_B*NJ"UNH>I=']+] JU*1\RE9Z);#J?J)U"L[%E:I>:<T@#
M&CB<O]VWJO:6E"G6UCI716>H6A%U,57T]1Z%KMZB>V@%"/K6U"XMP5PJ'$2C
M2-1M;IE2G>6=M78!C\],$AV 4'Y2$RA2X?=&:Y8PXKM^Q8<#[#=!Y9'=!#I;
M.R$7;[IP2$,)L(E#6ZKI>GZBUI^47MI0N>4[6FJTIV1_J&CZ51IA>:C^[[8T
MG-S;RELEPEE*#3ZK]+^B]; %5K7U]"TXUF_B!RW#O-?3<XEP !*JF<$]#^D7
MIYTPX@CGL.F=+%8KGYCJ2J<R(%"C<"UMV*&4;2G3MZ3!_092  [(YJUS6J9_
M/4?,[U,$[5G@3VP0#Q/V09X>,3,H)!"I!^;;*%6".;VVP1S;??#@7B:G'9OA
MY-09YYP\FK.: %?=#A3))*^,.=S$ K)?C#C4(.,L25W1I_4^JZ==^D'HH^LR
MI=>H'5.FUJ6HZ[:2>^GT1T]<>75O"]I1MW4Y+9JJ'U"TL-'HWT;Z3M[.]N*5
M/^\O6VJ,HWO6?5UZV=2[UO62T/+2Y33MJ7)1IA&L8 !_)A4=ZL^FNF5NIQ1\
MJQ]0.FDZ;Z[T_E#O*Y.H-/:'W%-A<7-M[UE>BLS36+C6_P"&SU5TKU,L*/G5
MJ72/6S*71?5K #S4+:PUF@ZII=V]%::E=UD%3Y9E*>F>L_I3U[T6UIJ4K>\U
MS0[S]RW8MW%KGZ=KUJVI:7#%P?2KN!VQ3;=%U(K\SF/YPB2<T K,Y13Y=3H%
MS^7Y75FAP4<Q54PAA;>4W@@'Y:C'2(V PW]L#@OS#9))PT>:ADJD;.,#EK-*
M@'[TU@?M 5.WL@ /&S'?C :UZ=OA ',IVKEG 5^04QB$(A2>\IAQB1[%@*5[
MO"$6<(N[ZL8"'$Q,S3"-_'#L@9=J^Z%/P@I(1,]L.*B0.Y)3PBY+JJ(UR $X
M]\:%Z6]%4*^L=1=4:SIW3VFZ59N\RM>:KK%XS3["SEASU*@YB4 Q* */3ST6
MT,4JUST]I8O.J=5I,Y#KO66KG\=U-J[RI);4N7.91!)Y:+*;,&C_ ';UK6YI
M,KV]S1J4*]&JT/IUJ-9AIU:51CI%KFD@@XB.I_1JXJ/M^D[ZY=U=Z6U[@D-O
M>CM=NZE2C8TZ[T#ZFG5_-L:HQ^1KD1XBGRU >9K4(,C)8*F1"]\.[=T.[</M
M@Y8I"J/'WP=IRXPN&6,I8P)COA/;O@S[?&,4"04/;M[8FZ7M*)&7&%!\0?=!
M(<G:F^#\_CX007A!FLH<756R7->R4.6J/89K#P*H)G@8<&U1S;0=L.Y'F>?-
MCW0Y'F:YGA#G5:R [7>$6_3_ *;]#=6=>:Y=U!1M],Z5T'4M:NJE1Q0-Y+&F
M],9EQ BRU/U5N>G?03I>X+*E:GK]9O4/6S[9X4FUZ7T9YITJ@P++Z\H$8H<#
M8=0W72]7UD]0[(LK,ZS]3J-IJMO97;'"HVXT+I)K3IUHYKFAU.H^G6K,RK13
MHT*=.C1I,;3I4J3&TZ5.FP<K64Z;   !( #^3.ZTK6=.L-7TN^I.H7NFZG9V
M]_87E!_WJ-U9W37TZC#FU[2(NKG5O171.CM;NE7J'TRJ5.A-2I%SG/<ZG9Z.
MFGN)+B2:MD_(8!(JWGHI_$/>6M1US5=0T;U(Z=%:UMK0NYJ5+]^]-/%5[VX%
MSK(+BF4/O-%Z2TKU)TVSYWT[ST^ZHL[Z^N P\J#0M6_"72EH#FAK'+AB$BI8
M>H/IMU]TO6M0W\7_ 'AZ1UZPH,:3S*;VK1%' 8A^$4OQ7(YSD:XLK* IY26S
MQ@>==5*51H"TBY04S";<HI"GJE(EX:4-0#E.PJ<8INIWU!X>!R\M9A<5G@N<
M-'GLYB&D#G/W5QQAI-8$J%1^!AI_$ ;?FQ7#[(!\X)(CYEWG&.7S6CB0,,8!
M;5!_K"2YQ.H._P"N ?,"\>TR@?.S=\Q6 2YJYA9=D+S@82!E (<DIX)P6)N"
MC)5[90F7'X1(IQ([A!^89YSP6+BIYH:&4WN(YL4:J(-N$5M'T*OY][<.-M1;
M;K5JFM7=RT@RDU7%W,>4- ))EG&F?Q->N>D5:GJCJ%.IJ'073>J<SJO1UGJ5
MN6GJ#5:#\-3KTJCFTJ;_ /F]-Q*"J[Y/]W%K:U+AO3GJ7T>;K4?3CKBBPFOI
M&HUFM=6TK4FL0UM/O'4Z;;FE]YI:VI3(>V>J^D7JK8'IGK_I.X%E?Z9=U7?Z
MY1:"VTU72;AP#;JSN6#S:-Q3)#@4*.#@&/#VN5J^&+5RV02H1%[,H(#EQ!_)
M"@A>S/"$YO'N@J0FWM2%#L?=!YG"<Y_&)/ 5,U'UQ_: C,<<Q 'F=YWPHJ-_
MSE$X=S56]I@I6:G'M@@UP,OO2QASO/! *+SY&:\()_$#8@>%&Z#RU1,&?,4G
MD(=R5#NGWPX"J0JS7=OAW-=$$K^=N0HL,M^DNDNJ^J[BK4;2ITNGM!U767NJ
M/=RM8FG4JB3VX9Q2=9^C%]T;87 IU&ZIZB:E8=*6PH5&AWGMM;I[[ITC)K:"
MG9%&Z]8O7SI[IVWJ-#JNE= :!>:]J%+[W-2?J&M.M*"KRH64W 3QBUNM:Z)U
M?U9UR@*3WZEZC:Y=7UD;FF_S!6H:#I7X6U:TD!:=5E4;5@:1T%T9TMT7I8;3
M:=/Z5T#2M M'^4WDIFK0TNE2:]P'YS@3O_DZJ6>HV=K?VE8%M6UO;>C=6]5I
M"$5*%<.:X(<Q#JG7/H#Z8ZQ<EKP+VETQ8:3?L+V<AJ,OM&;;U0],'<RQ<U>E
M/]H?IM?W#G.;7Z?ZKJZK94.9P(;1TSJ:G=L:T(0 UPQA?3C^)6]HM#3^RZUZ
M+I7+WOY@6M=<]/7=N $68HKNBK<=)]2>FW7%M;N/D_@NK=3T&^KL8UH9RV&L
M6@I GYOE-SEC.*QU?T,Z_OK6@QP-YTV_2.K+>N*<RZDS0KJXK<!Y0)V15;U?
MZ4>IVA,MGN;7KZ_T!U=I] <K>9Y%U=VC*;@T8D/( G M[ZV8RO3(94IFHZG4
M:\  AU*JA!QD1%)U2D]S.9*@;4"@-/WF[5!$*ZXK4Q(N#G(YH/W2@@.?K#*3
M3\K0\G:@).Q<8%0:_;,5P#14JIS%9D 22$HZY:/E\Q-S3:TD!4 >=DX+CJMH
MB$L/XJCRN1O,XCYLH#3JMBXD A@O*!>X)CR\T>9^*HG!?VK6YR$<[[JF)$IY
M@,]GU0IO*)#E1*S)S&"G>(<\WM!!S-#17ISY!QAU2IJ-JRFU2YPN6.Y6#$E#
M%1NG73+XL*K0+G@M4C&07[(/3'I1TA?V>D/JM;JW6U\+C2^GM/HDH65-9K-Y
M"4*FG;MJ59_<2<:3ZB>H5=WJIZI:=59?65_JC'-Z8Z?U ?,*^D:)4+A5K,<A
M9<W1>X."L:Q4_P!W=FWKK2Z^F]6:+3J-Z:Z_Z>J4]/ZKT(O!)HT[WE<VO;%Q
MYG6MRU](D!W*' $5M3I,N?6'TN8YS:?4G3MG<5M9T>@P-\I_4&AL%2K1"$M-
M:DZK3^4N<::AL>5=VM6U>" X5%YF/84J-J @(0<NR/,IUZ9"'!X5H3#'C!/X
MEIP! > A. (*90>2ZID(#]\3.8E! N&!#^=4:%).$$>>T@+,/4;47="-JM(S
M^93,20B:P4K?--)GL2"!5(*R./OAW-5=GRS&R4$-J$APS<I55E.#S5R20DGI
M,S@EUP$V\V^7='S715Q  !^\3@&@8K#'=,= ]?\ 4S:I')^X.DNHM8Y^?[A;
M^[[>ICEMBE5Z?_AT]3*C*S6U&/UC2J/3+?+<>7G>>IJMFB;#/=% :UI?I_T'
M9U0#7K=1=94KR[MP0J"RZ?HW?,X9CS -\4*GJ!_$1H5DPN!N+/I'HZ^O*HIH
M>8,OM7NJ;>940FB0BPVKUIUAZJ^H3@YC_)NM:T_IJU):TAS"S0+>G5+"3@:Q
M(P6+6KT]_#[T'<WUF&>5JG4=C5ZHU$N8 .=]QKSZZN**3RA3 M>F^G="Z>M0
MT,%MH>D:?I- ,&#11L*=-J;D_E$Y*U*G6855M5C:C9R/RO!$/M^JO3OHCJ*C
M4Y^>GK72VB:DU_F-Y7\PNZ#U42,5GZC_  W>DHJU^8U*]ATCINDUR7E7.;6T
MIM%S2I56D& 3Z.5-*>'/<'Z'UOUUI?WRI;Y=OJ/)RK@WE00NF7_JSTU-6LTO
MK:C>4V3"AHUVSNS@$FZ'?N[U?]:;('[C:]WT9?-8!,">E4R>^''2?XANO;;)
M@U'I70-00$(>8VM:U4X3"149;_Q+7WD*[RFUO3AA>!EYAIZR 98H(G_$A1=-
M0X>G=RUPV?\ XZ,?_P"QU%S!]UO]PKUH3>!K!G'/J'\1-T\H /PG0U9J(Y4_
M;:N=T,_'>NG5EP@:'BVZ:L+92!BPU;NJDYS!WKC'F:UZC^I^L/3YFT+G0=+I
M$YHUMG6<FXO,<MUT_P!3Z\Z2OU;JW56$HF+-*=;-R0_+%$].^D71E&O0<U]*
M^U#2:6M:BVHPJU_X_6//JJ"9'GAMO9VUO:4&291MJ-.A2:,/EIT@ .[_ '>E
MKVM<UP(<UP#FN!Q!!QA[NL_2OH3J*L\$&ZU'IK2ZMX.9W.2V\;3%4%9J'+%6
MHST\U#1:E4O/-HO5O4EJRF7E5IV]6YJ4@!/E'(@V14.D]4^J&@/<26"EK.BZ
MC28>5$Y+ZP<XCB^'&R];.M:#"/E;==.Z'=.:5D2ZD^B#),H<;#U_U*G,^6V[
MZ$MZJ#F4!SJ.ILRS QAP;_$-10KRKZ>U?$?O: O\15,/_.3TZ<6JLD75U@"X
M_B,NA44KY'IU3#.59)YFKDJD-.I?Q!]95OE^<6'2&BV8+Y*6&XN:Z#&1!R@_
MO+U>]8+PEH'^K5>DK%H<B.< [3ZIF9@<TH:[4M=]7M=:T,#J5YU=IMI3>6@A
MQ)TS3Z+QS+-'C"4,?4]*M2UJJQ?VFM]==:7@>2$5])E]38?\V*;+/^''TSN!
M3FUVKZ(-=J*JJZIK+Z[B=Y)AK>DO2/TWZ<#/+Y?W-T7T]8.!I-Y*9YK>W:5:
M) K 9:VEM;,: &MMZ%*BUH$@ VF !_\ =W"__]E02P,$%     @ ;#@-6QH1
M2"C% 00 .ITO !$   !S<')Y+3(P,C4P-C,P+FAT;>R]>7<;R7(G^O?SI\#(
M;^S;Y]V0<E_4RQRVEK;&ZF9;E,;V^\<GETBQW"# 6P D\7[ZB2R0$BE1(B0"
M1(+-ZV,U212JLC*V7T3&\L/_>G<T'KW!?M9-)S_^,[_/_GF$DS3-W>3UC_^\
M=_#HV;-__E\__<,/_P-@]/CIL]]&O^';T5Z:=V_P<3=+X^ELT>/H+P>_?C=Z
M-AEW$QS]Q\\OGH\>3]/B""?S$8P.Y_/CAP\>O'W[]GXNW60V'2_F]*S9_30]
M>C ".+WYHQY#_?OH<9CCZ*%@0@-SP,5+P1YR]Y#Q^T)(\?\Q]I"Q<U^;'I_T
MW>O#^>@OZ;M1_18]>S+!\1A/1D^[29BD+HQ'!V=/_2LM,]T?[8W'HQ?U:[/1
M"YQA_P;S_>5-#^>T'[0GD]F/]\XM_:V\/^U?/^#>^P?OZC7WEA<]?!?[<>[>
M7UM_':X4C)D'RP\O7#J_]%*]O'1^_M+NP@+.7RT?T#[.Z=7P['K:^3^^<'G]
M.(;9^\O??7+]A?>KGYY=VKW[W'UY748E>:7XV>63Z>0WHGS?I<N_EN?]@_G)
M,3Z@"V&RO/+]JF;=96NB-^ /_N/7YP?I$(\"?/SJBQF\#N'X_3=+F,7A>Z<?
MT/>%.KMX=MR?O+\R]#,X/@S]41AXL3(/,Y*=74M+A;K4V15O4N\/C(/D9]],
MT\5D?NY!PW=FF.Z_GKYY</KAA65U[^9 GU]XT-GU'_;XP;P/DUF9TH(K+U<2
M##+RX<&8,LP6\?('GWYX<3_Z^:<;1W^\<-%BWG^6M_P#^O3]CF%W^:/I@XOO
M.YLJP>V7&'QYQ;D7^^Q+7;@S$D^)RT1,L ?X;HZ361?'"#BPWK"-,Q#WV3E"
M7+ZH+U%!"& "N+GWTS^,?CC$D.F_HQ_FW7R,/W$&__;#@^7/]:]'. ^#2@3\
MVZ)[\^.]1],)K6H.+XF5[HW2\K<?[\UIL0\&/?.@WO7!Z6U_B--\,IK-3\;X
MX[WCD*N:?NB.WWU_%/K7W>1A6,RG_Z,[.I[V)"/S[_].TI+QW4/V/;S%^$<W
MAWI?F'5_1PCYOQ>S^4/.V/_\_G@ZZ^K+/.QQ'*IN__[>L-K<O3E[6.YFQ^-P
M4@6\?OI#]^YA71/VRQ^[G'$R_/A! XPZ(MK3_PI996^M!VUU!L6= 1=YA)*X
M5CP)Q4RY-YJ$(WH*D?/ARS[O]?WCQ9(\IWOR;OX""^W6?P4?;$3A0*C(0:%D
MX+A!*,6C-<I:>LJ]T9(\/]X[%:R'>='G<'+O)R'T#P\N+/+R-<N<51#<0Y*%
MGJ*3@J")E@F=3Y)'SFU:?<V%!U2"%3 <#2AE"D3:$_ E.V+V8K22GU^S%7*E
M-1>O6;+90K#)@C**]MD: R9)VC$I,T9<?<W::>ZL8*!BDJ!L<!"4HC4[5KPM
M JT2UU\SST*&@ A6:T$[0_]XHS7(X@SSP174^6S-I$0>GN&*IX0]POAWNM,T
M/Z6_S3Y>OC,^H]4*BJQ;SJT%+V5EF*RSH@U"QN_]]&]B16[@5I&P@36"]B*@
M V^]A>Q4#ARC%#FNOK,LHS/69 @IT-(\_>,XER"(0WP6JO"T!FZ@M5F)09"L
MZ00J):0-T!QL$L5*ACPQN_J:LT<50[&0+",9%D:!,R420W.Z5936N"](W:IK
M1BE4BD@\EP+MLR:=X65R0,Q0F&/2!Z_/<\,>L4(>V&$<7G\;!Y0PGN%*BW-)
MY9@*+4EXVH+DD<0KTSX$76(QUCO'SB_NR82T_LDC6ET?QL^J&OY7//FV13)"
M0,9RI]UJVQBQ9&E(PZ(@1>"*@EAB@,*CY::D$&(YO])'B[Y_+U/_B:%_,LD5
MA7_;8H$P.T&2U?8T)R=*9, C:2ME'2DO(3@IQB0T*5WTF:W.I%([9U&37!KE
MZ+V3AA D,9+B)3BD/Q3U>2:5QGQFS4_[D ;79+EHK8LFHB/DH@O)@HL03/ 0
M(MKH13$LR[-%GV+0AX^F1T?=O++J;&^2J\TGPTU^5H>?:"[,01(,-6"%4Z!(
MMX!+),>\N*!RDMYE>HO%I%M^X=5_O3IX3/!EUCV<=&,"#OT"R3P_N+CTS[P*
M3QB])0FSV9"2<%4I*2?!DR$1*=.K"'N-5^$NLJ)UO9\E\A:"J]X2:0@RR:*$
M-3S8=;U*H*6:2$\0VFC:MF ABI2(\PLW!EURCG_\*OOS0^SI?8Y[/*S(\ V2
M<S@]PE<3<D;'!)+ROTS'%6+]$KK)\^ELMC\YP+3H"2OA;*_O9O01,2/]N[1$
M+\.[C[? ("$(83F0!28#)V0$KSQM06%:V**9]N;3+<B8NB/23#_> _JTBB6M
MVES@W8>$8"%/YW!Z+6F)%7?*"$($]&3@KC*88)(VR4;0##&8Q'A1Y>.=(HF(
MV.^7_>,!-4]>'^#K@06^24><?]_3&YU_YV>_/;WB5?GG7O4C]:(B&2["FTDE
M5NT)6=HL$Z3DT/MH%%?AXS<]7<\+K!B:7O31-!^1]N[>='D1QB\KD">V__T4
M,._WO_33Q?%^OY2*.>)O=+<G[QV-)Q_\C&_3II_SS?[QT6&'Y<D[8L>*U_=+
MZ1+VOV(ETR=J[,%%A-YC05+X"6<__5!=_8>SP;.F=8T&U_]A=6M_O#<C/V)<
MW>SA;X=]77;UG^',4;[_;I;)/1EN?_Z>PZ^SZ:(??AM"&0]/WWT@#+T[H_=+
MA!]<=!X40T6X4D600I(^)?6:6+QW]E4<#.G9;UVNOY<.^]&P;+S4:7[T[%\O
MFLV/OWQVN]F2W,M?,SWLW?&X2]U\N9.CW!U52DXG'QCD1761,/\>^OG)R^H*
M+CEP]O/)^4_VWG6S>S_5[2*.^EO7+V9[KWO$^JPS(EWZQ*]82/48]PO9PT#Z
MM][XW#.?$S=,9KCJ,Q]\M!D/+MOYXT''O=^X.;UF10D_+>,?&AA_?Y_WG[TG
M8;YPJ>0?'K'\Y.SWLX<\N, VG^$B0?B!L#GA'$+D!'<->,XYZ, X$QF-0M8:
M%Y'\/OR]G^9%FN_W!]B_(4(MZ79&UM-/-T\QM3K%#$BV%HI)26B#\)YDKKK5
MY)U&<MG)I6*%D<-== BM4>R]89C36]?O//G;H@)[@@W3R8""+I"O&H+IY& ^
M37]LGH1\&R0D3*>(>DEX(J&(!0(O&0SA8&>UUTJ4UDCX>:$;E.4+?(.3!:&^
MC/W!XOAX?/)>;\XV3$.].@WU.FF819%:$-&J-R\)]GLL&M"+H+F,KEC;&@W/
MY.MIZ/K_$\8+_/GD_8__0G<,?3H\>4Z4'%^4Q_<7/9L<+^:SX0JQ+A-\;C&_
M8JA'84,THL>_+0@+G7QF)><NG;VH_D3U(-;/:,N#DOE2_D]]\HN??!/OK 1;
M-\L[.R)E)FJC")XDK/%8R2-$;@6YI899&[R-!5N5LJ4?_-[D/9^FP8<YIS0?
M36?S_?++=)IG!^0DWTX]:4L6*==3:!^(UQ6"]XD6(E.2(6NEL5D]66,8:=IG
MS*^(EN3 5OJ%\>_DE1V&&>['<?=ZH.G/)X]H?UY/^Y/]\HS(?79%OJB]GDW(
M2,ZG?8>WU"8ZK8OB1.N$@TO*(0:K0#O-N#>":[=QO7:K<,VJ[L5::1@D"J5
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MK:PI,LEDX;0"J;T')7F H$GC>X=*6I^X;G=\5@M'*2VHAY2RR-*"L+FB+B;
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M0S">:2U,9.K:R>P5L>W1FZQ3Q:^;,$.7JLT#NW4O^[M-92S&++GS EAFGG
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M'+;'M^KJ\AZDQD\9,T*SFS\%7F^Y%+< =:WGT%JSSUMMBLKMFV<NBT&Q9U=
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M@..71@"&0R?GT;#BZ0"#]XDI;I @C)5@HT;:A>POLH2QD4%JSQ[B*NX2&,2
M$@K T$/?$&*,/?0-WT[BI:W+1,K+,J1G>0*KO]7?HK=:&0R$3<FY8?/P@U5:
M^V76A[=F/VXC0U)'=6(8N>P[(NX"1H8)@@CQ!)- /5O-:-HD<#G7<"\[!7<V
M"F^*=NNZ)V[7]% #SOMH>FS<BQXD'6"I5^P*L 2PM&-8PLXK&8W(L.0\XE)F
M/Y9RAQ3W)DF5@8G0;81)]P=+<J!U'[-J3@^6'BNBNE<G^1"]X _CJ1V"PWOL
MED5?R'F(=L.)6P54>&,#0YK2DCSE!;*E7E,+B4DBTB>RTL=AHRS;'> _U63
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M)IS]3(L5,DD'Q +!SGC-G.);F\"UV@Y^!RXF)[J'AL/I-3( 4 )0 F8%4-H
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MM08OGFNP*#(:4U"$6;*27O2@R-^KD1]?Q*+VOMW0:/(:Y)]^KX^U&LBO]'
M^;_-3M_..9N5PI^.(@"8 ICJ+W<>!4SAZ&R2&6@8+1V'O.+(I5C&'2I&5<@^
M6USI5O.@T.#N8(J( >MEE+ O\@\P!3!U &P*, 4P=1>F./'".2)1-$$BSH/.
MGE&4&7),-(89J^16FGCO :8T'RC3QRAB7^0?8 I@Z@#8%& *8.HN3#G->/:'
M!/*1Z0PT.OM(*I;Q1)H)XV4@<;NQQ=W!%-4#T<LP8U_D?\LP!>6"_8TEOIF>
MQTE5M[(VJ$9Q"B-N3S[V"$E,D,3TB*UVK,9>*X\"%=G04#PAZ[-3C!G7-&FA
M;=);B2X6S?=Z/!K?-CBVW)1ZH*#&\ 2%O"^T T0"9@5$>B@B"1F,Q PQ4P:W
M!R61(X0B6J8LXA@)UEOI5+HG1-*TCPDO@$B 2(!(P*R 2-]2Z,$%IR67A=CL
M]'!L+#*21T2%P#AHA2->\9$VBAGN Y'$P,C[1_?T4L0!D0"1 )%.B5D!D7ZG
M)@!'2IDW"%,?LH_$-+(&Q^PHT1 \#T[X%43:*#RX'T12X"/U0LBA#+&_H</7
M<5H-QPV4'H(AT0MV_G9*_P$LBCY9%(^5TD2BQ%Y+@I0W'O&$"3(X&:3+7&E/
ML!5J*W6,65'NL(*1#[1F8*ST*>'I-(T+@+\#X5J /X"_,B[8^@Q91"(1<7;9
MDZ'()!)*@J\TD5-&^0K\;1+6W"G\$3H0,,,*X._QB0CP=R!<"_ '\%?F#S,?
M=30!,1,%XM:*[,E9C%3"D8OBYKFMU%WN%/Z4'F@*WA_ WZ,3$>#O0+@6X _@
MKP1L8S(\$(XRS)D,8(HAG;3.?R49+36!F)7!&9L$;'<*?Y0.-(;<H5[!'U1[
M]C=D^^+<CC[&JAYE.<P$'N:G#]5'6X^:RHY"&\W-SYIUA/UDZZ%UPXBR_*$F
MRVC51#^;U--ZGZ,D(> +-@]DCH&I\\#Z'>D4BSX@;'SVU5/^R<:D$!4T$$TU
M<6H[DRI+;MJ+\45^\/,X:NI/L;-\?KG6M?\]'I:5_FO6N,4<>C-Z?ZU4SR9U
MD[_Z*?\Z^O@V3NIQR*;3F_3!?MGZGCD!DZE7)E,/+)M^J!L 5 !4 -3> VJ0
M99Q,THC24A!+F$7&6HV(-,)[;?._:FL%L0< J!1:/ ">]E'; )X"G@*>]AY/
M+=.4:F%1DEPBSK!")F1755/BC2.,L54'=>-RWD/ 4PD970"H?50W *@ J "H
MO0=4XPG/'F5 5-(,B588Y+012&#&$Z>:">6V5HU\ (!*#)0S]PI0H:ZYQT'R
M97F&"N>C-W_H4UHT3QC/W##VS@ ZHC2_[R TV$+;RW-/ 0=24MR%XHAC3Y##
MSB%%) V64V?9RF;])M'O-6;0KLP9+@88]W_/_0Z_'[M-<YJF!T#BP? M0")
M8@N)FB9#,RXBZF)"O(2AG>0)&6TCE3@Z+LTVXM=[A,12!\T40") XN,3$2#Q
M8/@6(!$@L6L&DKPP2D;D+<Z0*+5 QF*%9.#,::MID'(;(>@]0J(R ZP-0")
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MU7@V;:9V5%ZXFC4QE)D ?GQQ.9N63T:0]0)&9)^-R,-O"W7:MN,]E@TVP8A
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ML("C84<9MD6!= >@M&%'^3ZUWC86ARWE7FA[@$[0*T>B5\XNLDTR!;W2'U$
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MGW,C9-G>HPV/I9#LW;A_3=13S1DVV0.0+?5\^IM9 /ANJ1_L;K"[)F+L-DD
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MC:7BA[2/\_DLM4-LIR>^6RZ:A9DAZ>\]%5&+L2[U6.KAZQP[/#@XK>,43_F
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MMT%$ *Q5K]UF%.OY^8:2O(TI<*KF(XR_C+=P#.\<E[-4E;^E8@,( OEJ>#'
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MU$9D5@TJIU?8/_3OP6TW@(3#O5F]X/;HW3F#4YBNJU[<:'S<5:O>3BKNI%>
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M3R#7;5 <C3D3?<8+SC98 ?!Z0MBW,F,V?%.H$:S\'%AH-K? N?WNK_)6D6G
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M K9V.&]8 G_Q2L,KP>K@#25(9AI@/XPON8U>&*;VWK#2P*=*$L$MR$<5*D
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M$^ZA*D%V\T@H-<BE\'+&VY+ "PI15(9SMM\>Q 00;U01922\H8;7M,H6 .>
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M9[N]&(_^<Z.N:7L_]M7D9^YWOS$K#0$H5QOXE<*T6RCP-[_=05T>/OE'6*1
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M^ 1E:&M[*<25MD?EQ)/0%\-?=GIIP+QN-=+%5G * +\*\#]TV+0+WUL6XN\
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MF!N6.+]?I(CY\Q">9W$KJ3TZC ..C+SQYD7'KJ-UOBV;OEY.4WZ*;N#)UQ[
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MV@9'RBWX<%W5,P**["8J)[>VF=V$Q()@+IR%[@GF0D@L".PZ</J=D09=;S5
M+[#30%.-2S.XWB.GRK1[4O@,M?".4ZM@-EN19Z1@!3A@4@B2<VT(<TY;F5H1
MQ]E#IRU7E#%;@-/&$TJ$EH)(C!0Z+@MJC5:2Q5_93NO9FBNG?%04=*#.VV>8
M\XS[C P M88AW@'( A\'(#L0D!E&,R%,2B1- 90*%9,<^V'9A!8TIL;!WT<
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M&G*_O?X3V>G?:F+Y8#AJ/3V>&R\N>,AN*DOCU<P$-2A>4WE]V5M<$C1KNQ^
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M22(35B3B4)N1SXT;;)0G2<"-@3N384ORR,ZDKF[0=_35D >M<X,9< XD#6;
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M?RQO,>MXS4[\>V/=?/PCD&"-F4AC]5LSK^^MK =B.S!QL6Q-_-"[&1!3(\G
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MU,S$<<XV-FN4BYET.B."IIJ(-*9$6>U(EL4)Y;FV*5.',367[$HW2]\!QV*
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M7"+=R=.EN^!29(5W)'(MB"P94* L'%$61$]0J2CB8*8]ESI1%PTI.0:.8]"
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M&#LWQPW.6G=F[>[>Z]0\+6*AZ(=)4A"P2A+ZD2B@=N=(BD*G8#T+VCR96,8
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M<W<\8?N]>MG?>(W%7AFS /L3)Z]R8PQT8]0&[1_82S=,WF&?O>IL\N_V!EN
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M@JG@M2^H/0I/R($:HZBM<-:1J"+(4FI#'=!E+H:"<R%B&KQR::63(H(Y:)4
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M"0W-[(/HN;NF0'RY,*RV1BNP->LYA]758I;%4^;WU<<%^HKL"3 W*UWIBJ2
MN14H.%X"HT;)2'*6F<!-2=D@*_3!,:/W[0YM&/EM^C]VMHX_7:%$_&7^YA]K
ML-#?10\Z M7Y<_&Y.G8^/T!)C:Y$:JIZ@S338KU7XW5@?C?/870T;J#G'4[A
M^.EFNL2!9[7NQFU>7<&.SP$++"N[O-U,4KF&"WPW@G2OSSQ[E'.CXO/)FVD=
M' 1P< N'?9L=;=,YXMK/.*H;'(%M./.C8!/7<^ /$$- [W"^((?0KO=7[>(6
MO4>!^$$H%GN/QX0 IE]7$Y^9#J_*@V$6LWI.:HMD'K-*;ZLVBZ%+<\C/FN+P
M5G@%?WLVF:8>3K3364:.!P(**SAJ=&I49_@J_2MKCJEJEWR%G_;]BSD <9L#
MJ8]QS4\NT$?2PZB;T;7;P=N';5*Z*R(R0=;/L0;8B>PXS3-O01:B,5!S/\EK
M0%@Z783A*E%./'A]FX22_%"X" L)$6PL83GM+_6"T"I[92M8?JTD 0_'V>+C
M#X>6TCNM!^S3'>LXZT*TA]_0[N>=;BW X:OE.L=NJFQ(UO  GNKC&)391!1O
M4 PV.]MKHW7'P;G;K:-)F2GGL/O3F#WPU6*2!^$"!76G<06_7&_Q?L_HVJC"
M:C?&MTWGTYUPYHY+87/SZVF 4R) M$T>) E@]JWPH0TD&3'W46)N/#@PEN%,
M9O$07,IAXW8@,]SA XHD>(V32=WBEL6DHR'4<X#AOK#$*J4(%P##DU9%*08-
M:$88_GPPO-9R6Z((%.W$ULIM(PO/)K JWRIBW(&&Y(!\04[5\A*)'2<[+VNZ
M; 57)TX];&]U/GFZG-V3BF2'Z*Z];W/5@^0G[!K)C(1<6*$^G=1B<X42_>,D
M1UX:2=I_%<0+TWE.<KW&L<.[''J_+1IU\C[7>?P +%N?U_T#]QD^ ?C,FQQ;
MB5FWN)S L09D@"T?+!!31P@_]U1P9XQNH/$$KH=[;A65[4Z@KOI37(Z)^4]@
M7#%5-IK( Q$\)"(=<\1JZ0C7PH9$@Z+E8""$\$D%YA0).'U5JI(3HU,BB49C
M<(!KP>QN%.(=6%2PQ/^9=??L8AXN MHM@)IS7.+-IYL[RW<?-K?X0(50""QX
M6Q KBCS'0I%2,TE\Z;43P9G$!HJ0)@E_E9'XE!3ZL"0QO%2$&D6=";+TZ* ^
MNE<M35$Z7I;$F)(262A#7 $OK:)-,8#BEV98#.63]S(88A.%[0DB$,=-(L*7
MNHPJ4*T'Q5!OT05PX?UR';M!NJ#;_[Y ;\(2Z.[9!E'+/5K^\W\X'E'0C3$'
MU87E'#F6#>*JJHGEK$&UL]H8M5L4@SZDG)_=V)[6^UKVH>#$4!!^&+)ECY7@
M]7U7\#^U#P $^.(FU@"BS4Z^AK>]@LOP[K,%ICVU-K!?+.N$JYPWM>EJ_+$1
ML\M0]Q6I/4*V/OON>TU>YWU7Z9JRX>H*734VKW5O_? Q'.&],KOR/_O"O1(8
MJ'2.$LYB!!C.!;&1"B(*6RB9$BW#H*_]XV9=7U]/5_GD0?3\E)<(M.7A9'Z>
M5AX.&[#VH3'770I>N%C==]'_P>Z7[_+T>K>\DVG^'W[SBK[_?E^A(.Y>A%.>
M3WJGDCEMZUP>.'[^*U6\?86ZP5\SHC^Z&L&GYWX(L,55P($590A$:C#'K0*%
M&Z-+!3?6*LN?0QC\&JLJQK>U])]?YOW\.3M&;E!H'8D%\LM\\M:O%MA7&V0^
MVX;W.W6++Y.+0R7F4XE(A/ @YTQ0Q"G&"8LT6)I*'8I!J-+X@M&H+"G*B 7G
MSI&2!4J\ QP5+!>*%O<YC_=@-[U-;5GY%A "L]C_"+8_MBNIXK$<ES!UR. S
MD<%C6"H&:SPBC%D>GK!(:8IH Y\\F<6<M],D?C5X=7(5;<@N070<YAY##6A[
M!V_S\S1>+LXF/V'5R (>;\\GFQJ9+6O9;K+:7X9BC3)%U(4GR7.@6)? ,%$<
M;!MM9;*\T"H.LL>>2X*\S<+C_>+-)]CF<"14F2.CZ'.8+P#NMOE9,2^Q]@GA
MTD^ 9H?A*'BI7DE%FWYF9^B/6U[68:8<J<3(VS+:":;6PMWJCCQ=%:E?5*OJ
M<_'\8]B!R=]0O,PP6#<'R+#)C OKV)O26S-P&S8/&&'OYC,4V7Q@^>T1X<[J
M0-YRL;Z\ZEV,/+L=H88WR^F FZACEG5=T#D+B36Z5^.G'$;=.%?S+3>G5S]A
M$SB\62X^3-%X2NO9K+Z/=8V1ULMMS*E]]3VFR]!ZP9I'-!M2+_N8CNRB24W(
M9B(&G&%)T^L;@'O3U02#-=GKUUB&S4;ACP%,DNS$K;^3P\"=(]'=-@5]%O:E
MSHF(F8[QJ&I+T]>!;LQ7 +MU\1&_C;<Z)@?O?@$> 2($+3CA*8((YC20TFA*
MDL,F_TE9/TS_I2)$:D#_NA TD58Q8BPVNG'2T8+Y8()^* 3<-?GNLZYL\AT#
MV0%R_'<+%OAR7^>,'>38\".02\@L!W]$Q;]?X==?[G?#^%_][UVT=VD[89QM
ME1O7@9S^6G)"\#+630NS%)_,X7VW 4G3!K[-\H6E3MQZ.D-'3$X\WM\@9+58
M_#FY6< I5U5/&@UNGX46Z)%J!:O$#!_DHUG<DF @=^ @0R?M 'C^>3ZY^))E
MD?<Z]Z/U$9TU8OJZR07:J)F#YP+:_64@(F?H\1:)Z)+C)$4/<B/!3Z(L>4%9
ML,8, [_!"EJ(@FAN))&"!^SD"890,E8&+TH3!@4&^R3,[^T.=";.7L,F:[<C
MD26B. 5H5..!\PXBU036(:0V#!I !L7YH^0$8H\LKCZ#F\XPZ6D]:PL3,!X[
MGZ]SHEQH%X0/.8$@6*F!NH4M2&(V$*D\J-2"":*8%,DQ4+E.#V;T4!V%IX:(
MH SH2>Y)Z4!M.N @[KQUBO)!N&2+1]H2A&>*D=#SXB0B(-MXNQ:5SVG@O) T
M+0((0N4#T3%BCV.MB $A"7>Q8%6KR(R/+X77CM+@?K\3@\=9-H<-[R8!LW^X
MK59\(9=>&2RUVI+2%L"?FC%B8XR$!LH, Q5(F=@]+\NT\RPIHEQ4( >L(@[8
MF]"H+2^CY#X-YF[MUWX@5>WLH-H[+G]>G7:1ZP$^E^Q_O(IQ8W=?-YJQ54%U
MEA!BV?4LU+5_?0NSCWLG;;X0Z$X"Z_U@I[/6HKQ/(<3^VM_/F9$':W_O;8I]
MWPE,.=DM&WLU%&G*,O<;;-NV$WH/;)4+'S)NSREGBT2P2Y>MT.F 5%4+L$TH
M''B]S?5OC,A]WN,FDH])4#50VH3/M^7@"0 D7K#"8U_=(@5*9"P$ 0$J";6L
ML$HSK\IBT. ?0%")UP2/0]F52<04D1)?"A.2<4#*9E>8YIKDM^F/*E[@[K]U
MN9@__#)_\ZG./?SK8KDM:C_?>O>A*.IPY_]C(/8NCP0H#QCS*I/?/>D6CQ.)
M]1ZY&$T*Z>?-A5U^ZO+P[+U7=1(F@I;1):\U&,8:&V J3DR$?Y2U-#HJN"C]
M<\1;OCX'L!.Q(QY&SL?T!@]WEF_<EJ!5=ISF3T?07X!]I.3!AL2!?1@@:R,
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MO,;#_CG.X?W^G"PCK*Z*F?_PZZ"></NF:0HDM;BY@2?/5V=PV0Q^MY/Y I1
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M:?41W6FSJ<]=X;$9LU].;S*CIQC'UF2/J#0LI'1263#V$I:$H5 W#/YA)5-
MR52(07PUE%0YZ00IA18@&0M.C  D#??R0EE?Q%(=7VLR?B)M:T:_\A=TTC&O
ME(B1H!N9 !M88A3G)'(EO'$6>Y)]#>K__]E[T^8VCFQ!]/O\B@K?VS?D""2[
M<JU,:=Y$J"V[1Q/>PG+WQ'QRY"I6&P1P48 D]J]_YV15@0 !2MQ9H,K139%
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MK=^/P*Z[?%3XI2MTNT:.'QQNAQ79YQ,B]J)S+0/H=VN+TR7*N_](LS^ZTUV
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MC3B4Q\N\C^N5<]ZA6,UG\?)J^QC*7>B50Y&CO-Q!PUV$.UU>PB@L3)W!PE9
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M"W?7G2 #N[]]?/^/@[N CP_OH3<1/'*2SDG6NXJV_-,.7C3;<-'.C]7RA3T
M9;A<>F&!"29@EB&SFR(=8\,M!$JS]L ;<J>9U<<YR?-F\;T[LB]^O+3N.T?S
MKPCH.&&<93$2;T0@0DI+++6,,.M-=!',]+AGU2:;JLB-)V5BN8%;($XE1R(-
MO.0^NH2CIG;[QWPW;P=K_'[A=_MN:NNS9G@!GN\OQT%:CRXV"5W-NX/<",3M
MLT(T^&M7/ ;8L/,5H%.KF/1XG45L WM"1S+<U,5A.JXUOUC"Y,*SOLVBFD,(
MA@__+(Y--AB_O<GW<&'3KV!Q'97YI-B#TJY[]S#G?$%;WK'&+)T8-N[XSKW;
M4]O.[E^P;UN?;K<^O+_&RFS0,OPYZ65LU\YU_PD7R3QX@J%N0(=8OH\A@Q5+
MA#;%)=FOW99]P&OY%ZI*BKI]U98*.<''KY:U6_=NYLSV/L[7TXN]PEFU4V9@
MP3'[T[L.?"CCI_8CO%I\^SE\Z>  KT>ADD78>G4Z7_9MM+)NV!</8VO^?DTY
MRM=$D$N'>/>VFE=G;"C>+P$/6C&'P;F(>A3&:]JD*/@".>XD2X0O+&,SBP>W
M<S;/VC96=FQTIMFZSR9'DR"?XZ%%;A?HY)5N#8":HH:'16^S .B><1[V@:<<
MEO;C#$':M4F<X'9>^&]W5"YTJ766Z&;H &++,O8*EX\H,K:G&_2O_@(\ 43R
MVTT#VAS)P3Z@ $Z/^/,O' '1A3PRLO8QS39*M>4NPJ#0'/$,UZ^^A6=\J.?3
M%M[=]K8Q'XEAB?ZQC'#S*=Z&D2=@=LOE.O-<Q+CF2['.(7#EFXZ%^8J\87L!
MJ2PP?CE;U*/_Z\+_M5V"_%GOUV?#T0C5+T2C?UX#RRO:"T^6)].3BT(W^.Q"
M$=T6M*T%F._![H<7/JAN,>\Q31J,5H\R </7W5?SY>J@E;_MU[@\DF43]#P"
ME]60.-#V<)Z#:+"+57B.[:RV2V/<6C-J<]8[U[3'/=D2L9V_YD#J %:M7D*+
MWLW:!:/KF4?_0:?K["J:G;CH5YO5UN5\_;[5-$%83#MELO6<@!Q'C3)/$?I7
ME^!@]Y?I[>*DW=IEMUQL5J#AU,UI7U$;/R#N[[J!LD2<].UY,N+:A77UM-TQ
MNF_ZLMTS!'W>5EM:G(]B*T%B=(EL,[^-K=TY*)K6HLT>ND/S@'H>N 0-\/T!
MY&X[X5^,!MIJWP \B"OQ:OA) S1$*L%B)4DE,&-UF8@1T1+JDS>*,5NIO09Y
M0?N*1J=(,& D"\4L,3Y(8EF(9<6Y-(8>&@[4M7#8">1^_X_?;MFE@1]+EX87
MV0#XE-OD CH=0V</5CHN3$D"-0D.V%BB::5()2IC:9# #?=:8-TG4MR^=0<_
M8<>!%& 'M:8;R!B[;+[-Q=X@,EKG6L=Y<G;=AAWMJ3^84[>1/9UA=85,WA98
MFX8@-F"AZMG&XL+1KX"K*,A6.W)M*Z 2/V%/_<MFW,:%@=(*<&)IYTLPVM%1
MV8M?O*57_;)VUC>=V!5^AS9ZK0FO8R7R6(G\T)7(=*Q$'BN1QTKD8ZM$'DN*
M?[]*,V@CM#DK/**'^X'F,U36!^\L2=)((BSJDQ;.B\7@A+8Z1E[M98V&9&-I
M*^(-:)Y"2)Q JA5A.DH&MHJA5?A"UFB7Z?X&E)-=M1$]]B1[D_%^$NQYC@Z1
M.)3HVU94&,/I_!@F-DRZ<O+L=-F*(;^HO[TH1^A"R'WCLTO% 6B&9W7U15U_
M>]DYDYO#SG:20=RZ <;4--UG#=PWZYP_ON^(M5WCD)'=13\_ T4V)=2N/N2B
MEEP:,0M]X.PB^+X32?FV#3G46XL#B) V;-?6SV/ H=Z/OK5)N5<$^@X3)@(S
MV;KU<F*@$..9I_VM7=CN8<A5:&89YIW;R(!<314P^5Z2I)G18,MY:?<:.]Z8
M7#<[W0J&OUG'W^<_=5#Z6][IP7$J%TGJ0T!\TQ8V'@&)%EFGQ(KD6"^R\=4'
MW+'X"O[,27U7X/6UK+ M/?#N>!BKRFII-=').R*<\<16UA"C6:F#]D+[O7)\
MD/XA5MB'@&.! JTJ8GC7D2"(RE?QHJ"E3\MXMYK[/T_G4U VF^__>UVOSK$I
MV9NZ\=-Y Y3W.SS^;U.XYILB-F AHQ:Q7,?KZ:1W#\%E:*39'S$O[0DB<M>;
M*T1/D%6?8388PC,SL&W(]CR_A? - YE/%(%[@CCFZRY_ "3GNU.[C,T8OMRO
M.;]P(F&?&Y"6K[O\142ZWV*><Q8*'%*-?6LP'0>8V]N9GR\777/#39X&+&;X
M#ED?*4\<"Z?*$GA9F22QV"(&&#FCGG-E=-@;8Q,L+Q57I&):8*E6(-I;1FC2
M5@3/X1:QGZ"&!)RIMD6^"VS<<= V^<MMS^S;GW_XXE3O<E*V_Q^VB[;=7*Z[
M;?E9@_"8H!0L/MCI^BA:YR>E1:"5A].O- %)B86=O"(A,.]]*%6E]ESX=\28
M7^WRE^6[3'K_1##]&I<9B79=^SA!+^2KFE_2ZRSN[9O6"=Y=?1.D*D\ @G38
M^+0 E2OC5&LA#1]WI'.*&BE)9!'T+B85<494A.H0:=!*'^AO<AO<^7494\0^
M90_#<.C1\9M%#Y"C9#E<2%/RJ(E3'EA.Z21Q'AM/*1&U==98FNX?;4:N\P6N
M,U;07@FD'7L%U,:X_- 5;?S0%D^];3 Y;;>$]EY-7%.I("2C) 4&-&,LBFG#
MB>6*.YXH*ZN]RH.;F+BM9]2?QK">QE_2EK3NM_O#?-GO\G=TJEW#V'U XP.O
M'JCY\=V6,HA-.2^0I:NTJSLPMME$3<X9O^1/?#DH%K&%U?^CZ/[[GZOL6;TJ
MTM.%Y'!Y^'P@?KR<3.WY?+W:#F?2$ICD7_KK/;+:11-?-A%$&G#A \&?;RX6
M :O81%.Q(C+GOIV_[)^R<RE<&S91N3;H1$^D^LM54:<VDGKES?3Q;RQ/M#ZB
MY=[ZQD<XEO_YU]7R,!IU46>4;<[Z/]\OY^M9(!WII?S?8=)#7W,;D7_9QN7Q
M@RLQ<#?X7=(<TM\.CL(''] MX>VTXW$MY]O+Y]BZLP^'YL<=X(X'A+J^I\!X
MEYUQ[>CW;4/:JS "]($!"KB.W_]_W[!O'@2XFVR-/A]IL6KGAA2]:!LL^&^M
MHE[K='8:VSP!UG_F8%K&5_+A'LVS8C4/"\!#RO+(6)XQ8[F4)<+$R%P&Q5R^
MJ(UF8VY?'?4 M>3OKGD>W-Z7CAKNOR,_N]^LS%M2U,U-^OFB[2G;UWNCKQZ,
MVF8%O\"3;DU;S_$4GE8J;[]]-K\6/.]%4#\H2)\$>M?&Q]O;5!><]R$AFM_^
MH+SB<,Q#)QH24X[(Q",1E9#$&D,)I\SP:%,ES-[L%B-9*;C%>YPEPE? Y4%0
M$JV"EB;YLI+I,V'6;EYY&R[;\N*V+NO>EWOWZ%DU816=&'-U]&PDW&='N*,L
M>0X@?58H^=7(DA2E,I$%0CW&SZFG1)><DDI65$G#;+6?[HHCM[3S@AB+B6$Z
MX-BG4A)#2^D98XKJO737)Y E<D(5G5 ]RI+'(MS;VIY]*&2T/1_8]L0LU67M
M5WVR3]?R:[0^1XWAJ!G/J#$\GL; J$K2:D:,I&!]!EEAQITEJ:J2#2Y%SLO+
M&@/WRH$N@1,\.&H9%#..J"#!65D:XW62;  :PX3KJSMYC#3[[&AV%"// :3/
M"B6_&C%B0I(5IXZD9"P1#D2"\6!35EI)6:DDE-FK]W7!<:T$B!$;!!$J&N*<
M+L%B%='9Q+PL#[2_?FPQPB:5XJ,8&;C-.<8[GR+>>2B%V7ZTRY [++?1T-8<
M;4;K<U0;CH,%C6K#XZD-LE24!AU)E7PBHK*4:$49\<91SKE*J=)[,SHILSR
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ME6-WG9@D<=S@7%W.DF-6\WT;0"66@K><:"\"$5PFL!M\292MJA2%"KHJ+]L
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MPAR5U ?N:&+[H9YFU6",ISO*;<9\;VJ#.@ZU851W;^Z=TYQ948*2RZTFPOM
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M\??.W87^WQD:K*L>(:XP#H>T[2,P3TM;F<@J,+B2LV"4^)(8S@)Z9BITP\A
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MG//1JI#\_?@H_6D,ZVG\)5TVC;<\9W\[[[Z\KM_R.JM_/": CL^!LH%W.RP
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MBWV_HXL] 8Y_YEA:-E?RX1S,R$B. ( C(WDD1O(.3+J1C0R/"D:M\CF<X@C
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M,0<9;0(GLUB*?&J9PXN<\33V=A*W(<\\L$2.E7+/M7S72ZW$3V+++>S C8K
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MUS?P0Q3%;NA'T3_MLW^MS[\!,-CL_?L0C8EW]YQD_?FM"B_E+Q VT];%__X
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M-P"[NL.6JUPO ^99&S1J\H_?OSNBT[#U4V4P6N_Z<] #U9,HX6(\KFHHQ"#
M^"HI7_%V*$>35'XW'H@QP,20Y)8'OTH2JS]XBZ>;=IMIF8HCN9BZ:G;*U-):
MS-"?9NZ>,X?%/ZK40_"A%:+-E&$J'D\:N.0"_ #0(20I-Z/T!UQ&/$,KS2\Q
MIJBNAPG.]\VF.&IZ4TIDW#(R4^F:+$@3FRJ-D<'2;>":1?1Z@QI0\''_^<<.
M8K6%8@ARP(H-Y6([.0*9!,CY6AA:<7SD<J'>>';>J^0LGC.3[=.-EJ]48(GS
MOXA@AS/%\9C3C'62:5+IPKY;P>#3<:""917WFG8._J7&)FIL>N+EY=O4V$2-
M3=381(U-ARX;'>@/9$H8=VW0.4-R)[$#N\]L%F,<W658+85[56#CU9?$X:J8
MEAE.^S.Z"V0>J<I"Q$SS:!W=^Z;]A*9>'"+>J;"W0,+R"S#)TFL3#@7XG_!?
M#D9G)9QXF9[<@,'/;SK+N6[VCO]*% '*H@\9#:1\3 Q0:O*6 H=9L/;]+%C[
M005KE*D<%E9CX%%RYNV'/HZI,+$#GW)>CQ'JE,[$V&;/=JHY+)CE'R6#]TZ.
MC'(5]Y_#KSE"\,SX[8N3SMI%90R;99MF+'Z=)'1>SW-]8C-W/8MJD1-5)205
MFO6=3)7<J'N"7G>6?YRH8G=OJ4:*&\CYX8N-$1(T7>9?GF15HO%F+K69,P0#
M75E5V6TL7HF],C'8]0T.D7WF>4D0>],_Z,4L0K>%Q[HW0A-!PULA2PL?W[W!
M$!K#AAUPG5X;GNS;;C3]$\.#M9D4_RP*7">*0S]QO<B/W.#;M^!6Y#+:>?.)
M\S6,LQHEI:(D(;!;9(0.<NRZX>@ASR*1Y:UTT<=APP5W*J[;!H^/8)_QUY0#
MOI:*7^>FG99A]V.Y,V/P^APBQ]O11)V),,424QQQ*'5'F""%?V$*#Q,"E['J
M#C[6:%QEQ<RL.D$4*8V$B..=FO:<U>-!,P,;[_O?/LQ.DI)'UI?JH'$(?/G
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MX$'K QVJ#Z3Z0*H//,GZ0(TK''Z?.9)#4Y1P"4>W<Y_#.+>CY"0>?D] ! :
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M$.%;TM\GUU^*$(]UYLB-TQNT*4*\868P04ZAX O$D)<@3$*5YT,5GU!%GX5
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MM]^+WYVWWXV43/*YSO1NX$9V35WSRFHYN)@P[%%B>.W,0S2-+Q(^[7P#!]B
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MM*J"!NL?%4UP5=+HBMS.E_5:Z!QJ#6977CDO:-RDP;=93NLZT]BZ^#HZP+"
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MT>3KN?3 0YBDT3LY-X?>K^#UK^\/3DM.#GO*#DH06>7B5% QA& R-O#A98?
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MZOHAU'G!R8N"W:.*?GMD*M['/.GK/:?OH^,G3[Y_]N*)_P]'9N0G#)3DJ$/
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MM$"Y3J4R7\"B7'LAP>?D@"4Y_09!-<F<.2+>O-K03[5@U>72A&S'IKFX8&3
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MD%[T<)*];<WG)CO]D27M1U.!_[+.?BP;N>MQ=OK/'NA_\A#"WT,* U')X3H
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M^["+Q3[;(-F7-T+VW_+B2A46>@T,^L^80LL?!PR1KN7%NI_2?(J/T36SDCL
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ME(4F><&PDF1H P/#E454ID:.H_;OGF091&JE'O%+,Y4$GHC5J*S2#\Z#0EG
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MSN5N^\N[/-_3.,NP5GHG\I)=LT90A]\]>O3GH _=O9,^ZJZ<7G7 D>/WX>+
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MJD$*O_V76 3;D*2#-5K/L'O*Z=1A^;JA^:C?-'IKR],=J0^^R#AG;QDV3^:
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MH4C18:A^\[4F[:&%D$A)4]ZT*&)).K^%7_IH$FRS<7YXF+X\SD0@Q;/E'@6
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M/NP NX8'HB>6.8HVNXLF%_Q3.\ 6W0R).A*>2%*1(%^7PKT QW$+JHP4HI"
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MU/E@)AALR ]M3'<,1\J8"+HIU_EN13](IN#A$QTJ3%)Y?(@IH(Z")@"E95.
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M%J>Y/'P%2P^ZO.^8IBF4;8CA^:U?"U//P7ESJZ'D_+1#VG,,?>HC'/*B;O=
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M,@5]I9I+H[Z)3!81VF=(O@1]#V,#Y-EEG(_69SE:$=XM3>^X2XN &;6>I:]
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M? L.S<"6#FM"*9.PK<,WR\,'1HL ##P ?G)A,"\831&"I[E8B>S432!V9OF
MD9;'WT6.AL+Z=GX!,9598R-\R'[:E"N85Y=%4RM;;.@>R$Y)MLV[PZ1J=HZ5
MVN<N-J)E"4W*D^7O"FD+J!95LTMA=[-J=R2L@U(;XZ_ZG9OFP:F(R,1BZ\"C
M?!#S;\/X7_,7R&C:" %3#Y0H(%!TM9.GCFA::"Z Q&0-WFFZXB^RW[)FP[CS
MD"!GR&?6,D#X!4-\"^DI'RR]0;@YA<<J3=4E,Q#C8\J''E_%>K;,=CN.$#BP
M@C-]+_(=3%_YL#4]SLHAM(&#0-"?8I[F[BT\A6"VGBZ>DX, U^TJ!N3-KO'A
M$/,0_2HIW'J\0N'Q2P5KPRV0+DX=PC)YR<"QSOBZVG<*Z^LR_KW"C8&3;0YZ
M-7$449'5_JWL@>,Q[.E\W'-D#YID4MBUB>U/5(9T%BZEB^96B;?CXX-#FZFI
M'V\>>0+XZ_.-.EOJ'4CB02K<\)FQ%73$#F$XWIC)+T'C\2"OH_F=.G"?0)7]
M45SJ7QUA$V*!SJK@UDI5JS2'H2$X+S+J47O#')JM% Q61;K(1F_,]H4_&CT\
M1P<&]YK.9.M>8GFB0/JF53WRZ@QD]1H[&C-5,4;S;_55SO':*[0"YV>%><;7
M,&FF5]E.H-FO?D]6=,>=VB2HY"MT4#G+'=AL*/TL6->7Y>G)]VX_"P]#DMEU
M2 _PN(G"[[I?Z2I(]WC*IS6(;-&8]LJS9GVQM"")T>,;F0F="0W_#Y(>1Y11
ME[8#&;[:\9T."SB6J;VFX+Y,ZRQFFK(9976K**N',\IJ1EG-**O/AK+Z8X5-
M;K3];\B/:A?_/WM?VB1'D67[5_++F,&S4+460 )]4@NZAQYH,"0>]CY&9GA6
M!HJ,R(ZEDIQ?_^[J?CV65$D4527)L9F&JLJ,Q?VZ^UW./>>7 $'!)H9OJ::&
M96(L[[RFF.YGCNG>,=UT1VF)NZD/4$>QB5BI(!D!/QHK/BBA;^MV#8:4)!Q'
MN(EFCS7UC=6/D*IV-Y ($^H/D3J78L34FZ-LP/MK8J4\E)E-"6T"JP 60K,5
M\B'#GU"=I,J9[VU#V79M_]VVN:H\49Y@DQ],7=#./_PQ3'^H$JX@'-,N09CI
MI!)WARIQW-1EYB],$T%":3FF&7I7\=WB!J=($""4\J2=-E,DB$\W;%=6Z7:B
M_\K3F)W9FRGCF!]M9N_%S]^;@B+2$[6]BM0V];@-#"\0+7W.&;[/^]K4[O?X
M?=2Z]"<!7ZP[M/D)&YD.\,IY/YA$8;MT,E7Y6M1*P03>8!Z(\M(HV+<+NO5:
M?EL>T'C#]-@(S& A,^G&#@3!=MY['":SPBR",#%;V03>Y[KW>S7?JX7,;7ZT
M?$H52^Y+;A'_;5=6CF"0XU)]H,# *;*&)%?RG=6C==H<^A);ND>KB5%PC-_!
MB;_?$_BQ;\>V>G,YP.X#MU$572P:*&"8S"+N55C%%5N%4+$M2()9CER.*YNZ
MVY6'SF8!1\PI<Z1EX8[LKAMP5C*=NS2=E.*W*7X+$#ZZA7-;*ZPA,$S'WE\^
M.4-=]A #=LYZ6[A=^?Z/2P)8[\L-UMBHWOR;4V;!7NAE,'(<G6)!>)AVM%]<
MG9==1^6T'_(W[M@T1;;ZX8>7GFC9?"*P-'-;PR[O1-AZHWT-C"-@_1>P%\&M
MW:!KFFSHV@\CJ&4/2S:E,*^M,_&<= ^PAB$\@X>VW".Q%P,#:%\HVN'23]+(
MT 2=5XFO7Z*2F)HHA0DC.Y7]962@_QZ:JWSUT_Y0KEY=M!=P@JMAXN\\M_=A
M:+LA9SEM-D[Z"EHH7; (0=ADY>B?L%!,"DN,N_3$6..8S9[GGG/N?MLE'>OW
MR3;)%,CXU.!HON8M#89WNMO]6E<J,X?8V\K3+V+#$EJ8)#61V51P[M3IX2^1
MO:/U,G"JB/+6T2J!K]!+T&O% L'<<=)U)?J'+>7#L9-EAP'])<?;IOE V_V0
M0&U;89IO!'RY#S-XC4[;3\:3VJI,F60?9*.9=)04$%*</(UF[H-1DLF339A7
M %.J;8W2G0&N8;A!VV@ &A/LH.R'WN+> M[!=R(B%'!H$2S$1%"VEU,NE>_1
MP(G$+&IVFZ@S,EWE[])+P-<PWS!])VSM!C(V;4(9P3"TH43.,)N",2'\F,[*
MWH+'>A7&CJZ[*R])*==>+T"@M"L(1Y]_X_N#J!$:^7.CD0ARL*L]?!)U<%#Y
MHM)!<J,G-QO1 2&Z8)M#3X?S>*(DI(PQZA<K[*&*5 >GEC;JF@J=4KXY:O59
M@,W[_.*Q[-Q8BYDV2-.)[=4*?3^T9VGW!^'\5%$77IQ(([!CKA= YDU=#4?'
M !S!0$-8C?E'[N#[Q[<OM'T5 G_!.3H8D;EY";9*7=+4N!#NHJ!))6MC:L!\
MC[T<OE/*,[EI&"0/D%_[$>!%_C.@C.)I_ 3L3-3;LMUS]@+G:S;IA/;E7"],
MMLJP&F@H>"&P?0;#G^:P.,^AO&,?AMMRKWSJF\U&W._1OW<#3U8^TXYK&#5E
MC+-KMY3BT<&T!0$1/VXLDFTS8?425N]6L7J/$U8O8?425N]^,*)]*L'L;S/E
M+%\:P^  =ABFM/6N<2"3-AU:LX5[9CLH&HB$B+5C@\RL?!?7[N.N+R([DP<(
M-[WVO5#H4/J!M:0Q^TC85%!6,0\\)F@,!N(;NQR,V<*4[!_ 4_4/A/^(IN6P
M8+H/+YX\^?K+9T_"/VAOT2$[.N)F3U/:X)^3W3S !^B^06T4W.(G%A:F&.[]
MQ</'3\,_S^#6]\8 O[AX^N7C1T^???7%UX^?//WBZ>,O_^OY$39C/IF^>>/<
M 9ZS\F,E)QH-V9DQPLWLV>/'7_G=S)P:\:7NR]HC-(PTH CI?:C%3;!]]SMZ
MN'^QVXVB]HCTH>6F7^%SV^Q<,6". M,#/3(861Q5N9U@4;2O%8FA+S%1+0*1
M+"NG%/]QZ96@8)HL(I*I5$J['=/1))FB=EGGB:8/+HZT/LCB%]L%K6 \V70Y
MF^-K[?HC%D\'WQ"^#WY7\+G2@9,.G+_TP*%\(;>C6U4M%;CT_9(I6WBW)\[]
M'OQ[->[2M)XOG+;,7C8IO2E29;GV%F0ZHXK9VXIO:5M/V_JM;^L0F.O&W9(/
MXHE'ME%%=-1SP%5J<$:)[6%]LB4\)>/,2Z],WA(>C:0N:W?9]*6_![D]R?*3
MY=^ZY4?&CC2Z-1KG48K ;8O( B_I;!WRT]D(#4,ZX5;"6FW9"5N<L' U]96K
ML3%!6."2Z2?3OW73QW?>[)2#<<F2!7X[3:6F"#19[5VG/.=-=D3'8QCK#>8F
M9CE5(4_3(IDR9;<1\N9UE*5,6TK:4NYQ%>7]>X-].!2U!P<:1%P$#K>K;*98
M8&&3R5=,2^3VEPAJH&(_OH3RODU( GXDKE-RQLJRB JP]-BBL!*UJ#%DMA-F
M<]^K31(*0W%B&#'FPU!Q?=V(A)C 6\&*$<#LQ;/36DAKX5;7PL3PC7U**DQH
MZ?T'RYY59S ;D*U$23CZ"$F C+MZ&M*&H=4P=Z\21=760U!U5K*>*U<7(KC,
M&8B*0"PU$J1&Z[)JNIZ;%XAI/JVDM)+NX%2AGHM#&U+!HD<#OW(]]BT8O3N+
MD*#D6YL7#GOX6B<].6_JYOA@UQPOYJSYDX?J"1:!T.Y*"\>!<U,Q.B0GS0X4
MU_ @A'E>DV8KQ."M\UV.")3GOD?/P3[Z,EAJC3"ZK6K*62'Z?_[X<T252PV8
MT?>)D4XDQV1C)/Y<[7+WW$"V5[.[8,+ 63R?T2A5]&!$2CQ^)O126"9N*94
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MS?-> 4,+&:XX?0A^5@3:X#)3J[51.Z[1^UV9_MAQ ;1'!>_:^'+8A#)#5#[
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M(),T:-EMM&JV]Y["5)>-/KP>B;UQ]@8O4:%F1:I]Z_3_W1'(D[Q%CL')>U_
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MIW(2_?>CYY^S<@MUWDCDPU"6INL?7+9$[.JN2C 7>ND"%2<0>H,*GS+7X.[
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M3:]&2:6Z$S3L*&.BYY"7AR7,&U9;ZSX!F!;-_WM#."OI.$$,T,RSES"/ %S
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MKXMKGN;H+YDC-Y_4&(<=Y+V6S-8LL%UUCR47UB4!^/<(GSL2["2P-*4M:*%
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M.[H.YH:3;DD,G+MFN-P1#NL/;32?%6[R.Z$MF'JHUJC,R. C 6'7S42$4X%
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M0$9[;8%71]I)L6?:%:6X6O1F_& XY3^RS@ [Y"H!XZC^%STI&!1UO_H-V#^
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M-32(B7X,]DC\.HTA*-#.'>5C,%1#X%^]J:30]3?LK'"7,%FC>QK"#(B_(_*
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M0D029FR<79YDV\FV[S1EYWEYT2!976'%\@KYB;!C0A.==*62K=ZZK2(W=U/
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M6E2W%=SHRIH<A?&V@F>[1)#T,ES&(N0]79@+9KC7Y!O\$CYTCDBOKB',/S7
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MH1&5.$G&[Y-: 3\<1.55<W*F%2Z!@=]K@9";6PAC0Z9IU^U05>@IPYNB&WY
ME% OR 0PU&PUU!5&ID>G555T6+'0:G*W'25?M"@#)E#!R5YS.IMFGA?'2UH4
M\)&7.TQAM:?EA?F9K$PR3ZQ7,7GLNUP"F8<ZGV_@S-5HQ:(TW3LO_)DGP\5%
MF>1HUR'JH[/W7U[]9[>.SQDE# ^/F>2J"B] 0'M*8G0[?"C-NM D-14'HZ/=
MPM\J=,?VIP-O-1K"<6"U<0Y/KPYL F,N/R($3">)M,9'1O"G;U:?E9_38\*G
MRRLV!RF\1Q?$1NB!4#4(U88'WW+&[3E<0*XP^S4XR='@*3,(YWJYQZ^A;XET
MQ%@=W);% -L//%@Q8!7@R'8MBH1CQ8.FW;OY?<AK6_C-:(YED![WW9Y7NW[_
M?WO7UMTVCJ2?9W\%3^;,3GK64 @0),&DI\_QY+*3Z?1EX_29?>L#XF)Q(DM>
M4HKC^?5;!9 2=;%CR[(MV^@'MV-1)%BH^U=5F/5/2KS)NH"G@<'\T&0/I, *
M9G4SDSXMA(]8))EZ6;=MZ]6_C<T@6;Y<0A5,5F&(!#H3U!*>ZGM^L#B4NEXI
M7828>:EIZ)96?-F"I0OBO8GLR(?*T>*6] 6\4X]75UH.48*G+W/1-?CFJEQR
MC#C6>%& YG8 \XS26EG5..9;3?&HCY#.ZZ7SEM*VOBO$]>&=MM"*&_ _UV8(
M2K1L+%L%A-UXG<>T4@+X]FM;H7ZHIH/H'7 ,;!EF[ X6B7(V9YS%#(%#-!GN
M5JXYI%,<2WR(&KZS,WY^>M\Y=HAF9\%6[MP:@ '\ V0(V1^E$W:JLW5XNR6G
MMYV!L"H'+@OB_$/W&,?&F)*;S-N'X&NM.FC'(ICV*G0X3F:C:74Z6K[OXO@W
M/Z6XD_5QXW)\4V^.<,H@GC@T&SG;A6UHE775S)VGC4G5":I,)R5+52;-MGK1
M^@U<]KINY.[W;?DF$P[K:G.=J \<WH=]H<O:P[>EVKEF:8V%-^CKG#6(_CG$
MVNNEKK'^-L^5L_8OZ#=W.&E3I7YUO00K?A\!=A>3.%WN&1(A!J")YZDIMIPN
M/::5(^WOW[^?VQ"']\U7@#*X>.E54?$L!72T%19# 6\ML6_;K!B!J$-4>#R3
M-5A.8[HQ9]U.H>,E6__*%V_X??'K[+>A;%CP$E+JP*$QOC_<P+G:C3&N4[BL
M^RK?158@*#/3%>V#NFBAKGGLJ[L>Y54&6:S =:FY5:$%07OD\3FGS7 <C@?G
MOE3'$]!C#8:.CI;+UM?YD6LO>_F3MS;9F+FO/ K8[O7RR7J+EF,U:?SF3U0U
M]^1[DN'+/3SO(P3C"+E1I=0.'T<^ 3: &\YJA[K/I;CW6IU@SIG4U=9YA[SJ
MMFC#HUP[=W?A&3[1E6 C92MOKR\BY?9]OCYG4(W19,$E&*.#ZIB-YWLY\H#$
M>%Y%=V;:JAJ%XZ=:K78M\G=3;BX41C0*"XODS@JYS,(LIR<:A& =G^)1HBNG
MCBS&9<W'WA]TD[,<.YXN]'S;2NVF=^XBV?!XW!X$R2X1ZWGK:0<QHA89=]>N
MH5_+:LUIL3:X7[K2"<0B'8'>5=M7,5Z7I1X$MZ1<YR4@O335!K6ZDJ9R0@ZW
M0EEL>MFL:Z:O#C9ZWAOK8+K#H?J.?9>9NR@QMG+GJVL3\J"UR4*9(\NTVW&!
M,C_H*B*OJ##"U(D+M< _37?R$Z:4585'E^'8S+F_*9MAY$;=&12:[L"%"9X/
MY1G!'[X0LK@]BH*'/O8% 2XR<@,>_;F;1KH[-&VJ\=SE:W&@BN?ZQ1&K3EJ/
MZ\G9=+A:-PM!V^)4EX/Y('4L]\%V@;9(OKW]IKJ&SK&Y*/?O,HH-?.J=?51=
MBQLNLHI78X$@9;#.=W[WYT><M$7;KD)L/A>H9R2]1EL,&^J/)G)=OSB7/\C<
MHF"Q;7'92$SP+T8'[:%WWN"U\T+&G;'S5_3GA,J3R6P\'W"]+#ZM#O1#X[NA
MDGXV29N[[XSFR!S[B:XN(>!C):R01SX W^"T,0=7&Y@S[ZOQ^Q[]<WU8%! 8
MS:./U;KJ)HR;'<^A<?8S+-O%U^:+K#!SLC85\])A/:%:*50KW7JU$@O52J%:
M*50KA6JEG;AL5]K^;F+:QZKY'+V3+BZ_ICM[3Z[4/7BS_VTFY'2"Z3_5S\#U
MO(PV%I\/EW0E)O\W\X-FNO$3EV7S%L<!>\=D\)=O^KH+WMRG[=E]:TY;@N-2
M*2Y(7-J-=B*(]Q?=J/EVY.?JEE0GL-KIZF8,HG?.4>X0!/!UWYFRGB'2QF+&
M#J*/LZ:I,!D']A:32GA8Z#R]]=OG6CH'];US<T]QVP\VP%^X[J[7ID/GP-^N
M,8$,"W/=!/WL40.KZ:7QW2&E70U+]^QV8>[6[NW]C1;9J.X>!^T-^G[Y02_U
MAE'[".)H+'Q9X*1+PV-AV;^ CBCA:J!*<A#]79[(9MXBH5UJ;#K%0J%N>>^;
M6AJ(,C ]-_G<MKUU=0*.AK  G\_"$D0?W7O@1_K>* =AVA$Z^6T(\E.E-7C_
M;V4S71QGX+LKX)N_#8X&;:>$ZU#M0+\S!X&XP[Y[,8,[M*"%23M1/>AFV/JG
M^@1BCSB>U,B19 /1YETJJ[-F%_T7QZ-)B4,7<3\.VN(8A4%QBYECYX1K&+$C
MV27YCSWKMP??FF91<-G>S7]RWJ5DD5:S>MSE)_W(7Q_D-(@1@[]?ST[;2LB9
M@_QQ%@*F/$!$JGKS/%PLSU#*'5S>RVRVJ9BSH1E'8V.TF\K@+CR=^D#-3[FK
M7.^W;./27K?B*H&N 'NT:=UUZ./:^9A[ C;NP8*]MQ$"CM/SQ3GW$C;P'!/3
M;3K4A??-<'&!@^*Q#<@# -WGL_$"2-AXK2RQ9&O65ARL-K_[Z/M@+<O3Z;EJ
M<;[H<@X@Y'X6.-:<4MV9*]VPDDU93U0F,W\R3%NBT^,!W>V;UZ<7,DFW^]WF
MSE&=A2%]>]%W41%YR OYS'=A8WY]<:G"VAUYO#$=XP7> =ZN$!4N6?^>.V=F
MTQ$SWTSV1.W!*KYVY\RA [Y48_/KS)^YZ ;&M_).Q_A\T5KXI2U$Z<APT T^
M:W?24_ 43*COHVR-F+=TU5R>?+??%1-EJ&>!=>9]PI?(_-GXV#D%"SE$/\@-
M8?1>05_.W;FF$*[YRMCN=@ZIN]+C%-J@9FF;/>)H935R8.I"^WANG+BB?C!^
MV B-'H@V)PY W\3I<QHX6[=J!R_++>.6+"N=;V6;'U>LN+TY.3-N\Y;&]N-T
M!>,=.Y^11>A\7I'92D97B;9P,/SIBNC@@D.$#N+"[#N'T4\T0;_"=:?CT"?9
M5)V[59K6;S$ZV(@>)N<*VA=#"KS>1^%R T_[ARNT!4_]PDWO"!_)NI2@W,DO
M7T?FW-=1MJYG/1N9KFH-973:%49U)SQ\VOS]]L$KI8K8I7#LO&\Y]=!ZRU$+
M-L(B@]&DF=5FSDA=I4LW-P3_N<IM7@_W3YMK2> P!3=1I#WHK#TS<7%3\%D,
M=C;W9M*;IC]![\K/<@7KV)/0'P[DX%*\H(,HYN_JW:7-SV@N?D@+O![ZP7\?
MY_=^AR]'8_(C5@KBA1[1!$KC1&HW[V)>>0@.0E>DRV,^K])=V\?]/<[K:=<X
M_=,L*G*03\Z,_(SL9.:3&EHN=R4P+6LMF,D5=2H7XB*C7"1H70WIJ O$?-#>
M!;[1"?@1G>+N&'F33A]$OUQ+C.;>5E=JW795*!=:1J9V8Q[<2\ _;2UG&D>9
M=/?UKWZ A9!M%],01-(=ZN(+3]N:(1]1XDDR6#G9.:NN1PH=#(A\P2<Z:,'(
M9H+SG@\VE58N/W<QQ<?I9)#S1<7EB9D.HK^9>56S[V08^MIN5PZV.#T37VWY
MSHU[I9ZN6ASYT"R]0K?:U<7V]PM\PYGS@APUG8^&=%S0?H)6.NI42'\USGOL
MU+!/J#D]UKM!:=H-VXFQ?BQ2N_DTI';257N"@%FSV5=2U+X.8'[_V7CMK*6K
M.FUMQ1NN$$=FS5%X[[NUCEFK0"YVXUS,T)IY7]HWQ!+TMH?P6]':2K3C,HB]
M(Z!Z[LXB@>K2NU_0<A^W0@1&KCM RA'M[>M%@6/KS;BLWFPZG/@BW[L,!5IL
M_=6SJ-*(>H+JJW['X7?L=Q]?N0*'?<65WJ-Q88/HMS$F+INI.^KBJ"L#:E,$
MO>IIW,+?O-+[U7>F;8:AGJ(3__-D)0@-Q2BA&.76BU&24(P2BE%",<I>'%5*
MN!@4:.N6'M[]\393D:O.1_J[\X_VVNU((9YT3MS[L3NY'C=_]1RXS>)UV2+@
ME:NO^/2?9ZZ!U5'FW>]&Z833,B-QPF/"2Y:0LE24Y,+&W"@J1)P\\[G^K]./
MQO[UV>O?8RMU1G-&;&SA.\KFH !93A2WEBJ>4VOA.V-Y BN$^[_\:5J//B&
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MP#N?H,()6OW^(C(F>6)U3H3$B"R7"1'@8!&6EB7\$BN3WUBK![SS@;!(D,.
M=SY2:@>6#D0.1 YXYY/!51XWWFFUI25BEX;%">%I+(@T)82BAINR5-*J?.WH
MU4+HQ*8B;0/M0I=8!IV2U.8ZLUS&<58&O#/(93 <@<@[BJZ5*!@MLACBXQ2B
M:ZX,$27+(%).M!+"Q#:_<2;RT>.=H>_SRGAGI@7V=^:DC!F8124XF,5,D(11
MQ4N6:YNNEP%1:3B++3"8R8!',TM*K@M26"WB.+%9RI-[P3N/9%V-9=2!BGN"
M=JZLZC8;/KG1FAJ9$0/* IR<C!')-:@#;J@I5*S29$U[;+V;]P: _F0T2ER
M/P/\N<^FO"B,23(KB3$Y)[Q,$B)C:XF-F68T4;*@:Q''=85Q-_ G+RUE)L&(
MB,=@!*@B0D#84V:%RB%>HO#CIBO=8;LGDTRE:4G YX'5@F.$3924)+DL4E&8
M,M%KH.)-Z+H]_*DH!SW,&-$I.G,T8:20'#B )5F9Y0)"RQMS0( _GZ#""5K]
MWK1ZF2:\Y!D(9"P@V$JE!%U9Y,1:4Q:Y2%*EB]VX6 '^W'L6"7(8X,]'2NW
MTH'(@<@!_GPR,,OCAC]UEAB96D.8S'.<[\>)U&5,"J4I^)\Z*?E::P3/8IUH
MH8C6I?7M%)()0;22,4TL*Q,6X,\@E\%P!"+O*KJ&<)BR0B0D34#O\+(TI*19
M3E*EI*!:%T+QW437CQC^#.V>5X8_E2[R4H Q+&P.O)-Q0426<6(RRFD:LYBK
MM6Q.K(W(\@R,H9*NF2DC@M*$,.#!0C-NJ0KPY^TW>V:2:TH+0XR0G'"1)Z1(
MLHSD,36%+ MJ^%JG[M9;%[#.!R#BP6[?F]W.LH)381+"J2K@!XB84*4@*K5"
M%!F$%W+-;E]7&'>#=5I!8P@F&"E+#(12"&H*E:?@/(A8,FU-GJV52%QWI;O#
M.F,M3)Z*G"2EQ=52H*L!)<<LS6B:RX1G-U9RN\$Z+3-"Y#%:TA@\-RXMD=0P
MPC*ILRS/C>)BQW0-6.=34#A!J]\?UBDRQ7EJ031Q7'5A%)$X@8<G(HFSF!5,
MK"6-MG.Q M:Y]RP2Y#!@G8^4VH&E Y$#D0/6^60PE<>-=:9%*0UC*4DD+R$4
MM0DI$S>K5LI4<JY%GJVZK2P1*HLY^*EE48#;&F>D4$P1FS#)64QC:G7 .H-<
M!L,1B+RKZ#H7B;9Y0F)+(5(6RH":BAF)"RIBDR4L27<473]BK#.T>EX9ZRQH
M8;*R4$3EG!$>,T-DHG"$E])I3)/,%&M8)YC,O#1,$,9+/!8TB8'?,D.L+4R>
MX>C!_'Y&VWZ0LUI&1T-Y]N6;J-CMN1]70RI3%8-XICG1ROD6[FQ508DIJ>"Q
M2%21[X[P]X!4OJEJHZ:3 $X&<'(O#2WGA:;8V2CR6!)>:DI$R27.(^5IJ:0J
MBS5HZKKRMQMP,K>YMHQI(A(\L-=030JC,T*+@I>VL#JQ:S#J=5>Z.W"2I\J4
M)BF(MADVN,8IN"5I04I0:/ BPL;KDR!O0M?MP4F=%S23)B:EP7TOM")E%EMB
MD,ZI,;84:S#J#>D:P,FGH'""5K^_<S=C945A.:%ID1*NK20R3@S)!<O+%(*"
MPJR=6+^=5Q7 R;UGD2"' 9Q\I-0.+!V('(@<P,DG X(\;G"29\R:!$+ N+ X
MAQ;/I:,6SYN1#%LL1;K>B&FD,30I+(DSJ0D7 @+9C%*2ECK61C(J,8%Q)^ D
M$P=IQ@(T^>2D,IB-1TGD"]HY3*+*+&,DS4M!>"(ID:5-B19%H84N4EN4NXFM
M[PZ:?&.4.2E-'27;A=BA%_.6\4D=6TMYF9(BQPX2+2PI#.-$RZ)02<$%E6MI
M^B05(C<(K6'K)A<J)5(F8%<YM5(8^ ,FS.\!G_Q13H<C8\;1D0)B[#E J6B2
MI*R(24S!J^!9+$@!\D]HFA=%GDG*M-P9Y>^ME?)=-99C585FRH!7[K?U%85(
MLZPHB>84%:$U1,!/HK0J>%%D.E=K]8O7%<?=X)4IA"Z)I9H8*Q!/M9H(JR6A
M7.DLS4RNS=HHUNNN=(?-E%F1B)+B:9F6@9JS!1&I9D1ENA1Y&I<T61MS>Q.Z
M;H]7QGE>IFD.&MAD>(RY8:1(<T'@K[(LTT+&8FUP[ WI&O#*IZ!P@E:_/ZUN
M2J8$BTE&TX)P6RA2*@,^KK2R2$I!2[F6^-G.R;I3O)(%O#+(X7X3.>"5@:4#
MD0.1'RJ1 S*RUPSZN/%*36V:*9,2D27@MBJEB;1Y#A%_5DK!F,RSM2)?6H(S
M6BA#3*IQ<*S*29$I1:BU5A2QSG.]H4OI-O#*T$GY1(4R6(U'2>0+TF4FMX;F
MEE"5Q(0;(8GD>4:D5D85W#*JU\K[MPNM[[:3L@VNL]!)N5](96R 1<HD1SR<
M$YYK0V2I,J),H7BJ8U,F:VEO!CQ!TRPC7+(4)R1*4O R)TKRS+ $$]#WTTEY
M.#)?I3N#\ETU_?>IG,)[?MYWP%)Q60AP2K0;BRB-(:7.!?Q@!:-*ZZ)8<TJV
MWH![ RP_F., 5@:P<K]M;V8E59G.B*8( 99X^#0M4Y*G69H;EIJ$K;7A7%<4
MKXY377;(I8QIGL8%R01B:A0GQ!<F)H*).$O!1[!\?2K,-1>Z%::VL5=?%"P'
M508*3H.%2?.$E$JFA"5)+)562DBU2ZK> %4M@*PQGCF>0D ([E.N(=@#!DBY
M252LF!#KN,8-Z7K%U=Z:E?ID:OA(W@)>>?&249 )'V2BZ/^7@J1?8GU0&V2#
M'"XZG305KO=E;4:P\"_F&J_[//DNZ,00].V9X9$T%R:'L"U3X/YQB-M(*:P"
M=SR/I2W35*8W-CS>!^R)^YU$?46 5(,H[C>1 Z0:6#H0.1#YH1(YH#=[S:"/
M&U+-TH3;V"8$G-"<<*WA-YTH8K-2J[3(:$+7(N8R4Q!/"T%,EECT<35\!VN7
M"VEHJO.BQ&/G[Z0%- Z8ZM.4RF V'B61+PBO90EAM+ DQM833B6>Z)4)DM.,
MJTRFMI1KYV1M%UZ'%M!]8<-[!U9M4N96&THL991PE5,"[RNQ)9'F258F*EN;
ME&J4-29..&$:K]2<D1*[EEFL"Z/STF0%#<#J%8%5P?(BEY)ATVV*(QTM$0D5
M1-D\CVEADVS]O+FM-R  JWLOIL$ WYL!IE2)0J<E8:* *,%-A2UQ\DM>4J,E
MS=)\?5#,-45Q-UV@21X;SE1*RE)@ 96,VP[+O,PT+S,1EVM3:Z^[TMUU@6J6
MTM0D.9%98=Q1=D06\,]4T%QG@H./LC9FX"9TW1X$IF41,RUSDI?P@\>9)=((
MK#423&<I%WR]7_6&='V<7: !57U8"C%8G7NS.D4NTB))*<DU!P_<*M"3/"Y)
M5G"="V8RM7YVTG8.X)UVJ09(-<CAGA,Y0*J!I0.1 Y$?*I$#>+/7#/JX(57*
MF:(F*XDP6A.>)QF1B3$DS@L5)X::9+TCIRB,8BD.O$L+[%+E*1&6&J)T0=.8
M*YUG=W7D9X!4GZA4!K/Q*(E\P8&?QFJ1RI+8E!6$TR(A)1.4Q$E66I8R*_7:
M5-WM8NN[@U3_(<<S69]'27SC5E7X798C\\/WNOH2J9%L0'/"VD[(J&JFQ(S,
M"3S2K>_4U,^ZMVGWQ'/-($F*5"2+_U+@!%TUIR-Y_M*.S-?^7F>P]?^:-=/*
MGG<OY*XAS536TU=N7PDNH'E9RL:,*B3#"@<LR +/YC'+%_^)S4RX%=@U9]7+
MN/.R3>.#/&4T%QDO6)+SG*5_Z@/2GXTYA76.YK2JQOBZQ)'L$AH]^^$YG6<Q
M<=O:%UN^S?V]]@KX![^A:3V(JG$SK6?>@9C4T1D8=+@F@C6#0X&7:Z.CZ21J
M0(8:>QY-AR:2UE9HPZLO!DR[->/&H*QJEP!NHHF-,)$>82:=T.?J.W )$/O%
MK[[]JH9R?&RB0S4=S$4!Z-7]#!S_@#B>/1R._\\_"L;B5S]/QJ3'G!%( 1K,
M2-8ULB5RV;-(-LC6L'@-(A"]!RZ(>"R0D9&US?%LY Q*=$1^#*S]2%D[>3BL
M_=' _1OXO7%\>#+1E05O$5GTP/-RH^JJ]-R\K)G!9CVOOERDH ^0W^6R39 >
M;HZ _7^>?/$U9"QW'@^/Y%A'X'\YFP$7S(O,:-)>,!W*:70&:[H/TW*Z2;88
M'_"TVXJ-CG#VC8VZ9O1V7USRES]\&E:-V\0#H/JQ 9J!O:^F0T>]B?OG=%@;
MXZYI(GBOS[!![@K<^ :\^JKYC$PTQ3LY%Q48K#:@18U$IH"-E5$#2X$M:A4N
MWLO]2E]%I5%R!AN*SZM@3[]4>B9'N+\@B=,9K-.Y_.B8-/ZY1JIA5-83>$,"
M7O_(U ?1V1!X<2H_X\_N-=R#SX837-"),=,(A!Z9Q;'4Z>D(Q $6NPTG.9ZN
MS8F$UX:M&QF%O#DZCYI9^2_X!S(P?N>TGGRIFN[6S0S67<]P.3>I9]LU#U1C
M-9HY>^<$42[I"B?LX_.5G7&[$;D= 2*O7H]O[L@^OW2P%-^LACX]:70_(=[I
MFT5?6^%6[E8-1+_ ),K9=+(2)P_0*/JWSMWO/1EVEY>3KTA1I%)+$A#:N>GT
M(?/2?;LH.O5YGIXA^#<!*IFO+]DK9S6T._8=JQ]@9V<G*[9Y-4[WBX-'ML6R
M_@\;S1'HR V5%;T7*<'8@6S@>UPMK+^!-FL#^R7/9)EZ\;XH.QKS)3Y<YKAA
MO<)2K5O@C+]G@>4/8!O\G_VSA-NP4WELO)]!I 7"O)2C,WG>O'KVXG;9>H=L
MO)R0PL\7C+W&H+OEPYME1*_#@]_B.K;#&&,M$WBAJD.#TGUU U-T^Y!N(/NS
M'_:7N>8[[W8,WP%4&>%BX"K)EA[>_7$W/()Z;<WS<MG&4Q#JJOH=(Y[L=_-U
M6)75M-E23YUY@2@G(WT[BLL%F]D 7!"_SAXS_8?/)CM'YJ+=;<40EXZ/ L'!
MRPF8HLELVE=A-(X'\9^ZZ]&QD:>->=D8H!:X<ALVO&O/Z#5[H,-35J-J>OZR
MN\.BBZ.7]VX9[$\7<9?7F!N_1+?Y4L&^_:U>NG6]?45<VKVRB3N^T=)R.0BP
M?;Y_KG8[S^)T&C634:5O@@2(O2CN61.U*\E/*S=]'?S(WA"<Z;+7JK&,(MPY
MGT6M5,3)=>#17='_)O'UE8@=[0N=GZH\OW&YJ^5*^*6MN%2/?Z,-\<X5.5RZ
MSX4%.Q6=9$!O17B>$@UO1_WL(05E-*P1Y1].IZ?-RQ<OSL[.!HU1@^/)EQ>'
MM1I"V-.\,/I8UB^TG,H7-,NI2,4+)'*1NK&+"?S&"PH$J\^)^9K\3@?#Z<G%
MNW.1 G"KTT9-?-7 2Y<6Q"Q JXBOT<+39L(Q@_C1-%.7(GV->^%2: 83:._'
M\*#3]EDN6]_ESY]7\X_@7^5Y! 0RM1DK@RG'UL^)0,JZ#&1MCJMF6LOQ%/.M
M-'_51(?C,:;Q/AJXS10S\N\F]4E$8_+C062K49?=Q6\?O7V-%_PD@=H1\_GZ
MY+M%-D\&Q?M E$8R8$]%;=Q5%=>C(]P-]"VE14)9RF+X*8KTA<XREL<:-"[;
M2X7[M_.1/&NNK$[9)>KT]:RN$:1:T:?B8G4Z1T"%4ZAQ4*@/4*'2>$!!/23I
MJ[\\%?T0%.L-%6OKA=+X_MW0UQ/R:STYF3C,]O"X-J[@Z"#23A.ZGE#?$GJ
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MGHIDA[SFOC'@>]>S&?WOWSY^B-Z/FZE+\[V9J!FF'AWL0E_Y#O3V,]U^!K_
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MIAH.*OB^MS.(0J!=H-W#HMU.5?"OM6E<&9"K)'H]K(Q='Q\05'$0B4"[0+M
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M&Z*K5Q/<NMO:"I5\B,XPQ#J>KLBETA)!J(*B=>4K+P;1?IP:FUJO'\,_5LD
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M3R>#AL6.?.O^7JIC2';Q15?UB99&=K&\AF AMT58#.YO4<VFGA(&B%2/S6:
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M"-YA$>_L8C,@HIZ"??^QKXQK1Q_%)^(JBKS3(,#Q>B\%8EQZ&8/D(?))1[7
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MEMG%+[Q*IYY'VB2W49(ZP7_[.P"F'WE^&$'$*2X0HXD(4014M6Y&$1PE)1U
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MJ1QE>D&*(\P0N^FXBW(Y0C[VHE9&"Q43,%A]6BS5!YR>.\F&ED3PR(>]_YA
ML$N>5W#JIOX353I&NYA2!",@,038/KZ&49 ??B,EY!8C'2_/LD0-C+O .&PX
M_0'_GOE/3L BS=D"$-%3\.\8XW^J\>*OY([#\!7!A^[2]P]^)2&T*3)&-EHS
M2D!P9OU<<UTX#99'-E5Z=L5D81/@UQ4L/C-FR;MH[P3I?EK,%2=B*K1JVIQ+
MR#)\XCQ6"A)68/%UPM22V]'+W#0AIY67_TTF8=!S>O1$<8+Z\>=5\E$ND]K
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M=H.A./J7H?0QPSJL@N@Y0:LXVC;:V+5'[^0U0]Y3\#$J)"=W@+X%2!&3LG:
MM*@VDU,T9G_2P5A)SK;"7;E(QW.DJ#S*<W0D,V\MC?(<&2J,,G;FS6513"T\
M0Y"$D"4_3E+(:L,! +?NW^-T$WG+U>7.#_%N0P[Q6*\%QRBED5HP"*));GP8
MQ,8!044:Z6A9KA5YS5E?4=9#PKHG6-_FK.-B1+VG52?O)0?#X8R;"P+*7P .
MA1'*H<_\5?"687YY W0XBPU2$W*2;;<.607"/H^@ $51F@(2<T!.BHKG!$'A
MO?Q!H9/ZHM=,6.^D"!WY;>U;N_IJ60A/D6)%;YUX&=^GX(*@' BT^^D%5D24
M\ (]T7.2H]X?(7=!B2T>_$N(0Y@S(\\_AKQ(P1$RV1;FO4 [PNF3SI* O.0/
MKQPCD@M"KU!7Q]N_<K)YN!Q\G 5EG18P+7Q57O."/U?BKU#&P>*BNPR56@;K
M,#<^'X'F(6ET$G#PL2<:IJ.Z]+>@:Z;<MUI6^+>4LV"^-+LR5LJ%'&SP4TIS
M:P@O*+#!?XD"<+@ 0CC$'"Q#"=4\I@!",N+^V)"$\ML--B\)P'W#IF &R'TN
M*\*/^_+\&IRL P#>)3AW/D,*ZYY'L7!T]U/OMTQ8_IU5"BJU ;SWF2QJ2;[8
M@(L;0G6KM0+HZP5Q+T1J!MCHTF(#6K14;T"_XZ<,3Z@XRE_"(33H -? 5%#C
MIRD(?R:N+5T^GJ-B2HY<&."],I3'JI#!NK^?>_#!>G&!7?K"H^_>T$)-WQ\A
M:T7@AL38?V4A1M^]IDS]H!=I+$I]%[,'05'D&",IBD<9B&U2R4CP!?!017VS
MP@N$IJ1["BI^NHXQ=81-TED80593&^4DS2@MZIBI[ UGBE7/< 1IO<JD.F9*
M%;OL;(^XF1]BQ\-YZJ+K J8[^%VQ_P12)PO+F1CC36FB@B@5<2'-^9G>V^".
M.(^QYZ>TVJQ^L58+ST$[NQ:"FZ@YE->Y<9+-%80M3$4T$R1I-#<$0U"J!N(]
M(.'F'%85QSLBS^P_.-LIZ=0R*02T#"54GX:I[_E!EA(-M% P80*34J!DLB4]
MG;&F.1E*%W.E*V06'!9>-RG-N[#S*L][9[E!-U&X9CD49I+<=7'9X#:4T]7E
M $$;#L$BIQX,11G9D_MHE3X[,9X8%B]11H(T$K1YE+49[5(IBW7U<@BCQL/)
M=3!=*)Y#6#:;,:"6WV HF\?%5CFHL^ MX221O]T%.%<VD NX&X8J5+W#(8Z=
M@ BGI][6#WV0K.#9$^ G*FIQ+1 ?A<GAI7&D$J9F2W/I8;STM@KNUQ+W3IE[
M;*@N&:N$X ?@>7(4N5<+<L<Q?7$HCVS:I2-E;N[B<^$/R?T&X_0.,\3M BIK
MHHHG+*F4.N+D)2>&R>#^7-UD!A*X]Z,0@L(G:'[<UE+0,J3Y*>6EP7ADC"$/
M^_^\)-I8NC_U/-(FX?^Y\4/\9NRF4'J(4UJ('Q#01$O-4<>#"^T]1&<8:NV=
M@M=:1:6Y!Z+\8.8#3S=QE*TWZ.WK[_0Z+<QRR_?WD-**1!4B2@*MKXCHV/I+
MSUE8F GU%P$MZ1'3(HP\@&(/"[0BL]".URCB*+8^2SN=<!'GN">"EJ&+^))(
M]M$>8_ZT21'*T^I#"[HG,7\S2\#AFDM#:V-.MF,,XM"0*4,]HV5_!05&EZL)
M&@SH;Z\-.@4&M1J9LD"E@J": 5'I%0LV3#]D\")*_)H20=-N376\5)X".SSE
MQS![3/#O&<BI3]-1:PMJB)(SB5U+XU@9ZJ *WSFC9&X?ILZ^I*/2D%[.P2D#
MIS?&2'ZO-;N'+C^[04;DGJLXVC+#'CWZRY6H*R52.4:['2JE?Z4<KV:?$A)3
M8CG>TJ1H+J2H(I:GN4#AY$S_TVY_(1O\-ZJ6T+R[Q_YRMF4>'M>I' L>)J<M
M9EL&#GOG)Y^NR(MW#;YYG*1W1+2SARPFY7=*<UP@F"6":2(Q3P03_<.M= E&
MEM [6<&:^&)-8HUK C:H4\*@!TQ>!<YZ;-R$H(& B%Z;,P1WT;W)JSP<+%75
MZAT30OSL%D3U!L"I8*-<2[N)A]FS$-B8?6Z$*4%WJH-PJN%V6L%N4LZ=?-PH
M37M07/3\_8(=[_?,B6%>^04T7<B7R:+B8C.B#"MD*?BBN*G<V"6N'$%:N]7V
MCEQ,<>:F+(&-4)D4;%BBQJOI&(J_^X#3 GUZ:@D-2+";]83K.:DFILQ0G.E%
M*>4[3+$\"EQH_JI(5$V68:+9^9/?R)R2R2=1P?3EP]_(@R&[O0I6Y/<\"M<G
M%$!=@D<P8IN#$H+8DW."66$9R7"7\&HFV)ODW^=$&$2\5'DR$@HI&_CXN5:G
MNN?%9L1<$DBS9A,^XG7ZF:U3B-?4YR4MUX JUF(T \(&=F)W<QIZ%_@)!Q$%
M6>8Q?-/%7$&>ANYYQ0#&XO8T\ADTL"C1%H&9Q\QB6:9IW4SM<GZ<_A,R1Y:K
M]\YO42SRD2?)Q3E$I"EIN!))-FGRU2BRXV*B*Q[.2"VH.WB8IL7 @HZ8I+X+
M16D+_%O]LP>-]_3FU_/HY#:.MI$"AW8IE.+F5R23-NVF5\M9\"4R5;%1 '-N
M=+++F<M3J]&6TM=?%#C;B>2+0(YUENL!JW"ZE4.=+W#J^(%^,5HC<^(JD89
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MP;]G\%8_<2?U)%R9@AZB!*G+VF"5W#S(.5&#D5P*<$[L!& JXZE6J5;_PUZ
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M)QXK2Q0CH]+0Q2=2#&XIP]G"XI12B4O+DE^O43ZLYNSH.JQN?J.R8(46N/V
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MY21,U31M#HLJG!QG^^8:[[GX)]5UAQ@FR/^[\ &2,O3NQL.8RDZM4IR4-#6
MO&QT?C%?C"0W2G-D46LT2U%,$]T9P$>=W4*7P.#$DGAB2?8^UI\3U52=B.*?
MGX9Y3;$]#2&<;/MK*:V5_YX.*_T['W[!J\@#J! -9C0?TVA@F4I>3QY""?H*
MN"Y#EPR0HT#F*P3+TE0?FT)'0I7I\U(M*.UUT $-B,<4["\_NQOXKCXXV_$E
M81@I)&@A(*;S%;G#(O0X7ZMS<!;CF%;@@.$G56>7B5%FC!7JS:\P"66;J_+>
M,LSM&5 &-?D81H^0W0''F9H3RD?P;)^?-*I43ZM77[P0Y"DICC!3UTVM#@]@
M#=<B3V&LI"GHY D/LY]Y'<TDRIDP9?J>SD2MSE_"4=,L,,-EYUV,-V1 "L/A
MDO>B")WZ)0H N.<=.=D01+4,I:"OV$_(GRXR^!A9#/SX&*_E^36 P T(])+"
MNOCD$,R.8\OE45X%]N/"1,37#%:R%)^.4SE&<,,7:DT7"B(&M1=;RI4<V3 Z
M0=&IVD3-J#NJF"AIF38X88;8_/*Z 4S6_ 43$2D7&88D+IIN/,G@NT#%ZT*'
M6L@2LMG\9F,K(.^QD?ROL2HB#W5\1QJFR77(+IR_87^]@;C))[) :TS_"(5
M<F',GF:^%*HXFS$ C+ Y+Y"8->+39DUH!1-)H?^#[T1;C&K_=CP>Y78T(VQ(
M# JE]"'BH7-744P?\.2!T)^D([3A;Y0#@7.M&* $V11H!C^;!!%8R#2,*13W
M&=&@?L_(Q"[!QS+=_EX01)2BN2QZ%9P$EI@ G9YC1T_? DYHMG,-2M.<_]J6
M QU-37MH,3.E1<R.C9FZ42"80?VYLIQY!\_B<O4Q8?4Z)UMLN$Q-R9Y$JQ/(
M4J"4CXJM4KJK8"4CK#@F6+G/=KN OL=. ,&N5T'T?!W20'HJO4TL22919[&T
M0!]) Q@$7-/$:OG-E_BE5>=6P*]?C/)G_7X/2?8.O3N<^BSV2UDT4T$2G>$0
MKR@$J[%=K-:INH"Z4B,2::7[LJE&%R=KR'NOB*F@EY\C8:1JQ -;'>3OL.)A
MVKDI2MY>?J;HD!3FAJEW8_>$5;R]_(P*@EQA-"AJ3!>19CS93A'(1F!ODO_R
M%Y\(#$0?WJORO.4$63CSZ5^UZ\D,Q2 *\9YE<EQEH0>B:W=*_&AK35G58-NI
MWW9BF,FZ$^R+8U&HN# @3T%"=$B&.2<&I:"$%%FYXOWZ\E:DBD>B8&6T)W10
MQ69J'AJE82[M;,J4ZT^)RP@QI<Q6C>QK"IQ@H"YX/I#]NN *>!Y7%_SK3*R&
MGZ^&_@KA'251?R1WTMO7;U_KJ?;Z(R+D ;'QM<VRK]-X'%K]]4O@=5!9XA_I
M,3?'J 1XS/UC*D"Q680 )WA<C%1.I"NC5D>,L#$(ZDF,M,)*&]L62!G@8?Y$
M),+D[I[FVA)$CFCFY8!CGO)@C(_)?G[Z?W]E3RDS?4S"#KDK2B?)W]4"B=?:
M#^%Q)\(;^5NZ"?;D%PF1! (CF; V5TE8WZ<'G=#_(#X;S?:JPNIVY0<X/G=2
MO!Z?LLH-;I04$K2T7K6G<7)+5G+K3/^X3^_N$:-EYKF;./7@*&==>9L-SAY.
M.M=,K_S$=0*(MKL,O8OQJ5^<'&+T6$#A)03?&,C2DI.MB'(L)=@TIRR0!C(
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M1PW-M#M3Q@(Y'9XW?&)NYH;!4D940BH/"_/(C&9IX)*3A!^#64HO;;_#)&W
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M5!?P2@"<^;A)%6IM1HAEM:WB9+'Z%H9N_!3Z;AXOWBT2 48%MR09=P8#SXH
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M97Z6,>AX^.2Q!YDX:?,1T1C?#$.)2B,.]DCJ<AWZFU8PEC.%X>=#C 5:Q$B
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M!&='0I!F9TN(HXA!\S398#'R+U0M9J79R2IB;N(X;44(ZV 5$?):6+J];$C
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MQJ(M>HX<4#GG400:9RE?:'ST'WZ2-(AWZ1:QN_@O?Y_[OF#&PHHGC<U[S@L
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M79@-G0R6)!?-2_]RU.]OQ[VHMW@E@YD^AT[X,!,N2 LE'\?!+=9LL>*I8(:
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MG<U),Y<$) '.-@,?ETFN>L.A%ARWTI!3?#-C[+M/X?N+50[SR8 C9#J=O/U
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ML\(E>Z2=:J7#SH*@12S/29<\',VFTCX"9Q"^6V=>&5(LB'POIUI2T>2]=E"
MV22@5\8Q,_2SU$,@O4SB9/0<77C2I4VM7XQ*/&.OV#[VHFH9<BD)8RC'0PDZ
M98:WCNAD;/_S!]L/UHZZ!* R]O\R!MB\'5@^)X..]0'0,]6\T@^\FI-,V/S
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ME7$#9[74PC_%(YH0FGL:=>P=8&;2,<(S%K2?O?)7&SI4G]P%B, &9L4;S*@
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MV74AQ0WGNP+?ZQ0$.NJ*DXU0FMT=:9W[3:WWR2FSP%,6^]]VZ*T$27K]1XZ
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MF$I'6WC8<M]%PS,=;1AB/9H'H9XZT/S?"T*S1-BH#E3^LB!42H>GZD#HKPM
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MO."/W$LRD*0K=.$#=@@&:[A5Z&Y"\1L<2J"<,-D8</V=_09P4C@(5F_HKUN
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M##8_03<(%'XFS#'NJLTRC*6L&;:!P;2!LN=89@66LN/:UO&N8JK,M">1F<;
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M,'6]*8H=/L5A,-1P6Q;*&>:.X++:;A.P]3)0]IG ZFL2H(^55PX$#TD<Y/Y
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MLI#3Z2JLV3M\_N3X5T5:OOZLA15J0:\1$>U"@8<E/4IB$VNQ;2[TP?SZU7A
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MD;+_'^TYJX; 8+$+6[$= D8(N=_M6^S?;?,-UMY7L?:ZB^U.=3*K,AP4<1K
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M))L\) @$2%AO),70.6TR1H9SM;5(V;YM#V_X\/UTN 9]ZP@5O'V6J)@=346
MD!;]*#@0L<%YT:WNL>[#>K37(\.F?AKZ!A/7,/+'MGJ@Z?T%.P]DABFKDC"M
M@R(,>4UA47N5U9['0:;/R_VM0=[-;2IZRP&9N$?5@YSL@)QDG_:_1 Z@*PC4
M2G"8:&^B89Y3VFPX:4TZDS5['ABDT)@TPD::8^UH]&QOLH\_2["3JHZ)Q#L"
M;0216)>GJV:Y+"NL'5=A\:\ZM&-(HXH&'-J 0_M*\C[@T'8 AW84TF@&'-J
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MQ\\M_\O=:;?REDN)3\KEB@(//GB-/H C**LU?-5 4QEFRH7._JA=_A8/%RR
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MIV[<.J \D!>5CI#TX@E/)]M^AP2>Q/D!+W#G'AD@'@/$8X!X#!"/P^<AC6:
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MN RDW09P:]TT%_LM,?+$Y<[P1+\XV56NXZ!>27@V-::CX<74LQ!'3-GM_VE
MEN1Z#Y"L@#'DN9B4FE/LG]@IY# V$3>Q*)N".H)PV346-&ZY%P7 UV^HFPU^
MYFB.OL9H/G\XC[_X<*AI&;9*^\P1/?G"(\+J-QX'FMLQ7Z9ODWMD='BKG<C)
MA:B$;%[N^%M5P]*=7V8U*)OD 0.U*,R09H]  +K)WY?M C%8*]\Q38)1%)$F
M&PU)Y$=L+3 /R\:3$DT(3U=/A,+NL6W5S[UPX19\2+@N>3Z$6=^C-^&=*<4<
MH\QWA[U%2V2=,YPJ[ACJ-,6U\VL)=O1C!B7XN4IPS6;8*!HTWV:I=)=(!+,;
M"J9M:\4$"95&@:$P;7_<(1,O=F2,$!9+*QA6;$"NK($MHEEV(PM[_[ZVS3VC
M[+:8I+E!\4Q+J33-KD*\*@Z8&AY/A8&;:'%UZ>:R:$V6[Q* \:.1JSTSE3:F
M$]R:@/NP.VIJ36OF<S R9R_A87 T'JDCXU%Z>^,^0P!J"Q53E&X\EE,%'D$C
MU8J@;\$L:@_K,O"A31TUQ5)D:5L2>G_K/2CK903N>ED(YS+_/#P</1WU'N+?
M?0#M*.P VH77>?"GLFC"HMD>@E<AF(.['+Q:DV\-! I*S+^@68BG3(;$)MG,
M,AF*:'T6IAHVZ=D W*09;_6>T%'1U1SAU=UC,)((P&(>:N22EVA3=8[TU@VN
MYTB^ RO<<Z)^P1<W9_/#3&-+\PSSQC3/FF*92GSP$9O[3 ^ JP%P-0"NOB_
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M^IN4JS*71/35Z54^EQ:]"+8?=<>F5\L6RQ+)-:G,:>7.LJPV+%O];2$'I,2
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M5Z+N<C>8$[?#%->^G7\H@,*#?\(VI0OCSDGMMB+V:[C'?HNYE\)OL>%BW:D
MGZ^YUSG?VCTP'!VLD0G4384?9>5]0 DXU:^FN/\%W<DP%)O@K<[Y^;O)$%FX
M]JT]<5R.W(Z&5(/G$(3.M>!WY!W#3JFC2WPD"C3ZFKCARO;"CZU1%)(F"BL"
M/M0PA0"YW.4:)MJ%M/=P4X8DW*/H59=,BB"52S@FBC*"PY @:.;D9F828T06
M<)!97B0\Y;VT(?INJ2EY]Q%$"0+7C+E>X)D$IU^C8/G@8W#F*Z5Y5&K?&*SI
M#85J'7IH$K;-=R+HR K&;M)=2 LR0DG;JY.R_ B6 9_ZOJOH'Y%PI!/!KP'7
MP6T7<!;73-?@]*>7$>1R8/17/0"3\33OY*! JI=>>"%G),E>7VG"*'\ [1Y9
M_");.V41V =6H4&P7[YR65%.8Q8: 41^=?O=ND@K;=9<$<*'YIG7OL2;H_0L
M2F+%,-(3$]'8TJ.]P@4TP1^Z>$JXJZ(V:TAS:->1.1A,F"81C9(FY$#0) 1.
M4JVUN7^.E%,TJ_C= J$L,"DP- S5VI?;*RMS"0XF<SEDHN:2S,*#L0;E0S#S
M["/.'RP.H]1PRC8\8O].*A)M=&^0@DX3-LGQ+BUB'<8+#^(*!@NHS7AMJI5;
M,32D86)E/B7XX&3%Y&JI7$I2U5&"<8AIAJQ$#<BU3?GC3K+ 3\_.A&?@9.#7
M\&F) #'+^29J#23 1G'&]K;SB9IA63.BD*R4F(:#PS0*RN[A:5; O.)$V^0[
MKZ79U7K_DM/:AM-U-Y!V240"%[ IC:N<$_S7<+M5)<Z;[LPV6?D1)]54-W)E
M@U3:?8;G_E!6VOR''W"F&32#DM6-U3 H<8S8[0:I5FN!5+]I'K\PR"5O#;V7
M_7?'GSU8,[C-WT/ZUE%+/>AJ)W5/>B%?@^DT5*M\AD_#;@QIV+!\%*(?,7N.
M@PFV,(+J!FCD:WO(4\[.]T]Q6QF<TDE93+&NHD;]=M8V2O29>[9&^(FF!#U0
M*M2AF9I+9:E X62]Q=!!$<FJ*BF6VAL7M[: 5@ >Z*J'DW,/$<095ZWS2-!B
M%!SL%^WH?TOE=O@U>=RF&0"U_]1QGGV/UXXZ*I%V6@NAL)7I=PU"3#='L1IJ
M3:H<'):?UA1DVGJ?P'Y(<JKQ$%%:WA:W NQ7D>+.,C7[[3@2OQ[\T3%S.E?Z
MJ#-Z'*Q/K2THVPN"4@INBBN9+28@.)RN,A$YSXKN8WYJ\:/!SS@S4FAQ(Q7M
M7G<@#QC070.Z:T!W'7UN?O+K3LV [AK070.Z:T!W?<UD3N"4B^_1V9>%T.75
M/V'44E>.D,L1DM[NJ26](U8QL:]C/"@RCZ?3+,D(C$/YU+@OSH!W7RMF=-6H
M+62#,?II9,X!67HD]1ITUA>T;8<[7?:Y2]]-L2H<%F>!"7G6CK[H"%)T77$A
M/$?9U^Z#,70.W6B@1(59=1%'[TU<$7^&QOV)"WE=E#E.FM*1V/69[?<R.1BY
MV=-DCX.CL#?2<@!P98U975LWN_Y4EY$FTDV^7I?44P@3HW'TVAPO+J<,HQ&X
M.EF9.A>K'S]FH0(K]/4T&H0S& BRR<MBAC']Z58*!NM9M=_328JM!/(RX^"3
MSBJA,R4(JVE@ G,-FL "=[@=>!Q^E(]=3'B:Z>\@J'Q28]],Q3).&X<>PTV
M?O?'1N 4H)JIES.-81T20QX]A&#PD$?_2M%@&WPD.@8Z5G"X<4\FM'U<(5'1
MAC1UZT3MR4GKM' GNKHTL.E[=!;P$TU?<^ <D%P;N(]8\@9^!<<Q9QT_8 ,J
M N7A'?V.5*/HYP>@%&*/\4.Y9*K.@N)W.P'_)\&7NFE 2!O 8?]9EL!"*NH>
MX <"*20&QCE/&7%W&T1P'*"XS H85WJO##2QPF35(E($E6QC(ELY6I=DV+&%
MMKP<8:XT)8!@>]D&=*8R@E+OC-5I"6SLEH(L;U&;92)3?"Z4 0HS,8D%(+O4
MM%M+?HY3'PX38#,LR#94K8\.H0C?8G2^<NL;W;X!&&S7G6L#;6E2 ^I E/1-
M!NMI4X^4^"NG!J'#^\_!C2U)4UGDJZV +*;E,Q-#'&GRDTS(C[%J-O%\R:S6
M>"S7[6K])=@#QAH#G7DSL]$6?1Z>[G3G/%1'@$;T?JX6P2*E.L_K/6?0X;RW
M[-[C--4^X63]KAME[GY''2V 1=X$K;F"JFDP^52/P@/#.,H"RQ*1)]3G!S\P
M>!_&%^Y*$4E(\ZTC1&26,2: 5Z!NR:_;\DPBMA9X:FL* QMLD4 Z!4 (/%T@
MP@'&)).:Q=/M].RK[/2LY[:_<JN3MI:?A.W\9U6V.V=TAU>-6EOMP?ON1[<$
M]-@4CJM:43@3?L22%EB,JEDRZK&,+#%L_]DSBDYY-40'>>AP+<RKV:/)MV$S
MZ$AMAV4M/(X1"X2W\7&A71) ;P2==C^;<2FU[=FFT3*FD9OQ$5P/6 E>-4>(
M&4.+=QY@% .,8H!1##"*HZ<AC6: 40PPB@%&,?1@^'TG,@94^U?)8YQ-J<K<
M%#6U$]C3'L^B36.)YC_6'&6$$U#S\K:P,/1- 1E+Z]T? .HGP.Y@)[3_H($#
M5 8F]-/(6G<Y G)%N0_!!A9MY/ G!Z;H<48U"%ZL-HS6N[U!G\ #JGJ*/^OA
MQ:$FQ#KB8*:D%R%?5MT0%BT6-B"5P@\]XJ1K;^8WG'"7.;K?A&\8R^8:I.X*
M=?U,S<?.1:0WLNHTFVBOZA=?F"+"TZ(FHHALZC' XT]I@LUX)CW!2L+8])<5
MW&,FM]1M;5E%>'WBO*<A;Q5^ZFKM:A1Z5F"J:>P-?$:FL9<+BON[H\-BZ=)
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M5U;WT<GH'*U>L*WA<_KK;/#;X/C3@.STT\%Q[XBM]\\?!M10^/3X!(S_P]_
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MPHXY_$0KX=U9[],A_N3S\.CHW2=XX8_@2)X<'W[JG[?7*M[-1BRF\G?NP_=
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M-?2FX3>3(,17YT-3><4LRY#JM>JXYG#;)(&&%5"/HW *1@H#;DJU&W<./.3
M0PX\]+C 0\^ZU!H''G+@(0<><N"AA^UY;% !X(#5<Y$+P^!J:NY#*RX"79(G
MY))4CH?/4@,,V! M=_BYZ"RW^RJ5%<N&=!5&LHL-T=,8D\&>@M5<YA1[:K*%
MM[@YLSE"DD*%]/[X4=4$"Y!D))RW:^_2N EF?Z'/XK1D8[VLY!;.\R!2B%AB
MYNY^-E]*)[3@7J+FC7.U*//4A&N-W(S0>Z^026,F/B]#=@((%L,N'MSSH]18
M<CN@63$.O_6QR$7,20NYB+6F@ZI]LJ*\( &049# 'V<U+>D=H?ZVO$HS8PRW
M-[*'HY,S,[E&EJ28K;1O3;/)NZ)R">XLIONNIBNGZWF06&8]F_@B:6)1;&!3
MTVM>AJC?4>ZBUCU:,<K6UJB:!C]8;3 _V^8I+PM-"W*3ZRUBFBK>'PGCN^VL
M;@EAS&U7KJNZ[=;QL4%5MR1B8U$TD.9#@T6A"F!@@$@5"[]M^[-T5S!P [>I
M/K%"('.<^3Z&.6!9+FDKZ6?I!,4/%EA?/K0B5[*(*BD&OGTESR!YNDJ4Z&N[
MUK<^RA1ZV3N7M%U%3C[N-JI=C.2*4UNR*U<D+8)AMZV];=B\YP89^JU#)X=E
MD(<7L/^BTF6"MHA&L<W+7)_2,)S!&';'B]B(;U!K"]:LR%@S2J&2!G/BS.9P
MM%8G^F)-9,_MRIW:E3>H1!QYG$[Z.J- ]B_+B9'YS=8TM'P<($F=2\2V)F*?
M=3L1.RKS2]G]3 ZR2_NTB 2V94K),F;[?[WV4X62J>=LKTW6O-$9FL)[BL2N
M3W=>^T0L$VUOQ=OXSV?X/R]][\7.GK?59A^+QJ$(2$DK(_;Z9%_>QLOW;W?Y
M,_P?:"%--'QM^,=S<6%9;K#PH(5UH<$43KRB0*0S?$[ZS=QMBZQ1&$//@8TK
MC5#/3D\4:P@J]]=*:3V'ED'7O/(]Z+6]76[-WGZWM(J<D(G+9KELUN/-9CWO
M4FM<-LMELUPVRPF9W(]'\KS;'DDO#/-21=X9)3\.O%-M"H-UV57&XRXUQG.H
MT2Z$>38(-5H#7^<K,,AK<,SL@X^54<@U O7:D944)A>ZTZ\I#1?((A?'U*KE
M;9-Q3[2:$3J<99YS:JKV2RY>T7[NM>FNVBLVDFS0?O1H5?WFE!\E "?EWZKT
M-%X+SKF*, D-[<?8,;U?E9#&5UAX27#%5<8>8EMUEJ#A] NG[6JGPY55Q]HM
MLU(B&C'*C <Z7:ZAK41M8(+#.YZDZPG'>CUN57* -GQ5"DIK%-15A.;:V]EH
MUWFPU&7H^&>9SH,X\MYBE/&=4MRYI]9KO,W2LFA$1FJ3Z>9S8%,R)O?5S!LU
MBK-7.OFLQPDGY^HH&04*>),G.6'!]<XQ1^1RD'C_4\(_5%[H>:3QU@W@]@VF
MJ,AEM$BI[#.BP4P0/7?82F6V@9;+]EK1VB]V]K;&V[6(G,Q93K13M]@ME5*.
M,(0#-]>",-@GP9(TX&7RKY$\OWX3:RJYV#@7W,2(YL!#4 +6V$"?,MSE1OW9
MLN1MQ#J%0(O,2S+<#*OZ<@.9@5?$_-@BX0U>J!)\D_."\:JES 9:A 0G4IQ%
MWE:  /0)5PDHV%>VN6"&3$.8.O9\$_.PY1HSXV2FZ7G2^DA4A'=D+!VUI38(
M!X=[E^1T*V$E.SCN$UN0K!DB#-*\4=?,;DV+Y,U4D!:^WBN8<LBZ17-:UZ]S
MY Q=G-P;A-+Y=/NS0VVOZCJT<"HC[A/QB.W6(@(SGI DBYSH^I[!+"OIILS_
M%D^L(JV5XSD+P9<H:DOQ6RZHKOO>"R^_L87?^'OY#^T2E]_31G<*=FJCV"#@
MR.<6[U9;817O79!>:]'!OH(9[[JENW*:(A)%WQOEE8*"KEMKZ5E[BK_6]$XC
M+NN$1LJM_0J9+"8[D8#-LQSU(-GS=8NF>XMF@[0..KUH>(G =Q@QHX5";MU\
M81:*+ 83NA!+@*-@]N-A(_/ X;Y4?EN915P4I2DJ#U(BYL,S2SN/YHC_JD=8
M* I74K$#GW?<Q!WO\^JRM]Z&B0/EJ509H5>\-3A?>SCYGB+ 9K:0.@R'U1S@
M+:-,&6[ >;F@ZH%I!D[I),"G6F]=O5(FKR0-76,IW:25=!L]SVC:4;$(/HZ+
MP"EZ(\7Z[7&19ZY*W.%J'*[&X6K^\?1%EUKC<#4.5^-P-?>,J[D;&(ULR-^Y
MY]X]:.7L?-@_&GC_' Z_\8AZP)WR<3CJ#XZ.>L>#DT\CIR]O^@5Y"SL-P?+>
M@W=&O_..@JLNG>A8#E*+-YN,XY2:S)X*ACSA&JQP9]F&9O4[^D5)<&7JHT<+
M2;%BFW[/\B^^0;3D:AKD!J@B)& 5HWR<AO$\X5P//'("WS)M =Q^Q\UY>\[O
M=QMW>"C.]YDJP+_K+,30H?H>**KOSB?X"6F$@@W9J7E-]7V:S3!7839-X1$<
M')-X&#%9D"[(@@!#01X3$88!V,$.#W=,)1Y%.WR6UT ^JX"Z:V!T##UK9TE$
MA!\^7T*#E(3$^\-_=[PA<W4C;8'N:WW"6'R-ILZ;!4DBTC9:Y7',S3YD\G6F
M/_!(2Q'%B,C#%'&'\/8Y'GVS<H'!OC"K%^I6IUF!05IX&I)E:C3@>48G)-:3
M%Q?<5^8%_%KSB1B$&DMX/UWQKM^B%G*MQYUQ_R<P$&G#5#@R$_/D\O:K"X4%
M\]S'A4NF=&KWNT,<SIWO?M6QCLMD\*<*2YS>'2MV'I*F4IG*,HG,\NC.#L@K
MTZ\CI)DT8Z+R^J(6J[GJ;;"K+S(QVF=*$7 #EJM("HR11#=1\PLDWFC)S4H2
M!QZ3PQZ'N0KHCME\T4R85-N,W1KJ7?J N]$+8==D8B73W6.FZ"H-B17]/IM,
MXM""JM*'(IH@^3&=2&&^&L:F,+(P*&H[*!T@>A>-69<+ALBO=YQQ:TS+6KP8
M>V_="AW[4K<VRSO$==U]."L?QXN\>W56N(+MQ11EE#<U1H6]79I$-*R<VDH9
M;S,H*C"$3<4%6V"4W50B3+>@E"VEMNM[FB7F!GMU!;VDPI'(ZR=!/#/ RQ98
M\NK:AEUGC.*GB*>N>GY=X.*LE'B#-4K:S!QB0) 17;!#]B^"V1@/" 36D<:I
MVA"9TF&_WZ6)9V1)93>GL1&&D2WL]TWI5)X\G>Q:7P NII5$I!BAO4+AMS'B
M(F US+-<(Q+(%!#)26WBL"8KK_ _RFC*UH[ 0ZT%$UQA6 ]/8RY74+D<LN"8
MA%F94VT1KL@_2C!XHEAD+IF)B[W62(7$@P+M0,NHNI[V"_MANDP.]@%8EM@T
MVCW@\ T2+ 6AC:UF4,78/U%1T]5LVR,:KJ%O\]_5"#57=9T:]'HBUJ A0/8W
M^B'4*.-3$DX&T3J%#(_>SUH!-H9JC4$V=#]NB[_R/!@5'\>WO<VZM2SM"<UM
MZ1<8_RC"_X]E*VQOZ(TIJ_;V'TVD%H'3YXW%8HXLD161,+LW#U)%8&T9:;D$
ME5A%,75]_-VL<]]+2=]B@K[!K'I6X%&M)SLK.#5A?H"UGV1+KCIC0 Z2/!+6
M"K?E)_J*8I&%7RY@)\4SO*6J%/Z*<XWGPC!-153+:[M0 >M()VJ*>M])@!,5
MT>IMW5*E#:I_D8G!"["2P*7$Q&Q6II)$L"KEH)L&Z10C,#LW2R([$)4#43D0
MU8_IF&Z!J%YVJ34.1.5 5 Y$]1/)B1Z5[0G&9Y5%J_R-9A9-LH,A@CZ66.2/
MZ:WI!<9<9^@S4-@U4D68QV/X [VV./6-'Y;$\"OX7#$-!CKS]"_V%<(X#\L9
M\EZ&VART+5MVJ^A![,;HNYD&60R;7(-N,6FBHR*$'&!:PKR<D4P%53WD05RP
MP=SP5GV+:5-2;A&+-^"]H@R:B[P&.]YQYJ'R'AJX02-VKA(5VGUIO5(CQ\>^
M'=G'MK"!ME71K$;;'U93C.6#\)88RL>V&>.^?O-,TI*)#GT3"8$\!_;]"9>X
M4$:QEDU47R1[ >L4/JI(N]N<:YA&$H*K,Y-@GI;#_MS*'>\=*W54OKID38.*
MIF31-NA<#V&<7]UAW"VK[==L]!PH^CH:Z'$M=%CI*_*_)'MJL%96]T\HQX7"
M%C/X[Q]EREX;3D$U@=6UB),U$1Z2EI3PC)00L18'+-0"RXTLOMLJ@%%K69 4
M&<<D=!K]*F J7&9"FJEH*:FX)ML-3F&>@=?'E?!;Z[V(\$=8=H-$OV:-MQ>^
M7U MDI:++.0JV)D6PE9O- GF*C5[QTH7K>YPEAIE"FNOA)=&,A9:B-2I\Q*C
M+]Q0HA:BWH(1?X(H I46 >G41,$,3#O,%1IU( FX5?OT>%E%YW=W7E_;&-:8
MN>(Z)3*7*DD%?'EX5[V[L=NNV8RAYPL2TJG8HP(31UK)G#9[B2A;8KJJ$:F"
MB=(0KH ?![3CJW_CC@*?Y:IEQ]7Y5HX20 \&$2R5N*!'(B&SXA"_U0RW?]3V
MC\MM36)U#;DU(C)CDG#U5*JYP64.X]0U\]%(SF*=FQ%Z1?2K;X1_](QA\1]K
M-.DF>/@GJ.3 ;8&AQ)BMKT4<?,['%V7"\%#K!GK>X<;"ASO26.G8)^)8A2AA
MC+JN<NCL>$.,BPJ+@C -I<UI*T%2-(=,$);8A AFHP/+,T/$8%8-L911%U3A
M*RP3Q4V4K1,3<+9W4R9N@CWZ*BL3XCH:!WK!6?!9O*\.E)$\2LGH6S*D."[F
M9KL]VV&R]PH4"XM:@55;H1 D(:'#9N2BZNG2+L4[6CES')+;] ],N*?=1G*?
MD9L/F\A%/&]XCEV::))HP.VO:#JX;=9DE2H@HX</$9Q^:-WA][03!Y@2 4>P
MEO%8+R^.IP(E3\D(T8\BLMVQ@JLFNF66U>/3$<CWC!>5EVC$*QC0Q4")!8E7
M&4^+'XTGJ+8JT6E=D.:1WMI:WMA4<[SQMH)M.MK!;UR0 1K/T&D(O*E*%>+"
MT R$?]'HC]7B"G6SK+X]\(C%#RWZ+ZJ5;I3?&/S?NGIAS";V2NJ(7Q<3873$
M355%3\"=9I@/F1<,&A!2 X*$("8!O"H);."-5$3O=,GGMF5<PSF*)$D\.BVO
MU<HH6I0$XS6X0<PZ4XA"8B(TS: ]T;:1 JEU2&VR8)J5NBA<K)D><"=E#PXV
M(2JI=6B)6W#"MA>HG 3U)\ZH D:U A1S" >>,.&VYLA"0 ^@E)*>""BX!B8&
MN""JJ'LG,O,8GX?1D:\\""[>FFY7(8<&HRJR(53SI:%U6:$E83J/:6+5>@S)
M&M9=?"LRZ=OLK=_)5>JD5%RVTF4K'W&V\E676N.RE2Y;Z;*53DKE?ASA9YWV
M@]&Q E.X8TYOCZ46L&%?P\-);0S]+%))S(X+^UN43>2:(8UW3Y9/3 $I>"I$
M88 VOUCYE'Z)56Y)]"J$QHI!+P^@F\)B1?+RR]C6<<8/?:TTK:&L(D6M(D*<
MXF,X]\S9P(+"OCH/*(X<_\P*/ELT:RM%I6]N&WGZ[GW7K#8OCO[S+RKYO_C+
M7E;M>7/<X&"+XRAQR^X#I\O+UZ]>[)G_VZ<-AXX-G&DX5>"!>/D3L*FS<F&?
MM:^?[NS^5?\\1(K^>:'>% J<>^@H/FSI\>9,QVP9JX2\T;\W/X/?1>9XH/OO
M/]MY^>JOZS9 V&%^641K+W[Y?&=__V87PS_SU;;J4Q;75>O:LPJ2V-3 #UI?
MIW:@DWEB[?>[.[NOX+-+G,-AD,C(PD]7G!?K2CE6^=(UA_O^CSS<OW,_OUG-
MPT2X)&L+J7UP75=^A>-HY)U>!/D,KB^I$PKO1%>9PTXW3,/V./DFONS>WHM7
M^]X@\?K0MC3SSE0 F_^HA)MZ>_N[#^8]1T'J'<9JFOE>O^>]WM][^G#>K;<0
M^-@;KW^!  I3A^R=<$7O;2RC;P^.;71G#M#\></IL ?S4OVPY8V^=GB[ _O&
M#O?W>M&/Y'B^PXYS=F>71N-A=]P/W9(_L[1"F,V7WA97!'-(@'.7*3BE!!?B
M$ +F M=8]FX%N!6PL1VWT4NXGV6)6GI'1Z</YI7V=O=?//=&84S1PC[C9@[S
M6^7J'YD#L>)I[N\]F'>K>9HD7.I]CI,D#F;%@?>K2J&)\%=:/)@7%F\PS*_D
M-?\KI$6_$V:S ^]+SJ]K??@SW]R9V;<\*V^3M+NO"._1KYL2X>UT;T(_/NF-
M59+\+0M"L+,/5N.ZCVWV;\I>=(\=9[TD?7[7/7G+S/_-3+RGSZ$AZ%KN[^[_
MLK_[0J+]T./W=7C=QVN^55AI5A#R&!OUWP@Z7GJ[+U_?GSUV'^]IF62GN2HP
MS[^X7VO]L>V3/_I<>QA;Y0.P"5Q([C&N@UJMY>XK>*?[-"+LIS]I>3Q_M*EG
M4]/(]GJ_?%T@Z<%UP]N_9442%!<'4X6HP+\IZ8P73UX]OL[8?_URU_N@>R0O
M+K)DYGN'*H5V??E)8<8'W>&6@?@;LHL:*]'W^IIE%LNR@C@OO+\%L_F!=X3E
M\5\[VN!?B&E\]/#H@2GGJPA6JGH[FYU[59J@3A<4U7CRL6A.$\?6L,/$"2I4
M2-Z6^E,3)LU9['B[(GE@%E@69R:T;V0Q[@OC</U;1" SC0^BAXB^2!# KC2\
MAHA_WNW2\ \J(";6;D'B-9<#SK*B'!?RYX4TEHBPP6<'4PLAXDBRD:4P.V,-
M7:]XL+,T8?D[8<;'BE7BZ=7,./9*<U.W-G5?='OJ]E&27>4XE!V;O@U)1LVI
M3F!+F+!%/"N319"JK,2=GPB7JE<1B05B?ZX\RVH?#G 3CJ>&.)U(</2OD5MN
MJO!X\>5"RQT-/-3(251%:P KC0HM-#M;X^"I2DS&2X_H\O(,#A=OD0=I,8M9
M$T:SS4GS#/=X89IYNPKN'UX$Y,JS77GVG<PL5YZ]IF.Z59[]NDNM<>79KCS;
ME6>[\NS[L>A?=MNB[R'Q$UJ>!][G "W/+NW4Z\QZ8JO"<N=9%E%=M,5<1?10
M(3(D)500+=RF0A&%Y(3%JA>J;XR<NG@5N;!$T*HI,&/B_J+?&J<"+?2*>A5%
M8(0U.PP*UI*A'O4U\Z0H(@EO+VO=8D.UDA.8C20S$\1)R8RM-2*L@+FFJ#([
M8WW'@G4F*:34)(<BMB]-X*MKVF,B[!2IWH#%PRSV7GR$)N^6 G#-68J_*@)4
M&#[.Y,6H VK<91.A&$Y9\X@XI[CC\31D%XO> 3DB]<[4$G]#'2YRJ? 1HO?C
M&R9=#./Y6N>*9'MRF D<GV#"='_%A:-P&]T"O;.8N9@#^&'@3<J<'L7?+>*T
MQ.&15Y0&4^W\]>]%/Z$7JU%^\2<N[''M)GDK^I[[X+# C2B/9)J_5:F:Q&$<
MY)UC<VRT=*NB[->J545S7]FVF1F)6H^W$^(5YVV!9.Z"0O/VNXF\=B*_[OAI
M7R#+!YUB>#".RA")JK.\8[/XO(V!4V22 WH%(OQH'C]".&DO )O3NH7-ND$J
M>J#Y'ZUCG20!Z)E-F\&^MW632L9:/PC;56L5$\;S.BLHV@['UB+F;%.2F+.E
M+.!X+)A#LB@4LW;3.3.)\V)1O3:'+1OM(^> Y:[-63I3^93X/O'A17685<?J
M/<T$NO.W$SWJE%V7YFM%SUD;XXRE!!N#$A<RF\C\*$JRX1H_J4B'F%LHTP07
MQ$\>7!'ONM:5](G(<QVY;OO,I852T7UR+G%5Z+)W].N!FP_?.1^J4<D5.O;"
M$0LK'/H<=Z]6>N6)R(,T;/G&K\9BD)H1[&ZTWYD$>[O=M@G>D7OW,?A#@=/9
MI7G43B!.REFT@#2EM?&7<_&A8;')^L$]E"BS+=KGUG5'6A1\LJ[<#9FBEYGH
M+;$=3,]GT0ES6DLC12]*Y'*(2ZW1 EM(2]L0E>J$':U@ C<*%J"@=.%MC<L%
M!R=B,03HBUNU<?L-\ZZ'9!&]SR+?FR09_0=V+-3- <>AH)-F#D:CFL4A?#B/
M];_@EA?_+H,O\%,*>4?9%1U4\R0@]:&++%\$4]K&0CS6PB A:8\Y._IP;S)P
MRC2XA*X/F#X-?PVSI9Q L\H<&PO_PF^$QQL%R_(8Z9"*11[CLY,L_ (]"?\(
MQB3,JZ5!@J(,$B%6#T-!5Z&X29 CD]YEEI1\CH;Q99P0G"?C#^ 1>9;'Q8RC
M2"';7_,2AC+TP ><Q6A=C?')]((H#3R&K2GS=0A RRGAW1+4<:&0N$^")DDP
M$UVU7$W+1/X-/XC3@%1;H(,#9CN7"(_12($[3XE:4&.53)1B',4<\/$MR:2L
MJ:)6BVI4=\*)J?N?U9U"60DXQW27%]+%OCV*E)Z>XTAKDQ*)\*?X"&0YBL7J
M0/6SQKBF2D6%60>PPK/0=(451N%Y?@4G:Y$I"JIIJ[: I9,$.:LQ%_HORJRC
M% XT%1GE4["T2+/=O\5JWMH(69/:ANX-+F]9=')7VB;;9,:24A'I!Y'55->?
M+W@+KN0(6T*<7]W:)S3]=?0"+VGI()&NP9CG&A.L0/4M^V'F."+1ITA047)E
MG$4U/:>J ;3FZ+5\L+O9-YP%?\:S<J8OU%KFOB@F"<PDMB^V#CF6-">QHQKR
M1"]8*T:YZFF07,2XT"@N>L#:_D%Q-0X:J\ARCS'$&2-WZ,K]9S,5H7T*!]8:
M'V-%S.S<+#[S) F?MS3+1+4)8]:XEW&C%1B+::PU+R/JR3D<.S&L>U%9!.\[
MC.=$?RHR=211I473: ^1,U@K+]84.EE$$G44*N>MI@!9:5]E(0O$7]_AW;7H
M'7['X7<<?N=1X7>>[7:I-0Z_X_ [#K_C\#OW%+[;ZW;X;D@H]ERQY]VE?7K'
M^Y0FI#+  K1_+FHRUYS](C\^1X^>I$5%6@^Q)G#_$CUY;>*35B?[5TF98^BG
M^G?M"A'7PXP?[&!&BC3+&ZJ:^@LPZ'^QOMS*U33((VHY8?R5R+7Q_=9>AP4R
MI8C3%MD,FQ9H?0G,78(K0*]?;(.?2G?7.N#8,RC"S2)_IHO&BH,>]&XLHF<T
M&N$R'5FB!YMB-2HY*W!+886_9B]T>BZS6]BE.6Q&5Z=R&!LA_JOE[&WI>9+E
M--HH@1A/,-B)PGXXM-$VUU;5IK.(D/@Z5XR I#DFM9#8GJ)_(AU>TR>A]LWF
M"?FK;4$/D5/<J,''HI8.#[TM (J!"Y-K15 <[2BQJ,1PC296XVS6 -![=FD$
M#JH]66W:;#8IGBYU:-6?.$_Y-,,8E,3,XQE&\+<Q[DH'66MR2N]@..,W;"A:
M7JA+HV--]\FF3?<H6':I*TU/PFF\$?VW5$&GD/<;UX'_+H-\T:WJA88!01LF
MN$)!HM((=MN(T?[F;YP"M0_DE7Q+YSO!I!$[#Y6?(*:FKG9 P6@+]T]I-6VW
M,O"P4AJWI:\KO>B-&' JJ.[2</MFO#>B_\3AZ%(/;MRFPZY:IV:AW8>XNI/X
MBVHXK[0)4-XQJ.IM#"@Z-PXHNCS:C:6=Q6; L3#%.JEKW2U1BP7[PF:;ZD:A
M .E(_OFO?X7S?^'7_]K[U],7+SH4;-SO?K!QRECD V^$43O!"W5I"33K![K4
MMHHLA)P16J*#/R_B<4S5=XL@O #'"X_B179O6/R;10>P_& "_B$W&CZD(J%:
M-82V5#2P0Z*6B$3![4 @$LPP).6:!1<\L"JMOAF'OL@807P%$Q"-U>)*J;1F
MLS0?2KM:_:D[B*[ Q I"X7SI\+B@H%T?-5K'F8#KFP4G4@Q(8;Y)"1]P(:05
MXL$2Q# $)XTA.-@8'$<J,MT4Y'RG)AD=36F&6,OX4F"@O:-?#11P0OUK8.^K
M$X F1YYAO:@W+_.B#'2Y0]0V6E5),*M 2WUG6X4PSPED9/-RM+KE819>%1'_
M6UB_6\TW0=;2N9OKWU2HW@"5.E+&QO8S@S^$'VW3_2U<U0UFK?V^FLUK[^G.
M\ZWQ]E:\K3,'7[T-(CLG]I*Q>) L*%E&&M:T<U40K:_=?,<;3E:J=J5AEL^R
MVON8X[A0B:;-BU.P3^*(<<-2H:Q+PK@"N62R,2RR5CBYO#]*&#;,LF"#");-
M15,XV^9S!>9."/[9F)H%CUX$7U3J\X9BM4PS+UE%Q(5BOB:6S6XT&\-LL12O
M%2J_I'DCK<>!I2)+J@\AEL#J0;Q75G XWNW0C82&P4!,LRQ"K#I,8MB,8%OF
M2G#*.0GT>$T7F8?P$@@\_AUM:];/<(2XI%E7-V6TK<(":"0@K.IV:B5"Z0EH
M@Z_4K.L."B-X;JY<4Y3OZZI\F',)RJE_5=GW!UJ, A6Z>]/P.[?O_SVC61/Q
MMH* %1AQ(1.EG!." ;QQ$J1?#KQ",X[Q#T47OBXXZE!]#M7G4'V/"M6WUZ76
M.%2?0_4Y5-\]H_KN:M0[LMT.C[W/P_/CP6CD??XP.!N<O//K*8] EW5$;'OV
MLR?@/7+]7[U>WB:39;,USKVH1,(&KK,#^[1195>TVZOV0._O[N\\O[.HYVV&
MXNZI2, 3/OW0._O8ZP\^G0_[O:.1=W(Z..N=#T^.1[XW/.[;_<>T]L1JOW;%
MR-:&KX./A[[ GS\!NR\K%_9Y\/SESNY?]<]#=%7GA7I3J'F )8('?UG5AT&/
MB3W]-_KW!VWB+WS_O6<[NT^?_W7=*OW+.OD3.:V>[[Q^<<.K[U?-9F=W;T70
MYOOU5Z[9C!H:#OO/?LXBN)F"R/);11]OU8WF_-:^RQQ>*P,/_L%V\"_%+]Y9
M'%X$>>0=95?PX<77%3 >\G+HM%#7<3!3F[\@.MW%;C%LRDB=QXO$K8:[[6.C
MF40A[/X%$C4,R%3'7,T)TD]4N+";"R9]FYE>81<>FIE^]&MKT(K:3ZP?6'K_
MIIS/58ZTMP?=:?F*@G2GH17.V7'.3O=M<>?LW(.S\P&K$X\PK#A6^=09=QT=
M*N?IW'D7NY6P$</DW)Q[='-N[\H\O=:5^:&9GY^8TG-&M#.BN[F4G1%]#T9T
M/PG*PALME,+"%F^D5<V3/Y2S(SHZ;LZBOO,N=LMB\\;,F=?W<"9GF%$[)-QP
M=MMTP=[UE8P/Q<*^=QQ9M[R)FSL/NW?K/.R_^E['X>7^SW8:X/7@HO0__[+_
ME]9M[(>=!C?>IGX*\O%&DU(7BG[+0>W&Y1MWDN_%#_\D@VG#Q^$NUH?7^T93
MR?5A'9;;-\JTWBD8?:&E<NFF>C>&24_UMVZJ?W\?SN-4S2]R^%]=,^[F>=?&
M2.9YW\WS[^Y#$B!Q$[M;@Z(G]J&;V'<[L5=#-1T)5NS^E&I&5\W_0*KY?U9-
MY?^.#)G$*9))++(U59/7T4NX@FY7T.T*NC>CH/N[F7#H'I$*A07J#?&YX6J6
M5-*=3(36&% GN^=.7O\&X9N'0IST[29B%QKDI!0WV$S;Y /0F5S.Y'(FES.Y
M[L[D>OLX3:ZOI1$>K[WE3!QGXC@3QYDX#W?&.1/G<9DX?7>PWX>!MT8%VF74
MG!WS&$X59\?<N1USS[I37GTF>ALS%9V!\[@,G$-GX+@3_QY.?+?_=L44^/LO
MXRQ:_N,__O[+Q6*6_./_ 5!+ P04    " !L. U; <SX-?<(  "&3   #P
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M[N_)(?T5L8^_G!S:OS_V/U!+ P04    " !L. U;#FK^Q?4(   =00  #P
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M=7]KL?[\<4!]GQ^P7\&B6NAN/_%^'HL-R@D27MK-J]#D' /BJNHI3/>Z--@
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MMQF_$:Y=@^I3(M61]:Z"%5=Q?90@B4;R:B!TP'$N@L\].2A1VO#3M\@F2DZ
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M67SS9+1KCV?\'U!+ 0(4 Q0    ( &PX#5O9D5Y7#:T& %AF!P 1
M      "  0    !I;6<W-S@R-C0W-U\P+FIP9U!+ 0(4 Q0    ( &PX#5L:
M$4@HQ0$$ #J=+P 1              "  3RM!@!S<')Y+3(P,C4P-C,P+FAT
M;5!+ 0(4 Q0    ( &PX#5MZ^P.BL5X! &[E%  1              "  3"O
M"@!S<')Y+3(P,C4P-C,P+GAS9%!+ 0(4 Q0    ( &PX#5MYTXYAHJP  -R3
M!@ /              "  1 .# !S<')Y+65X,3!?,2YH=&U02P$"% ,4
M" !L. U; <SX-?<(  "&3   #P              @ '?N@P <W!R>2UE>#$P
M7S,N:'1M4$L! A0#%     @ ;#@-6PYJ_L7U"   '4$   \
M ( ! \0, '-P<GDM97@S,5\Q+FAT;5!+ 0(4 Q0    ( &PX#5N$]+B@Z@@
M  -!   /              "  27-# !S<')Y+65X,S%?,BYH=&U02P$"% ,4
M    " !L. U;NEW51SX'  "E40  #P              @ $\U@P <W!R>2UE
?>#,R7S$N:'1M4$L%!@     (  @ [@$  *?=#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>spry-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:spry="http://ars-pharma.com/20250630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="spry-20250630.xsd" xlink:type="simple"/>
    <context id="C_807c7cfb-8b89-40e4-984b-323428f58c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_828dc3d1-fee8-4736-9111-5a0102de64e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8337c8b0-3081-4566-b477-4a0f04a2f5aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_83b0f481-c291-42bf-a1fd-628b8759542f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_83d2f352-620d-436d-9ef5-e92a513b8f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_869de754-f3e6-4177-9331-4ed5d47c7e01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_86b564d1-cec7-431b-b172-b26077a97bfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_87fd2cd8-129a-414e-99c1-03cc3ad545e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8855f418-1ce9-40e1-ba74-585019621581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_88a3e244-24a0-4aeb-bc44-0d55744142b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8a13184c-6bcb-4906-a160-a36e0d4656ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8af74f27-94e0-4415-9f6e-42b1b5332edb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8b011e99-1250-4ca4-a497-f2a90edcba13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8b918b45-e66c-471b-9415-84b94cdb93dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8bf5456c-aadb-4e60-b041-d6db39979b70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8c487881-ba76-4097-b6c8-427e2b451999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8c610e5a-69e3-4dbb-91d0-cbfccda23506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">spry:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_8dd7ea83-dd18-4eb9-9282-167ae56ead5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8e9dbd5e-9d63-4ed5-9644-7a43dd445156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8f694959-366e-4e19-a611-37c4b53e615c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_90480581-aab4-4026-b4e1-0aeaa37e50ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_91159948-e700-40b8-abf5-96f418841f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_91a268b1-3615-40a5-ae0c-938276bfc07f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureAwardsOrOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_91a3dda9-27ba-40ae-acc1-7312fbbb4c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9409939c-9f3f-4a0a-9fa8-269dcaf95cb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_952043ab-5fba-4c7d-bfff-86d859fc075f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsGrantedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_955465f7-5718-4609-97eb-6c7ac882fbc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_95e31fb6-2b47-410f-b070-55db285d63d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_95f04ac1-14ef-4698-b351-83ecaff48cdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_98d3f585-f5dc-49db-8505-5f7d6f4a006b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_98f4fdcb-e4e1-4865-9ef5-c4363da98d19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9926d4b4-fa02-421b-8525-65d964045c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_99e7eb22-c9bf-4bcf-8348-7f1f227a5e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_99ec2511-459f-4c45-8f1e-cd91504cd76d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9a4b43ec-ca53-4df2-bd72-e2b244eaca24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:CommercialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9ab27dfe-3c05-41c3-886f-a2b0e4136b85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9c214f10-a914-4d27-a1b0-da1ea243e703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9c7e6e23-0000-4ddc-a5c9-a2b708744fd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:ROWLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9fd25023-3042-461b-9a6d-57b976f28f60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2016And2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a16758cc-95a6-438f-b28f-9eb55360c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a17bc1f5-5be5-45a5-b3d5-0e7a29e42cf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="C_a1b6d996-a8c0-4025-9859-7563f538ccfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a207a717-bac8-486f-8afe-c9df9c813261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a2cae88d-596b-47ea-be90-36c21e8fc71b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a3dc6a53-1c90-4d3f-b90b-fea8237b5cd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:OrbiMedAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a417b738-34c6-435f-98b6-b7335b68b8a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a650b87a-1c00-4b79-a58c-69715046ebb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a668bc1e-23db-4ea8-85ec-8d8056d6f34d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a7e67462-553c-488d-9b14-c09155e03b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a9963800-3add-4281-aca5-d9f4f016ca70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a9a7be28-24b1-4e30-816e-ff9e76477575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:LauraShawverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ac30d314-86f3-4148-b29a-7d12452b392a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ad92b4a7-9dd4-43d7-8f4e-0ecdae3b7b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ae56245d-14e4-4425-a73a-af69dd8543a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_af065405-07da-4d8f-9aad-88eb0dcc47a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_af689524-2c04-42d2-a16f-31b2d40284b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b04c992f-7141-450b-a7c4-9f61a9eb497b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b05d88b5-cf1f-422b-b672-31550bb59ffd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b0d7c1bf-c559-41f1-bb73-15d4ca13613b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_b1018c50-39c0-4a1e-a69c-876377e82ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b2af9dda-1f32-4532-acbd-bda315dd18f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b2e00eb5-14d4-4be6-9263-605eaadf4494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b3290235-3d4c-4e7f-9944-799740aa251b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b4c93365-0858-428d-a34d-b5add11a9639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:IntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_b5cccac4-7ff4-4dd5-9952-e4d8fb70e5e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b67f6b97-19bd-4541-ba67-b60ffde15be3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfRecordatiLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="C_b6c4e388-e63f-477d-add2-c9ae15d79bd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b79419a0-d171-46d7-996c-18c142afc6c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b8271b46-8d08-46dd-ad0b-ac8a80d68454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b92085ed-7b67-4267-a76c-73095df42f5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b963ff18-7450-4060-ad3c-efc70564a546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b9e6449d-ad47-43a6-9843-3ac845071d45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ba7df335-5578-421e-8c2a-d36e33edcb60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:OrbiMedAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_bb2d95de-4594-438d-9c55-a3a55b7278da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_bbfe4e30-cf8e-45b4-9694-9eb0e8f2297b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_bd86d1ef-eeff-4adf-8a19-f69f6a8e45f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_bdb38646-dad4-46e9-bb80-804ebaf2c503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:RestrictedStockUnitsGrantedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bea2c90b-ecb9-4b59-93cf-dda1fa71fada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_beeef49f-dee6-4fb9-a634-f1430f58cd42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_bf13c693-c4c5-4d64-bff3-5e485417c1b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_bf31afc7-406c-4630-becf-7735028ce61b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_bf5281ce-db7a-495f-ab02-93574c48462a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_bfd38f7d-69e0-47b4-8cde-fe7dddca6c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_bff2f443-6b3b-461a-ba19-428c01a04487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c12a3d9a-b30c-47d9-bb6d-6f0ae9453472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureAwardsOrOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="C_c2299308-80d9-4f3e-8124-02a70b3c491a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c263fc35-be1c-4365-9aa0-2c5ad53934fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c28eee89-e582-4ada-b83c-1d83ed541c9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_c2c7df1f-3bbc-45b1-969f-8aabc9c9acc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c38ed128-079d-4241-b04b-554e67e4475f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c59d3a87-64b2-48e5-b806-8ca9b8489a28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c703154e-f609-4897-84a5-dd320a085d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c77c3709-162d-4edf-953a-4ab1c1e3faef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c7d4f909-e24a-452d-82cf-9bb2659ab99f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c7e544c9-751c-4210-b224-6b0035e4618e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c8ac2384-1b58-47dc-915d-83a7ba54ecc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ca70d85e-c0cc-4722-8d9c-3028532be956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_cc8627a9-0c70-4d03-b571-48b53e518a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ccda22c2-6677-4cce-ab78-990354649056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">spry:EuropeanMedicinesAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="C_ccfcc4d8-af04-4d3d-b28f-3c979e5d0771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ceb11ad1-2588-4e17-af28-fe15173ba3d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cfed3148-1f6d-4764-881f-dc1ce6517210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d04fa5cc-8928-4685-ad0a-fe068b728fac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d088454f-4075-431f-b4bb-11f7b482ba95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d0bb372c-0ecd-453e-b973-012e84044734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d10f176e-9429-4ccb-a20f-413c86b3a44b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d188a46c-d138-46be-af79-eb7c3b01af79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:CapitalizedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d1c3a878-557f-48fb-9597-d12ba95d1e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:OmpiSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d905b4b3-9373-4262-8390-864c35ac6e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d9365522-fb46-46b1-bc6e-284e0bac324d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d93ac729-d7c9-434a-8a9b-7e60266ca1ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_d9e4baf7-c70d-4264-86fb-6110e1b37685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_dad879fd-9fd0-4630-936d-24ba4a2d140a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:TitleAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_db43d886-40d2-497e-a347-d9adf0486580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dbca97a3-dc8a-458f-86e0-c938df8b9878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">spry:HeadquartersAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_dcc2baa6-8c87-4f57-a3dc-79e85b7ce8e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dcce5799-5869-4e9b-9399-9d7c6125048f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_dcdc4492-adbe-44e9-8b69-d68a7d4bae66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dd3a8cfa-4023-4a91-9e13-79918b2abe74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dda44404-ce43-4ae0-930d-c039cfc589f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ddc169de-f0a1-4298-8916-2c62ad23e107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ddff9d59-8efa-4f5b-b496-c704a0bada3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_de447bf5-c664-451c-be04-6c477bce8fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_df005c86-508d-44b0-ae4f-f72b61e895e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_df32a54d-3ac5-44ae-877c-73959c6f6097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_df4a29c9-2002-49c3-bbf7-c84fa9b0edbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_e0a90922-dcd0-49c2-a9be-fb3989e9dc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_e0fe3c7b-f600-4c9b-b811-bf543aef3ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e127c89b-57cc-45dd-88e0-5952c92514a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EuropeanEconomicAreaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="C_e154ceb7-5441-4be7-956a-04c0dc49d336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e1d0ae97-b485-4671-bf99-135c430e8fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e3d262bc-6795-406d-8d91-24b3907b6289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="C_e6beb23c-440b-4e94-b575-d556e723f9a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e8814f36-7086-44f4-9a53-259022c64732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eae13608-8a7d-49cd-b8b1-4837d9244b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_eaee139f-06ad-4880-b611-5bd0dea21a98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:LauraShawverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_eda30636-7284-432d-8ca2-1f8a4dc398d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_efde3903-153e-4b55-ad5d-f7a9987f9a59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f02958dd-2171-4f6b-bf03-9a0ffab81bfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f04745e7-fc61-4f44-a90e-0375301533ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f0d8db66-c63b-4744-af9a-66b508f6e408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f1c8cad0-d5f3-4e51-9804-2b151cd3b1f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f1fd271e-7bfe-45dd-855c-01e649527ae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f3358bc3-9806-4dc0-ae94-6af64c1d3c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f340b5d5-a46d-487a-bb76-a006e0f3faee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:TitleAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f342e672-771e-4d11-b09d-5aa31a2a64f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f4436849-9fcc-4497-a985-5fa9db7ac33e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f5b73dfd-e33e-4e24-ab07-812aebbe06f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f685dc68-99f3-45c7-888f-f64255a00ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f686fc0b-340d-4ecf-a20d-89f3341462b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f9587472-b812-4c26-9f12-b181d477afd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f9b7e8e0-49aa-425f-b6ac-7a1e94633629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_faf7e39c-0f29-434d-b6fb-e1d303cebf23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RenaissanceLakewoodLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_fb686167-75bd-4d07-b3af-efcd511a43d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fd906f79-8562-4a95-bd43-4d251d2344c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:DevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_feb3d59c-08cc-44f9-9f9d-a605f5002728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_004bb578-b8b4-4b1e-b080-94149f0f6733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_021eefc7-cfee-4d52-8b2d-03167d9c4f45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0290e712-16a0-4589-8318-f1315dc7c60a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:FirstCommercialSaleOfNeffyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:CommercialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <context id="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">spry:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_05f55f90-a226-4553-acf7-98941d6f746b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_060127b3-af69-4d7f-a100-67b6e7eb8bca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_064e952a-b57a-45b7-b072-cc0c1681aeea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_072805c1-e17f-45e5-a672-6a75206ddbb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_081fe4fa-2c69-4289-b02a-3b63500a1252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0833639e-5a42-456b-b01e-000950904f01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_09f9802b-bfdd-4db9-acd2-6c382a188d1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0aeae9af-4a88-43bd-a834-adb7075f5c02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0bd8344d-6c3d-4f4c-9193-8180e76f5899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d03ed93-9080-4cf9-9b33-e460f48b48e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0d090888-c874-48f6-b153-a3c2f3e3fe8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2016And2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0de8676d-aca6-49a6-8113-220f9d24f1c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0e0c015a-4832-4ce2-aa6e-7f1681a3ba80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0f4f1f4e-cff5-4294-8295-0850b8d49cb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0fc3a621-041e-400f-9a4b-601457b85fd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_10d6fbd1-42f4-43a6-a7b7-6fc8c0df13bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1168bae1-a4d7-42ba-a4a1-1aaae5e9cecd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_12bac910-38cc-4107-8957-20fd4415cbd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_13db5f9c-2f06-4b3c-be00-958784249b0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_147fd450-9410-4b8e-a22c-51b186dd1d12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_150214a2-c270-468d-9a06-7728c1a7db0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_16dc4749-c6ec-4139-b8ad-4dcea1d2fb78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_18b0f553-9076-4f15-9748-2023f42761a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_18b0fdd1-a485-4c6b-9072-308bd98cfbbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1becd9ce-e5df-4cc7-96cc-1fff890d77d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:KathleenScottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_1c56c487-e024-4724-81ae-947caaa88834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_1d2c0919-4138-4410-8ede-0f80ab424b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_1d5db0ae-f190-4d5e-9227-dbb3463af2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">spry:SoftwareLicenseSubscriptionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1db62f10-470a-43d8-99c5-9ef506d240f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1ef13204-b17d-483a-99d0-289ce05e08db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_1f628d09-1530-45b7-881c-0af4b02a1014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1ffef034-5c87-41ce-88e2-2b53d4ffa344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20001566-4a25-416a-94b7-ca46e23b8755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:AlexanderFitzpatrickMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_21364033-0f4b-4e67-a4e7-7235b02ffe34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2196e376-19a2-4b1d-bec7-939794646f60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_21fe8e44-bec9-4153-ad91-5b5867687e88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2241ca04-d0e3-4458-81a0-72b7a112643d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">spry:EquityOfferingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EquitySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:DevelopmentAndRegulatoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_238c6043-2b99-4906-9c2c-f32a420101fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_24048e4a-2861-4e82-9a25-7bcab8c32310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_247f0be8-9254-4ed7-af0a-c83a543c7393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_2534ad0d-4f31-47a1-99a9-04102ea40a7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2798c3f2-23d6-4afc-8238-e8955f00db8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_2799d300-1237-43a9-b5b0-5d5699ea13d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_286db13c-dcd3-4bda-8947-71e23b80ce46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:PacificLinkConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_295e6502-8b12-4686-a1ab-212436254537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:Share-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_298d2778-7e68-42a6-ac6a-7d397a9e29f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">spry:NewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_2a05683e-e9ad-48bf-82d5-1bac47afff01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_2c9e3e1d-19ca-41b7-84e3-5196425f10d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2e38c3cc-e6d7-4425-85b9-bc2d6e8c7279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:AggregateSaleOfRecordatiLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="C_2e65281f-ba53-4d3f-a689-1260aaaf239d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_31e9248e-ea58-43c7-baab-8f7cb2a5c62d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3384a69b-8620-4b79-a234-cd7344debc19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3571bb42-9451-44e2-9e1c-0598970a2964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_35887e57-d648-48c5-aa33-441fa8e48cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:KathleenScottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_374c6b30-c221-46de-a6b2-30e2bb48619d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_375c7fdb-6931-4298-a1cb-0a3d7c761910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_38363ca6-7cce-4222-abc8-30485789e9f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_38aa7ddf-8d81-40f0-b406-1b66b957af89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_38ebd40d-47cc-434d-adce-a43b467c8b30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a9f4cd4-fb54-4828-96ba-ce70b60363d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3b5b2d22-53f7-4c9d-8b99-321480d17789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3b7fe764-d042-4e16-bcf8-711a85614de6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3b8087a0-6412-4ff5-90a6-c0f272af562e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3c5642d7-6f8a-4a44-acf5-5d6d63e1e69e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3c6b92a6-dd38-411f-8214-dba5099c8f52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:RestrictedStockUnitsGrantedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_3cf5d1b5-d177-4592-87ff-f0e88882461a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3e249227-20e2-4988-9bf2-7e870713555f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EuropeanEconomicAreaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_3f30c2eb-5568-4234-8acd-723e1a049bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:PediatrixAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f547b95-0c7d-4909-a139-bea14be39173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4029b4bb-de28-4de7-8408-45df90688cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_41ef6930-d9f2-4459-a547-37d492c3f1c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_43967981-d479-4db2-8fce-ee96cfa44034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_450d35f9-0df1-4549-a5f8-a9c9ea015932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_45813144-0748-490f-bd01-ce77ea3bf89b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="C_460d3d8c-ddbf-4c5d-a288-dca013f2b32b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:SarinaTanimotoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_470f916f-7869-4e25-8dd3-760ff2bc2856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_47e7fcde-f00c-42a6-a53e-32799f721460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_486e30e1-067a-4d74-b32c-7b5cd57c48a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4883e707-b9b1-4461-b2de-ffc404f7e7bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_490ab03b-38cf-4134-9ab1-2f6b7f250c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_49c47b49-d4ac-4136-84a2-4bc4a2103d17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="C_4d5e4244-5624-4eb9-83c5-28bcd9c0f0f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockReservedForFutureEmployeeStockPurchasePlanIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d7fc657-c0ab-4f3d-9b5c-9106d31bfc5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4fc5fa74-f0e8-45a7-8703-dc0cc39277c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4fc6cb5f-4180-41ac-b434-d6945583ee10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">spry:RevenueUnderCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_50bfc96e-86b2-4bfa-93e5-4dd89fe4840d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_51ba7095-5039-485e-900a-2f239350359c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_51f70a11-69b0-4dbd-9cc6-efbfee56c21f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_53ececee-4b8b-4df1-8752-18134066f9be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_551d5f3f-f834-4e2e-af4a-07c630cc9151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_563a8ff6-fcbe-42af-ac8a-285febbe3949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-09</startDate>
            <endDate>2024-11-09</endDate>
        </period>
    </context>
    <context id="C_58518720-4bc3-47a8-a449-980f97f2e742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">spry:RichardLowenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">spry:PlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_59f4bf3a-7f8e-4ad6-a506-194c1950572a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5a15e9e6-1bc3-4167-8e8e-c79dcf3954c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5a8cb702-3dbe-4910-ae11-39b78feaa28c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5c380126-d22f-440a-80fa-e358a5a088b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5c7ce1c8-b99f-46f8-92aa-5a9614bb368d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5d036733-4b5d-4177-a142-b4f41043ac6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5d09679a-e12c-4e0f-932f-d6350e656399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5d3ab776-018e-4dde-8537-5db78360a3b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5ed4cad0-90aa-4443-919a-3ab354fd0721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">spry:CapitalizedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">spry:FairValueInputsLevel1AndLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_65ed12ba-e864-459f-ae4c-a7e1d4cf3b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">spry:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-30</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_6770ee9a-57e6-4eef-bbaf-3da967bec8b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_681b9e90-c822-4025-8193-e866cdf0d681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6b05c4b6-d7fb-473f-ab92-1227f461cbd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6c6d2854-3599-431a-a593-98e4379c15e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6ccd2d37-27d6-4e02-9364-bcfbddaf6936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6ec3f271-be32-423b-9498-2f0527f50596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6edac6ab-835a-4f3c-a70b-1468370bc85c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AlfresaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6f03d69b-1284-4bc4-8234-9a7df3551bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6f2fdca3-8c4d-435f-b8c0-6a77fe46d870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">spry:EquityOfferingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:EquitySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_704928fd-7ecc-4aeb-aad1-e86385ad44c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_707e3c08-3d58-422c-9b32-bda32bcab502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_707ffda4-d1e9-4317-b368-b5b461d89663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_70a2fe72-2e5d-43a9-845b-e6ad6d4e993a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:RecordatiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_71398ff7-c6c1-4c72-ad74-10d8e3e3bf31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_72c960a2-6882-42be-9586-209e84ad98f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_72dc1e89-7658-40c1-8ca3-952db65ab782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_758bf922-ece9-4a0b-b463-8ee0919f4a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_758fe697-6dbc-4923-9ddf-258ba4a7c8ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">spry:MarlinspikeGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_75927173-b0be-40a6-8cb0-9cafd6cc1be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:SeqirusAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="C_76f794c5-9e6a-42a7-b227-1abf0ce9a252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">spry:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7763ab6b-709b-4a5c-8ecc-4d9c9531a9e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_77cdd9e5-e0da-4ed0-91c5-452beda8f96e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:ROWLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_783dccc0-475e-4692-b8a3-08a49e9999dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">spry:FairValueInputsLevel1AndLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_7b9bded7-8bb0-4033-b376-cee3038595c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:ALKCo-PromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:AegisTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7d4c367f-9884-46d1-8862-8e2ef2c52541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7d548bc4-9a01-48d0-9705-9105c2226181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:CommonStockOptionsGrantedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7dfae0a7-c976-445c-9186-28e526f9917d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">spry:OmpiSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7e3f31da-ca14-42b4-8b0b-1e8aeb740579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">spry:ALKFinancingLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">spry:ALKCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ec42259-6316-479d-8953-352d08d61678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">spry:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_7efb2cf9-3f33-4407-a356-10f47479dfdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">spry:MedicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7f5fc329-380e-42ec-8c1f-ae79663067f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">spry:FoodAllergyResearchAndEducationIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>spry:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Doctor">
        <measure>spry:Doctor</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <ecd:TrdArrDuration
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_ad4d9779-575d-4186-8b1b-fc1541c2406f">P225D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_3dd4a219-c3f1-45c4-a510-ce89c31b117c">P723D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_f950c7d7-a7c7-4646-8766-6c37be33debe">P723D</ecd:TrdArrDuration>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_1d23aaee-7552-4452-9655-3f8609a8fe5d">Q2</dei:DocumentFiscalPeriodFocus>
    <ecd:TrdArrDuration
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_3d174add-7623-4ae8-9797-d84da1eb32db">P723D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_d8473ea2-8b5c-4cce-9351-7c2f730e1c07">P723D</ecd:TrdArrDuration>
    <dei:AmendmentFlag
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e324cbe0-4ca3-4579-93c8-f86f08039a95">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_8c4dbcf9-929d-4c9e-87d4-8a5fbf679880">0001671858</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_ebefd36b-fe27-48f4-bfba-f1b716fcaabf">--12-31</dei:CurrentFiscalYearEndDate>
    <ecd:TrdArrDuration
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_8dc82fb0-1b46-4787-a221-9fc255c4e9d0">P366D</ecd:TrdArrDuration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      id="F_55f58a5e-df5f-428b-a6a9-abe7b92f60d3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      id="F_1ceb97c8-7d6c-486d-a483-90c72cdf6027"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-6"
      id="F_a0276b15-2565-43a7-b2cc-bff166e8c881"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="INF"
      id="F_626c3f50-1884-4203-bf7b-50eea6c01f4f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_84bd9e86-c4c0-4576-8d3c-cc8e99b6414a">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_a3d1a69c-3526-47f0-8446-eecbcc1ae152">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_0378e3ae-bf42-4733-82db-009973ae9d8e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e6d0fbaf-2805-48e6-a8e8-646d446d4f8f">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_6340f8a6-abd4-4d6a-875c-3957669c7cbd">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_8a202602-6a2a-4337-9d46-578d1e6e7c00">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_79416c9e-7d5b-4ea9-8dd2-e59aaab23009">001-39756</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e10d1d8f-50fa-4225-a266-d696e53686c7">ARS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d14d7c17-130b-4c3d-af0e-d28ce32399c2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_35ed6db7-5205-4e12-8c11-e14559df1e5b">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_428af333-e844-4a33-a3dc-5b94de48209b">11682 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_b5c8bb64-ee03-49d9-9fdc-a9a867ad5702">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_cbc300d6-debf-4ede-839a-e4f82beb720d">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_7b2b0dc1-f35d-478f-a0e2-6254df6c65ba">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c4218a8b-4cf1-40b7-a78c-c4fff3b8e997">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_1b870d62-529e-47ca-957d-a6905526b040">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_7bd31892-0d09-40ec-9702-7d39149ce488">771-9307</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_00784e88-198d-4b07-93d1-a2befff57750">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_76891632-8f31-4673-949b-aa4f1f71f466">SPRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_772d4642-8376-4818-a22a-a42fd1c83a1c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_a6789284-9ea4-4eb4-9a17-441218e2b7cf">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_2a7a5f18-8a67-4579-a4cb-3cfe9e25585f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c7d796bb-0ced-4b3e-885d-a92dee2df45b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_250edfec-ecc9-4dc0-85a3-a0e0c2b1563a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_6bf1412b-3e26-4bfd-8a07-da2a1d251981">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d3590ffc-ba24-4052-ae85-1dcab1a32062">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_48a5969c-49a1-4573-9e11-e0e95705ece3">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_45813144-0748-490f-bd01-ce77ea3bf89b"
      decimals="INF"
      id="F_280097ee-3d9b-4ba8-9411-d6b17efff9c9"
      unitRef="U_shares">98826337</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_6bc6e2b4-e80b-4f1f-b5b1-0836d0f0c40d"
      unitRef="U_USD">51540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_aa3b2cf0-b8a8-4ca0-aaa9-73da35e81a4f"
      unitRef="U_USD">50817000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_438b2d94-d948-469b-9c48-06475cd0aa6d"
      unitRef="U_USD">188590000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_8b58d3eb-cae7-47ff-acf9-242057bb805d"
      unitRef="U_USD">263205000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_9d0ec9f4-fa86-465f-9185-0a74b90f7e94"
      unitRef="U_USD">25126000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_2d580372-0043-417f-a2ca-e58a8a94299c"
      unitRef="U_USD">8175000</us-gaap:AccountsReceivableNetCurrent>
    <spry:InventoryCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_286fc6de-7f7b-4cc9-a0c4-c1ba525c3d45"
      unitRef="U_USD">8738000</spry:InventoryCurrent>
    <spry:InventoryCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_2ccf3749-5133-47f8-8bdf-a3f0096d68c3"
      unitRef="U_USD">5212000</spry:InventoryCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_62b28f30-b1f8-4bd0-9351-11c101d2c35d"
      unitRef="U_USD">7442000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_0bc76e95-b1bc-4665-924b-74c9f671d212"
      unitRef="U_USD">6886000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_025c9ad3-8223-41c5-ad94-85601f16cf1f"
      unitRef="U_USD">281436000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_495c1d83-4710-4db2-8d47-dc2841846ee8"
      unitRef="U_USD">334295000</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_b199f355-2288-443d-ab3c-65444889c847"
      unitRef="U_USD">13374000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_20211350-d9b3-4248-ae70-a950180ce33c"
      unitRef="U_USD">5307000</us-gaap:InventoryNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_f27c8ccd-1daf-4da8-9105-cec35607fcf9"
      unitRef="U_USD">1564000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_567231c0-106c-47bc-8bb1-cbc9c1803206"
      unitRef="U_USD">37000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_9350ca24-ef37-408d-85a1-f75da56c3af5"
      unitRef="U_USD">1075000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_af9256fa-2f89-4c16-84cb-d77e13897692"
      unitRef="U_USD">1029000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_f90e2594-b8e3-4ef7-8025-cf47705d2d7f"
      unitRef="U_USD">12972000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_156a1ebf-1ee1-4da9-ab66-7e7c4cfe66ad"
      unitRef="U_USD">7371000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_fb7416cc-33b3-4304-be7c-266e9b69f65c"
      unitRef="U_USD">3051000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_61b1480b-e4ec-461d-b090-17fb6e458e18"
      unitRef="U_USD">3114000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_c039731c-ed5f-4fbc-b2c0-b9ec54a2f179"
      unitRef="U_USD">313472000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_c4a0131e-c9ad-4638-b422-8aca6356ee51"
      unitRef="U_USD">351153000</us-gaap:Assets>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_23a9616b-e112-4e5f-836a-3b19bacb955e"
      unitRef="U_USD">1091000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_8e34408f-a795-4a12-93db-773279330c2d"
      unitRef="U_USD">656000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_c010c547-75c7-485e-9067-963cc10dd083"
      unitRef="U_USD">44264000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_e9a98c28-c6a2-4475-84f4-33e762961b75"
      unitRef="U_USD">22841000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_d96bf2f6-a8a7-4237-ab9e-a4311b552631"
      unitRef="U_USD">746000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_f8802588-ef47-4af3-bd8d-4b5c63dfa65d"
      unitRef="U_USD">557000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_7fe93b52-5837-42ea-83ea-38cc639a9e88"
      unitRef="U_USD">589000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_557ea347-97c3-44e2-ba6d-ee40ecfef75a"
      unitRef="U_USD">42000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_c408262c-7491-497f-9adf-3bab18f3abd8"
      unitRef="U_USD">45599000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_ff429793-1d34-4964-af21-a6bf98200048"
      unitRef="U_USD">23440000</us-gaap:LiabilitiesCurrent>
    <spry:FinancingLiability
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_6f8fd067-a92f-4fd1-afd6-1e9e10c8f209"
      unitRef="U_USD">71959000</spry:FinancingLiability>
    <spry:FinancingLiability
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_68d5592f-7250-43b4-a33b-d610e793527a"
      unitRef="U_USD">69383000</spry:FinancingLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_e64c7779-0a2e-456d-a0a4-81cd1f56dbd5"
      unitRef="U_USD">1103000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_5a2bb907-e8d2-4cc5-a647-7198d4847900"
      unitRef="U_USD">1532000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_33f759ee-4679-4a24-b236-926c6f9a4b9e"
      unitRef="U_USD">1072000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_d05c9550-f8c1-41f2-9002-e40f4cb6db5f"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_5ccfa7a2-af0e-4a07-9f8d-3d10b9c83b74"
      unitRef="U_USD">1418000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_45ca28bd-be4a-4084-b197-0a6839fe23bc"
      unitRef="U_USD">0</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_4fc66b76-fea1-404f-a884-d2cdb653389b"
      unitRef="U_USD">121151000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_b2e23254-4ab6-408f-8bfd-2c4d4c26a56e"
      unitRef="U_USD">94355000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="4"
      id="F_708ba146-4db8-480f-a47e-32024a252e3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="4"
      id="F_76d353b0-fc97-455e-b8cd-c9b7a7289dcd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_d674b6fb-d151-4557-a3ec-3b3428b844b2"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_65e83f6c-d15d-456a-a61a-90b50b5fb418"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_0b51edb2-98f9-4b7d-993a-f8083d8960a0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_a2b5298e-0335-4605-9668-521a26f4b91a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_38126b5f-e352-4feb-a24d-3b5e519da551"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_ffe9aa1c-d50b-4f23-90e5-e0b93cf0857a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_626b22e2-3a88-47ba-944b-b05020a658db"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_2e796df2-77cd-499a-8999-881fbf610f6f"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_90e14721-8d31-4971-803f-cd0a68add7fa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_d86b1b8f-da89-4abd-873f-7f28a658dfb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_25685330-a5f8-4349-8939-c098dc7bbc0a"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_5d9f953f-1a57-410e-b691-572e79364840"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_b33a0ac2-8007-4ed9-8d6e-6cb6194bd26e"
      unitRef="U_shares">98697658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_1572344f-41a8-43ee-b532-b5f74839e99a"
      unitRef="U_shares">98697658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_81032eb2-a2ef-46bd-adc6-b21b7ab7f365"
      unitRef="U_shares">97954172</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_ef3c5c53-7f0c-4e34-85b6-26f1178c52f4"
      unitRef="U_shares">97954172</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_e6e58e74-aa74-48c1-b146-51fd67fac905"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_5d57f2ac-650c-452e-b0ed-0baf5136fe84"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_54ee4257-648f-4149-a6eb-6b6df2cdccec"
      unitRef="U_USD">394485000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_b84b5fb3-ca9f-4757-a059-37a5a589a919"
      unitRef="U_USD">379873000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_b607d579-8fed-475c-984f-3661008d3b9b"
      unitRef="U_USD">-46000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_bb3f0b36-4b89-4480-a783-3514a11178a5"
      unitRef="U_USD">220000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_7c868f22-a520-4b2f-afa9-8fb68e96617d"
      unitRef="U_USD">-202128000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_0c5336a8-a179-42a2-8adc-ed2d8585c48e"
      unitRef="U_USD">-123305000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_ce9c3ef6-c011-47bd-aa96-dd1ec038e9bc"
      unitRef="U_USD">192321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_99a34ae8-62c0-4000-934d-1fedd9e10384"
      unitRef="U_USD">256798000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_1d169661-1a86-4590-87be-4b3df2ec2e99"
      unitRef="U_USD">313472000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_11b200bf-b732-40fa-ad9d-b9e8ec7e125c"
      unitRef="U_USD">351153000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_783dccc0-475e-4692-b8a3-08a49e9999dd"
      decimals="-3"
      id="F_91460fa9-6712-4a67-9826-6e753f3e6edc"
      unitRef="U_USD">12800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_828dc3d1-fee8-4736-9111-5a0102de64e0"
      decimals="-3"
      id="F_54ae07ec-7e5f-4c23-85a9-dffd8275fcef"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce"
      decimals="-3"
      id="F_075a45b0-2b54-43ef-80ed-1dd88ae1cb6e"
      unitRef="U_USD">20563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1"
      decimals="-3"
      id="F_65d351a9-6c8a-4c27-80c5-f16270d207fe"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_21fe8e44-bec9-4153-ad91-5b5867687e88"
      decimals="-3"
      id="F_d5de03b1-b859-45c8-a028-944b9ffb27a2"
      unitRef="U_USD">2594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4fc6cb5f-4180-41ac-b434-d6945583ee10"
      decimals="-3"
      id="F_db086b31-1c22-4205-a571-472bfe3c4903"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9"
      decimals="-3"
      id="F_3e9c00d7-bcf6-47ba-a309-9615eb39e6f0"
      unitRef="U_USD">2804000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a"
      decimals="-3"
      id="F_bf2c02b1-f84f-4ca8-8b50-b64d7344cd03"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8855f418-1ce9-40e1-ba74-585019621581"
      decimals="-3"
      id="F_4ebdd02f-4639-4e76-bd8b-0ba808cb80f8"
      unitRef="U_USD">323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74"
      decimals="-3"
      id="F_5e17296d-ce50-44a2-98b6-075a37625f07"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b0f481-c291-42bf-a1fd-628b8759542f"
      decimals="-3"
      id="F_4f730172-730f-4afc-a96d-0e29f601adac"
      unitRef="U_USD">323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93"
      decimals="-3"
      id="F_21ddb225-ee0d-4db6-9c5e-70ce3f908afe"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_5d5ca5ec-bf8a-40f9-8225-22746c8f758c"
      unitRef="U_USD">15717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_181eb934-f6aa-4fdc-b682-8b444b1b37f2"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_16d37dae-66e3-4cf3-a1a4-67063f7877b2"
      unitRef="U_USD">23690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_5e54caa9-6750-4e9f-b258-7bc243e58b14"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789"
      decimals="-3"
      id="F_14ac524f-d257-4ead-b6ea-d5069d0b0c7d"
      unitRef="U_USD">866000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81"
      decimals="-3"
      id="F_5855747d-f025-42e3-91f7-09ecd12fecb8"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a"
      decimals="-3"
      id="F_d301a45f-814d-4346-9f62-294bae2714ac"
      unitRef="U_USD">1354000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494"
      decimals="-3"
      id="F_a8fec7db-afff-414c-97e0-04801363e2a0"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <spry:CostOfGoodsSoldOperatingExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_4edadcab-b4f6-4398-b277-f79402a3ae6b"
      unitRef="U_USD">4984000</spry:CostOfGoodsSoldOperatingExpense>
    <spry:CostOfGoodsSoldOperatingExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_39c6df06-fcee-4709-b4ab-465004c05041"
      unitRef="U_USD">0</spry:CostOfGoodsSoldOperatingExpense>
    <spry:CostOfGoodsSoldOperatingExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_c6de63a6-e407-4662-8769-91776be6f9ee"
      unitRef="U_USD">6078000</spry:CostOfGoodsSoldOperatingExpense>
    <spry:CostOfGoodsSoldOperatingExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_932b9afa-a2c9-453a-9401-6f4864788552"
      unitRef="U_USD">0</spry:CostOfGoodsSoldOperatingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789"
      decimals="-3"
      id="F_57c48420-9d55-4cce-8b7e-c50424f5fa07"
      unitRef="U_USD">582000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81"
      decimals="-3"
      id="F_610e9fbe-9f6b-486d-93a6-af00b88de340"
      unitRef="U_USD">518000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a"
      decimals="-3"
      id="F_53b5cca3-2317-42cc-b963-58ab37d7fd2d"
      unitRef="U_USD">1245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494"
      decimals="-3"
      id="F_aa014c4d-ac37-4cd4-98d1-36fc579eda8b"
      unitRef="U_USD">1245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_d230eb62-af6a-4b77-aded-343507386cee"
      unitRef="U_USD">4035000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_3c700361-cbde-4fc6-9f72-5b8e82e885aa"
      unitRef="U_USD">6896000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_dcfab2e1-7844-4f5f-a36d-b9981a55a2be"
      unitRef="U_USD">6987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_05cd1eff-f8b5-478e-ad45-880ee348a43d"
      unitRef="U_USD">12130000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_3b5b2d22-53f7-4c9d-8b99-321480d17789"
      decimals="-3"
      id="F_07d8e294-4d6f-4066-ba99-6a6f778f3921"
      unitRef="U_USD">107000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_a7e67462-553c-488d-9b14-c09155e03b81"
      decimals="-3"
      id="F_fd9b5224-2ff3-442b-b85e-d0244249cd62"
      unitRef="U_USD">114000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_3b671b89-0f6e-4e29-9e7b-6c895df1172a"
      decimals="-3"
      id="F_d6113fb4-cd0b-4ca8-ad63-e8317b4e7abf"
      unitRef="U_USD">231000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_b2e00eb5-14d4-4be6-9263-605eaadf4494"
      decimals="-3"
      id="F_9ce73430-484b-40b7-911e-f453137ba640"
      unitRef="U_USD">208000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_ffc62dbb-2519-4648-9b29-4b272b3f5c7a"
      unitRef="U_USD">54312000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_c1b056ba-a623-4a3f-b797-c595da255562"
      unitRef="U_USD">8944000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_e0dbbc07-46d5-48c4-8dbf-a2a7fb1ee3f7"
      unitRef="U_USD">95416000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_9c416001-a4c7-42ab-838e-b91ba6759e5d"
      unitRef="U_USD">16902000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_98dd517e-3ad7-4e0a-9fe6-b5687ecd28b2"
      unitRef="U_USD">63331000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_36ddd976-d4bf-46ea-a50e-a5ba6a0a031a"
      unitRef="U_USD">15840000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_deb3b4c2-54ef-4a01-aa7c-9e9473e5d810"
      unitRef="U_USD">108481000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_1bd2131f-a741-493a-b7f6-4c0bdc86bd24"
      unitRef="U_USD">29032000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_56168117-f847-4c47-93da-e32efd713a1d"
      unitRef="U_USD">-47614000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_0ebaf6f7-32f3-4c74-bfe9-457327df03ef"
      unitRef="U_USD">-15340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_41c5bb16-e9d6-44d8-afe6-2f9e9939a76e"
      unitRef="U_USD">-84791000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_b8344235-ce38-4e81-b7ee-4f8359c6d1e4"
      unitRef="U_USD">-28532000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_ea80c87c-d258-474f-acd8-03482f858af8"
      unitRef="U_USD">2731000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_e56d9603-396a-4d76-b112-2981a0ee1082"
      unitRef="U_USD">2824000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_14542fe9-1a72-409a-964e-25500d870e08"
      unitRef="U_USD">5968000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_50e223c9-02cd-4d38-a90e-b12ddc4db5c8"
      unitRef="U_USD">5724000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_1e60c861-7c9c-4f01-90f9-83b81c10a57d"
      unitRef="U_USD">-44883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_facf1c16-5e0d-4f92-9f1d-ce369e42324d"
      unitRef="U_USD">-12516000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_c3ce8e9d-39e5-4aa5-afa0-7f0e45fad6be"
      unitRef="U_USD">-78823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_5ef94d14-6be9-4e73-8f88-8ff6ea29d19a"
      unitRef="U_USD">-22808000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_e6b73ecd-09c1-4fcd-aef7-252d18281b72"
      unitRef="U_USD">-118000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_d6bdc8f8-226a-413a-9aa8-1695cc8a1697"
      unitRef="U_USD">-21000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_a382285a-f646-4307-9dc1-821c9b133372"
      unitRef="U_USD">-266000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_9c14505d-2621-4a59-b895-5034f428357b"
      unitRef="U_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_cfd0d1e5-4574-40c1-b0bb-7162da42ba37"
      unitRef="U_USD">-45001000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_82f92cfd-2bef-4498-b64f-98ae260eb469"
      unitRef="U_USD">-12537000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_ffc5976e-ca0f-4685-9a07-6d43b8a82d66"
      unitRef="U_USD">-79089000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_4483cf1b-5ffb-46a5-98b6-f3c09229aa96"
      unitRef="U_USD">-23002000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="2"
      id="F_1fb532db-0a36-436a-91ac-c7a4079408d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="2"
      id="F_80987f4b-2c1f-4e62-9c15-ac27a0fdcc1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="2"
      id="F_21b7db48-8484-496f-bf49-16e39917f133"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="2"
      id="F_fb225c9e-1279-426d-8a65-0eed7f95e048"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_1bf95aa3-9ca0-4e14-8073-cdeeb626da74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_4fad5f8d-3f95-4c06-a20c-3022634e894b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="2"
      id="F_6ea323f7-88c3-496f-830d-83b271f3e612"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="2"
      id="F_ad9abca3-91a2-4d3e-8838-7d8c700c3dd0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="0"
      id="F_a09d95d1-ffd9-49b2-8e98-b83dbf6197ee"
      unitRef="U_shares">98361771</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="0"
      id="F_3d17650d-10fd-47e4-a0f3-eb1dd61e3bb0"
      unitRef="U_shares">98361771</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="0"
      id="F_7c43be36-2a08-49a7-b931-2158764ac752"
      unitRef="U_shares">96827687</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="0"
      id="F_3831fd35-0cfc-4840-8c69-63da320f6b33"
      unitRef="U_shares">96827687</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_59c2f059-b42f-4b00-b18a-adba39f86fbb"
      unitRef="U_shares">98212035</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_fa59b2af-72b3-4d8f-b452-6363a51f6dd3"
      unitRef="U_shares">98212035</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="0"
      id="F_1cdceb14-c371-4963-b6fc-ccd8215076c0"
      unitRef="U_shares">96656690</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="0"
      id="F_7e5c6b0a-2b25-47d7-9d61-12fdb0956b28"
      unitRef="U_shares">96656690</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3f547b95-0c7d-4909-a139-bea14be39173"
      decimals="INF"
      id="F_556e6449-1a85-4a83-82f8-56863e04ff85"
      unitRef="U_shares">97954172</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3f547b95-0c7d-4909-a139-bea14be39173"
      decimals="-3"
      id="F_0448d27d-86c0-4298-9b04-651d0f6b6825"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f685dc68-99f3-45c7-888f-f64255a00ab0"
      decimals="-3"
      id="F_ac99ebe6-235d-467e-9c4f-430d2d25136c"
      unitRef="U_USD">379873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a15e9e6-1bc3-4167-8e8e-c79dcf3954c2"
      decimals="-3"
      id="F_274434f9-aa33-495d-9109-5ff141897c3d"
      unitRef="U_USD">220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c38ed128-079d-4241-b04b-554e67e4475f"
      decimals="-3"
      id="F_dc3f7181-d019-4bd5-92b0-a1fe2b541cc1"
      unitRef="U_USD">-123305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_493ef0f0-3000-4436-8fd0-4467a78e4b09"
      unitRef="U_USD">256798000</us-gaap:StockholdersEquity>
    <spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares
      contextRef="C_a1b6d996-a8c0-4025-9859-7563f538ccfb"
      decimals="INF"
      id="F_fcf34cf7-de05-4d1d-9fc0-9e8f66c0478b"
      unitRef="U_shares">175632</spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_1c56c487-e024-4724-81ae-947caaa88834"
      decimals="-3"
      id="F_07b73562-a16c-498b-ac22-bc2468c0c17c"
      unitRef="U_USD">725000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261"
      decimals="-3"
      id="F_ae746763-0918-4681-ba9a-2ea967753ddc"
      unitRef="U_USD">725000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1c56c487-e024-4724-81ae-947caaa88834"
      decimals="-3"
      id="F_2f8d1bff-6b78-4963-9314-62b55611ab2d"
      unitRef="U_USD">5539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261"
      decimals="-3"
      id="F_10ded9c2-64a6-40e6-b9fa-1a28a7bb273b"
      unitRef="U_USD">5539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d04fa5cc-8928-4685-ad0a-fe068b728fac"
      decimals="-3"
      id="F_2570a442-7e75-4cb9-ace4-621e50e2c24b"
      unitRef="U_USD">-148000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cc8627a9-0c70-4d03-b571-48b53e518a3e"
      decimals="-3"
      id="F_75516c4c-6146-4535-b06e-138315c3d65a"
      unitRef="U_USD">-33940000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a207a717-bac8-486f-8afe-c9df9c813261"
      decimals="-3"
      id="F_006bdf4c-1a36-4146-bbd0-93caf71f16a1"
      unitRef="U_USD">-34088000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51"
      decimals="INF"
      id="F_b86abe5b-00af-47f9-87fa-5f711dbdd55c"
      unitRef="U_shares">98129804</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_599bc6bc-8a46-4a88-90b7-a41bbf074a51"
      decimals="-3"
      id="F_c5aa59d8-d47d-4ba4-b764-21ce0464b671"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0fc3a621-041e-400f-9a4b-601457b85fd3"
      decimals="-3"
      id="F_3b56b860-8908-4acb-a7ed-65db9c7b1806"
      unitRef="U_USD">386137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9e6449d-ad47-43a6-9843-3ac845071d45"
      decimals="-3"
      id="F_b20b52f1-4d1f-4542-aad3-b5cb69d8b1ae"
      unitRef="U_USD">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_71398ff7-c6c1-4c72-ad74-10d8e3e3bf31"
      decimals="-3"
      id="F_700490fa-096f-419a-9f88-c1a04f3ec230"
      unitRef="U_USD">-157245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4fc5fa74-f0e8-45a7-8703-dc0cc39277c4"
      decimals="-3"
      id="F_3b25a917-ed17-4535-be41-3f5acca2bf78"
      unitRef="U_USD">228974000</us-gaap:StockholdersEquity>
    <spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan
      contextRef="C_6c6d2854-3599-431a-a593-98e4379c15e6"
      decimals="INF"
      id="F_63ab889f-8bba-4f14-a749-3c19322907d2"
      unitRef="U_shares">567854</spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_bf5281ce-db7a-495f-ab02-93574c48462a"
      decimals="-3"
      id="F_f3713e92-6a3c-4056-ad31-22cd349d62fe"
      unitRef="U_USD">2697000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_6b45c7aa-88e0-4f3e-befa-05fcd235db72"
      unitRef="U_USD">2697000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bf5281ce-db7a-495f-ab02-93574c48462a"
      decimals="-3"
      id="F_f9c25701-f5a9-4774-ab92-802a8936625f"
      unitRef="U_USD">5651000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_908c601f-c499-40a9-9a80-e7620bc1fcfa"
      unitRef="U_USD">5651000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6b05c4b6-d7fb-473f-ab92-1227f461cbd1"
      decimals="-3"
      id="F_2fd87c66-3c95-42f9-97a7-aa5a5261e46b"
      unitRef="U_USD">-118000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_72c960a2-6882-42be-9586-209e84ad98f1"
      decimals="-3"
      id="F_9312463e-38db-4f5c-ac48-2fab9670a0a8"
      unitRef="U_USD">-44883000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_f50ee9da-5b60-40e9-8637-99c169b9fe64"
      unitRef="U_USD">-45001000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1"
      decimals="INF"
      id="F_d12d911a-4be4-43eb-8419-0f5a9e537fae"
      unitRef="U_shares">98697658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bca79118-bd9a-4bd7-bee0-9cccbea563f1"
      decimals="-3"
      id="F_d9c5cfc9-7ef7-4482-abf6-2c26239a8d41"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9926d4b4-fa02-421b-8525-65d964045c82"
      decimals="-3"
      id="F_edd5dc1d-0207-4b52-b859-86a3c4269fa1"
      unitRef="U_USD">394485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_df4a29c9-2002-49c3-bbf7-c84fa9b0edbb"
      decimals="-3"
      id="F_0d26a2a0-a875-4e99-a26b-545595da1eba"
      unitRef="U_USD">-46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ca70d85e-c0cc-4722-8d9c-3028532be956"
      decimals="-3"
      id="F_7fd93687-c627-46a8-875c-0972bbfb30d8"
      unitRef="U_USD">-202128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_0638ce1f-ac37-4452-a724-d895d49bc715"
      unitRef="U_USD">192321000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6"
      decimals="INF"
      id="F_9718a38a-389b-4d7b-9773-a367a4897175"
      unitRef="U_shares">96414963</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3a256f6c-abda-402b-9e9d-46e81f1afbe6"
      decimals="-3"
      id="F_ded89d74-89db-48ce-89e7-f76e21e36f89"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d4c367f-9884-46d1-8862-8e2ef2c52541"
      decimals="-3"
      id="F_80387429-a18c-4a13-8904-f06530a0fafe"
      unitRef="U_USD">362004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e8814f36-7086-44f4-9a53-259022c64732"
      decimals="-3"
      id="F_69057f78-454c-4783-9cc9-c2127aaba2c5"
      unitRef="U_USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1018c50-39c0-4a1e-a69c-876377e82ea5"
      decimals="-3"
      id="F_e040b05a-8c0e-45cc-91f9-8699ac61e483"
      unitRef="U_USD">-131303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3571bb42-9451-44e2-9e1c-0598970a2964"
      decimals="-3"
      id="F_43866600-4223-4731-91a8-79fe3ed078fc"
      unitRef="U_USD">230760000</us-gaap:StockholdersEquity>
    <spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares
      contextRef="C_374c6b30-c221-46de-a6b2-30e2bb48619d"
      decimals="INF"
      id="F_766fb98b-8738-4db9-80ab-57d7e621d857"
      unitRef="U_shares">159086</spry:StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleasedShares>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_060127b3-af69-4d7f-a100-67b6e7eb8bca"
      decimals="-3"
      id="F_3a307e75-c311-4506-8584-21793b629e02"
      unitRef="U_USD">258000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b"
      decimals="-3"
      id="F_4950d941-e1b7-4a06-9665-154a5a183cf9"
      unitRef="U_USD">258000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_060127b3-af69-4d7f-a100-67b6e7eb8bca"
      decimals="-3"
      id="F_02e99f2f-fb0b-40e0-81fd-d8c6a3008ba3"
      unitRef="U_USD">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b"
      decimals="-3"
      id="F_625f6c0b-ad07-41fd-af23-901b8bb0a723"
      unitRef="U_USD">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c263fc35-be1c-4365-9aa0-2c5ad53934fd"
      decimals="-3"
      id="F_211e897e-350d-4e97-bf55-44f04605f3c0"
      unitRef="U_USD">-173000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f3358bc3-9806-4dc0-ae94-6af64c1d3c84"
      decimals="-3"
      id="F_02a799e0-8748-422a-846a-4e861d20c45b"
      unitRef="U_USD">-10292000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_13db5f9c-2f06-4b3c-be00-958784249b0b"
      decimals="-3"
      id="F_25d66cde-fdf3-4963-9748-5314dc0f1596"
      unitRef="U_USD">-10465000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5c380126-d22f-440a-80fa-e358a5a088b2"
      decimals="INF"
      id="F_fbbccb0d-1add-44cd-8f89-964a40acd972"
      unitRef="U_shares">96574049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5c380126-d22f-440a-80fa-e358a5a088b2"
      decimals="-3"
      id="F_8d8182a4-e318-4680-93cf-dec46ee74ae0"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bd86d1ef-eeff-4adf-8a19-f69f6a8e45f6"
      decimals="-3"
      id="F_ac467b50-b2ac-4d5a-a682-33fd6ded2ee2"
      unitRef="U_USD">365577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dcdc4492-adbe-44e9-8b69-d68a7d4bae66"
      decimals="-3"
      id="F_2498e404-e8a2-4748-93b1-854765625dd7"
      unitRef="U_USD">-124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cfed3148-1f6d-4764-881f-dc1ce6517210"
      decimals="-3"
      id="F_8849c4be-3de0-4b0f-a281-4822b1a4a3ba"
      unitRef="U_USD">-141595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_490ab03b-38cf-4134-9ab1-2f6b7f250c1e"
      decimals="-3"
      id="F_d5ea83f7-b53e-4839-972f-628de5c7aafd"
      unitRef="U_USD">223868000</us-gaap:StockholdersEquity>
    <spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan
      contextRef="C_51ba7095-5039-485e-900a-2f239350359c"
      decimals="INF"
      id="F_1e95efca-de09-477d-b350-815e37c54a1e"
      unitRef="U_shares">365748</spry:StockIssuedDuringPeriodSharesStockOptionsExercisedUnderEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_efde3903-153e-4b55-ad5d-f7a9987f9a59"
      decimals="-3"
      id="F_a1bb7d68-483b-48f6-b558-99eb6abdaa99"
      unitRef="U_USD">545000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_fb4e13db-0f6c-4495-8bd2-a37cea57b1d4"
      unitRef="U_USD">545000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_efde3903-153e-4b55-ad5d-f7a9987f9a59"
      decimals="-3"
      id="F_1a222ae2-d660-4614-b1b8-44a26289af63"
      unitRef="U_USD">3365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_35f21e8d-cafe-4fb7-8e71-54dde6d292ae"
      unitRef="U_USD">3365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_09f9802b-bfdd-4db9-acd2-6c382a188d1e"
      decimals="-3"
      id="F_b09703dd-9b70-47c6-9e98-f88ef4f79906"
      unitRef="U_USD">-21000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_707ffda4-d1e9-4317-b368-b5b461d89663"
      decimals="-3"
      id="F_a72e06c5-af0a-4c5b-877e-15e27d990e49"
      unitRef="U_USD">-12516000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_ac608a8d-d98f-4d8d-b842-dc1b5c64a329"
      unitRef="U_USD">-12537000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b963ff18-7450-4060-ad3c-efc70564a546"
      decimals="INF"
      id="F_f9f1cf0a-9b99-487d-901d-a47a379c9bc3"
      unitRef="U_shares">96939797</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b963ff18-7450-4060-ad3c-efc70564a546"
      decimals="-3"
      id="F_6ef7c79e-e837-4336-bb4b-3da6b7e18618"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9409939c-9f3f-4a0a-9fa8-269dcaf95cb6"
      decimals="-3"
      id="F_30ccf8f2-69a7-4acf-95b4-19ec8beca29c"
      unitRef="U_USD">369487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_43967981-d479-4db2-8fce-ee96cfa44034"
      decimals="-3"
      id="F_e68475ac-6c0b-4475-a7fc-e7b86c58ea87"
      unitRef="U_USD">-145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_704928fd-7ecc-4aeb-aad1-e86385ad44c7"
      decimals="-3"
      id="F_c1819fc5-dcbf-4f60-bcfa-c2456e6664b9"
      unitRef="U_USD">-154111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b"
      decimals="-3"
      id="F_7641e822-b380-4b02-94f5-705a5b0d12d6"
      unitRef="U_USD">215241000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_7d34aadf-7848-4635-8817-e7ac41a3b94d"
      unitRef="U_USD">-78823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_74dfca08-945d-4199-aff2-b76e371d3cea"
      unitRef="U_USD">-22808000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_f635ad57-30d6-41c5-bff7-539f71f4cfc9"
      unitRef="U_USD">10669000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_1faf0b2a-e512-4bde-a0f9-0fca19a28b86"
      unitRef="U_USD">6680000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_076270de-3fae-4e0c-81f1-4831f1a6480b"
      unitRef="U_USD">559000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_4641e531-d8d8-418e-8d9a-de0201804593"
      unitRef="U_USD">29000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_d8696176-021e-4103-8483-2cfda1e60950"
      unitRef="U_USD">3428000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_37c84947-3dd0-46c6-b665-6739ab1f87a2"
      unitRef="U_USD">3884000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:InventoryWriteDown
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_b020fb8d-6190-4bf7-93aa-30b3cd17fc8d"
      unitRef="U_USD">2160000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_9990977c-3e67-446c-bed5-c3412d8a4ed3"
      unitRef="U_USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_e0f28214-0165-4c10-994f-abf98df382e7"
      unitRef="U_USD">14375000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_7feaa0c7-79ef-4a8e-822d-b591dd4fa70e"
      unitRef="U_USD">-0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_175ae11c-8b44-417a-b5f5-9242af9c60e1"
      unitRef="U_USD">13232000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_02ed5771-7dba-4721-8379-9625a9d60077"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_523b78f6-92d4-44aa-98ee-b6bb9708e635"
      unitRef="U_USD">697000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_b9d653d4-61eb-4177-9543-fcdbc68bf566"
      unitRef="U_USD">-1564000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <spry:IncreaseDecreaseInDonationOfEquipment
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_b3c340a2-acd6-4e16-a868-5db0b0c16bc8"
      unitRef="U_USD">0</spry:IncreaseDecreaseInDonationOfEquipment>
    <spry:IncreaseDecreaseInDonationOfEquipment
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_a67833d1-0a52-4656-b63e-92e5cd407570"
      unitRef="U_USD">-30000</spry:IncreaseDecreaseInDonationOfEquipment>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_97039375-082f-411d-a2e2-215df0d5aa81"
      unitRef="U_USD">16981000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_d88cc909-317c-4a0d-aaf0-f284887bffbd"
      unitRef="U_USD">4410000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <spry:OperatingRightOfUseAssetsAndLeaseLiabilities
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_63976016-538c-441b-98f8-dfe9a24facb0"
      unitRef="U_USD">92000</spry:OperatingRightOfUseAssetsAndLeaseLiabilities>
    <spry:OperatingRightOfUseAssetsAndLeaseLiabilities
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_b55cbfa7-9e90-4ff1-ac5e-ffec72297263"
      unitRef="U_USD">-10000</spry:OperatingRightOfUseAssetsAndLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_35bc1872-4054-4695-a5ec-c5a9e6c56880"
      unitRef="U_USD">-240000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_ce6b1378-b1cb-4727-b340-6dfc4021d978"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_c0bf602c-bbbb-4cec-a93a-df9f9d42ab98"
      unitRef="U_USD">-80334000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_4237fca8-24a8-47bc-9325-01d6d65d0324"
      unitRef="U_USD">-13989000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_d8036098-7023-45c4-89be-96d98d01b566"
      unitRef="U_USD">65723000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_570e8b52-2e2e-468a-ac41-68b1e6127b62"
      unitRef="U_USD">151038000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_79aebf01-8005-4419-bb7b-474bccb9f6e7"
      unitRef="U_USD">143500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_af91feab-2e16-465e-a577-8dddb4e37c19"
      unitRef="U_USD">130000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_9f77dee2-bf60-4ddc-93c3-502a3bdaa5af"
      unitRef="U_USD">142000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_6264e468-e0cb-4c98-8b90-a347adbca1b2"
      unitRef="U_USD">121000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_2596cf38-155f-411c-aabc-814da9d17662"
      unitRef="U_USD">77635000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_92ad15f8-ef79-42b1-8995-2a9efd292683"
      unitRef="U_USD">-21159000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_2264a341-96d7-4c29-b915-960e9ac70b94"
      unitRef="U_USD">3422000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_2d0b54ef-8bdf-44ef-8f69-358c524a098f"
      unitRef="U_USD">803000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_55bab86f-f574-486c-814a-d4add87db736"
      unitRef="U_USD">3422000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_404f6e12-4447-4df9-8700-5fbe3c578e2e"
      unitRef="U_USD">803000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_78cc131a-519f-4b20-9e5a-ba95ef17a8f8"
      unitRef="U_USD">723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_c9fbf403-cdbb-4326-ae8e-e18b6524f713"
      unitRef="U_USD">-34345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_294fe00e-67bd-4fd1-b0e4-6bdb121d233e"
      unitRef="U_USD">50817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3571bb42-9451-44e2-9e1c-0598970a2964"
      decimals="-3"
      id="F_4592d43b-1e87-424b-9a87-1476cb922b2d"
      unitRef="U_USD">70971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_f66cd343-471f-4207-81bf-e6f7010701cc"
      unitRef="U_USD">51540000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b"
      decimals="-3"
      id="F_5202cab0-285a-4531-a7bd-97dbadb571e0"
      unitRef="U_USD">36626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_177aaeaa-659b-40e6-81a9-6643d7a7c688"
      unitRef="U_USD">5860000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_ab55ba1a-b947-4c6b-b4c4-b806d37c3154"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <spry:FinancingLiabilityIncludedInAccountsReceivable
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_5e1ef613-9edc-403c-93bb-0ea4d2d5c4bb"
      unitRef="U_USD">2576000</spry:FinancingLiabilityIncludedInAccountsReceivable>
    <spry:FinancingLiabilityIncludedInAccountsReceivable
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_e5820ff2-fce0-4971-a869-3f2ab0949806"
      unitRef="U_USD">0</spry:FinancingLiabilityIncludedInAccountsReceivable>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_abc7c796-7497-41d3-81fb-922fa2a48a39"
      unitRef="U_USD">1630000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_459172eb-3208-471b-94d4-768a82476d7d"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_1fceb9b3-ae1e-4b53-a74e-b34893b1fc79">&lt;p id="fn_business" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ARS Pharmaceuticals, Inc. (&#x201c;ARS&#x201d;, &#x201c;ARS Pharma&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company focused on the commercialization and development of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (currently identified in the EU by the trade name &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EURneffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is the first and only FDA and European Commission-approved needle-free epinephrine product, and the first new delivery method for epinephrine in more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company incorporated in Delaware in January 2016 and is located in San Diego, California. The Company has a wholly owned subsidiary, ARS Pharmaceuticals Operations, Inc., incorporated in Delaware in August 2015, through which it conducts substantially all its operations. ARS Pharmaceuticals Operations, Inc. has a wholly owned subsidiary in Ireland, ARS Pharmaceuticals IRL, Limited, to facilitate the filing of regulatory approval for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in European countries.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses in most years since its inception and had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025. The Company had cash, cash equivalents, and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025 and has not generated positive cash flows from operations in most years. To date, the Company has funded its operations primarily with proceeds from the merger with Silverback in November 2022 (the &#x201c;Merger&#x201d;), private placement of convertible preferred stock, issuance of common stock, licensing, supply and distribution agreements, bank debt, and net product sales. The Company&#x2019;s currently available cash, cash equivalents, and short-term investments as of June 30, 2025 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date these financial statements are issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From August 5, 2015 (inception) through June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has devoted substantially all of its efforts to developing intellectual property, conducting product development and clinical trials, organizing and staffing the Company, business planning, raising capital, building infrastructure, pre-commercial and commercial activities, and providing general and administrative support for these operations. The Company has a limited operating history, and the sales and income potential of the Company&#x2019;s business and market are unproven. Management expects operating expenses to increase for the foreseeable future, and there can be no assurance that the Company will achieve profitability in the future, or if achieved, that it will be sustained on a continuing basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <spry:PeriodForFirstNewDeliveryMethodOfEpinephrine
      contextRef="C_b8271b46-8d08-46dd-ad0b-ac8a80d68454"
      id="F_d9a0adf6-8acc-4814-b73e-ad0134674320">P35Y</spry:PeriodForFirstNewDeliveryMethodOfEpinephrine>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5"
      decimals="-5"
      id="F_a7d28211-fc8c-4051-9f01-1aff22acb697"
      unitRef="U_USD">-202100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_055e3503-7f8c-4a8a-9330-00cfe3fe57c5"
      decimals="-5"
      id="F_c8134b28-ea24-4797-a2a9-7d350bcc0366"
      unitRef="U_USD">240100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_9e006611-d697-4014-b43c-33020c34d997">&lt;p id="fn_ssap" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company&#x2019;s financial statements are presented on a condensed consolidated basis, which include the accounts of ARS Pharmaceuticals, Inc., ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#x2019;s functional and reporting currency is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income in the condensed consolidated statements of operations and comprehensive loss. All adjustments considered necessary for a fair presentation have been included.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, the condensed consolidated statements of stockholders&#x2019; equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, are unaudited. The balance sheet as of December 31, 2024 was derived from the audited financial statements as of and for the year ended December 31, 2024. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of June 30, 2025, the condensed consolidated results of its operations for the three and six months ended June 30, 2025 and 2024, and its cash flows for the six months ended June 30, 2025 and 2024. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2025 and 2024 are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or any other period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements are revenue recognized under collaboration agreements, accruals for variable components of product revenue, accruals for research and development expenses, and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents include cash readily available in checking, money market mutual funds, and short-term investments with remaining maturities when purchased of 90 days or less. The Company considers all highly liquid investments with remaining maturities when purchased of 90 days or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable includes trade accounts receivable from product sales to customers, partner receivables for reimbursable research and development costs, royalties, license fees, and milestone payments under the Company&#x2019;s collaboration agreements, and partner receivables for supply of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;under the Company&#x2019;s supply agreements. Trade accounts receivable are recorded at wholesale acquisition cost (&#x201c;WAC&#x201d;), less purchase price discounts, prompt pay discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company&#x2019;s estimate of losses over the life of the receivables. The Company determines the allowance for credit losses for accounts receivable based on each customer&#x2019;s or partner&#x2019;s accounts receivable balance and age, their financial condition, and the general economic environment. The Company must also use professional judgment for its allowance for credit losses on trade accounts receivable as &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was commercially launched in September 2024 and historical data is limited. The Company is currently operating under the Title Agreement (as defined in &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) with its Title Agent (as defined in &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and the Title Agent retains all credit and collection risk on product sales to the Company&#x2019;s wholesale distributors and pharmacy customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses was deemed necessary at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 or December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests excess cash in investment grade fixed income securities. These investments are included in short-term investments on the condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss) gain, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Realized gains and losses on the sale of securities are recognized in net loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and short-term investments are carried at fair value. The carrying amounts of all accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, and contract liability are considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews its financial instruments portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is also subject to credit risk related to its accounts receivable from product sales and revenue under collaboration and supply agreements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is distributed primarily through wholesale distributors and pharmacies. These entities are not obligated to purchase any set number of units and they distribute &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on demand as orders are received. The Company enters into collaboration and supply agreements with pharmaceutical companies under which the Company is entitled to receive payments for royalties, license fees, milestone achievements, reimbursable costs for research and development services, and supply of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company extends credit to its customers and partners in the normal course of business after evaluating their overall financial condition. As stated above, the Company is currently operating under the Title Agreement with its Title Agent and the Title Agent retains all credit and collection risk on sales to the Company&#x2019;s wholesale distributors and pharmacy customers. The Company&#x2019;s Title Agent accounts for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s accounts receivable balance as of June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. One additional customer accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of accounts receivable as of June 30, 2025. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, four and six customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s gross product sales, with each individual customer ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s gross product sales, respectively. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025, one customer accounted for all revenue under collaboration agreements and supply agreements. For the three and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, one customer accounted for all revenue under collaboration agreements, and there was no product sales or revenue under supply agreements. Historically, the Company has not experienced any credit losses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process, and include labor and overhead. Inventories are stated at the lower of cost or net realizable value, and are determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered. Such impairment charges, if any, are recorded in cost of goods sold on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes inventory costs after regulatory approval, when future commercialization is considered probable, and a future economic benefit is expected to be realized. Prior to regulatory approval, the Company records inventory costs as research and development expenses. As such, when regulatory approval is received, this may result in zero-cost inventory which does not have a carrying value. This inventory is available to the Company to utilize for commercial operations as well as ongoing research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally five years. Repair and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate, including its eventual residual value. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. The Company has not recognized any impairment losses from inception through June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the initial classification and measurement of its right-of-use (&#x201c;ROU&#x201d;) asset and lease liabilities at the lease commencement date and thereafter, if modified. The Company recognizes a ROU asset for its operating leases with lease terms greater than 12 months. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The lease liability is calculated by using the present value of all lease payments, with the present value determined by using the incremental borrowing rate for operating leases determined by using the incremental borrowing rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment as well as a review of peer companies. Variable charges for common area maintenance and other variable costs are recognized as expense as incurred. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s revenues consist of product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and revenue derived from its collaboration, out-licensing, and supply agreements. See &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more detail on product revenue, and &lt;/span&gt;&lt;a href="#fn_collab_outlicense"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8 &#x2013; Collaboration and Out-Licensing&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more detail on revenue from collaboration agreements, out-licensing agreements, and supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). The provisions of ASC 606 require the following steps to determine revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, determines whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold primarily consists of direct and indirect costs related to the manufacture of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, supply agreement fees, and royalties on product sales. Prior to the FDA approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in August 2024, costs incurred for the manufacture of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;initially reflects a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, external research and development costs incurred under agreements with contract research organizations, investigative sites and consultants to conduct clinical studies, costs related to compliance with regulatory requirements, costs related to manufacturing the Company&#x2019;s product candidates (including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; prior to FDA approval in August 2024) for clinical trials, and other allocated expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for research and development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company uses judgments and estimates to determine the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Selling, General and Administrative Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative costs are expensed in the period incurred. Selling, general and administrative costs primarily consist of marketing-related expenses, salaries and related expenses for personnel, including meals and travel-related expenses incurred by the sales team, stock-based compensation,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax, and other consulting services, and insurance costs.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for producing advertising are expensed when incurred. Costs for communicating advertising, such as search engine marketing, banner advertisements, social media advertisements, and print advertisements, are recorded as prepaid expenses and then expensed when the advertisement occurs. For the three and six months ended June 30, 2025, advertising costs were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; advertising costs were incurred for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Fees&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred to acquire technology licenses and milestone payments made on existing agreements are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes expense for awards subject to performance-based milestones over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and recognizes forfeitures as they occur. In the event that stock-based awards are granted in contemplation of or shortly before a planned release of material non-public information, and such information is expected to result in a material increase in the share price of the Company&#x2019;s common stock, the Company may consider whether an adjustment to the observable market price is required when estimating the grant date fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss typically consists of the change in unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, stock options, warrants, and unvested restricted stock units, are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,436,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,318,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,484,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280)&#x2013;Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 was effective for the Company on January 1, 2024 for annual periods and on January 1, 2025 for interim periods. The adoption of ASU 2023-07 resulted in enhanced disclosures as included in &lt;/span&gt;&lt;a href="#fn_segments"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 15 &#x2013; Segment Information&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and did not impact the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements &#x2014; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards, other than those noted below, and any issued but not yet effective standards will not have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Income Taxes (Topic 740)&#x2013;Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2023-09&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The amendments in this update are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company does not expect to early adopt the new standard. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2023-09 on the financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the income statement within continuing operations of public business entities. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The impact of adoption of this ASU on the Company&#x2019;s disclosures is currently being evaluated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_9a78dd46-7507-4e36-b9fe-8aabe141d463">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company&#x2019;s financial statements are presented on a condensed consolidated basis, which include the accounts of ARS Pharmaceuticals, Inc., ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#x2019;s functional and reporting currency is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income in the condensed consolidated statements of operations and comprehensive loss. All adjustments considered necessary for a fair presentation have been included.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, the condensed consolidated statements of stockholders&#x2019; equity for the three and six months ended June 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, are unaudited. The balance sheet as of December 31, 2024 was derived from the audited financial statements as of and for the year ended December 31, 2024. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2024, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of June 30, 2025, the condensed consolidated results of its operations for the three and six months ended June 30, 2025 and 2024, and its cash flows for the six months ended June 30, 2025 and 2024. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2025 and 2024 are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or any other period.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e501b86a-2ca9-42f9-947b-100b193722eb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements are revenue recognized under collaboration agreements, accruals for variable components of product revenue, accruals for research and development expenses, and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_5e3af28f-e6b4-42f1-94c2-f2b16f353cc2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents include cash readily available in checking, money market mutual funds, and short-term investments with remaining maturities when purchased of 90 days or less. The Company considers all highly liquid investments with remaining maturities when purchased of 90 days or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_b1439fab-9e00-4ffb-b644-85b5aff75837">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable includes trade accounts receivable from product sales to customers, partner receivables for reimbursable research and development costs, royalties, license fees, and milestone payments under the Company&#x2019;s collaboration agreements, and partner receivables for supply of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;under the Company&#x2019;s supply agreements. Trade accounts receivable are recorded at wholesale acquisition cost (&#x201c;WAC&#x201d;), less purchase price discounts, prompt pay discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company&#x2019;s estimate of losses over the life of the receivables. The Company determines the allowance for credit losses for accounts receivable based on each customer&#x2019;s or partner&#x2019;s accounts receivable balance and age, their financial condition, and the general economic environment. The Company must also use professional judgment for its allowance for credit losses on trade accounts receivable as &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was commercially launched in September 2024 and historical data is limited. The Company is currently operating under the Title Agreement (as defined in &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) with its Title Agent (as defined in &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and the Title Agent retains all credit and collection risk on product sales to the Company&#x2019;s wholesale distributors and pharmacy customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses was deemed necessary at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 or December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_f567c8df-c275-4a77-8236-94c15b0eeb5a"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_823e69f4-3caa-4a5c-ae18-07ec9730d30c"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_452d9c37-0e06-4814-b217-6b2bf7f61534">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests excess cash in investment grade fixed income securities. These investments are included in short-term investments on the condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss) gain, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Realized gains and losses on the sale of securities are recognized in net loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e0652903-2825-47e0-bc2a-cd84935368cd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and short-term investments are carried at fair value. The carrying amounts of all accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, and contract liability are considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_9ed77a5a-3e7c-4191-9124-edcbe339e81a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews its financial instruments portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is also subject to credit risk related to its accounts receivable from product sales and revenue under collaboration and supply agreements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is distributed primarily through wholesale distributors and pharmacies. These entities are not obligated to purchase any set number of units and they distribute &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on demand as orders are received. The Company enters into collaboration and supply agreements with pharmaceutical companies under which the Company is entitled to receive payments for royalties, license fees, milestone achievements, reimbursable costs for research and development services, and supply of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company extends credit to its customers and partners in the normal course of business after evaluating their overall financial condition. As stated above, the Company is currently operating under the Title Agreement with its Title Agent and the Title Agent retains all credit and collection risk on sales to the Company&#x2019;s wholesale distributors and pharmacy customers. The Company&#x2019;s Title Agent accounts for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s accounts receivable balance as of June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. One additional customer accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of accounts receivable as of June 30, 2025. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, four and six customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s gross product sales, with each individual customer ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s gross product sales, respectively. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025, one customer accounted for all revenue under collaboration agreements and supply agreements. For the three and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, one customer accounted for all revenue under collaboration agreements, and there was no product sales or revenue under supply agreements. Historically, the Company has not experienced any credit losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f340b5d5-a46d-487a-bb76-a006e0f3faee"
      decimals="2"
      id="F_f5c35c4b-d3fd-4e2b-a05d-53b4f0b06997"
      unitRef="U_pure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_dad879fd-9fd0-4630-936d-24ba4a2d140a"
      decimals="2"
      id="F_a6c382b4-c0aa-4e8d-a932-448369a18cbe"
      unitRef="U_pure">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_76f794c5-9e6a-42a7-b227-1abf0ce9a252"
      decimals="2"
      id="F_ee85f94f-dd19-477b-9796-b3dca9523d93"
      unitRef="U_pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8dd7ea83-dd18-4eb9-9282-167ae56ead5d"
      decimals="2"
      id="F_e99ea4ea-a1aa-43ea-924c-d158ee83663c"
      unitRef="U_pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f9b7e8e0-49aa-425f-b6ac-7a1e94633629"
      decimals="2"
      id="F_fd14c282-239e-4e08-b3b9-b4d0a5dd222b"
      unitRef="U_pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ae56245d-14e4-4425-a73a-af69dd8543a2"
      decimals="2"
      id="F_5b0cad06-450b-4880-b8c0-77d475efdebf"
      unitRef="U_pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2534ad0d-4f31-47a1-99a9-04102ea40a7b"
      decimals="2"
      id="F_32f5d02c-4c72-4d0d-bc03-7aca3c05f393"
      unitRef="U_pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5d3ab776-018e-4dde-8537-5db78360a3b6"
      decimals="2"
      id="F_e976b586-a9fa-449b-b4c6-504d06819ca4"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b5cccac4-7ff4-4dd5-9952-e4d8fb70e5e9"
      decimals="2"
      id="F_9422260f-2739-4058-b1d5-54d3660626e1"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c7e544c9-751c-4210-b224-6b0035e4618e"
      decimals="2"
      id="F_6eb62f63-3188-4403-ab84-84f5d9525e76"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c59d3a87-64b2-48e5-b806-8ca9b8489a28"
      decimals="2"
      id="F_38534594-8003-4475-a0e2-ead34bfd6a28"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e6beb23c-440b-4e94-b575-d556e723f9a2"
      decimals="2"
      id="F_c8c81a47-5e5a-41c1-9f99-4714884a5c66"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_147fd450-9410-4b8e-a22c-51b186dd1d12"
      decimals="2"
      id="F_33844e9f-19b8-4b7c-9f4d-2468cbb93d7d"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a16758cc-95a6-438f-b28f-9eb55360c257"
      decimals="2"
      id="F_0b80eac6-37d6-485e-a16b-67ba3c430b7c"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_91a3dda9-27ba-40ae-acc1-7312fbbb4c65"
      decimals="2"
      id="F_6b87aa97-1146-43f9-bf48-e62035d34d6b"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ac30d314-86f3-4148-b29a-7d12452b392a"
      decimals="2"
      id="F_fb7e07f4-6cfb-405f-a216-0778e4f846e8"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_49c47b49-d4ac-4136-84a2-4bc4a2103d17"
      decimals="2"
      id="F_6aa679e8-18cc-40de-961d-a401b8c24eaa"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_486e30e1-067a-4d74-b32c-7b5cd57c48a6"
      decimals="2"
      id="F_90725aa6-3d6f-443b-a11c-b32e68f1eac2"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_12bac910-38cc-4107-8957-20fd4415cbd0"
      decimals="2"
      id="F_b11e49bb-12e7-4ec6-9ed4-40012ff2dd16"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d0bb372c-0ecd-453e-b973-012e84044734"
      decimals="2"
      id="F_7520f997-b34b-4e16-9ff5-38ed8d41cdd5"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_eae13608-8a7d-49cd-b8b1-4837d9244b48"
      decimals="2"
      id="F_b832164f-00af-44f5-adb3-8ed6615a442a"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_3c5642d7-6f8a-4a44-acf5-5d6d63e1e69e"
      decimals="2"
      id="F_8e5fe81c-b295-4fcf-a089-852c579d759c"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8bf5456c-aadb-4e60-b041-d6db39979b70"
      decimals="2"
      id="F_20a5671d-b2da-410d-baff-ed988cec0122"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_470f916f-7869-4e25-8dd3-760ff2bc2856"
      decimals="2"
      id="F_0e77d18a-963b-4dd5-8c79-c499ae347925"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_47e7fcde-f00c-42a6-a53e-32799f721460"
      decimals="2"
      id="F_24387df7-bc57-4174-8496-9cf491a93f18"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2196e376-19a2-4b1d-bec7-939794646f60"
      decimals="2"
      id="F_e0ad0975-2cb5-43b0-9212-581e92b8bfaf"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_3384a69b-8620-4b79-a234-cd7344debc19"
      decimals="2"
      id="F_35f12412-a27e-475e-80ea-fecbade9323e"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8e9dbd5e-9d63-4ed5-9644-7a43dd445156"
      decimals="2"
      id="F_18e38c1e-bfb9-4905-889e-4947a75a85e8"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5d09679a-e12c-4e0f-932f-d6350e656399"
      decimals="2"
      id="F_b48092df-045a-4ec1-9fab-c6250457e971"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_bbfe4e30-cf8e-45b4-9694-9eb0e8f2297b"
      decimals="2"
      id="F_a4cafdec-6a9a-414e-9ae2-2bd2d6b32e43"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_72dc1e89-7658-40c1-8ca3-952db65ab782"
      decimals="2"
      id="F_ca924d42-96a3-4491-bacd-e3d7a89b90f5"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_758bf922-ece9-4a0b-b463-8ee0919f4a31"
      decimals="2"
      id="F_59ab10ef-06a9-4319-a7fa-bb6b8b589d1c"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b05d88b5-cf1f-422b-b672-31550bb59ffd"
      decimals="2"
      id="F_8ca7a594-1415-40b1-8821-5b8cf5df6bdb"
      unitRef="U_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_f7d3f55d-c0fa-4205-8764-124ee40259e8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process, and include labor and overhead. Inventories are stated at the lower of cost or net realizable value, and are determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered. Such impairment charges, if any, are recorded in cost of goods sold on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes inventory costs after regulatory approval, when future commercialization is considered probable, and a future economic benefit is expected to be realized. Prior to regulatory approval, the Company records inventory costs as research and development expenses. As such, when regulatory approval is received, this may result in zero-cost inventory which does not have a carrying value. This inventory is available to the Company to utilize for commercial operations as well as ongoing research and development activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_59b28ef8-97e1-405b-8bd0-0a92a99bf764">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally five years. Repair and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_09882667-e449-4288-b042-a668f25a48d6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate, including its eventual residual value. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. The Company has not recognized any impairment losses from inception through June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e0d6b957-7c56-421f-b382-3f9577dc7a9e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the initial classification and measurement of its right-of-use (&#x201c;ROU&#x201d;) asset and lease liabilities at the lease commencement date and thereafter, if modified. The Company recognizes a ROU asset for its operating leases with lease terms greater than 12 months. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The lease liability is calculated by using the present value of all lease payments, with the present value determined by using the incremental borrowing rate for operating leases determined by using the incremental borrowing rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment as well as a review of peer companies. Variable charges for common area maintenance and other variable costs are recognized as expense as incurred. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_7c1c88e7-0328-47d1-bb47-4648892fd168">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow.&lt;/span&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e17711ab-6368-4772-94b0-80e0c7b58342">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s revenues consist of product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and revenue derived from its collaboration, out-licensing, and supply agreements. See &lt;/span&gt;&lt;a href="#fn_revenue"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3 &#x2013; Revenue&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more detail on product revenue, and &lt;/span&gt;&lt;a href="#fn_collab_outlicense"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8 &#x2013; Collaboration and Out-Licensing&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more detail on revenue from collaboration agreements, out-licensing agreements, and supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). The provisions of ASC 606 require the following steps to determine revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, determines whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_2b604bd9-a1a6-472e-8555-12c2bfa57c9e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold primarily consists of direct and indirect costs related to the manufacture of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for commercial sale, including salaries and related expenses for personnel, stock-based compensation, third-party manufacturing costs, raw material and component costs, packaging services, freight, storage costs, distribution fees, amortization of capitalized in-licensed costs, supply agreement fees, and royalties on product sales. Prior to the FDA approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in August 2024, costs incurred for the manufacture of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were recorded as research and development expenses, which resulted in zero-cost inventory. As a result, the cost of goods sold related to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;initially reflects a lower average per unit cost of materials, as previously expensed zero-cost inventory is utilized for commercial production and sold to customers.&lt;/span&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d441152c-c69f-4da7-ab32-8cb5bbc46588">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, external research and development costs incurred under agreements with contract research organizations, investigative sites and consultants to conduct clinical studies, costs related to compliance with regulatory requirements, costs related to manufacturing the Company&#x2019;s product candidates (including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; prior to FDA approval in August 2024) for clinical trials, and other allocated expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for research and development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company uses judgments and estimates to determine the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_ee60ff92-d0d4-4394-8cef-c6b4cd2f2267">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Selling, General and Administrative Costs&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative costs are expensed in the period incurred. Selling, general and administrative costs primarily consist of marketing-related expenses, salaries and related expenses for personnel, including meals and travel-related expenses incurred by the sales team, stock-based compensation,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; legal fees incurred relating to corporate and patent matters, professional fees incurred for accounting, auditing, tax, and other consulting services, and insurance costs.&lt;/span&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e195c082-bc0a-4b9a-9863-9296a6864c13">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for producing advertising are expensed when incurred. Costs for communicating advertising, such as search engine marketing, banner advertisements, social media advertisements, and print advertisements, are recorded as prepaid expenses and then expensed when the advertisement occurs. For the three and six months ended June 30, 2025, advertising costs were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; advertising costs were incurred for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-5"
      id="F_7f15ebee-ca47-4ff4-93e2-289a6828401e"
      unitRef="U_USD">20900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_e369646e-7c3f-4128-9050-159fa617ac17"
      unitRef="U_USD">31900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="INF"
      id="F_863fb5da-eb22-4c6c-a29f-38e4609a2f86"
      unitRef="U_USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="INF"
      id="F_224cc319-0255-46a0-8640-88744bc67ae1"
      unitRef="U_USD">0</us-gaap:AdvertisingExpense>
    <spry:PatentsCostsPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_9f0075e1-3c02-4291-a813-409c7c2d1781">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;</spry:PatentsCostsPolicyTextBlock>
    <spry:LicenseFeesPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d8b56833-4be6-4c87-8981-33a7e6744102">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Fees&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred to acquire technology licenses and milestone payments made on existing agreements are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.&lt;/span&gt;&lt;/p&gt;</spry:LicenseFeesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d649d82a-6800-4a96-8a32-60aebe1bee72">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes expense for awards subject to performance-based milestones over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and recognizes forfeitures as they occur. In the event that stock-based awards are granted in contemplation of or shortly before a planned release of material non-public information, and such information is expected to result in a material increase in the share price of the Company&#x2019;s common stock, the Company may consider whether an adjustment to the observable market price is required when estimating the grant date fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_df3ae300-b895-4605-af26-aef4745b00dd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss typically consists of the change in unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e6c96b38-17f5-4fed-8b62-9fbba01a0416">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="INF"
      id="F_95201d32-412d-4b6a-9783-a47ec5d6d1e8"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_eaf4cf64-7856-4047-a356-c7e4bd0a28fe">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, stock options, warrants, and unvested restricted stock units, are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,436,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,318,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,484,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_3abcc79d-34e7-475a-a88d-509609608955">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following securities are excluded from the calculation of weighted-average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,436,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,318,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,484,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c7d4f909-e24a-452d-82cf-9bb2659ab99f"
      decimals="0"
      id="F_2894a0d8-585a-411d-bb19-eecd01169766"
      unitRef="U_shares">45456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9ab27dfe-3c05-41c3-886f-a2b0e4136b85"
      decimals="0"
      id="F_128c84d2-f8bd-4787-abd7-79f1c6c8f9ee"
      unitRef="U_shares">45456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3b8087a0-6412-4ff5-90a6-c0f272af562e"
      decimals="0"
      id="F_f61962f1-8ddc-45ef-ae8b-f663bd16d9cd"
      unitRef="U_shares">17271990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f686fc0b-340d-4ecf-a20d-89f3341462b6"
      decimals="0"
      id="F_924e92e9-ddb4-4e66-be4f-0011d35ab288"
      unitRef="U_shares">14436432</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dcce5799-5869-4e9b-9399-9d7c6125048f"
      decimals="0"
      id="F_f54edde6-3983-43fc-9009-090fe130a214"
      unitRef="U_shares">1382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_af689524-2c04-42d2-a16f-31b2d40284b6"
      decimals="0"
      id="F_90f78ff5-e4f2-4cbb-bbf0-880d2b8ff74b"
      unitRef="U_shares">2763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_870302c2-624d-42de-8e50-5e3b75538372"
      unitRef="U_shares">17318828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="0"
      id="F_ccb39a9b-e046-486d-bbff-bb40a96b4917"
      unitRef="U_shares">14484651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_96a39e89-33e3-46b9-a7c4-cf3cfa4a9d60">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280)&#x2013;Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 was effective for the Company on January 1, 2024 for annual periods and on January 1, 2025 for interim periods. The adoption of ASU 2023-07 resulted in enhanced disclosures as included in &lt;/span&gt;&lt;a href="#fn_segments"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 15 &#x2013; Segment Information&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and did not impact the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements &#x2014; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards, other than those noted below, and any issued but not yet effective standards will not have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Income Taxes (Topic 740)&#x2013;Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASU 2023-09&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The amendments in this update are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company does not expect to early adopt the new standard. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2023-09 on the financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASU 2024-03&#x201d;). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the income statement within continuing operations of public business entities. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The impact of adoption of this ASU on the Company&#x2019;s disclosures is currently being evaluated.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d79c6628-446f-4476-9d2a-534cd9f8a47f">&lt;p id="fn_revenue" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s revenues consist primarily of product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;revenue derived from its collaboration and out-licensing agreements, and revenue from its supply agreements. See &lt;/span&gt;&lt;a href="#fn_collab_outlicense"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8 &#x2013; Collaboration and Out-Licensing&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for further discussion related to revenue from collaboration, out-licensing, and supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was approved by the FDA in August 2024, and the Company began generating product revenue from sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in September 2024. The Company uses a third-party logistics provider (&#x201c;3PL Agent&#x201d;) to fulfill orders of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to the Company&#x2019;s customers. The 3PL Agent provides services to the Company that include warehousing, distribution, order and accounts receivable management, and data management.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into a title model agreement (&#x201c;Title Agreement&#x201d;) with an affiliate of the 3PL Agent (the &#x201c;Title Agent&#x201d;) so that the Title Agent may purchase and take title to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and then sell it to the Company&#x2019;s wholesale distributors and pharmacy customers that have contracted to make a purchase. Under the Title Agreement, the economic substance of the transaction is such that the Company does not recognize revenue until &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is sold and title has transferred from the Title Agent to a wholesale distributor or pharmacy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also entered into sales agreements with pharmacies that are not subject to the Title Agreement. Under these agreements, the pharmacy holds &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;under consignment. Under the consignment model, the Company recognizes revenue when &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is sold to a patient, at which point title transfers from the Company directly to the patient.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product revenue is recorded with each sale at the transaction price, net of reserves for variable components, including but not limited to distribution service fees, prompt pay discounts, product returns, chargebacks, rebates, and co-payment assistance, which are collectively referred to as &#x201c;Gross-to-Net Adjustments.&#x201d; Estimates for Gross-to-Net Adjustments are reassessed each reporting period, and adjustments are recorded on a cumulative catch-up basis, which would affect product revenue and net loss in the period of adjustment. Trade accounts receivable due to the Company from contracts with its customers are stated in the condensed consolidated balance sheet, net of various allowances as described in the Accounts Receivable and Allowance for Credit Losses policy in &lt;/span&gt;&lt;a href="#fn_ssap"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components. Variable consideration is included in the transaction price only to the extent it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain Gross-to-Net Adjustments. The specific considerations that the Company uses in estimating the amounts related to Gross-to-Net Adjustments are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distribution Service Fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchased amount. These fees are recorded as other current liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commercial Pharmacy Discounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides discounts to its pharmacy customers. These discounts are a contractually fixed percentage of WAC and are a direct reduction from the WAC price they are charged. They are calculated at the time of sale based on the purchased amount. These discounts are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Prompt Pay Discounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company incentivizes on time invoice payments through prompt pay discounts. Prompt pay discounts are typically taken by customers, so an estimate of the discount is recorded at the time of sale based on the purchased amount. Prompt pay discount estimates are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Certain government entities and covered entities (e.g. Veterans Administration, 340B covered entities) can purchase the product at a price discounted below WAC. The difference between the government or covered entity purchase price and WAC will be charged back to the Company. The Company estimates the amount of chargebacks based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Rebates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides commercial rebates to pharmacy benefit managers and managed care organizations and is subject to mandatory discount obligations under the Medicare, Medicaid, and Tricare programs. The rebate amounts for these programs are determined by contractual arrangements or statutory requirements. Rebates are owed after the product has been dispensed to a patient and the Company has been invoiced. The Company estimates the amount in rebates based on the expected number of claims and the related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Co-payment Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company offers co-payment assistance programs to commercially insured patients whose insurance requires a co-payment to be made when filling their prescription. The Company estimates the amount of co-payment assistance based on the expected volume and the average buy down rate associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment programs estimates are recorded as other current liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Customers have the right to return damaged product, product that is within six months or less of the labeled expiration date, or product that is past the expiration date by no more than twelve months. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was commercially launched in September 2024 and due to the lack of historical sales and returns data, the Company used professional judgment and industry data to estimate returns. As time passes and historical data becomes available, the Company will use historical sales and returns data to estimate future product returns. A r&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;eserve for potential product returns is recorded as other current liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_398b6d63-a0a0-4cb8-8b17-0dc7e870d985">&lt;p id="fn_inventories" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company began to capitalize the inventory costs associated with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;upon FDA approval in August 2024 when future commercialization was considered probable, and it was determined that the inventory had a probable future economic benefit. These inventory costs consist primarily of purchased materials, third-party manufacturing costs, and packaging and serialization services. Noncurrent inventory consists of inventory anticipated to remain on hand for more than one year from the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capitalized inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reported as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to FDA approval in August 2024, costs incurred for the manufacturing of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were recorded as research and development expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which upon approval resulted in zero-cost inventory. The Company held &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in zero-cost inventory as of June 30, 2025 and December 31, 2024, respe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ctively, none of which was determined to be obsolete as of each period end. The Company expects to fully utilize its zero-cost inventory in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <spry:ScheduleOfInventoryTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_1d53e583-7627-46aa-a5f5-96351ca43a0b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capitalized inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reported as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</spry:ScheduleOfInventoryTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_cafea093-0519-425b-9019-a68165266383"
      unitRef="U_USD">17784000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_89d494cf-f9ba-443a-a8db-a450bbbf6b0a"
      unitRef="U_USD">4674000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_2675c25a-cbed-4803-944c-5471cf29965e"
      unitRef="U_USD">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_75be4421-5058-41e6-88f1-5396e4233541"
      unitRef="U_USD">19000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_929de8bb-614c-4b85-b6fa-d2262a40514e"
      unitRef="U_USD">6488000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_249446dc-3176-4da6-8c2a-ac23af8f1aa7"
      unitRef="U_USD">5826000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_97f01d3d-e59c-4a78-9f24-6d3b9200019d"
      unitRef="U_USD">2160000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_fe227823-e49b-49df-a048-78d992b069b7"
      unitRef="U_USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_e1a1dbdc-f1c0-4db6-b1e9-b3749bad81be"
      unitRef="U_USD">22112000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_afc7f21a-7689-4bba-9afe-f3412807db53"
      unitRef="U_USD">10519000</us-gaap:InventoryNet>
    <spry:InventoryCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_6945d913-e88c-4ebe-bd15-71dfd5c4578c"
      unitRef="U_USD">8738000</spry:InventoryCurrent>
    <spry:InventoryCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_eae006e8-3e47-4070-aedb-535e623a7791"
      unitRef="U_USD">5212000</spry:InventoryCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_72e90930-5d2c-41e7-94a7-56d6ddd6da31"
      unitRef="U_USD">13374000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_efdc31a8-1bfe-4645-b9e5-9aaea345e614"
      unitRef="U_USD">5307000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_dd0ff421-3761-4fcc-b23f-74c9d622171c"
      unitRef="U_USD">22112000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_4e1a2699-a516-45f7-b052-b955c442ed0d"
      unitRef="U_USD">10519000</us-gaap:InventoryNet>
    <spry:ZeroCostInventory
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-5"
      id="F_8672090e-d255-47a3-bbcc-2eb84c44a014"
      unitRef="U_USD">9800000</spry:ZeroCostInventory>
    <spry:ZeroCostInventory
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-5"
      id="F_7bc2d7f9-d7dc-406a-98d4-791d9de200ec"
      unitRef="U_USD">11700000</spry:ZeroCostInventory>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_21e90473-c6a5-449a-8507-65b82686ea77">&lt;p id="fn_fv_measurements" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:86%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:24.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unobservable inputs in which little or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table identifies the Company&#x2019;s assets that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods present&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ed. During the three and six months ended June 30, 2025, the Company purchased &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in short-term investments and there were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in maturities of short-term investments. During the three and six months ended June 30, 2024, the Company purchased &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in short-term investments and there were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in maturities of short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s short-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is less than one year from the respective balance sheet date. The Company's money market mutual fund holdings are highly liquid and invest primarily in cash and U.S. Treasury securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There was a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million net unrealized loss on available-for-sale securities for the three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a0276b15-2565-43a7-b2cc-bff166e8c881;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;immaterial&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million unrealized loss on available-for-sale securities for the three and six months ended June 30, 2024, respectively. Management determined that the gross unrealized losses on the Company&#x2019;s available-for-sale securities as of June 30, 2025 were primarily attributable to current economic and market conditions and not credit risk. As of June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses was recorded. It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell any investments prior to recovery of its amortized cost basis, which is expected to be at maturity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued interest on the Company's available-for-sale securities was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025 and is included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any liabilities that were measured at fair value on a recurring basis.&lt;/span&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <spry:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1
      contextRef="C_dda44404-ce43-4ae0-930d-c039cfc589f0"
      decimals="-3"
      id="F_82b75faf-b012-4e1e-b79f-1054885018e1"
      unitRef="U_USD">0</spry:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_629ad40a-f151-4d3f-952d-90ddcf636408">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table identifies the Company&#x2019;s assets that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_de447bf5-c664-451c-be04-6c477bce8fb5"
      decimals="-3"
      id="F_efbb2db1-5626-4366-b737-a17c31a48c4b"
      unitRef="U_USD">51248000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <spry:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="C_af065405-07da-4d8f-9aad-88eb0dcc47a7"
      decimals="-3"
      id="F_51cb474e-de7a-48cd-9497-8424e469df2a"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedGains>
    <spry:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="C_8f694959-366e-4e19-a611-37c4b53e615c"
      decimals="-3"
      id="F_6b72f57e-a026-4dd6-903c-2ff444178e2d"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_de447bf5-c664-451c-be04-6c477bce8fb5"
      decimals="-3"
      id="F_4861a3fd-b89c-42fd-9206-06fb93f5d666"
      unitRef="U_USD">51248000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2"
      decimals="-3"
      id="F_2e7e51df-ec2b-488f-96e8-9413b5f50d94"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <spry:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2"
      decimals="-3"
      id="F_8bcaa1b4-1ecb-4ce4-898f-aad04a2607b2"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedGains>
    <spry:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="C_16dc4749-c6ec-4139-b8ad-4dcea1d2fb78"
      decimals="-3"
      id="F_fd17bfcc-af7b-458d-bd12-684a1a623e6f"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a650b87a-1c00-4b79-a58c-69715046ebb2"
      decimals="-3"
      id="F_2299c92a-7a5b-44eb-b9ad-3b481cab69d7"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb"
      decimals="-3"
      id="F_ca23a617-c5bc-4cc3-84c5-ebd677d75c63"
      unitRef="U_USD">188636000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb"
      decimals="-3"
      id="F_cb78e716-6ce4-4f39-9260-294108d4419b"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb"
      decimals="-3"
      id="F_aa856c9d-b3de-475c-ac20-3923df3bb0a5"
      unitRef="U_USD">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f34780e7-0ad9-4ad8-8876-10b29c9bf4bb"
      decimals="-3"
      id="F_6777c266-5223-4b64-add4-13cc3ab8fc49"
      unitRef="U_USD">188590000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77"
      decimals="-3"
      id="F_622dea28-b039-460b-ad8e-0c828fb21cc2"
      unitRef="U_USD">239884000</spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_41ef6930-d9f2-4459-a547-37d492c3f1c2"
      decimals="-3"
      id="F_c6d80d4f-53f5-41e1-bf58-642dd5172ce3"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_41ef6930-d9f2-4459-a547-37d492c3f1c2"
      decimals="-3"
      id="F_7ad6a021-99a3-4207-a51c-0cd05882743f"
      unitRef="U_USD">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue
      contextRef="C_7ab2b106-ec79-4526-a4e8-f9dcc15e4c77"
      decimals="-3"
      id="F_98bd4a23-702e-4418-a168-4d0c0183d71f"
      unitRef="U_USD">239838000</spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_91159948-e700-40b8-abf5-96f418841f9a"
      decimals="-3"
      id="F_ea3b7ede-8098-47b4-a930-97cc373e8d31"
      unitRef="U_USD">6506000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <spry:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="C_fb686167-75bd-4d07-b3af-efcd511a43d8"
      decimals="-3"
      id="F_5e5b7c6f-85ec-4707-8e96-6c9f757f2162"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedGains>
    <spry:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="C_5a8cb702-3dbe-4910-ae11-39b78feaa28c"
      decimals="-3"
      id="F_a6ca374f-dfc6-494f-94f1-4c254cd22f2b"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_91159948-e700-40b8-abf5-96f418841f9a"
      decimals="-3"
      id="F_aa1deca9-3b74-424d-bdbc-4901598ec6d0"
      unitRef="U_USD">6506000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef"
      decimals="-3"
      id="F_2746e649-6006-4982-a09d-6bf34833b274"
      unitRef="U_USD">42382000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <spry:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef"
      decimals="-3"
      id="F_684e2ee2-46cc-4221-a3a0-9927dda5d874"
      unitRef="U_USD">5000</spry:CashAndCashEquivalentsGrossUnrealizedGains>
    <spry:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="C_90480581-aab4-4026-b4e1-0aeaa37e50ff"
      decimals="-3"
      id="F_a9d084b0-8f68-44ac-b497-ee7d1b643753"
      unitRef="U_USD">0</spry:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c77c3709-162d-4edf-953a-4ab1c1e3faef"
      decimals="-3"
      id="F_251ce7ac-2594-45ff-98e7-4e47127fc2e5"
      unitRef="U_USD">42387000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13"
      decimals="-3"
      id="F_5cffe487-919d-4a44-82cd-1ffcea6e4337"
      unitRef="U_USD">262990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13"
      decimals="-3"
      id="F_d10744d6-a060-49b3-8c79-e509030df903"
      unitRef="U_USD">223000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13"
      decimals="-3"
      id="F_0af805da-8cc3-4777-b35d-415fcc6a339a"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_8b011e99-1250-4ca4-a497-f2a90edcba13"
      decimals="-3"
      id="F_f2b53eee-2f10-4a57-bd1a-2193ad8b0340"
      unitRef="U_USD">263205000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5"
      decimals="-3"
      id="F_f5c47043-e8fd-4d93-8347-e39026497d58"
      unitRef="U_USD">311878000</spry:CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_83d2f352-620d-436d-9ef5-e92a513b8f77"
      decimals="-3"
      id="F_aae00729-7105-4361-973a-56ad3586de0b"
      unitRef="U_USD">228000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_83d2f352-620d-436d-9ef5-e92a513b8f77"
      decimals="-3"
      id="F_99bec9e2-3b71-457f-be00-b8a3f6cebc13"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue
      contextRef="C_5fb75318-e3c3-45f9-8f27-6db6fab7c5b5"
      decimals="-3"
      id="F_ab8f4508-01a3-48ab-8dbf-3f39774dde49"
      unitRef="U_USD">312098000</spry:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue>
    <spry:Fairvalueliabilitieslevel2Tolevel1Transfersamount1
      contextRef="C_072805c1-e17f-45e5-a672-6a75206ddbb8"
      decimals="-3"
      id="F_57cdecce-22eb-4b56-88c3-4fcbea6bace9"
      unitRef="U_USD">0</spry:Fairvalueliabilitieslevel2Tolevel1Transfersamount1>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef"
      decimals="-5"
      id="F_423adf0c-912a-4c0a-a829-844176d7c064"
      unitRef="U_USD">31400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_1d2c0919-4138-4410-8ede-0f80ab424b2f"
      decimals="-5"
      id="F_e0e872d0-6812-40cc-b589-9ace7cde2b28"
      unitRef="U_USD">65700000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_5a1ad23e-4db4-4974-8c84-ec78ef8c1eef"
      decimals="-5"
      id="F_ce2102cb-9c6b-41dc-bdff-dbc9bd41bbcb"
      unitRef="U_USD">80000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_1d2c0919-4138-4410-8ede-0f80ab424b2f"
      decimals="-5"
      id="F_9323b7ca-c516-4157-bb30-37d1572f4eb5"
      unitRef="U_USD">143500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_d9365522-fb46-46b1-bc6e-284e0bac324d"
      decimals="-5"
      id="F_61158e58-be1f-40d6-8b51-043a650a6b0e"
      unitRef="U_USD">87600000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_95e31fb6-2b47-410f-b070-55db285d63d5"
      decimals="-5"
      id="F_4af39e70-ee4b-41f6-82a6-5b5c4ee69173"
      unitRef="U_USD">151000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_d9365522-fb46-46b1-bc6e-284e0bac324d"
      decimals="-5"
      id="F_0c1a7329-9e9c-4dff-848f-6631546a4105"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_95e31fb6-2b47-410f-b070-55db285d63d5"
      decimals="-5"
      id="F_21df220c-d618-4eed-a99b-375f90e1cf5a"
      unitRef="U_USD">130000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-5"
      id="F_7c94f94a-48f1-469d-a239-fb1ed7120278"
      unitRef="U_USD">-100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_ce745dbd-9bd2-48df-8e2a-2d7a7b47444d"
      unitRef="U_USD">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-5"
      id="F_e36138ed-8651-419e-9ea7-1dafaf7c978a"
      unitRef="U_USD">-200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="0"
      id="F_b880d8f4-1326-4eed-a073-7a477886b9d1"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="0"
      id="F_9bf4f453-410c-403a-a617-8b702c9321da"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-5"
      id="F_69127b1b-5bf4-4f76-8058-bd3b208c1c62"
      unitRef="U_USD">1000000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="0"
      id="F_35ded23c-7ee7-4fff-99cc-86eb74489f96"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="0"
      id="F_2aa87d44-0f73-4e84-8bb2-abb5d7f107ba"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_df2e3118-6ac9-471d-b239-2d860db91273">&lt;p id="fn_bs_details" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other long-term assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid supply agreement fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized software implementation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued gross-to-net adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued marketing related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c57609eb-867c-4b3d-a9d3-18e819207f25">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <spry:PrepaidMarketingExpenses
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_58a3eb52-68ce-4aaa-bfdc-6aa3be1df187"
      unitRef="U_USD">3447000</spry:PrepaidMarketingExpenses>
    <spry:PrepaidMarketingExpenses
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_c98f860b-5814-4e17-bbaa-878ffed05487"
      unitRef="U_USD">3169000</spry:PrepaidMarketingExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_a0efad83-c4be-442e-b4f2-4a045831e8f7"
      unitRef="U_USD">1012000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_3da57052-6b35-447d-a31b-19f44a2b07cb"
      unitRef="U_USD">1261000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivable
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_7d1a3d85-59fa-479b-a29d-ea50f91ae115"
      unitRef="U_USD">956000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_e6270ccd-3e2f-485c-964b-cac90ae0b354"
      unitRef="U_USD">987000</us-gaap:InterestReceivable>
    <us-gaap:OtherReceivables
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_7d1e4225-b206-4aca-bbce-e509d50b3007"
      unitRef="U_USD">2027000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_fc89d0b2-e902-4f84-b5cd-8627eb538634"
      unitRef="U_USD">1469000</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_6fa51434-b382-4ff8-b62a-5e6c16a31802"
      unitRef="U_USD">7442000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_34b844b4-85c1-474f-8b9a-4823706f4da1"
      unitRef="U_USD">6886000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_803a1fe9-6215-4347-8b15-cd70728b5ec0">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other long-term assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid supply agreement fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized software implementation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <spry:PrepaidSupplyAgreementFee
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_95001ded-cfed-4c7a-9c67-b14d4be07480"
      unitRef="U_USD">2863000</spry:PrepaidSupplyAgreementFee>
    <spry:PrepaidSupplyAgreementFee
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_68a99d4c-58e0-496d-a1b0-3f73db730cd7"
      unitRef="U_USD">2800000</spry:PrepaidSupplyAgreementFee>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_4a7ba691-f63e-4f2e-abb5-5c0b8345fa42"
      unitRef="U_USD">188000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_91e0f54d-b4a8-4f1d-a029-58abd685df33"
      unitRef="U_USD">314000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:OtherAssets
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_5098b0bb-e24c-4089-8fe6-3a139fc1ca94"
      unitRef="U_USD">3051000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_e1045cc5-01c4-4fb5-8f21-51d1fdc7476d"
      unitRef="U_USD">3114000</us-gaap:OtherAssets>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_8abd34a2-d5b1-434e-89f8-a13c57dbd4aa">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued gross-to-net adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued marketing related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_efbf22d4-7fa0-4e8f-bead-e769a73303ee"
      unitRef="U_USD">15559000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_0dd1c0aa-7990-41c0-89bc-610c0e99c837"
      unitRef="U_USD">9870000</us-gaap:AccountsPayableCurrent>
    <spry:AccruedGrossToNetAdjustments
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_9d0f4b03-d0c9-4724-8357-60eba64002ee"
      unitRef="U_USD">11341000</spry:AccruedGrossToNetAdjustments>
    <spry:AccruedGrossToNetAdjustments
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_c7d04b41-cb85-4347-b4e7-7bb5df98ec87"
      unitRef="U_USD">2179000</spry:AccruedGrossToNetAdjustments>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_76966d8e-bbb7-4021-a19b-ef197b634a94"
      unitRef="U_USD">6374000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_d55e50c5-854f-4cbb-beff-36965a519547"
      unitRef="U_USD">1855000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_035de0ca-d4f6-4f7f-9423-3b7269579fab"
      unitRef="U_USD">4306000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_196bc8b6-c848-4077-8996-c35cbafcd529"
      unitRef="U_USD">2293000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <spry:AccruedInventory
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_50818bf9-4a82-46d0-beaf-a79e59f081e9"
      unitRef="U_USD">539000</spry:AccruedInventory>
    <spry:AccruedInventory
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_b3f6205a-7770-4951-8dac-f440c171be99"
      unitRef="U_USD">4255000</spry:AccruedInventory>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_1ea0b222-76c6-4fc9-baa7-eb0ca146071b"
      unitRef="U_USD">6145000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_5418ddd6-e220-4b85-9a26-07c294c44f94"
      unitRef="U_USD">2389000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_ccaebbcb-e337-487e-acf3-f4e747ade2f5"
      unitRef="U_USD">44264000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_6bc510ef-9494-469e-8d7c-e5c770b04911"
      unitRef="U_USD">22841000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_799c8266-91e8-4c67-a406-ae3e8481c934">&lt;p id="fn_intangibleassetsnet" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in &lt;/span&gt;&lt;a href="#fn_inlicense_supply"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10 &#x2013; In-Licensing and Supply&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, under the Aegis Agreement the Company capitalized a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment in August 2024 and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment in September 2024. Capitalized milestone payments are amortized on a straight-line basis over the estimated life of the intellectual property of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, beginning from the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in September 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in &lt;/span&gt;&lt;a href="#fn_collab_outlicense"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8 &#x2013; Collaboration and Out-Licensing&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, under the Recordati Termination Agreement the Company capitalized the achievement of a &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in U.S. dollars) milestone in June 2025. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capitalized milestone payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are amortized on a straight-line basis over the estimated life of the intellectual property of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, beginning from the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EURneffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in June 2025.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net, all of which are finite-lived, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amortization expense for the three and six months ended June 30, 2025 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; int&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;angible assets were held as of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amortization expense recognized for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, estimated future amortization expense for capitalized intangible assets for the next five years is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (remaining six months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <spry:CapitalizedMilestonePayments
      contextRef="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b"
      decimals="-5"
      id="F_017081a2-7cc4-49f6-b66e-219e503019c7"
      unitRef="U_USD">2500000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_1168bae1-a4d7-42ba-a4a1-1aaae5e9cecd"
      decimals="-5"
      id="F_41081089-bb88-4049-8e43-2c5c9dc6f7ef"
      unitRef="U_USD">5000000</spry:CapitalizedMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_5ed4cad0-90aa-4443-919a-3ab354fd0721"
      id="F_c94add7f-169f-4e06-b5c6-59138d773618">P14Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <spry:CapitalizedMilestonePayments
      contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b"
      decimals="-5"
      id="F_a532ffa1-27aa-461d-b64b-2a3c40282af4"
      unitRef="U_EUR">5000000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b"
      decimals="-5"
      id="F_82c8b203-0f58-43e7-8c9d-337016682d2a"
      unitRef="U_USD">5900000</spry:CapitalizedMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_d188a46c-d138-46be-af79-eb7c3b01af79"
      id="F_c5d418f2-2c0a-4e1c-9614-0d7b29afc39e">P13Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_041c5527-7e2c-4e81-ad3d-8b53b0e4db31">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net, all of which are finite-lived, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <spry:CapitalizedMilestonePayments
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_ccb06058-7e27-4766-a2cf-d47ed90ee87d"
      unitRef="U_USD">13360000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_633708e8-cd7b-4134-b260-d831788c6f4e"
      unitRef="U_USD">7500000</spry:CapitalizedMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_9579b8eb-015d-461b-a820-31238815321d"
      unitRef="U_USD">388000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_21e1f115-323b-4850-a82f-ad731c42ef0a"
      unitRef="U_USD">129000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_47faf510-fb4c-4cfa-8b1a-58d4f4fd018d"
      unitRef="U_USD">12972000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="-3"
      id="F_77507b9d-c5c4-4ee9-a4b5-73aaa1ac9d08"
      unitRef="U_USD">7371000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-5"
      id="F_2d08b821-2dd4-4339-a317-dd8e8f2587c4"
      unitRef="U_USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_66567eb8-6d0d-4514-9ffe-27a161e05447"
      unitRef="U_USD">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_bf31afc7-406c-4630-becf-7735028ce61b"
      decimals="0"
      id="F_90f52db1-14e0-4831-b791-702ac1d3381a"
      unitRef="U_USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="0"
      id="F_8600a2e0-5520-416f-8fb0-d13bb91d5e28"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="0"
      id="F_42546271-6dd5-47b8-a8c1-04bf4baf830b"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e4c4b00d-8878-43e6-b4e2-7e6036fd795b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, estimated future amortization expense for capitalized intangible assets for the next five years is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (remaining six months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_81af259a-0da0-4ff5-aa55-b3fd27917854"
      unitRef="U_USD">476000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_d54531f6-8db3-4f8f-b15f-5b251965d880"
      unitRef="U_USD">517000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_368a15fb-3f31-4943-b896-026b89d741b4"
      unitRef="U_USD">517000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_0fe7d450-2532-4ee4-8b89-a794bca10589"
      unitRef="U_USD">517000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_cc70c231-a234-4881-bebd-611c4fe05acc"
      unitRef="U_USD">517000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_5bab8b53-dd80-4951-a0e0-c1d1ae914349"
      unitRef="U_USD">2544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_a2123611-81bf-4d0f-89af-227f2a6c8102">&lt;p id="fn_collab_outlicense" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Collaboration, Out-Licensing&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and Related Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into collaboration and licensing agreements, including supply and distribution, to license certain rights to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; clinical, regulatory, and/or commercial milestone payments; payment for clinical and commercial supply; and royalties or a transfer price on the net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, revenue is recognized from non-refundable, upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If the license is subject to repurchase by the Company, at its option, control of the license is not considered transferred to the customer, and in such case, the Company would account for the proceeds allocated to such license as either a financing obligation or a lease in accordance with ASC 606. Future amounts received related to the license which is subject to the Company&#x2019;s repurchase, such as royalties or milestone payments, would be accounted for as additional financing proceeds and would increase the financing obligation on the Company&#x2019;s condensed consolidated balance sheet. The Company would record such financing obligation as revenue when the right to repurchase has lapsed or was exercised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  If the license is not a distinct performance obligation, the Company evaluates the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. At the inception of each arrangement that includes clinical, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized when the underlying performance obligation has been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Transaction Price Allocation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of each arrangement, the Company identifies its distinct performance obligations and allocates the transaction price to the performance obligations based upon their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. The best evidence of standalone selling price is an observable price of a good or service when sold separately by an entity in similar circumstances to similar customers. Since the Company typically does not have such evidence, the Company estimates standalone selling price so that the amount that is allocated to each performance obligation equals the amount that the Company expects to receive for transferring the promised goods or services. The methods that the Company uses to make such estimates include (1) the adjusted market assessment approach, under which the Company forecasts product sales in the appropriate market, considers probability of commercialization success, and estimates discount rates; and (2) the expected cost of satisfying the performance obligations inclusive of a reasonable margin, also known as the expected cost plus margin approach.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Revenues&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For arrangements that contain research and development commitments, any arrangement consideration allocated to the research and development work is recognized as the underlying services are performed over the research and development term, if the criteria for over time recognition are met. If the over time recognition criteria are not met, research and development performance obligations are recognized at a point in time, when the research and development work is completed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical and Commercial Supply&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered customer options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. Revenue from product sales to the Company&#x2019;s collaboration partners is recognized at the point in time that the collaboration partner obtains control, which is typically based upon the terms of delivery of the product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalty/Transfer Price Revenues&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For arrangements that include sales-based royalties or transfer price, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Alfresa Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2020, the Company signed a Letter of Intent (&#x201c;LOI&#x201d;) with Alfresa Pharma Corporation (&#x201c;Alfresa&#x201d;) for the right to negotiate a definitive agreement for the exclusive license and sublicensable right to develop, register, import, manufacture and commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Japan in exchange for an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In April 2020, the Company entered into a Collaboration and License Agreement for the rights pursuant to the LOI. Under the agreement, the Company delivered a license to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;technology, completed a required clinical study, and remains obligated to use commercially reasonable efforts to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in Japan. The parties agreed to share the cost of any additional clinical studies required for approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Japan. Alfresa is solely responsible for regulatory and commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use in Japan. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in Japan; or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years after the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million received under the LOI, the Company was initially eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments upon achievement of certain clinical and regulatory milestones. Further, the Company is eligible to receive a negotiable transfer price expected to be in the low double-digit percentage on net sales subject to the regulatory approval to commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the commencement of this collaboration, the Company identified the following performance obligations: the license for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and research and development services, both of which have been completed. The Company determined the initial transaction price to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which includes a clinical milestone as it was deemed not probable of significant reversal at the inception of the agreement. Due to the uncertainty in the achievement of the regulatory and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2020, the Company earned a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment upon the completion of a clinical milestone in Japan. In November 2024, the Company earned a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment upon the completion of a regulatory milestone in Japan. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments that the Company was eligible to earn, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; has been earned and a final $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million regulatory milestone remains. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue related to the Alfresa Agreement. As of both &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; contract liability recorded for the final regulatory milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recordati Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2020, the Company entered into a License and Supply Agreement (the &#x201c;Recordati Agreement&#x201d;) with Recordati Ireland, Ltd. (&#x201c;Recordati&#x201d;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Europe and certain European Free Trade Association, Russia/the Commonwealth of Independent States, Middle East and African countries (the &#x201c;Recordati Territory&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Under the terms of the Recordati Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and a regulatory milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during 2020.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the commencement of this collaboration, the Company identified the following performance obligations: the license for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the Recordati Territory and the research and development services. The Company determined the initial transaction price to be the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, at inception of the contract, the variable consideration associated with future milestone payments was fully constrained and excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The transaction price was allocated to the performance obligations based on the estimated stand-alone selling price of each performance obligation. In November 2020, the Company earned a regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 22, 2023, the Company and Recordati entered into a termination agreement (the &#x201c;Recordati Termination Agreement&#x201d;), pursuant to which, among other things, the Company and Recordati agreed to terminate the Recordati Agreement. Pursuant to the Recordati Termination Agreement, the Company reacquired all of the Recordati Rights, paid Recordati a one-time upfront payment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in U.S. dollars), and has agreed to pay additional payments upon achievement of certain milestones including: (i) an EMA regulatory milestone payment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, (ii) a milestone payment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Recordati Territory, and (iii) royalty payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate from sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Recordati Territory (collectively, the &#x201c;Recordati Rights&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the Recordati Rights at the time of entering into the Recordati Termination Agreement had no alternative future use and therefore recorded the &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment to Recordati as an in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expense presented within research and development expense. The Recordati Termination Agreement ended the Company&#x2019;s performance obligations pursuant to the Recordati Agreement and consequently the existing contract liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million previously received from Recordati was recorded against IPR&amp;amp;D expense presented within research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. Accordingly, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue has been recognized subsequent to the Recordati Termination Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, the EMA regulatory milestone was met and a &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in U.S. dollars) expense was recorded in research and development expense in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company paid the EMA regulatory milestone to Recordati in July 2024. In June 2025, the first commercial sale milestone was met for the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Recordati Territory. As a result, the Company capitalized the &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lion ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in U.S. dollars) milestone for the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Recordati Territory to intangible assets in the accompanying condensed consolidated balance sheets. The Company paid the first commercial sale milestone to Recordati in July 2025. The intangible assets will be amortized through the cost of goods sold in the accompanying condensed consolidated statements of operations &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and comprehensive loss on a straight-line basis over the estimated life of the intellectual property of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each of the three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in royalty expense from the sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the Recordati Territory as cost of goods sold in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pediatrix Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2021, the Company entered into a Collaboration and Distribution Agreement with Pediatrix Therapeutics, Inc. (&#x201c;Pediatrix&#x201d;) for the exclusive license and sublicensable right to develop, import, manufacture or have manufactured commercial product, file and hold regulatory approvals and commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the People&#x2019;s Republic of China, Taiwan, Macau, and Hong Kong (the &#x201c;Pediatrix Territory&#x201d;). Under the agreement, Pediatrix is responsible, at its sole cost and expense, for all ongoing development work that is necessary for or otherwise supports regulatory approval in the Pediatrix Territory, including all clinical trials, and activities related to post-approval commitments and commercialization tests. In addition, Pediatrix is responsible for commercialization activities and may elect to assume responsibility for manufacturing and supplying drug product for commercial use. The Company is responsible for the manufacturing of product for clinical studies as well as commercial supply, all at a negotiated transfer price. Either party may terminate the agreement for certain breaches of the agreement. Unless terminated earlier by either or both parties, the term of the agreement will continue until the later of (i) expiration of the last-to-expire patent in the Pediatrix Territory, (ii) the expiration of all regulatory exclusivities that cover &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Pediatrix Territory, or (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years after the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Pediatrix Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In addition, the Company is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments upon achievement of certain regulatory and commercial sales milestones. The next eligible milestone is a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million regulatory milestone. Subject to regulatory approval, the Company will earn tiered royalties in the low double-digits on annual net sales in the region and will receive a per unit supply price for the sale of commercial supply to Pediatrix.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the commencement of this collaboration, the Company identified performance obligations related to the delivery of the license for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the Pediatrix Territory and manufacturing of product for clinical studies and commercial supply. The Company concluded that the license was distinct from potential supply obligation. The supply provisions are effectively options granted to Pediatrix to purchase future goods and did not contain a material right. The Company determined the initial transaction price to be the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment. Due to the uncertainty in the achievement of all the developmental and commercial milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. The Company recognized revenue of the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Seqirus Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company entered into a License and Distribution Agreement (the &#x201c;Seqirus Agreement&#x201d;) with Seqirus Pty, Ltd. (&#x201c;Seqirus&#x201d;) for the exclusive license to commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in Australia and New Zealand (the &#x201c;Seqirus Territory&#x201d;). Under the Seqirus Agreement, the Company is responsible for the transfer of know-how, which includes regulatory materials, regulatory data, and commercialization data, and also for the manufacturing of product for commercial supply which is available to Seqirus at a negotiated price. Seqirus is solely responsible for all regulatory and commercialization activities in the Seqirus Territory. Either party may terminate the Seqirus Agreement for certain breaches. Unless terminated earlier by either or both parties, the initial term of the Seqirus Agreement is 15 years from the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the Seqirus Territory. The Seqirus Agreement will automatically renew for two-year periods unless either party gives a notice to terminate at least 12 months prior to the end of the initial or any renewal term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Seqirus Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in May 2024. In addition, the Company was eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments upon achievement of certain event milestones. Subject to regulatory approval in Australia and New Zealand, the Company will also receive a per unit supply price for the sale of commercial supply to Seqirus.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the commencement of this collaboration, the Company identified one performance obligation which is the delivery of the license for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the Seqirus Territory in combination with the transfer of know-how. The Company determined that the option to purchase the commercial supply does not represent a material right. The Company determined the initial transaction price to be the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment. Due to the uncertainty in the achievement of all the regulatory milestones, the variable consideration associated with these future milestone payments has been fully constrained and is excluded from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. The variable consideration will be reassessed at each reporting period. In May 2024, the Company delivered the license for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the Seqirus Territory in combination with the transfer of know-how and recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue. In August 2024, the first milestone event was met and the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ALK Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the Company entered into a Collaboration, License and Distribution Agreement (the &#x201c;ALK Collaboration Agreement&#x201d;) with ALK-Abell&#xf3; A/S (&#x201c;ALK&#x201d;). Pursuant to the ALK Collaboration Agreement, the Company granted to ALK a worldwide (other than the United States, Japan, mainland China, Hong Kong, Taiwan, Macau, Australia and New Zealand) (&#x201c;ALK Territory&#x201d;), exclusive license under certain of the Company&#x2019;s patents and know-how to develop, manufacture and commercialize products containing epinephrine administered intranasally, including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EURneffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the trade name for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the European Union) (epinephrine nasal spray) (&#x201c;Products&#x201d;), for all human uses, including the immediate or emergency treatment of allergic reactions (including Type I) and anaphylaxis and urticaria, and other future indications as agreed by the parties. If the Company develops any new intranasally administered product that contains epinephrine and files a new drug application in the United States for such product (&#x201c;New Product&#x201d;), upon ALK&#x2019;s request such New Product will be included as a Product under the ALK Collaboration Agreement, subject to ALK bearing the costs of development of such New Product for its licensed territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the ALK Collaboration Agreement, the Company is obligated to transfer to ALK the existing marketing authorizations for the Products in the ALK Territory. The Company is also required to conduct certain development and regulatory activities for Products in support of obtaining further regulatory approval of Products in the ALK Territory and will transfer such regulatory approvals to ALK. ALK is obligated to use commercially reasonable efforts to obtain and maintain regulatory approval for Products through the European Commission and within specified countries within the ALK Territory. Following such approval for a Product in each indication within specified countries within the ALK Territory, ALK is obligated to use commercially reasonable efforts to commercialize such Product in such indication in such countries and to achieve first commercial sale of a Product in certain countries in accordance with a timeline specified in the ALK Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the ALK Collaboration Agreement, ALK made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment to the Company in November 2024, and the Company earned $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EURneffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the ALK Territory in June 2025. The Company is eligible to receive additional outstanding regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and sales-based milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, provided that $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of such sales-based milestones are contingent upon the Company obtaining regulatory approval for the Product in Canada by a specified time. The Company is entitled to receive tiered royalty payments on net sales in the mid- to high-teens, subject to certain standard reductions and offsets. Royalties will be payable, on a Product-by-Product and country-by-country basis, until the latest of the expiration of the licensed patents covering such Product in such country, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the first commercial sale of such Product in such country, or expiration of regulatory exclusivity for such Product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contract will expire upon the expiration of the last-to-expire royalty term for all Products in the ALK Territory, unless terminated earlier. Either the Company or ALK may terminate the ALK Collaboration Agreement in the case of the other party&#x2019;s insolvency or in the event of an uncured material breach of the other party, except that the Company may not terminate the ALK Collaboration Agreement for ALK&#x2019;s material breach of its commercial diligence obligations. ALK may terminate the ALK Collaboration Agreement for convenience upon 12 months&#x2019; prior written notice or for a safety or regulatory concern. The Company may terminate the ALK Collaboration Agreement in the event ALK makes certain challenges to certain of the Company&#x2019;s patents. Prior to a change of control and outside of a set period of time after which the Company commences change of control negotiations, the Company may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area (&#x201c;EEA&#x201d;) upon prior written notice to ALK and payment of a termination fee that is the higher of an agreed mid-nine digit amount and the fair market value of the Products business in the EEA at the time of such termination (the &#x201c;Repurchase Option&#x201d;). The Company may also terminate the ALK Collaboration Agreement if ALK commercializes a non-injectable epinephrine product or manufactures such a product in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the ALK Collaboration Agreement, the Company and ALK also entered into a commercial supply agreement (the &#x201c;ALK Supply Agreement&#x201d;) in November 2024, under which the Company will supply ALK&#x2019;s requirements (and ALK will purchase from the Company its requirements) of Products for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for a specified supply price, after which ALK may elect to transition to itself or its contract manufacturer the manufacture and supply of Products. The contract term for the ALK Supply Agreement is coterminous with the ALK Collaboration Agreement. Either the Company or ALK may terminate the ALK Supply Agreement in the event of an uncured material breach of the other party.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Assessment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that the ALK Collaboration Agreement and the ALK Supply Agreement qualify as a contract with a customer under ASC 606 as one combined arrangement. The Company identified the following performance obligations: (i) exclusive commercialization license in the European Economic Area (the &#x201c;EEA License&#x201d;); (ii) exclusive commercialization license in the rest of the ALK Territory (the &#x201c;ROW License&#x201d;) and; (iii) five separate development and regulatory services performance obligations. The Company also evaluated the (i) promise to add a New Product and new indications to the ALK Collaboration Agreement, and (ii) the promises under the ALK Supply Agreement, and concluded that these promises did not meet the definition of a performance obligation nor did these promises convey a material right to ALK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is the estimated transaction price at contract inception. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The outstanding regulatory milestone payments (totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) were fully constrained at contract inception and as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as a result of the uncertainty of whether any of the milestones will be achieved. In making the assessment of the constraint utilizing the most likely amount method, the Company considered the stage of development, and the risks associated with the remaining development required to achieve the milestones, as well as whether the achievement of the milestone is outside the control of the Company or ALK. The Company determined that the commercial milestone ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) and the sales-based milestones and royalties will be recognized on the later of when the related sales occur or when control of the associated license has been transferred, as the Company determined that such sales-based consideration relates predominantly to the licenses granted to ALK. The Company reevaluates the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and will include regulatory milestones in the transaction price if it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At contract inception, the Company determined the estimated standalone selling prices for each performance obligation in order to allocate the transaction price among the performance obligations. The standalone selling price for the licenses was estimated using the adjusted market assessment approach. Under this method, the Company forecasted future cash flows expected in the ALK Territory, the probability of commercialization success, and a market discount rate. To estimate the standalone selling prices of the development and regulatory services, the Company forecasted its expected costs of satisfying each performance obligation inclusive of an appropriate margin for that service.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company allocated the total transaction price to each performance obligation on a relative standalone selling price basis and determined whether revenue should be recognized at a point in time or over time. The Company allocated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the EEA License performance obligation; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the ROW License performance obligation; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the development and regulatory services performance obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue should be recognized when, or as, an entity satisfies a performance obligation by transferring a promised good or service to a customer, i.e., when the customer obtains control of the good or service. The licenses granted to ALK are being accounted for as distinct performance obligations. The licenses relate to functional intellectual property for which revenue is recognized at a point in time. In the case of the EEA License, the Company evaluated the impact of the Company&#x2019;s Repurchase Option, and determined that, as a result of the Company&#x2019;s ability to repurchase the license, control of the EEA License has not been transferred to ALK under ASC 606. The Company determined that the transaction price allocated to the EEA License should be accounted for as a financing liability, due to the repurchase price being greater than the original selling price of this performance obligation. Control of the EEA License will not be considered transferred to ALK until such time that the Repurchase Option lapses, which under the terms of the ALK Collaboration Agreement, will occur upon the expiration of the contract, or exercise by the Company of the Repurchase Option. In November 2024, the Company recognized the transaction price allocated to the EEA License of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as a financing liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the case of the ROW License, the point in time for recognition of revenue was shortly after the inception of the contract because the customer obtained control of the license and was able to use and benefit from its right to use the intellectual property at that po&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;int. In November 2024, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue for the transaction price allocated to the ROW License.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development and regulatory services performance obligations under the ALK Collaboration Agreement each represent a separate performance obligation. The development and regulatory services, which are transferred to the customer over time, were provided to ALK from inception of the agreement and are expected to continue through 2028. Revenue related to the development and regulatory services performance obligations was initially recorded as contract liability and is being recognized as services are performed based on the costs incurred through the end of each reporting period, as a percentage of the estimated total costs to be incurred for these performance obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In November 2024, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue related to the development and regulatory services performance obligations. For the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue related to the development and regulatory services performance obligations, respectively, which is recorded as revenue under collaboration agreements in the accompanying condensed consolidated statement of operations and comprehensive loss. As of June 30, 2025, the accompanying consolidated balance sheet includes a contract liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million classified as current and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million classified as noncurrent associated with these performance obligations and based on the expected period of performance for the development and regulatory services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2025, ALK completed the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EURneffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in the ALK Territory, and the Company began generating revenue from product sales to ALK, earned royalties from the use of the EEA License, and also earned the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million commercial milestone. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million commercial milestone, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized as revenue under collaboration agreements for the three and six months ended June 30, 2025 in the accompanying condensed consolidated statement of operations and comprehensive loss. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the EEA license and recognized as an increase to the financing liability, along with $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to royalties earned in the EEA.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had accounts receivable and contract liability balances of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, associated with the ALK Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ALK Contract Liability&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the contract liability from the ALK &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration Agreement is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized under the ALK Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ALK Financing Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the financing liability from the ALK Collaboration Agreement is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial milestone allocated to the EEA License&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales-based royalties earned in the EEA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ALK Co-Promotion Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2025, the Company and ALK-Abell&#xf3;, Inc. (&#x201c;ALK U.S.&#x201d;, an affiliate of ALK) entered into a co-promotion agreement (the &#x201c;ALK Co-Promotion Agreement&#x201d;) to co-promote &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; specified pediatricians and other prescribers in the U.S. Accordingly, the Company granted ALK U.S. a non-exclusive, royalty-free license to use the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pursuant to the terms of the ALK Co-Promotion Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the ALK Co-Promotion Agreement, ALK U.S. was obligated to start its promotion activities in May 2025 and meet specified ramp-up milestones and minimum detail requirements, using sales representatives that meet specific qualifications. In addition, during the term of the ALK Co-Promotion Agreement and for 180 days thereafter, ALK U.S. will not market, sell or manufacture any injection product containing epinephrine in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is the principal of all sales transactions of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the U.S. and, subject to the terms of the ALK Co-Promotion Agreement, continues to have sole responsibility for all U.S. commercialization activities, including marketing, medical affairs, market access, production, distribution, pharmacovigilance, quality and safety.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will pay ALK U.S. a base fee to compensate ALK U.S. for its promotion activities.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Payments to ALK U.S. for the services performed during the first year of the arrangement will be deferred and paid in the second year of the arrangement. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from the Company starting in the second year of the arrangement equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the portion of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% market share threshold during years three and four of the arrangement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ALK Co-Promotion Agreement expires on the fourth anniversary of the commencement of promotion activities thereunder. Either party may terminate the ALK Co-Promotion Agreement in the event of an uncured material breach of the other party or for either party&#x2019;s change of control. The Company may terminate the ALK Co-Promotion Agreement in the case of ALK U.S.&#x2019;s insolvency, if ALK U.S. fails to meet specified ramp-up timelines, or if ALK U.S. markets, sells or commercializes any non-injection product containing epinephrine in the U.S. After the first six months, the Company may terminate the ALK Co-Promotion Agreement if minimum detail requirements are not met for a consecutive three-month period. After the first year, the Company may terminate the ALK Co-Promotion agreement for any reason or no reason for a fee (as described below). After the first year, ALK U.S. may terminate the ALK Co-Promotion Agreement for any reason or no reason, and the Company may terminate the agreement in the event ALK U.S. restructures its sales force.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon termination of the ALK Co-Promotion Agreement by the Company for convenience, so long as ALK U.S. has met specified performance thresholds during the term, the Company is obligated to pay ALK U.S. a specified mid-to-low double-digit percentage of the portion of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; net sales generated from the ALK U.S.-targeted prescribers in excess of a specified mid-quartile market share threshold that increases over time up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for a specified period after termination, which period decreases in duration the later that the termination occurs. Upon termination of the ALK Co-Promotion Agreement by the Company in connection with a change of control of the Company, the Company is obligated to pay ALK U.S. a one-time mid-seven digit to low eight-digit termination fee in an amount that increases the later that the termination occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluated the terms of the ALK Co-Promotion Agreement and determined that it is a vendor arrangement with ALK U.S. During the three and six months ended June 30, 2025, the Company has recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in ALK-related selling, general, and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss, and the corresponding liability was recorded in other accrued liabilities in the accompanying condensed consolidated balance sheet as of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <spry:UpfrontPayment
      contextRef="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2"
      decimals="-5"
      id="F_9498d6ad-8860-44a5-b9f1-dd599faa7596"
      unitRef="U_USD">2000000</spry:UpfrontPayment>
    <spry:LicenseAgreementExpirationTerm
      contextRef="C_2b453910-3154-4dd2-ae97-baf6c3d4cbd2"
      id="F_0df202cf-4eb0-44e7-ac33-7306c81eaeee">P10Y</spry:LicenseAgreementExpirationTerm>
    <spry:UpfrontPayment
      contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c"
      decimals="-5"
      id="F_31d422a3-06cc-489c-a7b0-8486086687da"
      unitRef="U_USD">2000000</spry:UpfrontPayment>
    <spry:MilestonePayments
      contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c"
      decimals="-5"
      id="F_0f8eae68-72ba-4612-b47b-7b036cbd6162"
      unitRef="U_USD">13000000</spry:MilestonePayments>
    <spry:InitialTransactionPrice
      contextRef="C_c2c4fb1c-f14c-485c-ad68-e14ff92c700c"
      decimals="-5"
      id="F_690feb1d-66d6-48c5-907a-1d40fa337522"
      unitRef="U_USD">7000000</spry:InitialTransactionPrice>
    <spry:MilestonePayments
      contextRef="C_2798c3f2-23d6-4afc-8238-e8955f00db8e"
      decimals="-5"
      id="F_223aa4ef-9866-4477-9bb6-7319013964c5"
      unitRef="U_USD">5000000</spry:MilestonePayments>
    <spry:RegulatoryMilestonePayment
      contextRef="C_247f0be8-9254-4ed7-af0a-c83a543c7393"
      decimals="-5"
      id="F_dbfe16cb-e273-491f-946b-5a361d5f66e0"
      unitRef="U_USD">6000000</spry:RegulatoryMilestonePayment>
    <spry:MilestonePayments
      contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba"
      decimals="-5"
      id="F_86b402d2-f716-4a6a-bbae-10928355d475"
      unitRef="U_USD">13000000</spry:MilestonePayments>
    <spry:MilestonePaymentsEarned
      contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba"
      decimals="-5"
      id="F_cef56bbb-31c2-4122-a60a-24bf08b9a1b6"
      unitRef="U_USD">11000000</spry:MilestonePaymentsEarned>
    <spry:RemainingRegulatoryMilestone
      contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba"
      decimals="-5"
      id="F_6f3328b4-96f2-4394-b4f6-9cddea32c13a"
      unitRef="U_USD">2000000</spry:RemainingRegulatoryMilestone>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_6edac6ab-835a-4f3c-a70b-1468370bc85c"
      decimals="-6"
      id="F_69e36887-916e-4409-9dc0-83b250f8b81d"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_5b6f7d29-af45-4777-a3a1-ded15ca737ba"
      decimals="-6"
      id="F_87cf47e8-aca7-449c-88d5-846f96c0802e"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_b3290235-3d4c-4e7f-9944-799740aa251b"
      decimals="-6"
      id="F_d2d8ae3c-a6c6-4aa5-bad0-27c076d5610c"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_bea2c90b-ecb9-4b59-93cf-dda1fa71fada"
      decimals="-6"
      id="F_930e79e2-a01d-45c6-8f45-70a0a9dc67d7"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_bf13c693-c4c5-4d64-bff3-5e485417c1b2"
      decimals="-3"
      id="F_80a0bd7c-d311-4816-abc5-f91a3149bff1"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_1db62f10-470a-43d8-99c5-9ef506d240f9"
      decimals="-3"
      id="F_9dcb2b04-9c8e-491b-8a7c-2d3a79f6eda9"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <spry:UpfrontPayment
      contextRef="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e"
      decimals="-5"
      id="F_91d09ba8-065e-4868-bb21-e3bdc7e17f82"
      unitRef="U_USD">11800000</spry:UpfrontPayment>
    <spry:RegulatoryMilestonePayment
      contextRef="C_ac725f32-f6ab-45b2-a5f2-41552991fc1e"
      decimals="-5"
      id="F_08ae3f43-4c5f-4770-99bb-fe37fdac1d78"
      unitRef="U_USD">6000000</spry:RegulatoryMilestonePayment>
    <spry:InitialTransactionPrice
      contextRef="C_38aa7ddf-8d81-40f0-b406-1b66b957af89"
      decimals="-5"
      id="F_a8f62e8e-99ef-4cdc-a876-187618d3df01"
      unitRef="U_USD">11800000</spry:InitialTransactionPrice>
    <spry:RegulatoryMilestonePayment
      contextRef="C_0aeae9af-4a88-43bd-a834-adb7075f5c02"
      decimals="-5"
      id="F_0a0b602b-f66b-49d4-93e1-3e5968672f33"
      unitRef="U_USD">6000000</spry:RegulatoryMilestonePayment>
    <spry:UpfrontPayment
      contextRef="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d"
      decimals="-5"
      id="F_78e907d0-9353-4e0f-a728-1f93414ae646"
      unitRef="U_EUR">3000000</spry:UpfrontPayment>
    <spry:UpfrontPayment
      contextRef="C_4bd2598d-40c3-4a3d-94bb-a9922129b27d"
      decimals="-5"
      id="F_f0f2f67d-ee9a-4695-a205-a64fdc8538de"
      unitRef="U_USD">3300000</spry:UpfrontPayment>
    <spry:MilestonePayments
      contextRef="C_ccda22c2-6677-4cce-ab78-990354649056"
      decimals="-5"
      id="F_8b3d4445-c526-4a38-80a7-6a77b6702e77"
      unitRef="U_EUR">2000000</spry:MilestonePayments>
    <spry:MilestonePayments
      contextRef="C_b67f6b97-19bd-4541-ba67-b60ffde15be3"
      decimals="-5"
      id="F_f000907f-cf69-4d7a-8414-ff9f6141b316"
      unitRef="U_EUR">5000000</spry:MilestonePayments>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_2e38c3cc-e6d7-4425-85b9-bc2d6e8c7279"
      decimals="-5"
      id="F_54f2f1ea-99ae-44f1-b2ca-d463d1bd7955"
      unitRef="U_EUR">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <spry:UpfrontPayment
      contextRef="C_0833639e-5a42-456b-b01e-000950904f01"
      decimals="-5"
      id="F_f38cc3b8-bf3d-44d6-853a-2d0caf091643"
      unitRef="U_EUR">3000000</spry:UpfrontPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_feb3d59c-08cc-44f9-9f9d-a605f5002728"
      decimals="-5"
      id="F_63c6465f-435c-4528-ab74-c3942536d712"
      unitRef="U_USD">3100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_a417b738-34c6-435f-98b6-b7335b68b8a7"
      decimals="-6"
      id="F_e3befb8f-4a6d-4845-bdab-4dbf505a9d58"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <spry:MilestonePayments
      contextRef="C_8b918b45-e66c-471b-9415-84b94cdb93dc"
      decimals="-5"
      id="F_c906248e-230a-45a0-bb6b-cef2d1e626ab"
      unitRef="U_EUR">2000000</spry:MilestonePayments>
    <spry:MilestonePayments
      contextRef="C_8b918b45-e66c-471b-9415-84b94cdb93dc"
      decimals="-5"
      id="F_ddcb7fa9-f32e-4e33-b156-7674be5feb39"
      unitRef="U_USD">2100000</spry:MilestonePayments>
    <spry:AggregateMilestonePayments
      contextRef="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2"
      decimals="-5"
      id="F_62954855-1d52-4113-bcf9-0c90421362f9"
      unitRef="U_EUR">5000000</spry:AggregateMilestonePayments>
    <spry:AggregateMilestonePayments
      contextRef="C_503db9de-0d84-4f5e-9af2-9fc55ebd02d2"
      decimals="-5"
      id="F_e705a902-2c59-48e2-aa4f-7031630ea2a4"
      unitRef="U_USD">5900000</spry:AggregateMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_c28eee89-e582-4ada-b83c-1d83ed541c9b"
      id="F_4f849b96-09c7-4ad1-85eb-1192ce28a841">P13Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:RoyaltyExpense
      contextRef="C_375c7fdb-6931-4298-a1cb-0a3d7c761910"
      decimals="-5"
      id="F_851e8267-ee33-4c36-b0dc-dc13264a696c"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_70a2fe72-2e5d-43a9-845b-e6ad6d4e993a"
      decimals="-5"
      id="F_3311e9eb-369e-403d-a8ed-d8d533a1f5d7"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <spry:LicenseAgreementExpirationTerm
      contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2"
      id="F_bffd98d9-6476-4ff8-85b9-ee05630d090f">P10Y</spry:LicenseAgreementExpirationTerm>
    <spry:UpfrontPayment
      contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2"
      decimals="-5"
      id="F_4afd9259-6e1f-4165-8059-432dd1275155"
      unitRef="U_USD">3000000</spry:UpfrontPayment>
    <spry:RegulatoryAndCommercialSalesMilestones
      contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2"
      decimals="-5"
      id="F_e30b8752-8733-4c8a-b4a7-79a6f2467c7f"
      unitRef="U_USD">84000000</spry:RegulatoryAndCommercialSalesMilestones>
    <spry:RegulatoryMilestonePayment
      contextRef="C_f0d8db66-c63b-4744-af9a-66b508f6e408"
      decimals="-5"
      id="F_7767ed02-bfc4-4e99-8c3c-63d0c601a978"
      unitRef="U_USD">4000000</spry:RegulatoryMilestonePayment>
    <spry:InitialTransactionPrice
      contextRef="C_e1d0ae97-b485-4671-bf99-135c430e8fd2"
      decimals="-5"
      id="F_7132d68a-87dc-4c87-b34d-0c398752ae21"
      unitRef="U_USD">3000000</spry:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_3f30c2eb-5568-4234-8acd-723e1a049bc1"
      decimals="-5"
      id="F_740f1cf2-0618-4d88-98d9-957a304295b0"
      unitRef="U_USD">3000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <spry:UpfrontPayment
      contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b"
      decimals="-5"
      id="F_6e95e614-7eb8-4c96-a296-d0e10ada179a"
      unitRef="U_USD">500000</spry:UpfrontPayment>
    <spry:RegulatoryAndCommercialSalesMilestones
      contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b"
      decimals="-5"
      id="F_cf22e430-9e74-463d-8a67-19b6321990c6"
      unitRef="U_USD">4500000</spry:RegulatoryAndCommercialSalesMilestones>
    <spry:InitialTransactionPrice
      contextRef="C_f4436849-9fcc-4497-a985-5fa9db7ac33e"
      decimals="-5"
      id="F_4c72c090-3a0a-4939-8a07-f78a64b6e301"
      unitRef="U_USD">500000</spry:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_807c7cfb-8b89-40e4-984b-323428f58c0b"
      decimals="-5"
      id="F_1622b577-fcb7-495f-8c83-db32b21e387b"
      unitRef="U_USD">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_75927173-b0be-40a6-8cb0-9cafd6cc1be4"
      decimals="-5"
      id="F_31475a81-f243-4ecf-859d-35ff8e6ccddc"
      unitRef="U_USD">1500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <spry:UpfrontPayment
      contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef"
      decimals="-5"
      id="F_4fec10b6-50b2-41b0-8c4f-9fd442093755"
      unitRef="U_USD">145000000</spry:UpfrontPayment>
    <spry:UpfrontPayment
      contextRef="C_004bb578-b8b4-4b1e-b080-94149f0f6733"
      decimals="-5"
      id="F_47d0b5ba-fd3c-4395-8950-b2fe0e2ce2e7"
      unitRef="U_USD">5000000</spry:UpfrontPayment>
    <spry:RegulatoryMilestonePayment
      contextRef="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f"
      decimals="-5"
      id="F_c924423e-09ae-43ab-b321-5624a182456b"
      unitRef="U_USD">15000000</spry:RegulatoryMilestonePayment>
    <spry:SalesBasedMilestones
      contextRef="C_494153ea-57f1-4bae-bd54-e5aad6e8f97f"
      decimals="-5"
      id="F_521ca523-b3a1-4849-8b67-a32bf84ff334"
      unitRef="U_USD">300000000</spry:SalesBasedMilestones>
    <spry:ContingentSalesBasedMilestones
      contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef"
      decimals="-5"
      id="F_8c8b30e5-3c19-4e58-9d26-122700a1ee08"
      unitRef="U_USD">55000000</spry:ContingentSalesBasedMilestones>
    <spry:LicenseAgreementExpirationTerm
      contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef"
      id="F_0aba2311-6f77-42e6-baf9-8707ee6014b7">P15Y</spry:LicenseAgreementExpirationTerm>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="C_563a8ff6-fcbe-42af-ac8a-285febbe3949"
      id="F_9f9c0aa9-9d89-4047-9514-94d6d2b63c22">P5Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <spry:UpfrontPayment
      contextRef="C_36c635cc-c946-4fd2-a16c-4a98c7d388ef"
      decimals="-5"
      id="F_4c043903-f31c-4139-9e05-31d04cade507"
      unitRef="U_USD">145000000</spry:UpfrontPayment>
    <spry:RegulatoryMilestonePayment
      contextRef="C_38363ca6-7cce-4222-abc8-30485789e9f7"
      decimals="-5"
      id="F_872e2872-747f-4ad7-b001-db589de88155"
      unitRef="U_USD">15000000</spry:RegulatoryMilestonePayment>
    <spry:CommercialMilestonePayments
      contextRef="C_38363ca6-7cce-4222-abc8-30485789e9f7"
      decimals="-5"
      id="F_5ca5eab9-48d5-4f17-8432-1918566d45ef"
      unitRef="U_USD">5000000</spry:CommercialMilestonePayments>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_3e249227-20e2-4988-9bf2-7e870713555f"
      decimals="-5"
      id="F_32486b5c-31a1-4bae-ae7d-c408f8ebf421"
      unitRef="U_USD">69400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9c7e6e23-0000-4ddc-a5c9-a2b708744fd4"
      decimals="-5"
      id="F_c200a0d7-d5cf-4d3a-81cc-25f9da091302"
      unitRef="U_USD">73100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9c214f10-a914-4d27-a1b0-da1ea243e703"
      decimals="-5"
      id="F_94ca9f3a-ccd2-417b-8723-3ce4bec4a9bb"
      unitRef="U_USD">2600000</us-gaap:RevenueRemainingPerformanceObligation>
    <spry:FinancingLiability
      contextRef="C_e127c89b-57cc-45dd-88e0-5952c92514a1"
      decimals="-5"
      id="F_5ecc0b65-871d-44df-b43d-4b6f7769af6b"
      unitRef="U_USD">69400000</spry:FinancingLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_77cdd9e5-e0da-4ed0-91c5-452beda8f96e"
      decimals="-5"
      id="F_fb6f861b-36b4-4752-b1d0-e6ad646f66b6"
      unitRef="U_USD">73100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_b0d7c1bf-c559-41f1-bb73-15d4ca13613b"
      decimals="-5"
      id="F_153f108a-9c9d-4328-a261-97b7f6994524"
      unitRef="U_USD">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_8af74f27-94e0-4415-9f6e-42b1b5332edb"
      decimals="-5"
      id="F_51502627-81fb-430c-8ec8-0f2475357c2b"
      unitRef="U_USD">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_d10f176e-9429-4ccb-a20f-413c86b3a44b"
      decimals="-5"
      id="F_f3db24d7-1ae4-47a4-8bda-026dede3e4a3"
      unitRef="U_USD">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b"
      decimals="-5"
      id="F_4ded735a-ffc9-4ecf-85ac-c1e286111ce3"
      unitRef="U_USD">700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_22cfb5a3-bb46-4d63-b2e1-1fe78534e79b"
      decimals="-5"
      id="F_e408e9c7-9d35-4e23-949a-8f2ad4b1f778"
      unitRef="U_USD">1100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <spry:CommercialMilestonePayments
      contextRef="C_e3d262bc-6795-406d-8d91-24b3907b6289"
      decimals="-5"
      id="F_ba8d23d8-50fb-4823-b984-03c80d12aef6"
      unitRef="U_USD">5000000</spry:CommercialMilestonePayments>
    <spry:CommercialMilestonePayments
      contextRef="C_e3d262bc-6795-406d-8d91-24b3907b6289"
      decimals="-5"
      id="F_62d4e84b-70ae-4274-9241-2a867c4d5974"
      unitRef="U_USD">5000000</spry:CommercialMilestonePayments>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0290e712-16a0-4589-8318-f1315dc7c60a"
      decimals="-5"
      id="F_23c71250-2fd0-47de-bc02-cdcd7f65b9ee"
      unitRef="U_USD">2600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_9a4b43ec-ca53-4df2-bd72-e2b244eaca24"
      decimals="-5"
      id="F_9e7a3bab-e5eb-40ad-81bf-1bed62233efe"
      unitRef="U_USD">2600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <spry:IncreaseToTheFinancingLiability
      contextRef="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0"
      decimals="-5"
      id="F_451464a4-da9c-46c3-9f5b-39d8fbae368a"
      unitRef="U_USD">2400000</spry:IncreaseToTheFinancingLiability>
    <spry:RoyaltyIncomeNotRecognized
      contextRef="C_6b3853b0-d05c-46cd-94d4-ae67f907fdd0"
      decimals="-5"
      id="F_f07823c0-b513-410b-ba7d-cfbc16fc9937"
      unitRef="U_USD">100000</spry:RoyaltyIncomeNotRecognized>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b"
      decimals="-5"
      id="F_7b77abf5-9550-4da1-b674-f41ca0fe910b"
      unitRef="U_USD">5500000</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b"
      decimals="-5"
      id="F_f236f0af-fd29-4948-81b6-ed2105d6a2e1"
      unitRef="U_USD">1800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_0f129467-b39c-4e78-8824-9134d808db7f">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the contract liability from the ALK &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration Agreement is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized under the ALK Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ALK Financing Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the financing liability from the ALK Collaboration Agreement is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:83.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial milestone allocated to the EEA License&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales-based royalties earned in the EEA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0bd8344d-6c3d-4f4c-9193-8180e76f5899"
      decimals="-3"
      id="F_587cdb62-5f9e-41d8-b8e2-c47624a75336"
      unitRef="U_USD">2089000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_551d5f3f-f834-4e2e-af4a-07c630cc9151"
      decimals="-3"
      id="F_9b7c46c2-3ddc-4abd-9232-02cd66b08111"
      unitRef="U_USD">-240000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d5564be7-538a-42aa-902d-e6f7ad4c1b4b"
      decimals="-3"
      id="F_09492cc3-ec82-4048-90a0-926257d2f5f0"
      unitRef="U_USD">1849000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7e3f31da-ca14-42b4-8b0b-1e8aeb740579"
      decimals="-3"
      id="F_6b3c214c-affe-473b-8efb-775cb75222ff"
      unitRef="U_USD">69383000</us-gaap:ContractWithCustomerLiability>
    <spry:IncreaseToTheFinancingLiability
      contextRef="C_d1c3a878-557f-48fb-9597-d12ba95d1e11"
      decimals="-3"
      id="F_19754c0e-cd98-4440-9cae-5685040ae4d4"
      unitRef="U_USD">2435000</spry:IncreaseToTheFinancingLiability>
    <spry:RoyaltyIncomeAllocatedToTheEEALicense
      contextRef="C_d1c3a878-557f-48fb-9597-d12ba95d1e11"
      decimals="-3"
      id="F_c28ee824-0caa-4181-8ca1-c8f8d8a7e77b"
      unitRef="U_USD">141000</spry:RoyaltyIncomeAllocatedToTheEEALicense>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_c703154e-f609-4897-84a5-dd320a085d31"
      decimals="-3"
      id="F_e129e0a7-f7a3-4df0-a8f2-be8e3e491be8"
      unitRef="U_USD">71959000</us-gaap:ContractWithCustomerLiability>
    <spry:NumberOfPediatricians
      contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4"
      decimals="0"
      id="F_ca92c3e1-361d-4445-815c-2261df757889"
      unitRef="U_Doctor">9000</spry:NumberOfPediatricians>
    <us-gaap:CollaborativeArrangementRightsAndObligations
      contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4"
      id="F_989d352b-ca76-4b57-9e4d-aec8ad12de14"> Payments to ALK U.S. for the services performed during the first year of the arrangement will be deferred and paid in the second year of the arrangement. In addition to the base fee, ALK U.S. will be eligible to receive performance-based bonus payments from the Company starting in the second year of the arrangement equal to 30% of the portion of neffy net sales generated from the ALK U.S.-targeted prescribers in excess of a specified initial market share threshold in year two or a 50% market share threshold during years three and four of the arrangement.</us-gaap:CollaborativeArrangementRightsAndObligations>
    <spry:PerformanceBasedBonusPaymentsPercentage
      contextRef="C_064e952a-b57a-45b7-b072-cc0c1681aeea"
      decimals="2"
      id="F_7c1fa8a7-8a12-485c-9140-35032cf4a8b5"
      unitRef="U_pure">0.30</spry:PerformanceBasedBonusPaymentsPercentage>
    <spry:ThresholdPercentageOfValueChangeInEquitySecurities
      contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4"
      decimals="2"
      id="F_19b9b6f5-8a56-4297-be41-fba18d28901b"
      unitRef="U_pure">0.50</spry:ThresholdPercentageOfValueChangeInEquitySecurities>
    <spry:ThresholdPercentageOfValueChangeInEquitySecurities
      contextRef="C_e64bfcdb-5535-4f74-be3c-80e4877e0ce4"
      decimals="2"
      id="F_2a1ef7e8-0c26-4c6a-a555-23a18f75693f"
      unitRef="U_pure">0.50</spry:ThresholdPercentageOfValueChangeInEquitySecurities>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_3cf5d1b5-d177-4592-87ff-f0e88882461a"
      decimals="-5"
      id="F_05ae8e2d-32df-4b1b-a74b-273adf0d5091"
      unitRef="U_USD">1400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0f4f1f4e-cff5-4294-8295-0850b8d49cb5"
      decimals="-5"
      id="F_edd1dca6-a364-4e25-9714-c9c7b3db8f1f"
      unitRef="U_USD">1400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_ccfcc4d8-af04-4d3d-b28f-3c979e5d0771"
      decimals="-5"
      id="F_9869b299-8890-4658-b664-5eafed3a1488"
      unitRef="U_USD">1400000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_4d079bb0-21ee-4c23-ae03-36a654ff09d0">&lt;p id="fn_commitmentscontingencies" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2021, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;38-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; noncancelable office space lease for its current headquarters location in San Diego, California. Under the terms of the agreement, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;there is no option to extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the Company is subject to additional charges for common area maintenance and other costs.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Monthly rental payments due under the lease commenced on December 6, 2021 and escalate through the lease term. The Company prepaid the first month&#x2019;s rent upon execution of the lease, and the lease agreement provided full rent abatement for the second and third months of the rental term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As there was not an implicit rate within the lease, the discount rate was determined by using a set of peer companies incremental borrowing rates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2025, the Company entered into a lease amendment to its headquarters location lease (the &#x201c;Headquarters Amendment&#x201d;), pursuant to which the Company will relocate to a new office space located in the same building. In May 2025, the Company took possession of the new office space upon substantial completion of the landlord&#x2019;s work. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the remaining lease term of the new office space is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months. Monthly lease payments increased when the Company took possession of the new office space and will escalate through the lease term, resulting in an annualized payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company remains subject to additional charges for common area maintenance and other costs. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has one option to extend the lease for an additional term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the monthly payment amounts would be determined by the landlord at the then-prevailing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon entering into the Headquarters Amendment, the Company remeasured the right-of-use asset and lease liability pertaining to its current headquarters, and as a result recorded an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to both its right-of-use asset and lease liability on its condensed consolidated balance sheet. Upon possession of the new office space, the Company recognized a right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on its condensed consolidated balance sheet. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As there was not an implicit rate within the lease amendment, a discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% was determined using a set of peer companies&#x2019; incremental borrowing rates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes supplemental lease information (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.9030000000000005%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;______________&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs in each of the three and six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, future minimum non-cancelable operating lease payments are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (remaining six months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less lease liability, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 24, 2023, Aera A/S, an IP consultancy firm in Denmark representing an unidentified opponent, filed a notice of opposition with the European Patent Office (the &#x201c;EPO&#x201d;) in respect of EP 3678649 (the &#x201c;EP &#x2018;649 Patent&#x201d;), which is a patent directed to a nasal spray formulation of epinephrine, and uses thereof. The Company filed a response to the notice of opposition on December 15, 2023. The EPO scheduled oral proceedings on October 7, 2025, and the Company will continue to vigorously defend the EP &#x2018;649 Patent. The results of any notice of opposition are inherently unpredictable and uncertain and could result in the EPO finding the patent to be invalid or unenforceable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 25, 2025, Aptargroup, Inc. and Aptar France SAS (collectively, &#x201c;Aptar&#x201d;) filed a suit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. in the United States District Court for the Southern District of New York. Aptar alleges the Company violated the Defend Trade Secrets Act (18 USC &#xa7; 1836), misappropriated trade secrets under New York state law, and committed various breaches of contract. The complaint was served to the Company, and the Company filed a motion to dismiss on June 12, 2025. Aptar subsequently filed opposition to the motion to dismiss on July 28, 2025. The Company intends to vigorously defend itself in this matter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Regardless of the outcome, involvement in legal proceedings may have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. The Company cannot predict the outcome of these suits, and failure by the Company to obtain favorable resolutions could have a material adverse effect on its business, results of operations, and financial condition. The Company&#x2019;s chances of success on the merits of these suits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of June 30, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Except as described above, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or other body pending or, to the knowledge of the Company&#x2019;s executive officers, threatened against or affecting the Company, the Company&#x2019;s common stock, any of its subsidiaries or its subsidiaries&#x2019; officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unconditional Purchase Obligations and Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unconditional purchase obligations and commitments are defined as agreements to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, the Company enters into arrangements with suppliers, manufacturers, and various other companies that supply goods or services. These arrangements can include unconditional purchase obligations and commitments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total amount of unconditional purchase obligations related to the supply of raw materials is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025. Payment obligations by year are as follows: 2025 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), 2026 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), 2027 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), 2028 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per year thereafter through 2035. During the three and six months ended June 30, 2025, the Company made &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in payments under these agreements, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; payments were made under these agreements during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total amount of commitments related to the ALK Co-Promotion Agreement is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025. Payment obligations by year are as follows: 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; payments were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;made under this agreement during the three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total amount of commitments related to a corporate sponsorship agreement with Food Allergy Research and Education, Inc. is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025. Payments by year are as follows: 2025 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), 2026 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) and 2027 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). During the three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company made &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in payments under this agreement, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; payments were made under this agreement during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total amount of unconditional purchase obligations related to hosted software license subscription fees is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025. Payments by year are as follows: 2025 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), 2026 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), and 2027 (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). During the three and six months ended June 30, 2025, the Company made &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in payments under this agreement, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; payments were made under this agreement during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amounts above do not represent the entire anticipated spend in the future but represent only those items for which the Company is contractually obligated. For this reason, these amounts do not provide an indication of the Company&#x2019;s expected future cash outflows related to purchases and commitments.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_30c25de7-59dd-4755-a53d-eebf628aa5a2">In October 2021, the Company entered into a 38-month noncancelable office space lease for its current headquarters location in San Diego, California. Under the terms of the agreement, there is no option to extend the lease, and the Company is subject to additional charges for common area maintenance and other costs.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_8c610e5a-69e3-4dbb-91d0-cbfccda23506"
      id="F_04227f3e-33ce-48d5-b512-1e0da0f97d6b">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_8586e76c-fc2e-4bf4-8526-a7a4fa2675e4">there is no option to extend the lease</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7"
      id="F_eda2d732-2fe1-420d-9870-fbe8aef5ac14">In January 2025, the Company entered into a lease amendment to its headquarters location lease (the &#x201c;Headquarters Amendment&#x201d;), pursuant to which the Company will relocate to a new office space located in the same building. In May 2025, the Company took possession of the new office space upon substantial completion of the landlord&#x2019;s work. As of June 30, 2025, the remaining lease term of the new office space is 36 months. Monthly lease payments increased when the Company took possession of the new office space and will escalate through the lease term, resulting in an annualized payment of $0.6 million. The Company remains subject to additional charges for common area maintenance and other costs. The Company has one option to extend the lease for an additional term of three years, and the monthly payment amounts would be determined by the landlord at the then-prevailing rate.Upon entering into the Headquarters Amendment, the Company remeasured the right-of-use asset and lease liability pertaining to its current headquarters, and as a result recorded an additional $0.1 million to both its right-of-use asset and lease liability on its condensed consolidated balance sheet. Upon possession of the new office space, the Company recognized a right-of-use asset and lease liability of $1.6 million on its condensed consolidated balance sheet. As there was not an implicit rate within the lease amendment, a discount rate of 8% was determined using a set of peer companies&#x2019; incremental borrowing rates.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      id="F_21edd13f-7922-40c8-bf22-3992601da88f">P36M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="C_707e3c08-3d58-422c-9b32-bda32bcab502"
      decimals="-5"
      id="F_978a43a6-f1ad-45c0-a613-5143fb1083b7"
      unitRef="U_USD">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_03de0838-bdd7-4a51-8af0-ab4b061cd8d7"
      id="F_6d8ca5cd-7eea-4175-8728-faa9de5e18ce">The Company has one option to extend the lease for an additional term of three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_a17bc1f5-5be5-45a5-b3d5-0e7a29e42cf9"
      id="F_09da0a7a-9a68-4711-aeee-0d0181992013">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_dbca97a3-dc8a-458f-86e0-c938df8b9878"
      decimals="-5"
      id="F_2616c7a3-6fd0-4e63-9204-0a16a571c596"
      unitRef="U_USD">100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_74ebfc77-727d-4452-8e52-5aa0eb03239c"
      unitRef="U_USD">1600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="2"
      id="F_442dadf2-7215-483a-97a9-5e755b2d3a3f"
      unitRef="U_pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_7d4a2b5c-871a-4ab1-bcfc-954cff1b53bd">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes supplemental lease information (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.9030000000000005%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.344000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;______________&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs in each of the three and six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LeaseCost
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_573c2aa6-13f0-4f1a-8939-c73d9f07b67b"
      unitRef="U_USD">159000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_67fc17b5-e5e9-4378-89f0-c1f4092224ce"
      unitRef="U_USD">57000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_829ba460-d5bf-4cf4-9300-fef0db3c7aef"
      unitRef="U_USD">219000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_54605b14-acdd-4bd8-9641-0b8c0f16fc52"
      unitRef="U_USD">113000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_a0d05305-8e7d-470d-a4bb-743ae10b17e5"
      unitRef="U_USD">63000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_3e0c8d14-e581-4bb1-b83c-822199e170a4"
      unitRef="U_USD">61000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_b850523a-0395-4611-ab17-98ad57e08f1f"
      unitRef="U_USD">126000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_72b20bfc-cca8-49a8-b884-3480c865d6ae"
      unitRef="U_USD">122000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_8a5248bd-e58a-42b9-a1ef-3a26c594c354">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, future minimum non-cancelable operating lease payments are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (remaining six months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less lease liability, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_115553f5-9cc5-4c8f-8f41-71e71f52e5e6"
      unitRef="U_USD">310000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_a4a07e55-b6d7-4da8-8112-550e20fae76c"
      unitRef="U_USD">609000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_0932ad01-ce0d-40ba-a3fc-cf809915dd3a"
      unitRef="U_USD">627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_ff5afacd-28f0-479f-aae5-3aaef1d59809"
      unitRef="U_USD">318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_52951485-ffcf-4b65-8f96-6e2034297262"
      unitRef="U_USD">1864000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_b07a369c-8f33-4bf5-af77-6765712e03f7"
      unitRef="U_USD">203000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_05b1ad6c-dc26-475c-a558-35aa4c299fda"
      unitRef="U_USD">1661000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_14589b1d-196d-43d0-a067-065fdfc2a31e"
      unitRef="U_USD">589000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_01267790-0086-49e4-8e30-7f34a2e39918"
      unitRef="U_USD">1072000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_f4c5ea98-9800-40ac-b4d5-9bee7a532d04"
      unitRef="U_USD">57600000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_42be5ae7-f24d-4a59-b857-4153a5254ac2"
      unitRef="U_USD">900000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_f93810f6-9daf-46b4-b832-64ed529a5602"
      unitRef="U_USD">10500000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_15b90e97-8ca2-4e84-ba10-517922a1c77d"
      unitRef="U_USD">11800000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_ba034426-d802-4d84-9645-98511de93c66"
      unitRef="U_USD">13800000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <spry:UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour
      contextRef="C_bff2f443-6b3b-461a-ba19-428c01a04487"
      decimals="-5"
      id="F_63ef0387-f91e-490b-9afc-9951163179d0"
      unitRef="U_USD">2900000</spry:UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_88a3e244-24a0-4aeb-bc44-0d55744142b3"
      decimals="-5"
      id="F_1203bc50-dadd-43fa-91bf-e6376e6b1370"
      unitRef="U_USD">3000000</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_87fd2cd8-129a-414e-99c1-03cc3ad545e7"
      decimals="-5"
      id="F_8c007bd8-8667-482f-9624-72d02a7b3b39"
      unitRef="U_USD">7300000</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_4d7fc657-c0ab-4f3d-9b5c-9106d31bfc5a"
      decimals="-6"
      id="F_0c429187-531f-4a1a-aff6-a01475b981f5"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_dd3a8cfa-4023-4a91-9e13-79918b2abe74"
      decimals="-6"
      id="F_7e7c3cd9-2133-479c-9b92-49179a9e2de9"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <us-gaap:OtherCommitment
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-5"
      id="F_4e98e4f3-47f0-4a2a-962e-99b418daa2d7"
      unitRef="U_USD">26800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-6"
      id="F_794bfe7f-0e3f-4c1a-a606-9d37a338ea9d"
      unitRef="U_USD">0</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-5"
      id="F_2f8abfe0-7658-48dd-a824-484e33bfd6eb"
      unitRef="U_USD">4400000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-5"
      id="F_93e8aa86-9280-48f2-9600-7c177178779b"
      unitRef="U_USD">14200000</us-gaap:OtherCommitmentDueInThirdYear>
    <us-gaap:OtherCommitmentDueInFourthYear
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-5"
      id="F_5c24846b-141f-4b76-ad7b-23bab67e090c"
      unitRef="U_USD">4600000</us-gaap:OtherCommitmentDueInFourthYear>
    <us-gaap:OtherCommitmentDueInFifthYear
      contextRef="C_df32a54d-3ac5-44ae-877c-73959c6f6097"
      decimals="-5"
      id="F_0bca16c4-15be-4fa7-b7db-7b988be45369"
      unitRef="U_USD">3600000</us-gaap:OtherCommitmentDueInFifthYear>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_f342e672-771e-4d11-b09d-5aa31a2a64f1"
      decimals="-6"
      id="F_9e065a27-a71a-409a-b0d1-05524a2ad4f8"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_7b9bded7-8bb0-4033-b376-cee3038595c4"
      decimals="-6"
      id="F_97413cda-41d0-4885-afd4-5e60aaa229f6"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_2799d300-1237-43a9-b5b0-5d5699ea13d6"
      decimals="-6"
      id="F_8414434e-5b12-4808-8ebd-f9af719bde8c"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_98f4fdcb-e4e1-4865-9ef5-c4363da98d19"
      decimals="-6"
      id="F_d6d5c34f-dc53-454a-8734-de7b43fb3b64"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <us-gaap:OtherCommitment
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-5"
      id="F_c54689a2-5038-4590-9226-3d737a182b8f"
      unitRef="U_USD">10000000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths
      contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310"
      decimals="-5"
      id="F_05eb94de-de24-42d3-827e-1e695131daa4"
      unitRef="U_USD">4000000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear
      contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310"
      decimals="-5"
      id="F_be13f876-539f-4675-86a3-b5c524183265"
      unitRef="U_USD">5000000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear
      contextRef="C_24048e4a-2861-4e82-9a25-7bcab8c32310"
      decimals="-5"
      id="F_545cb3b1-7057-4b9f-b3dc-d45f9a7b7bd4"
      unitRef="U_USD">1000000</us-gaap:OtherCommitmentDueInThirdYear>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_7f5fc329-380e-42ec-8c1f-ae79663067f3"
      decimals="-6"
      id="F_2e37d979-7590-4f70-89e8-61ca9e28da1b"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_c2299308-80d9-4f3e-8124-02a70b3c491a"
      decimals="-5"
      id="F_32d384c0-5307-4ef9-b84c-dc37916cf0a2"
      unitRef="U_USD">2000000</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_10d6fbd1-42f4-43a6-a7b7-6fc8c0df13bb"
      decimals="-6"
      id="F_98eebff6-bd49-471c-9c52-61887bdb0f52"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_a9963800-3add-4281-aca5-d9f4f016ca70"
      decimals="-6"
      id="F_c810e3df-68f6-420e-8b66-abffe6ef9bc4"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95"
      decimals="-5"
      id="F_8644b45a-b3ff-4aa6-a816-a19152020336"
      unitRef="U_USD">2500000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
      contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95"
      decimals="-5"
      id="F_b1c553ee-6951-45aa-8522-e253c8ba3a52"
      unitRef="U_USD">600000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
      contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95"
      decimals="-5"
      id="F_d7994de6-86da-43da-aaf1-eaaabd37d308"
      unitRef="U_USD">1500000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
      contextRef="C_d905b4b3-9373-4262-8390-864c35ac6e95"
      decimals="-5"
      id="F_3ec5f2fc-68ed-4c8f-a0a1-4eaf987174a8"
      unitRef="U_USD">400000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_c2c7df1f-3bbc-45b1-969f-8aabc9c9acc2"
      decimals="-5"
      id="F_c1104608-51d9-405b-a315-fb75d4f6025b"
      unitRef="U_USD">500000</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_ceb11ad1-2588-4e17-af28-fe15173ba3d7"
      decimals="-5"
      id="F_a087a57f-e96f-4838-80df-bf7961af6523"
      unitRef="U_USD">800000</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_bfd38f7d-69e0-47b4-8cde-fe7dddca6c40"
      decimals="-6"
      id="F_59a26fdd-7a5a-4436-8676-c4b50e170dba"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:UnrecordedUnconditionalPurchaseObligationsPaid
      contextRef="C_1d5db0ae-f190-4d5e-9227-dbb3463af2c0"
      decimals="-6"
      id="F_cfcd9388-7e4f-4d15-a88e-c52cd5db0459"
      unitRef="U_USD">0</spry:UnrecordedUnconditionalPurchaseObligationsPaid>
    <spry:InLicensingandsupplyTextblock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_f9cbe5d1-51bd-4120-8692-ef649e7dc5fe">&lt;p id="fn_inlicense_supply" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. In-Licensing and Supply&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement with Aegis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2018, the Company entered into a License Agreement (the &#x201c;Aegis Agreement&#x201d;) with Aegis Therapeutics, LLC (&#x201c;Aegis&#x201d;), a wholly owned subsidiary of Neurelis, Inc. Under the Aegis Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable, rights to certain proprietary Aegis technology, patent rights and know-how to develop and commercialize epinephrine products. The Company utilizes this technology in its sole commercial product, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As consideration for the license, the Company paid an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which was recorded in research and development expenses in the condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to make aggregate milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of certain regulatory and commercial milestones. Regulatory milestone payments under the Aegis Agreement are recorded upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. Prior to the FDA approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in August 2024, regulatory milestone payments were recorded as research and development expenses in the condensed consolidated statement of operations. The Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment to Aegis upon the achievement of a regulatory milestone during 2019, and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment to Aegis upon the FDA&#x2019;s acceptance of the Company&#x2019;s new drug application submission for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which occurred in the third quarter of 2022. Since the approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in August 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;regulatory milestone payments have been capitalized as intangible assets in the accompanying condensed consolidated balance sheets. Amortization expense has been recorded to cost of goods sold, in the accompanying condensed consolidated statements of operations and comprehensive loss, on a straight-line basis over the estimated life of the intellectual property of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. In August 2024, a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone was met for achieving FDA approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone was met for the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As a result, the Company capitalized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as intangible assets in the accompanying condensed consolidated balance sheets in the third quarter of 2024. The Company paid the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone for achieving FDA approval of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in September 2024 and paid the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone for the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in October 2024. The next milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is due upon the achievement of certain annual net product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also pays royalties based on a mid-single-digit percentage of net product sales on its or its sublicensees&#x2019; net sales of the Licensed Products (as defined in the Aegis Agreement) on a product-by-product basis. Royalties are recorded to cost of goods sold in the period the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, OrbiMed Advisors LLC (&#x201c;OrbiMed&#x201d;) entered into an agreement with Aegis, to purchase the rights, royalty interests, and related sales milestone payments on net product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company will make all future payments under the Aegis Agreement to OrbiMed. As described in &lt;/span&gt;&lt;a href="#fn_relatedparties"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 14 &#x2013; Related Party Transactions&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a member of the Company&#x2019;s Board of Directors is a General Partner at OrbiMed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is responsible for reimbursing Aegis for patent costs incurred in connection with prosecuting and maintaining patent rights that are specific to epinephrine or epinephrine &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;products. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; expenses were recognized in connection with legal patent fees for each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may terminate the Aegis Agreement with 30 days writt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;en notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In conjunction with the Aegis Agreement, the Company also entered into a supply agreement (the &#x201c;Aegis Supply Agreement&#x201d;) with Aegis that allows the Company to purchase materials for preclinical, development and commercial use at predetermined prices. The Company may elect to have Aegis supply minimum quantities but there are no minimum or maximum purchase obligations under the Aegis Supply Agreement unless this election is made. The parties may terminate the Aegis Supply Agreement at any time by mutual agreement. In addition, the parties may terminate the Aegis Supply Agreement in the event of certain breaches of the Aegis Supply Agreement or upon the earlier of the expiration or termination of the Aegis Agreement or June 2028. The Aegis Supply Agreement term may be extended by mutual written agreement. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Aegis Supply Agreement, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; payments were made to Aegis in each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing Agreement with Renaissance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2020, the Company entered into a manufacturing agreement with Renaissance Lakewood, LLC (&#x201c;Renaissance&#x201d;), which was subsequently amended in July 2023, September 2024, and July 2025 (the &#x201c;Renaissance Agreement&#x201d;). Pursuant to the Renaissance Agreement, Renaissance agreed to manufacture for, and provide to the Company, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nasal unit dose sprays (&#x201c;Renaissance Products&#x201d;). The Company is obligated to provide Renaissance with certain supplies to manufacture the Renaissance Products and to purchase from Renaissance a mid-double-digit percentage of the Company&#x2019;s annual aggregate Renaissance Product requirements in the EU, and a high double-digit percentage of the Company&#x2019;s annual aggregate Renaissance Product requirements in the U.S. The Renaissance Agreement contains conventional commercial pharmaceutical manufacturing provisions including certain minimum purchase amounts to be determined in the future based on forecast needs and minimum batch size projections. The Company may also request Renaissance to perform certain services related to the Renaissance Product, for which the Company will pay reasonable compensation to Renaissance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the amendment in September 2024, the amended initial term of the Renaissance Agreement commenced on September 17, 2024, and will terminate (a) for Renaissance Product designated for commercial sale in the U.S., on December 31 immediately following the fifth anniversary of the initial U.S. launch date (&#x201c;U.S. Initial Term&#x201d;), and (b) for Renaissance Product designated for commercial sale in the EU, on December 31 immediately following the fifth anniversary of the initial EU launch date (&#x201c;EU Initial Term&#x201d;), in each case unless earlier terminated by one of the parties. The U.S. Initial Term and EU Initial Term automatically renew for successive two-year terms (&#x201c;Renewal Term&#x201d;). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Supply Agreement with Ompi&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company entered into a supply agreement (the &#x201c;Ompi Supply Agreement&#x201d;) with Nuova Ompi S.r.l. (&#x201c;Ompi&#x201d;), pursuant to which Ompi has agreed to supply glass microvials to support the Company&#x2019;s manufacture and commercialization of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under the Ompi Supply Agreement, the Company has committed to purchase, and Ompi has committed to supply, specified annual minimum quantities of glass microvials, which may be increased with prior notice by the Company or through the rolling forecast process, subject to a specified annual cap. Ompi is obligated to establish the relevant manufacturing force, assets and capabilities needed to comply with its supply obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, as partial consideration for the supply arrangement, the Company made an upfront payment of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in U.S. dollars) to Ompi. The supply price for the glass microvials is specified in the Ompi Supply Agreement, subject to an annual adjustment that is capped at a specified percentage except in the case of material and extraordinary increase in Ompi&#x2019;s cost of manufacturing the glass microvials.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Ompi Supply Agreement will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and may be terminated (i) upon the parties&#x2019; mutual written consent, (ii) by the Company for any reasonable business reasons (in which case the termination will become effective at the end of the following calendar year), or (iii) by the non-breaching party if the other party is in material breach of the Ompi Supply Agreement and fails to cure such breach within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after receipt of notice thereof from the non-breaching party.&lt;/span&gt;&lt;/p&gt;</spry:InLicensingandsupplyTextblock>
    <spry:UpfrontLicenseFees
      contextRef="C_c8ac2384-1b58-47dc-915d-83a7ba54ecc7"
      decimals="-3"
      id="F_6edf3f49-2022-49dc-97fa-630522240e53"
      unitRef="U_USD">50000000</spry:UpfrontLicenseFees>
    <spry:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      decimals="-5"
      id="F_aded3d4a-6c34-4181-9892-1271c617938a"
      unitRef="U_USD">20000000</spry:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones>
    <spry:RegulatoryMilestone
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      decimals="-5"
      id="F_7785afc9-7ee7-411d-9265-064761a7b15b"
      unitRef="U_USD">500000</spry:RegulatoryMilestone>
    <spry:RegulatoryMilestone
      contextRef="C_d93ac729-d7c9-434a-8a9b-7e60266ca1ba"
      decimals="-5"
      id="F_8dfcb68a-1080-4026-87e2-152ce92bffb1"
      unitRef="U_USD">1000000</spry:RegulatoryMilestone>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0e0c015a-4832-4ce2-aa6e-7f1681a3ba80"
      id="F_831b2cae-30fc-4d1d-8bda-47e178608b7e">P14Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <spry:CapitalizedMilestonePayments
      contextRef="C_c144dbed-7e0d-46fc-8627-5af0dc04de5b"
      decimals="-5"
      id="F_c59ff8f2-5308-4c8d-a39d-22eb95edf5b2"
      unitRef="U_USD">2500000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_e0a90922-dcd0-49c2-a9be-fb3989e9dc06"
      decimals="-5"
      id="F_96ff58b8-6cd0-4fd8-a214-2cb0606df432"
      unitRef="U_USD">5000000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_b4c93365-0858-428d-a34d-b5add11a9639"
      decimals="-5"
      id="F_5c221013-f6c0-4ec1-8cc8-b56fec1511f3"
      unitRef="U_USD">7500000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_298d2778-7e68-42a6-ac6a-7d397a9e29f5"
      decimals="-5"
      id="F_99e7e65d-f63b-4966-94ab-ab08caec73dc"
      unitRef="U_USD">2500000</spry:CapitalizedMilestonePayments>
    <spry:CapitalizedMilestonePayments
      contextRef="C_beeef49f-dee6-4fb9-a634-f1430f58cd42"
      decimals="-5"
      id="F_ad4b56a9-15fe-45fe-b6d9-14c824a52156"
      unitRef="U_USD">5000000</spry:CapitalizedMilestonePayments>
    <spry:MilestonePaymentDueOnAchievementOfAnnualSales
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      decimals="-5"
      id="F_da439673-46cc-4d27-85a2-623472373555"
      unitRef="U_USD">2000000</spry:MilestonePaymentDueOnAchievementOfAnnualSales>
    <spry:LegalPatentFees
      contextRef="C_2a05683e-e9ad-48bf-82d5-1bac47afff01"
      decimals="0"
      id="F_d54f6651-0780-414b-9502-3aa7ee8c46e3"
      unitRef="U_USD">0</spry:LegalPatentFees>
    <spry:LegalPatentFees
      contextRef="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6"
      decimals="0"
      id="F_76957d54-f231-4ed5-b093-cc6f88e88e74"
      unitRef="U_USD">0</spry:LegalPatentFees>
    <spry:LegalPatentFees
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      decimals="0"
      id="F_08a9f815-6b60-4df5-95a0-c4b67356e5e6"
      unitRef="U_USD">0</spry:LegalPatentFees>
    <spry:LegalPatentFees
      contextRef="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017"
      decimals="0"
      id="F_217b13c0-97fa-4705-ba8c-6dca98307fce"
      unitRef="U_USD">0</spry:LegalPatentFees>
    <spry:NoticePeriodDescription
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      id="F_f8952ce7-a310-4432-9f10-9ea9c13f5539">The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.</spry:NoticePeriodDescription>
    <spry:SupplyAgreementExpense
      contextRef="C_2a05683e-e9ad-48bf-82d5-1bac47afff01"
      decimals="0"
      id="F_fd846bc2-85de-45e3-8ac0-c75c80b3e734"
      unitRef="U_USD">0</spry:SupplyAgreementExpense>
    <spry:SupplyAgreementExpense
      contextRef="C_ce3ac21a-b014-41f9-b634-31c37ad51fc6"
      decimals="0"
      id="F_7401ec6f-6322-4da0-abc7-062da80fdaab"
      unitRef="U_USD">0</spry:SupplyAgreementExpense>
    <spry:SupplyAgreementExpense
      contextRef="C_a2cae88d-596b-47ea-be90-36c21e8fc71b"
      decimals="0"
      id="F_0429bba1-99de-4f43-bfac-3bd6a4ab39bb"
      unitRef="U_USD">0</spry:SupplyAgreementExpense>
    <spry:SupplyAgreementExpense
      contextRef="C_7bb3f5ae-afb2-44ac-84a0-36de9d4bb017"
      decimals="0"
      id="F_e2558d86-dde6-4325-9057-67b2cc33fbcb"
      unitRef="U_USD">0</spry:SupplyAgreementExpense>
    <us-gaap:ContractTerminationClaimsDescription
      contextRef="C_faf7e39c-0f29-434d-b6fb-e1d303cebf23"
      id="F_b49ba2ee-c94d-455a-a1a2-2ac9ebed6aeb">Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.</us-gaap:ContractTerminationClaimsDescription>
    <spry:UpfrontPayment
      contextRef="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991"
      decimals="-5"
      id="F_1de15d30-f6f9-480f-94ea-1cfc9622a762"
      unitRef="U_EUR">3000000</spry:UpfrontPayment>
    <spry:UpfrontPayment
      contextRef="C_d8c71eb6-d9a2-462a-9cd5-a2de07335991"
      decimals="-5"
      id="F_d20b3490-d19f-469a-8176-7479a1d5ecac"
      unitRef="U_USD">3200000</spry:UpfrontPayment>
    <spry:SupplyAgreementExpirationDate
      contextRef="C_7dfae0a7-c976-445c-9186-28e526f9917d"
      id="F_87acdcba-f595-4a9a-8abd-2edb48a8ee37">2035-12-31</spry:SupplyAgreementExpirationDate>
    <spry:AgreementTerminationDueToMaterialBreach
      contextRef="C_7dfae0a7-c976-445c-9186-28e526f9917d"
      id="F_482a296b-ae25-497d-abc5-f8298073c5a5">P90D</spry:AgreementTerminationDueToMaterialBreach>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e77a85a8-8fcb-4b9c-a7a9-98208d8c48c6">&lt;p id="fn_equity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Common Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Authorized Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s current Amended and Restated Certificate of Incorporation authorizes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,161,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future awards or option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,062,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,905,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future employee stock purchase plan issuances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,811,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,223,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,192,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,338,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2025, the Company filed an automatic shelf registration statement on Form S-3ASR with the Securities and Exchange Commission which became effective upon filing (the &#x201c;Shelf Registration Statement&#x201d;). The Shelf Registration Statement allows the Company, from time to time, to offer and sell any combination of shares of the Company&#x2019;s common stock and preferred stock, various series of debt securities, and/or warrants to purchase any of such securities, either individually or in combination with other securities, in one or more offerings. The Company simultaneously entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SM &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sales agreement (the &#x201c;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales Agreement&#x201d;) wit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;h Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) to allow the Company to offer, sell and issue shares of the Company&#x2019;s common stock from time to time through Cantor acting as sales agent and up to a maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities have been sold pursuant to the Shelf Registration Statement or Equity Sales Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_ce13f3ac-8001-40f5-a502-ece21c33698d"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_f684d17c-7278-48cf-8237-dd2cccd0676c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_5bb61955-e2eb-4256-b947-18de1d868539"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_345903e8-b6c8-40b5-bc8c-664e8aba9a1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_976d4521-fd28-49af-8293-a363b3f1207b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,161,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future awards or option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,062,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,905,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future employee stock purchase plan issuances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,811,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,223,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,192,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,338,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</spry:ScheduleOfCommonStockReservedForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_952043ab-5fba-4c7d-bfff-86d859fc075f"
      decimals="INF"
      id="F_8f1df26b-5f3e-4745-a991-31293eaf7493"
      unitRef="U_shares">17271990</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7d548bc4-9a01-48d0-9705-9105c2226181"
      decimals="INF"
      id="F_fe569e2d-1cc8-41c1-8031-75716592a7c6"
      unitRef="U_shares">15161180</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3c6b92a6-dd38-411f-8214-dba5099c8f52"
      decimals="INF"
      id="F_216f5a82-951e-4d57-bc8a-f77fadbfe330"
      unitRef="U_shares">1382</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bdb38646-dad4-46e9-bb80-804ebaf2c503"
      decimals="INF"
      id="F_9df5731b-ff9a-4b1f-9cc4-7865576f4695"
      unitRef="U_shares">2763</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c12a3d9a-b30c-47d9-bb6d-6f0ae9453472"
      decimals="INF"
      id="F_50611d8e-7fcf-47a1-8612-c9b13336ff78"
      unitRef="U_shares">8062484</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_91a268b1-3615-40a5-ae0c-938276bfc07f"
      decimals="INF"
      id="F_77855711-4d05-4406-b06d-d1c605e69f08"
      unitRef="U_shares">5905773</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_df005c86-508d-44b0-ae4f-f72b61e895e8"
      decimals="INF"
      id="F_738491d3-ba6c-4c94-86e5-17f1cce8a140"
      unitRef="U_shares">2811182</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4d5e4244-5624-4eb9-83c5-28bcd9c0f0f1"
      decimals="INF"
      id="F_9684cd83-bbe3-4499-be46-7906cc64f998"
      unitRef="U_shares">2223100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ad92b4a7-9dd4-43d7-8f4e-0ecdae3b7b74"
      decimals="INF"
      id="F_fb4b293d-3c95-4ebb-b919-ac88699d80df"
      unitRef="U_shares">45456</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3a9f4cd4-fb54-4828-96ba-ce70b60363d6"
      decimals="INF"
      id="F_b251656b-3b59-4744-a892-7bf0a0d92190"
      unitRef="U_shares">45456</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="INF"
      id="F_e3ec372f-503d-4ff2-b321-b0fc69f17b82"
      unitRef="U_shares">28192494</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="INF"
      id="F_4e519692-a8a8-41d9-b816-de4263ae81cd"
      unitRef="U_shares">23338272</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_6f2fdca3-8c4d-435f-b8c0-6a77fe46d870"
      decimals="-5"
      id="F_f1c026c1-839a-4ef5-b39b-4232fb2a83cd"
      unitRef="U_USD">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_2241ca04-d0e3-4458-81a0-72b7a112643d"
      decimals="INF"
      id="F_855a93ec-e60d-4819-a71b-dcad86057b31"
      unitRef="U_shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c4204177-b4e2-49ae-945b-7c7efca0ab19">&lt;p id="fn_sbc" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three and six months ended June 30, 2025, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on of stock compensation expense was capitalized into inventory, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock-based compensation expense was capitalized into inventory during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, the total unrecognized stock-based compensation expense related to outstanding employee options was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a remaining weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,382&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; restricted stock units outstanding, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverba&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ck&#x2019;s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,918&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,679&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;25,737,116&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were authorized under the 2016 and 2020 Equity Incentive Plans, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;7,765,139&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future grant, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,033,358&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were outstanding. As of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,634,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were authorized under the 2018 Equity Incentive Plan, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;297,345&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future grant, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,240,014&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were outstanding. The Company does not intend to grant future stock options or other equity awards under the 2016 or 2018 Equity Incentive Plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the Company&#x2019;s equity incentive plans expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the date of grant and generally vest over a four-year period, with vesting either occurring at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% at the end of the first year and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to the Company&#x2019;s non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Subject to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,161,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,158,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;630,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;417,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,540,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The exercisable shares subject to options outstanding at June 30, 2025 in the table above include vested and early exercisable awards. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#x2019;s common stock for all options that were in-the-money at June 30, 2025. The aggregate intrinsic value of options exercised during the six months ended June 30, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of option grants for the six months ended June 30, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The total fair value of shares vested during the six months ended June 30, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options granted was estimated using a Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) with&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The fair value of stock options was determined using the Black-Scholes assumptions below. Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The fair market value of the Company&#x2019;s common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Given the Company&#x2019;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free Interest Rate. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Dividend Yield.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_16495948-839f-46d2-b66d-7fa61f842761">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_59f4bf3a-7f8e-4ad6-a506-194c1950572a"
      decimals="-3"
      id="F_adcb83f2-e1e2-4c62-81c5-8a54b29f8e7f"
      unitRef="U_USD">664000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_31e9248e-ea58-43c7-baab-8f7cb2a5c62d"
      decimals="-3"
      id="F_d7ae8d92-49fe-4abe-988c-6e8f3a3e904b"
      unitRef="U_USD">913000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_150214a2-c270-468d-9a06-7728c1a7db0d"
      decimals="-3"
      id="F_236db389-4dba-427b-8a21-a97d38d4c313"
      unitRef="U_USD">1327000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b92085ed-7b67-4267-a76c-73095df42f5b"
      decimals="-3"
      id="F_25215e1e-6707-4370-912a-1a6d5df5535d"
      unitRef="U_USD">1824000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_05f55f90-a226-4553-acf7-98941d6f746b"
      decimals="-3"
      id="F_708e384a-3367-44e7-921c-1aed963af213"
      unitRef="U_USD">4707000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b04c992f-7141-450b-a7c4-9f61a9eb497b"
      decimals="-3"
      id="F_ea8e3c66-0a11-4909-8606-43cac381afa5"
      unitRef="U_USD">2452000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ddc169de-f0a1-4298-8916-2c62ad23e107"
      decimals="-3"
      id="F_bf39a3f6-2a3d-4f1b-8764-f182e06b7072"
      unitRef="U_USD">9342000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6f03d69b-1284-4bc4-8234-9a7df3551bf6"
      decimals="-3"
      id="F_b85095a2-7d60-4fe9-8450-3a45bbe84303"
      unitRef="U_USD">4856000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_75619626-30d3-47c2-9ee0-d51a7e3a24e8"
      unitRef="U_USD">5371000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_f0a7a6e9-22e9-484e-8b13-a2b44002fe02"
      unitRef="U_USD">3365000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_5e86ddd3-ea6e-47cc-9c40-12896f55928f"
      unitRef="U_USD">10669000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_b4783232-9501-4246-b495-3df7525dbed5"
      unitRef="U_USD">6680000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-5"
      id="F_6fe07844-3b64-4ecb-a095-d31264bd87af"
      unitRef="U_USD">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_6283136f-edf0-4b21-9472-3f9b46cd0a15"
      unitRef="U_USD">500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="0"
      id="F_a8c25b28-5f51-4d23-895c-0c5b48218258"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="0"
      id="F_9ca0ff0d-bf8e-4842-9c42-6f24d261efb7"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-5"
      id="F_ce26cab0-ef12-4dae-b77c-6cdb91a70eec"
      unitRef="U_USD">53900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_b09c37bf-d560-45bd-a349-9f99e01b9d5c">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_021eefc7-cfee-4d52-8b2d-03167d9c4f45"
      decimals="0"
      id="F_bbfeeb73-93d7-40b1-bd5b-a643b28921f0"
      unitRef="U_shares">1382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_081fe4fa-2c69-4289-b02a-3b63500a1252"
      decimals="0"
      id="F_7b461ce6-f7dd-4368-8dba-f73d1ffe1e9d"
      unitRef="U_shares">2763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_65ed12ba-e864-459f-ae4c-a7e1d4cf3b23"
      id="F_2f6aea47-b498-42ff-b95b-15b81a3fe2a7">In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverback&#x2019;s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). There were 111,918 shares and 43,679 shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024, respectively.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_8c487881-ba76-4097-b6c8-427e2b451999"
      decimals="INF"
      id="F_db2dfb74-02e4-42b7-a991-a1aa6125ff38"
      unitRef="U_shares">111918</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_8337c8b0-3081-4566-b477-4a0f04a2f5aa"
      decimals="INF"
      id="F_db1ddc84-8cc0-4bd8-b93e-aeff6ca47dd5"
      unitRef="U_shares">43679</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0d090888-c874-48f6-b153-a3c2f3e3fe8a"
      decimals="INF"
      id="F_19f40a36-f8b2-4942-90f1-4acccd52e4b1"
      unitRef="U_shares">25737116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9fd25023-3042-461b-9a6d-57b976f28f60"
      decimals="INF"
      id="F_13f38460-33e9-4ad1-9a8d-a09e84489536"
      unitRef="U_shares">7765139</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9fd25023-3042-461b-9a6d-57b976f28f60"
      decimals="INF"
      id="F_99d6f5d5-a0a1-423b-b31d-e4b87ea017bf"
      unitRef="U_shares">13033358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_7ec42259-6316-479d-8953-352d08d61678"
      decimals="INF"
      id="F_5e1672a2-b858-4ed3-9b01-167b607d09b6"
      unitRef="U_shares">6634333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109"
      decimals="INF"
      id="F_01732960-7574-4458-b6d9-04997ac326fe"
      unitRef="U_shares">297345</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c9a15e9c-7ce4-4a3f-9f69-c69b2f5c3109"
      decimals="INF"
      id="F_8fcb7fe8-716a-48cd-8bf2-ef51f400e798"
      unitRef="U_shares">4240014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_1c26e16c-77d1-4bf9-8603-54949aa517a2">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_e905fe69-c3a0-41ef-a0a3-80d67c3b6d6b"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_9ab653d3-86c5-4d6d-a553-9c186aacb11a">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Subject to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,161,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,158,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;630,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;417,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,271,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,540,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="0"
      id="F_3d7a00e2-1741-466f-bb34-89f66d988ce7"
      unitRef="U_shares">15161180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_18b0f553-9076-4f15-9748-2023f42761a7"
      decimals="2"
      id="F_e55efcdd-545c-450e-91e0-a7996c683caf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_10644691-54ea-4654-b3d9-f38bfbc2f9c8"
      unitRef="U_shares">3158150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_341d4803-6597-4e62-8b5e-29feb1f9c4af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_c0825b49-dc9e-4313-ad50-ec95523b3c62"
      unitRef="U_shares">630187</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_7fc93b38-28b0-42c1-a9f5-2028d07e6f34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="0"
      id="F_85f6c4a3-aa13-4251-94ba-ffe7ac37d626"
      unitRef="U_shares">417153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <spry:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_4fbd9d3c-6096-41f2-8f3e-c45599ccc044"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.23</spry:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="0"
      id="F_d37625cd-9a61-45aa-aa7b-76876618ae92"
      unitRef="U_shares">17271990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="2"
      id="F_f2aa0678-67b9-4b88-8aa2-f9f665c3d709"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_d5341043-c0b4-4330-bb8b-be49d4da0617">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_4f42548e-20de-483b-b37f-2a0b45a48efe"
      unitRef="U_USD">174541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="0"
      id="F_c863744d-ecc7-4ae9-b29c-2b5f88a4784e"
      unitRef="U_shares">9540712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="2"
      id="F_e7bf0d38-962e-42c8-b76a-c847b56e14fe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_f408892f-c581-4315-af02-e9b4c5045563">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_eda30636-7284-432d-8ca2-1f8a4dc398d4"
      decimals="-3"
      id="F_c5dda70c-b835-44b4-8d81-ffd584d44569"
      unitRef="U_USD">114815000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_64feec86-edff-427e-ab41-a67868f63e00"
      unitRef="U_USD">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-5"
      id="F_d629feb4-ba6c-4200-946e-dd16a1705e84"
      unitRef="U_USD">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_643a242a-c65b-4511-bb61-a4fe25d74692"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="2"
      id="F_e2ae5e9a-ccb6-418a-8065-808a72249966"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_49e97d89-03c8-402b-bbda-3b91b62707c0"
      unitRef="U_USD">12200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-5"
      id="F_e9781d35-d6c5-402c-ab7b-84131e203401"
      unitRef="U_USD">9900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_3f070790-3737-4614-8d40-ce912517731b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options granted was estimated using a Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) with&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_fdb99798-fee1-4d27-becc-24f247a5ba0f">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      id="F_c92eee71-6e06-4543-b845-906531f1de42">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="3"
      id="F_fe8abb5c-dc11-42f1-93b6-ee5309a4f3f3"
      unitRef="U_pure">0.867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="3"
      id="F_b62c7884-d79e-4297-9072-356ee8564738"
      unitRef="U_pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="3"
      id="F_44982bdb-1f28-4d95-8f8d-f6d008127dad"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="3"
      id="F_4ada4fed-40eb-4e94-ab96-1d6ce3bd0110"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="2"
      id="F_a47bf71e-2973-480b-bfe8-00a76264b243"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="2"
      id="F_fd763901-abd4-466e-83a9-ab962b27d822"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_71c6dae0-2a7e-48b9-8457-08bd5a3976dc">&lt;p id="fn_ebp" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Employee Benefit Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2022, the Company adopted a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#x2019;s U.S. employees. The plan allows eligible employees to defer, at the employee&#x2019;s discretion, pretax compensation up to the Internal Revenue Service (the &#x201c;IRS&#x201d;) annual limits. The Company matches up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of an employee&#x2019;s pay that they contribute to the plan, subject to IRS limitations. Expenses associated with the Company&#x2019;s matching contribution totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the three and six months ended June 30, 2025, respectively. Expenses associated with the Company&#x2019;s matching contribution totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the three and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_1ef13204-b17d-483a-99d0-289ce05e08db"
      decimals="2"
      id="F_487e4808-d8cb-499a-871a-c2480b6a7386"
      unitRef="U_pure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-5"
      id="F_50e031ab-ad8d-4c82-be2c-ae3e617e344b"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-5"
      id="F_ebb02820-077a-4a45-9d66-adef8dbe606d"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-5"
      id="F_0af3b6be-935a-42d3-8303-4255717f6c00"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-5"
      id="F_e4c21873-538c-452f-bdc8-cfc929f907c7"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c2d5cecf-c4dc-44d8-b77b-46904410f5fd">&lt;p id="fn_relatedparties" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Related-Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2015, the Company entered into a consulting agreement, superseded in July 2022, for regulatory and development services with Pacific-Link Regulatory Consulting, Inc., an entity owned by the President/Chief Executive Officer/director and his spouse, the Chief Medical Officer of the Company. The Company incurred consulting expenses related to this agreement totaling &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the three and six months ended June 30, 2025, respectively, and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the three and six months ended June 30, 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2018, the Company entered into a consulting agreement with Marlinspike Group, LLC (&#x201c;Marlinspike Group&#x201d;) to provide management, business consulting services and business development support. The managing member of Marlinspike Group is the Chair of the Board of Directors of the Company and one of its stockholders. The Company incurred expenses related to this agreement of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2021, the Company entered into a consulting agreement, as amended in April 2022, with a member of the Board of Directors of the Company for general advice and assistance with the development of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and any future product candidates. As compensation for the consulting services the Company granted the member of the Board of Directors &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;590,950&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock options that vest over a four-ye&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ar period. The Company incurred less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in stock-based compensation expense related to this agreement in each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in &lt;/span&gt;&lt;a href="#fn_inlicense_supply"&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10 &#x2013; In-Licensing and Supply&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company is required to make milestone payments to Aegis upon achievement of certain regulatory and commercial milestones, and royalty payments to Aegis based on net product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In November 2024, OrbiMed entered into an agreement with Aegis to purchase the rights, royalty interests, and related sales milestone payments on net product sales of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;neffy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. A member of the Company&#x2019;s Board of Directors is a General Partner at OrbiMed. The Company incurred &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in royalty expense payable to OrbiMed during the three and six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_f1c8cad0-d5f3-4e51-9804-2b151cd3b1f2"
      decimals="-5"
      id="F_4a9a620b-cad2-4ee4-9469-673fb9cefab9"
      unitRef="U_USD">600000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_286db13c-dcd3-4bda-8947-71e23b80ce46"
      decimals="-5"
      id="F_5832a40f-b3a8-4ccd-8e46-c1979ef61d78"
      unitRef="U_USD">1300000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_d088454f-4075-431f-b4bb-11f7b482ba95"
      decimals="-5"
      id="F_13fc4b5d-3ebb-4736-97c9-b376493b69c0"
      unitRef="U_USD">500000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_ddff9d59-8efa-4f5b-b496-c704a0bada3e"
      decimals="-5"
      id="F_3a18db0f-4bb9-45f5-b342-8158e44f3369"
      unitRef="U_USD">1300000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_2c9e3e1d-19ca-41b7-84e3-5196425f10d7"
      decimals="-5"
      id="F_346343d7-a501-44e1-a5bc-ab6e9fc2be19"
      unitRef="U_USD">100000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_db43d886-40d2-497e-a347-d9adf0486580"
      decimals="-5"
      id="F_a9f1d7ed-53aa-4f8c-8846-280312913bb1"
      unitRef="U_USD">100000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_1ffef034-5c87-41ce-88e2-2b53d4ffa344"
      decimals="-5"
      id="F_d820ca1f-853a-408c-8cd3-8672cea31103"
      unitRef="U_USD">100000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_758fe697-6dbc-4923-9ddf-258ba4a7c8ea"
      decimals="-5"
      id="F_f694f81d-8de7-44d8-b481-144c0fd7c89e"
      unitRef="U_USD">100000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_50bfc96e-86b2-4bfa-93e5-4dd89fe4840d"
      decimals="INF"
      id="F_d435f204-f9c1-49c7-bc9c-34d29f7c50ff"
      unitRef="U_shares">590950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4883e707-b9b1-4461-b2de-ffc404f7e7bd"
      decimals="-5"
      id="F_39fe83fe-adb0-49ae-90f8-46cfe7b540de"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2e65281f-ba53-4d3f-a689-1260aaaf239d"
      decimals="-5"
      id="F_13b9d2e6-dafd-4316-afe6-0a2d0691d0ea"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b2af9dda-1f32-4532-acbd-bda315dd18f0"
      decimals="-5"
      id="F_d650a30b-6751-4af1-9182-f0ade5cc6098"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d036733-4b5d-4177-a142-b4f41043ac6a"
      decimals="-5"
      id="F_81162a53-d20f-431c-8b9d-e1ce92def27b"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_ba7df335-5578-421e-8c2a-d36e33edcb60"
      decimals="-5"
      id="F_0a79e279-1fba-45c0-932d-86b7840d5d11"
      unitRef="U_USD">900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_a3dc6a53-1c90-4d3f-b90b-fea8237b5cd5"
      decimals="-5"
      id="F_ea785081-d9c2-4bd9-aa52-74715c45553f"
      unitRef="U_USD">1400000</us-gaap:RoyaltyExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_14970636-4061-4c31-9288-f4b79dac5128">&lt;p id="fn_segments" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reports segment information using the management approach and views its operations and manages its business as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_626c3f50-1884-4203-bf7b-50eea6c01f4f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;), who is the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_84bd9e86-c4c0-4576-8d3c-cc8e99b6414a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, allocates resources and evaluates the performance of the operating segment based on historical and projected product sales, segment operating expenses, and condensed consolidated net loss, as reflected in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;accompanying condensed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consolidated statements of operations and comprehensive loss, which is the segment measure of loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The segment reports that are provided to the CODM are tracked against the Company&#x2019;s internally budgeted expenses. The segment operating expense categories consist primarily of the Company&#x2019;s functional departments: Clinical, Development, Medical Affairs, Sales and Marketing, and General and Administrative. The CODM does not review assets when evaluating the operating segment&#x2019;s performance; therefore, this information is not presented.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment reporting for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue under collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue under supply agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Medical affairs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total segment operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_909281c7-ede0-4bba-b36a-471c7ddb5563">The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;), who is the Chief Executive Officer, allocates resources and evaluates the performance of the operating segment based on historical and projected product sales, segment operating expenses, and condensed consolidated net loss, as reflected in the accompanying condensed consolidated statements of operations and comprehensive loss, which is the segment measure of loss.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_e0014c33-75d5-4b1b-8417-36bbcea6dfc8">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment reporting for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue under collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue under supply agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Medical affairs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total segment operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_783dccc0-475e-4692-b8a3-08a49e9999dd"
      decimals="-3"
      id="F_e183f9f8-4cf9-45bf-b1b7-be8bff3f98f9"
      unitRef="U_USD">12800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_828dc3d1-fee8-4736-9111-5a0102de64e0"
      decimals="-3"
      id="F_8e166274-2a49-495c-8bc5-052e999de2a5"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5285bbba-cbf6-4e81-ac67-5853e6f856ce"
      decimals="-3"
      id="F_f94f9190-6f88-4d53-9acb-149b2afcf6b0"
      unitRef="U_USD">20563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ec2f7f48-8de4-407b-81b7-b503b3fa84f1"
      decimals="-3"
      id="F_696fdf12-7e71-4560-8ae6-6e7d56c78811"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_21fe8e44-bec9-4153-ad91-5b5867687e88"
      decimals="-3"
      id="F_7ce21211-7c59-4dbb-9aa1-4e5ee054fa61"
      unitRef="U_USD">2594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4fc6cb5f-4180-41ac-b434-d6945583ee10"
      decimals="-3"
      id="F_6d51b5c6-b483-491a-b0e6-beedb06f5188"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2ee7d3c5-7e49-4641-8059-57fd8f16f9e9"
      decimals="-3"
      id="F_dcf22dfa-f11c-4542-915e-eb1e89ae873b"
      unitRef="U_USD">2804000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ce1a93d8-6354-407d-a58c-a0ceb324b08a"
      decimals="-3"
      id="F_7b8d9579-3980-4857-a5b8-bd939cfca472"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8855f418-1ce9-40e1-ba74-585019621581"
      decimals="-3"
      id="F_c5411d89-235e-4dcf-ab6c-f3eea401a1ef"
      unitRef="U_USD">323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3b5e182e-82a4-424c-ae80-f76d2cad3d74"
      decimals="-3"
      id="F_7adb092a-c6c3-4a5e-90ba-04c032ceddd7"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b0f481-c291-42bf-a1fd-628b8759542f"
      decimals="-3"
      id="F_1db5deb2-d8a9-43f4-ac67-ca50e1b32e6c"
      unitRef="U_USD">323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_aa1a5b03-e654-4a0e-be06-1a5a2f0dcc93"
      decimals="-3"
      id="F_e27f1ca6-9c9e-471c-b747-526c64af946c"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_11d8ba90-a450-4057-bedd-99391fad1738"
      unitRef="U_USD">15717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_c318ac1d-cfbd-44e4-b6cc-4157ad17ff47"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_6524c2ab-f461-448e-9fd8-8265179dc50e"
      unitRef="U_USD">23690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_8d8add8f-1c4e-4953-a606-57bf56feefa9"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <spry:SegmentOperatingExpenses
      contextRef="C_bb2d95de-4594-438d-9c55-a3a55b7278da"
      decimals="-3"
      id="F_c2b1b8fd-3d79-45bd-b7ae-1d8e1b535d8f"
      unitRef="U_USD">4984000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_95f04ac1-14ef-4698-b351-83ecaff48cdb"
      decimals="-3"
      id="F_204095b2-9150-406e-89f5-35ba339eed98"
      unitRef="U_USD">0</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_86b564d1-cec7-431b-b172-b26077a97bfe"
      decimals="-3"
      id="F_b9cb926f-1131-4c03-b67c-5cb09d51c324"
      unitRef="U_USD">6078000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_f9587472-b812-4c26-9f12-b181d477afd4"
      decimals="-3"
      id="F_d7df24e8-d5aa-479f-8d8d-55dfde2faae8"
      unitRef="U_USD">0</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_4029b4bb-de28-4de7-8408-45df90688cf8"
      decimals="-3"
      id="F_2e00e262-faca-4f0a-bf72-8000d655302f"
      unitRef="U_USD">1250000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_6ccd2d37-27d6-4e02-9364-bcfbddaf6936"
      decimals="-3"
      id="F_d903610f-6bfe-4a1f-9fbb-c743408cd6ef"
      unitRef="U_USD">1226000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_e154ceb7-5441-4be7-956a-04c0dc49d336"
      decimals="-3"
      id="F_11847366-3b53-4464-8e20-e739d1f4784a"
      unitRef="U_USD">2454000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_681b9e90-c822-4025-8193-e866cdf0d681"
      decimals="-3"
      id="F_0d7475aa-7b35-49db-9ff5-1b22d53562b3"
      unitRef="U_USD">4042000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_fd906f79-8562-4a95-bd43-4d251d2344c8"
      decimals="-3"
      id="F_3cd7c537-d4ab-4c38-ac6e-15295426e7f3"
      unitRef="U_USD">2151000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_a668bc1e-23db-4ea8-85ec-8d8056d6f34d"
      decimals="-3"
      id="F_dc496ca4-efbc-4e6a-b38a-6e102f21ec0d"
      unitRef="U_USD">2591000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_99e7eb22-c9bf-4bcf-8348-7f1f227a5e4c"
      decimals="-3"
      id="F_889b85dc-249b-4afb-97e1-8754e33f5992"
      unitRef="U_USD">3252000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_f1fd271e-7bfe-45dd-855c-01e649527ae5"
      decimals="-3"
      id="F_fbf26e1e-ffc1-4623-b8ad-442703c08d2d"
      unitRef="U_USD">4099000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_3b7fe764-d042-4e16-bcf8-711a85614de6"
      decimals="-3"
      id="F_5bca549a-d054-469f-873e-e7999698fce7"
      unitRef="U_USD">1073000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_6770ee9a-57e6-4eef-bbaf-3da967bec8b1"
      decimals="-3"
      id="F_5d061cdd-73ea-476a-af10-9cbf77dbbacf"
      unitRef="U_USD">421000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_7efb2cf9-3f33-4407-a356-10f47479dfdb"
      decimals="-3"
      id="F_dbf89ae6-346f-4a2f-8dea-040cd896d135"
      unitRef="U_USD">2018000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_18b0fdd1-a485-4c6b-9072-308bd98cfbbe"
      decimals="-3"
      id="F_c220a0e6-7515-4848-be62-fee8827f3074"
      unitRef="U_USD">754000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_51f70a11-69b0-4dbd-9cc6-efbfee56c21f"
      decimals="-3"
      id="F_8e5acf1f-ed38-46de-b4ff-2ba50c03e4cf"
      unitRef="U_USD">40925000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_b79419a0-d171-46d7-996c-18c142afc6c1"
      decimals="-3"
      id="F_dc036b93-ce08-4181-93a9-5906eb7516a5"
      unitRef="U_USD">2694000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_53ececee-4b8b-4df1-8752-18134066f9be"
      decimals="-3"
      id="F_4d3f8ad6-2328-45a3-9848-3558f99383ac"
      unitRef="U_USD">67682000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_7763ab6b-709b-4a5c-8ecc-4d9c9531a9e9"
      decimals="-3"
      id="F_86e43333-3378-45a7-af13-1d66312f8fc2"
      unitRef="U_USD">4145000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_5c7ce1c8-b99f-46f8-92aa-5a9614bb368d"
      decimals="-3"
      id="F_213777b4-4c1e-4ca0-bb2a-8fca5239344c"
      unitRef="U_USD">7118000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_38ebd40d-47cc-434d-adce-a43b467c8b30"
      decimals="-3"
      id="F_89f98c42-f1bf-4205-9687-2a3d66266b53"
      unitRef="U_USD">5505000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_0d03ed93-9080-4cf9-9b33-e460f48b48e1"
      decimals="-3"
      id="F_3f37908b-fdc1-44c3-96f5-f3bc4e82e7aa"
      unitRef="U_USD">15837000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_f5b73dfd-e33e-4e24-ab07-812aebbe06f1"
      decimals="-3"
      id="F_db8acede-c8f5-41ad-8f72-dd72b44d7e1c"
      unitRef="U_USD">9195000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_8a13184c-6bcb-4906-a160-a36e0d4656ae"
      decimals="-3"
      id="F_77004250-c7db-4e90-9ea5-bd740ad8e83a"
      unitRef="U_USD">5371000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_1f628d09-1530-45b7-881c-0af4b02a1014"
      decimals="-3"
      id="F_4d3ecbd1-3618-405d-ad90-cc3a5a629364"
      unitRef="U_USD">3365000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_295e6502-8b12-4686-a1ab-212436254537"
      decimals="-3"
      id="F_1c58b982-3968-4bbb-bc01-5f6433ef8b1d"
      unitRef="U_USD">10669000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_dcc2baa6-8c87-4f57-a3dc-79e85b7ce8e5"
      decimals="-3"
      id="F_c5a15d02-4546-40ca-adbf-8a71920be95d"
      unitRef="U_USD">6680000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_955465f7-5718-4609-97eb-6c7ac882fbc5"
      decimals="-3"
      id="F_9d530643-fb81-489b-8ace-a607680de573"
      unitRef="U_USD">459000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_f02958dd-2171-4f6b-bf03-9a0ffab81bfe"
      decimals="-3"
      id="F_7ac2eb8e-3ae5-47ff-91e0-6553d18e70ce"
      unitRef="U_USD">38000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_e0fe3c7b-f600-4c9b-b811-bf543aef3ed8"
      decimals="-3"
      id="F_783ae627-7304-49ec-b2e0-2a28e81639cd"
      unitRef="U_USD">491000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_450d35f9-0df1-4549-a5f8-a9c9ea015932"
      decimals="-3"
      id="F_57094773-6143-40f6-9604-0f18f00464f2"
      unitRef="U_USD">117000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_320b958e-f0dc-40ee-acf5-1e5a31ecea24"
      unitRef="U_USD">63331000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_8df8a0e2-a13e-451c-abc3-9c1efdaeb83d"
      unitRef="U_USD">15840000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_d7b6e4bf-8b01-420b-9f6c-86dd841214ed"
      unitRef="U_USD">108481000</spry:SegmentOperatingExpenses>
    <spry:SegmentOperatingExpenses
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_6a536844-0ba5-46a2-824b-2d01f995032c"
      unitRef="U_USD">29032000</spry:SegmentOperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_f257f533-f6f9-4607-9f3a-4d29ace2a04e"
      unitRef="U_USD">-47614000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_34705c22-253d-4134-9fad-769a16b3e7c2"
      unitRef="U_USD">-15340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_c9e5ad84-6228-4b7c-95bb-ce8737fd465b"
      unitRef="U_USD">-84791000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_9b71846b-8684-4f9f-9b66-9a439c180ae3"
      unitRef="U_USD">-28532000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_44ff2847-df83-47ee-b184-c6f597afd840"
      unitRef="U_USD">2731000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_cef58853-f835-4883-9bf8-7cb93c94a72f"
      unitRef="U_USD">2824000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_34a9d4af-397c-4930-9ba5-9228b0b1e908"
      unitRef="U_USD">5968000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_a83ec7a5-ea03-4157-b27c-955320eac071"
      unitRef="U_USD">5724000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      decimals="-3"
      id="F_86108058-b6bd-4125-98c8-e7dd6908876f"
      unitRef="U_USD">-44883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6ec3f271-be32-423b-9498-2f0527f50596"
      decimals="-3"
      id="F_ad30f7af-74d5-4d19-bf07-0c7f675c42e6"
      unitRef="U_USD">-12516000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      decimals="-3"
      id="F_540f1b64-bf99-4627-ad2f-36b68ea4d621"
      unitRef="U_USD">-78823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_21364033-0f4b-4e67-a4e7-7235b02ffe34"
      decimals="-3"
      id="F_678e1b06-75f6-428e-a481-8970b867ea82"
      unitRef="U_USD">-22808000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_869de754-f3e6-4177-9331-4ed5d47c7e01"
      id="F_c84b6f20-e06b-4885-901f-0165de3de986">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.  The Company is currently evaluating the provisions of the new law and the potential effects on its financial position, results of operations, and cash flows. As of the date of these financial statements, the Company has not completed its assessment, and therefore no adjustments have been made.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_0fad6172-f0f0-4cf7-af27-c4ff1c471ff3"
      id="F_ecd341b6-0340-4b23-bbc1-78f04ec18803">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended June 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated trading plans for the orderly disposition of the Company&#x2019;s securities as set forth in the table below.&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Adoption /&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Shares of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Termination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Rule&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-Rule&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name and Position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10b5-1&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;10b5-1&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;to be Sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Richard Lowenthal&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, on behalf of Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020*&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 14, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Richard Lowenthal&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 14, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sarina Tanimoto&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, on behalf of Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020*&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Medical Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 14, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sarina Tanimoto&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, on behalf of Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006*&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Medical Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 14, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laura Shawver&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Director&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Kathleen Scott&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 22, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 22, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Alexander Fitzpatrick&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Legal Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Termination&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 29, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Alexander Fitzpatrick&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Legal Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 29, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on November 27, 2024 and amended on December 13, 2024 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*	This plan, together with the other three plans marked with an asterisk in this table, are treated as a single &#x201c;plan&#x201d; because the individual constituent contracts with each broker-dealer, when taken together as a whole, meet all of the applicable conditions of Rule 10b5-1(c) under the Exchange Act and remain collectively subject to the provisions of such rule, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;including that a modification of any individual contract acts as modification of the whole contract.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_d9da9546-e0e1-4e71-b3d8-a6442c0cbd91">Richard Lowenthal</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_9ca178c5-5668-4082-9871-26855d3b2acf">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_3cd75323-389e-42cd-aada-a541827aa79a">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_35efb4c1-590e-4c91-850c-6d68c18e4e0c">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_d9205b96-8cbc-4781-b224-bd1aae21dd4e">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_665207ef-3c22-4ab7-be7a-036893bd1f4a">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_3211695d-a961-42e9-ab7c-5031d37e43fc">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_f04745e7-fc61-4f44-a90e-0375301533ee"
      decimals="0"
      id="F_21c9466f-2b7c-4cf0-a781-d24ee778cb1e"
      unitRef="U_shares">1050000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_58518720-4bc3-47a8-a449-980f97f2e742"
      id="F_576d3583-2ca7-4054-8965-7ee825681307">May 14, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_94a0cda7-780e-4fa0-ab6d-227368d88e3d">Richard Lowenthal</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_773d8bd2-8686-4c5d-b6f7-f8e37f198c67">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_aaa60f08-3751-4f4a-af26-49a55144f69e">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_bb9b391e-9910-4a7b-9459-6d2428842f85">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_2632de7b-f5dc-4775-b09a-cdb99270c54f">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_8501f2a2-8191-4253-b98c-f5a5962b296f">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_52a43fd7-8aa7-47a3-8f8e-25bb8f80ce7e">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_98d3f585-f5dc-49db-8505-5f7d6f4a006b"
      decimals="0"
      id="F_fdf1b5e7-e203-4508-aebc-fe4ebbcafc73"
      unitRef="U_shares">1050000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_d9e4baf7-c70d-4264-86fb-6110e1b37685"
      id="F_c8921960-8657-44ce-8b26-613dc88e0f75">May 14, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_6d842c07-b023-4c84-ae68-321c4b27df5e">Sarina Tanimoto</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_4edd1ea6-edc8-4562-a4d4-84e1e9c0c535">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_99ee36fa-ee74-4b33-a0ff-f02d213ca913">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_4bf12e38-ae40-4c1c-8885-b69c7e2017e2">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_d2a2c55b-baf0-413d-be71-37a9589eb3df">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_c14dc822-d557-4132-9a4f-f236b6785853">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_b534b469-908d-45aa-8897-ffeb97835cd9">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_460d3d8c-ddbf-4c5d-a288-dca013f2b32b"
      decimals="0"
      id="F_d63ea5fe-2a77-4e74-adb0-9cd1f65d3b47"
      unitRef="U_shares">1050000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_f1ae420f-61e6-446f-b4d9-9fd8003f6543"
      id="F_80012983-538c-4bbe-b167-5cca81dd98c4">May 14, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_cd97b874-9f76-4648-8664-e614150204c9">Sarina Tanimoto</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_6a4d119e-e8a4-4873-9366-701e9ab91e4d">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_669418e3-41c9-416d-8cb8-c5f8896d3ba4">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_f8100502-bb77-455d-9c75-6180a2dfe765">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_0d8e7587-3bf7-451d-8e66-2f16157a346d">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_f2e88704-9f0c-44af-a1e2-26ad6677ec48">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_b86c445f-4922-49ec-a054-438306029287">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_238c6043-2b99-4906-9c2c-f32a420101fd"
      decimals="0"
      id="F_59bae225-3a4b-44f3-b344-a9aa5a44d876"
      unitRef="U_shares">1050000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_0de8676d-aca6-49a6-8113-220f9d24f1c3"
      id="F_b783df73-0f16-48ce-b302-09180e632357">May 14, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_919e6b9c-c742-402e-a3c7-47cd50136e99">Laura Shawver</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_5c020f57-dc99-4971-b381-eb184083c979">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_449d1e40-870a-4bd1-8b4a-42545bcacb98">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_7f7df22d-8368-4e1d-9ed6-1994bf9fd3f4">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_45cebe39-df64-4b05-ac59-bc97f7d8f07e">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_d7916ae0-be4a-49dc-b60f-e83685eefb8d">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_30cf89f4-1595-4dfa-a03e-7827b50fc9e1">May 21, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_eaee139f-06ad-4880-b611-5bd0dea21a98"
      decimals="0"
      id="F_462fe3ed-09f3-4549-91fb-94a24c5d8547"
      unitRef="U_shares">128562</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_a9a7be28-24b1-4e30-816e-ff9e76477575"
      id="F_6e3cb662-57b8-43a1-abf5-d899d8d95f9b">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_d0ff14b5-970c-4d8f-9e24-da99c39481a8">Kathleen Scott</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_c1335290-0111-4608-9cb6-1579976a12da">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_8985669b-d41c-4dfe-84df-cdc94996d7c6">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_591f3f1d-ef8a-42fd-8fda-14cd656e7def">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_06938b15-b0f2-46f9-85d2-c6db8750b132">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_077b5576-1e60-4be2-9578-7b5abb59a083">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_8eb2c820-6159-4f9c-bcef-9afa93b81ba7">May 22, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_1becd9ce-e5df-4cc7-96cc-1fff890d77d3"
      decimals="0"
      id="F_d1f56ce5-8639-4ccd-af77-ef6ba822a76e"
      unitRef="U_shares">50000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_35887e57-d648-48c5-aa33-441fa8e48cf4"
      id="F_0e7fe17f-1c30-4e8a-a476-adcec94f21dd">May 22, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_0efa8b37-d894-47de-abc6-ce9c45d0eb3f">Alexander Fitzpatrick</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_cc4a98e5-dbf7-4aee-bd78-bd2921cdd99e">Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_6fa1c6d6-d18a-4b64-81b5-75657e25e321">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_4a017509-6860-41d9-99e0-828065f21f46">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_98927921-dbd4-4573-bca5-2330acdcc8ac">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_90170264-56ba-447d-96b5-54e3c0c288a7">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_a178e7c5-6cee-4441-b8fc-4770afb55a51">May 29, 2025</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_b6c4e388-e63f-477d-add2-c9ae15d79bd9"
      decimals="0"
      id="F_6534f0f3-a257-4dd3-ad3c-f6bdc5961317"
      unitRef="U_shares">100000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_20001566-4a25-416a-94b7-ca46e23b8755"
      id="F_aab0af8f-04df-41ad-8c68-7164c6a5fba5">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_f3b7fde1-f121-4c71-acea-4601736b3c69">Alexander Fitzpatrick</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_82797aa2-da95-4b0f-8318-cf77019f366d">Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_11c89d5b-2897-422d-8b80-b7b1eda16577">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_370e42c5-bb83-44a0-b0f2-47b6d4b680b4">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_d2515e37-a69e-4383-a937-5817d6847558">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_1b902da7-7ba7-406f-ae8e-ab82d6548432">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_97859351-7d41-4fc7-a40b-694d782e6c76">May 29, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_99ec2511-459f-4c45-8f1e-cd91504cd76d"
      decimals="0"
      id="F_142c1e6b-8edd-4736-a3ee-079c03e1e33f"
      unitRef="U_shares">100000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_ecfee034-2dea-4d42-b7b8-20d9ed7be691"
      id="F_befd85ab-f529-4193-b281-036bf252fadb">January 30, 2026</ecd:TrdArrExpirationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
